Page last updated: 2024-12-05

vincristine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
VincagenusA plant genus of the family Apocynaceae.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]
CatharanthusgenusA plant genus of the family Apocynaceae. It is the source of VINCA ALKALOIDS, used in leukemia chemotherapy.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]
VincagenusA plant genus of the family Apocynaceae.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]

Cross-References

ID SourceID
PubMed CID164145
SCHEMBL ID18402663
MeSH IDM0022676
PubMed CID5978
CHEMBL ID90555
CHEBI ID28445
SCHEMBL ID3709
MeSH IDM0022676

Synonyms (53)

Synonym
leurocristine
NCGC00346731-01
AB01566898_01
SCHEMBL18402663
leucristine
vincristin
CHEBI:28445 ,
vinkristin
22-oxo-vincaleukoblastine
SRI-10749-04
NCI60_026703
vincasar (1:1 sulfate salt)
vincrex (1:1 sulfate salt)
vincaleukoblastine, 22-oxo- 22-oxovincaleukoblastine
VIN ,
lilly 37231 (1:1 sulfate salt)
oncovin (1:1 sulfate salt)
vincristinum [inn-latin]
vincrystine
C07204
22-oxovincaleukoblastine
NCGC00163700-01
HMS2090E19
bdbm50139772
D08679
tecnocris (tn)
vincristine (inn)
NCGC00163700-04
NCGC00163700-02
tox21_112067
dtxsid1032278 ,
cas-57-22-7
dtxcid9012278
vincrstine
tecnocris
oncotcs
CHEMBL90555
gtpl6785
OGWKCGZFUXNPDA-XQKSVPLYSA-N
SCHEMBL3709
tox21_112067_1
NCGC00263543-01
SRI-10749-05
methyl (1r,9r,10s,11r,12r,19r)-11-(acetyloxy)-12-ethyl-4-[(13s,15s,17s)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0^
oncovin (brand name)
vincristine (leurocristine)
Q408977
rel-vincristine
1217704-92-1
leurocristine;nsc-67574;22-oxovincaleukoblastine
methyl (1r,9r,10s,11r,12r,19r)-11-acetyloxy-12-ethyl-4-[(13s,15s,17s)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.01
vincristinum (inn-latin)
l01ca02

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were calculated by use of noncompartmental methods."( Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
Beijnen, JH; Borst, P; Nooijen, WJ; Schinkel, AH; van Asperen, J; van Tellingen, O, 1996
)
0.29
"The half-life (t1/2) of VBL during its terminal phase of elimination was longer in mdr1a (-/-) mice than in wild-type mice."( Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
Beijnen, JH; Borst, P; Nooijen, WJ; Schinkel, AH; van Asperen, J; van Tellingen, O, 1996
)
0.29
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" MRP type efflux pumps may limit the bioavailability of EGCG."( Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
Hong, J; Lambert, JD; Lee, SH; Sinko, PJ; Yang, CS, 2003
)
0.32
"The synthesis and optimization of a series of orally bioavailable 1-(1H-indol-4-yl)-3,5-disubstituted benzene analogues as antimitotic agents are described."( Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.
Bukhtiyarova, M; Chao, W; Dorsey, BD; Flubacher, D; Flynn, GA; Fujimoto, T; Husain, A; Joseph, RW; Kelly, MJ; Lee, KJ; Lee, Y; Liu, B; Lu, Y; Mihelcic, J; Moffett, KK; Moore, WR; Nelson, D; Ochman, AR; Saporito, MS; Schumacher, A; Shetty, RS; Springman, EB; Stojanovic, A; Williams, K, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"The benzothiophene LY329146 reverses the drug resistance phenotype in multidrug resistance protein (MRP1)-overexpressing cells when dosed in combination with MRP1-associated oncolytics doxorubicin and vincristine."( Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.
Dantzig, AH; Hauser, KL; Kroin, JS; Law, KL; Norman, BH; Palkowitz, AD; Shepard, RL; Sluka, JP; Starling, JJ; Tabas, LB; Winter, MA, 1999
)
0.49
" Lead compounds were shown to inhibit tumor growth in several nude mouse xenograft models, with high potency and efficacy, when dosed either orally or intravenously."( Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
Afragola, J; Ayral-Kaloustian, S; Beyer, C; Gibbons, J; Hernandez, R; Lucas, J; Nguyen, T; Zhang, N, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
tubulin modulatorAny substance that interacts with tubulin to inhibit or promote polymerisation of microtubules.
microtubule-destabilising agentAny substance that interacts with tubulin to inhibit polymerisation of microtubules.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
drugAny substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (8)

ClassDescription
vinca alkaloidA group of indole-indoline dimers which are alkaloids obtained from the Vinca genus of plants, together with semi-synthetic and fully synthetic analogues.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
formamidesAmides with the general formula R(1)R(2)NCHO (R(1) and R(2) can be H).
organic heteropentacyclic compound
organic heterotetracyclic compound
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Vincristine Action Pathway105
vindoline, vindorosine and vinblastine biosynthesis240
vindoline and vinblastine biosynthesis635

Protein Targets (64)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency1.32070.00308.794948.0869AID1347053
EWS/FLI fusion proteinHomo sapiens (human)Potency19.49600.001310.157742.8575AID1259252; AID1259253; AID1259255
polyproteinZika virusPotency1.32070.00308.794948.0869AID1347053
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.68760.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency5.35380.173734.304761.8120AID1346924
Fumarate hydrataseHomo sapiens (human)Potency1.17700.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency0.18560.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency5.35380.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency0.15630.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.07270.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.99260.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency0.56230.00527.809829.0929AID588855
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.22950.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency0.13330.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency11.52260.01237.983543.2770AID1346984; AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency0.00200.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.21310.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.22030.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.09270.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.37580.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency0.02370.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency5.12290.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.48990.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency27.54040.00108.379861.1304AID1645840
polyproteinZika virusPotency1.17700.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency3.00590.00018.4406100.0000AID720579; AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency0.00670.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.58070.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency3.54810.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.10440.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency0.01780.000618.41981,122.0200AID1688
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.09440.000627.21521,122.0200AID743219
gemininHomo sapiens (human)Potency0.29860.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.18610.005612.367736.1254AID624032; AID624044
lamin isoform A-delta10Homo sapiens (human)Potency0.00110.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.02370.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.47060.00339.158239.8107AID1347407; AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency0.00840.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.02370.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.72210.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.74980.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-4A chainHomo sapiens (human)IC50 (µMol)0.50000.00051.968010.0000AID214333
Tubulin beta chainHomo sapiens (human)IC50 (µMol)0.50000.00052.052910.0000AID214333
ATP-dependent translocase ABCB1Homo sapiens (human)Ki213.00000.02002.35948.5900AID681356
Tubulin alpha-3C chainHomo sapiens (human)IC50 (µMol)0.50000.00051.955510.0000AID214333
Multidrug resistance-associated protein 1 Homo sapiens (human)IC50 (µMol)70.00000.00153.71109.6600AID679011
Tubulin alpha-1B chainHomo sapiens (human)IC50 (µMol)0.50000.00051.955510.0000AID214333
Tubulin alpha-4A chainHomo sapiens (human)IC50 (µMol)0.50000.00051.955510.0000AID214333
Tubulin beta-4B chainHomo sapiens (human)IC50 (µMol)0.50000.00051.968010.0000AID214333
Tubulin beta-3 chainHomo sapiens (human)IC50 (µMol)0.50000.00051.894510.0000AID214333
Tubulin beta-2A chainHomo sapiens (human)IC50 (µMol)0.50000.00051.968010.0000AID214333
Beta-tubulin Leishmania donovaniIC50 (µMol)1.00001.00001.38002.0000AID247537
Tubulin beta-8 chainHomo sapiens (human)IC50 (µMol)0.50000.00051.968010.0000AID214333
Tubulin beta-2B chainBos taurus (cattle)IC50 (µMol)1.80000.25001.88388.7000AID214005
Tubulin alpha-3E chainHomo sapiens (human)IC50 (µMol)0.50000.00051.955510.0000AID214333
Tubulin alpha-1A chainHomo sapiens (human)IC50 (µMol)0.50000.00051.955510.0000AID214333
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)1.80000.25001.87798.7000AID214005
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)1.80000.25001.86568.7000AID214005
Canalicular multispecific organic anion transporter 1Homo sapiens (human)Ki802.00004.70006.40508.1100AID681596
Tubulin alpha-1C chainHomo sapiens (human)IC50 (µMol)0.50000.00051.955510.0000AID214333
Tubulin beta-6 chainHomo sapiens (human)IC50 (µMol)0.50000.00051.968010.0000AID214333
Tubulin beta-2B chainHomo sapiens (human)IC50 (µMol)0.50000.00051.968010.0000AID214333
Tubulin beta-1 chainHomo sapiens (human)IC50 (µMol)0.50000.00051.987010.0000AID214333
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)23.89000.10472.71957.0795AID1197747; AID699543
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki13.70000.08002.46889.8000AID1197747; AID699543
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)44.00000.05002.37979.7000AID699542
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki42.00000.04401.36305.0000AID699542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Ki10.47000.11002.02675.5000AID681382
ATP-dependent translocase ABCB1Homo sapiens (human)Ki2148.00003.40003.40003.4000AID681382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (260)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of microtubule polymerizationTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4A chainHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
odontoblast differentiationTubulin beta chainHomo sapiens (human)
microtubule-based processTubulin beta chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin beta chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta chainHomo sapiens (human)
regulation of synapse organizationTubulin beta chainHomo sapiens (human)
spindle assemblyTubulin beta chainHomo sapiens (human)
cell divisionTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta chainHomo sapiens (human)
mitotic cell cycleTubulin beta chainHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3C chainHomo sapiens (human)
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1B chainHomo sapiens (human)
microtubule-based processTubulin alpha-1B chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1B chainHomo sapiens (human)
cell divisionTubulin alpha-1B chainHomo sapiens (human)
cellular response to interleukin-4Tubulin alpha-1B chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-4A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-4A chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta-4B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-3 chainHomo sapiens (human)
axon guidanceTubulin beta-3 chainHomo sapiens (human)
netrin-activated signaling pathwayTubulin beta-3 chainHomo sapiens (human)
dorsal root ganglion developmentTubulin beta-3 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-3 chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2A chainHomo sapiens (human)
oocyte maturationTubulin beta-8 chainHomo sapiens (human)
spindle assembly involved in female meiosisTubulin beta-8 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-8 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-8 chainHomo sapiens (human)
microtubule-based processTubulin beta-2B chainBos taurus (cattle)
nervous system developmentTubulin beta-2B chainBos taurus (cattle)
positive regulation of axon guidanceTubulin beta-2B chainBos taurus (cattle)
biological_processTubulin alpha-3E chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3E chainHomo sapiens (human)
neuron migrationTubulin alpha-1A chainHomo sapiens (human)
startle responseTubulin alpha-1A chainHomo sapiens (human)
intracellular protein transportTubulin alpha-1A chainHomo sapiens (human)
microtubule-based processTubulin alpha-1A chainHomo sapiens (human)
centrosome cycleTubulin alpha-1A chainHomo sapiens (human)
smoothened signaling pathwayTubulin alpha-1A chainHomo sapiens (human)
memoryTubulin alpha-1A chainHomo sapiens (human)
adult locomotory behaviorTubulin alpha-1A chainHomo sapiens (human)
visual learningTubulin alpha-1A chainHomo sapiens (human)
response to mechanical stimulusTubulin alpha-1A chainHomo sapiens (human)
glial cell differentiationTubulin alpha-1A chainHomo sapiens (human)
gene expressionTubulin alpha-1A chainHomo sapiens (human)
dentate gyrus developmentTubulin alpha-1A chainHomo sapiens (human)
cerebellar cortex morphogenesisTubulin alpha-1A chainHomo sapiens (human)
pyramidal neuron differentiationTubulin alpha-1A chainHomo sapiens (human)
cerebral cortex developmentTubulin alpha-1A chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1A chainHomo sapiens (human)
response to tumor necrosis factorTubulin alpha-1A chainHomo sapiens (human)
locomotory exploration behaviorTubulin alpha-1A chainHomo sapiens (human)
microtubule polymerizationTubulin alpha-1A chainHomo sapiens (human)
forebrain morphogenesisTubulin alpha-1A chainHomo sapiens (human)
homeostasis of number of cells within a tissueTubulin alpha-1A chainHomo sapiens (human)
regulation of synapse organizationTubulin alpha-1A chainHomo sapiens (human)
synapse organizationTubulin alpha-1A chainHomo sapiens (human)
cell divisionTubulin alpha-1A chainHomo sapiens (human)
neuron apoptotic processTubulin alpha-1A chainHomo sapiens (human)
motor behaviorTubulin alpha-1A chainHomo sapiens (human)
cellular response to calcium ionTubulin alpha-1A chainHomo sapiens (human)
organelle transport along microtubuleTubulin alpha-1A chainHomo sapiens (human)
neuron projection arborizationTubulin alpha-1A chainHomo sapiens (human)
response to L-glutamateTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1A chainHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
microtubule-based processTubulin alpha-1C chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1C chainHomo sapiens (human)
cell divisionTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-6 chainHomo sapiens (human)
neuron migrationTubulin beta-2B chainHomo sapiens (human)
microtubule-based processTubulin beta-2B chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2B chainHomo sapiens (human)
modulation of chemical synaptic transmissionTubulin beta-2B chainHomo sapiens (human)
positive regulation of axon guidanceTubulin beta-2B chainHomo sapiens (human)
embryonic brain developmentTubulin beta-2B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2B chainHomo sapiens (human)
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (85)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
GTPase activityTubulin beta-4A chainHomo sapiens (human)
calcium ion bindingTubulin beta-4A chainHomo sapiens (human)
protein bindingTubulin beta-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4A chainHomo sapiens (human)
GTP bindingTubulin beta-4A chainHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
GTPase activityTubulin beta chainHomo sapiens (human)
structural molecule activityTubulin beta chainHomo sapiens (human)
protein bindingTubulin beta chainHomo sapiens (human)
protein domain specific bindingTubulin beta chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin beta chainHomo sapiens (human)
GTPase activating protein bindingTubulin beta chainHomo sapiens (human)
MHC class I protein bindingTubulin beta chainHomo sapiens (human)
protein-containing complex bindingTubulin beta chainHomo sapiens (human)
metal ion bindingTubulin beta chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta chainHomo sapiens (human)
GTP bindingTubulin beta chainHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
hydrolase activityTubulin alpha-3C chainHomo sapiens (human)
metal ion bindingTubulin alpha-3C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
GTP bindingTubulin alpha-3C chainHomo sapiens (human)
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
double-stranded RNA bindingTubulin alpha-1B chainHomo sapiens (human)
GTPase activityTubulin alpha-1B chainHomo sapiens (human)
structural molecule activityTubulin alpha-1B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-1B chainHomo sapiens (human)
GTP bindingTubulin alpha-1B chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-4A chainHomo sapiens (human)
hydrolase activityTubulin alpha-4A chainHomo sapiens (human)
protein kinase bindingTubulin alpha-4A chainHomo sapiens (human)
metal ion bindingTubulin alpha-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
GTP bindingTubulin alpha-4A chainHomo sapiens (human)
double-stranded RNA bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-4B chainHomo sapiens (human)
protein bindingTubulin beta-4B chainHomo sapiens (human)
MHC class I protein bindingTubulin beta-4B chainHomo sapiens (human)
metal ion bindingTubulin beta-4B chainHomo sapiens (human)
unfolded protein bindingTubulin beta-4B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4B chainHomo sapiens (human)
GTP bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-3 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-3 chainHomo sapiens (human)
protein bindingTubulin beta-3 chainHomo sapiens (human)
GTP bindingTubulin beta-3 chainHomo sapiens (human)
peptide bindingTubulin beta-3 chainHomo sapiens (human)
metal ion bindingTubulin beta-3 chainHomo sapiens (human)
netrin receptor bindingTubulin beta-3 chainHomo sapiens (human)
GTPase activityTubulin beta-2A chainHomo sapiens (human)
protein bindingTubulin beta-2A chainHomo sapiens (human)
metal ion bindingTubulin beta-2A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2A chainHomo sapiens (human)
GTP bindingTubulin beta-2A chainHomo sapiens (human)
molecular_functionTubulin beta-8 chainHomo sapiens (human)
GTPase activityTubulin beta-8 chainHomo sapiens (human)
metal ion bindingTubulin beta-8 chainHomo sapiens (human)
GTP bindingTubulin beta-8 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-8 chainHomo sapiens (human)
GTPase activityTubulin beta-2B chainBos taurus (cattle)
metal ion bindingTubulin beta-2B chainBos taurus (cattle)
protein heterodimerization activityTubulin beta-2B chainBos taurus (cattle)
molecular_functionTubulin alpha-3E chainHomo sapiens (human)
protein bindingTubulin alpha-3E chainHomo sapiens (human)
hydrolase activityTubulin alpha-3E chainHomo sapiens (human)
metal ion bindingTubulin alpha-3E chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
GTP bindingTubulin alpha-3E chainHomo sapiens (human)
structural molecule activityTubulin alpha-1A chainHomo sapiens (human)
protein bindingTubulin alpha-1A chainHomo sapiens (human)
hydrolase activityTubulin alpha-1A chainHomo sapiens (human)
identical protein bindingTubulin alpha-1A chainHomo sapiens (human)
protein-containing complex bindingTubulin alpha-1A chainHomo sapiens (human)
metal ion bindingTubulin alpha-1A chainHomo sapiens (human)
protein heterodimerization activityTubulin alpha-1A chainHomo sapiens (human)
GTP bindingTubulin alpha-1A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
structural molecule activityTubulin alpha-1C chainHomo sapiens (human)
protein bindingTubulin alpha-1C chainHomo sapiens (human)
hydrolase activityTubulin alpha-1C chainHomo sapiens (human)
metal ion bindingTubulin alpha-1C chainHomo sapiens (human)
GTP bindingTubulin alpha-1C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
molecular_functionTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-6 chainHomo sapiens (human)
protein bindingTubulin beta-6 chainHomo sapiens (human)
metal ion bindingTubulin beta-6 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-6 chainHomo sapiens (human)
GTP bindingTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-2B chainHomo sapiens (human)
protein bindingTubulin beta-2B chainHomo sapiens (human)
metal ion bindingTubulin beta-2B chainHomo sapiens (human)
protein heterodimerization activityTubulin beta-2B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2B chainHomo sapiens (human)
GTP bindingTubulin beta-2B chainHomo sapiens (human)
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (66)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusTubulin beta-4A chainHomo sapiens (human)
cytosolTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
axonemeTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4A chainHomo sapiens (human)
internode region of axonTubulin beta-4A chainHomo sapiens (human)
neuronal cell bodyTubulin beta-4A chainHomo sapiens (human)
myelin sheathTubulin beta-4A chainHomo sapiens (human)
intercellular bridgeTubulin beta-4A chainHomo sapiens (human)
extracellular exosomeTubulin beta-4A chainHomo sapiens (human)
mitotic spindleTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
cytoplasmTubulin beta-4A chainHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionTubulin beta chainHomo sapiens (human)
nucleusTubulin beta chainHomo sapiens (human)
nuclear envelope lumenTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
cytosolTubulin beta chainHomo sapiens (human)
cytoskeletonTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta chainHomo sapiens (human)
azurophil granule lumenTubulin beta chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin beta chainHomo sapiens (human)
cell bodyTubulin beta chainHomo sapiens (human)
membrane raftTubulin beta chainHomo sapiens (human)
intercellular bridgeTubulin beta chainHomo sapiens (human)
extracellular exosomeTubulin beta chainHomo sapiens (human)
mitotic spindleTubulin beta chainHomo sapiens (human)
protein-containing complexTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
nucleusTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
microtubuleTubulin alpha-3C chainHomo sapiens (human)
cytoplasmTubulin alpha-3C chainHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmTubulin alpha-1B chainHomo sapiens (human)
extracellular regionTubulin alpha-4A chainHomo sapiens (human)
cytosolTubulin alpha-4A chainHomo sapiens (human)
cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-4A chainHomo sapiens (human)
cytoplasmTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
extracellular regionTubulin beta-4B chainHomo sapiens (human)
nucleusTubulin beta-4B chainHomo sapiens (human)
cytosolTubulin beta-4B chainHomo sapiens (human)
cytoskeletonTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
axonemal microtubuleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4B chainHomo sapiens (human)
azurophil granule lumenTubulin beta-4B chainHomo sapiens (human)
intercellular bridgeTubulin beta-4B chainHomo sapiens (human)
extracellular exosomeTubulin beta-4B chainHomo sapiens (human)
mitotic spindleTubulin beta-4B chainHomo sapiens (human)
extracellular vesicleTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
cytoplasmTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
lamellipodiumTubulin beta-3 chainHomo sapiens (human)
filopodiumTubulin beta-3 chainHomo sapiens (human)
axonTubulin beta-3 chainHomo sapiens (human)
dendriteTubulin beta-3 chainHomo sapiens (human)
growth coneTubulin beta-3 chainHomo sapiens (human)
neuronal cell bodyTubulin beta-3 chainHomo sapiens (human)
intercellular bridgeTubulin beta-3 chainHomo sapiens (human)
extracellular exosomeTubulin beta-3 chainHomo sapiens (human)
cell peripheryTubulin beta-3 chainHomo sapiens (human)
mitotic spindleTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
cytoplasmTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2A chainHomo sapiens (human)
intercellular bridgeTubulin beta-2A chainHomo sapiens (human)
extracellular exosomeTubulin beta-2A chainHomo sapiens (human)
mitotic spindleTubulin beta-2A chainHomo sapiens (human)
extracellular vesicleTubulin beta-2A chainHomo sapiens (human)
cytoplasmTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-8 chainHomo sapiens (human)
intercellular bridgeTubulin beta-8 chainHomo sapiens (human)
extracellular exosomeTubulin beta-8 chainHomo sapiens (human)
mitotic spindleTubulin beta-8 chainHomo sapiens (human)
meiotic spindleTubulin beta-8 chainHomo sapiens (human)
microtubuleTubulin beta-8 chainHomo sapiens (human)
cytoplasmTubulin beta-8 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainBos taurus (cattle)
nucleusTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
microtubuleTubulin alpha-3E chainHomo sapiens (human)
cytoplasmTubulin alpha-3E chainHomo sapiens (human)
condensed chromosomeTubulin alpha-1A chainHomo sapiens (human)
nucleusTubulin alpha-1A chainHomo sapiens (human)
cytosolTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
axonemal microtubuleTubulin alpha-1A chainHomo sapiens (human)
plasma membraneTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
neuromuscular junctionTubulin alpha-1A chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin alpha-1A chainHomo sapiens (human)
recycling endosomeTubulin alpha-1A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
cytoplasmTubulin alpha-1A chainHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleusTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
vesicleTubulin alpha-1C chainHomo sapiens (human)
membrane raftTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmTubulin alpha-1C chainHomo sapiens (human)
nucleusTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-6 chainHomo sapiens (human)
intercellular bridgeTubulin beta-6 chainHomo sapiens (human)
extracellular exosomeTubulin beta-6 chainHomo sapiens (human)
mitotic spindleTubulin beta-6 chainHomo sapiens (human)
cytoplasmTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
nucleusTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainHomo sapiens (human)
intercellular bridgeTubulin beta-2B chainHomo sapiens (human)
mitotic spindleTubulin beta-2B chainHomo sapiens (human)
Schaffer collateral - CA1 synapseTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1140)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID662232Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1347476Cytotoxicity against golden hamster BHK21 cells at 100 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1386566Cell cycle arrest in human PANC1 cells assessed as increase in accumulation at G2/M phase at 100 nM after 18 hrs by Hoechst 33342 staining based FACS analysis relative to control
AID312020Cytotoxicity against human A172 cells after 6 days2007Journal of natural products, Dec, Volume: 70, Issue:12
Inhibitory effects of diterpenoid alkaloids on the growth of A172 human malignant cells.
AID274814Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 31.6 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID154247Compound was tested for T/C range at optimal dose of 3.0 mg/kg for antitumor activity against P388 leukemia cells in mice; value ranges from 165-1811991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity.
AID729776Cytotoxicity against human MES-SA/Dx5 cells after 72 hrs by Presto Blue assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
AID318685Cytotoxicity against multidrug resistant P-gp expressing human KBV20C cells assessed as cell viability after 48 hrs by MTS assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis of curcumin mimics with multidrug resistance reversal activities.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1211876Unbound biliary clearance in iv dosed Sprague-Dawley rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1545750Inhibition of bovine brain microtubule polymerization incubated for 60 mins by spectrophotometric method2019European journal of medicinal chemistry, Dec-01, Volume: 183Indole: A privileged scaffold for the design of anti-cancer agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID521209Antiproliferative activity against mouse astrocyte cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID606222Cytotoxicity against vincristine-sensitive human KB cells in presence of 0.1 ug/ml vincristine2011Journal of natural products, May-27, Volume: 74, Issue:5
Grandilodines A-C, biologically active indole alkaloids from Kopsia grandifolia.
AID348006Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 316 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID15472Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells.
AID1317631Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID662218Antiproliferative activity against human PLC/PRF/5 cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID8893Synergism with indomethacin in A549 cells2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID400175Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 5 ug/disk after 12 days by potato disk assay
AID137489Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 0.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID586593Growth inhibition of pig LLC-PK1 cells in presence of P-glycoprotein inhibitor LY3359792011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID1286274Cytotoxicity against human vincristine-sensitive KB cells assessed as cell viability after 72 hrs by MTT assay2016Journal of natural products, Jan-22, Volume: 79, Issue:1
Aspidofractinine and Eburnane Alkaloids from a North Borneo Kopsia. Ring-Contracted, Additional Ring-Fused, and Paucidactine-Type Aspidofractinine Alkaloids from K. pauciflora.
AID1549406Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, May-01, Volume: 169Synthesis and biological activities of artemisinin-piperazine-dithiocarbamate derivatives.
AID412960Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID261536Cytotoxicity against human MCF7 cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID132569Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 3.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1360501Growth inhibition of human LO2 cells at 0.1 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID1308557Cytotoxicity against human HCT8/VCT cells assessed as growth inhibition after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID1189184Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID303722Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 10 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID604369Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 150 nM after 24 hrs by FACS analysis (Rvb = 10.9 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID586592Growth inhibition of pig L-MDR1 cells overexpressing human P-glycoprotein2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID1055905Cytotoxicity against human NCI-H157 cells at 100 uM after 24 hrs by sulforhodamine B assay2013European journal of medicinal chemistry, , Volume: 70Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
AID347988Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 0.3 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID44202Effect on cross resistance of CCRF-CEM cells resistant to vincristine.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1211800Drug excretion in iv dosed Sprague-Dawley rat assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID214891beta-Tubulin GTPase activity at 10 uM concentration.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.
AID311670Cytotoxicity against human KB/VJ300 cells2007Journal of natural products, Nov, Volume: 70, Issue:11
Biologically active aspidofractinine, rhazinilam, akuammiline, and vincorine alkaloids from Kopsia.
AID509780Induction of apoptosis in human KB/VCR cells expressing Pgp assessed as down-regulation of Bcl-2 expression at 0.2 uM after 48 hrs by Western blotting2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
AID1189149Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID1631484Growth inhibition of human KB/VJ300 cells after 72 hrs by MTT assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Vobatensines A-F, Cytotoxic Iboga-Vobasine Bisindoles from Tabernaemontana corymbosa.
AID774653Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei 427 after 3 days by Alamar Blue assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID335775Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.16 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID634822Cytotoxicity against vincristine-selected multi drug-resistant human KB cells after 72 hrs by sulforhodamine B and MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID367228Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and activity evaluation of benzoylurea derivatives as potential antiproliferative agents.
AID357845Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method
AID94332Compound was evaluated for its cytotoxicity against vincristine-sensitive KB/S human oral epidermoid carcinoma cell lines.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Conodiparines A-D, new bisindoles from Tabernaemontana. Reversal of vincristine-resistance with cultured cells.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID681382TP_TRANSPORTER: inhibition of Verapamil binding in membranes from Vinblastine-induced Caco-2 cells1999The Journal of pharmacology and experimental therapeutics, Jan, Volume: 288, Issue:1
Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
AID302404Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID307745Growth inhibition of human A2780 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells.
AID411445Ratio of IC50 for human KB 8.5 cells to IC50 for human KB cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
AID347997Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 10 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID750812Cytotoxicity against human prostate cancer cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID1126633Anticancer activity against human NCI-H157 cells at 100 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID312972Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.
AID1070460Induction of apoptosis in human CCRF-CEM VCR/R cells assessed as cell viability at 2.5 uM after 72 hrs by CellTitre-Blue assay relative to control2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Simplified pretubulysin derivatives and their biological effects on cancer cells.
AID1905035Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID303715Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 100 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID750813Cytotoxicity against human breast cancer cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID1308560Resistance index, ratio of IC50 for human A549/CDDP cells to IC50 for human A549 cells2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID274812Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 3.16 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID383220Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at subG0 phase at 1 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID93939The compound was tested in vitro for growth of inhibitory activity against lymphoid leukemia L1210 cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
New anticancer agents: alterations of the carbamate group of ethyl (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)car bamates.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID96219Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant KB subclones passaged in the presence of doxorubicin 0.09 uM by 50%2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID679011TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells1996The Journal of biological chemistry, Apr-19, Volume: 271, Issue:16
ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids.
AID1360490Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID332251Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2002Journal of natural products, Feb, Volume: 65, Issue:2
Cytotoxic effect (on tumor cells) and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes.
AID1431460Cytotoxicity against human PC3 cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID1177868Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
AID137811Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 3 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID616587Cytotoxicity against human KB cells after 72 hrs by SRB assay2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
AID348167Cytotoxicity against human MIAPaCa2 cells after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Design, synthesis and biological evaluation of novel stilbene-based antitumor agents.
AID311669Cytotoxicity against human KB cells2007Journal of natural products, Nov, Volume: 70, Issue:11
Biologically active aspidofractinine, rhazinilam, akuammiline, and vincorine alkaloids from Kopsia.
AID1631493Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Minor Pyranonaphthoquinones from the Apothecia of the Lichen Ophioparma ventosa.
AID729775Resistance factor, ratio of IC50 for human KB-VIN10 cells to IC50 for human KB cells2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
AID1177866Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
AID607670Resistance factor, ratio of IC50 for drug-resistant MDR1-deficient human NCI/ADR cells expressing Pgp in absence of vinblastin to IC50 for drug-sensitive human MCF7 cells in presence of 50 nM vinblastin2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.
AID725097Cell cycle arrest in human HT-29 cells assessed as accumulation at G2 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID1235358Antiproliferative activity against human KB-VIN10 cells expressing P-gp170/MDR after 72 hrs by methylene blue assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes.
AID1899073Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay
AID332255Cytotoxicity against bovine Bon-Fib cells after 48 hrs by MTT assay2002Journal of natural products, Feb, Volume: 65, Issue:2
Cytotoxic effect (on tumor cells) and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes.
AID1184238Antitumor activity against Agrobacterium tumefaciens -induced tumor at 1000 ug/ml after 21 days by potato disc bioassay technique2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID302402Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID335774Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.8 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID98159Concentration required to inhibit proliferation of cultured lymphoid leukemia L1210 cells to 50% growth over 48 hours1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antimitotic agents: structure-activity studies with some pyridine derivatives.
AID1184239Antitumor activity against Agrobacterium tumefaciens -induced tumor at 100 ug/ml after 21 days by potato disc bioassay technique2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID411444Antiproliferative activity against human KBV1 cells after 3 days by SRB assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
AID587605Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID750819Cytotoxicity against human leukemia cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID1700960Inhibition of N,N'-Ethylenebis(iodoacetamide) binding to beta-tubulin in human HepG2 cells assessed as reduction in EBI/beta-tubulin adduct formation at 5 uM preincubated for 2 hrs followed by EBI addition and measured after 1.5 hrs by Western blot analys
AID1406662Inhibition of tubulin (unknown origin) polymerization assessed as polymerized tubulin level at 5 to 25 uM by fluorescence assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors.
AID303711Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 1 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID750815Cytotoxicity against human melanoma cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID1691058Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved caspase-3 expression at 0.1 uM measured after 24 hrs by Western blot analysis
AID634925Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis, molecular docking study and antitumor activity of novel 2-phenylindole derivatives.
AID679022TP_TRANSPORTER: inhibition of LTC4 uptake (LTC4: 0.01 uM, Vincristine: 100 uM) in liver plasma membrane vesicles of Wistar rat1990The Journal of biological chemistry, Nov-05, Volume: 265, Issue:31
ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates.
AID756582Competitive binding affinity to pig brain tubulin vinblastine binding site at 0.1 to 100 uM after 1 hr by mass spectrophotometric analysis in presence of vinblastine2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.
AID634926Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis, molecular docking study and antitumor activity of novel 2-phenylindole derivatives.
AID408772Cytotoxicity against human KB-VIN cells by sulforhodamine B assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
AID607671Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.
AID687161Ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1355100Antiproliferative activity against human KBV cells after 48 hrs by MTT assay
AID274811Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 1 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID367230Cell cycle arrest in human CEM cells assessed as accumulation at G2/M phase at 0.1 uM after 12 hrs by flow cytometry2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and activity evaluation of benzoylurea derivatives as potential antiproliferative agents.
AID750816Cytotoxicity against human ovarian cancer cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID616984Antiproliferative activity against MDR-1 overexpressing human 786-0 cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.
AID661462Antiproliferative activity against rat C6 cells at 0.1 to 10 uM after 48 hrs by neutral red incorporation assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID132555Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 1.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1761217Cytotoxicity against human MCF-T cells assessed as cell survival measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID771213Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID138166Number of survivors on 60th day at dose 0.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID291929Cytotoxicity against human DU145 cells by SRB microtiter plate assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
AID132347Percent increase in life span at dose 1.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1481840Resistance factor, ratio of IC50 for human KB/VCR cells to IC50 for human KB cells2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression.
AID272515Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID616994Antiproliferative activity against MDR-1 overexpressing human 786-0 cells in presence of MDR1 inhibitor verapamil2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.
AID729778Cytotoxicity against human MES-SA cells after 72 hrs by Presto Blue assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
AID347118Inhibition of ornithine decarboxylase in human HT-29 cells assessed as release of radioactive CO2 from [14C-carboxyl] ornithine2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events.
AID408774Selectivity index, ratio of ED50 for human KB cells to ED50 for vincristine-resistant human KB-VIN cells2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
AID766787Inhibition of porcine brain tubulin polymerization at 1 uM measured every 30 seconds for 30 mins2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID46882Inhibition against CRFF-CEM-T-Cell leukemic cell line1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
In vitro metabolic transformations of vinblastine: oxidations catalyzed by human ceruloplasmin.
AID471347Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2009Journal of natural products, Sep, Volume: 72, Issue:9
Biscarpamontamines A and B, an aspidosperma-iboga bisindole alkaloid and an aspidosperma-aspidosperma bisindole alkaloid, from Tabernaemontana sphaerocarpa.
AID274819Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 1 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1631483Growth inhibition of human KB/S cells after 72 hrs by MTT assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Vobatensines A-F, Cytotoxic Iboga-Vobasine Bisindoles from Tabernaemontana corymbosa.
AID288985Antiproliferative activity against human MCF7 cells after 5 days2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells.
AID607675Effect on bovine brain microtubule depolymerization assessed as decrease in absorbance at wavelength 340 nm after 15 mins2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID54072Synergism with sulindac in DLKP cells2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID1320992Cell cycle arrest in human HCC1428 cells assessed as accumulation at G2/M phase at 1 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 9.17%)2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors.
AID420238Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, antimicrobial and cytotoxic activities of some 5-arylidene-4-thioxo-thiazolidine-2-ones.
AID1639310Cytotoxicity against human KB/S cells after 72 hrs by MTT assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
Conolodinines A-D, Aspidosperma- Aspidosperma Bisindole Alkaloids with Antiproliferative Activity from Tabernaemontana corymbosa.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID133208Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 0.2 mg/Kg as range.1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew.
AID96221Compound concentration required to reduce the cell proliferation of Wild type and drug-resistant KB subclones passaged in the presence of etoposide 7 uM by 50%2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1221969Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID662223Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1075749Competitive inhibition of dog brain tubulin using BODIPY FL-vinblastine as substrate at 10 uM incubated for 30 mins prior to substrate addition measured after 30 mins by fluorescence assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.
AID1235362Antiproliferative activity against human KB-7d cells expressing MRP after 72 hrs by methylene blue assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes.
AID1320991Cell cycle arrest in human HCC1428 cells assessed as accumulation at S phase at 1 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 21.01%)2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors.
AID96220Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID678982TP_TRANSPORTER: inhibition of EGCG in MRP2-expressing MDCKII cells2003Biochemical and biophysical research communications, Oct-10, Volume: 310, Issue:1
Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID137809Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 3.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID291931Cytotoxicity against multidrug resistant human KB-Vin cells by SRB microtiter plate assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
AID1347473Cytotoxicity against human NCI-H157 cells at 10 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1360502Growth inhibition of human LO2 cells at 0.5 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID586588Growth inhibition of dog MDCK2 cells in presence of P-glycoprotein inhibitor LY3359792011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID1308561Cytotoxicity against human MCF7/DX cells assessed as growth inhibition after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID704748Cytotoxicity against human HCT116 cells2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.
AID1267185Potency index, ratio of vincristine IC50 to docetaxel IC50 for displacement of [3H]-paclitaxel from biotinylated porcine tubulin2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID145212In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
O-Phosphonatomethylcholine, its analogues, alkyl esters, and their biological activity.
AID771217Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID750818Cytotoxicity against human CNS cancer cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID662228Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID412966Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID1347477Cytotoxicity against golden hamsterBHK21 cells at 10 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1381594Inhibition of tubulin (unknown origin) polymerization assessed as tubulin assembly rate by fluorescence assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.
AID1287981Cytotoxicity against human HeLa cells after 3 days by SRB assay2016European journal of medicinal chemistry, Apr-13, Volume: 112Discovery of novel 2-phenyl-imidazo[1,2-a]pyridine analogues targeting tubulin polymerization as antiproliferative agents.
AID1612626Antiproliferative activity against human ADR-resistant Bel7402/ADR cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID780977Cytotoxicity against human KB-VIN10 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
AID137652Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 0.22 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID347996Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 10 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1612627Drug resistance index, ratio of IC50 for ADR-resistant human Bel7402/ADR cells to IC50 for human Bel7402 cells2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID515576Anticancer activity against human Hep3B cells after 3 days by SRB assay2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues.
AID263819Cytotoxicity against human PA1 cells by clonogenic assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID478017Antiproliferative activity against human K562/A02 cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID1126635Anticancer activity against human NCI-H157 cells at 1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID274813Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 10 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1317640Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 0.5 uM after 18 to 24 hrs by propidium iodide staining based flow cytometry (Rvb = 67 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID247363Compound was tested for growth inhibition of human non-small cell lung cancer NCI-H460 cell line2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Novel diarylsulfonylurea derivatives as potent antimitotic agents.
AID288986Cell cycle arrest in MDA-MB-231 cells by accumulation at G2/M phase after 24 hrs by flow cytometry2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells.
AID1431461Cytotoxicity against human NCI-H460 cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID1184240Antitumor activity against Agrobacterium tumefaciens -induced tumor at 10 ug/ml after 21 days by potato disc bioassay technique2014European journal of medicinal chemistry, Sep-12, Volume: 84Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.
AID1441901Cell cycle arrest in human HCC1428 cells assessed as accumulation at G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 62.61%)2017European journal of medicinal chemistry, Mar-31, Volume: 129Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents.
AID1459597Cytotoxicity against human KB/S cells assessed as reduction in cell viability after 72 hrs by MTT assay2016Journal of natural products, 10-28, Volume: 79, Issue:10
A Hexacyclic, Iboga-Derived Monoterpenoid Indole with a Contracted Tetrahydroazepine C-Ring and Incorporation of an Isoxazolidine Moiety, a Seco-Corynanthean, an Aspidosperma-Aspidosperma Bisindole with Anticancer Properties, and the Absolute Configuratio
AID1386564Cell cycle arrest in human MCF7 cells assessed as increase in accumulation at G2/M phase at 100 nM after 18 hrs by Hoechst 33342 staining based FACS analysis relative to control
AID1905058Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID1070462Induction of apoptosis in human CCRF-CEM cells at 1 to 100 nM after 48 hrs by propidium iodide staining-based flow cytometry2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Simplified pretubulysin derivatives and their biological effects on cancer cells.
AID1189146Antiproliferative activity against human A2780 cells after 48 hrs by SRB method2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID1189148Antiproliferative activity against human HCT8 cells after 48 hrs by SRB method2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID1514568Cytotoxicity against human KB cells after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Seco-4-methyl-DCK derivatives as potent chemosensitizers.
AID750820Cytotoxicity against human NSCLC cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID292432Cytotoxicity against A549 cells after 48 hrs by MTT assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Stellettins L and M, cytotoxic isomalabaricane-type triterpenes, and sterols from the marine sponge Stelletta tenuis.
AID1331343Cytotoxicity against human Chang cells by MTT assay2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Biological Evaluation
AID272492Antiproliferative activity against MDA435/LCC6 cells by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID766783Inhibition of tubulin polymerization in human NCI-H522 cells assessed as beta-tubulin accumulation in cytoskeletal fraction at 100 nM after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead.
AID137643Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 6.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1267186Displacement of [3H]-paclitaxel from biotinylated porcine tubulin after 25 mins by competitive binding assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID1239588Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Nocarbenzoxazoles A-G, Benzoxazoles Produced by Halophilic Nocardiopsis lucentensis DSM 44048.
AID329735Cell cycle arrest in human K562 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
AID1509488Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 100 uM relative to control2019European journal of medicinal chemistry, Aug-15, Volume: 176Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.
AID1318676Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121neo-Clerodane diterpenoids from Scutellaria barbata mediated inhibition of P-glycoprotein in MCF-7/ADR cells.
AID348002Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 100 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID509754Cytotoxicity against human KB cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
AID1254793Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel spirobicyclic artemisinin analogues (artemalogues): Synthesis and antitumor activities.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID98899Inhibitory activity against growth of L1210 cell line1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
AID348168Cytotoxicity against human SNU423 cells after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Design, synthesis and biological evaluation of novel stilbene-based antitumor agents.
AID348004Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 100 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID263817Cytotoxicity against human KB cells by clonogenic assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID662255Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at G2 phase after 24 hrs by FACS analysis (Rvb = 26.1%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID302385Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID1413121Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2018MedChemComm, Jul-01, Volume: 9, Issue:7
Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents.
AID1308546Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID616509Drug resistance index, ratio of IC50 for vincristine-resistant human KB cells to IC50 for human KB cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
AID662231Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1431464Resistance factor, ratio of IC50 for human CCRF-CEM/VBL cells to IC50 for human CCRF-CEM cells2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID1347523Cytotoxicity against golden hamster BHK21 cells after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1317632Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human MCF7 cells2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID1672883Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization.
AID95339Cytotoxicity was evaluated against KB CV-60 cells at 0.1 ug/mL; No cytotoxicity2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Synthesis and evaluation of 4-deacetoxyagosterol A as an MDR-modulator.
AID1317644Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells after 24 to 48 hrs by Annexin V/7-AAD staining based flow cytometry (Rvb = 4.90 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID302386Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID303712Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 3.16 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID274825Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 0.1 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1327085Antiproliferative activity against human K562/A02 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents.
AID274809Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 0.1 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1564925Selectivity index, ratio of IC50 for human CCRF-CEM/VBL cells to IC50 for human CCRF-CEM cells2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID134629Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 0.2 mg/Kg as the ratio of median survival time of treated mice to control mice1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew.
AID1514563Reversal ratio of IC50 for paclitaxel-induced cytotoxicity against human A2780/TAX cells in absence of compound to IC50 paclitaxel-induced cytotoxicity against human A2780/TAX cells in presence of compound2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Seco-4-methyl-DCK derivatives as potent chemosensitizers.
AID1691094Induction of microtubule disruption in human KB7D cells at 1 uM measured after 24 hrs by DAPI staining based deconvolution fluorescence microscopic analysis
AID1612617Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID1413120Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2018MedChemComm, Jul-01, Volume: 9, Issue:7
Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents.
AID1331341Cytotoxicity against human SiHa cells by MTT assay2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Biological Evaluation
AID335777Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.0064 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID302400Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID1347474Cytotoxicity against human NCI-H157 cells at 1 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID94501Antiproliferative activity against drug-resistant tumor cell line KBMDR.1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity.
AID132715Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID687167Ratio of IC50 for human CCRF-CEM/VM-1-5 cells IC50 for human CCRF-CEM cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID687165Ratio of IC50 for human K562/HHT300 cells to IC50 for human K562 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID137642Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1760387Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 method2020European journal of medicinal chemistry, Dec-15, Volume: 208Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID634821Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B and MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID153566Increase in the life span of mice implanted with lymphocytic leukemia P388 at the highest nontoxic dose of 1.5 mg/kg given to the compound intraperitoneally1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
New anticancer agents: alterations of the carbamate group of ethyl (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)car bamates.
AID132563Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 1 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID509782Induction of apoptosis in human KB/VCR cells expressing Pgp assessed as up-regulation of Bax expression at 0.2 uM after 48 hrs by Western blotting2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
AID659303Ratio of GI50 for human vincristine-resistance KB cells to GI50 for wild type human KB cells2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Anti-AIDS agents 89. Identification of DCX derivatives as anti-HIV and chemosensitizing dual function agents to overcome P-gp-mediated drug resistance for AIDS therapy.
AID247537Compound was tested for inhibition of tubulin polymerisation2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Novel diarylsulfonylurea derivatives as potent antimitotic agents.
AID303707Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 316 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1197743Inhibition of human OATP1B1-mediated [3H]estrone 3-sulfate at 100 uM after 5 mins relative to control2015European journal of medicinal chemistry, Mar-06, Volume: 92Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID681356TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells2002Pharmaceutical research, Jun, Volume: 19, Issue:6
Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
AID662253Cell cycle arrest in human SNU398 cells assessed as accumulation at sub-G1 phase after 24 hrs by FACS analysis (Rvb = 1.2%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID57711In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
O-Phosphonatomethylcholine, its analogues, alkyl esters, and their biological activity.
AID302387Cytotoxicity against human H295R cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID1639311Cytotoxicity against human KB/VJ300 cells after 72 hrs by MTT assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
Conolodinines A-D, Aspidosperma- Aspidosperma Bisindole Alkaloids with Antiproliferative Activity from Tabernaemontana corymbosa.
AID1760425Cytotoxicity against human KBV cells by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1126630Anticancer activity against Syrian golden hamster BHK21 cells at 10 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID348169Cytotoxicity against human UCI101 cells after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Design, synthesis and biological evaluation of novel stilbene-based antitumor agents.
AID1347571Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and cytotoxic activity of N-Modified oleanolic saponins bearing A glucosamine.
AID420974Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Synthesis and biological evaluation of abietic acid derivatives.
AID662229Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1462513Inhibition of bovine brain tubulin polymerization2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms.
AID184451Acute iv toxicity against rat after a dose of injection1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID771208Cytotoxicity against vincristine-resistant human KB cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID762816Antiproliferative activity against temperature-sensitive rat lymphatic endothelial cells after 48 hrs by MTS assay2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Structure, synthesis, and biological activity of a C-20 bisacetylenic alcohol from a marine sponge Callyspongia sp.
AID261541Cytotoxicity against mouse 4T1 cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID1320988Cytotoxicity against human HCC1428 cells assessed as decrease in cell viability at 1 uM after 60 hrs by xCELLigence system2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors.
AID1905059Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID23734Micelle/water partition coefficient (Pmic) of the compound was determined1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography.
AID725099Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID94502Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID137815Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 4 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID347993Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 3.16 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1347475Cytotoxicity against human NCI-H157 cells at 0.1 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1239589Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Nocarbenzoxazoles A-G, Benzoxazoles Produced by Halophilic Nocardiopsis lucentensis DSM 44048.
AID408776Cytotoxicity against human MCF7 cells by sulforhodamine B assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
AID347989Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 0.3 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1197747Inhibition of human OATP1B3-mediated [3H]CCK-8 after 5 mins by Dixon plot method2015European journal of medicinal chemistry, Mar-06, Volume: 92Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID494515Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID1267181Displacement of [3H]-colchicine from biotinylated porcine tubulin after 2 hrs by competitive binding assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID302075Antiproliferative activity against human MCF7 cells after 5 days by microplate assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
[(2-Phenylindol-3-yl)methylene]propanedinitriles inhibit the growth of breast cancer cells by cell cycle arrest in G(2)/M phase and apoptosis.
AID1905028Resistance index, ratio of IC50 for antiproliferative activity against human vincristine-resistant HCT-8/VCR cells to IC50 for antiproliferative activity against HCT-8 cells2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID303723Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 31.6 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID263813Cytotoxicity against human MCF7 cells by clonogenic assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID1394815Inhibition of porcine brain tubulin polymerization assessed as tubulin polymerization level by measuring arbitary units at 3 uM by fluorescence analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
AID662219Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID98692Inhibitory concentration against proliferation of cultured lymphoid leukemia L1210 cells during 48 hrs.1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines).
AID1177862Cytotoxicity against vinblastine-resistant human CCRF-CEM cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
AID750817Cytotoxicity against human colon cancer cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID553917Displacement of [3H]colchicine from tubulin at 30 uM2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.
AID510640Selectivity index, ratio of IC50 for green monkey Vero cells over IC50 for human HeLa cells2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID137482Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 1 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1347570Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and cytotoxic activity of N-Modified oleanolic saponins bearing A glucosamine.
AID263821Cytotoxicity against human Colo320DM cells by clonogenic assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID1308559Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID1577680Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by SRB assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID604377Induction of apoptosis in human HCT116 cells at 150 nM after 24 hrs using FITC-TUNEL staining by flow cytometry2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID1360495Growth inhibition of human SMMC7721 cells at 0.01 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID137485Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID347984Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 0.1 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID263812Cytotoxicity against human MCF7 cells by MTT assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID1327087Antiproliferative activity against human KB/VCR cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents.
AID1691057Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved PARP expression at 0.1 uM measured after 24 hrs by Western blot analysis
AID766784Inhibition of tubulin polymerization in human NCI-H522 cells assessed as alpha-tubulin accumulation in cytoskeletal fraction at 100 nM after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead.
AID1672882Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization.
AID398246Antitumor activity against vincristine-resistant mouse P388 cells implanted in CDF1 mouse at 0.2 mg/kg assessed as median survival time relative to control2004Journal of natural products, Feb, Volume: 67, Issue:2
Biological activity and chemistry of taxoids from the Japanese yew, Taxus cuspidata.
AID302401Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 0.1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID662221Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1211823Drug excretion in iv dosed human assessed as compound excreted into bile after 72 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID356663Cytotoxicity against human SMMC7721 cells by MTT assay2003Journal of natural products, Dec, Volume: 66, Issue:12
Xanthanolides, germacranolides, and other constituents from Carpesium longifolium.
AID26811Partition coefficient (logP)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID138175Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 0.2 mg/Kg as percent ratio of median survival time of treated mice to control mice1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew.
AID681121TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID137481Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 0.33 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID290589Ratio of IC50 for KB8.5 cells to IC50 for KB cells2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization.
AID1125803Cytotoxicity against human KB cells after 72 hrs by methylene blue assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones.
AID137638Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 5.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID587604Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID1221977Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1169799Cytotoxicity against vincristine-resistant human KB/VJ300 cells2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Cytotoxic vobasine, tacaman, and corynanthe-tryptamine bisindole alkaloids from Tabernaemontana and structure revision of tronoharine.
AID274824Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 316 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID261537Cytotoxicity against human Aro cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID1691056Cell cycle arrest in human KB-VIN cells assessed as increase in accumulation at sub-G1 phase at 0.01 to 0.1 uM measured after 24 hrs by propidium iodide staining based flow cytometry
AID303706Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 100 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID725337Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID355580Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1631494Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Minor Pyranonaphthoquinones from the Apothecia of the Lichen Ophioparma ventosa.
AID307749Growth inhibition of multidrug-resistant human 2780AD cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells.
AID681613TP_TRANSPORTER: intracellular accumulation in MDR1-expressing LLC-PK1 cells2000Molecular pharmacology, Jan, Volume: 57, Issue:1
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID687166Ratio of IC50 for human CCRF-CEM/C2 cells IC50 for human CCRF-CEM cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID95674Antiproliferative activity against drug-resistant tumor cell line KBwt.1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity.
AID354537Cytotoxicity against rat C6 cells after 3 days treated 4 hrs before db-cAMP challenge by MTT assay1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID274816Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 316 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1308541Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID214889beta-Tubulin GTPase activity at 1 uM concentration.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.
AID587601Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID303725Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 316 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1197745Inhibition of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control2015European journal of medicinal chemistry, Mar-06, Volume: 92Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID137830Number of survivors on 30th day at dose 1 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID137803Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 1 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID83753Inhibitory activity against growth of HT-29 cell line1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
AID1612621Antiproliferative activity against human taxol-resistant A549/TR cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID1185437Antiproliferative activity against human KB cells2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents.
AID478012Antiproliferative activity against human K562 cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID1778141Cytotoxicity against human vincristine-resistant KB cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
The Bisindole Alkaloids Angustilongines M and A from
AID1183745Cell cycle arrest in human PC3 cells at 500 to 2000 nM incubated for 24 hrs followed by compound washout measured after 24 hrs2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID302086Cell cycle arrest in MDA-MB-231 cells by accumulation at G2/M phase at 0.1 uM after 24 hrs by flow cytometry2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
[(2-Phenylindol-3-yl)methylene]propanedinitriles inhibit the growth of breast cancer cells by cell cycle arrest in G(2)/M phase and apoptosis.
AID661471Cytotoxicity against mouse astrocytes assessed as decrease in cell viability at 0.1 uM after 48 hrs by Hoechst 33342 staining2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
AID1177869Resistance factor, ratio of IC50 for vinblastine-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
AID1317641Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 0.5 uM after 18 to 24 hrs by propidium iodide staining based flow cytometry (Rvb = 8.5 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID725338Cell cycle arrest in human HT-29 cells assessed as accumulation at G1 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID333842Cytotoxicity against human KB cells
AID274831Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 100 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID587602Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID1564847Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by MTS assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID681566TP_TRANSPORTER: intracellular accumulation in Bsep-expressing LLC-PK1 cells2000Molecular pharmacology, Jan, Volume: 57, Issue:1
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID662226Antiproliferative activity against human JHH4 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID303719Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 0.3 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1663826Antiproliferative activity against human HL60 cells incubated for 2 days by MTT assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Isolation and biological activity of agrostophillinol from kaffir lime (Citrus hystrix) leaves.
AID137630Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 3.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID290586Antiproliferative activity against KB cells2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization.
AID347986Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 0.1 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1441900Antiproliferative activity against human HCC1428 cells at 1 uM up to 60 hrs by RTCA2017European journal of medicinal chemistry, Mar-31, Volume: 129Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents.
AID400177Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 1.5 ug/disk after 12 days by potato disk assay
AID1308556Resistance index, ratio of IC50 for human A2780/TAX cells to IC50 for human A2780 cells2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID607672Resistance factor, ratio of IC50 for Pgp-deficient human MCF7/VP cells expressing MRP1 in absence of vinblastin to IC50 for drug sensitive human MCF7 cells in presence of 50 nM vinblastin2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.
AID1321001Inhibition of bovine brain tubulin polymerization at 5 uM measured every minute for 1 hr by spectrophotometric method2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors.
AID408775Cytotoxicity against human A549 cells by sulforhodamine B assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
AID642532Growth inhibition of human KB-7d cells after 72 hrs by methylene blue assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
AID408777Cytotoxicity against human HCT8 cells by sulforhodamine B assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
AID1254792Cytotoxicity against human KB/VCR cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel spirobicyclic artemisinin analogues (artemalogues): Synthesis and antitumor activities.
AID303705Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 31.6 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1183742Cell cycle arrest in human PC3 cells assessed as rounded cells at 500 nM after 24 hrs by propidium iodide staining-based flow cytometry2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID586586Growth inhibition of dog MDCK2 cells2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID580238Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID275847Antiproliferative activity against KBV1 cells expressing MDR12007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
AID132547Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intraperitoneally at a dose of 1 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID302392Cytotoxicity against human HT29 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID642533Growth inhibition of human KB-S15 cells after 72 hrs by methylene blue assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
AID662220Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1125806Cytotoxicity against human vincristine/paclitaxel-resistant KB-VIN10 cells overexpressing P-gp170 after 72 hrs by methylene blue assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones.
AID348005Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 316 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID247688inhibitory concentration against human MDR KB/V cell line2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer.
AID1424394Cytotoxicity in human KB cells assessed as reduction in cell viability2017European journal of medicinal chemistry, Dec-15, Volume: 142Recent advances (2015-2016) in anticancer hybrids.
AID275849Ratio of IC50 for KBV1 cells to IC50 for KB cells2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
AID87571Cytotoxicity tested against Hela C1 cells1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.
AID214005In vitro inhibition of tubulin polymerization measured as turbidity formed by centrifugation1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1183746Cell cycle arrest in human RD cells at 1000 to 2000 nM incubated for 24 hrs followed by compound washout measured after 24 hrs2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID347999Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 31.6 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID312973Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.
AID106322In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
O-Phosphonatomethylcholine, its analogues, alkyl esters, and their biological activity.
AID1906173Binding affinity to beta-tubulin colchicine binding site in human HeLa cells assessed as decrease of adduct formation by measuring gray value measured at 25 uM incubated for 2 hrs followed by addition of EBI measured after 1.5 hrs by EBI competition based
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1331342Cytotoxicity against mouse B16F10 cells by MTT assay2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
Biological Evaluation
AID332252Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay2002Journal of natural products, Feb, Volume: 65, Issue:2
Cytotoxic effect (on tumor cells) and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes.
AID367227Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and activity evaluation of benzoylurea derivatives as potential antiproliferative agents.
AID1286275Cytotoxicity against human KB/VJ300 cells assessed as cell viability after 72 hrs by MTT assay2016Journal of natural products, Jan-22, Volume: 79, Issue:1
Aspidofractinine and Eburnane Alkaloids from a North Borneo Kopsia. Ring-Contracted, Additional Ring-Fused, and Paucidactine-Type Aspidofractinine Alkaloids from K. pauciflora.
AID1694426Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
AID762817Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Structure, synthesis, and biological activity of a C-20 bisacetylenic alcohol from a marine sponge Callyspongia sp.
AID84292Tested for cytotoxicity against HT-29 (MDR)cells2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Molecular basis of the antitumor activities of 2-crotonyloxymethyl-2-cycloalkenones.
AID1347522Cytotoxicity against human NCI-H157 cells after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1386568Cell cycle arrest in human PANC1 cells assessed as accumulation at G1 phase at 100 nM after 18 hrs by Hoechst 33342 staining based FACS analysis (Rvb = 70.7%)
AID509753Cytotoxicity against human KB/VCR cells expressing Pgp after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
AID1564916Binding affinity to tubulin (unknown origin) assessed as reduction in Beta-colfragment production at 100 uM after 30 mins by coomassie brilliant blue staining based trypsin proteolysis assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID681091TP_TRANSPORTER: intracellular accumulation in KB-3-1 and C-A120 cells1997Molecular pharmacology, Mar, Volume: 51, Issue:3
Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P.
AID1183739Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase at 500 nM after 24 hrs by propidium iodide staining-based flow cytometry2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID1674855Inhibition of tubulin polymerization in human MOLM-13 cells assessed as disruption of microtubule network at 200 nM after 18 hrs by FITC-staining based flow cytometry analysis2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization.
AID1691097Induction of microtubule disruption in human KB-VIN cells assessed as polymerized fraction at 0.01 uM measured after 16 hrs by SDS-PAGE analysis (Rvb = 23.1 to 25.5%)
AID96362Effect on the proliferation Wild -type and Drug- resistant KB subclones passaged in the presence of vincristine 0.02 uM2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID681572TP_TRANSPORTER: drug resistance in BCRP-expressing MEF3.8 cells2003Cancer research, Mar-15, Volume: 63, Issue:6
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
AID383223Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at G2/M phase at 1 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID54073Synergism with tolmedin in DLKP cells2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID355578Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID1459598Cytotoxicity against human KB/VJ300 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016Journal of natural products, 10-28, Volume: 79, Issue:10
A Hexacyclic, Iboga-Derived Monoterpenoid Indole with a Contracted Tetrahydroazepine C-Ring and Incorporation of an Isoxazolidine Moiety, a Seco-Corynanthean, an Aspidosperma-Aspidosperma Bisindole with Anticancer Properties, and the Absolute Configuratio
AID431399Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1183747Cell cycle arrest in human RD cells at 500 nM incubated for 24 hrs followed by compound washout measured after 24 hrs2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID661467Cytotoxicity against mouse astrocytes assessed as decrease in cell viability at 1 to 10 uM after 48 hrs by neutral red incorporation assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
AID587600Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID303709Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 0.1 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID771185Toxicity in KM mouse allografted with mouse H22 cells assessed as body weight at 0.25 mg/kg, ip administered on day 1 and 4 measured on day 8 (Rvb = 30 +/- 3.24 g)2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID290588Antiproliferative activity against KBV1cells2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization.
AID274827Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 1 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID302388Cytotoxicity against human Ovcar3 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID1441902Cell cycle arrest in human HCC1428 cells assessed as accumulation at S phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 24.46%)2017European journal of medicinal chemistry, Mar-31, Volume: 129Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents.
AID1166300Cytotoxicity against human NCI-H157 cells by sulforhodamine B assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
AID132554Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 0.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID15625Statistical significance of IC 50 values; Expressed as R value1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells.
AID1126631Anticancer activity against Syrian golden hamster BHK21 cells at 1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1413119Antiproliferative activity against HEL cells after 48 hrs by MTT assay2018MedChemComm, Jul-01, Volume: 9, Issue:7
Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents.
AID275846Antiproliferative activity against KB8.5 cells expressing MDR12007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
AID131673Increase in life span at the highest nontoxic dose against P-388 tumor cell after 1 day at 2.7 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines).
AID1691099Induction of microtubule disruption in human KB-VIN cells assessed as polymerized fraction at 1 uM measured after 16 hrs by SDS-PAGE analysis (Rvb = 23.1 to 25.5%)
AID274823Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 100 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID510639Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID302037Cytotoxicity against human multidrug resistant Lucena1 cells assessed as cell viability after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines.
AID725096Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID8306In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle.
AID412961Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID1905033Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID509779Induction of apoptosis in human KB/VCR cells expressing Pgp assessed as morphological changes using DAPI staining at 0.2 uM after 48 hrs by fluorescence microscopic analysis2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
AID1360503Growth inhibition of human LO2 cells at 2.5 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID1235361Antiproliferative activity against human KB-S15 cells expressing P-gp170/MDR after 72 hrs by methylene blue assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes.
AID1317642Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 0.5 uM after 18 to 24 hrs by propidium iodide staining based flow cytometry (Rvb = 18.8 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1183743Cell cycle arrest in human RD cells assessed as rounded cells at 500 nM after 24 hrs by propidium iodide staining-based flow cytometry2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID1413123Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2018MedChemComm, Jul-01, Volume: 9, Issue:7
Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents.
AID335778Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.00128 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID1899072Resistant index, ratio IC50 for KB-V1 cells over IC50 for KB cells
AID1564900Inhibition of porcine tubulin at 5 uM in presence of GTP measured every minute for 1 hr by microplate reader analysis2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID274798Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID704749Cytotoxicity against mouse L1210 cells2011ACS medicinal chemistry letters, Dec-08, Volume: 2, Issue:12
10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.
AID274818Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 0.3 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID303702Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 1 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1177867Cytotoxicity against human H1299 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
AID1327088Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents.
AID1126183Antiproliferative activity against human NCI-H157 cells at 100 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases.
AID1239592Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Nocarbenzoxazoles A-G, Benzoxazoles Produced by Halophilic Nocardiopsis lucentensis DSM 44048.
AID1347524Cytotoxicity against human HepG2 cells by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1308545Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID272493Antiproliferative activity against adriamycin resistant P388 cells by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1549407Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, May-01, Volume: 169Synthesis and biological activities of artemisinin-piperazine-dithiocarbamate derivatives.
AID404804Antiproliferative activity against human MDA-MB-231 cells after 4 days by microplate assay2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Aroyl hydrazones of 2-phenylindole-3-carbaldehydes as novel antimitotic agents.
AID1691063Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved caspase-9 expression at 0.1 uM measured after 24 hrs by Western blot analysis
AID613825Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1564917Binding affinity to tubulin (unknown origin) assessed as reduction in alpha-N fragment production at 100 uM after 30 mins by coomassie brilliant blue staining based trypsin proteolysis assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID1899069Antiproliferative activity against human KB/VCR cells measured after 72 hrs by SRB assay
AID750814Cytotoxicity against human renal cancer cells after 48 hrs2013European journal of medicinal chemistry, Jun, Volume: 64Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
AID137659Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2 mg/kg/day; 0/111985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID681170TP_TRANSPORTER: drug resistance in MRP1-expressing HEK293 cells2003Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 31, Issue:8
Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1).
AID699543Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID420239Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, antimicrobial and cytotoxic activities of some 5-arylidene-4-thioxo-thiazolidine-2-ones.
AID771216Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID303720Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 1 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1183740Cell cycle arrest in human RD cells assessed as accumulation at G2/M phase at 500 nM after 24 hrs by propidium iodide staining-based flow cytometry2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID46881Inhibitory concentration against human T-cell leukemic cell line (CRFF-CEM) in vitro1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
In vitro metabolic transformations of vinblastine: oxidations catalyzed by peroxidase.
AID1308555Cytotoxicity against human A2780/TAX cells assessed as growth inhibition after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1308562Resistance index, ratio of IC50 for human MCF7/DX cells to IC50 for human MCF7 cells2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID355581Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID1360496Growth inhibition of human SMMC7721 cells at 0.1 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID609240Cytotoxic activity against drug-resistant MDR1-deficient human NCI/ADR cells expressing Pgp after 48 hrs by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.
AID1691087Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved caspase-9 expression at 0.1 uM measured after 48 hrs by Western blot analysis
AID302390Cytotoxicity against human Aro cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID1441893Inhibition of alpha-tubulin polymerization in human HCC1428 cells at 1 uM after 24 hrs by confocal microscopic method2017European journal of medicinal chemistry, Mar-31, Volume: 129Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents.
AID1495281Resistance factor, ratio of IC50 for human K562/VCR cells to IC50 for human K562 cells2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID680417TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Vincristine: 300 uM) in membrane vesicle from MRP3-expessing HEK 293 cell2001Cancer research, Oct-01, Volume: 61, Issue:19
Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
AID137812Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 4.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1125807Cytotoxicity against human vincristine/paclitaxel-resistant KB-S15 cells overexpressing P-gp170 after 72 hrs by methylene blue assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones.
AID306140Cytotoxicity againt human A2780 cells2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Structure-activity relationships of some taxoids as multidrug resistance modulator.
AID1612613Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID137497Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 2.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID94357Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID134628Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 0.2 mg/Kg as in the presence of vincristine at 0.1 mg/kg as the ratio of median survival time of treated mice to control mice1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew.
AID1386570Cell cycle arrest in human PANC1 cells assessed as accumulation at G2/M phase at 100 nM after 18 hrs by Hoechst 33342 staining based FACS analysis (Rvb = 13.7%)
AID1211840Total biliary clearance in iv dosed Sprague-Dawley rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID449569Cytotoxicity against human MKN28 cells by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Synthesis of gibberellin derivatives with anti-tumor bioactivities.
AID1691035Antiproliferative activity against human KB-VIN cells incubated for 48 hrs by SRB assay
AID303700Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 0.1 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID96598Concentration that causes a mitotic index (number of cells in mitosis divided by total cells) of 0.5 for cultured lymphoid leukemia L1210 cells during an exposure period of 12 h1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Antimitotic agents: ring analogues and derivatives of ethyl [(S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7- yl]carbamate.
AID1677376Cytotoxicity against human PBL assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1691088Induction of apoptosis in human KB-VIN cells assessed as increase in activated gammaH2AX expression at 0.1 uM measured after 48 hrs by Western blot analysis
AID1431462Cytotoxicity against human NCI-H526 cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID687159Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID333150Cytotoxicity against human BGC823 cells2004Journal of natural products, Sep, Volume: 67, Issue:9
Diterpenoids from Isodon melissoides.
AID1239590Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Nocarbenzoxazoles A-G, Benzoxazoles Produced by Halophilic Nocardiopsis lucentensis DSM 44048.
AID1317643Induction of apoptosis in human MCF7 cells assessed as viable cells after 24 to 48 hrs by Annexin V/7-AAD staining based flow cytometry (Rvb = 72.30 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID1327086Antiproliferative activity against human KB cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents.
AID580237Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID1235359Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes.
AID137804Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 2.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID681084TP_TRANSPORTER: uptake in membrane vesicles from GLC4/ADR cells1999British journal of pharmacology, Feb, Volume: 126, Issue:3
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.
AID1758186Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
AID634825Resistance index, ratio of IC50 for vincristine-selected multi drug-resistant human KB cells to IC50 for human KB cells2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID96774Fraction of cell population of cultured lymphoid leukemia L1210 cells in mitosis at a dose of 0.3 uM after 24 hr1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines).
AID134235Acute iv toxicity against mice after a dose of injection1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID135631Number of survivors on 60th day at dose 1 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID553916Inhibition of tubulin polymerization after 60 mins2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.
AID431395Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID263815Cytotoxicity against human WRL68 cells by clonogenic assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID156357Compound was evaluated for in vitro growth inhibition activity against sensitive PC-6 cell line.1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells.
AID275844Cytotoxicity against COLO205 cells2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
AID687158Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID604367Cell cycle arrest in human HCT116 cells assessed as accumulation at sub-G1 phase at 150 nM after 24 hrs by FACS analysis (Rvb = 6.2 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID398247Antitumor activity against vincristine-resistant mouse P388 cells implanted in CDF1 mouse at 0.1 mg/kg assessed as median survival time relative to control2004Journal of natural products, Feb, Volume: 67, Issue:2
Biological activity and chemistry of taxoids from the Japanese yew, Taxus cuspidata.
AID302389Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID725336Cell cycle arrest in human CAL33 cells assessed as accumulation at S phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID302406Cell cycle arrest in human A549 cells assessed as accumulation at sub Go phase at 0.1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID274820Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 3.16 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID616513Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
AID274817Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 0.1 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID478006Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID131823Increase in life span at the highest nontoxic dose against P-388 tumor cell after 1-9 day at 0.33 mg/kg1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines).
AID1360498Growth inhibition of human SMMC7721 cells at 2.5 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID662224Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID347995Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 3.16 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1906189Binding affinity to beta-tubulin colchicine binding site in human HeLa cells assessed as inhibition of EBI-beta-tubulin adduct formation measured at 5 to 25 uM incubated for 2 hrs followed by addition of EBI measured after 1.5 hrs by EBI competition based
AID227573Relative resistance is the ratio of IC50 values of drug with JTV-519 to that without the reversing agent2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID274832Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 316 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID616511Cytotoxicity against adriyamycin-resistant human MCF7 cells over expressing P-glycoprotein after 72 hrs by SRB assay2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
AID354543Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID780985Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
AID478018Antiproliferative activity against human KB/VCR cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID94097Mitotic index (fraction of cells in mitosis divided by total cells ) for cultured lymphoid leukemia L1210 cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
New anticancer agents: alterations of the carbamate group of ethyl (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)car bamates.
AID1126634Anticancer activity against human NCI-H157 cells at 10 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID137496Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 1 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID214333The compound tested for the inhibition of tubulin polymerization.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity.
AID302395Cytotoxicity against human OE33 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID362794Cytotoxicity against vincristine resistant human KB/VJ300 cells2008Journal of natural products, Sep, Volume: 71, Issue:9
Jerantinines A-G, cytotoxic Aspidosperma alkaloids from Tabernaemontana corymbosa.
AID189629The capillary permeability of radioligand was measured in Rat brain1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID132706Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 4.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID303718Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 0.1 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID604379Cell cycle arrest in human HCT116 cells assessed as increase of phosphorylated histone H3 at Ser10 level at 150 nM after 24 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID263818Cytotoxicity against human PA1 cells by MTT assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID263814Cytotoxicity against human WRL68 cells by MTT assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID261533Cytotoxicity against human HepG2 cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID261542Cytotoxicity against mouse BNL cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1189147Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID586587Growth inhibition of dog MDCK2-MDR1 cells overexpressing human P-glycoprotein2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1190828Cytotoxicity against human KB/VCR cells after 72 hrs by SRB method2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Multidrug resistance-reversal effects of resin glycosides from Dichondra repens.
AID312971Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.
AID659302Cytotoxicity against human KB cells at 4 uM after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Anti-AIDS agents 89. Identification of DCX derivatives as anti-HIV and chemosensitizing dual function agents to overcome P-gp-mediated drug resistance for AIDS therapy.
AID586589Growth inhibition of dog MDCK2-MDR1 cells overexpressing human P-glycoprotein in presence of P-glycoprotein inhibitor LY3359792011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID1221970Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID771209Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID604368Cell cycle arrest in human HCT116 cells assessed as accumulation at G0/G1 phase at 150 nM after 24 hrs by FACS analysis (Rvb = 76.5 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID725098Cell cycle arrest in human CAL33 cells assessed as accumulation at G2 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID302405Cell cycle arrest in human A549 cells assessed as accumulation at sub Go phase at 1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID291930Cytotoxicity against human ZR751cells by SRB microtiter plate assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
AID1431458Cytotoxicity against human CCRF-CEM/VBL cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID1185441Antiproliferative activity against human KB-S15 cells2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents.
AID679134TP_TRANSPORTER: drug resistance in KB-TAX50 cells2004Cancer research, Jul-01, Volume: 64, Issue:13
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
AID365697Inhibition of Agrobacterium tumefaciens-induced tumor growth in potato tuber disk after 21 days2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID103092Cytotoxicity against MCF-7/Adr cells.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells.
AID1317646Induction of apoptosis in human MCF7 cells assessed as necrotic cells after 24 to 48 hrs by Annexin V/7-AAD staining based flow cytometry (Rvb = 6.75 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID137820Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID261532Cytotoxicity against human HeLa cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID263816Cytotoxicity against human KB cells by MTT assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1905036Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID1185442Antiproliferative activity against human KB-7d cells2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents.
AID580240Antiproliferative activity against human 1A9 cells after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID412965Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
AID362793Cytotoxicity against vincristine sensitive human KB/S cells2008Journal of natural products, Sep, Volume: 71, Issue:9
Jerantinines A-G, cytotoxic Aspidosperma alkaloids from Tabernaemontana corymbosa.
AID687164Ratio of IC50 for doxorubicin-resistant human K562 cells to IC50 for human K562 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1452457Inhibition of tubulin (unknown origin) polymerization by fluorescence assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance.
AID661468Cytotoxicity against mouse astrocytes assessed as decrease in cell viability at 1 to 10 uM after 48 hrs by propidium iodide incorporation assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
AID1514569Resistance ratio of IC50 for human KBV cells to IC50 for human KB cells2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Seco-4-methyl-DCK derivatives as potent chemosensitizers.
AID247260Compound was tested for growth inhibition of human colon carcinoma HCT116 cell line2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Novel diarylsulfonylurea derivatives as potent antimitotic agents.
AID392698Cytotoxicity against human MCF7 cells2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis and SAR of vinca alkaloid analogues.
AID662217Antiproliferative activity against human SNU398 cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID272494Antiproliferative activity against P388 cells by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID101573Inhibitory activity against growth of MCF-7 cell line1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
AID699542Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1899075Resistant index, ratio IC50 for K562/Adr cells over IC50 for K562 cells
AID303701Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 0.3 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1887848Resistance index, ratio of IC50 for antiproliferative activity against vincristine resistant human HCT-8/VCR cells to IC50 for antiproliferative activity against human HCT-8 cells2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
AID288990Effect on cell morphology in human U87 cells assessed as disruption of microtubule network and loss of function at 10 nM after 3 hrs2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells.
AID272516Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant P388 cells2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID290590Ratio of IC50 for KB8.5 cells to IC50 for KB V1 cells2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization.
AID1189151Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID681616TP_TRANSPORTER: drug resistance in MDR1-expressing MCF7 cells2003Pharmaceutical research, Jan, Volume: 20, Issue:1
Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents.
AID449568Cytotoxicity against human HepG2 cells by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Synthesis of gibberellin derivatives with anti-tumor bioactivities.
AID274826Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 0.3 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID725340Cell cycle arrest in human HL60 cells assessed as accumulation at sub-G1 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID411442Antiproliferative activity against human KB cells after 3 days by SRB assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
AID725342Cell cycle arrest in human CAL33 cells assessed as accumulation at sub-G1 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID1239259Induction of microtubule destabilization in human A549 cells at 1 uM after 24 hrs by DAPI staining-based immunofluorescence confocal microscopic analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling.
AID604381Cell cycle arrest in human HCT116 cells assessed as increase of phosphorylated histone H3 at Ser10 level at 150 nM after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 1.4 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID404813Effect on cell morphology in human U87 MG cells assessed as disruption of microtubule network at 10 nM by confocal fluorescence microscopy2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Aroyl hydrazones of 2-phenylindole-3-carbaldehydes as novel antimitotic agents.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID662225Antiproliferative activity against human JHH2 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1564918Binding affinity to tubulin (unknown origin) assessed as reduction in alpha-C fragment production at 100 uM after 30 mins by coomassie brilliant blue staining based trypsin proteolysis assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID404265Inhibition of beta tubulin polymerization at 20 uM2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Benzoylurea derivatives as a novel class of antimitotic agents: synthesis, anticancer activity, and structure-activity relationships.
AID137655Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 1 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1354579Growth inhibition of human KB/VJ300 cells after 72 hrs by MTT assay2018Journal of natural products, 05-25, Volume: 81, Issue:5
Ajmaline, Oxindole, and Cytotoxic Macroline-Akuammiline Bisindole Alkaloids from Alstonia penangiana.
AID302085Cell cycle arrest in MDA-MB-231 cells by accumulation at G2/M phase at 0.01 uM after 24 hrs by flow cytometry2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
[(2-Phenylindol-3-yl)methylene]propanedinitriles inhibit the growth of breast cancer cells by cell cycle arrest in G(2)/M phase and apoptosis.
AID137797Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 1.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1327084Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents.
AID1905057Resistance index, ratio of IC50 for antiproliferative activity against human adriamycin-resistant A549/ADR cells to IC50 for antiproliferative activity against human A549 cells2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID397122Inhibition of HIV1 RT
AID687168Ratio of IC50 for human CCRF-CEM/VLB100 cells IC50 for human CCRF-CEM cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1564921Selectivity index, ratio of IC50 for human KBtax cells to IC50 for human KB cells2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID1386569Cell cycle arrest in human PANC1 cells assessed as accumulation at S phase at 100 nM after 18 hrs by Hoechst 33342 staining based FACS analysis (Rvb = 11.1%)
AID348001Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 31.6 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1495279Antiproliferative activity against human K562/VCR cells after 72 hrs by CCK8 assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID334033Cytotoxicity against human CCRF-CEM cells1997Journal of natural products, Nov, Volume: 60, Issue:11
Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID634823Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID155859Compound was evaluated for in vitro growth inhibition activity against multi drug resistant (MDR) PC-12 cell line.1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells.
AID135632Number of survivors on 60th day at dose 1.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID729780Cytotoxicity against human KB cells after 72 hrs by SRB assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
AID303703Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 3.16 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID137816Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 5.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1063555Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Synthesis and biological evaluation of 6H-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5(6H)-ones as antimitotic agents and inhibitors of tubulin polymerization.
AID1221976Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID261548Microtubule disassembly in Ovcar3 cells at 5 uM2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID1564924Antiproliferative activity against human CCRF-CEM/VBL cells assessed as reduction in cell viability after 72 hrs by MTS assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID1481839Antiproliferative activity against human KB/VCR cells after 72 hrs by SRB assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression.
AID94355Antiproliferative activity against drug-resistant tumor cell line KB7D.1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity.
AID347117Cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 30 nM after 24 hrs by flow cytometry2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events.
AID303699Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID251633Compound was tested for inhibition of tubulin polymerisation at 1 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Novel diarylsulfonylurea derivatives as potent antimitotic agents.
AID449567Cytotoxicity against human A549 cells by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Synthesis of gibberellin derivatives with anti-tumor bioactivities.
AID274810Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 0.3 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1269621Inhibition of bovine MAP rich tubulin polymerization at 1 uM measured every 2 mins for 30 mins by UV-visible spectrophotometric analysis2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
AID420973Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Synthesis and biological evaluation of abietic acid derivatives.
AID360087Cytotoxicity against hamster BHK21 cells after 72 hrs by MTT assay2007The Journal of biological chemistry, Oct-26, Volume: 282, Issue:43
(R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1.
AID303724Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 100 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID587603Antiproliferative activity against human DU145 cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID132709Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 4 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1126636Anticancer activity against human NCI-H157 cells at 0.1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID303704Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 10 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID347987Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 0.3 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1177861Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
AID1455044Antiproliferative activity against human KB/VCR cells after 72 hrs by sulforhodamine B assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID411443Antiproliferative activity against human KB 8.5 cells after 3 days by SRB assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID303710Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 0.3 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID347994Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 3.16 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1183748Cell cycle arrest in human HepG2 cells at 500 to 2000 nM incubated for 24 hrs followed by compound washout measured after 24 hrs2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
AID771191Antitumor activity against mouse H22 cells allografted in KM mouse assessed as tumor growth inhibition at 0.25 mg/kg, ip administered on day 1 and 4 measured on day 8 relative to control2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID94356Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID400174Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 10 ug/disk after 12 days by potato disk assay
AID771190Antitumor activity against mouse H22 cells allografted in KM mouse assessed as tumor growth inhibition at 0.5 mg/kg, ip administered on day 1 and 4 measured on day 8 relative to control2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID681609TP_TRANSPORTER: drug resistance in MRP1-expressing PEAKSTABEL cells2003Molecular cancer therapeutics, Mar, Volume: 2, Issue:3
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey.
AID1320990Cell cycle arrest in human HCC1428 cells assessed as accumulation at G1 phase at 1 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 69.83%)2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors.
AID1211862Unbound biliary clearance in iv dosed human after 72 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID272510Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1125808Cytotoxicity against human VP16-resistant KB-7d cells overexpressing MRP after 72 hrs by methylene blue assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones.
AID261534Cytotoxicity against human H295R cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID1899068Antiproliferative activity against human KB cells measured after 72 hrs by SRB assay
AID609239Cytotoxic activity against drug-sensitive Pgp-, MRP1-deficient human MCF7 cells after 48 hrs by sulforhodamine B assay in presence of 50 nM vinblastin2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.
AID678899TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse1996Journal of the National Cancer Institute, Jul-17, Volume: 88, Issue:14
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
AID681132TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID98163Concentration that inhibits proliferation of cultured lymphoid leukemia L1210 cells to 50% control growth during 48 h1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Antimitotic agents: ring analogues and derivatives of ethyl [(S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7- yl]carbamate.
AID1700532Binding affinity to beta-tubulin in mouse 518T2 cells at 0.1 to 50 uM measured after 1.5 hrs using Alexa Fluor 532 dye by copper-mediated click reaction based SDS PAGE analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
A Multipronged Approach Establishes Covalent Modification of β-Tubulin as the Mode of Action of Benzamide Anti-cancer Toxins.
AID137629Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 2 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID137484Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2.7 mg/kg/day; 0/111985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132215Percent increase in life span at dose 0.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID132359Percent increase in life span at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID367229Cell cycle arrest in human CEM cells assessed as accumulation at G2/M phase at 3.2 uM after 12 hrs by flow cytometry2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and activity evaluation of benzoylurea derivatives as potential antiproliferative agents.
AID132716Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 6.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID291927Cytotoxicity against human A549 cells by SRB microtiter plate assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
AID132346Percent increase in life span at dose 1 mg/kg/day in 10 mice implanted with P388 leukemia cell line1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID642528Growth inhibition of human KB cells after 72 hrs by methylene blue assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
AID662233Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID347992Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 1 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID94498Antiproliferative activity against drug-resistant tumor cell line KBCamp.1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID687157Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID275870Induction of apoptosis in HeLa cells assessed as effect on sub-G1 population2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
AID132544Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia cells intraperitoneally at a dose of 0.22 mg/kg per day for 1-9 scheduled days1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID611277Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID137632Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 3 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1691084Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved PARP expression at 0.1 uM measured after 48 hrs by Western blot analysis
AID1905056Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID132550Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intraperitoneally at a dose of 2 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1733062Cytotoxicity against human L02 cells assessed as cell viability after 24 hrs by MTT assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Synthesis of artemisinin-piperazine-furan ether hybrids and evaluation of in vitro cytotoxic activity.
AID263820Cytotoxicity against human Colo320DM cells by MTT assay2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities.
AID299210Inhibition of tubulin polymerization at 20 uM2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID1691086Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved caspase-8 expression at 0.1 uM measured after 48 hrs by Western blot analysis
AID634824Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors.
AID51924Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID348007Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 316 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID227402Chemosensitizing index is the ratio of IC50 (vincristine) to that of IC50 (vincristine+sinensetin)2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID1360499Growth inhibition of human SMMC7721 cells at 5 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID292435Cytotoxicity against HT29 cells after 48 hrs by MTT assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Stellettins L and M, cytotoxic isomalabaricane-type triterpenes, and sterols from the marine sponge Stelletta tenuis.
AID662230Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1906328Binding affinity to beta-tubulin colchicine binding site in human HeLa cells assessed as decrease of adduct formation by measuring gray value measured at 5 uM incubated for 2 hrs followed by addition of EBI measured after 1.5 hrs by EBI competition based
AID586594Growth inhibition of pig L-MDR1 cells overexpressing human P-glycoprotein in presence of P-glycoprotein inhibitor LY3359792011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID153671In vitro inhibitory concentration required against murine P388 leukemic cells proliferation2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle.
AID272511Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID311084Cytotoxicity against human KB cells2007Journal of natural products, Aug, Volume: 70, Issue:8
Leuconoxine, kopsinitarine, kopsijasmine, and kopsinone derivatives from Kopsia.
AID580241Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID272512Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant MDA435/LCC6 cells2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1514560Potentiation of paclitaxel-induced cytotoxicity against human A2780/TAX cells assessed as paclitaxel IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 3970 nM)2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Seco-4-methyl-DCK derivatives as potent chemosensitizers.
AID662251Cell cycle arrest in human SNU398 cells assessed as accumulation at G1 phase after 24 hrs by FACS analysis (Rvb = 55.8%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1694423Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
AID662227Antiproliferative activity against human JHH7 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID302394Cytotoxicity against human OE19 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID383222Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at S phase at 1 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID347983Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1887835Antiproliferative activity against human HCT-8 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
AID303714Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 31.6 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1564920Antiproliferative activity against human KBtax cells assessed as reduction in cell viability after 72 hrs by MTS assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID137978Number of survivors on 30th day at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1612618Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID274829Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 10 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID606221Cytotoxicity in vincristine-resistant human KB/VJ300 cells in presence of 0.1 ug/ml vincristine2011Journal of natural products, May-27, Volume: 74, Issue:5
Grandilodines A-C, biologically active indole alkaloids from Kopsia grandifolia.
AID616510Cytotoxicity against vincristine-resistant human KB cells over expressing P-glycoprotein after 72 hrs by SRB assay2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
AID348166Cytotoxicity against human MDA-MB-231 cells after 48 hrs by alamar blue assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Design, synthesis and biological evaluation of novel stilbene-based antitumor agents.
AID408771Cytotoxicity against human KB cells by sulforhodamine B assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
AID1617118Antiproliferative activity against human KB/VJ300 cells assessed as reduction in cell growth after 72 hrs by MTT assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Macroline-Sarpagine Bisindole Alkaloids with Antiproliferative Activity from
AID662222Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID580244Antiproliferative activity against human KBVIN cells expressing P-glycoprotein after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID1677375Cytotoxicity against human PBL assessed as reduction in cell viability in presence of mitogenic stimulus phytohaemagglutinin incubated for 72 hrs by MTT assay
AID1347478Cytotoxicity against golden hamster BHK21 cells at 1 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID367226Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and activity evaluation of benzoylurea derivatives as potential antiproliferative agents.
AID410696Cytotoxicity against human Jurkat cells in presence and relative to TRAIL2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
TRAIL-enhancing activity of Erythrinan alkaloids from Erythrina velutina.
AID135650Number of survivors on 60th day at dose 2 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID771215Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID303716Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 316 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID662256Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at sub-G1 phase after 24 hrs by FACS analysis (Rvb = 1.4%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1431463Cytotoxicity against human NCI-H211 cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID292433Cytotoxicity against SMMC7721 cells after 48 hrs by MTT assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Stellettins L and M, cytotoxic isomalabaricane-type triterpenes, and sterols from the marine sponge Stelletta tenuis.
AID332254Cytotoxicity against CHO cells after 48 hrs by MTT assay2002Journal of natural products, Feb, Volume: 65, Issue:2
Cytotoxic effect (on tumor cells) and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes.
AID132710Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 5.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID8894Synergism with sulindac in A549 cells2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1564923Selectivity index, ratio of IC50 for human KB/VCR cells to IC50 for human KB cells2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID642531Growth inhibition of human KB-VIN10 cells after 72 hrs by methylene blue assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
AID306139Cytotoxicity againt multidrug-resistant human 2780AD cells2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Structure-activity relationships of some taxoids as multidrug resistance modulator.
AID355583Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID510638Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and biological evaluation of (+)-labdadienedial, derivatives and precursors from (+)-sclareolide.
AID1785485Inhibition of EBI binding to beta tubulin in human A2780S cells at 5 to 25 uM preincubated for 2 hrs followed by addition of EBI and measured after 2 hrs by western blot assay
AID1758196Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in vincristine IC50 at 5 uM incubated for 48 hrs by CCK-8 assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
AID1221975Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID616508Drug resistance index, ratio of IC50 for adriyamycin-resistant human MCF7 cells to IC50 for human MCF7 cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
AID357846Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method
AID662252Cell cycle arrest in human SNU398 cells assessed as accumulation at G2 phase after 24 hrs by FACS analysis (Rvb = 38.2%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID274830Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 31.6 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1126632Anticancer activity against Syrian golden hamster BHK21 cells at 0.1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID404805Antiproliferative activity against human MCF7 cells after 5 days by microplate assay2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Aroyl hydrazones of 2-phenylindole-3-carbaldehydes as novel antimitotic agents.
AID261540Cytotoxicity against human PT45 cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID586590Ratio of GI50 for dog MDCK2-MDR1 cells overexpressing human P-glycoprotein to GI50 for dog MDCK2 cells2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID587607Antiproliferative activity against human KBVIN cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID586595Ratio of GI50 for pig L-MDR1 cells overexpressing human P-glycoprotein to GI50 for pig LLC-PK1 cells2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID1189154Drug resistance index, ratio of IC50 for cis-platinum-resistant human A549 cells to IC50 for human A549 cells2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID137637Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 4 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID153936Long-term survivors (LTS) for 60 days at optimal dose of 3.0 mg/kg for antitumor activity against P388 leukemia cells in 15 mice.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID133209Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 0.2 mg/Kg in the presence of vincristine at 0.1 mg/kg as range.1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew.
AID1211843Total biliary clearance in iv dosed human after 72 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1564922Antiproliferative activity against human KB/VCR cells assessed as reduction in cell viability after 72 hrs by MTS assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID1612620Drug resistance index, ratio of IC50 for taxol-resistant human HCT8/T cells to IC50 for human HCT8 cells2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID291495Growth inhibition of NCI/ADR cells expressing Pgp/MRP12007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.
AID1455043Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties.
AID1070470Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTitre-Blue assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Simplified pretubulysin derivatives and their biological effects on cancer cells.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID138176Compound was evaluated for antitumor activity in P388/VCR-bearing mice at 0.2 mg/Kg in the presence of vincristine at 0.1 mg/kg as percent ratio of median survival time of treated mice to control mice1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew.
AID355586Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID1441903Cell cycle arrest in human HCC1428 cells assessed as accumulation at G2/M phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12.93%)2017European journal of medicinal chemistry, Mar-31, Volume: 129Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents.
AID291494Growth inhibition of Pgp deficient MCF7 cells expressing MRP12007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.
AID348003Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 100 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1355103Resistance ratio of IC50 for human KBV cells to IC50 for human KB cells
AID261539Cytotoxicity against human HT29 cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID137829Number of survivors on 30th day at dose 0.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID94510Antiproliferative activity against drug-resistant tumor cell line KBV20C.1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity.
AID725339Cell cycle arrest in human CAL33 cells assessed as accumulation at G1 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID272491Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1189155Drug resistance index, ratio of IC50 for doxorubicin-resistant human MCF7 cells to IC50 for human MCF7 cells2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID1347525Antitumor activity against Agrobacterium tumefaciens-induced tumor after 21 days by potato disc bioassay technique2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID288984Antiproliferative activity against human MDA-MB-231 cells after 4 days2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells.
AID662254Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at G1 phase after 24 hrs by FACS analysis (Rvb = 66.8%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1347472Cytotoxicity against human NCI-H157 cells at 100 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID613827Ratio of IC50 for vinblastine100-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
AID85754In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
O-Phosphonatomethylcholine, its analogues, alkyl esters, and their biological activity.
AID431396Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1431457Cytotoxicity against human CCRF-CEM cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID137831Number of survivors on 30th day at dose 1.5 mg/kg/day in 10 mice implanted with P388 leukemia cell line; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID661469Cytotoxicity against mouse astrocytes assessed as decrease in cell viability at 0.1 uM after 48 hrs by neutral red incorporation assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
AID1126629Anticancer activity against Syrian golden hamster BHK21 cells at 100 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1267187Displacement of [3H]-vinblastine from biotinylated porcine tubulin after 15 mins by competitive binding assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID1354578Growth inhibition of human KB/S cells after 72 hrs by MTT assay2018Journal of natural products, 05-25, Volume: 81, Issue:5
Ajmaline, Oxindole, and Cytotoxic Macroline-Akuammiline Bisindole Alkaloids from Alstonia penangiana.
AID515577Anticancer activity against vincristine-resistant human Hep3B cells after 3 days by SRB assay2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues.
AID1317639Cell cycle arrest in human MCF7 cells assessed as accumulation at sub-G0 phase at 0.5 uM after 18 to 24 hrs by propidium iodide staining based flow cytometry (Rvb = 1.4 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID54074Drug interaction towards DLKP cell line was determined in terms of combination index in presence of Indomethacin; Not available2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID1327093Inhibition of alpha tubulin polymerization in human A549 cells at 50 nM by Hoechst 33258 staining based fluorescent microscopic analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents.
AID335776Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.032 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID400176Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 2.5 ug/disk after 12 days by potato disk assay
AID272514Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681596TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells2002Pharmaceutical research, Jun, Volume: 19, Issue:6
Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?
AID1691083Cell cycle arrest in human KB-VIN cells assessed as increase in accumulation at sub-G1 phase at 0.1 uM measured after 48 hrs by propidium iodide staining based flow cytometry
AID291496Growth inhibition of Pgp deficient MCF7/VP cells expressing MRP12007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.
AID302036Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines.
AID318684Cytotoxicity against human KB cells assessed as cell viability after 48 hrs by MTS assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis of curcumin mimics with multidrug resistance reversal activities.
AID1355094Antiproliferative activity against human KB cells after 48 hrs by MTT assay
AID604388Inhibition of alpha-tubulin polymerization in human HT1080 cells assessed as disruption of microtubule structures at 100 nM after 4 hrs using Hoechst staining by fluorescence microscopic analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID360086Cytotoxicity against human MRP1 expressing hamster BHK21 cells after 72 hrs by MTT assay2007The Journal of biological chemistry, Oct-26, Volume: 282, Issue:43
(R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1.
AID1691062Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved caspase-8 expression at 0.1 uM measured after 24 hrs by Western blot analysis
AID302393Cytotoxicity against human PT45 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID1481780Antiproliferative activity against human KB cells after 72 hrs by SRB assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression.
AID347985Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 0.1 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID771184Toxicity in KM mouse allografted with mouse H22 cells assessed as body weight at 0.5 mg/kg, ip administered on day 1 and 4 measured on day 8 (Rvb = 30 +/- 3.24 g)2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID410694Growth inhibition of human Jurkat cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
TRAIL-enhancing activity of Erythrinan alkaloids from Erythrina velutina.
AID420975Selectivity index, ratio of CC50 for african green monkey Vero cells to CC50 for human HeLa cells2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Synthesis and biological evaluation of abietic acid derivatives.
AID115658Compound was evaluated in vivo for antileukemic activity by calculating Percent increase in life span at dose of 2 mg/kg1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Antimitotic agents: ring analogues and derivatives of ethyl [(S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7- yl]carbamate.
AID1189150Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
AID1612610Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID247314Inhibition of human non-small cell lung cancer A549 cell proliferation2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Novel diarylsulfonylurea derivatives as potent antimitotic agents.
AID152731Compound was evaluated for antitumor activity against mice implanted with lymphatic leukemia P388 cells (10e6 tumor cells) after intraperitoneal administration of 2 mg/kg per injection (1-5 days)1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Antimitotic agents: structure-activity studies with some pyridine derivatives.
AID1691085Induction of apoptosis in human KB-VIN cells assessed as increase in cleaved caspase-3 expression at 0.1 uM measured after 48 hrs by Western blot analysis
AID1063556Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2
Synthesis and biological evaluation of 6H-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5(6H)-ones as antimitotic agents and inhibitors of tubulin polymerization.
AID586591Growth inhibition of pig LLC-PK1 cells2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.
AID302391Cytotoxicity against human A549 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1612619Antiproliferative activity against human taxol-resistant HCT8/T cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID699527Selectivity index, ratio of IC50 for human liver OATP1B1 to IC50 for OATP1B32012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID662234Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1360504Growth inhibition of human LO2 cells at 5 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID521208Antiproliferative activity against mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID291928Cytotoxicity against human KB cells by SRB microtiter plate assay2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
AID132549Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intraperitoneally at a dose of 2.7 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID84293Tested for cytotoxicity against HT-29 (wt)cells2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Molecular basis of the antitumor activities of 2-crotonyloxymethyl-2-cycloalkenones.
AID408778Cytotoxicity against human PC3 cells by sulforhodamine B assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
AID302407Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 0.1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID355582Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1514564Reversal ratio of IC50 for cisplatin-induced cytotoxicity against human A2780/CDDP cells in absence of compound to IC50 for cisplatin-induced cytotoxicity against human A2780/CDDP cells in presence of compound2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Seco-4-methyl-DCK derivatives as potent chemosensitizers.
AID687160Ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID729777Cytotoxicity against human KB-VIN10 cells after 72 hrs by SRB assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
AID137657Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intraperitoneally at a dose of 2.7 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID1413122Antiproliferative activity against human WM9 cells after 48 hrs by MTT assay2018MedChemComm, Jul-01, Volume: 9, Issue:7
Design, synthesis and bioactivity investigation of tetrandrine derivatives as potential anti-cancer agents.
AID290583Cytotoxicity against COLO205 cells2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization.
AID592817Inhibition of pig tubulin polymerization at 3 uM2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Inhibitors and promoters of tubulin polymerization: synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents.
AID137808Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 2 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID302403Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 0.1 uM after 24 hrs2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines.
AID261535Cytotoxicity against human Ovcar3 cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID604370Cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at 150 nM after 24 hrs by FACS analysis (Rvb = 8.5 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID1185440Antiproliferative activity against human KB-VIN10 cells2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents.
AID661470Cytotoxicity against mouse astrocytes assessed as decrease in cell viability at 0.1 uM after 48 hrs by propidium iodide incorporation assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
AID1612624Drug resistance index, ratio of IC50 for VCR-resistant human K562/VCR cells to IC50 for human K562 cells2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID725341Cell cycle arrest in human HT-29 cells assessed as accumulation at sub-G1 phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID1778140Cytotoxicity against human vincristine-sensitive KB cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
The Bisindole Alkaloids Angustilongines M and A from
AID94335Compound was evaluated for its cytotoxicity against vincristine-resistant KB/VJ300 human oral epidermoid carcinoma cell lines.1998Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13
Conodiparines A-D, new bisindoles from Tabernaemontana. Reversal of vincristine-resistance with cultured cells.
AID275845Antiproliferative activity against KB cells expressing MDR12007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
AID392699Cytotoxicity against human HeLa cells2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis and SAR of vinca alkaloid analogues.
AID687162Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1495280Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID422062Cytotoxicity against multidrug-resistant human KB/VCR cells by SRB assay in presence of MDR reversing agent verapamil2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID94181Cytotoxicity was evaluated against KB-C2 cells at 0.1 ug/mL; No cytotoxicity2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Synthesis and evaluation of 4-deacetoxyagosterol A as an MDR-modulator.
AID132568Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 2 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID274822Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 31.6 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID587606Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.
AID1577678Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 48 hrs by SRB assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID613826Ratio of IC50 for homoharringtonine300-resistant human K562 cells to IC50 for human K562 cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
AID400178Antitumor activity against mouse P388 cells xenografted mouse assessed as increase in life span relative to control
AID137665Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 0.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID679221TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, Vincristine: 30 uM) in membrane vesicles from MRP7-expressing HEK293 cells2003Molecular pharmacology, Feb, Volume: 63, Issue:2
Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
AID1691100Induction of microtubule disruption in human KB7D cells assessed as polymerized fraction at 0.01 uM measured after 16 hrs by SDS-PAGE analysis (Rvb = 26.4 to 29%)
AID1691064Induction of apoptosis in human KB-VIN cells assessed as increase in activated gammaH2AX expression at 0.1 uM measured after 24 hrs by Western blot analysis
AID1887845Antiproliferative activity against vincristine resistant human HCT-8/VCR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
AID1317645Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells after 24 to 48 hrs by Annexin V/7-AAD staining based flow cytometry (Rvb = 16.05 %)2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID274815Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 100 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1564839Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTS assay2019European journal of medicinal chemistry, Nov-01, Volume: 1814(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
AID771207Cytotoxicity against human MX1 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID725100Cell cycle arrest in human HT-29 cells assessed as accumulation at S phase at 0.5 uM after 24 hrs flow cytometry2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives.
AID1691098Induction of microtubule disruption in human KB-VIN cells assessed as polymerized fraction at 0.1 uM measured after 16 hrs by SDS-PAGE analysis (Rvb = 23.1 to 25.5%)
AID1612622Drug resistance index, ratio of IC50 for taxol-resistant human A549/TR cells to IC50 for human A549 cells2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID1239257Inhibition of porcine tubulin polymerization at 10 uM measured every min for 30 mins by spectrophotometric analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling.
AID137634Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 4.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID274828Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 3.16 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID9049Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID335772Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 20 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID1733061Cytotoxicity against human SMMC-7721 cells assessed as cell viability after 24 hrs by MTT assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Synthesis of artemisinin-piperazine-furan ether hybrids and evaluation of in vitro cytotoxic activity.
AID1760388Antiproliferative activity against human K562/VCR cells incubated for 72 hrs by CCK8 method2020European journal of medicinal chemistry, Dec-15, Volume: 208Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID94511Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID771206Cytotoxicity against taxol-resistant human MX1 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID1254791Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel spirobicyclic artemisinin analogues (artemalogues): Synthesis and antitumor activities.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID275848Ratio of IC50 for KB8.5 cells to IC50 for KB cells2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition.
AID1169798Cytotoxicity against vincristine-sensitive human KB cells2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Cytotoxic vobasine, tacaman, and corynanthe-tryptamine bisindole alkaloids from Tabernaemontana and structure revision of tronoharine.
AID1899071Antiproliferative activity against human KB-V1 cells measured after 72 hrs by SRB assay
AID1221968Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1612623Antiproliferative activity against human VCR-resistant K562/VCR cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
AID335773Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 4 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID780975Cytotoxicity against human KB-7d cells overexpressing MRP assessed as growth inhibition after 72 hrs by methylene blue staining-based assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
AID1905060Resistance index, ratio of IC50 for antiproliferative activity against human paclitaxel-resistant A2780/TAX cells to IC50 for antiproliferative activity against human A2780 cells2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
AID347990Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 1 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID354541Inhibition of tubulin polymerization in rat C6 cells after 4 hrs1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID1617117Antiproliferative activity against human KB/S cells assessed as reduction in cell growth after 72 hrs by MTT assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Macroline-Sarpagine Bisindole Alkaloids with Antiproliferative Activity from
AID261538Cytotoxicity against human A549 cells by MTT assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.
AID1360500Growth inhibition of human LO2 cells at 0.01 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID1691101Induction of microtubule disruption in human KB7D cells assessed as polymerized fraction at 0.1 uM measured after 16 hrs by SDS-PAGE analysis (Rvb = 26.4 to 29%)
AID355584Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1360489Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID137821Number of survivors of DBA2 mice on 60th day after inoculation with L1210 leukemia cell line intravenously at a dose of 6.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID679133TP_TRANSPORTER: drug resistance in KB-VIN10 cells2004Cancer research, Jul-01, Volume: 64, Issue:13
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
AID348000Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 31.6 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1691093Induction of microtubule disruption in human KB-VIN cells at 1 uM measured after 24 hrs by DAPI staining based deconvolution fluorescence microscopic analysis
AID98513Tested for the inhibition of L1210 cell proliferation.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
New alpha-amino phosphonic acid derivatives of vinblastine: chemistry and antitumor activity.
AID604384Induction of apoptosis in human HCT116 cells at 150 nM after 48 hrs using FITC-TUNEL staining by flow cytometry (Rvb = 7.3 %)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
AID132705Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 3 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID679495TP_TRANSPORTER: efflux in Mrp1-expressing HEK293 cells1997Molecular pharmacology, Sep, Volume: 52, Issue:3
Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells.
AID1899070Resistant index, ratio IC50 for KB/VCR cells over IC50 for KB cells
AID1691102Induction of microtubule disruption in human KB7D cells assessed as polymerized fraction at 1 uM measured after 16 hrs by SDS-PAGE analysis (Rvb = 26.4 to 29%)
AID1370622Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Cytotoxicity and inhibition of leukemic cell proliferation by sesquiterpenes from rhizomes of Mah-Lueang (Curcuma cf. viridiflora Roxb.).
AID680789TP_TRANSPORTER: intracellular accumulation in MRP2-expressing LLC PK1 cells1999Molecular pharmacology, Dec, Volume: 56, Issue:6
Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
AID1694422Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
AID780976Cytotoxicity against human KB-S15 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
AID580242Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID1308558Resistance index, ratio of IC50 for human HCT8/VCT cells to IC50 for human HCT8 cells2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID335771Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 100 ug/mL1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic constituents from Hyptis verticillata.
AID290587Antiproliferative activity against KB8.5 cells2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization.
AID1431459Cytotoxicity against human HCT116 cells assessed as decrease in cell proliferation after 72 hrs by Alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
AID274821Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 10 nM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID680268TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Vincristine: 200 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID1312221Growth inhibition of human NCI-H157 cells at 100 uM after 48 hrs by SRB assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Solution-phase microwave assisted parallel synthesis, biological evaluation and in silico docking studies of N,N'-disubstituted thioureas derived from 3-chlorobenzoic acid.
AID580243Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID580239Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Mar-01, Volume: 19, Issue:5
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
AID311085Cytotoxicity against human KB/VJ300 cells2007Journal of natural products, Aug, Volume: 70, Issue:8
Leuconoxine, kopsinitarine, kopsijasmine, and kopsinone derivatives from Kopsia.
AID771214Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.
AID1166301Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
AID132564Percent increase in life span of DBA2 mice after inoculation with L1210 leukemia intravenously at a dose of 2.5 mg/kg per day1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID356664Cytotoxicity against human HO8910 cells by MTT assay2003Journal of natural products, Dec, Volume: 66, Issue:12
Xanthanolides, germacranolides, and other constituents from Carpesium longifolium.
AID1321000Induction of microtubule depolymerization in human HCC1428 cells at 1 uM after 24 hrs by DAPI staining-based confocal microscopic method2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and biological evaluation of novel macrocyclic bisbibenzyl analogues as tubulin polymerization inhibitors.
AID1347479Cytotoxicity against golden hamster BHK21 cells at 0.1 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Newly designed organotin(IV) carboxylates with peptide linkage: Synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations.
AID1360497Growth inhibition of human SMMC7721 cells at 0.5 ug/ml after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological activities of dithiocarbamates containing 2(5H)-furanone-piperazine.
AID411446Ratio of IC50 for human KBV1 cells to IC50 for human KB cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
AID1177863Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach.
AID1308544Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.
AID302074Antiproliferative activity against human MDA-MB-231 cells after 4 days by microplate assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
[(2-Phenylindol-3-yl)methylene]propanedinitriles inhibit the growth of breast cancer cells by cell cycle arrest in G(2)/M phase and apoptosis.
AID411441Antiproliferative activity against human COLO205 cells after 24 hrs by MTS assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
AID1691034Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1070461Induction of apoptosis in human CCRF-CEM VCR/R cells at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Simplified pretubulysin derivatives and their biological effects on cancer cells.
AID1239591Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Nocarbenzoxazoles A-G, Benzoxazoles Produced by Halophilic Nocardiopsis lucentensis DSM 44048.
AID1317630Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay2016European journal of medicinal chemistry, Sep-14, Volume: 120N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.
AID683251Inhibition of MAP rich tubulin polymerization in bovine brain at 1 uM after 5 mins by spectrophotometric analysis2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies.
AID137490Number of survivors of DBA2 mice on 30th day after inoculation with L1210 leukemia cell line intravenously at a dose of 1.5 mg/kg/day; 0/101985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.
AID355585Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID292434Cytotoxicity against AGS cells after 48 hrs by MTT assay2007Journal of natural products, Jul, Volume: 70, Issue:7
Stellettins L and M, cytotoxic isomalabaricane-type triterpenes, and sterols from the marine sponge Stelletta tenuis.
AID687163Ratio of IC50 for doxorubicin-resistant human HL60 cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID303721Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 3.16 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID449566Cytotoxicity against human HT-29 cells by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Synthesis of gibberellin derivatives with anti-tumor bioactivities.
AID347998Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 10 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1899074Antiproliferative activity against human K562/Adr cells measured after 72 hrs by SRB assay
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1441892Inhibition of bovine brain tubulin polymerization at 5 uM measured every 1 min for 1 hr by spectrophotometric method2017European journal of medicinal chemistry, Mar-31, Volume: 129Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents.
AID303713Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 10 nM after 24 hrs by flow cytometric analysis2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID383221Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at G0/G1 phase at 1 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID478016Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID347991Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 1 nM after 24 hrs by FACS analysis2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1514561Potentiation of cisplatin-induced cytotoxicity against human A2780/CDDP cells assessed as cisplatin IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 43.11 nM)2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Seco-4-methyl-DCK derivatives as potent chemosensitizers.
AID87758Cytotoxicity tested against Hela T5 cells1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (240)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (2.50)18.7374
1990's23 (9.58)18.2507
2000's77 (32.08)29.6817
2010's111 (46.25)24.3611
2020's23 (9.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 87.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index87.19 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index153.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (87.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews8 (3.25%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other238 (96.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (990)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's [NCT01925131]Phase 150 participants (Actual)Interventional2014-06-13Completed
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma [NCT00075582]Phase 3390 participants (Actual)Interventional2004-09-04Completed
Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma: A Randomized, Controlled, Phase III Comparative Trial [NCT00088530]Phase 3140 participants (Actual)Interventional2004-07-31Completed
Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00041132]Phase 256 participants (Actual)Interventional2002-09-30Completed
ALinC 17, Classification ©), B-precursor Induction Treatment (I) [NCT01225874]3,762 participants (Actual)Interventional1999-12-31Completed
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome [NCT00074490]Phase 2442 participants (Actual)Interventional2004-01-01Terminated(stopped due to Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2)
A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, Zanubrutinib, in Combination With Lenalidomide Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma [NCT05200312]Phase 236 participants (Anticipated)Interventional2022-02-01Recruiting
A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma [NCT00058422]Phase 265 participants (Actual)Interventional2003-02-10Completed
A Single Arm Trial of Systemic And Subtenon Chemotherapy For Groups C And D Intraocular Retinoblastoma [NCT00072384]Phase 330 participants (Actual)Interventional2007-04-16Completed
Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma [NCT00038142]Phase 246 participants (Actual)Interventional1997-11-30Terminated(stopped due to Low Accrual)
A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease [NCT00302003]Phase 3287 participants (Actual)Interventional2006-02-28Completed
Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma [NCT03952572]Phase 3244 participants (Anticipated)Interventional2019-05-10Recruiting
A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL) [NCT00262925]Phase 212 participants (Actual)Interventional2006-06-30Terminated(stopped due to slow accrual)
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma) [NCT00031590]Phase 230 participants (Actual)Interventional2001-04-30Terminated(stopped due to The study was terminated prematurely due to slow accrual.)
Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET [NCT01542736]Phase 28 participants (Actual)Interventional2007-05-31Completed
"A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol" [NCT00002766]Phase 3170 participants (Actual)Interventional1996-03-31Completed
A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma [NCT00027846]Phase 2378 participants (Actual)Interventional2003-08-31Completed
Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study [NCT00026208]Phase 276 participants (Actual)Interventional2001-06-30Completed
A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations [NCT05521087]Phase 180 participants (Anticipated)Interventional2024-05-29Not yet recruiting
Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin Lymphoma, Phase II [NCT00070018]Phase 246 participants (Actual)Interventional2004-02-29Completed
Two Cycles of Pad Combination (Ps-341/Bortezomib, Adriamycin, and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients [NCT01370434]Phase 243 participants (Actual)Interventional2006-07-31Completed
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System [NCT00867178]Phase 133 participants (Actual)Interventional2009-02-25Completed
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor [NCT00352534]Phase 3808 participants (Actual)Interventional2006-10-30Active, not recruiting
CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients. [NCT05844670]Phase 4100 participants (Anticipated)Interventional2023-04-20Recruiting
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors [NCT00379340]Phase 3395 participants (Actual)Interventional2007-02-26Active, not recruiting
Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas [NCT02213913]Phase 1/Phase 246 participants (Anticipated)Interventional2014-07-29Active, not recruiting
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP: a Randomized, Open, Multicenter Clinical Study [NCT05280626]Phase 2100 participants (Anticipated)Interventional2022-03-25Not yet recruiting
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [NCT03518112]Phase 26 participants (Actual)Interventional2018-04-18Terminated(stopped due to Due to Competing Studies)
A Phase II Study of R-CHOP With Intensive CNS Prophylaxis and Scrotal Irradiation in Patients With Primary Testicular Diffuse Large B-cell Lymphoma [NCT00945724]Phase 254 participants (Actual)Interventional2009-04-30Active, not recruiting
Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors [NCT00006734]Phase 3587 participants (Actual)Interventional2001-05-31Completed
A Phase II, Randomised Study of CHOP-R in Combination With Acalabrutinib Compared to CHOP-R in Patients With Newly Diagnosed Richter's Syndrome and a Platform for Initial Investigations Into Activity of Novel Treatments in Relapsed/Refractory and Newly Di [NCT03899337]Phase 2105 participants (Anticipated)Interventional2019-07-23Recruiting
A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL [NCT01287741]Phase 31,418 participants (Actual)Interventional2011-07-26Terminated(stopped due to The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.)
A Multicentre Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) [NCT04914741]Phase 1/Phase 280 participants (Actual)Interventional2021-06-29Active, not recruiting
A Phase I/II Study of RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas [NCT01198665]Phase 1/Phase 246 participants (Actual)Interventional2010-07-31Completed
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma [NCT00005780]Phase 226 participants (Actual)Interventional2000-06-01Completed
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy [NCT01871766]Phase 298 participants (Actual)Interventional2013-12-04Active, not recruiting
A Prospective Phase II Study of Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Patients With Newly Diagnosed Extra-nodal NK/T-cell Lymphoma [NCT04484506]Phase 2150 participants (Anticipated)Interventional2011-10-20Recruiting
Efficacy of Consolidative Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Limited-stage Follicular Lymphoma: Wuhan University Cancer Center -NHL01 Trial [NCT02449252]Phase 3120 participants (Anticipated)Interventional2015-10-31Recruiting
International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma [NCT01355445]Phase 2120 participants (Actual)Interventional2012-01-31Completed
Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia [NCT01358253]Phase 4100 participants (Actual)Interventional2010-12-31Completed
A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib [NCT04546620]Phase 2453 participants (Anticipated)Interventional2021-10-19Recruiting
A Single-arm, Multi-center, Phase Ib/II Study of Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients (Xplore Trial) [NCT05577364]Phase 1/Phase 254 participants (Anticipated)Interventional2022-11-01Recruiting
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy [NCT02427620]Phase 2131 participants (Anticipated)Interventional2015-06-03Active, not recruiting
Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma:a Prospective Randomized Phase III Study [NCT02359162]Phase 350 participants (Actual)Interventional2015-05-31Terminated(stopped due to The study is out of date)
Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas [NCT00069238]Phase 231 participants (Actual)Interventional2003-09-19Completed
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults With Acute Lymphoblastic Leukemia/Lymphoma [NCT03023046]Phase 254 participants (Actual)Interventional2017-02-23Completed
Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial [NCT03617432]Phase 2114 participants (Anticipated)Interventional2018-08-28Recruiting
PROTOCOL TREATMENT for Acute Lymphoblastic Leukemia Ph '(BCR / ABL) POSITIVE PATIENTS AGED> 55 YEARS [NCT01376427]100 participants (Anticipated)Interventional2007-01-31Recruiting
Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC [NCT01303887]Phase 3680 participants (Anticipated)Interventional2009-10-31Recruiting
Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018 [NCT04681417]Phase 2/Phase 3225 participants (Anticipated)Interventional2021-03-25Recruiting
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma [NCT01856192]Phase 2349 participants (Actual)Interventional2013-08-27Active, not recruiting
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00137111]Phase 3501 participants (Actual)Interventional2000-07-08Completed
Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma [NCT00133991]Phase 223 participants (Actual)Interventional2005-07-31Completed
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia [NCT03564704]Phase 2/Phase 380 participants (Anticipated)Interventional2016-02-14Recruiting
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients [NCT00392327]Phase 3379 participants (Actual)Interventional2007-03-26Active, not recruiting
Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia [NCT03613428]Phase 1/Phase 212 participants (Anticipated)Interventional2018-12-01Not yet recruiting
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma [NCT02073097]Phase 1/Phase 248 participants (Actual)Interventional2015-01-28Active, not recruiting
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma [NCT03553238]Phase 2/Phase 370 participants (Anticipated)Interventional2016-02-14Recruiting
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse [NCT04546399]Phase 2550 participants (Anticipated)Interventional2020-12-04Suspended(stopped due to Other - FDA Partial Clinical Hold)
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas [NCT01837862]Phase 1/Phase 236 participants (Anticipated)Interventional2013-10-22Recruiting
Carboplatin Periocular Injection in the Treatment for Retinoblastoma--A Single Center, Randomized Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma [NCT02137928]Phase 350 participants (Anticipated)Interventional2006-01-31Recruiting
Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years [NCT01358201]Phase 4100 participants (Anticipated)Interventional2010-05-31Recruiting
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life [NCT00911183]Phase 267 participants (Actual)Interventional2008-12-02Completed
A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) [NCT01148446]Phase 3226 participants (Actual)Interventional2003-01-31Completed
A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old C [NCT03892330]Phase 4120 participants (Anticipated)Interventional2019-06-01Not yet recruiting
A Phase II Study Of Pegylated Liposomal Doxorubicin (Doxil) In Combination With Rituxan, Cyclophosphamide, Vincristine and Prednisone (DR-COP) In Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas [NCT00184002]Phase 268 participants (Actual)Interventional2003-01-10Completed
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia [NCT04638790]Phase 3300 participants (Anticipated)Interventional2020-02-01Recruiting
A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma [NCT02043587]Phase 231 participants (Actual)Interventional2014-01-31Terminated(stopped due to Original investigator for the trial has left)
"First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at High Risk, Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation" [NCT01045889]Phase 227 participants (Actual)Interventional2007-01-31Completed
Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months) [NCT00096135]168 participants (Actual)Interventional2004-11-30Completed
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With [NCT03003520]Phase 246 participants (Actual)Interventional2017-02-28Completed
A Phase 1b, Open-Label, Multicenter Study of FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma [NCT05934097]Phase 10 participants (Actual)Interventional2022-12-31Withdrawn(stopped due to This study was withdrawn (Sponsor decision).)
A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia [NCT03991884]Phase 124 participants (Actual)Interventional2019-09-24Completed
A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade®) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma [NCT00376961]Phase 268 participants (Actual)Interventional2006-08-31Completed
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia in Adults [NCT06034561]Phase 250 participants (Anticipated)Interventional2023-09-30Not yet recruiting
Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study [NCT02223208]Phase 1/Phase 289 participants (Actual)Interventional2014-09-30Active, not recruiting
A Study Comparing the Efficacy and Safety of Genotype-guided R-CHOP-X Versus R-CHOP in Patients With Diffuse Large B-Cell Lymphoma [NCT05351346]Phase 31,100 participants (Anticipated)Interventional2022-06-01Recruiting
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years [NCT01096368]Phase 3479 participants (Actual)Interventional2010-05-07Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) [NCT00792948]Phase 297 participants (Actual)Interventional2009-09-01Active, not recruiting
A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI>=3) Diffuse Large B-Cell Lymphoma [NCT03283202]Phase 135 participants (Actual)Interventional2017-10-04Completed
A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL) [NCT03851081]Phase 1/Phase 20 participants (Actual)Interventional2021-01-21Withdrawn(stopped due to no accrual)
Randomized Phase II Study to Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated Peripheral T-cell Lymphoma [NCT02445404]Phase 2134 participants (Anticipated)Interventional2015-09-23Recruiting
Phase II Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R in Untreated De Novo Diffuse Large B-Cell Lymphomas [NCT03188198]Phase 260 participants (Anticipated)Interventional2016-06-01Recruiting
An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A [NCT02406092]Phase 3122 participants (Actual)Interventional2015-10-13Completed
The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma:a Phase II Clinical Trial in China [NCT05046314]Phase 230 participants (Anticipated)Interventional2024-10-28Not yet recruiting
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma [NCT01798004]Phase 1150 participants (Actual)Interventional2013-04-08Active, not recruiting
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]Phase 266 participants (Actual)Interventional2010-12-14Completed
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma [NCT01175356]Phase 199 participants (Actual)Interventional2010-10-04Active, not recruiting
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen [NCT02481310]Phase 1/Phase 238 participants (Actual)Interventional2015-10-28Active, not recruiting
A Phase 1, Open-label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With High Risk (IPI 3 or More) Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3B Follicular Lymphoma. [NCT02343536]Phase 159 participants (Actual)Interventional2015-04-29Completed
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alon [NCT02855359]Phase 224 participants (Actual)Interventional2016-08-31Terminated(stopped due to Sponsor decision based on portfolio prioritization)
Three Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Study [NCT05080010]Phase 3500 participants (Anticipated)Interventional2020-11-01Recruiting
An Open-Label, Single Arm Study of MK-8808 in Patients With Advanced CD20-Positive Follicular Lymphoma [NCT01370694]Phase 17 participants (Actual)Interventional2011-08-19Terminated(stopped due to The study was terminated for business reasons.)
Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental [NCT03669783]Phase 3110 participants (Anticipated)Interventional2019-01-01Not yet recruiting
A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects With Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic [NCT04448834]Phase 20 participants (Actual)Interventional2022-01-31Withdrawn(stopped due to Study not moving forward)
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma [NCT04388839]Phase 228 participants (Anticipated)Interventional2020-09-27Recruiting
A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor [NCT02639650]Phase 3214 participants (Anticipated)Interventional2016-03-01Recruiting
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) [NCT00354835]Phase 3481 participants (Actual)Interventional2006-12-26Completed
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults [NCT02003222]Phase 3488 participants (Actual)Interventional2014-05-19Active, not recruiting
A Phase II Study Of Rituximab-CHOP With Pegylated Liposomal Doxorubicin In Patients Older Than 60 Years Of Age With Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma [NCT00101010]Phase 280 participants (Actual)Interventional2005-09-30Completed
A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement [NCT04432714]Phase 1/Phase 281 participants (Anticipated)Interventional2020-06-09Recruiting
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia [NCT02723994]Phase 2171 participants (Actual)Interventional2016-09-30Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT00390793]Phase 2107 participants (Actual)Interventional2006-09-28Active, not recruiting
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults [NCT02228772]Phase 119 participants (Actual)Interventional2014-12-31Completed
Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH-21, R-BL-M-04 and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit and High-Grade B-cell Lymphoma Not Otherwise [NCT03479918]Phase 380 participants (Anticipated)Interventional2018-03-15Recruiting
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental Arms [NCT05848765]Phase 2284 participants (Anticipated)Interventional2023-09-04Recruiting
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial [NCT05331521]Phase 3406 participants (Anticipated)Interventional2021-04-07Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly- [NCT04824092]Phase 3899 participants (Actual)Interventional2021-05-11Active, not recruiting
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 [NCT03643276]Phase 35,000 participants (Anticipated)Interventional2018-07-15Recruiting
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL) [NCT03571321]Phase 115 participants (Anticipated)Interventional2019-05-28Recruiting
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT01424982]Phase 288 participants (Actual)Interventional2011-10-05Active, not recruiting
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia [NCT01085617]Phase 31,033 participants (Actual)Interventional2010-12-31Active, not recruiting
A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma [NCT02116959]Phase 16 participants (Actual)Interventional2014-07-23Terminated(stopped due to Low accrual)
A Pilot Phase II Study for Children With Infantile Fibrosarcoma [NCT00072280]Phase 27 participants (Actual)Interventional2004-11-30Terminated(stopped due to Due to poor accrual)
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer [NCT01222780]Phase 122 participants (Actual)Interventional2010-09-30Completed
Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) [NCT02228512]Phase 1/Phase 20 participants (Actual)Interventional2014-08-15Withdrawn
A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies [NCT00051311]Phase 262 participants (Actual)Interventional2003-01-03Completed
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas [NCT00043979]Phase 260 participants (Actual)Interventional2002-09-19Completed
A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG [NCT00039377]Phase 258 participants (Actual)Interventional2002-04-30Completed
A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas [NCT00077207]66 participants (Actual)Interventional2004-07-31Completed
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-naïve Patients With MCD Subtype DLBCL [NCT05234684]Phase 3150 participants (Anticipated)Interventional2022-11-02Recruiting
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT02303821]Phase 1130 participants (Anticipated)Interventional2015-02-16Recruiting
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) [NCT02112916]Phase 3847 participants (Actual)Interventional2014-10-04Active, not recruiting
"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia" [NCT01920737]Phase 239 participants (Actual)Interventional2013-08-31Active, not recruiting
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) [NCT00972478]Phase 1/Phase 283 participants (Actual)Interventional2010-11-15Active, not recruiting
Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R [NCT00736450]Early Phase 137 participants (Actual)Interventional2008-07-23Terminated(stopped due to Manufacturer is no longer making the drug.)
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) [NCT04663347]Phase 1/Phase 2662 participants (Anticipated)Interventional2020-11-03Recruiting
A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma [NCT03943901]Phase 226 participants (Anticipated)Interventional2021-02-17Recruiting
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas [NCT03220022]Phase 154 participants (Anticipated)Interventional2018-03-16Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma [NCT05504291]Phase 228 participants (Anticipated)Interventional2022-11-04Recruiting
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features [NCT05382338]Phase 3225 participants (Anticipated)Interventional2023-02-20Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma [NCT05304585]Phase 3205 participants (Anticipated)Interventional2022-08-04Recruiting
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance i [NCT04994132]Phase 3118 participants (Anticipated)Interventional2021-09-14Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) [NCT04322318]Phase 2221 participants (Anticipated)Interventional2020-10-19Recruiting
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) [NCT04307576]Phase 36,430 participants (Anticipated)Interventional2020-07-13Recruiting
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) [NCT03533582]Phase 2/Phase 3537 participants (Anticipated)Interventional2018-05-24Recruiting
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]Phase 3475 participants (Anticipated)Interventional2017-08-08Recruiting
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) [NCT02981628]Phase 280 participants (Anticipated)Interventional2017-06-19Active, not recruiting
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients [NCT02724579]Phase 245 participants (Anticipated)Interventional2017-11-17Recruiting
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [NCT02101853]Phase 3669 participants (Actual)Interventional2014-12-17Active, not recruiting
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma [NCT01193842]Phase 1/Phase 2107 participants (Actual)Interventional2010-10-06Completed
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment [NCT00980460]Phase 3236 participants (Actual)Interventional2009-09-14Active, not recruiting
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma [NCT00408005]Phase 31,895 participants (Actual)Interventional2007-01-22Active, not recruiting
HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma [NCT01356680]Phase 31,100 participants (Actual)Interventional2012-01-13Completed
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age [NCT02017964]Phase 226 participants (Actual)Interventional2013-12-24Completed
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) [NCT00075725]Phase 33,154 participants (Actual)Interventional2003-12-29Completed
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease [NCT00025259]Phase 31,734 participants (Actual)Interventional2002-09-30Completed
SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) [NCT00004031]Phase 3397 participants (Actual)Interventional1997-07-31Completed
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma [NCT04323956]Phase 150 participants (Actual)Interventional2020-06-15Active, not recruiting
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT03147612]Phase 221 participants (Actual)Interventional2018-02-08Active, not recruiting
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) [NCT03126916]Phase 3724 participants (Anticipated)Interventional2018-05-14Active, not recruiting
Irinotecan and Temozolomide for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy [NCT03359005]Phase 260 participants (Anticipated)Interventional2018-02-07Recruiting
Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study [NCT01230983]Phase 3573 participants (Actual)Interventional1996-06-30Completed
A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma [NCT01309789]Phase 139 participants (Actual)Interventional2011-02-28Completed
PI3Kδ Inhibitor Parsaclisib in Combination With Cyclophosphamide, Doxorubicin, Vincristine and Prednisone in Participants With Previously Untreated Peripheral T-cell Lymphoma [NCT05238064]Phase 1/Phase 230 participants (Anticipated)Interventional2022-03-31Not yet recruiting
Immune Reconstitution and Biomarker Identification in Patients With Newly Diagnosed Low and Intermediate Risk Hodgkins Lymphoma Receiving Chemotherapy With or Without Radiation Therapy: TXCH-HD-12A [NCT01858922]Phase 240 participants (Actual)Interventional2012-12-19Active, not recruiting
Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL) [NCT01251107]Phase 3331 participants (Actual)Interventional2000-03-31Completed
Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment [NCT01156883]76 participants (Actual)Interventional2010-04-30Completed
A Single Arm, Multi-center, Phase II Clinical Trial of Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma and CD79A/CD79B Genetic Abnormality [NCT04668365]Phase 259 participants (Anticipated)Interventional2020-12-25Recruiting
Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma [NCT04067037]Phase 260 participants (Anticipated)Interventional2019-08-26Recruiting
A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL) [NCT01334502]Phase 126 participants (Actual)Interventional2012-03-31Completed
A Phase Ⅱ Study of Erythropoietin for Management of Anemia Caused by Chemotherapy in Patients With Diffuse Large B-cell Lymphoma [NCT02890602]Phase 253 participants (Actual)Interventional2012-09-01Completed
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas [NCT01030900]Phase 250 participants (Actual)Interventional2009-10-22Completed
A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma [NCT01026220]Phase 3166 participants (Actual)Interventional2009-12-07Completed
A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas [NCT00006721]Phase 3571 participants (Actual)Interventional2001-03-31Active, not recruiting
A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma [NCT00770224]Phase 287 participants (Actual)Interventional2009-04-30Completed
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors [NCT01014767]Phase 327 participants (Actual)Interventional2009-11-30Terminated(stopped due to PI departure from coordinating institution)
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma [NCT00577993]Phase 3210 participants (Actual)Interventional1998-03-16Completed
A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-dose Methotrexate (MTX)-Based Chemo-immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma [NCT00734773]Early Phase 10 participants (Actual)Interventional2008-11-30Withdrawn(stopped due to Lack of funding)
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors [NCT01946529]Phase 224 participants (Actual)Interventional2013-12-27Active, not recruiting
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00878254]Phase 225 participants (Actual)Interventional2009-03-25Active, not recruiting
EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial [NCT02858804]Phase 455 participants (Anticipated)Interventional2016-01-31Recruiting
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma [NCT00669877]Phase 256 participants (Actual)Interventional2002-08-31Completed
Multicenter Clinical Study With Early Treatment Intensification In Patients With High- Risk Hodgkin Lymphoma, Identified As FDG-PET Scan Positive After 2 Conventional ABVD Courses [NCT00795613]Phase 2450 participants (Anticipated)Interventional2008-06-30Active, not recruiting
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients. [NCT00659269]Phase 3319 participants (Actual)Interventional2006-07-31Completed
The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Rand [NCT05018520]Phase 3800 participants (Anticipated)Interventional2021-09-17Recruiting
An Open-Label, Randomized, Pharmacokinetic Study of vinCRIStine Sulfate LIPOSOME Injection Ready-to-Use (VSLI-RTU) Formulation (1-Vial) and Marqibo® Formulation (3-Vials) in Patients With Hematological Malignancies [NCT04243434]Phase 156 participants (Anticipated)Interventional2020-08-15Not yet recruiting
Phase III Study of the Interest of Radiotherapy After 4 or 6 Cycles of CHOP 14 Rituximab Regimen of Chemotherapy , Patients With Agressive Localized Lymphoma [NCT00841945]Phase 3334 participants (Actual)Interventional2005-04-30Terminated(stopped due to other drugs other studies)
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma [NCT03853044]Phase 223 participants (Anticipated)Interventional2018-12-29Active, not recruiting
AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB - LR and PNET 5 MB - WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION, AND REGISTRY FOR MB OCCU [NCT02066220]Phase 2/Phase 3360 participants (Anticipated)Interventional2014-06-30Active, not recruiting
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi. [NCT05058404]Phase 3602 participants (Anticipated)Interventional2021-12-01Recruiting
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL [NCT04529772]Phase 3600 participants (Anticipated)Interventional2020-10-08Recruiting
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) [NCT04301076]Phase 130 participants (Anticipated)Interventional2021-08-31Recruiting
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs [NCT02337985]Phase 110 participants (Anticipated)Interventional2015-11-20Active, not recruiting
A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (BCVP-R) for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First- [NCT00428142]Phase 295 participants (Actual)Interventional2007-05-01Completed
A Prospective, Single Arm, Open Label, Clinical Trial to Evaluate the Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage [NCT04440267]Phase 250 participants (Anticipated)Interventional2020-06-20Not yet recruiting
A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM) [NCT00054158]Phase 224 participants (Actual)Interventional2004-08-31Completed
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia [NCT03504644]Phase 1/Phase 274 participants (Anticipated)Interventional2018-08-13Recruiting
Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma [NCT00004231]Phase 20 participants Interventional1999-10-31Completed
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254) [NCT02163356]Phase 14 participants (Actual)Interventional2014-05-31Terminated(stopped due to drug supply)
Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia [NCT02072785]Phase 3480 participants (Anticipated)Interventional2013-06-30Recruiting
A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma [NCT01864109]Phase 283 participants (Actual)Interventional2013-05-31Active, not recruiting
Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma [NCT03553537]Phase 3100 participants (Anticipated)Interventional2018-06-30Not yet recruiting
A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma [NCT02455245]Phase 3160 participants (Anticipated)Interventional2015-03-31Recruiting
A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy [NCT00109837]Phase 279 participants (Actual)Interventional2005-04-30Completed
Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease [NCT00002462]Phase 3615 participants (Actual)Interventional1989-09-30Active, not recruiting
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute [NCT02036489]Phase 4107 participants (Actual)Interventional2008-01-31Completed
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in [NCT06099366]Phase 2116 participants (Anticipated)Interventional2024-01-15Not yet recruiting
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11) [NCT05008224]Phase 2146 participants (Actual)Interventional2021-10-07Active, not recruiting
Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma [NCT02617485]Phase 3143 participants (Actual)Interventional2015-12-31Completed
An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT02337478]Phase 25 participants (Actual)Interventional2015-06-05Terminated(stopped due to The study was stopped early due to futility.)
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma [NCT06172296]Phase 3478 participants (Anticipated)Interventional2024-02-14Not yet recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1) [NCT06091254]Phase 3478 participants (Anticipated)Interventional2023-12-12Recruiting
N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma [NCT04947501]Early Phase 130 participants (Anticipated)Interventional2021-06-22Recruiting
Longitudinal Quality of Life Study Among Participants With AIDS-Associated Kaposi Sarcoma at Bugando Medical Centre, in Mwanza, Tanzania [NCT03596918]10 participants (Actual)Observational2018-10-10Completed
Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL) [NCT00103285]Phase 35,377 participants (Actual)Interventional2005-04-11Completed
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [NCT03749018]Phase 230 participants (Anticipated)Interventional2019-01-02Active, not recruiting
Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma [NCT00126191]Phase 210 participants (Actual)Interventional2005-07-31Terminated(stopped due to closed due to slow accrual)
A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia [NCT05157971]Phase 16 participants (Anticipated)Interventional2022-03-17Recruiting
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone [NCT02143414]Phase 253 participants (Actual)Interventional2015-06-30Active, not recruiting
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma [NCT01783535]Phase 2174 participants (Anticipated)Interventional2013-06-19Active, not recruiting
A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma [NCT00004197]Phase 20 participants Interventional1999-06-25Completed
A Phase I Trial Using Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies [NCT00718757]Phase 14 participants (Actual)Interventional2005-01-31Completed
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma [NCT02538926]Phase 20 participants (Actual)Interventional2018-07-01Withdrawn(stopped due to Drugs unavailable)
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma [NCT06045247]Phase 240 participants (Anticipated)Interventional2024-03-31Not yet recruiting
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [NCT05476770]Phase 154 participants (Anticipated)Interventional2022-11-11Recruiting
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia [NCT02877303]Phase 280 participants (Anticipated)Interventional2016-11-01Recruiting
A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma [NCT03817853]Phase 4114 participants (Actual)Interventional2019-02-26Completed
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00549848]Phase 3600 participants (Actual)Interventional2007-10-29Completed
A Phase 1b, Open-Label, Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With R-CHOP in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) [NCT04974996]Phase 10 participants (Actual)Interventional2022-02-01Withdrawn(stopped due to Decision to not proceed with study.)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL) [NCT00098839]Phase 1/Phase 2134 participants (Actual)Interventional2005-02-28Completed
A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination With Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin With Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-aspar [NCT01324180]Phase 114 participants (Actual)Interventional2011-07-18Completed
A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk) [NCT00974792]Phase 2150 participants (Anticipated)Interventional2006-01-31Recruiting
Study to Evaluate Efficacy and Safety of Glivec® in Combination With Vincristine and Dexamethasone in Patients With Lymphoid Blast Crisis CML or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Relapse or Refractory [NCT00763763]Phase 255 participants (Actual)Interventional2004-12-31Completed
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB T [NCT00057811]Phase 297 participants (Actual)Interventional2004-06-30Completed
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. [NCT00801281]Phase 3250 participants (Actual)Interventional2007-02-28Completed
Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients With Non-Hodgkin's Lymphoma [NCT00651755]23 participants (Actual)Interventional2008-03-31Completed
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00061945]Phase 1/Phase 2302 participants (Actual)Interventional2003-06-30Completed
A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine [NCT00059839]Phase 3129 participants (Actual)Interventional2003-11-30Completed
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00450801]Phase 222 participants (Actual)Interventional2004-04-30Completed
Phase II Study of Pembrolizumab In Combination With R-CHOP for Patients With Untreated, High-Risk, Non-Germinal Center-Derived DLBCL [NCT03995147]Phase 251 participants (Anticipated)Interventional2019-08-29Recruiting
Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation [NCT00006184]Phase 220 participants (Actual)Interventional2001-02-08Completed
Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma [NCT00004228]Phase 3393 participants (Actual)Interventional2000-06-30Completed
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial [NCT00901069]Phase 112 participants (Actual)Interventional2009-05-31Completed
Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL) [NCT00900445]0 participants (Actual)Observational2008-03-24Withdrawn
A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination With Vincristine/Doxorubicin/Dexrazoxane, in Children With Relapsed/Refractory Solid Tumors or Leukemia [NCT00933985]Phase 122 participants (Actual)Interventional2009-06-30Terminated
A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA [NCT00002878]Phase 30 participants Interventional1997-06-30Completed
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) [NCT03962465]Phase 136 participants (Anticipated)Interventional2022-07-22Active, not recruiting
A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma [NCT00101101]Phase 243 participants (Actual)Interventional2004-07-31Completed
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma [NCT02703272]Phase 372 participants (Actual)Interventional2016-07-01Terminated(stopped due to IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).)
Multicenter, Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH-21, R-mNHL-BFM-90 and (Auto-SCT)in Patients With DLBCL [NCT02842931]Phase 3300 participants (Anticipated)Interventional2015-02-28Recruiting
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Yo [NCT00646854]Phase 3136 participants (Actual)Interventional2008-06-30Completed
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents [NCT02684708]Phase 32,200 participants (Anticipated)Interventional2015-10-01Active, not recruiting
CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday [NCT00683319]50 participants (Anticipated)Observational2008-04-30Active, not recruiting
ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) [NCT00967057]Phase 3470 participants (Anticipated)Interventional2002-10-31Completed
A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) [NCT00873093]Phase 2148 participants (Actual)Interventional2009-03-31Completed
A Pilot Study of Intravenous Topotecan and Vincristine in Combination With Subconjunctival Carboplatin for Patients With a History of Bilateral Retinoblastoma and Refractory/Recurrent Intraocular Disease (IND# 104,942) [NCT00980551]0 participants (Actual)Interventional2010-05-31Withdrawn(stopped due to No enrollment and competing studies)
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity [NCT02779283]Phase 17 participants (Actual)Interventional2016-01-13Completed
A Prospective Phase II Trial of Modified MRC UKALL Ⅻ/ECOG E2993 Regimen in the Treatment of Low Risk Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia for Young Adults [NCT02660762]Phase 2100 participants (Anticipated)Interventional2016-01-31Recruiting
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma [NCT00581776]Phase 230 participants (Actual)Interventional2005-05-31Completed
An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma [NCT00825149]Phase 1137 participants (Actual)Interventional2009-02-28Completed
DFCI ALL Adult Consortium Protocol: Adult ALL Trial [NCT01005758]Phase 2180 participants (Anticipated)Interventional2009-01-31Not yet recruiting
Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts [NCT04542824]Phase 1/Phase 2102 participants (Anticipated)Interventional2020-08-20Active, not recruiting
A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL) [NCT05888493]Phase 3108 participants (Anticipated)Interventional2023-10-02Recruiting
A Randomized Trial Comparing Z-Dex With VAD as Induction Therapy for Patients With Multiple Myeloma [NCT00006232]Phase 3200 participants (Anticipated)Interventional1996-10-31Completed
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma [NCT05675410]Phase 31,875 participants (Anticipated)Interventional2023-05-11Recruiting
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) [NCT01359592]Phase 2159 participants (Actual)Interventional2011-09-30Active, not recruiting
A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell L [NCT04799275]Phase 2/Phase 3422 participants (Anticipated)Interventional2021-05-20Recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom [NCT03914625]Phase 36,720 participants (Anticipated)Interventional2019-07-03Recruiting
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma [NCT00670358]Phase 1/Phase 2138 participants (Actual)Interventional2008-08-25Active, not recruiting
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma [NCT01336933]Phase 234 participants (Actual)Interventional2011-07-06Completed
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma [NCT00352027]Phase 281 participants (Actual)Interventional2006-07-20Completed
A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma (DLBCL) [NCT03742258]Phase 112 participants (Actual)Interventional2019-03-13Active, not recruiting
A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma [NCT00506142]Phase 254 participants (Actual)Interventional2007-11-30Completed
An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine®) Associated With RCHOP Chemotherapy and Rituximab (MabThera®) Maintenance in Patients With First-line Advanced Follicular [NCT00896519]Phase 230 participants (Anticipated)Interventional2009-03-31Not yet recruiting
Multicenter Study of Phase II With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet ®), Vincristine, Prednisone, (R-COMP) in Non-Hodgkin's Lymphoma Diffuse Large B Cell in Cardiopathic Patients [NCT01009970]Phase 250 participants (Anticipated)Interventional2010-05-31Recruiting
An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL). [NCT00494780]Phase 259 participants (Actual)Interventional2007-06-30Completed
Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX [NCT00299182]Phase 1/Phase 250 participants (Actual)Interventional2006-03-31Completed
A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple M [NCT00441168]Phase 230 participants (Actual)Interventional2006-12-31Terminated(stopped due to TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved)
A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide [NCT00267046]Phase 249 participants (Actual)Interventional2005-12-31Completed
Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas [NCT00991211]Phase 3549 participants (Actual)Interventional2004-01-31Completed
Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL [NCT00121199]Phase 273 participants (Actual)Interventional2005-06-30Completed
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX [NCT04216524]Phase 240 participants (Anticipated)Interventional2020-05-29Recruiting
A Single-arm, Multi-center, Phase II Clinical Trial of R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Medium to High Risk/High Risk Diffuse Large B Cell Lymphoma [NCT04214626]Phase 260 participants (Actual)Interventional2020-01-02Active, not recruiting
Rituximab, Methotrexate, Procarbazine, Vincristine, Lenalidomide (RL-MPV) Followed by BBC (BCNU, Busulfan, Cyclophosphamide) High-dose Chemotherapy With Auto-HCT and Maintenance Therapy With Nivolumab in Newly Diagnosed Primary CNS Lymphoma [NCT05425654]Phase 230 participants (Anticipated)Interventional2021-05-17Recruiting
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma [NCT01865110]Phase 3623 participants (Actual)Interventional2013-11-30Active, not recruiting
Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma [NCT00577096]120 participants (Actual)Interventional2001-10-31Completed
International Phase II Study Evaluating the Association of CHOP-rituximab With Consolidation by Early Ibritumomab Tiuxetan-Y90 in Patients Aged 65 to 80 Years With CD20+ Large Cell Malignant Lymphoma and no Prior Therapy [NCT00690560]Phase 230 participants (Actual)Interventional2007-05-31Completed
A Phase II, Prospective, Multi-center Study of Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS [NCT04181489]Phase 255 participants (Anticipated)Interventional2019-01-01Recruiting
Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients. [NCT02670317]Phase 21 participants (Actual)Interventional2016-09-30Terminated(stopped due to GA101-CHOP not advantage from rituximab-CHOP)
Clinical Study of Modified Carboplatin/Vincristine Chemotherapy Regimen for Visual Function Protection in Children With Optic Pathway Gliomas [NCT05278715]Phase 275 participants (Anticipated)Interventional2022-04-13Recruiting
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging [NCT00822120]Phase 2371 participants (Actual)Interventional2009-07-31Completed
A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [NCT00594815]52 participants (Actual)Interventional2002-08-28Completed
A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma [NCT00719472]Phase 3451 participants (Actual)Interventional2008-07-31Completed
Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP [NCT00450385]Phase 257 participants (Actual)Interventional2007-04-24Terminated(stopped due to Investigator Decision due to insufficient accrual.)
A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma [NCT00787527]Phase 1/Phase 214 participants (Actual)Interventional2008-11-30Completed
Safety and Efficacy Study of Mitoxantrone Hydrochloride Liposome Injection Plus Cyclophosphamide,Vincristine and Prednison (CNOP)in Diffuse Large B Cell Lymphoma [NCT02595242]Phase 10 participants (Actual)Interventional2015-06-30Withdrawn
A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia [NCT00764907]Phase 34,000 participants (Anticipated)Interventional2002-11-30Recruiting
A Phase II Study of VcR-CVAD With Rituximab Maintenance for Untreated Mantle Cell Lymphoma [NCT00433537]Phase 277 participants (Actual)Interventional2007-05-31Completed
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients [NCT00931918]Phase 2206 participants (Actual)Interventional2009-10-31Completed
A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Relapsed/Refractory Pediatric Solid Tumors [NCT00786669]Phase 113 participants (Actual)Interventional2008-10-31Completed
A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy for Patients With High Risk Diffuse Large B-Cell Lymphoma [NCT02636322]Phase 260 participants (Actual)Interventional2016-03-29Completed
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission [NCT00002514]Phase 31,929 participants (Actual)Interventional1993-05-07Completed
Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) [NCT00968253]Phase 1/Phase 224 participants (Actual)Interventional2009-11-30Completed
A Phase 1/1B Dose-Escalation Study to Determine the Safety and Tolerability of SCH 717454 Administered in Combination With Chemotherapy in Pediatric Subjects With Advanced Solid Tumors (Protocol No. 05883) [NCT00960063]Phase 14 participants (Actual)Interventional2009-11-11Terminated(stopped due to Study was terminated for business reasons.)
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma [NCT00554788]Phase 360 participants (Actual)Interventional2008-02-04Active, not recruiting
A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors [NCT00138216]Phase 142 participants (Actual)Interventional2005-10-31Completed
Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia [NCT01005914]Phase 211 participants (Actual)Interventional2009-06-30Terminated(stopped due to Increased rate of bacterial infections)
A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors [NCT01528046]Phase 126 participants (Actual)Interventional2012-09-24Completed
Smart Stop: A Phase II Trial of Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Prior to and With Standard Chemotherapy for Patients With Newly Diagnosed DLBCL [NCT04978584]Phase 260 participants (Anticipated)Interventional2022-03-03Recruiting
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma [NCT02306161]Phase 3312 participants (Actual)Interventional2014-12-12Active, not recruiting
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity [NCT00092222]Phase 275 participants (Actual)Interventional2004-10-28Active, not recruiting
Protocol for the Study and Treatment of Patients With Intraocular Retinoblastoma [NCT00186888]Phase 3107 participants (Actual)Interventional2005-04-07Active, not recruiting
HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET [NCT00736320]Phase 31,150 participants (Actual)Interventional2009-11-30Active, not recruiting
A Pilot Study for Soft Tissue Sarcoma [NCT00662233]Early Phase 128 participants (Actual)Interventional1991-10-31Completed
A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) [NCT01186328]Phase 16 participants (Actual)Interventional2010-08-24Terminated(stopped due to Enzon Pharmaceuticals decided to end its development of EZN-3042.)
AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH CD22-POSTIVE NON-HODGKIN'S LYMPHOMA [NCT01055496]Phase 1103 participants (Actual)Interventional2010-03-31Completed
A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas [NCT02700022]Phase 11 participants (Actual)Interventional2016-10-31Terminated(stopped due to Lack of funding)
Phase I Study of Pegylated Liposomal Doxorubicin Combined With Cyclophosphamide and Vincristine in Treatment Progress, Relapse, and Refractory Solid Tumors in Children [NCT04213612]Phase 121 participants (Anticipated)Interventional2019-12-30Not yet recruiting
Phase II Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma 54179060LYM2003 (Nick Name: IVORY Study) [NCT02670616]Phase 224 participants (Actual)Interventional2016-05-01Completed
A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents With an Interval Compression Schedule in Newly Diagnosed Patients With Localized Ewing Sarcoma Family of Tumors [NCT00618813]35 participants (Actual)Interventional2008-03-31Completed
Conservative Treatments of Retinoblastoma [NCT02866136]Phase 2133 participants (Anticipated)Interventional2012-02-29Active, not recruiting
CHOP-Campath, A Pilot Study of CHOP Plus Campath for the Primary Treatment of ALK-ve Peripheral T Cell Lymphoma [CHOP-CAMPATH] [NCT00562068]Phase 130 participants (Anticipated)Interventional2007-05-31Recruiting
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma [NCT03786783]Phase 242 participants (Actual)Interventional2019-01-14Active, not recruiting
A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease [NCT06023641]Phase 1/Phase 2100 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma [NCT05201248]Phase 149 participants (Actual)Interventional2022-03-10Active, not recruiting
Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma [NCT02293109]Phase 110 participants (Actual)Interventional2015-12-17Completed
A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma [NCT01403415]Phase 113 participants (Actual)Interventional2011-09-30Completed
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma [NCT01399372]Phase 291 participants (Actual)Interventional2011-09-30Completed
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors: An Open-label, Phase II, Single-arm, Multi-center Trial [NCT04796012]Phase 1/Phase 223 participants (Anticipated)Interventional2023-04-18Recruiting
Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma [NCT00920153]Phase 3442 participants (Actual)Interventional2008-05-31Terminated(stopped due to Other new drugs)
Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia [NCT00671658]Phase 2220 participants (Actual)Interventional2002-11-30Completed
A Randomized Phase II Study of Dose-Adjusted EPOCH-R and R-VACOP-B in Primary Mediastinal (Thymic) Large B-Cell Lymphoma [NCT00983944]Phase 20 participants (Actual)Interventional2009-09-30Withdrawn(stopped due to Inadequate Accrual)
A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL) [NCT00671034]Phase 3166 participants (Actual)Interventional2008-07-21Completed
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma [NCT01092182]Phase 2194 participants (Actual)Interventional2010-03-25Completed
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma [NCT00567567]Phase 3665 participants (Actual)Interventional2007-11-05Completed
A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014) [NCT02611492]Phase 3265 participants (Anticipated)Interventional2016-04-30Recruiting
An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgk [NCT00562965]Phase 329 participants (Actual)Interventional2007-11-30Terminated(stopped due to See termination reason in detailed description.)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) [NCT04166409]Phase 3220 participants (Anticipated)Interventional2020-01-31Recruiting
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic L [NCT03384654]Phase 247 participants (Actual)Interventional2018-05-14Completed
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP [NCT02889523]Phase 1/Phase 2214 participants (Actual)Interventional2016-10-31Active, not recruiting
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) [NCT00199069]Phase 4720 participants Interventional1993-04-30Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]Phase 2/Phase 363 participants (Actual)Interventional2008-07-14Completed
A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly [NCT00722137]Phase 3487 participants (Actual)Interventional2008-05-01Completed
Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT00618501]Phase 250 participants (Anticipated)Interventional2005-10-31Completed
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination W [NCT04884035]Phase 1174 participants (Anticipated)Interventional2021-09-15Recruiting
Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. [NCT01848132]Phase 2121 participants (Actual)Interventional2013-10-03Completed
Treatment of High Risk Adult Acute Lymphoblastic Leukemia [NCT00853008]Phase 4100 participants (Anticipated)Interventional2003-01-31Completed
Randomized Phase II Study of Dose-Adjusted EPOCH vs. NHL-15 Chemotherapy for Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NHL) [NCT00005964]Phase 259 participants (Actual)Interventional2000-05-31Completed
A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy [NCT00971763]Phase 262 participants (Actual)Interventional2006-03-31Completed
Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-cell Non-Hodgkin's Lymphoma [NCT00006669]Phase 20 participants (Actual)Interventional1999-09-30Withdrawn
"Nutritional Ergogenic Aids: The Effects of Carbohydrate-Protein Supplementation During Endurance Exercise" [NCT00972387]12 participants (Actual)Interventional2009-08-31Completed
A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma [NCT00000681]Phase 124 participants InterventionalCompleted
Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia [NCT00005945]Phase 33,054 participants (Actual)Interventional2000-06-30Completed
A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma [NCT00017290]Phase 30 participants Interventional2000-11-30Active, not recruiting
A Pilot Study Of Tandem High Dose Chemotherapy With Stem Cell Rescue Following Induction Therapy In Children With High Risk Neuroblastoma [NCT00017368]Phase 242 participants (Actual)Interventional2001-04-30Completed
Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma [NCT02951728]Phase 1/Phase 258 participants (Anticipated)Interventional2016-10-31Active, not recruiting
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults [NCT00797810]Phase 425 participants (Anticipated)Interventional2006-12-31Recruiting
Feasibility Study of CO-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma [NCT00799136]Phase 26 participants (Actual)Interventional2008-02-29Completed
GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis [NCT00537550]0 participants Interventional2000-07-31Completed
[NCT00541411]10 participants (Anticipated)Interventional2003-06-30Active, not recruiting
An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma [NCT00451178]Phase 2101 participants (Actual)Interventional2007-05-31Completed
A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia [NCT00440726]Phase 1/Phase 231 participants (Actual)Interventional2006-08-04Completed
A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma [NCT00290433]Phase 255 participants (Actual)Interventional2003-09-30Completed
A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma [NCT00301821]Phase 2107 participants (Actual)Interventional2006-01-31Completed
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib [NCT01324596]Phase 31,132 participants (Actual)Interventional2011-04-30Completed
Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma [NCT00354744]Phase 3109 participants (Actual)Interventional2006-07-31Completed
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma [NCT00392990]Phase 225 participants (Actual)Interventional2007-02-06Completed
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia [NCT00136084]Phase 3238 participants (Actual)Interventional2002-08-31Completed
Treatment of High Risk Renal Tumors: A Groupwide Phase II Study [NCT00335556]Phase 2291 participants (Actual)Interventional2006-06-30Completed
Phase 1 Study of Copanlisib With Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas [NCT04933617]Phase 18 participants (Actual)Interventional2022-03-24Completed
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study [NCT04745832]Phase 382 participants (Actual)Interventional2021-08-13Terminated(stopped due to Discontinuation of zandelisib program)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) [NCT02684058]Phase 2151 participants (Actual)Interventional2017-12-28Completed
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma [NCT02561273]Phase 1/Phase 254 participants (Actual)Interventional2015-09-28Completed
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies [NCT00381680]Phase 3275 participants (Actual)Interventional2007-03-31Completed
A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy [NCT00335738]Phase 3331 participants (Actual)Interventional2005-12-31Completed
Multiple Myeloma Treatment With Thalidomide. Three Randomized Studies on Thalidomide as Induction Treatment Before Autotransplant (MY-TAG) or With a Conventional Chemotherapy (MY-DECT) and as Consolidation/Maintenance at Plateau Phase (MY-PLAT). [NCT01070862]Phase 30 participants Interventional2003-05-31Completed
A Phase II Randomized Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old o [NCT00290498]Phase 267 participants (Actual)Interventional2005-08-01Completed
Phase II Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-angiogenic Approach [NCT00250718]Phase 217 participants (Actual)Interventional2004-10-31Terminated(stopped due to Low rate of accrual)
A Phase I Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin [NCT00993044]Phase 113 participants (Actual)Interventional2009-09-30Completed
German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) [NCT00199004]Phase 460 participants (Anticipated)Interventional2004-04-30Completed
Phase I/II Study of Bortezomib (VELCADE) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma [NCT00477412]Phase 1/Phase 2107 participants (Actual)Interventional2007-04-03Completed
Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation [NCT00209222]Phase 3360 participants (Anticipated)Interventional2004-07-31Recruiting
Autologous Blood or Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning [NCT00238368]Phase 259 participants (Actual)Interventional2004-02-29Completed
A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma [NCT01949818]Phase 4120 participants (Anticipated)Interventional2012-09-30Recruiting
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Who Had Complete Remission as Assessed by PET-CT After Immune-chemotherapy [NCT05874778]Phase 2108 participants (Anticipated)Interventional2023-05-15Not yet recruiting
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma [NCT05996185]Phase 236 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Phase II Trial of Stanford VI ± Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease With 3+ Risk Factors: the G6 Study [NCT00225173]Phase 245 participants (Anticipated)Interventional2001-10-31Terminated
A Pilot Induction Regimen Incorporating Topotecan for Treatment of Newly Diagnosed High Risk Neuroblastoma [NCT00070200]Phase 131 participants (Actual)Interventional2004-03-31Completed
Frontline Selinexor(ATG-010) Plus R-CHOP Therapy for High-risk GCB-subtype Diffuse Large B-Cell Lymphoma [NCT05422066]Phase 250 participants (Anticipated)Interventional2022-07-26Recruiting
Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma [NCT00335140]Phase 226 participants (Actual)Interventional2007-08-23Terminated(stopped due to slow accrual)
An Open, Single-arm, Multicenter Study of R-CMOP Protocol for Primary Treatment of Diffuse Large B-cell Lymphoma Based on Cardiac Function Screening [NCT05777369]30 participants (Anticipated)Interventional2023-03-31Not yet recruiting
Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb. [NCT02012088]Phase 291 participants (Actual)Interventional2013-10-11Active, not recruiting
Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemoth [NCT00006258]Phase 20 participants Interventional1997-11-30Completed
Phase II Trial of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated Intermediate or High Grade Non-Hodgkin's Lymphoma [NCT00005959]Phase 20 participants Interventional1999-12-31Active, not recruiting
A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All [NCT00005977]Phase 383 participants (Actual)Interventional2000-09-30Completed
Phase 1/2 Study of Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors [NCT04890093]Phase 1/Phase 264 participants (Anticipated)Interventional2024-01-03Not yet recruiting
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma [NCT03269669]Phase 295 participants (Anticipated)Interventional2018-01-23Recruiting
Multicentre Study to Determine the Cardiotoxicity of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone) Compared to R-COMP (Rituximab, Cyclophosphamide, Liposomal Doxorubicin, Vincristin and Prednisolone) in Patients With Diffu [NCT00575406]Phase 294 participants (Actual)Interventional2007-12-31Completed
A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma [NCT00193479]Phase 251 participants (Actual)Interventional2003-04-30Completed
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia [NCT00176462]Phase 260 participants (Actual)Interventional2001-02-28Completed
Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive [NCT00556127]Phase 294 participants (Actual)Interventional2002-06-30Completed
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas [NCT05389423]Phase 120 participants (Anticipated)Interventional2023-06-27Recruiting
A Phase II Study of Ibrutinib Plus Rituximab Followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: Window II Protocol [NCT03710772]Phase 250 participants (Anticipated)Interventional2019-05-01Active, not recruiting
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) [NCT03136146]Phase 242 participants (Anticipated)Interventional2017-08-09Recruiting
A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients Wi [NCT04660799]Phase 250 participants (Actual)Interventional2021-02-24Completed
Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia [NCT02199184]Phase 26 participants (Actual)Interventional2015-01-14Completed
A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE). [NCT02110069]Phase 24 participants (Actual)Interventional2017-06-14Terminated(stopped due to This study was challenged by the incidence of KHE with KMP as this continued to be extremely rare, and very sporadic. In July of 2019 grant renewal funding ended.)
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL) [NCT01523977]Phase 122 participants (Actual)Interventional2011-11-30Completed
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) [NCT01190930]Phase 39,350 participants (Actual)Interventional2010-08-09Active, not recruiting
Treatment of Children With Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD) [NCT00107198]Phase 2188 participants (Actual)Interventional2006-01-02Active, not recruiting
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma [NCT01606878]Phase 146 participants (Actual)Interventional2013-04-29Completed
A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 [NCT01332968]Phase 31,401 participants (Actual)Interventional2011-07-06Completed
Radiation Therapy Followed by Chemotherapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma [NCT01321008]Phase 1/Phase 21 participants (Actual)Interventional2011-05-31Terminated(stopped due to Slow Accrual)
Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma [NCT00877110]Phase 171 participants (Actual)Interventional2009-04-02Completed
Association of Rituximab to Immunochemotherapy With CVP + Interferon in Newly Diagnosed Follicular Lymphoma Patients With Intermediate-high FLIPI Score. Phase II Study. [NCT00842114]Phase 250 participants (Actual)Interventional2006-02-28Completed
Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxor [NCT00726700]Phase 2109 participants (Actual)Interventional2004-05-31Completed
Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study [NCT00866307]Phase 1104 participants (Actual)Interventional2009-02-23Completed
A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT01004497]Phase 251 participants (Actual)Interventional2010-03-31Completed
AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia [NCT00613457]Phase 32,039 participants (Actual)Interventional2000-09-30Completed
A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma [NCT00516295]Phase 27 participants (Actual)Interventional2008-02-29Completed
A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas [NCT00669812]Phase 260 participants (Anticipated)Interventional2008-02-29Recruiting
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia [NCT05761171]Phase 278 participants (Anticipated)Interventional2023-11-20Recruiting
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies [NCT05292664]Phase 192 participants (Anticipated)Interventional2023-03-29Recruiting
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell [NCT04980222]Phase 240 participants (Anticipated)Interventional2022-03-22Recruiting
A Prospective, Single Arm, Open-label, Phase II Study of Chidamide in Combination With R-CHOP in the Treatment of de Novo, Elderly, High-risk Diffuse Large B-cell Lymphoma [NCT02753647]Phase 249 participants (Anticipated)Interventional2016-04-30Recruiting
Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study [NCT02396043]Phase 250 participants (Anticipated)Interventional2015-03-31Recruiting
A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Pa [NCT01200758]Phase 3410 participants (Actual)Interventional2011-02-15Completed
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26) [NCT00689845]120 participants (Anticipated)Interventional2007-06-30Recruiting
A Phase 1 Study Of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, In Combination With Chemotherapy In Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Or Lymphoblastic Lymphoma (LL) [NCT03792256]Phase 115 participants (Anticipated)Interventional2019-04-11Active, not recruiting
A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008. [NCT00707083]Phase 32,231 participants (Actual)Interventional2008-05-01Completed
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia [NCT02879643]Phase 136 participants (Anticipated)Interventional2017-01-31Recruiting
A Phase I Clinical Trial Evaluating the Combination of Volasertib (BI-6727) With Vincristine Sulfate Liposomal Injections (VSLI) in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia [NCT02861040]Phase 10 participants (Actual)Interventional2016-08-31Withdrawn
A Randomised Phase II Trial of Inotuzumab Ozogamicin Plus Rituximab & CVP (IO-R-CVP) vs Gemcitabine Plus Rituximab & CVP (Gem-R-CVP) for the First Line Treatment of Patients With DLBCL Who Are Not Suitable for Anthracycline Containing Chemotherapy [NCT01679119]Phase 2129 participants (Actual)Interventional2013-10-31Completed
Phase II Study Evaluating the Toxicity and Efficacy of a Modified German Paediatric Hodgkin's Lymphoma Protocol (HD95) in Young Adults (Aged 18-30 Years) With Hodgkin's Lymphoma [NCT00666484]Phase 247 participants (Actual)Interventional2008-03-31Completed
Treatment Intensification With R-ICE and High-Dose Cyclophosphamide for Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning [NCT00809341]Phase 227 participants (Actual)Interventional2009-01-31Terminated(stopped due to Low accrual)
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHO [NCT00877006]Phase 3447 participants (Actual)Interventional2009-04-30Completed
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia [NCT05660473]Phase 2100 participants (Anticipated)Interventional2022-10-31Recruiting
An Open-label, Multi-center, Phase Ib Clinical Trial of Chidamide Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphoma Patients [NCT02809573]Phase 130 participants (Actual)Interventional2016-08-11Completed
An International, Multicentre, Randomised Controlled Trial. Treatment for Classical Hodgkin Lymphoma in Children and Adolescents Standard Treatment (Chemotherapy and RT) Compared With Experimental Treatment (Chemotherapy Without RT or Restricted to RT) [NCT02797717]2,200 participants (Anticipated)Interventional2015-11-30Recruiting
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over [NCT02792491]Phase 257 participants (Actual)Interventional2012-08-31Active, not recruiting
A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Torisel-Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (T-R-CHOP), Torisel-Rituximab-Fludarabine-Cyclophosphamide (T-R-FC) and Torisel-Ritu [NCT01389427]Phase 1/Phase 241 participants (Actual)Interventional2011-11-30Completed
Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma [NCT01415765]Phase 1/Phase 20 participants (Actual)Interventional2011-07-15Withdrawn
Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status [NCT00333008]Phase 227 participants Interventional2006-05-31Recruiting
[NCT00162695]Phase 3400 participants Interventional1995-07-31Terminated
Open-labeled, Multicenter Phase II Study of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients With Non-conjunctival Ocular Adnexal MALT Lymphoma [NCT01427114]Phase 233 participants (Actual)Interventional2011-07-01Completed
Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province [NCT00846703]Phase 4600 participants (Anticipated)Interventional2008-07-31Recruiting
Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantl [NCT01527149]Phase 237 participants (Actual)Interventional2011-12-06Active, not recruiting
Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma [NCT00276640]3,417 participants (Actual)Interventional2004-04-01Completed
A Trial of Irinotecan (NSC# 616348) Plus Vincristine in Children With Solid Tumors [NCT00006095]Phase 120 participants (Actual)Interventional2000-07-31Completed
NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma [NCT00410631]Phase 3642 participants (Anticipated)Interventional2004-10-31Recruiting
Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) [NCT00199017]Phase 475 participants (Anticipated)Interventional2004-04-30Completed
Phase II Study of Methotrexate, Vincristine, Pegylated L-asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage [NCT00905034]Phase 237 participants (Actual)Interventional2009-03-31Completed
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults [NCT02166463]Phase 3600 participants (Actual)Interventional2015-03-19Active, not recruiting
A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy [NCT02085148]Phase 162 participants (Actual)Interventional2014-04-11Active, not recruiting
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas [NCT00554164]Phase 31,073 participants (Actual)Interventional2007-11-30Completed
A Randomized Study of Lamivudine Prophylaxis or Treatment Against Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen [NCT00201318]Phase 250 participants Interventional2001-09-30Completed
A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16) [NCT00187083]Phase 340 participants (Actual)Interventional1997-02-28Completed
Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study) [NCT00187122]42 participants (Actual)Interventional1993-03-31Completed
A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma [NCT00513955]Phase 250 participants (Actual)Interventional2006-06-30Completed
Large Cell Lymphoma, Pilot Study III [NCT00187070]8 participants (Actual)Interventional1997-12-31Completed
A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant [NCT00058305]Phase 228 participants (Anticipated)Interventional2003-03-31Completed
A Phase I/II Study of Rituximab Plus Vincristine Sulfate Liposomes Injection in the Treatment of Relapsed or Refractory Aggressive Non Hodgkin's Lymphoma [NCT01851551]Phase 1/Phase 222 participants (Actual)Interventional2001-09-30Completed
P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 2 Study [NCT02918747]Phase 2100 participants (Actual)Interventional2016-09-30Active, not recruiting
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992]445 participants (Anticipated)Interventional2006-01-31Recruiting
A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine [NCT01397825]Phase 1/Phase 245 participants (Actual)Interventional2011-08-09Completed
Phase I/II Study of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) and Dideoxyinosine (ddI) or Dideoxycytidine (ddC) in the Treatment of AIDS-Related Kaposi's Sarcoma [NCT00000954]Phase 172 participants InterventionalCompleted
Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma [NCT00002466]Phase 20 participants Interventional1990-05-31Completed
National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study [NCT00002610]Phase 3203 participants (Actual)Interventional1996-01-31Completed
PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL) [NCT00002676]Phase 236 participants (Actual)Interventional1995-07-31Completed
PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS [NCT00002802]Phase 3500 participants (Anticipated)Interventional1990-07-31Completed
MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood [NCT00002898]Phase 3400 participants (Anticipated)Interventional1995-01-31Completed
ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia [NCT00430118]Phase 34,559 participants (Actual)Interventional2000-07-31Completed
LSA5 PROTOCOL FOR THE TREATMENT OF ADVANCED PEDIATRIC AND ADOLESCENT NON-HODGKIN'S LYMPHOMA (NHL) [NCT00002691]Phase 20 participants Interventional1995-08-31Completed
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) [NCT00592111]Phase 221 participants (Actual)Interventional1996-03-31Completed
A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer [NCT00491946]Phase 424 participants (Anticipated)Interventional2004-06-30Recruiting
Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-07) [NCT01614132]Phase 1/Phase 233 participants (Actual)Interventional2009-01-31Completed
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia [NCT00494897]Phase 4374 participants (Actual)Interventional1996-06-30Completed
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]Phase 278 participants (Actual)Interventional2017-04-01Active, not recruiting
Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly [NCT00503594]Phase 292 participants (Anticipated)Interventional2007-07-31Recruiting
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive [NCT00526305]Phase 4100 participants (Anticipated)Interventional2000-01-31Completed
A Pilot Study of the Efficacy of the Chop-Montak Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma [NCT00513188]0 participants (Actual)Interventional2007-02-28Withdrawn
LAL-BR/2001: Study Treatment to Low Risk ALL [NCT00526175]Phase 4150 participants (Anticipated)Interventional2001-06-30Completed
LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia [NCT00526409]Phase 440 participants (Anticipated)Interventional2005-06-30Completed
Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL [NCT04231448]Phase 3423 participants (Actual)Interventional2020-05-21Active, not recruiting
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma [NCT03586999]Phase 1/Phase 218 participants (Actual)Interventional2018-11-07Active, not recruiting
Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma [NCT02845882]Phase 3150 participants (Anticipated)Interventional2016-01-31Active, not recruiting
Three Cycles Versus Six Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Randomized Control Study [NCT01906814]Phase 3179 participants (Actual)Interventional2013-08-31Active, not recruiting
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]Phase 3218 participants (Actual)Interventional2008-01-15Active, not recruiting
A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma [NCT01313884]Phase 23 participants (Actual)Interventional2011-05-31Terminated(stopped due to Study did not reach primary objective; study did not accrue enough patients.)
LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma [NCT04043494]Phase 3683 participants (Anticipated)Interventional2019-08-23Recruiting
Ma-Spore ALL 2010 Study [NCT02894645]Phase 4500 participants (Anticipated)Interventional2008-10-31Recruiting
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma [NCT02529852]Phase 1/Phase 259 participants (Actual)Interventional2015-11-04Completed
A Phase 2 Study to Investigate the Safety, Tolerability and Anti-tumor Activity of Golidocitinib in Combination With CHOP as the Front-line Treatment for Participants With Peripheral T-cell Lymphomas (PTCL) [NCT05963347]Phase 245 participants (Anticipated)Interventional2023-08-03Recruiting
A Phase Ib Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin (POLA) Plus Rituximab (R), Cyclophosphamide, Doxorubici [NCT03467373]Phase 1172 participants (Anticipated)Interventional2018-03-13Active, not recruiting
A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas [NCT00634179]Phase 1/Phase 237 participants (Actual)Interventional2008-02-29Completed
A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia [NCT03519984]Phase 13 participants (Actual)Interventional2018-05-09Terminated(stopped due to Study drug supply issue)
Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for In-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial [NCT00632827]Phase 221 participants (Actual)Interventional2008-07-01Terminated(stopped due to Manufacturing shortage of both Diftitox and Doxil)
A Randomized, Open-Label, Multicenter Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germi [NCT01040871]Phase 2164 participants (Actual)Interventional2010-01-31Completed
Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma [NCT01004991]Phase 1/Phase 214 participants (Actual)Interventional2010-01-31Completed
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia [NCT03488225]Phase 24 participants (Actual)Interventional2018-03-28Terminated(stopped due to the study was closed early due to competing trials)
The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma [NCT00002556]Phase 3312 participants (Actual)Interventional1994-07-31Completed
N7: EVALUATION OF MAXIMAL CHEMOTHERAPY DOSE INTENSITY PLUS MONOCLONAL ANTIBODY 3F8 IN THE TREATMENT OF NEUROBLASTOMA [NCT00002634]Phase 245 participants (Anticipated)Interventional1995-02-28Completed
A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4) [NCT00002700]Phase 3392 participants (Anticipated)Interventional1995-08-31Completed
Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma [NCT00003150]Phase 3630 participants (Anticipated)Interventional1997-12-31Completed
Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy [NCT00003204]Phase 3515 participants (Actual)Interventional1998-03-31Completed
Nephroblastoma Clinical Trial and Study [NCT00003804]Phase 3350 participants (Anticipated)Interventional1993-07-31Active, not recruiting
Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support [NCT00003846]Phase 225 participants (Actual)Interventional1999-07-31Completed
A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma [NCT00004188]Phase 3495 participants (Actual)Interventional2001-02-28Completed
Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide [NCT00004218]Phase 30 participants Interventional1999-10-31Completed
SIOP Study of Combined Modality Treatment in Childhood Ependymoma [NCT00004224]Phase 265 participants (Anticipated)Interventional1999-01-31Completed
A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltr [NCT00005796]Phase 110 participants (Actual)Interventional2000-02-29Completed
A Data Collection Study to Compare the Outcome for Children With Advanced Unilateral Retinoblastoma Treated With or Without Post-Enucleation Chemotherapy ± Radiotherapy on RB 2005 11 With Historical Controls Receiving no Additional Therapy [NCT00360750]0 participants Interventional2005-09-30Active, not recruiting
Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study [NCT00363090]Phase 1/Phase 284 participants (Anticipated)Interventional2006-09-30Recruiting
Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT [NCT02114229]Phase 2125 participants (Actual)Interventional2014-05-14Active, not recruiting
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor [NCT00085202]Phase 3416 participants (Actual)Interventional2003-08-31Active, not recruiting
A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma [NCT00075699]Phase 3840 participants (Anticipated)Interventional2003-09-30Completed
Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma [NCT00245089]Phase 241 participants (Anticipated)Interventional2004-05-31Recruiting
Hodgkin's Disease Study [NCT00416377]353 participants (Anticipated)InterventionalActive, not recruiting
Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma [NCT00278278]Phase 3150 participants (Anticipated)Interventional2003-09-30Active, not recruiting
Management of Children Aged Less Than 3 Years With Brain Tumors [NCT00281905]Phase 250 participants (Anticipated)Interventional1992-06-30Active, not recruiting
Protocol for Infants With Neuroblastoma Diagnosed Under the Age of One Year [NCT00287950]120 participants (Anticipated)Interventional1992-09-30Active, not recruiting
Phase 2 Study of Imatinib-Combined Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia [NCT00130195]Phase 2100 participants (Actual)Interventional2002-09-30Completed
A Phase I Study of CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas [NCT00323323]Phase 124 participants (Actual)Interventional2004-03-31Completed
A Clinical Study Was Conducted to Evaluate the Efficacy and Safety of the RCMOP Regimen Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. [NCT05990985]20 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors [NCT05620862]Phase 168 participants (Anticipated)Interventional2022-10-25Recruiting
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia [NCT00039130]Phase 2105 participants (Actual)Interventional2002-05-31Completed
Phase I Cinical Sudy of Lposomal Mitoxantrone Hydrochloride Combined With Cyclophosphamide, Vincristine, Etoposide and Prednisone (CMOEP) in Previously Untreated Peripheral T-cell Lymphoma [NCT05458180]Phase 118 participants (Anticipated)Interventional2022-07-07Not yet recruiting
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Phase II Clinical Study [NCT05457829]Phase 288 participants (Anticipated)Interventional2023-12-30Not yet recruiting
A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT,in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL [NCT03213977]Phase 3475 participants (Anticipated)Interventional2017-02-01Recruiting
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma [NCT00334867]Phase 30 participants (Actual)Interventional2005-12-31Withdrawn(stopped due to withdrawn)
Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia [NCT00343369]550 participants (Anticipated)Interventional2003-01-31Recruiting
A Multi-Center Randomized Study of Vincristine, Doxil and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Multiple Myeloma [NCT00344422]Phase 3198 participants (Actual)Interventional2000-10-31Completed
A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer [NCT00427570]Phase 30 participants Interventional1977-09-30Completed
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma [NCT01055314]Phase 2175 participants (Actual)Interventional2010-01-31Completed
First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents [NCT00433459]Phase 32,134 participants (Actual)Interventional2007-01-31Completed
Prognostic Significance of Early Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F] FDG) in Intermediate and High Grade Non-Hodgkin's Lymphoma [NCT00110006]0 participants (Actual)Interventional2004-12-31Withdrawn(stopped due to No accrual)
A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous St [NCT00499018]Phase 3399 participants (Anticipated)Interventional2006-01-31Active, not recruiting
Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults [NCT00131027]Phase 3240 participants (Anticipated)Interventional2002-09-30Recruiting
A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma [NCT00141648]70 participants (Actual)Interventional2000-09-30Completed
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) [NCT05578976]Phase 3900 participants (Anticipated)Interventional2023-02-08Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma [NCT05371093]Phase 3230 participants (Anticipated)Interventional2022-09-12Recruiting
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [NCT04759586]Phase 3244 participants (Anticipated)Interventional2021-10-05Recruiting
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas [NCT03984448]Phase 2/Phase 3363 participants (Anticipated)Interventional2019-10-22Active, not recruiting
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) [NCT03871257]Phase 3290 participants (Anticipated)Interventional2020-01-15Recruiting
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL) [NCT01371630]Phase 1/Phase 2276 participants (Anticipated)Interventional2011-08-26Recruiting
A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma [NCT00004112]Phase 30 participants Interventional1999-09-01Completed
CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma [NCT02319486]Phase 426 participants (Actual)Interventional2009-01-31Completed
Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma [NCT00079417]Phase 328 participants (Actual)Interventional2005-12-26Completed
Intravenous Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia and Allergy to E. Coli Asparaginase (IND 104224) [NCT00928200]Phase 11 participants (Actual)Interventional2009-04-13Terminated(stopped due to Study was terminated due to lack of accrual.)
Treatment of Older Adults With Acute Lymphoblastic Leukemia [NCT00973752]Phase 230 participants (Actual)Interventional2009-08-31Completed
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia [NCT02135874]Phase 218 participants (Actual)Interventional2014-10-27Completed
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma [NCT00501826]Phase 2160 participants (Anticipated)Interventional2007-07-11Recruiting
Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia [NCT01363128]Phase 272 participants (Actual)Interventional2011-07-12Completed
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Prospective, Single-arm, Single-center Clinical Trial [NCT05594784]Phase 260 participants (Anticipated)Interventional2022-10-08Recruiting
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation [NCT00653068]Phase 370 participants (Actual)Interventional2008-12-08Active, not recruiting
A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma [NCT00077285]Phase 265 participants (Anticipated)Interventional2003-10-31Active, not recruiting
Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma [NCT00005867]Phase 3310 participants (Anticipated)Interventional1998-01-31Completed
Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms [NCT00217425]Phase 246 participants (Actual)Interventional2006-09-14Completed
Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR) [NCT00526318]360 participants (Anticipated)Interventional2007-01-31Recruiting
Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase. [NCT00184041]Phase 247 participants (Actual)Interventional2004-07-31Completed
Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study [NCT00544219]156 participants (Actual)Interventional2007-09-30Completed
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00187005]Phase 353 participants (Actual)Interventional1998-07-31Terminated(stopped due to Toxicity)
Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II [NCT00187161]Phase 268 participants (Actual)Interventional1994-11-30Completed
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) [NCT02420717]Phase 211 participants (Actual)Interventional2015-07-15Terminated(stopped due to Study was closed early due to low accrual and lack of response.)
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00400946]Phase 3800 participants (Actual)Interventional2005-04-30Completed
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants [NCT06097364]Phase 3733 participants (Anticipated)Interventional2023-11-14Recruiting
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults [NCT04530565]Phase 3348 participants (Anticipated)Interventional2021-01-25Recruiting
An Open-Label, Phase I/II Study of ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma [NCT04517435]Phase 1/Phase 213 participants (Actual)Interventional2021-04-28Active, not recruiting
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or [NCT02875314]Phase 4250 participants (Anticipated)Interventional2015-09-30Recruiting
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL [NCT01516567]Phase 247 participants (Actual)Interventional2012-04-01Active, not recruiting
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial [NCT01516580]Phase 3482 participants (Actual)Interventional2011-12-31Active, not recruiting
A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) [NCT02568683]Phase 1/Phase 210 participants (Actual)Interventional2016-02-11Terminated
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. [NCT00336024]Phase 391 participants (Actual)Interventional2007-08-06Active, not recruiting
"Protocol CCAM 05-02 Phase I-II Study of Dose Dense of PEG Filgrastim and GM-CSF as Support for Dose Desnse CHOP-R Front Line Therapy for Aggressive Non Hodgkin's Lymphoma" [NCT01527422]Phase 1/Phase 260 participants (Actual)Interventional2006-01-31Completed
Pilot Study Assessing the Feasibility of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children With Wnt Positive Standard Risk Medulloblastoma [NCT02212574]Early Phase 16 participants (Actual)Interventional2017-04-04Terminated(stopped due to Participant relapses led to abrupt stop of study.)
HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD [NCT02661503]Phase 31,500 participants (Anticipated)Interventional2016-07-31Recruiting
A Phase II Study of Rituximab Intense Dosing With CHOP-21 (RID-CHOP) in Patients With Previously Untreated High or High-Intermediate Risk IPI (3-5) Diffuse Large B-Cell Lymphoma (DLBCL) [NCT01539174]Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to No Funding Source and Competing Trials)
[NCT01540812]418 participants (Actual)Observational2012-02-29Completed
EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] [NCT00002516]Phase 30 participants Interventional1992-07-31Active, not recruiting
A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin [NCT00002618]Phase 3242 participants (Anticipated)Interventional1994-12-31Completed
A PHASE II TRIAL OF EIGHT-WEEK STANFORD V CHEMOTHERAPY PLUS MODIFIED INVOLVED FIELD RADIOTHERAPY IN FAVORABLE, LIMITED STAGE HODGKIN'S DISEASE [NCT00002714]Phase 20 participants Interventional1995-04-30Completed
Induction Intensification in Infant ALL: A Children's Oncology Group Study [NCT00002756]Phase 2221 participants (Actual)Interventional1996-06-30Completed
Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B-Cell Non-Hodgkin's Lymphoma That is Refractory or Relapsed After Second-Line Combination Chemotherapy Revised Title Per 03/01 SR Pivotal Phase II Multicenter [NCT00006383]Phase 20 participants Interventional2000-06-30Completed
Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Stud [NCT00006461]Phase 382 participants (Actual)Interventional2000-10-31Completed
Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell S [NCT00003211]Phase 294 participants (Actual)Interventional1996-10-31Completed
Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. [NCT02752815]Phase 4290 participants (Anticipated)Interventional2016-06-14Active, not recruiting
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) [NCT00002531]Phase 20 participants Interventional1993-01-31Active, not recruiting
Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and Promace-Cytabom For Treatment of Post-Cardiac Transplant Lymphoproliferation. [NCT00002657]Phase 220 participants (Actual)Interventional1995-05-31Completed
European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) [NCT00020566]Phase 31,200 participants (Anticipated)Interventional2001-02-28Recruiting
A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia [NCT00022126]Phase 26 participants (Actual)Interventional2002-11-30Completed
A Phase I Trial of Combination Bryostatin-1 and Vincristine in HIV-Related B-cell Neoplasms [NCT00022555]Phase 112 participants (Actual)Interventional2001-11-30Completed
Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma [NCT00022945]Phase 20 participants InterventionalCompleted
A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia [NCT01769209]Phase 218 participants (Actual)Interventional2013-03-31Completed
A Study Of The Treatment Of Metastatic Neuroblastoma In Children More Than One Year Of Age At Diagnosis [NCT00024193]Phase 20 participants Interventional1999-04-30Active, not recruiting
A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Diseas [NCT00025363]Phase 2150 participants (Actual)Interventional2001-11-30Completed
MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood [NCT00025441]Phase 20 participants Interventional1998-11-30Completed
European Infant Neuroblastoma Study - Unresectable Tumors (MYCN Not Amplified) [NCT00025597]Phase 20 participants Interventional1999-07-31Completed
A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease [NCT00025636]Phase 3220 participants (Anticipated)Interventional2001-07-31Active, not recruiting
A Phase I Study To Evaluate The Safety Of Cellular Immunotherapy Using Genetically Modified Autologous Cd20-Specific Cd8+ T Cell Clones For Patients With Relapsed Cd20+ Indolent Lymphomas [NCT00012207]Phase 112 participants (Anticipated)Interventional2000-09-30Completed
A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma [NCT00028717]Phase 3400 participants (Anticipated)Interventional2001-02-28Active, not recruiting
Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma [NCT00032149]Phase 1/Phase 230 participants (Anticipated)Interventional2001-10-31Active, not recruiting
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma [NCT00000689]Phase 118 participants InterventionalCompleted
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia [NCT00015873]Phase 3350 participants (Anticipated)Interventional1999-05-31Completed
The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia [NCT00016302]100 participants (Actual)Interventional2001-04-30Completed
A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma [NCT00040690]Phase 2120 participants (Anticipated)Interventional2008-11-30Completed
Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Year [NCT00052936]Phase 31,506 participants (Actual)Interventional2001-01-31Completed
A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma [NCT00053872]Phase 3316 participants (Anticipated)Interventional2003-02-28Active, not recruiting
Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Includ [NCT00060385]Phase 2/Phase 33 participants (Actual)Interventional2003-03-31Terminated(stopped due to low accrual)
Pilot Study for Therapy Optimising for Hodgkin's Lymphoma in Childhood and Adolescence; Optimising Therapy for Boys With Hodgkin's Lymphoma in Intermediate and Advanced Stages. Safety and Efficacy Study for Drug Combination VECOPA [NCT00398554]Phase 216 participants (Actual)Interventional2005-06-30Completed
An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Fail [NCT00392340]Phase 263 participants (Anticipated)Interventional2008-03-31Active, not recruiting
Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00070447]Phase 20 participants Interventional2003-11-30Completed
2-CDA and Rituximab as Remission Induction and Rituximab as In Vivo Purging Prior to Peripheral Stem Cell Mobilization in Patients With Chronic Lymphocytic Leukemia (CLL) - A Prospective Multicenter Phase II Trial [NCT00072007]Phase 243 participants (Actual)Interventional2002-06-30Completed
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years; Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma [NCT00079105]Phase 2175 participants (Actual)Interventional2004-01-31Completed
Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma [NCT00079261]Phase 225 participants (Actual)Interventional2004-01-31Completed
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotep [NCT00392886]Phase 3120 participants (Anticipated)Interventional2004-03-31Active, not recruiting
Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma [NCT00135499]Phase 3138 participants (Actual)Interventional2001-10-16Terminated(stopped due to Recruitment too low)
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Protocol [NCT01464606]156 participants (Actual)Interventional2009-12-22Active, not recruiting
Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma [NCT00276666]Phase 229 participants (Anticipated)Interventional2001-11-30Active, not recruiting
A Phase I/II Trial of STI-571 and Chemotherapy in Lymphoid Blast Crisis of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoid Leukemia [NCT00015860]Phase 1/Phase 20 participants Interventional2001-05-31Completed
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL) [NCT00275106]Phase 3600 participants (Anticipated)Interventional2004-09-30Terminated(stopped due to Withdrawn due to an excess of toxic deaths)
Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma [NCT00017225]Phase 20 participants Interventional1997-05-31Completed
PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA [NCT00018954]Phase 20 participants Interventional1992-10-31Completed
A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma [NCT00020943]Phase 279 participants (Actual)Interventional2001-06-30Completed
A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051) [NCT00022737]Phase 3220 participants (Actual)Interventional2002-10-31Completed
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma [NCT05051891]Phase 3356 participants (Anticipated)Interventional2021-12-22Recruiting
Treatment Of Children Over The Age Of 1 Year With Unresectable Localized Neuroblastoma Without MYCN Amplification [NCT00025428]Phase 3100 participants (Anticipated)Interventional2000-12-31Completed
European Infant Neuroblastoma Study - Stage 4 With Bone, Lung, Pleura or CNS Involvement; MYCN Not Amplified [NCT00025623]Phase 20 participants Interventional1999-07-31Completed
Rituxumab Combined With Chemotherapy (PVB) For Poor Prognosis HIV-Related Non-Hodgkin's Lymphoma [NCT00031902]Phase 10 participants Interventional2001-10-31Active, not recruiting
Phase II Study Of Dose-Adjusted Epoch-Rituximab (EPOCH-R) Chemotherapy For Patients With Previously Untreated Aggressive CD20+ B-Cell Non-Hodgkin's Lymphoma (NHL) [NCT00032019]Phase 278 participants (Actual)Interventional2002-02-28Completed
Randomized Study of Radiotherapy in Patients With Stage 2B/3 (INSS) Neuroblastoma in Children Over 1 Year of Age [NCT00276731]Phase 30 participants Interventional1995-03-31Active, not recruiting
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas [NCT04199026]Early Phase 120 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Randomized Study of Two Methods of CNS Prophylaxis in Patients With Acute Lymphoblastic Leukemia [NCT00019409]Phase 30 participants (Actual)Interventional1999-10-31Withdrawn
Diffuse Large B Cell And Peripheral T-Cell Non-Hodgkin's Lymphoma In The Frail Elderly. Progressive And Cautious Treatment Strategy In Poor Status Patients. A Phase II Trial With Emphasis On Geriatric Assessment And Quality Of Life [NCT00039351]Phase 232 participants (Actual)Interventional2002-03-31Completed
N8: Dose-Intensive Chemotherapy Plus Biologics in the Treatment of Neuroblastoma [NCT00040872]Phase 20 participants Interventional2000-06-30Completed
Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse [NCT00049569]126 participants (Anticipated)Interventional2003-01-31Completed
An Open Label Prospective Randomised Study Comparing The Use Of Vincristine, Adriamycin And Cyclophosphamide (VAC) Versus Epirubicin, Cisplatin And Continuous 5-Flourouracil (ECF) In Patients With Unknown Primary Carcinoma (UPC) [NCT00022178]Phase 30 participants Interventional1998-12-31Active, not recruiting
A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV [NCT00052455]Phase 3500 participants (Anticipated)Interventional2002-10-31Completed
Protocol For The Treatment Of Children And Adolescents With Hodgkin's Disease [NCT00025064]Phase 2260 participants (Anticipated)Interventional2000-01-31Active, not recruiting
Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) [NCT00025103]Phase 275 participants (Anticipated)Interventional2001-05-31Active, not recruiting
European Infant Neuroblastoma Study - Stage 4S and Stage 4 (No Bone, Lung, Pleura or CNS); MYCN Not Amplified [NCT00025610]Phase 20 participants Interventional1999-07-31Completed
European Infant Neuroblastoma Study - Stage 2, 3, 4, and 4S; MYCN Amplified Tumors [NCT00025649]Phase 20 participants Interventional1999-07-31Completed
A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma [NCT00028886]Phase 3450 participants (Anticipated)Interventional2001-03-31Active, not recruiting
High Risk Neuroblastoma Study 1 Of Siop-Europe [NCT00030719]Phase 3175 participants (Anticipated)Interventional2001-12-31Recruiting
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]Phase 3116 participants (Actual)Interventional1995-10-30Completed
Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies [NCT00038207]Phase 229 participants (Actual)Interventional2000-06-30Completed
A Phase I Study Of G3139 Antisense Oligonucleotide (Oblimersen) In Combination With CHOP And Rituximab In Untreated Advanced Stage Diffuse Large B Cell Lymphoma [NCT00070083]Phase 10 participants Interventional2003-07-31Completed
Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation [NCT00209209]Phase 3570 participants (Anticipated)Interventional2004-01-14Active, not recruiting
Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease [NCT00041210]Phase 3850 participants (Anticipated)Interventional2001-10-31Active, not recruiting
Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia [NCT00411541]Phase 42,600 participants Interventional1995-04-30Completed
Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma [NCT00041327]Phase 219 participants (Actual)Interventional2002-10-31Completed
Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia [NCT00131053]Phase 2120 participants (Anticipated)Interventional2002-09-30Recruiting
Nephroblastoma (Wilms Tumour) Clinical Trial And Study [NCT00047138]Phase 3350 participants (Anticipated)Interventional2001-01-31Recruiting
Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) With Advanced Stage Diffuse Large B-Cel [NCT00080847]Phase 2160 participants (Actual)Interventional2004-03-31Terminated
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies [NCT00080925]Phase 120 participants (Anticipated)Interventional2004-02-29Completed
Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Pr [NCT00053768]Phase 3392 participants (Actual)Interventional2002-04-30Completed
Double Dose Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Stage Neuroblastoma and Sarcomas [NCT00165139]Phase 220 participants (Actual)Interventional1996-01-31Completed
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00165178]Phase 3498 participants (Actual)Interventional2000-09-30Completed
Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). [NCT00169156]Phase 227 participants (Actual)Interventional2005-12-31Completed
Molecular Risk Guided Treatment Of Diffuse Large B-Cell Non-Hodgkin's Lymphoma [NCT00055640]Phase 29 participants (Actual)Interventional2002-10-31Completed
A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors [NCT00186979]Phase 134 participants (Actual)Interventional2003-05-31Completed
Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia [NCT00187057]6 participants (Actual)Interventional2002-09-30Completed
A Multicenter, Phase 2 Study, to Evaluate Safety and Efficacy of an Acute Lymphoblastic Leukemia (ALL) Intensive Chemotherapy for Adult Lymphoblastic Lymphoma (LL). [NCT00195871]Phase 2155 participants (Actual)Interventional2004-02-29Active, not recruiting
A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (> 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia ( [NCT00199186]Phase 20 participants Interventional2002-03-31Recruiting
A Pilot Phase II Study to Determine the Safety of the Combination of ONTAK (DAB389IL-2), an Interleukin-2 Fusion Toxin, in Combination With CHOP in Peripheral T-Cell Lymphoma [NCT00337987]Phase 249 participants (Actual)Interventional2005-11-30Completed
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00558519]Phase 2318 participants (Actual)Interventional2008-03-12Active, not recruiting
A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (Vincristine Sulfate Liposomes Injection) in Adult Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients With P [NCT00495079]Phase 265 participants (Actual)Interventional2007-05-31Completed
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage [NCT01670084]Phase 20 participants (Actual)Interventional2012-12-31Withdrawn(stopped due to No Accrual)
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated [NCT02285062]Phase 3570 participants (Actual)Interventional2015-02-17Completed
Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL [NCT03704714]Phase 1/Phase 230 participants (Anticipated)Interventional2018-11-20Suspended(stopped due to Protocol being amended for stats/accrual changes as per PI)
A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma [NCT00003388]Phase 238 participants (Anticipated)Interventional1999-07-26Completed
DLCL002 Protocol for Young Patients With Newly Diagnosed High Risk Aggressive B-cell Lymphoma, a Multicenter Phase II Study [NCT03837873]Phase 2118 participants (Anticipated)Interventional2019-01-21Recruiting
Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment naïve Acute Lymphoblastic Leukemia [NCT03286634]Phase 260 participants (Anticipated)Interventional2017-04-18Recruiting
Short Chemo Radiotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab Tiuxetan (ZevalinTM) as Therapy for First and Second Relapse in Follicular Lymphoma [NCT00637832]Phase 21 participants (Actual)Interventional2008-04-01Terminated(stopped due to no information)
Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT00866749]Phase 2120 participants (Actual)Interventional2006-09-12Completed
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL) [NCT01839097]Phase 123 participants (Actual)Interventional2013-05-31Completed
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL [NCT03150693]Phase 3310 participants (Anticipated)Interventional2017-06-01Suspended(stopped due to Unacceptable Toxicity)
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma [NCT01231906]Phase 3642 participants (Actual)Interventional2010-11-22Active, not recruiting
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma [NCT02257242]Phase 111 participants (Actual)Interventional2017-05-10Completed
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL) [NCT00596154]Phase 233 participants (Actual)Interventional2004-12-31Completed
Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor [NCT05384821]Phase 1/Phase 228 participants (Anticipated)Interventional2022-09-14Recruiting
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL) [NCT05032183]Phase 1/Phase 240 participants (Anticipated)Interventional2022-02-17Recruiting
Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in Combination With Arsenic Trioxide (Trisenox) in Untreated Patients With Symptomatic Multiple Myeloma [NCT00201695]Phase 212 participants (Actual)Interventional2004-07-31Completed
Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Cyclophosphamide, Vincristine and Prednisone in the Treatment of Untreated PTCL [NCT04548700]Phase 163 participants (Anticipated)Interventional2020-12-24Recruiting
Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL. [NCT00244127]Phase 275 participants Interventional2002-10-31Active, not recruiting
Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma [NCT00245141]Phase 232 participants (Anticipated)Interventional2004-05-31Recruiting
[NCT00284271]Phase 265 participants (Actual)Interventional2004-01-31Completed
Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours [NCT00274911]Phase 230 participants (Anticipated)Interventional2004-02-29Active, not recruiting
UKCCSG Stage IIB/3 (INSS) Neuroblastoma Pilot Study [ENSG VI (Pilot 2B/3)] [NCT00416676]Phase 330 participants (Anticipated)InterventionalActive, not recruiting
Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Year [NCT00278421]Phase 3592 participants (Actual)Interventional2005-11-30Completed
Optimising Therapy for Boys With Hodgkin's Lymphoma and Quality Assurance of Therapy for Girls With Hodgkin's Lymphoma Until Start of a New Prospective Trial for Hodgkin's Lymphoma in Childhood and Adolescence [NCT00416832]Phase 2648 participants (Anticipated)Interventional2002-11-30Completed
Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study [NCT00107380]Phase 286 participants (Actual)Interventional2005-11-30Completed
2-Weekly CHOP Chemotherapy With Dose-Dense Rituximab for the Treatment of Patients Aged 61 to 80 Years With Aggressive CD-20 Positive B-Cell Lymphomas: A Phase-II/Pharmacokinetic Study (CHOP-R-ESC) [NCT00290667]Phase 2586 participants (Actual)Interventional2004-02-29Completed
[NCT00264953]Phase 31,395 participants (Actual)Interventional1998-05-31Completed
[NCT00265031]Phase 30 participants Interventional1999-01-31Completed
Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors [NCT00301782]Phase 288 participants (Anticipated)Interventional2005-06-30Completed
Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-d [NCT00278408]Phase 3700 participants (Actual)Interventional2005-11-30Completed
European Infant Neuroblastoma Study Final Protocol [NCT00417053]Phase 30 participants InterventionalActive, not recruiting
Treatment in First Line of Mantle Cell Lymphoma for Patients Under 66 Years by the VAD-CHLORAMBUCIL -Rituximab Regimen Followed by Intensification and Autologous PBSC Transplantation After Marrow Purging With Rituximab [NCT00285389]Phase 239 participants (Actual)Interventional2002-02-28Completed
A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Pediatric Patients With Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia [NCT00313053]Phase 14 participants (Actual)Interventional2004-09-30Terminated
Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma [NCT00303810]567 participants (Actual)Interventional2001-01-31Completed
Phase III, Double-Blind, Randomized, Placebo-Controlled Trial of FavID® (Id/KLH) and GM-CSF Following CHOP/Rituximab as First-Line Therapy in Subjects With High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma [NCT00324831]Phase 3480 participants (Anticipated)InterventionalSuspended
CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) [NCT00309881]Phase 275 participants (Anticipated)Interventional2003-04-30Completed
A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Adult Patients With Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia [NCT00313079]Phase 19 participants (Actual)Interventional2006-05-31Completed
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma [NCT01622439]Phase 1/Phase 250 participants (Actual)Interventional2012-06-30Completed
Treatment of Children With Diffuse Intrinsic Brain Stem Glioma With Standard Dose Irradiation and Vincristine Plus Oral VP-16, A POG Pilot Study [NCT00003935]Phase 131 participants (Actual)Interventional1999-09-30Completed
An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed by Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors [NCT00003203]Phase 2168 participants (Actual)Interventional1998-03-31Completed
A Phase Ib Trial of Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma [NCT04850495]Phase 124 participants (Anticipated)Interventional2021-11-16Suspended(stopped due to Pending amendment)
Randomized Phase III Study Using a Pet-driven Strategy and Comparing GA101 OR Rituximab Associated to a Chemotherapy Delivered Every 14 Days (ACVBP or CHOP) in DLBCL CD20+ Lymphoma Untreated Patients From 18 to 60 Presenting With 1 or More Adverse Prognos [NCT01659099]Phase 3671 participants (Actual)Interventional2012-09-30Terminated(stopped due to experimental treatment not Superior to standard - no need to continue the follow-up)
Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor [NCT00945009]Phase 3249 participants (Actual)Interventional2009-07-13Active, not recruiting
High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) [NCT01704716]Phase 33,300 participants (Anticipated)Interventional2002-02-28Recruiting
CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study [NCT01719835]Phase 287 participants (Actual)Interventional2012-03-31Active, not recruiting
Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL) [NCT01735747]Phase 216 participants (Anticipated)Interventional2008-06-30Active, not recruiting
An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma [NCT01746992]Phase 4200 participants (Anticipated)Interventional2012-09-30Active, not recruiting
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022) [NCT06175702]150 participants (Anticipated)Observational2023-12-25Not yet recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23) [NCT05605899]Phase 3300 participants (Anticipated)Interventional2023-02-10Recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Di [NCT03274492]Phase 31,000 participants (Actual)Interventional2017-11-16Active, not recruiting
Use of Dose Adjusted EPOCH-R in the Treatment of Childhood Mature B Cell Malignancies [NCT01760226]Early Phase 14 participants (Actual)Interventional2013-01-31Completed
A Prospective, Single-arm, Open-label, Phase 2 Study to Evaluate Efficacy and Safety of DA-EPOCH Regimen for Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis [NCT01818908]Phase 250 participants (Anticipated)Interventional2012-06-30Active, not recruiting
A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP. [NCT01843868]130 participants (Anticipated)Interventional2013-05-31Not yet recruiting
A Phase I Trial of Pevonedistat in Combination With Induction Chemotherapy for Adolescent and Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin Lymphoma [NCT03349281]Phase 16 participants (Actual)Interventional2019-03-25Completed
Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia [NCT01887587]Phase 15 participants (Actual)Interventional2013-06-30Terminated(stopped due to SAE- risk of overall protocol treatment outweighs benefits)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas [NCT01777152]Phase 3452 participants (Actual)Interventional2013-01-31Completed
A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma [NCT01700946]Phase 280 participants (Actual)Interventional2013-04-15Completed
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma [NCT00000801]Phase 233 participants InterventionalCompleted
A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia [NCT00001689]Phase 190 participants Interventional1998-01-31Completed
A Phase I Study of Combination Chemotherapy (Adriamycin, Bleomycin, and Vincristine) and Azidothymidine in the Treatment of AIDS Related Kaposi's Sarcoma [NCT00000987]Phase 136 participants InterventionalCompleted
Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma [NCT00001059]Phase 2120 participants InterventionalCompleted
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies [NCT05270057]Phase 133 participants (Anticipated)Interventional2023-01-26Recruiting
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors [NCT00001209]Phase 1120 participants Interventional1986-10-31Completed
Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma [NCT00002463]Phase 24 participants (Actual)Interventional1989-02-28Completed
TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS [NCT00002499]Phase 2/Phase 30 participants Interventional1990-01-31Active, not recruiting
"RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY (ATT) VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5" [NCT00002565]Phase 361 participants (Actual)Interventional1994-05-25Completed
Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II [NCT00002571]Phase 252 participants (Actual)Interventional1994-06-30Completed
INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY [NCT00002643]Phase 2130 participants (Actual)Interventional1995-04-30Completed
A Phase II Pilot Study of Short Term (12 Week) Combination Chemotherapy (Stanford V) in Unfavorable Hodgkin's Disease [NCT00002715]Phase 250 participants (Anticipated)Interventional1989-04-30Completed
FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study [NCT00002757]Phase 31,148 participants (Actual)Interventional2001-06-30Completed
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients [NCT03023358]Phase 3174 participants (Anticipated)Interventional2017-02-28Not yet recruiting
Multi-center Randomized Study to Compare Efficacy and Safety of Lenalidomide Plus CHOP (L-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma [NCT04922567]Phase 2289 participants (Anticipated)Interventional2021-04-01Recruiting
A Single-arm, Prospective Clinical Study on the Antitumor Activity and Safety of Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors [NCT05887726]Phase 230 participants (Anticipated)Interventional2023-08-01Not yet recruiting
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax [NCT05192889]Phase 1/Phase 290 participants (Anticipated)Interventional2022-08-25Recruiting
An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma [NCT02265770]Phase 2/Phase 3536 participants (Anticipated)Interventional2015-06-02Recruiting
A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation Status in Patients With Chronic Lymphocytic Leukemia (CLL) [NCT01463852]Early Phase 111 participants (Actual)Interventional2012-10-31Terminated(stopped due to Enrollment underperformance.)
A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma [NCT01468740]Phase 2130 participants (Anticipated)Interventional2004-03-31Recruiting
Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma [NCT01000285]Phase 1/Phase 218 participants (Actual)Interventional2010-09-30Completed
A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL [NCT04423926]Phase 1/Phase 291 participants (Anticipated)Interventional2020-06-10Recruiting
A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma [NCT02518750]Phase 23 participants (Actual)Interventional2016-11-23Terminated(stopped due to Due to slow accrual)
A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors [NCT00500890]Phase 32 participants (Actual)Interventional2005-09-02Terminated(stopped due to PI has left the institution)
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma [NCT00000658]Phase 3250 participants InterventionalCompleted
Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer [NCT00002476]Phase 30 participants Interventional1990-01-31Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN [NCT00002494]Phase 2134 participants (Actual)Interventional1992-05-31Completed
Pilot Study in AIDS-Related Lymphomas [NCT00002524]Phase 246 participants (Actual)Interventional1993-06-30Completed
TREATMENT OF PATIENTS WITH SUBOPTIMAL ('BULKY') STAGE IB CARCINOMA OF THE CERVIX: A RANDOMIZED COMPARISON OF RADICAL HYSTERECTOMY AND PELVIC AND PARA-AORTIC LYMPHADENECTOMY WITH OR WITHOUT NEOADJUVANT VINCRISTINE AND CISPLATIN CHEMOTHERAPY, PHASE III [NCT00002536]Phase 30 participants Interventional1996-12-31Completed
Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study [NCT00002548]Phase 3899 participants (Actual)Interventional1994-01-31Completed
Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) [NCT00199082]Phase 4650 participants (Anticipated)Interventional2002-07-31Completed
TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY [NCT00002704]Phase 2156 participants (Actual)Interventional1996-01-31Completed
Phase I Pilot Study of Multiple Cycles of High Dose Chemotherapy With Peripheral Blood Stem Cell Infusions In Advanced Stage Neuroblastoma [NCT00002740]Phase 130 participants (Anticipated)Interventional1996-05-31Completed
A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma [NCT00002590]Phase 2221 participants (Actual)Interventional1994-07-31Completed
PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA AND CLL [NCT00002908]Phase 20 participants Interventional1996-12-31Completed
Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old [NCT00002944]Phase 3428 participants (Actual)Interventional1997-04-30Completed
Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF [NCT00003490]Phase 230 participants (Anticipated)Interventional1998-10-31Completed
A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma [NCT00058370]6 participants (Actual)Interventional2003-02-28Completed
Evaluation of Chemotherapy as Initial Treatment for Retinoblastoma [NCT00002794]Phase 225 participants (Actual)Interventional1996-02-29Completed
PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS [NCT00002806]Phase 243 participants (Actual)Interventional1996-07-31Completed
Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study [NCT00002812]Phase 32,078 participants (Actual)Interventional1996-09-30Completed
A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies [NCT00003166]Phase 118 participants (Anticipated)Interventional1998-05-31Completed
"Prospective Non Randomized Study With Chemotherapy in Patients With Hodgkin's Disease and HIV Infection: Stanford V Regimen For Low Risk Patients, EBVP Regimen For High Risk Patients" [NCT00003262]Phase 230 participants (Anticipated)Interventional1997-05-31Active, not recruiting
Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradia [NCT00003700]Phase 2163 participants (Actual)Interventional1999-01-31Completed
Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma [NCT00003958]Phase 3702 participants (Actual)Interventional2002-09-30Completed
Intergroup Protocol for Treatment of Children With Hepatoblastoma [NCT00003994]Phase 3277 participants (Actual)Interventional1999-03-31Completed
A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas [NCT00003784]Phase 2102 participants (Actual)Interventional1999-05-31Completed
A Randomised Study of Timing of Thoracic Irradiation in Small Cell Lung Cancer (Study 8) [NCT00003364]Phase 3398 participants (Anticipated)Interventional1993-01-31Completed
Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia [NCT00199095]Phase 440 participants Interventional1997-02-28Completed
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) [NCT00199056]Phase 4225 participants Interventional1999-10-31Completed
Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) [NCT00198978]Phase 4377 participants (Actual)Interventional2003-01-31Completed
Phase I Trial of Liposomal Doxorubicin (Doxil) Based Combination Chemotherapy Regimen in AIDS-Associated Non-Hodgkin's Lymphoma [NCT00004162]Phase 148 participants (Anticipated)Interventional1997-06-30Completed
Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study [NCT00005578]Phase 3219 participants (Actual)Interventional1997-03-31Completed
ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study [NCT00005596]Phase 31,076 participants (Actual)Interventional2000-04-30Completed
A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO) [NCT04747912]Phase 225 participants (Anticipated)Interventional2021-03-02Recruiting
A Randomized, Phase 2 Study of Biomarker Guided Treatment in DLBCL [NCT04025593]Phase 2128 participants (Anticipated)Interventional2019-07-17Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma [NCT04625907]Phase 1/Phase 21,672 participants (Anticipated)Interventional2020-09-17Recruiting
Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of [NCT01478542]Phase 31,152 participants (Actual)Interventional2011-11-30Active, not recruiting
A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma [NCT00678327]Phase 31,202 participants (Actual)Interventional2008-08-29Active, not recruiting
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma [NCT00602667]Phase 2293 participants (Actual)Interventional2007-12-17Active, not recruiting
Multicenter Phase II Study for International Intraocular Retinoblastoma Classification Groups B, C & D Tumors Treated With Carboplatin-Etoposide-Vincristine-Cyclosporine-Focal Therapy Multimodality Protocol (OCRN Multicenter RB 2003) [NCT00110110]Phase 271 participants (Anticipated)Interventional2004-06-30Active, not recruiting
Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma [NCT03536039]Phase 228 participants (Actual)Interventional2016-01-27Completed
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednis [NCT01974440]Phase 3405 participants (Actual)Interventional2014-01-31Completed
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma [NCT01878617]Phase 2660 participants (Actual)Interventional2013-06-23Active, not recruiting
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) [NCT00198991]Phase 41,883 participants (Actual)Interventional2003-04-30Completed
Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia [NCT01319981]Phase 231 participants (Actual)Interventional2013-03-05Completed
A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors [NCT00061893]Phase 238 participants (Actual)Interventional2004-04-30Completed
UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy [NCT00083551]Phase 3668 participants (Actual)Interventional1998-08-31Completed
A Prospective Institutional Study for the Treatment of Children With Newly Diagnosed Langerhans Cell Histiocytosis Using a Cytarabine Contained Protocol [NCT04773366]Phase 3200 participants (Anticipated)Interventional2018-07-01Recruiting
A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods [NCT05359237]74 participants (Anticipated)Observational2022-11-16Recruiting
Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen [NCT01490060]47 participants (Actual)Interventional2012-05-31Completed
PS-341 and PS-341 + Epoch Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas [NCT00054665]Phase 250 participants (Actual)Interventional2003-02-28Completed
ALL Adult Consortium Trial: Adult ALL Trial [NCT00476190]Phase 2112 participants (Anticipated)Interventional2007-04-30Active, not recruiting
Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas [NCT00118209]Phase 3524 participants (Actual)Interventional2005-05-31Completed
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT00186875]Phase 247 participants (Actual)Interventional2003-11-30Completed
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) [NCT05518383]Phase 4300 participants (Anticipated)Interventional2022-05-25Recruiting
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Azacitidine and Chidamide Combined With CHOP (AC-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma With T-follicular Helper Phenotype (PTCL-TFH) [NCT05678933]Phase 3200 participants (Anticipated)Interventional2023-01-01Enrolling by invitation
Lenalidomide Combined With Anti-CD20 Monoclonal Antibodies-CHOP in Untreated Diffuse Large B-Cell Lymphoma Patients With MYC and BCL2 Co-expression : An Open-lable,Multicenter,Phase II Study [NCT04842487]Phase 280 participants (Anticipated)Interventional2021-04-10Not yet recruiting
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (A [NCT02566993]Phase 3613 participants (Actual)Interventional2016-08-30Completed
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System [NCT01831505]Phase 14 participants (Actual)Interventional2012-11-30Completed
A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) [NCT00882206]Phase 215 participants (Actual)Interventional2009-04-30Terminated(stopped due to Slow accrual)
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated [NCT02870907]Phase 2185 participants (Anticipated)Interventional2010-03-31Recruiting
A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma [NCT01746173]Phase 25 participants (Actual)Interventional2013-07-31Terminated(stopped due to Slow accrual and futility)
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma. [NCT02063022]Phase 3278 participants (Actual)Interventional2009-01-22Completed
Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia [NCT00038610]Phase 254 participants (Actual)Interventional2001-03-31Completed
A Multi-center, Prospective Clinical Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [NCT05164770]Phase 3160 participants (Anticipated)Interventional2021-03-01Recruiting
Lucentis in the Treatment of Retinoblastoma - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab in Subjects With Retinoblastoma [NCT01899066]Phase 220 participants (Anticipated)Interventional2013-07-31Recruiting
A Phase II Study of SGN-30 in Combination With CHOP in Anaplastic Large Cell Lymphoma [NCT00365274]Phase 26 participants (Actual)Interventional2006-08-31Terminated
Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China [NCT02405676]Phase 2/Phase 3200 participants (Anticipated)Interventional2015-01-31Active, not recruiting
Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index II or III Diffuse Large B Cell Lymphoma [NCT00039195]Phase 298 participants (Actual)Interventional2006-11-30Completed
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I) [NCT04402073]Phase 2205 participants (Anticipated)Interventional2022-11-11Recruiting
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents [NCT03206671]Phase 3650 participants (Anticipated)Interventional2017-08-03Recruiting
Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results [NCT00324467]Phase 2150 participants (Actual)Interventional2006-08-31Active, not recruiting
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL [NCT02626455]Phase 3547 participants (Actual)Interventional2016-01-06Terminated(stopped due to The study did not meet the primary endpoint. The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.)
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma [NCT00002318]Phase 3225 participants InterventionalActive, not recruiting
A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) [NCT00002576]Phase 3200 participants (Anticipated)Interventional1992-11-30Completed
Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia [NCT00002744]Phase 31,970 participants (Actual)Interventional1996-05-31Completed
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members [NCT00000703]45 participants InterventionalCompleted
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection [NCT00001339]Phase 242 participants Interventional1993-08-31Completed
Phase II Study of Neoadjuvant Vincristine, Ifosfamide, Doxorubicin, and AND G-CSF in Children With Advanced Stage Non-Rhabdomyosarcoma Soft Tissue Sarcomas [NCT00002804]Phase 243 participants (Actual)Interventional1996-09-30Completed
EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY [NCT00002816]Phase 3120 participants (Anticipated)Interventional1996-12-31Completed
Marrow-Ablative Chemo-Radiotherapy and Autologous Stem Cell Transplantation Followed by Interferon-Alpha Maintenance Treatment Versus Interferon-Alpha Maintenance Treatment Alone After a Chemotherapy-Induced Remission in Patients With Stages III or IV Fol [NCT00003152]Phase 3469 participants (Anticipated)Interventional1997-03-31Terminated(stopped due to low accrual)
RANDOMISED CLINICAL TRIAL OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE WITH MID-CYCLE VINCRISTINE (VICE) VERSUS STANDARD PRACTICE CHEMOTHERAPY IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER (SCLC) AND GOOD PERFORMANCE STATUS [NCT00002822]Phase 3400 participants (Anticipated)Interventional1996-03-31Completed
Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas [NCT00002569]Phase 3299 participants (Actual)Interventional1994-07-31Completed
PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA [NCT00002840]Phase 3350 participants (Anticipated)Interventional1996-08-31Completed
MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL [NCT00002599]Phase 3750 participants (Anticipated)Interventional1994-09-30Active, not recruiting
NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY [NCT00002611]Phase 33,031 participants (Actual)Interventional1995-07-31Completed
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FI [NCT00002665]Phase 250 participants (Anticipated)Interventional1995-07-31Completed
Pilot Study for the Treatment of Children With Newly Diagnosed Advanced Stage Hodgkin's Disease: Upfront Dose Intensive Chemotherapy [NCT00004010]Phase 299 participants (Actual)Interventional1999-10-31Completed
A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL [NCT00003578]Phase 3500 participants (Anticipated)Interventional1993-01-31Active, not recruiting
Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma [NCT00003650]Phase 3179 participants (Actual)Interventional1997-02-28Completed
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age. [NCT00002785]Phase 20 participants Interventional1996-07-31Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]Phase 31,500 participants (Anticipated)Interventional1998-12-31Active, not recruiting
Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol [NCT00002995]Phase 3483 participants (Actual)Interventional1997-08-31Completed
A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease [NCT00003421]Phase 3800 participants (Anticipated)Interventional1998-06-30Completed
Phase II Trial of Doxil, Vincristine and Decadron in Multiple Myeloma [NCT00003493]Phase 20 participants Interventional1998-11-30Completed
COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA [NCT00002803]Phase 244 participants (Anticipated)Interventional1995-07-31Completed
High Dose Combined Modality Therapy With Peripheral Blood Progenitor Cell Transplantation as Primary Treatment for Patients With Mantle Cell Lymphoma [NCT00003541]Phase 1/Phase 224 participants (Anticipated)Interventional1998-06-30Completed
RESPONSE DEPENDENT TREATMENT OF STAGES IA, IIA AND IIIA HODGKIN'S DISEASE WITH DBVE AND LOW DOSE INVOLVED FIELD IRRADIATION WITH OR WITHOUT ZINECARD: A PEDIATRIC ONCOLOGY GROUP PHASE III STUDY [NCT00002827]Phase 3294 participants (Actual)Interventional1996-10-31Completed
Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma [NCT00003595]Phase 3120 participants (Actual)Interventional1999-01-31Completed
Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA [NCT00002875]Phase 3421 participants (Actual)Interventional1996-12-31Completed
Vincristine, Etoposide and Cyclosporine A in Concert With Standard Dose Radiation Therapy in Diffuse Intrinsic Brain Stem Glioma - A Phase I Study of Dose Escalation of Vincristine [NCT00003625]Phase 17 participants (Actual)Interventional1998-12-31Completed
"A Phase II Up-Front Window Study of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study" [NCT00003955]Phase 277 participants (Actual)Interventional1999-09-30Completed
Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane With and Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma [NCT00003667]Phase 20 participants Interventional1998-09-30Completed
Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma [NCT00004039]Phase 20 participants (Actual)Interventional1998-06-30Withdrawn(stopped due to No patient accruals)
A Pilot Study of Dose Intensification of Methotrexate and Cyclophosphamide in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Non-Hodgkins Lymphoma and B-Cell All- A Limited Institution Phase III Pilot Study [NCT00003217]Phase 120 participants (Actual)Interventional1998-03-31Completed
A Phase II Study of the Safety, Efficacy and Pharmacokinetics of VX-710 in Combination With Doxorubicin and Vincristine in Patients With Small Cell Lung Cancer (SCLC) [NCT00003847]Phase 236 participants (Actual)Interventional1998-12-31Terminated
Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood [NCT00003859]Phase 3230 participants (Anticipated)Interventional1992-04-30Completed
Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized Aggressive Histologies of Non-Hodgkin's Lymphoma [NCT00005089]Phase 271 participants (Actual)Interventional2000-04-30Completed
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly [NCT01855750]Phase 3838 participants (Actual)Interventional2013-09-03Completed
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT02419469]Phase 21 participants (Actual)Interventional2015-11-13Terminated(stopped due to Slow Accrual)
A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] [NCT00379457]Phase 3600 participants (Anticipated)Interventional2006-06-30Recruiting
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. [NCT00002093]Phase 30 participants InterventionalCompleted
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma [NCT00002105]Phase 3220 participants InterventionalCompleted
Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma [NCT00002471]Phase 20 participants Interventional1990-02-28Completed
PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS [NCT00002489]Phase 20 participants Interventional1991-10-31Completed
A TRIAL OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH INTRAOCULAR RETINOBLASTOMA [NCT00002675]Phase 250 participants (Anticipated)Interventional1995-05-31Completed
"Minimal Initial Therapy (MIT) for Early Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy" [NCT00002987]Phase 3400 participants (Anticipated)Interventional1997-01-31Active, not recruiting
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated [NCT06091865]Phase 3904 participants (Anticipated)Interventional2023-12-11Recruiting
Ultimate Low Grade Glioma Study [NCT00003015]Phase 3200 participants (Anticipated)Interventional1997-01-31Active, not recruiting
A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors [NCT00003141]Phase 194 participants (Actual)Interventional1998-03-31Completed
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial [NCT00085735]Phase 3549 participants (Actual)Interventional2004-04-30Active, not recruiting
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV [NCT04139304]Early Phase 115 participants (Anticipated)Interventional2021-05-24Recruiting
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas [NCT00006436]Phase 268 participants (Actual)Interventional2001-01-29Active, not recruiting
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL) [NCT01390584]Phase 26 participants (Actual)Interventional2013-05-24Terminated(stopped due to slow accrual)
Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning [NCT00274924]Phase 2100 participants (Actual)Interventional2006-09-26Completed
Phase II Pilot Study Of Rituximab Plus CHOP In Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia [NCT00060346]Phase 216 participants (Actual)Interventional2004-10-05Terminated(stopped due to slow accrual)
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease [NCT00003389]Phase 3854 participants (Actual)Interventional1999-06-17Completed
Non-Hodgkin's Lymphoma T Cell Protocol [NCT00003423]Phase 3100 participants (Anticipated)Interventional1995-05-31Active, not recruiting
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotep [NCT00003273]Phase 20 participants (Actual)Interventional1997-11-30Withdrawn
Phase II Study of CHOP/Rituxan Plus VELCADE in Mediastinal Large B-cell Lymphoma [NCT00361621]Phase 23 participants (Actual)Interventional2006-07-31Terminated(stopped due to Closed due to slow accrual)
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN [NCT00002865]Phase 225 participants (Actual)Interventional1995-04-30Completed
A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma [NCT00003375]Phase 2/Phase 3370 participants (Actual)Interventional1998-10-31Completed
Phase I Study of Combination Immunochemotherapy in Patients With Advanced Colorectal Carcinoma [NCT00003543]Phase 118 participants (Anticipated)Interventional1998-06-30Completed
A Phase I/II Feasibility Study of Oral Etoposide Given Concurrently With Radiotherapy Followed With Dose Intensive Adjuvant Chemotherapy for Children With Newly Diagnosed High Stage Medulloblastoma [NCT00003573]Phase 253 participants (Actual)Interventional1998-11-30Completed
Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkin's Lymphoma: A Phase III Randomized Clinical Trial - Intergroup Collaborative Study [NCT00004179]Phase 3475 participants (Actual)Interventional1999-05-31Completed
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study [NCT00003783]Phase 236 participants (Actual)Interventional1999-03-31Completed
A Pilot Study of Mitoxantrone-Based Four Drug Reinduction in Combination With Bortezomib for Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Children and Young Adults [NCT02535806]Phase 22 participants (Actual)Interventional2015-07-31Terminated(stopped due to Funding source discontinued)
MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma [NCT02541565]Phase 130 participants (Actual)Interventional2015-11-24Completed
Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year [NCT00365755]Phase 30 participants InterventionalCompleted
A Safety Pilot Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors [NCT02786719]13 participants (Actual)Interventional2016-06-30Completed
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors [NCT02677116]Phase 168 participants (Actual)Interventional2016-08-29Completed
Phase I-II Study of Liposomal Vincristine (VSLI) and Dexamethasone in Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT00144963]Phase 1/Phase 236 participants (Actual)Interventional2002-07-31Completed
An Evaluation of the Pharmacokinetic Profile of VSLI (Vincristine Sulfate Liposome Injection, 0.16 mg/mL) in Patients With Malignant Melanoma and Hepatic Dysfunction Secondary to Metastases [NCT00145041]Phase 17 participants (Actual)Interventional2005-02-28Completed
A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castlem [NCT03864419]Phase 140 participants (Anticipated)Interventional2019-10-24Recruiting
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Ne [NCT02881086]Phase 31,000 participants (Actual)Interventional2016-08-31Active, not recruiting
Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial] [NCT00379041]Phase 31,158 participants (Anticipated)Interventional1993-09-01Active, not recruiting
The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma [NCT03045471]50 participants (Anticipated)Observational2017-03-01Not yet recruiting
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma [NCT01451515]Phase 223 participants (Actual)Interventional2012-05-25Completed
A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Ly [NCT02596971]Phase 1/Phase 291 participants (Actual)Interventional2015-12-22Completed
Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Random [NCT02428751]Phase 3216 participants (Anticipated)Interventional2015-09-30Recruiting
A Phase Ib/II, Open-Label Study Evaluating the Safety, Efficacy and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With B-Cell [NCT02055820]Phase 1/Phase 2267 participants (Actual)Interventional2013-11-17Completed
A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation [NCT02333513]100 participants (Anticipated)Interventional2015-02-28Not yet recruiting
Efficacy of Consolidative Involved-site Radiotherapy Following Sufficient Chemotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma: Wuhan University Cancer Center -NHL03 Trial [NCT02449265]Phase 3160 participants (Anticipated)Interventional2015-10-31Recruiting
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma [NCT06072131]Phase 3504 participants (Anticipated)Interventional2023-10-04Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome [NCT04623541]Phase 1/Phase 2184 participants (Anticipated)Interventional2020-11-25Recruiting
Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma [NCT02911142]Phase 1/Phase 212 participants (Actual)Interventional2017-07-03Active, not recruiting
A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma [NCT05899621]332 participants (Anticipated)Observational2023-06-01Recruiting
Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR-CHOP, for Previously Untreated Diffuse Large B-Cell Lymphoma [NCT05455697]Phase 1/Phase 235 participants (Anticipated)Interventional2023-01-26Recruiting
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology [NCT01228331]Phase 2/Phase 3745 participants (Actual)Interventional2010-10-31Active, not recruiting
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. [NCT05049473]Phase 2100 participants (Anticipated)Interventional2014-01-31Recruiting
A Randomized Controlled Study of Dasatinib Combined With Reduced Intensive Consolidation Chemotherapy in Newly Diagosed Philadelphia Chromesome Positive Adult Lymphoblastic Leukemia [NCT05026229]60 participants (Anticipated)Interventional2021-09-06Recruiting
Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial [NCT00003437]Phase 31,800 participants (Anticipated)Interventional1997-01-31Active, not recruiting
"A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With Poor Risk Medulloblastoma, PNET, and Disseminated Ependymoma" [NCT00003309]Phase 233 participants (Anticipated)Interventional1999-05-04Completed
Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma [NCT00392834]Phase 234 participants (Actual)Interventional2006-09-30Completed
Concurrent Ponatinib With Chemotherapy for Young Adults With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [NCT02776605]Phase 230 participants (Actual)Interventional2016-06-30Active, not recruiting
Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) [NCT01439347]Phase 326 participants (Actual)Interventional2012-03-31Terminated(stopped due to Sponsor decision)
A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy [NCT01414855]Phase 2100 participants (Actual)Interventional2011-08-31Completed
A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With [NCT01412879]Phase 253 participants (Actual)Interventional2011-11-30Completed
Open, Non-Interventional, Multicenter Trial of MabThera in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma [NCT02486952]154 participants (Actual)Observational2005-08-31Completed
Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma [NCT03018626]Phase 3402 participants (Anticipated)Interventional2017-07-27Recruiting
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I [NCT02553460]Phase 1/Phase 250 participants (Actual)Interventional2016-01-29Active, not recruiting
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor [NCT00084838]Phase 225 participants (Actual)Interventional2003-02-28Completed
Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas [NCT03036904]Phase 131 participants (Actual)Interventional2017-02-06Completed
Paediatric Hepatic International Tumour Trial [NCT03017326]Phase 3450 participants (Anticipated)Interventional2017-08-24Recruiting
A Phase ll Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (RM-CHOP) for Previously Untreated Aggressive Diffuse Large B-cell Lymphoma [NCT02531308]Phase 25 participants (Actual)Interventional2015-07-31Terminated(stopped due to poor accrual)
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [NCT02523976]Phase 230 participants (Actual)Interventional2015-08-01Completed
A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma [NCT02398240]Phase 240 participants (Anticipated)Interventional2015-05-31Completed
A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma [NCT00049036]Phase 2106 participants (Actual)Interventional2003-03-31Completed
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT04752163]Phase 1/Phase 217 participants (Actual)Interventional2021-03-25Completed
A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons [NCT04478292]Phase 3330 participants (Anticipated)Interventional2021-03-01Recruiting
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblast [NCT03860844]Phase 267 participants (Actual)Interventional2019-08-06Terminated(stopped due to Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.)
Dose/Schedule Finding Study of Palonosetron in Sarcoma Patients Receiving Multi-Day Chemotherapy With Adriamycin and Ifosfamide (AI) [NCT00410488]51 participants (Actual)Interventional2006-12-31Completed
Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring. [NCT00458848]Phase 2470 participants (Actual)Interventional2004-10-31Completed
A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma [NCT00389818]Phase 243 participants (Actual)Interventional2007-01-31Completed
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas [NCT01445535]Phase 115 participants (Actual)Interventional2009-01-13Completed
A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma. [NCT00211185]Phase 249 participants (Actual)Interventional2004-03-14Completed
Phase III Randomized Trial of Thalidomide/Dexamethasone vs VAD as Induction Chemotherapy for Newly Diagnosed Myeloma Patients and Evaluation of the Effects of Zoledronate on Chemotherapy Induced Apoptosis and Antigen Presentation. [NCT00215943]Phase 390 participants (Actual)Interventional2003-06-30Terminated(stopped due to Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective regimens.)
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 [NCT03755804]Phase 2250 participants (Anticipated)Interventional2018-12-12Recruiting
A Phase Ib/II Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) [NCT03571308]Phase 1/Phase 239 participants (Actual)Interventional2017-06-02Completed
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [NCT03117751]Phase 2/Phase 3790 participants (Actual)Interventional2017-03-29Active, not recruiting
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049]Phase 35,937 participants (Actual)Interventional2012-02-29Active, not recruiting
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma [NCT00574496]Phase 225 participants (Actual)Interventional2007-11-13Completed
A Rand. Trial Comp Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment [NCT00774202]Phase 2/Phase 317 participants (Actual)Interventional2003-11-30Completed
Phase II Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage [NCT00890656]Phase 290 participants (Actual)Interventional2003-06-30Completed
Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma [NCT01857934]Phase 2153 participants (Actual)Interventional2013-07-05Active, not recruiting
A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma ( [NCT01889069]Phase 3159 participants (Actual)Interventional2013-07-31Completed
Anti-PD-1 Antibody (Camrelizumab) Plus R-CHOP Regimen for the Primary Extranodal Treatment-Naive Diffuse Large B Cell Lymphoma (CREDIT): a Prospective, Multicenter, Single-Arm, Phase II Trial [NCT05093140]Phase 230 participants (Anticipated)Interventional2022-06-01Not yet recruiting
A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients With Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma [NCT00088881]Phase 262 participants (Actual)Interventional2004-12-31Terminated
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730 [NCT03817320]Phase 1/Phase 231 participants (Anticipated)Interventional2019-02-12Recruiting
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]Phase 3680 participants (Anticipated)Interventional2024-01-22Not yet recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgki [NCT03677141]Phase 1/Phase 2117 participants (Actual)Interventional2019-03-08Completed
Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma, A Phase I Study [NCT00509353]Phase 126 participants (Actual)Interventional2007-01-31Completed
BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma [NCT00049595]Phase 3552 participants (Actual)Interventional2002-08-31Completed
Phase Ib/II Study of Toripalimab In Combination With Rituximab Followed by R-CHOP Regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) for Elderly Naïve Patients With Diffuse Large B-cell Lymphoma [NCT04058470]Phase 1/Phase 2140 participants (Anticipated)Interventional2020-04-24Recruiting
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia [NCT01117441]Phase 36,136 participants (Actual)Interventional2010-06-30Completed
A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol [NCT00136435]Phase 2100 participants (Anticipated)Interventional2002-06-30Active, not recruiting
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667) [NCT03407144]Phase 2340 participants (Anticipated)Interventional2018-04-09Active, not recruiting
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma [NCT00003101]Phase 260 participants (Anticipated)Interventional1997-08-31Completed
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) [NCT00003215]Phase 3400 participants (Anticipated)Interventional1997-04-30Completed
Phase II CCOP Trial of High Dose Methotrexate/ARA-C and HCVAD for Newly Diagnosed Nodular and Diffuse Mantle Cell Lymphoma and Their Blastic Variants [NCT00003311]Phase 219 participants (Actual)Interventional1998-05-20Completed
ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study [NCT00005585]Phase 3838 participants (Actual)Interventional2000-04-30Completed
ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study [NCT00005603]Phase 3276 participants (Actual)Interventional2000-03-31Completed
Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study [NCT00003671]Phase 259 participants (Actual)Interventional1998-12-31Completed
A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups [NCT00003815]Phase 30 participants Interventional1994-06-30Active, not recruiting
A Phase I/II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients With Advanced Stage Diffuse Large B-cell Lymphomas [NCT00379574]Phase 1/Phase 249 participants (Actual)Interventional2006-09-30Completed
A Phase II, Randomized, Clinical Trial Assessing Efficacy And Safety Of Oral Prednisolone vs Intravenous Vincristine In The Treatment Of Infantile [NCT00555464]Phase 28 participants (Actual)Interventional2007-11-30Terminated(stopped due to The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas)
A Randomised Multicentre Trial of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy in Combination With Rituximab (Mabthera®) for Stage I - II Low Grade Follicular Lymphoma [NCT00115700]Phase 3150 participants (Actual)Interventional2000-02-29Completed
A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings [NCT01435018]Phase 3334 participants (Actual)Interventional2013-10-01Completed
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy [NCT01925612]Phase 287 participants (Actual)Interventional2013-08-31Terminated(stopped due to Sponsor decision based on portfolio prioritization and changing treatment landscape in frontline DLBCL)
Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa [NCT01775475]Phase 27 participants (Actual)Interventional2016-09-15Completed
A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma [NCT05600686]Phase 224 participants (Anticipated)Interventional2023-05-24Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085]Phase 34,772 participants (Anticipated)Interventional2019-10-31Recruiting
An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL [NCT01459887]Phase 3278 participants (Actual)Interventional2006-09-30Completed
Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma [NCT02727387]Phase 2155 participants (Actual)Interventional2009-06-01Completed
A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgki [NCT01724021]Phase 3743 participants (Actual)Interventional2012-12-31Completed
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alt [NCT02042391]Phase 260 participants (Actual)Interventional2015-02-03Completed
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia [NCT05303792]Phase 266 participants (Anticipated)Interventional2023-02-27Recruiting
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas [NCT04803201]Phase 2170 participants (Anticipated)Interventional2021-07-30Recruiting
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma [NCT00887146]Phase 3360 participants (Anticipated)Interventional2009-09-30Recruiting
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [NCT03808610]Phase 1/Phase 250 participants (Anticipated)Interventional2019-04-03Recruiting
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ [NCT03589326]Phase 3245 participants (Actual)Interventional2018-10-04Active, not recruiting
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD [NCT02298283]Phase 240 participants (Actual)Interventional2015-04-30Completed
NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma [NCT02035137]Phase 2114 participants (Actual)Interventional2014-07-31Completed
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) [NCT04221035]Phase 3800 participants (Anticipated)Interventional2019-11-05Recruiting
"Medical Treatment of High-Risk Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies" [NCT00846430]Phase 29 participants (Actual)Interventional2008-10-31Completed
Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI) [NCT02732015]Phase 237 participants (Actual)Interventional2016-10-12Terminated(stopped due to Terminated per PI's request)
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma [NCT05535166]Phase 2120 participants (Anticipated)Interventional2022-12-20Recruiting
A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy [NCT03505762]Phase 280 participants (Anticipated)Interventional2018-07-19Recruiting
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents [NCT03020030]Phase 3560 participants (Actual)Interventional2017-03-03Active, not recruiting
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS) [NCT02567435]Phase 3321 participants (Actual)Interventional2016-06-01Active, not recruiting
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Initial Treatment of Patients With Diffuse Large B-cell Lymphoma [NCT03022123]270 participants (Anticipated)Interventional2016-11-30Recruiting
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL [NCT01483690]Phase 1/Phase 223 participants (Actual)Interventional2011-12-31Terminated(stopped due to Toxicity)
A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincr [NCT02162771]Phase 3140 participants (Actual)Interventional2014-07-14Completed
An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients [NCT03318835]Phase 3162 participants (Anticipated)Interventional2017-08-22Recruiting
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer [NCT02299999]Phase 21,460 participants (Actual)Interventional2014-04-07Active, not recruiting
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) [NCT02404220]Phase 1/Phase 230 participants (Actual)Interventional2015-05-06Terminated
Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia [NCT05645718]Phase 227 participants (Anticipated)Interventional2023-07-14Recruiting
A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma [NCT03758989]Phase 240 participants (Anticipated)Interventional2019-05-08Recruiting
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia [NCT03229746]Phase 440 participants (Actual)Interventional2017-08-01Completed
Phase Ib - II Study of Entospletinib (ENTO) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With aaIPI>=1 Treated by Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP) [NCT03225924]Phase 1/Phase 225 participants (Actual)Interventional2017-07-26Terminated(stopped due to Stop of drug development)
A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) [NCT05681260]Phase 3200 participants (Anticipated)Interventional2023-02-06Recruiting
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) +/- Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative (Ph-) B-cell Lymphoblastic Lymphoma/Leuke [NCT05453500]Phase 230 participants (Anticipated)Interventional2023-03-27Recruiting
The Palliative Benefit of Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma: Wuhan University Cancer Center - NHL04 Trial [NCT02449278]Phase 3120 participants (Anticipated)Interventional2015-10-31Recruiting
A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Chemotherapy in the Treatment of de Novo Adult Philadelphia Chromosome-positive Acute Lymphoid Leukemia [NCT05466175]Phase 255 participants (Anticipated)Interventional2022-10-01Not yet recruiting
Zanubrutinib Combination With R-CHOP in Treating Patients With Newly Diagnosed Untreated Non-GCB DLBCL [NCT04835870]Phase 278 participants (Anticipated)Interventional2021-04-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00002766 (1) [back to overview]Complete Remission (CR)
NCT00003389 (3) [back to overview]Incidence of Second Cancers
NCT00003389 (3) [back to overview]5-year Overall Survival
NCT00003389 (3) [back to overview]Failure-free Survival at 5 Years
NCT00004031 (3) [back to overview]Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT00004031 (3) [back to overview]2-year Overall Survival Rates
NCT00004031 (3) [back to overview]2 Year Progression-free Survival
NCT00004228 (2) [back to overview]Percentage of Patients With Overall Survival as Assessed by Time to Death
NCT00004228 (2) [back to overview]Event-free Survival
NCT00005780 (10) [back to overview]Overall Survival (OS)
NCT00005780 (10) [back to overview]Percentage of Participants Whose Cancer Shrinks or Disappears After Treatment With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R)
NCT00005780 (10) [back to overview]Percentage of Participants With Grade 3 or Higher Serious and/or Non-serious Toxicity That Occurred That is at Least Possibly Related to Drug or Vaccine
NCT00005780 (10) [back to overview]Percentage of Participants With an Antibody Response to Idiotype Vaccine
NCT00005780 (10) [back to overview]Percentage of Participants With Induction of Type 1 Cytokine T-cell Response
NCT00005780 (10) [back to overview]Percentage of Participants With Antibodies to Keyhole Limpet Haemocyanin (KLH)
NCT00005780 (10) [back to overview]Progression Free Survival (PFS) in Participants Who Received Idiotype Vaccine
NCT00005780 (10) [back to overview]Time to Recovery of CD4 T Lymphocytes (CD4+)
NCT00005780 (10) [back to overview]Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R)
NCT00005780 (10) [back to overview]Here is the Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0).
NCT00006184 (2) [back to overview]Number of Participants With Adverse Events
NCT00006184 (2) [back to overview]Immune Response
NCT00006436 (16) [back to overview]Percentage of Participants With Complete Response
NCT00006436 (16) [back to overview]Number of Cycles of Hematologic Toxicity
NCT00006436 (16) [back to overview]Median Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)
NCT00006436 (16) [back to overview]Number of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia
NCT00006436 (16) [back to overview]Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0)
NCT00006436 (16) [back to overview]Percentage of Participants With CR/CRu Lasting 1 Year
NCT00006436 (16) [back to overview]Progression Free Survival at 1 Year
NCT00006436 (16) [back to overview]Recovery of CD4 T Cells (CD4) Counts
NCT00006436 (16) [back to overview]1 Year Overall Survival
NCT00006436 (16) [back to overview]Overall Response
NCT00006436 (16) [back to overview]Number of Participants With ≥ Grades 3-5 Non-hematologic Toxicity
NCT00006436 (16) [back to overview]1 Year Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)
NCT00006436 (16) [back to overview]Median Duration of Complete Response/Complete Response Unconfirmed
NCT00006436 (16) [back to overview]Median Overall Survival
NCT00006436 (16) [back to overview]Median Progression Free Survival (PFS)
NCT00006436 (16) [back to overview]Recovery of Human Immunodeficiency Virus (HIV) Viral Load
NCT00006721 (6) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00006721 (6) [back to overview]Progression-free Survival at 5 Years
NCT00006721 (6) [back to overview]Progression-free Survival at 2 Years
NCT00006721 (6) [back to overview]Overall Survival at 5 Years
NCT00006721 (6) [back to overview]Overall Survival at 2 Years
NCT00006721 (6) [back to overview]Objective Response (Confirmed and Unconfirmed Complete and Partial Responses)
NCT00025259 (4) [back to overview]Overall Survival
NCT00025259 (4) [back to overview]Event-free Survival
NCT00025259 (4) [back to overview]Disease Response Assessed by Modified RECIST Criteria
NCT00025259 (4) [back to overview]Grade 3 or 4 Non-hematologic Toxicity
NCT00026208 (7) [back to overview]Survival at 5 and 10 Years
NCT00026208 (7) [back to overview]Frequency of Complete Response
NCT00026208 (7) [back to overview]Early Treatment-related Toxicity
NCT00026208 (7) [back to overview]Overall Survival (OS)
NCT00026208 (7) [back to overview]Progression-free Survival (PFS)
NCT00026208 (7) [back to overview]Second Hodgkin's Disease Progression
NCT00026208 (7) [back to overview]Late Treatment-related Toxicity
NCT00027846 (6) [back to overview]Event-free Survival (EFS)
NCT00027846 (6) [back to overview]Overall Survival
NCT00027846 (6) [back to overview]Rate of Gross-total or Near-total Resection and Second Surgery After Chemotherapy
NCT00027846 (6) [back to overview]Local Control and Patterns of Failure
NCT00027846 (6) [back to overview]Event-free Survival
NCT00027846 (6) [back to overview]Event-free Survival (EFS)
NCT00031590 (1) [back to overview]Long Term Survival
NCT00038610 (3) [back to overview]Disease-Free Survival Rate at 2-year and 5-year.
NCT00038610 (3) [back to overview]Overall Survival Rate at 2-year and 5-year.
NCT00038610 (3) [back to overview]Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate
NCT00039130 (3) [back to overview]2 Year Overall Survival
NCT00039130 (3) [back to overview]Complete Response Rate
NCT00039130 (3) [back to overview]2 Year Event Free Survival
NCT00039195 (1) [back to overview]Progression Free Survival
NCT00039377 (5) [back to overview]5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups
NCT00039377 (5) [back to overview]5 Year Overall Survival for Autologous & Allogeneic Transplant Groups
NCT00039377 (5) [back to overview]Number of Participants Who Achieved a BCR-ABL Response at 12 Months
NCT00039377 (5) [back to overview]Disease Free Survival
NCT00039377 (5) [back to overview]Overall Survival
NCT00041132 (3) [back to overview]Overall Survival
NCT00041132 (3) [back to overview]Progression-free Survival
NCT00041132 (3) [back to overview]Response
NCT00043979 (14) [back to overview]Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy
NCT00043979 (14) [back to overview]Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)
NCT00043979 (14) [back to overview]Cluster of Differentiation 4 (CD4) Reconstitution
NCT00043979 (14) [back to overview]Number of Participants to Complete Conversion to >95% Donor Chimerism
NCT00043979 (14) [back to overview]Early Post Transplantation Relapse
NCT00043979 (14) [back to overview]Median Progression Free Survival
NCT00043979 (14) [back to overview]Number of Participants With Acute and Chronic GVHD
NCT00043979 (14) [back to overview]Median Time to Reach Absolute Neutrophil Count of 500/mm(3)
NCT00043979 (14) [back to overview]Number of Participants With Engraftment
NCT00043979 (14) [back to overview]Toxicity
NCT00043979 (14) [back to overview]Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)
NCT00043979 (14) [back to overview]Median Survival From Date of Progression
NCT00043979 (14) [back to overview]Median Time to Reach a Platelet Count of 50,000/mm(3)
NCT00043979 (14) [back to overview]Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant
NCT00049036 (1) [back to overview]Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment
NCT00051311 (9) [back to overview]Median Time to Neutrophil Recovery
NCT00051311 (9) [back to overview]Median Cycles of Induction Chemotherapy With Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, and Prednisone Given to Recipients
NCT00051311 (9) [back to overview]Percentage of Recipients Who Achieved Donor Chimerism at Day +14
NCT00051311 (9) [back to overview]Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis
NCT00051311 (9) [back to overview]Number of Recipients With a Response to Reduced-intensity Stem Cell Transplantation (RIST)
NCT00051311 (9) [back to overview]Median Time to Platelet Recovery
NCT00051311 (9) [back to overview]Number of Recipients Evaluable Who Achieved Full Donor Chimerism at Day+100
NCT00051311 (9) [back to overview]Number of Recipients Who Developed Chronic Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis
NCT00051311 (9) [back to overview]Number of Recipients With Non-serious Adverse Events
NCT00054665 (2) [back to overview]Number of Participants With Adverse Events
NCT00054665 (2) [back to overview]Clinical Response Rate
NCT00057811 (4) [back to overview]Response Rate
NCT00057811 (4) [back to overview]Grade ≥ 3 Stomatitis
NCT00057811 (4) [back to overview]Toxic Death
NCT00057811 (4) [back to overview]Minimal Residual Disease
NCT00058422 (1) [back to overview]Incidence of Adverse Experiences
NCT00059839 (1) [back to overview]Event-free Survival (EFS)
NCT00060346 (1) [back to overview]Objective Response to Treatment
NCT00061893 (2) [back to overview]Occurrence of Severe Toxicity
NCT00061893 (2) [back to overview]Event Free Survival
NCT00061945 (6) [back to overview]Number of Participants Achieving Complete Remission
NCT00061945 (6) [back to overview]Disease-free Survival, for Only Complete Response Patients
NCT00061945 (6) [back to overview]Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)
NCT00061945 (6) [back to overview]Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]Overall Survival
NCT00061945 (6) [back to overview]Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
NCT00069238 (2) [back to overview]Number of Participants With Adverse Events
NCT00069238 (2) [back to overview]Maximum Tolerated Dose (MTD) of Alemtuzumab
NCT00070018 (1) [back to overview]Progression-free Survival
NCT00072280 (1) [back to overview]"Failure-free Survival (FFS) in Chemotherapy Plus Possible Surgery Arm"
NCT00072384 (6) [back to overview]Patterns of Failure for Group C and Group D in Terms of Vitreous vs Patterns of Failure for Group C and Group D in Terms of Vitreous vs Retinal vs Both as Sites of Recurrence
NCT00072384 (6) [back to overview]Patterns of Treatment Failure vs. no Treatment Failure for Group C Eyes and Group D Eyes According to Initial Sites of Involvement
NCT00072384 (6) [back to overview]Event-free Survival (EFS)
NCT00072384 (6) [back to overview]Group C Eyes - Treatment Failure Within One Year
NCT00072384 (6) [back to overview]Group D Eyes - Treatment Failure Within One Year
NCT00072384 (6) [back to overview]Toxicity Associated With Chemotherapy
NCT00074490 (4) [back to overview]Percentage of Patients With Opportunistic Infection
NCT00074490 (4) [back to overview]Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD)
NCT00074490 (4) [back to overview]Percentage of Patients to Receive T Cell Infusion
NCT00074490 (4) [back to overview]Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)
NCT00075582 (6) [back to overview]Percentage of Patients With Stage 1, Clinical Group IIB or C (Node Positive) or Stage 2 Failure Free at 5 Years Following Study Entry
NCT00075582 (6) [back to overview]Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 2 Failure Free at 5 Years Following Study Entry
NCT00075582 (6) [back to overview]Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry
NCT00075582 (6) [back to overview]Percentage of Patients With Delayed Surgical Procedures
NCT00075582 (6) [back to overview]Cumulative Incidence of Patients Who Receive Reduced Doses of Radiation Therapy
NCT00075582 (6) [back to overview]Cumulative Incidence of Group III Patients Who Received With Reduced Radiotherapy Dose
NCT00075725 (7) [back to overview]Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions
NCT00075725 (7) [back to overview]Correlation of Early Marrow Response Status With MRD Positive.
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).
NCT00075725 (7) [back to overview]Correlation of Early Marrow Response Status With MRD Negative.
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).
NCT00077207 (6) [back to overview]Long Term Feasibility Success
NCT00077207 (6) [back to overview]Percent Probability of Progression-free Survival (PFS)
NCT00077207 (6) [back to overview]Percentage Probability of Event-free Survival (EFS)
NCT00077207 (6) [back to overview]Number of Participants Who Experienced a Grade 3 or 4 Thrombocytopenia and/or Neutropenia.
NCT00077207 (6) [back to overview]Number of Participants Who Experienced Toxic Death
NCT00077207 (6) [back to overview]Short Term Feasibility Success
NCT00079417 (5) [back to overview]Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0
NCT00079417 (5) [back to overview]Response Rate (RR) at Patient Level After the First Course of Therapy
NCT00079417 (5) [back to overview]Response Rate (RR) at Eye Levels After the First Course of Therapy
NCT00079417 (5) [back to overview]Event-free Survival
NCT00079417 (5) [back to overview]Event-free Survival Rate (EFSR) Defined as the Need for Non-protocol Chemotherapy, Enucleation, or EBRT at the Patient Level
NCT00083551 (1) [back to overview]Overall Survival
NCT00084838 (19) [back to overview]Grade 3-4 Allergy/Immunology
NCT00084838 (19) [back to overview]2-yr Overall Survival
NCT00084838 (19) [back to overview]Grade 3-4 Hepatic Events
NCT00084838 (19) [back to overview]Grade 3-4 Muscloskeletal Events
NCT00084838 (19) [back to overview]Pre-Radiation Therapy Chemotherapeutic Response
NCT00084838 (19) [back to overview]Grade 3/4 Events
NCT00084838 (19) [back to overview]Grade 3-4 Renal/Genitourinary Events
NCT00084838 (19) [back to overview]Grade 3-4 Pulmonary Events
NCT00084838 (19) [back to overview]Grade 3-4 Pain Events
NCT00084838 (19) [back to overview]Grade 3-4 Neurology Events
NCT00084838 (19) [back to overview]Grade 3-4 Metabolic/Laboratory Events
NCT00084838 (19) [back to overview]Grade 3-4 Infection/Febrile Neutropenia Events
NCT00084838 (19) [back to overview]Grade 3-4 Hemorrhage Events
NCT00084838 (19) [back to overview]Grade 3-4 Gastrointestinal Events
NCT00084838 (19) [back to overview]Grade 3-4 Dermatology Events
NCT00084838 (19) [back to overview]Grade 3-4 Constitutional Events
NCT00084838 (19) [back to overview]Grade 3-4 Cardiovascular Events
NCT00084838 (19) [back to overview]Grade 3-4 Blood/Bone Marrow Events
NCT00084838 (19) [back to overview]Grade 3-4 Auditory/Hearing Events
NCT00085202 (11) [back to overview]Associative Memory for Two Risk Group at Enrollment
NCT00085202 (11) [back to overview]Perceptual Speed for Two Risk Group at Enrollment
NCT00085202 (11) [back to overview]Perceptual Speed for Two Risk Group at 5 Years After Enrollment
NCT00085202 (11) [back to overview]Reading Decoding Composite Scores in the Intervention and Standard of Care Groups
NCT00085202 (11) [back to overview]Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors
NCT00085202 (11) [back to overview]Processing Speed for Two Risk Group at Enrollment
NCT00085202 (11) [back to overview]Number of Average Risk Patients Whose Treatment Failure Included the Posterior Fossa
NCT00085202 (11) [back to overview]Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.
NCT00085202 (11) [back to overview]Frequency of Mutations Associated With SHH and WNT Tumors
NCT00085202 (11) [back to overview]Associative Memory for Two Risk Group at 5 Years After Enrollment
NCT00085202 (11) [back to overview]Processing Speed for Two Risk Group at 5 Years After Enrollment
NCT00085735 (22) [back to overview]Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays
NCT00085735 (22) [back to overview]Event-free Survival (EFS)
NCT00085735 (22) [back to overview]Event-free Survival (EFS)
NCT00085735 (22) [back to overview]Overall Survival (OS)
NCT00085735 (22) [back to overview]Overall Survival (OS)
NCT00085735 (22) [back to overview]Incidence of Endocrine Dysfunction as Measured by Growth Hormone Stimulation Tests at the Time of Completion of Therapy by Radiotherapy (RT) Group
NCT00085735 (22) [back to overview]Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 2 (27 - 48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 1 (4-15 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 2 (27-48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Incidence of Grade 3+ Hearing Loss at 1-year Post Treatment as Assessed by CTCAE v4
NCT00085735 (22) [back to overview]Local Posterior Fossa (LPF) Failure Rate
NCT00085735 (22) [back to overview]Non-local Posterior Fossa (NLPF) Failure Rate
NCT00085735 (22) [back to overview]Non-posterior Fossa (NPF) Failure Rate
NCT00085735 (22) [back to overview]Overall Survival (OS) by Molecular Subgroup Based on Methylation Arrays
NCT00085735 (22) [back to overview]Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Endocrine Function by CSI Group
NCT00085735 (22) [back to overview]Post-treatment Grade 3+ Hearing Loss as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4
NCT00085735 (22) [back to overview]Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 1 (4-15 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 2 (27-48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 1 (4 - 15 Months Post Diagnosis).
NCT00088530 (4) [back to overview]Progression-Free Survival (PFS)
NCT00088530 (4) [back to overview]Overall Survival
NCT00088530 (4) [back to overview]Complete Response (CR) and Complete Response Unconfirmed (CRu)
NCT00088530 (4) [back to overview]Overall Response Rate (ORR) Lasting at Least 4 Months
NCT00088881 (4) [back to overview]Functional CR in Patients Treated With R-CHOP Followed by 90-Yttrium -Zevalin™.
NCT00088881 (4) [back to overview]Complete Response (CR) +Complete Response/Uncertain (CRu) in Patients Treated With R-CHOP Followed by 90-Yttrium -Zevalin™.
NCT00088881 (4) [back to overview]3-year Time to Treatment Failure (TTF) Rate
NCT00088881 (4) [back to overview]3-year Overall Survival (OS) Rate
NCT00096135 (1) [back to overview]Event-free Survival
NCT00098839 (4) [back to overview]Pharmacokinetics
NCT00098839 (4) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01%
NCT00098839 (4) [back to overview]Event-free Survival Rate
NCT00098839 (4) [back to overview]Remission Re-induction (CR2) Rate
NCT00101010 (2) [back to overview]Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses
NCT00101010 (2) [back to overview]Number of Participants Experienced Grade 3 or Higher Cardiac Toxicity After Treatment: Cardiac Toxicity as Measured by Left Ventricular Ejection Fraction (LVEF) on Echocardiogram (ECHO) After 8 Courses
NCT00101101 (3) [back to overview]Median Event Free Survival (EFS)
NCT00101101 (3) [back to overview]Rate of Immunological Response to Vaccination
NCT00101101 (3) [back to overview]Occurrence of Related Serious Adverse Events (SAEs)
NCT00103285 (10) [back to overview]Optimal Time Point for Advance Health Related Quality of Life Intervention
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-High Patients.
NCT00103285 (10) [back to overview]Early Marrow Status (EMS) by MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Low Patients
NCT00103285 (10) [back to overview]Event-Free Survival Probability According to MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]Health-related Quality of Life Relative to Physical, Social and Emotional Impairment
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]Overall Survival Probability (OS) According to Induction Day 29 MRD Status
NCT00107198 (5) [back to overview]Cure by AV-PC x 3 or AV-PC x 3 + IFRT for Stage I Unresected, Stage I Resected Whose Disease Recurred, and Stage II Patients
NCT00107198 (5) [back to overview]Cure by Surgery Alone in Stage I Resected Patients
NCT00107198 (5) [back to overview]Failure-free Survival (FFS)
NCT00107198 (5) [back to overview]Event-free Survival
NCT00107198 (5) [back to overview]Grade 3 or 4 Toxicity
NCT00107380 (3) [back to overview]Progression-free Survival (PFS) at 2 Years
NCT00107380 (3) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00107380 (3) [back to overview]Response Rate (Complete, Complete Unconfirmed, and Partial)
NCT00109837 (2) [back to overview]Toxicity
NCT00109837 (2) [back to overview]Continuous Complete Remission at 1 Year
NCT00118209 (3) [back to overview]Progression-Free Survival Rate at 2 and 5 Years
NCT00118209 (3) [back to overview]Overall Survival Rate at 2 and 5 Years
NCT00118209 (3) [back to overview]Response Rate
NCT00121199 (4) [back to overview]Objective Response (Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR))
NCT00121199 (4) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00121199 (4) [back to overview]Progression-free Survival at 1 Year
NCT00121199 (4) [back to overview]Progression-free Survival at 2 Year
NCT00126191 (2) [back to overview]Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt
NCT00126191 (2) [back to overview]Disease Free Survival
NCT00133991 (5) [back to overview]Event-free Survival
NCT00133991 (5) [back to overview]Percentage of Participants Experiencing Grade 3-5 Toxicity
NCT00133991 (5) [back to overview]Overall Response Rate
NCT00133991 (5) [back to overview]Overall Survival
NCT00133991 (5) [back to overview]Relapse Pattern
NCT00136084 (7) [back to overview]Minimal Residual Disease (MRD).
NCT00136084 (7) [back to overview]Relationship of Inhibition of DNA Synthesis and Clinical Response
NCT00136084 (7) [back to overview]Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO
NCT00136084 (7) [back to overview]Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)
NCT00136084 (7) [back to overview]To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy
NCT00136084 (7) [back to overview]Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.
NCT00136084 (7) [back to overview]To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy
NCT00137111 (7) [back to overview]Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells
NCT00137111 (7) [back to overview]Overall Event-free Survival (EFS)
NCT00137111 (7) [back to overview]Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).
NCT00137111 (7) [back to overview]Continuous Complete Remission Since Week 56 Therapy.
NCT00137111 (7) [back to overview]Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells
NCT00137111 (7) [back to overview]Minimal Residual Disease (MRD)
NCT00137111 (7) [back to overview]Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)
NCT00144963 (1) [back to overview]MTD of VSLI
NCT00145041 (3) [back to overview]Volume of Distribution
NCT00145041 (3) [back to overview]Clearance
NCT00145041 (3) [back to overview]T 1/2
NCT00176462 (1) [back to overview]Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
NCT00184002 (2) [back to overview]Number of Patients With Serious Adverse Events as a Measure of Safety and Tolerability
NCT00184002 (2) [back to overview]Percentage of Patients With Complete Response to the Combination Chemotherapy
NCT00186875 (4) [back to overview]Overall Survival (OS)
NCT00186875 (4) [back to overview]Response Rate
NCT00186875 (4) [back to overview]Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00186875 (4) [back to overview]Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00186888 (27) [back to overview]Number of Patients Recommended for and Utilizing Rehabilitation Services
NCT00186888 (27) [back to overview]Ocular Survival of Eyes in Stratum A and Stratum B Patients Based on IC Classification
NCT00186888 (27) [back to overview]Event-free Survival of Eyes in Stratum A and Stratum B Patients Based on IC Classification
NCT00186888 (27) [back to overview]Event-free Survival of Eyes in Stratum B Patients Responding to Window Treatment
NCT00186888 (27) [back to overview]Event-free Survival of Eyes of Stratum B Patients
NCT00186888 (27) [back to overview]Event-free Survival of Stratum A Patients
NCT00186888 (27) [back to overview]Event-free Survival of Stratum B Patients Responding to Window Treatment
NCT00186888 (27) [back to overview]Relationship Between Topotecan Clearance (CL) and CYP3A4/5 Genotype in Stratum B Participants.
NCT00186888 (27) [back to overview]Mean Primary Visual Cortex Function: Cluster Size
NCT00186888 (27) [back to overview]Event-free Survival Per Eye in Stratum A and Stratum B Patients Based on AJCC Classification
NCT00186888 (27) [back to overview]Mean Primary Visual Cortex Function: Maximum T-value
NCT00186888 (27) [back to overview]Relationship Between Topotecan Clearance (CL) and ABCG2/B1 Genotype in Stratum B Participants.
NCT00186888 (27) [back to overview]Ocular Survival Per Eye in Stratum A and Stratum B Patients Based on AJCC Classification
NCT00186888 (27) [back to overview]Ocular Survival of Stratum B Patients Responding to Window Treatment
NCT00186888 (27) [back to overview]Ocular Survival of Stratum A Patients
NCT00186888 (27) [back to overview]Ocular Survival of Eyes of Stratum B Patients
NCT00186888 (27) [back to overview]Ocular Survival of Eyes in Stratum B Patients Responding to Window Treatment
NCT00186888 (27) [back to overview]Change in Distortion Product Otoacoustic Emissions (DPOAEs)
NCT00186888 (27) [back to overview]Change in Parenting Stress Index (PSI)
NCT00186888 (27) [back to overview]Stratum B Response to Window Therapy
NCT00186888 (27) [back to overview]Stratum B Response Rate of Early Stage Eyes to Window Therapy
NCT00186888 (27) [back to overview]Number of Participants With Development of Pineal Cysts
NCT00186888 (27) [back to overview]Number of Participants With Change in Size of Pineal Gland
NCT00186888 (27) [back to overview]Assessment of School Readiness
NCT00186888 (27) [back to overview]Change in Cognitive Functioning
NCT00186888 (27) [back to overview]Change in Parent Report of Social-Emotional Factors
NCT00186888 (27) [back to overview]Change in Relevant Daily Living Skills
NCT00193479 (1) [back to overview]Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
NCT00211185 (9) [back to overview]Summary of Study Drug-Related (Possible, Probable, or Definite) Serious Adverse Events
NCT00211185 (9) [back to overview]Summary of Treatment-Related Adverse Events Greater Than or Equal to Grade 3 by System Organ Class
NCT00211185 (9) [back to overview]Summary of All Treatment-Related Adverse Events by Frequency in Greater Than 10% of Treated Participants
NCT00211185 (9) [back to overview]Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants
NCT00211185 (9) [back to overview]Overall Response in the Intent To Treat (ITT) Population
NCT00211185 (9) [back to overview]Overall Response in the Efficacy Analyzable (EA) Population
NCT00211185 (9) [back to overview]Progression-Free Survival
NCT00211185 (9) [back to overview]Percentage of Participants With Overall Survival
NCT00211185 (9) [back to overview]Duration of Response
NCT00215943 (4) [back to overview]Number of Participants With Adverse Events, by Group
NCT00215943 (4) [back to overview]Number of Participants With Progression Free Survival (PFS), by Treatment Arm
NCT00215943 (4) [back to overview]Overall Survival (OS), by Treatment Arm
NCT00215943 (4) [back to overview]Response Rates of VAD vs. Thalidomide/Dexamethasone
NCT00217425 (3) [back to overview]12-Month Progression-Free Survival (PFS)
NCT00217425 (3) [back to overview]3-Year Overall Survival
NCT00217425 (3) [back to overview]Overall Response Rate
NCT00262925 (2) [back to overview]Overall Survival
NCT00262925 (2) [back to overview]Complete Response Rate
NCT00267046 (2) [back to overview]Cumulative Incidence Rate of Oral Mucositis
NCT00267046 (2) [back to overview]Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles
NCT00274924 (2) [back to overview]2-year Progression-Free Survival (PFS)
NCT00274924 (2) [back to overview]5-year Overall Survival
NCT00290433 (1) [back to overview]3 Year Progression-Free Survival Rate
NCT00290498 (2) [back to overview]Response Rate R-HCVAD vs. R-CHOP
NCT00290498 (2) [back to overview]Progression Free Survival (Rate)
NCT00299182 (2) [back to overview]Days Platelets Count of < 100K/μL
NCT00299182 (2) [back to overview]Platelet (PLT) Nadir
NCT00301821 (4) [back to overview]Overall Survival
NCT00301821 (4) [back to overview]Progression-free Survival (PFS)
NCT00301821 (4) [back to overview]Overall Response Rate (ORR)
NCT00301821 (4) [back to overview]Event-free Survival After 12 Months
NCT00302003 (4) [back to overview]Event Free Survival (EFS)
NCT00302003 (4) [back to overview]Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).
NCT00302003 (4) [back to overview]Overall Survival
NCT00302003 (4) [back to overview]Intensive Therapy Free Survival (ITFS).
NCT00335140 (1) [back to overview]Complete Response Rate - Locally Reviewed
NCT00335556 (6) [back to overview]Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors
NCT00335556 (6) [back to overview]Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)
NCT00335556 (6) [back to overview]Event Free Survival Probability
NCT00335556 (6) [back to overview]Toxicity Rate
NCT00335556 (6) [back to overview]Response Rate
NCT00335556 (6) [back to overview]Number of Patients With INI1 Mutations in Renal and Extrarenal Malignant Rhabdoid Tumor by Fluorescent in Situ Hybridization
NCT00335738 (9) [back to overview]Pathological Features Present At Diagnosis - Iris Infiltration (II)
NCT00335738 (9) [back to overview]Pathological Features Present at Diagnosis - Scleral Invasion (SI)
NCT00335738 (9) [back to overview]Overall Survival (OS)
NCT00335738 (9) [back to overview]Pathological Features Present At Diagnosis - Anterior Chamber Seeding (ACS)
NCT00335738 (9) [back to overview]Event-free Survival (EFS)
NCT00335738 (9) [back to overview]Pathological Features Present At Diagnosis - Ciliary Body Infiltration (CBI)
NCT00335738 (9) [back to overview]Pathological Features Present At Diagnosis - Tumor Involving the Optic Nerve Posterior to the Lamina Cribrosa (LC) as an Independent Finding
NCT00335738 (9) [back to overview]Toxicity As Assessed By the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT00335738 (9) [back to overview]Pathological Features Present At Diagnosis - Posterior Uveal Invasion (PVI)
NCT00336024 (10) [back to overview]Rates of Nutritional Toxicities
NCT00336024 (10) [back to overview]Percentage of Participants With Event Free Survival (EFS)
NCT00336024 (10) [back to overview]Percentage of Participants With Any Acute Adverse Events
NCT00336024 (10) [back to overview]Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism
NCT00336024 (10) [back to overview]Number of Participants With Secondary Malignancies
NCT00336024 (10) [back to overview]Rates of Gastrointestinal Toxicities
NCT00336024 (10) [back to overview]Number of Participants With Chronic Central Hypothyroidism
NCT00336024 (10) [back to overview]Number of Participants With Chronic Diabetes Insipidus
NCT00336024 (10) [back to overview]Number of Participants With Chronic Low Somatomedin C
NCT00336024 (10) [back to overview]Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).
NCT00337987 (2) [back to overview]Number of Patients That Achieved a Complete Response or a Partial Response (PR)
NCT00337987 (2) [back to overview]Number of Patients That Achieved a Complete Response (CR)
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Social Functioning
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Total Score
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Cognitive Problems
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Communication
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Nausea
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Pain and Hurt
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Perceived Physical Appearance
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Procedural Anxiety
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Total Score
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Treatment Anxiety
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.3.0: Worry
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.4.0: Emotional Functioning
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQl v.4.0: Physical Functioning
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.4.0: Psychosocial Health
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.4.0: School Functioning
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.4.0: Total Score
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), PedsQL v.4.0:Social Functioning
NCT00352027 (76) [back to overview]Patient Quality of Life (QoL), Symptom Distress Scale
NCT00352027 (76) [back to overview]Prognostic Factors for Treatment Failure: Age
NCT00352027 (76) [back to overview]Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: (Echocardiogram)
NCT00352027 (76) [back to overview]Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: (Electrocardiogram)
NCT00352027 (76) [back to overview]Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: (Pulmonary Function)
NCT00352027 (76) [back to overview]Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: Thyroid (TSH)
NCT00352027 (76) [back to overview]Local and Distant Failure for Children Treated With Tailored-field Radiation
NCT00352027 (76) [back to overview]Prognostic Factors for Treatment Failure: Gender
NCT00352027 (76) [back to overview]Prognostic Factors for Treatment Failure: Histology
NCT00352027 (76) [back to overview]Prognostic Factors for Treatment Failure: Stage
NCT00352027 (76) [back to overview]Toxicities With Grade >1
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Physical Functioning
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Total Score
NCT00352027 (76) [back to overview]3-year Event-free Survival (EFS) Probability
NCT00352027 (76) [back to overview]3-year Event-Free Survival Probability
NCT00352027 (76) [back to overview]3-year Local Failure-free Survival Probability
NCT00352027 (76) [back to overview]3-year Overall Survival (OS) Probability
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Cognitive Problems
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Communication
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Nausea
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Pain and Hurt
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Perceived Physical Appearance
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Procedural Anxiety
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Total Score
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Treatment Anxiety
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Worry
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Emotional Functioning
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Physical Functioning
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Psychosocial Health
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: School Functioning
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Social Functioning
NCT00352027 (76) [back to overview]Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Total Score
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Cognitive Problems
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Communication
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Nausea
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Pain and Hurt
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Perceived Physical Appearance
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Procedural Anxiety
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Total Score
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Treatment Anxiety
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Worry
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Emotional Functioning
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Psychosocial Health
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: School Functioning
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Social Functioning
NCT00352027 (76) [back to overview]Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Total Score
NCT00352027 (76) [back to overview]Disease Failure Rate Within Radiation Fields
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Cognitive Problems
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Communication
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Nausea
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Pain and Hurt
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Perceived Physical Appearance
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Procedural Anxiety
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Treatment Anxiety
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Worry
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Emotional Functioning
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Physical Functioning
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Psychosocial Health
NCT00352027 (76) [back to overview]Parent Proxy Quality of Life (QoL), PedsQL v.4.0: School Functioning
NCT00352534 (4) [back to overview]Event Free Survival Probability
NCT00352534 (4) [back to overview]Incidence of Contralateral Kidney Lesions
NCT00352534 (4) [back to overview]Incidence of Renal Failure
NCT00352534 (4) [back to overview]Overall Survival (OS) Probability
NCT00354744 (3) [back to overview]Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy
NCT00354744 (3) [back to overview]Percentage of Patients Event Free at 4 Years Following Study Entry
NCT00354744 (3) [back to overview]Number of Patients With Complete or Partial Response Assessed by RECIST Criteria
NCT00354835 (13) [back to overview]Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15
NCT00354835 (13) [back to overview]Acute and Late Effects of VAC as Delivered on This Study to D9803 VAC
NCT00354835 (13) [back to overview]Incidence of Toxicity Related to VI Treatment in Patients With UGT1A1 Genotype
NCT00354835 (13) [back to overview]Incidence of Toxicity
NCT00354835 (13) [back to overview]Incidence of Bladder Dysfunction
NCT00354835 (13) [back to overview]Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison
NCT00354835 (13) [back to overview]Event Free Survival (EFS) by PAX Status
NCT00354835 (13) [back to overview]Event Free Survival (EFS)
NCT00354835 (13) [back to overview]Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 4
NCT00354835 (13) [back to overview]Response Rate (RR)
NCT00354835 (13) [back to overview]Overall Survival (OS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison
NCT00354835 (13) [back to overview]Overall Survival (OS)
NCT00354835 (13) [back to overview]Local Failure
NCT00365274 (1) [back to overview]Objective Response Rate (ORR)
NCT00376961 (4) [back to overview]Response Rate in Patients Treated With Rituximab-CHOPbortezomib Induction Therapy (R-CHOP-V) Followed by Bortezomib Maintenance Therapy(VM).
NCT00376961 (4) [back to overview]2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM)
NCT00376961 (4) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00376961 (4) [back to overview]2-year Overall Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM)
NCT00379340 (4) [back to overview]Event Free Survival Probability
NCT00379340 (4) [back to overview]Event Free Survival Associated With the Burden of Pulmonary Metastatic Disease
NCT00379340 (4) [back to overview]Event Free Survival (EFS) Probability
NCT00379340 (4) [back to overview]Event Free Survival Probability
NCT00379574 (2) [back to overview]Number of Patients Who Experienced Adverse Events
NCT00379574 (2) [back to overview]Number of Patients Who Achieved Complete Response
NCT00381680 (6) [back to overview]Adjusted Event Free Survival
NCT00381680 (6) [back to overview]Frequency and Severity of Adverse Effects
NCT00381680 (6) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00381680 (6) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00381680 (6) [back to overview]Event Free Survival (EFS)
NCT00381680 (6) [back to overview]Event Free Survival. EFS
NCT00389818 (1) [back to overview]Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .
NCT00392327 (14) [back to overview]The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients
NCT00392327 (14) [back to overview]Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 30+/-6 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 60+/-12 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients
NCT00392327 (14) [back to overview]Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma
NCT00392327 (14) [back to overview]Percent Probability of Event-free Survival (EFS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
NCT00392327 (14) [back to overview]Percent Probability of Overall Survival (OS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
NCT00392327 (14) [back to overview]The Estimated Full-scale IQ (FSIQ) at 30+/-6 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]Tumor Response to Radiation Therapy for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
NCT00392327 (14) [back to overview]The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]Tumor Response to Radiation Therapy for Patients With Medulloblastoma
NCT00392327 (14) [back to overview]Percent Probability of Overall Survival (OS) for Patients With Medulloblastoma
NCT00392327 (14) [back to overview]The Estimated Full-scale IQ (FSIQ) at 60+/-12 Months Post Diagnosis for SPNET Patients
NCT00392834 (1) [back to overview]Overall Survival (OS) at 1 Year
NCT00392990 (4) [back to overview]Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00392990 (4) [back to overview]Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate)
NCT00392990 (4) [back to overview]Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00392990 (4) [back to overview]Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00400946 (10) [back to overview]Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]Induction Infection Toxicity Rate
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival by Bone Marrow Day 18 Status
NCT00400946 (10) [back to overview]Post-Induction Nadir Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]Induction Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival
NCT00400946 (10) [back to overview]Asparaginase-Related Toxicity Rate
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival by MRD Day 32 Status
NCT00400946 (10) [back to overview]5-year Disease-Free Survival by CNS Directed Treatment Group
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00410488 (1) [back to overview]Palonosetron Response Rate in the 10 Day Study Cycle
NCT00433537 (3) [back to overview]2-year Progression-free Survival (PFS)
NCT00433537 (3) [back to overview]3-year Overall Survival (OS)
NCT00433537 (3) [back to overview]Complete Response (CR) Rate
NCT00441168 (3) [back to overview]Best Confirmed Disease Response
NCT00441168 (3) [back to overview]Best Reported Disease Response
NCT00441168 (3) [back to overview]Duration of Response (DOR)
NCT00450385 (1) [back to overview]Number of Participants From Whom Fixed Tissue Samples Were Collected for Future Studies.
NCT00450801 (4) [back to overview]Progression-free Survival Rate
NCT00450801 (4) [back to overview]Response Rate
NCT00450801 (4) [back to overview]Number of Patients Experiencing Adverse Events.
NCT00450801 (4) [back to overview]Overall Survival Rate
NCT00451178 (11) [back to overview]Overall Survival (OS)
NCT00451178 (11) [back to overview]Event-Free Survival (EFS)
NCT00451178 (11) [back to overview]Percentage of Participants With Complete Response (CR/CRu) and/or Post-Baseline PET-Negative Scan (Concordance Between Response and PET Scan)
NCT00451178 (11) [back to overview]PFS of Participants With High or Low Expression of Protein Biomarkers and Correlation of Biomarkers to PFS
NCT00451178 (11) [back to overview]Duration of Complete Response (CR or CRu)
NCT00451178 (11) [back to overview]PFS of Participants With High or Low Expression of Protein Biomarkers and Correlation of Biomarkers to PFS
NCT00451178 (11) [back to overview]Percentage of Participants With Complete Response (CR and CRu) and Objective Response [CR, CRu, and Partial Response (PR)] (Overall Response Rate)
NCT00451178 (11) [back to overview]Participants Who Had Treatment-Emergent Adverse Events (TEAEs) or Died (Evaluate Toxicity and Tolerability of R-CHOP Plus Enzastaurin)
NCT00451178 (11) [back to overview]Progression-Free Survival (PFS) Time
NCT00451178 (11) [back to overview]Percentage of Participants With a PET-Negative Scan (PET-Negative Rate)
NCT00451178 (11) [back to overview]Percentage of Participants Alive Progression-Free at Year 2 (2-Year PFS Rate)
NCT00458848 (3) [back to overview]Number of Patients Reaching Complete Hematological Response After Induction Therapy
NCT00458848 (3) [back to overview]Percentage of Participants Reaching Disease Free Survival
NCT00458848 (3) [back to overview]Percentage of Participants Reaching Overall Survival
NCT00477412 (4) [back to overview]Maximum Tolerated Dose of Bortezomib (Phase I)
NCT00477412 (4) [back to overview]Number of Participants With Overall Response Rate
NCT00477412 (4) [back to overview]Overall Survival
NCT00477412 (4) [back to overview]Time to Failure (Phase II)
NCT00494780 (15) [back to overview]Time to New Anti-follicular Lymphoma (FL) Therapy
NCT00494780 (15) [back to overview]Progression-Free Survival (PFS)
NCT00494780 (15) [back to overview]Vss at the Sixth Infusion (Week 15, Visit 22)
NCT00494780 (15) [back to overview]AUC(0-inf) and AUC(0-504) After the Sixth Infusion (Week 15, Visit 22)
NCT00494780 (15) [back to overview]Cmax and Ctrough at the Sixth Infusion (Week 15, Visit 22)
NCT00494780 (15) [back to overview]Median Percent Change From Visit 1 (Screening, Week -2) in Tumor Size at Visit 33 (24 Months After the Last Infusion of Ofatumumab)
NCT00494780 (15) [back to overview]Percent Change From Visit 1 (Screening) in Peripheral CD19+ and CD20+ Cell Counts at Visit 33 (24 Months After the Last Infusion of Ofatumumab)
NCT00494780 (15) [back to overview]Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Visits 1, 28, and 33
NCT00494780 (15) [back to overview]CL After the Sixth Infusion (Week 15, Visit 22)
NCT00494780 (15) [back to overview]Duration of Response
NCT00494780 (15) [back to overview]Half Life (t1/2) of Ofatumumab at the Sixth Infusion (Week 15, Visit 22)
NCT00494780 (15) [back to overview]Median Percent Change From Visit 1 (Screening) in Serum Complement (CH50) Levels at Visit 22
NCT00494780 (15) [back to overview]Number of Participants Who Experienced Any Adverse Event (AEs) From First Treatment to Visit 33 (24 Months After Last Infusion)
NCT00494780 (15) [back to overview]Number of Participants With Complete Remission (CR) at Visit 26
NCT00494780 (15) [back to overview]Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab)
NCT00495079 (4) [back to overview]Overall Survival
NCT00495079 (4) [back to overview]Clinical Response Assessment Per Independent Response Review Committee (IRRC) Evaluation
NCT00495079 (4) [back to overview]Complete Remission Plus Complete Remission Without Full Platelet Recovery (CR + CRi)
NCT00495079 (4) [back to overview]Duration of CR + CRi
NCT00506142 (1) [back to overview]Disease Control Rate
NCT00516295 (2) [back to overview]The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient.
NCT00516295 (2) [back to overview]Time to Disease Progression in Patients Receiving VTC With or Without Bevacizumab
NCT00549848 (6) [back to overview]Probability of CNS Relapse
NCT00549848 (6) [back to overview]Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.
NCT00549848 (6) [back to overview]Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%
NCT00549848 (6) [back to overview]Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%
NCT00549848 (6) [back to overview]Probability of Overall Survival
NCT00549848 (6) [back to overview]Probability of Event-free Survival
NCT00554788 (3) [back to overview]Percentage of Participants With Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00554788 (3) [back to overview]Response Rate to the Induction Phase of the Regimen
NCT00554788 (3) [back to overview]Event-free Survival (EFS)
NCT00555464 (2) [back to overview]Toxicity to Medications
NCT00555464 (2) [back to overview]Response of Hemangioma (IH) to Treatment
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00557193 (10) [back to overview]Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00558519 (5) [back to overview]Complete Response Rate
NCT00558519 (5) [back to overview]Disease-free Survival
NCT00558519 (5) [back to overview]Event-free Survival
NCT00558519 (5) [back to overview]Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)
NCT00558519 (5) [back to overview]Overall Survival
NCT00562965 (7) [back to overview]Number of Participants With Clinically Significant Change From Baseline in Laboratory Findings
NCT00562965 (7) [back to overview]Number of Participants With Grade 3 or 4 Treatment Emergent Adverse Events (TEAEs)
NCT00562965 (7) [back to overview]Percentage of Participants With Objective Response (OR)
NCT00562965 (7) [back to overview]Progression-Free Survival (PFS)
NCT00562965 (7) [back to overview]Number of Participants With Clinically Significant Change From Baseline in QT Interval Findings
NCT00562965 (7) [back to overview]Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT00562965 (7) [back to overview]Overall Survival Probability at Months 6, 12 and 24
NCT00567567 (14) [back to overview]Event-free Survival Rate
NCT00567567 (14) [back to overview]EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content & Pts>547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).
NCT00567567 (14) [back to overview]Duration of Greater Than or Equal to Grade 3 Thrombocytopenia
NCT00567567 (14) [back to overview]Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells
NCT00567567 (14) [back to overview]Proportion of Patients With a Polymorphism
NCT00567567 (14) [back to overview]Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies
NCT00567567 (14) [back to overview]Response After Induction Therapy
NCT00567567 (14) [back to overview]Surgical Response
NCT00567567 (14) [back to overview]Duration of Greater Than or Equal to Grade 3 Neutropenia
NCT00567567 (14) [back to overview]Topotecan Systemic Clearance
NCT00567567 (14) [back to overview]Type of Surgical or Radiotherapy Complication
NCT00567567 (14) [back to overview]OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology
NCT00567567 (14) [back to overview]Intraspinal Extension
NCT00567567 (14) [back to overview]Incidence Rate of Local Recurrence
NCT00574496 (3) [back to overview]Disease Relapse or Progression as Measured by CT Scan or PET
NCT00574496 (3) [back to overview]Overall Survival
NCT00574496 (3) [back to overview]Progression-free Survival at 1 Year
NCT00577096 (10) [back to overview]Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)
NCT00577096 (10) [back to overview]Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)
NCT00577096 (10) [back to overview]Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)
NCT00577096 (10) [back to overview]Number of Stem Cell Collection Attempts (Long Term)
NCT00577096 (10) [back to overview]Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)
NCT00577096 (10) [back to overview]Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)
NCT00577096 (10) [back to overview]Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)
NCT00577096 (10) [back to overview]Number of Stem Cell Collection Attempts (Short Term)
NCT00577096 (10) [back to overview]Total Number of Days of Stem Cell Collection (Long Term)
NCT00577096 (10) [back to overview]Total Number of Days of Stem Cell Collection (Short Term)
NCT00577993 (2) [back to overview]Number of Participants With Overall Survival (10 Years) by Treatment
NCT00577993 (2) [back to overview]Number of Participants With Progression Free Survival (10 Years) by Treatment
NCT00581776 (4) [back to overview]3 Year Overall Survival (OS)
NCT00581776 (4) [back to overview]3 Year Progression Free Survival
NCT00581776 (4) [back to overview]Complete Response Rate (CR) at the End of Induction Chemotherapy
NCT00581776 (4) [back to overview]Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR).
NCT00594815 (2) [back to overview]Total Number of Participants Who Experienced Acute Treatment Related Adverse Events
NCT00594815 (2) [back to overview]Progression Free Survival
NCT00602667 (62) [back to overview]Feasibility and Toxicity of Administering Consolidation Therapy Including Cyclophosphamide and Pharmacokinetically Targeted Topotecan to Patients With Metastatic Disease Based on the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity
NCT00602667 (62) [back to overview]Feasibility and Toxicity of Administering Oral Maintenance Therapy in Children <3 Years of Age as Measured by the Percentage of Total Scheduled Maintenance Doses Received
NCT00602667 (62) [back to overview]Feasibility and Toxicity of Administering Vinblastine With Induction Chemotherapy for Patients With Metastatic Disease as Measured by the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity
NCT00602667 (62) [back to overview]Methotrexate AUC0-66h in Induction Cycle 1
NCT00602667 (62) [back to overview]Methotrexate AUC0-66h in Induction Cycle 2
NCT00602667 (62) [back to overview]Methotrexate AUC0-66h in Induction Cycle 3
NCT00602667 (62) [back to overview]Methotrexate AUC0-66h in Induction Cycle 4
NCT00602667 (62) [back to overview]Methotrexate Clearance in Induction Cycle 1
NCT00602667 (62) [back to overview]Methotrexate Clearance in Induction Cycle 2
NCT00602667 (62) [back to overview]Methotrexate Clearance in Induction Cycle 3
NCT00602667 (62) [back to overview]Methotrexate Clearance in Induction Cycle 4
NCT00602667 (62) [back to overview]Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1
NCT00602667 (62) [back to overview]Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 2
NCT00602667 (62) [back to overview]Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 3
NCT00602667 (62) [back to overview]Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 4
NCT00602667 (62) [back to overview]Methotrexate Volume of Central Compartment in Induction Cycle 1
NCT00602667 (62) [back to overview]Methotrexate Volume of Central Compartment in Induction Cycle 2
NCT00602667 (62) [back to overview]Methotrexate Volume of Central Compartment in Induction Cycle 3
NCT00602667 (62) [back to overview]Methotrexate Volume of Central Compartment in Induction Cycle 4
NCT00602667 (62) [back to overview]OSI-420 AUC0-24h
NCT00602667 (62) [back to overview]Overall Survival (OS) Compared to Historical Controls
NCT00602667 (62) [back to overview]Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan
NCT00602667 (62) [back to overview]Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan
NCT00602667 (62) [back to overview]Percent of Patients With Sustained Objective Responses Rate After Consolidation
NCT00602667 (62) [back to overview]Percent of PET Scans With Loss of Signal Intensity
NCT00602667 (62) [back to overview]Percent Probability of Event-free Survival (EFS) for Medulloblastoma Patients
NCT00602667 (62) [back to overview]Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients
NCT00602667 (62) [back to overview]Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup
NCT00602667 (62) [back to overview]Percentage of Patients With Objective Responses Rate to Induction Chemotherapy
NCT00602667 (62) [back to overview]Rate of Distant Disease Progression
NCT00602667 (62) [back to overview]Rate of Local Disease Progression
NCT00602667 (62) [back to overview]Topotecan Apparent Oral Clearance in Maintenance Chemotherapy
NCT00602667 (62) [back to overview]Topotecan AUC0-24h in Consolidation Chemotherapy
NCT00602667 (62) [back to overview]Topotecan AUC0-24h in Maintenance Chemotherapy
NCT00602667 (62) [back to overview]Topotecan Clearance in Consolidation Chemotherapy
NCT00602667 (62) [back to overview]Concentration of Cerebrospinal Fluid Neurotransmitters
NCT00602667 (62) [back to overview]Number and Type of Genetic Polymorphisms
NCT00602667 (62) [back to overview]Number of Participants With Chromosomal Abnormalities
NCT00602667 (62) [back to overview]Number of Successful Collections for Frozen and Fixed Tumor Samples
NCT00602667 (62) [back to overview]Numbers of Patients With Gene Alterations
NCT00602667 (62) [back to overview]Numbers of Patients With Molecular Abnormalities by Tumor Type
NCT00602667 (62) [back to overview]Pharmacogenetic Variation on Central Nervous System Transmitters
NCT00602667 (62) [back to overview]Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2
NCT00602667 (62) [back to overview]4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]Cyclophosphamide Clearance in Induction Chemotherapy
NCT00602667 (62) [back to overview]Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 2
NCT00602667 (62) [back to overview]Erlotinib Apparent Oral Clearance
NCT00602667 (62) [back to overview]Erlotinib Apparent Volume of Central Compartment
NCT00602667 (62) [back to overview]Erlotinib AUC0-24h
NCT00602667 (62) [back to overview]Event-free Survival (EFS) Compared to Historical Controls
NCT00602667 (62) [back to overview]4-OH Cyclophosphamide AUC0-24h in Induction Chemotherapy
NCT00602667 (62) [back to overview]4-OH Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]CEPM AUC0-24h in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]CEPM AUC0-24h in Consolidation Chemotherapy Cycle 2
NCT00602667 (62) [back to overview]CEPM AUC0-24h in Induction Chemotherapy
NCT00602667 (62) [back to overview]CEPM AUC0-24h in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]Cyclophosphamide Apparent Oral Clearance in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2
NCT00602667 (62) [back to overview]Cyclophosphamide AUC0-24h in Induction Chemotherapy
NCT00618813 (5) [back to overview]Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 13 to Week 22
NCT00618813 (5) [back to overview]Incidence of Death
NCT00618813 (5) [back to overview]Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Enrollment to Week 12
NCT00618813 (5) [back to overview]Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 29 to Week 37
NCT00618813 (5) [back to overview]Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 23 to Week 28
NCT00632827 (4) [back to overview]Median Time to Response
NCT00632827 (4) [back to overview]Overall Survival Rate
NCT00632827 (4) [back to overview]Complete Response Rate
NCT00632827 (4) [back to overview]Progression Free Survival
NCT00634179 (2) [back to overview]An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria
NCT00634179 (2) [back to overview]Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)
NCT00651755 (6) [back to overview]Geometric Mean Area Under Curve (AUC) of Analyte, 2-dechloro-cyclophosphamide(2-deCI-CP), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]Geometric Mean Area Under Curve (AUC) of Analyte, 4-hydroxy-cyclophosphamide (4-OH-CP), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]Geometric Mean Area Under Curve (AUC) of Analyte, Prednisolone (PL), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]Geometric Mean Area Under Curve (AUC) of Analyte, Vincristine (VC), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]Geometric Mean Area Under Curve (AUC) of Analyte,Prednisone (PR), in Aprepitant Treatment and Control Group
NCT00653068 (4) [back to overview]Overall Survival (OS)
NCT00653068 (4) [back to overview]Toxic Death
NCT00653068 (4) [back to overview]Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy
NCT00653068 (4) [back to overview]Event-free Survival
NCT00659269 (4) [back to overview]Neurotoxicity Assessment at Cycle 4
NCT00659269 (4) [back to overview]Neurotoxicity Assessment at Cycle 2
NCT00659269 (4) [back to overview]Neurotoxicity Assessment at Baseline
NCT00659269 (4) [back to overview]Change in Neurotoxicity Assessment Between Cycle 4 and Baseline
NCT00669877 (2) [back to overview]Overall Response Rate: Percentage of Participants With Complete Remission (CR) or Partial Remission (PR)
NCT00669877 (2) [back to overview]Complete Remission Rate: Percentage of Participants With Complete Remission (CR)
NCT00670358 (3) [back to overview]Event-free > Survival at 12 Months (Phase 2, DLBCL/Mixed Dose Level 3)
NCT00670358 (3) [back to overview]Progression-free > Survival at 24 Months (Phase 2, Transformed/Composite)
NCT00670358 (3) [back to overview]Toxicity as Assessed by NCI CTCAE v3.0 (Phase I)
NCT00671034 (9) [back to overview]Percentage of Participants With Event-free Survival (EFS)
NCT00671034 (9) [back to overview]Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction
NCT00671034 (9) [back to overview]Asparaginase Level
NCT00671034 (9) [back to overview]Pharmacodynamics (PD)
NCT00671034 (9) [back to overview]Plasma and CSF Concentrations of Asparagine in ug/ml
NCT00671034 (9) [back to overview]Toxicities During Post Induction Intensification Therapy (All Grades)
NCT00671034 (9) [back to overview]Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)
NCT00671034 (9) [back to overview]Immunogenicity
NCT00671034 (9) [back to overview]Percentage of Participants With Complete Remission at the End of Induction
NCT00671658 (1) [back to overview]Number of Participants With a Response
NCT00719472 (6) [back to overview]Duration of Rituximab Infusion Including Dose Interruption Times
NCT00719472 (6) [back to overview]Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)
NCT00719472 (6) [back to overview]Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2
NCT00719472 (6) [back to overview]Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1
NCT00719472 (6) [back to overview]Percentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)
NCT00719472 (6) [back to overview]Maximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)
NCT00720109 (5) [back to overview]Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00722137 (11) [back to overview]Overall Response Rate (ORR)
NCT00722137 (11) [back to overview]18-Month Survival
NCT00722137 (11) [back to overview]Number of Participants Experiencing an Adverse Event (AE)
NCT00722137 (11) [back to overview]Time to Progression (TTP)
NCT00722137 (11) [back to overview]Overall Survival (OS)
NCT00722137 (11) [back to overview]Overall Survival (OS) in Long Term Follow-up Period
NCT00722137 (11) [back to overview]Progression Free Survival (PFS)
NCT00722137 (11) [back to overview]Time to Next Anti-lymphoma Treatment (TTNT)
NCT00722137 (11) [back to overview]Treatment-free Interval (TFI)
NCT00722137 (11) [back to overview]Overall Complete Response (CR + CRu)
NCT00722137 (11) [back to overview]Duration of Response
NCT00736450 (2) [back to overview]Number of Participants With Microarray Testing Results Are Completed Within 7 Days.
NCT00736450 (2) [back to overview]Time to Perform Microarray Study After Receipt of Tissue
NCT00770224 (4) [back to overview]5-year Overall Survival
NCT00770224 (4) [back to overview]5-year Progression-free Survival
NCT00770224 (4) [back to overview]Percentage of Participants With 3-year Progression-free Survival (PFS)
NCT00770224 (4) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00774202 (2) [back to overview]Relative Efficacy of the 2 Groups
NCT00774202 (2) [back to overview]Number of Participants With SAEs
NCT00787527 (3) [back to overview]Phase II MTD of Vorinostat
NCT00787527 (3) [back to overview]Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat
NCT00787527 (3) [back to overview]Phase I Maximum Tolerated Dose (MTD) of Vorinostat
NCT00792948 (3) [back to overview]Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00792948 (3) [back to overview]Overall Survival (OS)
NCT00792948 (3) [back to overview]Continuous Complete Remission (CCR) Rate
NCT00822120 (8) [back to overview]Percentage of HIV-positive Patients With 2-year Progression-free Survival (PFS) Treated With Initial 2 Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.
NCT00822120 (8) [back to overview]Percentage of HIV-positive Patients With 5-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging.
NCT00822120 (8) [back to overview]Number of HIV-negative Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00822120 (8) [back to overview]Percentage of HIV-negative Patients Who Are PET-positive After 2 Cycles of ABVD With 2-year PFS
NCT00822120 (8) [back to overview]Complete and Partial Response Rates for HIV-negative Patients Treated With Response- Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD
NCT00822120 (8) [back to overview]Number of HIV-positive Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00822120 (8) [back to overview]Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.
NCT00822120 (8) [back to overview]Percentage of HIV-negative Patients With 2-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging
NCT00846430 (4) [back to overview]At Least 50% Shrinkage in Tumor Measurements by Physical Examination
NCT00846430 (4) [back to overview]Improvement of Symptoms and Pain
NCT00846430 (4) [back to overview]No Reported Psychological Toxicity Based Upon Psychological Evaluations
NCT00846430 (4) [back to overview]Response by MRI Measurements
NCT00866307 (2) [back to overview]AALL08P1 Feasibility Outcome
NCT00866307 (2) [back to overview]AALL08P1 Safety Outcome
NCT00866749 (4) [back to overview]3-Year Event-Free Survival (EFS)
NCT00866749 (4) [back to overview]Overall Survival
NCT00866749 (4) [back to overview]Participants Achieving Negative Minimal Residual Disease (MRD)
NCT00866749 (4) [back to overview]Participants With a Complete Response (CR)
NCT00873093 (7) [back to overview]Toxic Death Rate
NCT00873093 (7) [back to overview]Severe Adverse Events (SAE) Rate.
NCT00873093 (7) [back to overview]Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy
NCT00873093 (7) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00873093 (7) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2
NCT00873093 (7) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00873093 (7) [back to overview]Event Free Survival
NCT00877006 (17) [back to overview]Kaplan-Meier Estimate for Duration of Response (DOR)
NCT00877006 (17) [back to overview]Change From Baseline to End of Treatment in the Global Health Status Score of the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30)
NCT00877006 (17) [back to overview]Worst Overall CTCAE Grade for Hematology Laboratory Test Results
NCT00877006 (17) [back to overview]Worst Overall Common Terminology Criteria for Adverse Events (CTCAE) Grades for Serum Chemistry Laboratory Test Results
NCT00877006 (17) [back to overview]Therapeutic Classification of Prior Medications
NCT00877006 (17) [back to overview]Therapeutic Classification of Concomitant Medications
NCT00877006 (17) [back to overview]Potentially Clinically Significant Abnormal Weight
NCT00877006 (17) [back to overview]Participants Who Died At the End of the Treatment Period or the Long-Term Follow-up Period
NCT00877006 (17) [back to overview]Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period
NCT00877006 (17) [back to overview]Eastern Cooperative Oncology Group (ECOG) Performance Status at the End of Treatment Period
NCT00877006 (17) [back to overview]Clinically Significant Abnormal Vital Signs
NCT00877006 (17) [back to overview]Percentage of Participants With Overall Response at End of Treatment Period
NCT00877006 (17) [back to overview]Percentage of Participants With Complete Response (CR) at End of Treatment Period
NCT00877006 (17) [back to overview]Participants With Disease Progression, Relapse or Death At the End of the Treatment Period or the Long-Term Follow-up Period
NCT00877006 (17) [back to overview]Overall Survival (OS)
NCT00877006 (17) [back to overview]Kaplan-Meier Estimate for Progression-free Survival (PFS)
NCT00877006 (17) [back to overview]Kaplan-Meier Estimate for Event-free Survival (EFS)
NCT00882206 (4) [back to overview]Level of Methylation
NCT00882206 (4) [back to overview]Level of Methylation
NCT00882206 (4) [back to overview]Level of Methylation
NCT00882206 (4) [back to overview]Response to Treatment
NCT00890656 (1) [back to overview]Number of Participants With Complete Remission
NCT00905034 (1) [back to overview]Complete Response (CR) Rate
NCT00911183 (4) [back to overview]Number of Participants in Complete Remission 6 Months After Randomization
NCT00911183 (4) [back to overview]Overall Survival Time
NCT00911183 (4) [back to overview]Number of Participants With Severe Toxicity
NCT00911183 (4) [back to overview]Progression-free Survival Time
NCT00928200 (1) [back to overview]Occurrence of a Dose-Limiting Toxicity
NCT00931918 (10) [back to overview]Complete Response Rate
NCT00931918 (10) [back to overview]Overall Response Rate (ORR)
NCT00931918 (10) [back to overview]Percentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher
NCT00931918 (10) [back to overview]Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category
NCT00931918 (10) [back to overview]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate
NCT00931918 (10) [back to overview]Duration of Response
NCT00931918 (10) [back to overview]Overall Survival
NCT00931918 (10) [back to overview]Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)
NCT00931918 (10) [back to overview]Progression-Free Survival Rate
NCT00931918 (10) [back to overview]Time to Progression (TTP)
NCT00945009 (5) [back to overview]Event-Free Survival (EFS)
NCT00945009 (5) [back to overview]Kidney Preservation After Preoperative Chemotherapy
NCT00945009 (5) [back to overview]Number of Patients Without Complete Removal of at Least One Kidney
NCT00945009 (5) [back to overview]Percentage of Patients Who Had Definitive Surgical Treatment
NCT00945009 (5) [back to overview]Percentage of Patients Who Experienced Partial Nephrectomy After Preoperative Chemotherapy
NCT00960063 (3) [back to overview]Best Overall Response Based on Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00960063 (3) [back to overview]Number of Participants With Dose Limiting Toxicities
NCT00960063 (3) [back to overview]Number of Participants Who Developed Anti-robatumumab Antibodies
NCT00968253 (3) [back to overview]Overall Response Rate (OR) Where OR = CR + CRp + CRi
NCT00968253 (3) [back to overview]Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT)
NCT00968253 (3) [back to overview]Participant Responses by Daily Dose Level Assignment (RAD001 5 mg, 10 mg and MTD 5 mg)
NCT00972478 (5) [back to overview]Response Rate (Complete Response [CR]+Partial Response [PR]) (Phase II)
NCT00972478 (5) [back to overview]Safe Dose of Vorinostat to be Used in Combination With R-CHOP Assessed by CTCAE Version 4.0 (Phase I)
NCT00972478 (5) [back to overview]Overall Survival (Phase II)
NCT00972478 (5) [back to overview]Progression-free Survival (Phase II)
NCT00972478 (5) [back to overview]Toxicity of Vorinostat-R-CHOP in Patients With Newly Diagnosed DLBCL
NCT00973752 (1) [back to overview]Overall Survival at One Year
NCT00980460 (5) [back to overview]Event-free Survival
NCT00980460 (5) [back to overview]Number of Cycles on Which Grade 3 or Higher Adverse Events Coded According to CTC AE Version 5 Were Observed
NCT00980460 (5) [back to overview]Disease Status at the End of 2 Courses of Therapy
NCT00980460 (5) [back to overview]Number of Deaths
NCT00980460 (5) [back to overview]Feasibility of Referral for Liver Transplantation
NCT00993044 (1) [back to overview]Dose Limiting Toxicity
NCT01000285 (8) [back to overview]Time to Progression
NCT01000285 (8) [back to overview]Effects of HTLV-1 Integration Sites After Treatment
NCT01000285 (8) [back to overview]Relation of NFκB Gene Expression Profile on Response
NCT01000285 (8) [back to overview]Effects of HTLV-1 RNA Load After Treatment as Measured by Hbz Messenger RNA
NCT01000285 (8) [back to overview]Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events
NCT01000285 (8) [back to overview]Effects of HTLV-1 Integrase Gene Sequence After Treatment as Measured by Nucleotide Divergence
NCT01000285 (8) [back to overview]Effects of on HTLV-1 DNA After Treatment as Measured by Proviral Loads
NCT01000285 (8) [back to overview]Efficacy of Treatment as Measured by Best Overall Response
NCT01004991 (1) [back to overview]Complete Response
NCT01026220 (7) [back to overview]Overall Survival
NCT01026220 (7) [back to overview]Grade 3 and 4 Non-hematologic Toxicities During Protocol Therapy
NCT01026220 (7) [back to overview]Relapse-free Survival
NCT01026220 (7) [back to overview]Event-free Survival for Rapid Early Response (RER) Positron Emission Tomography(PET)-1 Positive, RER PET-1 Negative
NCT01026220 (7) [back to overview]Event Free Survival
NCT01026220 (7) [back to overview]Second-event-free Survival
NCT01026220 (7) [back to overview]Safety Analysis and Monitoring of Toxic Death
NCT01030900 (4) [back to overview]Clinical Response on Study and at Relapse After Dose Adjusted - Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Rituximab (DA-EPOCH-RC)
NCT01030900 (4) [back to overview]Progression Free Survival (PFS)
NCT01030900 (4) [back to overview]Overall Survival (OS)
NCT01030900 (4) [back to overview]Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
NCT01040871 (7) [back to overview]Complete Response (CR) Rate
NCT01040871 (7) [back to overview]Overall Response Rate
NCT01040871 (7) [back to overview]Progression-free Survival (PFS)Rate at 1-year
NCT01040871 (7) [back to overview]Rate of Durable Complete Response
NCT01040871 (7) [back to overview]Rate of Durable Response
NCT01040871 (7) [back to overview]Subsequent Anti-lymphoma Therapy Rate at 1-year
NCT01040871 (7) [back to overview]Overall Survival Rate at 1-year
NCT01055314 (5) [back to overview]Feasibility of the Addition of Temozolomide to Chemotherapy Determined by Patient Enrollment
NCT01055314 (5) [back to overview]Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment
NCT01055314 (5) [back to overview]Event-Free Survival
NCT01055314 (5) [back to overview]Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0
NCT01055314 (5) [back to overview]Response Rate (CR + PR)
NCT01055496 (17) [back to overview]Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts
NCT01055496 (17) [back to overview]Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts
NCT01055496 (17) [back to overview]Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy
NCT01055496 (17) [back to overview]Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts
NCT01055496 (17) [back to overview]Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts
NCT01055496 (17) [back to overview]Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.
NCT01055496 (17) [back to overview]Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts
NCT01055496 (17) [back to overview]Mean Inotuzumab Ozogamicin Serum Concentrations
NCT01055496 (17) [back to overview]Mean Inotuzumab Ozogamicin Serum Concentrations
NCT01055496 (17) [back to overview]Percentage of Participants With a Treatment Emergent AE
NCT01055496 (17) [back to overview]Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy
NCT01055496 (17) [back to overview]Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1
NCT01055496 (17) [back to overview]Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2
NCT01055496 (17) [back to overview]Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts
NCT01055496 (17) [back to overview]Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts
NCT01055496 (17) [back to overview]Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts
NCT01055496 (17) [back to overview]Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts
NCT01092182 (5) [back to overview]Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval
NCT01092182 (5) [back to overview]Percentage of Participants With Kaplan-Meier Curve Event Free Survival (EFS) Constructed With an 95% Confidence Interval
NCT01092182 (5) [back to overview]Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
NCT01092182 (5) [back to overview]Kaplan-Meier Progression Free Survival (PFS) Constructed With an 95% Confidence Interval in Participants Who Underwent Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) and/or Computed Tomography (CT) Scans After Cycle 2
NCT01092182 (5) [back to overview]Percentage of Participants Kaplan-Meier Curve Overall Survival (OS) Constructed With an 95% Confidence Interval
NCT01096368 (10) [back to overview]EFS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy
NCT01096368 (10) [back to overview]EFS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation
NCT01096368 (10) [back to overview]EFS With Incomplete Resection After Initial Surgery, Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]EFS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]OS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only.
NCT01096368 (10) [back to overview]OS in Children With Incomplete Resection After Initial Surgery Who Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]OS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy
NCT01096368 (10) [back to overview]OS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation
NCT01096368 (10) [back to overview]Overall Survival (OS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01175356 (3) [back to overview]Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131
NCT01175356 (3) [back to overview]Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy
NCT01175356 (3) [back to overview]Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization
NCT01190930 (41) [back to overview]DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens
NCT01190930 (41) [back to overview]DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization
NCT01190930 (41) [back to overview]DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right
NCT01190930 (41) [back to overview]Sample Collection of Central Path Review Slides in B-LLy Patients
NCT01190930 (41) [back to overview]Overall Survival (OS) for B-LLy Patients
NCT01190930 (41) [back to overview]Event Free Survival (EFS) for B-LLy Patients
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional
NCT01193842 (14) [back to overview]Changes in Human Immunodeficiency Virus (HIV) Viral Load
NCT01193842 (14) [back to overview]Changes in Human Herpes Virus (HHV)-8 Viral Load
NCT01193842 (14) [back to overview]Changes in Epstein-Barr Virus (EBV) Viral Load
NCT01193842 (14) [back to overview]Event-free Survival (EFS) (Phase II)
NCT01193842 (14) [back to overview]Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)
NCT01193842 (14) [back to overview]Change in CD8 Cell Counts (Phase I)
NCT01193842 (14) [back to overview]Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)
NCT01193842 (14) [back to overview]Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)
NCT01193842 (14) [back to overview]Changes in Absolute CD4 Cell Counts (Phase I)
NCT01193842 (14) [back to overview]Tumor Response (Phase I)
NCT01193842 (14) [back to overview]Pharmacokinetic Clearance (Phase I)
NCT01193842 (14) [back to overview]Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)
NCT01193842 (14) [back to overview]Overall Survival (OS) (Phase II)
NCT01193842 (14) [back to overview]Changes in Human Herpes Virus (HHV)-8 Viral Load
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs) to Rituximab
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle
NCT01200758 (26) [back to overview]Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab
NCT01200758 (26) [back to overview]Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Responses Showing Time Saved of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Ctrough of Rituximab at Each Induction Treatment Cycle
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Percentage of Responses Who Showed Rituximab SC Formulation Convenient as Compared to Rituximab IV Formulation as Assessed by Physician/Nurse Opinion
NCT01200758 (26) [back to overview]Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)
NCT01200758 (26) [back to overview]Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase
NCT01200758 (26) [back to overview]Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL
NCT01200758 (26) [back to overview]Percentage of Participants Who Died
NCT01200758 (26) [back to overview]Overall Survival (OS)
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration
NCT01200758 (26) [back to overview]Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab
NCT01200758 (26) [back to overview]Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Human Antibodies (HAHAs) to Rituximab
NCT01231906 (1) [back to overview]Event-Free Survival
NCT01256398 (6) [back to overview]Response
NCT01256398 (6) [back to overview]Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]Overall Survival (OS)
NCT01256398 (6) [back to overview]Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]Disease Free Survival (DFS)
NCT01287741 (18) [back to overview]Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores
NCT01287741 (18) [back to overview]Time to Next Anti-Lymphoma Treatment (TTNALT)
NCT01287741 (18) [back to overview]Percentage of Participants With Adverse Events (AEs)
NCT01287741 (18) [back to overview]Overall Response Rate (ORR), Investigator-Assessed
NCT01287741 (18) [back to overview]Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed
NCT01287741 (18) [back to overview]Median Time to Overall Survival (OS)
NCT01287741 (18) [back to overview]Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01287741 (18) [back to overview]Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab
NCT01287741 (18) [back to overview]Overall Response Rate (ORR), IRC-Assessed
NCT01287741 (18) [back to overview]Complete Response (CR) at the End of Treatment, IRC-Assessed
NCT01287741 (18) [back to overview]Median Time to Event-Free Survival (EFS), Investigator-Assessed
NCT01287741 (18) [back to overview]Median Time to Disease-Free Survival (DFS), Investigator-Assessed
NCT01287741 (18) [back to overview]Duration of Response (DOR), Investigator-Assessed
NCT01287741 (18) [back to overview]Complete Response (CR) at the End of Treatment, Investigator-Assessed
NCT01287741 (18) [back to overview]Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score
NCT01287741 (18) [back to overview]Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score
NCT01287741 (18) [back to overview]Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores
NCT01287741 (18) [back to overview]Median Time to Progression-Free Survival (PFS), Investigator-Assessed
NCT01319981 (3) [back to overview]Overall Survival
NCT01319981 (3) [back to overview]Number of Patients With Complete Remission at One Year
NCT01319981 (3) [back to overview]Complete Response Duration
NCT01332968 (32) [back to overview]Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)
NCT01332968 (32) [back to overview]Overall Response (Follicular Lymphoma Population), IRC-Assessed
NCT01332968 (32) [back to overview]Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase
NCT01332968 (32) [back to overview]Disease-Free Survival (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
NCT01332968 (32) [back to overview]Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase
NCT01332968 (32) [back to overview]Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]Time to Next Anti-Lymphoma Treatment (Overall Study Population)
NCT01332968 (32) [back to overview]Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
NCT01332968 (32) [back to overview]Complete Response (Overall Study Population), IRC-Assessed
NCT01332968 (32) [back to overview]Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)
NCT01332968 (32) [back to overview]Complete Response (Overall Study Population), Investigator-Assessed
NCT01332968 (32) [back to overview]Complete Response (Follicular Lymphoma Population), IRC-Assessed
NCT01332968 (32) [back to overview]Complete Response (Follicular Lymphoma Population), Investigator-Assessed
NCT01332968 (32) [back to overview]Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
NCT01332968 (32) [back to overview]Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
NCT01332968 (32) [back to overview]Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)
NCT01332968 (32) [back to overview]Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed
NCT01332968 (32) [back to overview]Percentage of Participants With Adverse Events
NCT01332968 (32) [back to overview]Progression-Free Survival in the Overall Study Population, Investigator-Assessed
NCT01332968 (32) [back to overview]Overall Survival (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]Overall Response (Overall Study Population), IRC-Assessed
NCT01332968 (32) [back to overview]Disease-Free Survival (Overall Study Population)
NCT01332968 (32) [back to overview]Overall Response (Follicular Lymphoma Population), Investigator-Assessed
NCT01332968 (32) [back to overview]Overall Response (Overall Study Population), Investigator-Assessed
NCT01332968 (32) [back to overview]Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed
NCT01332968 (32) [back to overview]Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]Duration of Response (DOR) (Overall Study Population), Investigator-Assessed
NCT01332968 (32) [back to overview]Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]Event-Free Survival (Overall Study Population)
NCT01332968 (32) [back to overview]Event-Free Survival (Follicular Lymphoma Population)
NCT01332968 (32) [back to overview]Overall Survival (Overall Study Population)
NCT01336933 (6) [back to overview]Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment
NCT01336933 (6) [back to overview]Event Free Survival (EFS)
NCT01336933 (6) [back to overview]Overall Response Rates (ORR)= (Complete Response Rates (CR) + Partial Response Rates (PR))
NCT01336933 (6) [back to overview]To Evaluate the Safety and Tolerability of the Regimen by the Percent of Participants With Indicated Adverse Events
NCT01336933 (6) [back to overview]Percent of Patients Who Proceeded With Transplant
NCT01336933 (6) [back to overview]Overall Survival (OS)
NCT01359592 (4) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT01359592 (4) [back to overview]Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
NCT01359592 (4) [back to overview]Progression-free Survival (PFS) Within the PET+ and PET- Subgroups of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01359592 (4) [back to overview]Overall Survival of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01363128 (3) [back to overview]Number of Participants With Complete Remission (CR)
NCT01363128 (3) [back to overview]4-Year Overall Survival
NCT01363128 (3) [back to overview]4-year Event Free Survival
NCT01370694 (2) [back to overview]Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy
NCT01370694 (2) [back to overview]Clinical Response of Tumor to MK-8808/CVP Combination Therapy
NCT01390584 (5) [back to overview]Proportion of Patients Who Are PET Negative After Induction Treatment
NCT01390584 (5) [back to overview]Overall Survival
NCT01390584 (5) [back to overview]Complete Response (CR) Rate After Induction Treatment
NCT01390584 (5) [back to overview]Progression-free Survival at 36 Months Among Patients Who Are PET Positive After Induction Treatment
NCT01390584 (5) [back to overview]Progression-free Survival Rate
NCT01397825 (16) [back to overview]AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine
NCT01397825 (16) [back to overview]AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine
NCT01397825 (16) [back to overview]Overall Response Rate as Assessed by the Investigator [Phase 1]
NCT01397825 (16) [back to overview]Number of Participants With Treatment-Emergent Adverse Events [Phase 1]
NCT01397825 (16) [back to overview]Tmax: Time to First Occurrence of Cmax fo Alisertib
NCT01397825 (16) [back to overview]Cmax: Maximum Plasma Concentration for Alisertib
NCT01397825 (16) [back to overview]T1/2: Terminal Disposition Phase Half-life for Vincristine
NCT01397825 (16) [back to overview]Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1]
NCT01397825 (16) [back to overview]Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]
NCT01397825 (16) [back to overview]Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]
NCT01397825 (16) [back to overview]Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]
NCT01397825 (16) [back to overview]Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]
NCT01397825 (16) [back to overview]Cmax: Maximum Plasma Concentration for Vincristine
NCT01397825 (16) [back to overview]AUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine
NCT01397825 (16) [back to overview]AUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib
NCT01397825 (16) [back to overview]T1/2: Terminal Disposition Phase Half-life for Vincristine
NCT01399372 (5) [back to overview]Percentage of Participants With Neurocognitive Failure
NCT01399372 (5) [back to overview]Overall Survival
NCT01399372 (5) [back to overview]Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
NCT01399372 (5) [back to overview]Progression-free Survival
NCT01399372 (5) [back to overview]Percentage of Participants Experiencing Partial Response or Complete Response
NCT01412879 (4) [back to overview]Progression-Free Survival (PFS) at 2 Years
NCT01412879 (4) [back to overview]Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT01412879 (4) [back to overview]Response Rate (Complete and Partial Response)
NCT01412879 (4) [back to overview]5-year Overall Survival (OS)
NCT01414855 (13) [back to overview]Duration of Response (DOR)
NCT01414855 (13) [back to overview]Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment
NCT01414855 (13) [back to overview]Pharmacokinetics: Volume of Distribution (V) for Obinutuzumab
NCT01414855 (13) [back to overview]Pharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab
NCT01414855 (13) [back to overview]Pharmacokinetics: Clearance (Cl) for Obinutuzumab
NCT01414855 (13) [back to overview]Pharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)
NCT01414855 (13) [back to overview]Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment
NCT01414855 (13) [back to overview]Percentage of Participants With Adverse Events as a Measure of Safety
NCT01414855 (13) [back to overview]Progression-Free Survival (PFS) as Assessed by the Investigator
NCT01414855 (13) [back to overview]Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab
NCT01414855 (13) [back to overview]Number of Participants With Grade 3 to 4 Infusion-Related (IRR) Adverse Events (AE) in Participants Receiving Shorter Duration Infusion (SDI)
NCT01414855 (13) [back to overview]Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment
NCT01414855 (13) [back to overview]Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment
NCT01435018 (37) [back to overview]Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2
NCT01435018 (37) [back to overview]Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3
NCT01435018 (37) [back to overview]Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4
NCT01435018 (37) [back to overview]Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Number of Participants With Peripheral Neuropathy (PN)
NCT01435018 (37) [back to overview]Number of Participants With Symptomatic Peripheral Neuropathy (SPN)
NCT01435018 (37) [back to overview]Number of Participants With Treatment-related Toxicities and Adverse Events (AEs)
NCT01435018 (37) [back to overview]Self-reported Adherence to ART Therapy
NCT01435018 (37) [back to overview]Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Death for BV+ART vs PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Death for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Duration of Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Duration of Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Number of Participants With Objective Response for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Number of Participants With Objective Response for ET+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART
NCT01435018 (37) [back to overview]Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART
NCT01445535 (6) [back to overview]Number of Dose-Limiting Toxicities (DLT)
NCT01445535 (6) [back to overview]Number of Participants With Serious and Non-serious Adverse Events
NCT01445535 (6) [back to overview]Overall Progression Free Survival (PFS)
NCT01445535 (6) [back to overview]Number of Participants With a Response to Therapy
NCT01445535 (6) [back to overview]Maximum Tolerated Dose (MTD) of Siplizumab
NCT01445535 (6) [back to overview]Overall Survival (OS)
NCT01451515 (4) [back to overview]Probability of Overall Survival (OS)
NCT01451515 (4) [back to overview]Minimal Disseminated Disease (MDD)
NCT01451515 (4) [back to overview]Minimal Residual Disease (MRD)
NCT01451515 (4) [back to overview]Probability of Event-free Survival (EFS)
NCT01483690 (2) [back to overview]Number of Participants Who Experienced a Dose Limiting Toxicity (DLT).
NCT01483690 (2) [back to overview]Disease Response Rate After Treatment.
NCT01490060 (1) [back to overview]Complete Response
NCT01527149 (9) [back to overview]Change From Baseline in Percentage of Cells Positive for Ki67
NCT01527149 (9) [back to overview]Proportion of Patients Who Experience Complete Remission as Assessed by HSFCM
NCT01527149 (9) [back to overview]Median of Serum Complement CD20 Levels
NCT01527149 (9) [back to overview]Proportion of Patients Experiencing a Complete Response
NCT01527149 (9) [back to overview]Median Overall Survival (OS)
NCT01527149 (9) [back to overview]Median Progression-free Survival (PFS)
NCT01527149 (9) [back to overview]Number of Participants With at Least One Serious Adverse Event
NCT01527149 (9) [back to overview]Percentage of Participants With Autologous Stem Cell Transplantation
NCT01527149 (9) [back to overview]Time-to-tumor Progression (TTP) at 3 Years
NCT01542736 (5) [back to overview]Event-free Survival
NCT01542736 (5) [back to overview]Intellectual Competence Measured by IQ Score: Month 24
NCT01542736 (5) [back to overview]Intellectual Competence Measured by IQ Score: Month 60
NCT01542736 (5) [back to overview]Intellectual Competence Measured by IQ Score: Week 8
NCT01542736 (5) [back to overview]Overall Survival
NCT01700946 (4) [back to overview]3-year Overall Survival Rate of Patients With Relapsed ALL
NCT01700946 (4) [back to overview]3-year Event-free Survival Rates in Patients With Relapsed ALL
NCT01700946 (4) [back to overview]Mean of CD20 Expression Levels
NCT01700946 (4) [back to overview]Median CD20 Expression Levels
NCT01724021 (14) [back to overview]Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8
NCT01724021 (14) [back to overview]Summary of Observed Serum Rituximab Concentration
NCT01724021 (14) [back to overview]Rituximab Administration Satisfaction Questionnaire (RASQ) Score
NCT01724021 (14) [back to overview]Percentage of Participants With Anti-Rituximab Antibodies Over Time
NCT01724021 (14) [back to overview]Disease-free Survival (DFS)
NCT01724021 (14) [back to overview]Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time
NCT01724021 (14) [back to overview]Cancer Therapy Satisfaction Questionnaire (CTSQ) Score
NCT01724021 (14) [back to overview]Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])
NCT01724021 (14) [back to overview]Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6
NCT01724021 (14) [back to overview]Progression-free Survival (PFS)
NCT01724021 (14) [back to overview]Number of Participants With Treatment Emergent Adverse Events (AEs)
NCT01724021 (14) [back to overview]Event-free Survival (EFS)
NCT01724021 (14) [back to overview]Complete Response (CR) Rate
NCT01724021 (14) [back to overview]Overall Survival (OS)
NCT01746173 (2) [back to overview]Induction Response
NCT01746173 (2) [back to overview]24-month Progression-Free Survival Rate
NCT01769209 (7) [back to overview]Related Adverse Events (Grade 3, 4, 5)
NCT01769209 (7) [back to overview]Response Rate (RR)
NCT01769209 (7) [back to overview]Progression-free Survival (PFS)
NCT01769209 (7) [back to overview]Complete Response Without Platelet Recovery (CRp)
NCT01769209 (7) [back to overview]Complete Response (CR)
NCT01769209 (7) [back to overview]Failure-free Survival (FFS)
NCT01769209 (7) [back to overview]Overall Survival (OS)
NCT01775475 (8) [back to overview]Number of Patients Who Complete Treatment
NCT01775475 (8) [back to overview]Overall Response Rate
NCT01775475 (8) [back to overview]Overall Survival
NCT01775475 (8) [back to overview]Participants Who Experienced an Adverse Event
NCT01775475 (8) [back to overview]Change in Absolute CD4 Count From Baseline to Post-treatment
NCT01775475 (8) [back to overview]Progression-free Survival
NCT01775475 (8) [back to overview]Proportion of Patients Who Are Adherent to Antiretroviral Therapy
NCT01775475 (8) [back to overview]Proportion of Patients Who Are Adherent to Chemotherapy
NCT01777152 (7) [back to overview]Progression-free Survival Per Independent Review Facility (IRF)
NCT01777152 (7) [back to overview]Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)
NCT01777152 (7) [back to overview]Incidence of Adverse Events (AEs)
NCT01777152 (7) [back to overview]Incidence of Laboratory Abnormalities
NCT01777152 (7) [back to overview]Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)
NCT01777152 (7) [back to overview]Overall Survival (OS)
NCT01777152 (7) [back to overview]Objective Response Rate (ORR) Per IRF at End of Treatment
NCT01798004 (1) [back to overview]The Tolerability of BuMel Regimen
NCT01855750 (6) [back to overview]Percentage of Participants Who Achieved Complete Response (CR)
NCT01855750 (6) [back to overview]Overall Survival
NCT01855750 (6) [back to overview]Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population
NCT01855750 (6) [back to overview]Event-Free Survival (EFS) - Activated B-Cell (ABC) Population
NCT01855750 (6) [back to overview]Time to Worsening in the Lymphoma Subscale of Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)
NCT01855750 (6) [back to overview]Progression-Free Survival (PFS)
NCT01856192 (4) [back to overview]Proportion of Patients With Complete Response
NCT01856192 (4) [back to overview]Overall Survival Rate at 3 Years
NCT01856192 (4) [back to overview]3-year Progression-free Survival Rate
NCT01856192 (4) [back to overview]Proportion of Patients With Response
NCT01857934 (6) [back to overview]Local Failure Rate and Pattern of Failure
NCT01857934 (6) [back to overview]Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)]
NCT01857934 (6) [back to overview]Event-free Survival (EFS)
NCT01857934 (6) [back to overview]Dose Limiting Toxicity (DLT)
NCT01857934 (6) [back to overview]Feasibility of Delivering hu14.18K322A to 6 Cycles of Induction Therapy
NCT01857934 (6) [back to overview]Dose Limiting Toxicity (DLT) or Severe (Grade 3 or 4) VOD With hu14.18K322A With Allogeneic NK Cells in Consolidation
NCT01887587 (2) [back to overview]Adverse Events.
NCT01887587 (2) [back to overview]Optimal Dose of MLN9708
NCT01889069 (23) [back to overview]DLBCL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
NCT01889069 (23) [back to overview]DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab
NCT01889069 (23) [back to overview]DLBCL: Apparent Total Clearance (CL/F) of Rituximab
NCT01889069 (23) [back to overview]Percentage of Participants With Overall Survival (OS)
NCT01889069 (23) [back to overview]Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria
NCT01889069 (23) [back to overview]Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria
NCT01889069 (23) [back to overview]Percentage of Participants With Complete Response (CR) According to IWG Response Criteria
NCT01889069 (23) [back to overview]FL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
NCT01889069 (23) [back to overview]Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores
NCT01889069 (23) [back to overview]Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores
NCT01889069 (23) [back to overview]Percentage of Participants With Administration-Associated Reactions (AAR)
NCT01889069 (23) [back to overview]FL: Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)
NCT01889069 (23) [back to overview]DLBCL: Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events
NCT01889069 (23) [back to overview]DLBCL: Plasma Concentrations of Rituximab
NCT01889069 (23) [back to overview]DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21
NCT01889069 (23) [back to overview]DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21
NCT01889069 (23) [back to overview]Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria
NCT01889069 (23) [back to overview]Percentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs)
NCT01889069 (23) [back to overview]FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
NCT01889069 (23) [back to overview]DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab
NCT01925131 (3) [back to overview]Response Rate (CR+CRi) Among Expansion Cohort
NCT01925131 (3) [back to overview]Frequency and Severity of Toxicities
NCT01925131 (3) [back to overview]MTD of Inotuzumab Ozogamicin With CVP for Patients With Relapsed or Refractory CD22+ Acute Leukemia
NCT01925612 (6) [back to overview]Progression-free Survival
NCT01925612 (6) [back to overview]Incidence of Laboratory Abnormalities
NCT01925612 (6) [back to overview]Objective Response Rate
NCT01925612 (6) [back to overview]Complete Remission Rate
NCT01925612 (6) [back to overview]Incidence of Adverse Events
NCT01925612 (6) [back to overview]Overall Survival
NCT01946529 (1) [back to overview]Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants
NCT01974440 (14) [back to overview]Supplementary Analysis: Number of Participants With TEAEs: Participants With MZL
NCT01974440 (14) [back to overview]Supplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL
NCT01974440 (14) [back to overview]Supplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZL
NCT01974440 (14) [back to overview]Primary Analysis: Progression Free Survival (PFS): Stratified Analysis
NCT01974440 (14) [back to overview]Primary Analysis: Overall Survival (OS): Stratified Analysis
NCT01974440 (14) [back to overview]Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)
NCT01974440 (14) [back to overview]Primary Analysis: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT01974440 (14) [back to overview]Primary Analysis: Duration of Response (DOR): Stratified Analysis
NCT01974440 (14) [back to overview]Primary Analysis: Complete Response Rate (CRR): Stratified Analysis
NCT01974440 (14) [back to overview]Supplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL
NCT01974440 (14) [back to overview]Primary Analysis: Overall Response Rate (ORR): Stratified Analysis
NCT01974440 (14) [back to overview]Primary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire
NCT01974440 (14) [back to overview]Supplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL
NCT01974440 (14) [back to overview]Supplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL
NCT02017964 (5) [back to overview]Event-free Survival (EFS)
NCT02017964 (5) [back to overview]Percentage of Patients With Responses at 189 Days
NCT02017964 (5) [back to overview]Overall Survival (OS)
NCT02017964 (5) [back to overview]Progression-free Survival (PFS)
NCT02017964 (5) [back to overview]Percentage of Patients With Responses at 273 Days
NCT02035137 (2) [back to overview]Number of Participants With Grade 3 or Greater Non-hematologic Toxicities
NCT02035137 (2) [back to overview]Objective Tumor Response After One Course of Therapy
NCT02055820 (22) [back to overview]Doxorubicin PK: Cmax
NCT02055820 (22) [back to overview]Obinutuzumab PK: Cmax
NCT02055820 (22) [back to overview]Percentage of Participants Who Are Alive and Without Disease Progression at Month 12
NCT02055820 (22) [back to overview]Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification
NCT02055820 (22) [back to overview]Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC
NCT02055820 (22) [back to overview]Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC
NCT02055820 (22) [back to overview]Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)
NCT02055820 (22) [back to overview]Rituximab PK: Cmax
NCT02055820 (22) [back to overview]Rituximab PK: Cmin Within the Dosing Interval
NCT02055820 (22) [back to overview]Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)
NCT02055820 (22) [back to overview]Safety: Percentage of Participants With Adverse Events
NCT02055820 (22) [back to overview]Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)
NCT02055820 (22) [back to overview]Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)
NCT02055820 (22) [back to overview]Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval
NCT02055820 (22) [back to overview]Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)
NCT02055820 (22) [back to overview]Vincristine PK: Cmax
NCT02055820 (22) [back to overview]Prednisone Plasma PK: AUC
NCT02055820 (22) [back to overview]Prednisone Plasma PK: Tmax
NCT02055820 (22) [back to overview]Relative Dose Intensity of Venetoclax
NCT02055820 (22) [back to overview]Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy
NCT02055820 (22) [back to overview]Prednisone Plasma PK: Cmax
NCT02055820 (22) [back to overview]Cyclophosphamide PK: Cmax
NCT02101853 (4) [back to overview]Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients
NCT02101853 (4) [back to overview]Overall Survival (OS) of LR Relapse Patients
NCT02101853 (4) [back to overview]Overall Survival (OS) of HR and IR Relapse Patients
NCT02101853 (4) [back to overview]Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients
NCT02112916 (6) [back to overview]Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
NCT02112916 (6) [back to overview]EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
NCT02112916 (6) [back to overview]EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
NCT02112916 (6) [back to overview]EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
NCT02112916 (6) [back to overview]Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
NCT02112916 (6) [back to overview]Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
NCT02143414 (6) [back to overview]Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT02143414 (6) [back to overview]Minimal Residual Disease Negativity
NCT02143414 (6) [back to overview]Complete Response Rate (Cohort I)
NCT02143414 (6) [back to overview]Overall Survival Rate (Cohort I)
NCT02143414 (6) [back to overview]Incidence of Dose-limiting Toxicity (Cohort II)
NCT02143414 (6) [back to overview]Disease-free Survival (Cohort II)
NCT02162771 (4) [back to overview]Maximum Serum Concentration at Steady State (Cmax,ss)
NCT02162771 (4) [back to overview]Overall Response Rate (ORR) According to the 1999 International Working Group (IWG) Criteria
NCT02162771 (4) [back to overview]B-cell Kinetics (B-cell Depletion and Recovery)
NCT02162771 (4) [back to overview]Area Under the Serum Concentration-time Curve at Steady State (AUCtau)
NCT02166463 (3) [back to overview]Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale
NCT02166463 (3) [back to overview]Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death
NCT02166463 (3) [back to overview]Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review
NCT02257242 (3) [back to overview]Complete Response Rate
NCT02257242 (3) [back to overview]Maximum Tolerated Dose
NCT02257242 (3) [back to overview]Number of Participants Who Completed Six Cycles of Study Treatment
NCT02285062 (15) [back to overview]Kaplan-Meier (K-M) Estimate of Event Free Survival (EFS)
NCT02285062 (15) [back to overview]Kaplan-Meier Estimate of Progression Free Survival (PFS)
NCT02285062 (15) [back to overview]Percentage of Participants Who Achieved a Complete Response (CR)
NCT02285062 (15) [back to overview]Percentage of Participants Who Achieved an Objective Response
NCT02285062 (15) [back to overview]Mean Change From Baseline in the EQ-5D-3L Visual Analogue Scale (VAS)
NCT02285062 (15) [back to overview]Mean Change From Baseline in the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Index Score
NCT02285062 (15) [back to overview]Mean Change From Baseline in the FACT-Lym Additional Concerns Subscale
NCT02285062 (15) [back to overview]Mean Change From Baseline in the FACT-Lym Physical Well-Being Subscale
NCT02285062 (15) [back to overview]Mean Change From Baseline in the FACT-Lym Trial Outcome Index (TOI)
NCT02285062 (15) [back to overview]Percentage of Participants Who Completed the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Health Related Quality of Life (HR-QoL) Questionnaire
NCT02285062 (15) [back to overview]Percentage of Participants Who Completed the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire
NCT02285062 (15) [back to overview]K-M Estimate of Time to Next Lymphoma Therapy (TTNLT)
NCT02285062 (15) [back to overview]Mean Change From Baseline in the FACT-Lym Functional Well-Being Subscale
NCT02285062 (15) [back to overview]K-M Estimate of Overall Survival (OS)
NCT02285062 (15) [back to overview]K-M Estimate of Duration of Complete Response
NCT02306161 (3) [back to overview]Overall Survival
NCT02306161 (3) [back to overview]Frequency of Toxicity-events
NCT02306161 (3) [back to overview]Event-free Survival
NCT02319486 (1) [back to overview]Event Free Survival Rate
NCT02337478 (2) [back to overview]Number of Participants Able to Complete Two or More Courses of Therapy Regardless of Dose Modifications
NCT02337478 (2) [back to overview]Overall Survival
NCT02404220 (5) [back to overview]Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT02404220 (5) [back to overview]Percentage of Participants With Complete Remission (CR) at the End of Induction
NCT02404220 (5) [back to overview]Percentage of Participants With Overall Response at the End of Induction
NCT02404220 (5) [back to overview]Percentage of Participants With Overall Remission at the End of Induction
NCT02404220 (5) [back to overview]Percentage of Participants With Partial Response (PR) at the End of Induction
NCT02419469 (1) [back to overview]Event Free Survival (EFS)
NCT02420717 (4) [back to overview]Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
NCT02420717 (4) [back to overview]Overall Survival
NCT02420717 (4) [back to overview]Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)
NCT02420717 (4) [back to overview]Progression-free Survival
NCT02481310 (2) [back to overview]12-month PFS (Progression Free Survival) of Treatment With Ixazomib in Combination With DA-EPOCH-R (Phase II)
NCT02481310 (2) [back to overview]To Determine the Recommended Phase II Dose (RP2D) of Ixazomib in Combination With DA-EPOCH-R.
NCT02486952 (2) [back to overview]Percentage of Participants Who Were Alive
NCT02486952 (2) [back to overview]Probability of Event Free Survival (EFS)
NCT02535806 (4) [back to overview]2-year Overall Survival Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02535806 (4) [back to overview]Number of Subject With Adverse Events
NCT02535806 (4) [back to overview]Remission Rate Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02535806 (4) [back to overview]Post-induction Level of Minimal Residual Disease Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02541565 (1) [back to overview]Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT02553460 (1) [back to overview]Percentage of Treatment-related Mortality (TRM)
NCT02561273 (7) [back to overview]Complete Response Rate (Phase II)
NCT02561273 (7) [back to overview]Number of Participants With Adverse Events Graded According to CTC (Phase II)
NCT02561273 (7) [back to overview]Progression-free Survival
NCT02561273 (7) [back to overview]Overall Survival
NCT02561273 (7) [back to overview]Overall Response Rate
NCT02561273 (7) [back to overview]Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP
NCT02561273 (7) [back to overview]Number of Participants With Adverse Events Graded According to Common Toxicity Criteria (CTC) (Phase I)
NCT02566993 (25) [back to overview]Overall Survival (OS)
NCT02566993 (25) [back to overview]Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline
NCT02566993 (25) [back to overview]Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days
NCT02566993 (25) [back to overview]Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days
NCT02566993 (25) [back to overview]Overall Response Rate in Patients With Central Nervous System Involvement at Baseline
NCT02566993 (25) [back to overview]Duration of Response in Patients Without Central Nervous System Involvement at Baseline
NCT02566993 (25) [back to overview]Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days
NCT02566993 (25) [back to overview]Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days
NCT02566993 (25) [back to overview]Duration of Response in Patients With Chemotherapy-free Interval <90 Days
NCT02566993 (25) [back to overview]Duration of Response in Patients With Central Nervous System Involvement at Baseline
NCT02566993 (25) [back to overview]Duration of Response by Independent Review Committee
NCT02566993 (25) [back to overview]Overall Response Rate by Independent Review Committee
NCT02566993 (25) [back to overview]Progression-free Survival Rate at 6 Months by Independent Review Committee
NCT02566993 (25) [back to overview]Progression-free Survival Rate at 12 Months by Independent Review Committee
NCT02566993 (25) [back to overview]Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months
NCT02566993 (25) [back to overview]Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months
NCT02566993 (25) [back to overview]Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months
NCT02566993 (25) [back to overview]Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline
NCT02566993 (25) [back to overview]Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days
NCT02566993 (25) [back to overview]Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days
NCT02566993 (25) [back to overview]Progression-free Survival in Patients With Central Nervous System Involvement at Baseline
NCT02566993 (25) [back to overview]Progression-free Survival (PFS) by Independent Review Committee
NCT02566993 (25) [back to overview]Overall Survival in Patients Without Central Nervous System Involvement at Baseline
NCT02566993 (25) [back to overview]Overall Survival in Patients With Chemotherapy-free Interval < 90 Days
NCT02566993 (25) [back to overview]Overall Survival in Patients With Central Nervous System Involvement at Baseline
NCT02568683 (4) [back to overview]Number of Participants With AEs and Lab Abnormalities Not Defined as DLTs in Participants With Relapsed or Refractory B-cell NHL: Dose Escalation Stage
NCT02568683 (4) [back to overview]Number of VCR Doses
NCT02568683 (4) [back to overview]Duration of Exposure to ENTO
NCT02568683 (4) [back to overview]Number of Participants With Adverse Events (AEs) and Laboratory (Lab) Abnormalities Defined as Dose Limiting Toxicities (DLTs) in Participants With Relapsed or Refractory B-cell NHL: Dose Escalation Stage
NCT02596971 (18) [back to overview]Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
NCT02596971 (18) [back to overview]Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab
NCT02596971 (18) [back to overview]Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab
NCT02596971 (18) [back to overview]Percentage of Participants With Adverse Events
NCT02596971 (18) [back to overview]Percentage of Participants With Best Response of CR or PR During Study, as Determined by Investigator Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]Percentage of Participants With Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria
NCT02596971 (18) [back to overview]Percentage of Participants With CR at EOI, as Determined by the Investigator Using Lugano 2014 Criteria
NCT02596971 (18) [back to overview]Percentage of Participants With CR at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]Percentage of Participants With CR at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Lugano 2014 Criteria
NCT02596971 (18) [back to overview]Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria
NCT02596971 (18) [back to overview]Observed Serum Atezolizumab Concentration
NCT02596971 (18) [back to overview]Observed Serum Atezolizumab Concentration
NCT02596971 (18) [back to overview]Observed Serum Obinutuzumab Concentration
NCT02596971 (18) [back to overview]Observed Serum Rituximab Concentration
NCT02596971 (18) [back to overview]Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
NCT02596971 (18) [back to overview]Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Lugano 2014 Criteria
NCT02617485 (12) [back to overview]Cmax (Post 5th and 8th Infusion)
NCT02617485 (12) [back to overview]CLss (Post 5th and 8th Infusions)
NCT02617485 (12) [back to overview]Adverse Events
NCT02617485 (12) [back to overview]AUC (W1-W26) B-cell
NCT02617485 (12) [back to overview]AUC (W1-W26)
NCT02617485 (12) [back to overview]Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])
NCT02617485 (12) [back to overview]Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])
NCT02617485 (12) [back to overview]Ctrough (Before 8th Infusion)
NCT02617485 (12) [back to overview]T1/2 (Post 5th and 8th Infusions)
NCT02617485 (12) [back to overview]Kel (Post 5th and 8th Infusions)
NCT02617485 (12) [back to overview]Immunogenicity
NCT02617485 (12) [back to overview]Efficacy Assessment at Week 26
NCT02677116 (16) [back to overview]Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)
NCT02677116 (16) [back to overview]PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part C
NCT02677116 (16) [back to overview]PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part B
NCT02677116 (16) [back to overview]PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A
NCT02677116 (16) [back to overview]PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A
NCT02677116 (16) [back to overview]PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A
NCT02677116 (16) [back to overview]PK: Maximum Concentration (Cmax) of Olaratumab Part C
NCT02677116 (16) [back to overview]PK: Maximum Concentration (Cmax) of Olaratumab Part C
NCT02677116 (16) [back to overview]PK: Maximum Concentration (Cmax) of Olaratumab Part C
NCT02677116 (16) [back to overview]PK: Maximum Concentration (Cmax) of Olaratumab Part B
NCT02677116 (16) [back to overview]PK: Maximum Concentration (Cmax) of Olaratumab Part B
NCT02677116 (16) [back to overview]Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A
NCT02677116 (16) [back to overview]Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A
NCT02677116 (16) [back to overview]Progression Free Survival (PFS)
NCT02677116 (16) [back to overview]Percentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies
NCT02677116 (16) [back to overview]Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
NCT02684058 (53) [back to overview]LGG Cohort: Kaplan-Meier Estimates of Time to Response (TTR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: Kaplan-Meier Estimates of Time to Response (TTR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: Kaplan-Meier Estimates of Overall Survival (OS)
NCT02684058 (53) [back to overview]LGG Cohort: Clinical Benefit Rate (CBR) by Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: Clinical Benefit Rate (CBR) by Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: 2-year OS Estimate
NCT02684058 (53) [back to overview]HGG Cohort: Time to Response (TTR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG Cohort: Time to Response (TTR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: Immediate Reaction Once the Medication Was Placed Into the Mouth
NCT02684058 (53) [back to overview]HGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG Cohort: Kaplan-Meier Estimates of Progression Free Survival (PFS) as Per Investigatort Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG Cohort: Kaplan-Meier Estimates of Progression Free Survival (PFS) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG Cohort: Kaplan-Meier Estimates of Overall Survival (OS)
NCT02684058 (53) [back to overview]HGG Cohort: Clinical Benefit Rate (CBR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG Cohort: Clinical Benefit Rate (CBR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]Ctrough for Trametinib
NCT02684058 (53) [back to overview]Cmax for Trametinib
NCT02684058 (53) [back to overview]AUCtau for Trametinib
NCT02684058 (53) [back to overview]LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Fatigue Score
NCT02684058 (53) [back to overview]LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Global Health Score
NCT02684058 (53) [back to overview]LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Global Health Score
NCT02684058 (53) [back to overview]LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Pain Score
NCT02684058 (53) [back to overview]LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Pain Score
NCT02684058 (53) [back to overview]T1/2 for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]Tmax for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: After- Taste Once the Medication Was Swallowed
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Assessment: After- Taste Once the Medication Was Swallowed
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Immediate Reaction Once the Medication Was Placed Into the Mouth
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Taste of the Medication Before Rinsing the Mouth
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: Remaining After-taste Once Rinsing the Mouth With Water
NCT02684058 (53) [back to overview]Cmax for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]HGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria (Longer Follow-up Time)
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Questionnaire Item: Taste of the Medication Before Rinsing the Mouth
NCT02684058 (53) [back to overview]HGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Remaining After-taste Once Rinsing the Mouth With Water
NCT02684058 (53) [back to overview]HGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]HGG Cohort: ORR by Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]Ctrough for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]AUCtau for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]AUClast for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]AUClast for Trametinib
NCT02684058 (53) [back to overview]All-collected Deaths
NCT02684058 (53) [back to overview]LGG Cohort: ORR by Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Fatigue Score
NCT02684058 (53) [back to overview]Tmax for Trametinib
NCT02684058 (53) [back to overview]T1/2 for Trametinib
NCT02684058 (53) [back to overview]LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using Response Assessment in Neuro-Oncology (RANO) Criteria
NCT02684058 (53) [back to overview]LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria (Longer Follow-up Time)
NCT02684058 (53) [back to overview]All-collected Deaths
NCT02703272 (37) [back to overview]Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Time to Response
NCT02703272 (37) [back to overview]Part 2: Tumor Volume Reduction Rate at Day 14
NCT02703272 (37) [back to overview]Part 1 and Part 2: Gene Expression Evaluated by Disease-specific Biomarkers at Baseline
NCT02703272 (37) [back to overview]Part 1 and Part 2: Visual Analog Scale (VAS) Score for Palatability
NCT02703272 (37) [back to overview]Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Number of Participants With CD79B, CARD11, and MYD Mutations
NCT02703272 (37) [back to overview]Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]Part 1 and Part 2: Overall Response Rate (ORR)
NCT02703272 (37) [back to overview]Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy
NCT02703272 (37) [back to overview]Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability
NCT02703272 (37) [back to overview]Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups
NCT02703272 (37) [back to overview]Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation
NCT02703272 (37) [back to overview]Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Number of Participants With c-MYC Gene Rearrangement
NCT02703272 (37) [back to overview]Part 2: Overall Survival
NCT02703272 (37) [back to overview]Part 2: Percentage of Participants Who Achieved Complete Response (CR)
NCT02703272 (37) [back to overview]Part 2: Percentage of Participants Who Achieved Partial Response (PR)
NCT02703272 (37) [back to overview]Part 2: Percentage of Participants With EFS at 2 Years
NCT02703272 (37) [back to overview]Part 2: Percentage of Participants With EFS at 3 Years
NCT02703272 (37) [back to overview]Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
NCT02703272 (37) [back to overview]Part 2: Duration of Response
NCT02703272 (37) [back to overview]Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
NCT02732015 (1) [back to overview]Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose
NCT02786719 (2) [back to overview]Delay in Chemotherapy Administration Due to Prolonged Neutrophil Recovery
NCT02786719 (2) [back to overview]Incidence of Infection
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02855359 (2) [back to overview]Part A and Part B Outcome Measure: Incidence of Adverse Events
NCT02855359 (2) [back to overview]Part A and Part B Outcome Measure: Incidence of Laboratory Abnormalities
NCT03003520 (8) [back to overview]Participants With Treatment Emergent Adverse Events (TEAE)
NCT03003520 (8) [back to overview]Percentage of Participants Who Responded During Induction and Continued Into Consolidation Therapy (Database Cutoff Date: 02-Aug-2018)
NCT03003520 (8) [back to overview]Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy
NCT03003520 (8) [back to overview]Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for the Interferon Gamma Score (IFNG-Score) From Ribonucleic Acid (RNA)-Sequencing Data
NCT03003520 (8) [back to overview]Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Total Percentage
NCT03003520 (8) [back to overview]Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Percentage of Tumor Cells
NCT03003520 (8) [back to overview]Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) CD8 T-Cell Density
NCT03003520 (8) [back to overview]Participants With Treatment Emergent Adverse Events (TEAE)
NCT03023046 (5) [back to overview]Number of Participants With Adverse Events
NCT03023046 (5) [back to overview]Number of Participants With Morphological Complete Response Rate
NCT03023046 (5) [back to overview]Overall Survival
NCT03023046 (5) [back to overview]Event-free Survival
NCT03023046 (5) [back to overview]Number of Participants With Complete Measurable Residual Disease (MRD) Response Rate
NCT03384654 (13) [back to overview]Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
NCT03384654 (13) [back to overview]Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL
NCT03384654 (13) [back to overview]Event-free Survival (EFS)
NCT03384654 (13) [back to overview]Maximum Observed Serum Concentration (Cmax) of Daratumumab
NCT03384654 (13) [back to overview]Minimal Residual Disease (MRD) Negative Rate
NCT03384654 (13) [back to overview]Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)
NCT03384654 (13) [back to overview]Overall Response Rate (ORR)
NCT03384654 (13) [back to overview]Overall Survival (OS)
NCT03384654 (13) [back to overview]Minimum Observed Serum Concentration (Cmin) of Daratumumab
NCT03384654 (13) [back to overview]Relapse-free Survival (RFS)
NCT03384654 (13) [back to overview]Concentration of Daratumumab in Cerebrospinal Fluid (CSF)
NCT03384654 (13) [back to overview]Concentration of Daratumumab in Cerebrospinal Fluid (CSF)
NCT03384654 (13) [back to overview]Number of Participants With Anti-daratumumab Antibodies
NCT03488225 (5) [back to overview]Number of Participants With Adverse Events
NCT03488225 (5) [back to overview]Participants to Achieve Complete Remission (CR):
NCT03488225 (5) [back to overview]Overall Survival
NCT03488225 (5) [back to overview]Number of Participants With Minimal Residual Disease (MRD) Negativity
NCT03488225 (5) [back to overview]Event-Free Survival
NCT03518112 (5) [back to overview]Overall Survival
NCT03518112 (5) [back to overview]Participants With a Response
NCT03518112 (5) [back to overview]Number of Participants Negative for Minimal Residual Disease (MRD)
NCT03518112 (5) [back to overview]Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death
NCT03518112 (5) [back to overview]Duration of Response
NCT03589326 (1) [back to overview]Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase
NCT03596918 (1) [back to overview]Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire
NCT03786783 (5) [back to overview]"Percentage of Participants Who Are Feasibility Failure"
NCT03786783 (5) [back to overview]Event-free Survival
NCT03786783 (5) [back to overview]Percentage of Participants With Unacceptable Toxicity
NCT03786783 (5) [back to overview]Response Rate
NCT03786783 (5) [back to overview]Overall Survival
NCT03817853 (8) [back to overview]Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
NCT03817853 (8) [back to overview]Time to IRR From Infusion to Onset of the IRR During Cycle 2
NCT03817853 (8) [back to overview]Duration (In Minutes) of Obinutuzumab Administration by Cycle
NCT03817853 (8) [back to overview]Objective Response Rate (ORR) at the End of Induction (EOI) Therapy
NCT03817853 (8) [back to overview]Percentage of Participants With Adverse Events (AEs)
NCT03817853 (8) [back to overview]Percentage of IRRs Regardless of Grade by Cycle
NCT03817853 (8) [back to overview]Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
NCT03817853 (8) [back to overview]Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR
NCT03860844 (13) [back to overview]Cluster of Differentiation (CD)38 Receptor Density
NCT03860844 (13) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT03860844 (13) [back to overview]B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
NCT03860844 (13) [back to overview]AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]AML: Ceoi of Isatuximab
NCT03860844 (13) [back to overview]CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]AML: AUC of Isatuximab
NCT03860844 (13) [back to overview]Percentage of Participants With Complete Response (CR) Rate
NCT03860844 (13) [back to overview]Overall Response Rate (ORR)
NCT03860844 (13) [back to overview]Number of Participants With Infusion Reactions (IRs)
NCT03860844 (13) [back to overview]CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
NCT03860844 (13) [back to overview]B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT04660799 (14) [back to overview]Observed SC and IV Rituximab Area Under the Curve (AUCsc and AUCiv)
NCT04660799 (14) [back to overview]Subcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV)
NCT04660799 (14) [back to overview]Area Under the Curve (AUC) of Rituximab
NCT04660799 (14) [back to overview]Maximum Observed Serum Concentration (Cmax) of Rituximab
NCT04660799 (14) [back to overview]Number of Participants Positive for Anti-drug Antibodies (ADAs) to Rituximab
NCT04660799 (14) [back to overview]Number of Participants Positive for Anti-rHuPH20 Antibodies
NCT04660799 (14) [back to overview]Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT04660799 (14) [back to overview]Objective Response Rate (ORR), Complete Response (CR) or Partial Response (PR), as Determined by Investigator and IRC Using Lugano Response Criteria (LRC) for Malignant Lymphoma
NCT04660799 (14) [back to overview]Time to Cmax (Tmax) of Rituximab
NCT04660799 (14) [back to overview]Trough Serum Concentration (Ctrough) of Rituximab
NCT04660799 (14) [back to overview]CRR, as Determined by the Investigator Using Lugano Response Criteria for Malignant Lymphoma
NCT04660799 (14) [back to overview]Complete Response Rate (CRR) as Determined by the Independent Review Committee (IRC) Using Lugano Response Criteria (LRC) for Malignant Lymphoma
NCT04660799 (14) [back to overview]Number of Participants With Rituximab Administration-related Reactions (ARRs)
NCT04660799 (14) [back to overview]CRR, as Determined by IRC Using International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) 1999 Guidelines
NCT04745832 (2) [back to overview]Number of SAEs (Zandelisib When Combined With Rituximab)
NCT04745832 (2) [back to overview]Number of Treatment Emergent AEs (Zandelisib When Combined With Rituximab)

Complete Remission (CR)

complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks. The patient should have a neutrophil count > 1,000 x 10^6/1, a platelet count > 100,000 x 10^9/1, no circulating blasts, and < than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow. Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia. (NCT00002766)
Timeframe: 2 years

,
Interventionparticipants (Number)
Complete RemissionComplete Response (CR)FailureFailure-ProgressionRelapse
All-25014581
L-20501114100

[back to top]

Incidence of Second Cancers

Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years

Interventionparticipants (Number)
Arm A (ABVD)15
Arm B (Stanford V)19

[back to top]

5-year Overall Survival

Overall survival is defined as the time from randomization to death or last known alive. The 5-year survival rate is the probability a patient survives 5 years. (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years

InterventionProportion of patients (Number)
Arm A (ABVD)0.88
Arm B (Stanford V)0.88

[back to top]

Failure-free Survival at 5 Years

"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5

InterventionProportion of patients (Number)
Arm A (ABVD)0.74
Arm B (Stanford V)0.71

[back to top] [back to top]

2-year Overall Survival Rates

Percentage of participants surviving 2 years post registration (NCT00004031)
Timeframe: up to 2 years post registration

Interventionpercentage of participants (Number)
CHOP/CHOP-R x 371.1
CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant73.7

[back to top]

2 Year Progression-free Survival

Percentage of participants without disease progression up to 2 years post-registration. (NCT00004031)
Timeframe: From registration until death

Interventionpercentage of participants (Number)
CHOP/CHOP-R x 355.4
CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant69.1

[back to top]

Percentage of Patients With Overall Survival as Assessed by Time to Death

Overall survival will be computed by measuring the rate of deaths during induction due primarily to treatment toxicity and cumulative incidence of toxic deaths in induction or deaths in remission overall and separately for treatment groups defined by the two design factors. (NCT00004228)
Timeframe: 5 years

Interventionpercentage of participants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM96
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens84
A2 (Disseminated, No CNS - CCG Mod BFM w/Intens88
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy81
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens85
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens85
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment92

[back to top]

Event-free Survival

Assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause. Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification. (NCT00004228)
Timeframe: 5 years

Interventionpercentage of particpants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM88
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens82
A2 (Disseminated, No CNS - CCG Mod BFM w/ Intens80
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy63
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens82
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens84
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment90

[back to top]

Overall Survival (OS)

OS was determined by the Kaplan-Meier method and is defined as the time from treatment start date until date of death or last follow-up. (NCT00005780)
Timeframe: Time from treatment start date until date of death or date last follow-up, up to 250 months

InterventionMonths (Median)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab89.7

[back to top]

Percentage of Participants Whose Cancer Shrinks or Disappears After Treatment With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R)

Response was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma. Complete Response (CR) is a complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g., Lactate dehydrogenase (LDH) definitely assignable to the lymphoma. Complete Response Unconfirmed (CRu) is as per CR criteria except that if a residual node is > 1.5cm, it must have regressed by > 75% in the sum of the products of the greatest diameters (SPD). Partial Response (PR) is ≥50% decreased in the SPD of 6 largest dominant nodes or nodal masses. Stable Disease (SD) is defined as less than a PR but not progressive disease. Progression is ≥50% increase from nadir in the SPD of any previously involved node or the appearance of any new lesion. (NCT00005780)
Timeframe: After 6 cycles of EPOCH-R therapy, an average of 18 weeks

Interventionpercentage of participants (Number)
Complete ResponseComplete Response UnconfirmedPartial ResponseStable DiseaseProgression
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab80.87.77.703.8

[back to top] [back to top]

Percentage of Participants With an Antibody Response to Idiotype Vaccine

Participants with an immune response to idiotype vaccine measured by enzyme-linked immunosorbent assay (ELISA) to detect antibody binding to tumor cells. Positive response was defined as at least a fourfold increase in antibody titer. (NCT00005780)
Timeframe: Weeks 12 to 32

Interventionpercentage of participants (Number)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab30

[back to top]

Percentage of Participants With Induction of Type 1 Cytokine T-cell Response

Participants with tumor specific T-cell responses during B-cell recovery was assessed in a Clinical Laboratory Improvement Amendments (CLIA) certified lab and were measured by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT). A positive response required the response to be at least twice the negative controls. (NCT00005780)
Timeframe: After vaccinations administered at 0, 1, 2, 3 and 5 months

Interventionpercentage of participants (Number)
Peripheral blood mononuclear cells (PBMC)Granulocyte macrophage colony-stimulating factor (GM-CSF)Tumor necrosis factor α (TNFα)Interferon-gamma (IFN-γ)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab87655274

[back to top]

Percentage of Participants With Antibodies to Keyhole Limpet Haemocyanin (KLH)

Participants with an immune response against carrier molecule KLH measured by enzyme-linked immunosorbent assay (ELISA) to detect antibody binding to tumor cells. Positive response was defined as at least a fourfold increase in antibody titer. (NCT00005780)
Timeframe: After vaccinations administered at 0, 1, 2, 3 and 5 months

Interventionpercentage of participants (Number)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab74

[back to top]

Progression Free Survival (PFS) in Participants Who Received Idiotype Vaccine

PFS is defined as the time from start of treatment until disease relapse or progression, death, or last follow-up. Progression was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma and is defined as ≥50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously involved node or the appearance of any new lesion (NCT00005780)
Timeframe: Time from treatment start date until date of disease relapse or progression, death, or date last follow-up, an average of 25 months

InterventionMonths (Median)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab25.0

[back to top]

Time to Recovery of CD4 T Lymphocytes (CD4+)

Recovery of CD4+ was measured by flow cytometry. Blood samples were collected via apheresis and analyzed by multicolor flow cytometry in peripheral blood mononuclear cells (PBMCs) for cluster of differentiation 4 (CD4). Time to recovery of CD4 T lymphocytes was defined as the time required for CD4 T lymphocytes to increase above the lower limit of normal of the normal laboratory value range of 359 cells/mcL (NCT00005780)
Timeframe: After chemotherapy before vaccination, up to 6 months

InterventionMonths (Median)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab3

[back to top]

Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R)

PFS is time from on study date until disease relapse or progression, death, or date of last follow-up. Progression was measured by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphoma and is defined as ≥50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously involved node or the appearance of any new lesion. (NCT00005780)
Timeframe: From participants on study date until date of disease relapse or progression, death, or date of last follow-up, assessed up to 245.8 months

InterventionMonths (Median)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab23.5

[back to top]

Here is the Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0).

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00005780)
Timeframe: Up to 30 days after last intervention, up to 12.5 months or 1.04 years

InterventionParticipants (Count of Participants)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab26

[back to top]

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00006184)
Timeframe: 9 years

InterventionParticipants (Count of Participants)
Recipient - Chemotherapy Group10
Donor - Vaccination Generation Group10

[back to top]

Immune Response

Immune cell depletion is defined as immunosuppression of participants T cells prior to transplant measured by cluster of differentiation 4 (CD4) counts (i.e. cells) > 50 cells per ul.Immune T-cell depletion helps to reduce the ability to reject allogeneic cells in participants and is required for engraftment. Engraftment is the body's ability to accept donor cells. (NCT00006184)
Timeframe: 105 days

InterventionParticpants (Number)
Recipient - Chemotherapy Group7

[back to top]

Percentage of Participants With Complete Response

Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy). (NCT00006436)
Timeframe: The participants were followed for an average of 6 months to determine response to therapy.

Interventionpercentage of participants (Number)
Arm 1-Combination Chemo and Biological Therapy95

[back to top]

Number of Cycles of Hematologic Toxicity

Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). (NCT00006436)
Timeframe: Up to 112 cycles (each cycle is 21 days + 7 days window)

Interventioncycles (Number)
Febrile neutropeniaNeutropenia with a Nadir <500 cells/mm^3Neutropenia with a Nadir <100 cells/mm^3Thrombocytopenia with a Nadir <50,000 platelets/mm^3Thrombocytopenia with a Nadir <25,000 platelets/mm^3Anemia: hemoglobin <8 g/dL
Arm 1-Combination Chemo and Biological Therapy251127740636

[back to top]

Median Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)

PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival. (NCT00006436)
Timeframe: Participants were followed for up to 10.2 years to determine their response on interim PET scans.

Interventionyears (Median)
Interim PET positive participantsInterim PET negative participants
Arm 1-Combination Chemo and Biological Therapy10.2NA

[back to top]

Number of Participants With at Least One Hematologic Toxicity Event of Febrile Neutropenia

Toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Febrile neutropenia is defined as a life-threatening complication requiring hospitalization and urgent broad-spectrum antibiotics. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.

InterventionParticipants (Count of Participants)
Arm 1-Combination Chemo and Biological Therapy18

[back to top]

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC v2.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.

InterventionParticipants (Count of Participants)
Arm 1-Combination Chemo and Biological Therapy66

[back to top]

Percentage of Participants With CR/CRu Lasting 1 Year

"Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy).~Complete response unconfirmed (CRu) is when a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by > 75% in sum of the products of the greatest diameters or are < 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR." (NCT00006436)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Arm 1-Combination Chemo and Biological Therapy82.5

[back to top]

Progression Free Survival at 1 Year

PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). (NCT00006436)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Arm 1-Combination Chemo and Biological Therapy79.1

[back to top]

Recovery of CD4 T Cells (CD4) Counts

Participants with human immunodeficiency virus (HIV) who undergo chemotherapy may have a delay in the recovery of their normal CD4+ T-cells. This delay could result in an increased risk of infection. Recovery of CD4 cells counts is the time from end of therapy until the time that the CD4 counts first reached above 200 cells/uL. (NCT00006436)
Timeframe: From the end of chemotherapy every 3 months for the first 2 years

Interventionmonths (Median)
Arm 1-Combination Chemo and Biological Therapy2.5

[back to top]

1 Year Overall Survival

Overall survival is time from treatment start date until date of death or date last known alive. (NCT00006436)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Arm 1-Combination Chemo and Biological Therapy83.7

[back to top]

Overall Response

Overall response was determined by the Cheson Response Criteria. Participants with either a complete response (CR), complete response unconfirmed or partial response were considered responders. Less than a partial response was considered a non-response to therapy (i.e., Stable Disease and/or Progressive Disease). Complete response was defined as the disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size. Complete response unconfirmed is a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. Partial response is defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting for a period of at least one month. (NCT00006436)
Timeframe: The participants were followed for an average of 6 months to determine response to therapy.

InterventionParticipants (Count of Participants)
Complete ResponseComplete Response UnconfirmedPartial ResponseNon-Responder - Stable DiseaseNon-Responder - Progressive Disease
Arm 1-Combination Chemo and Biological Therapy5310111

[back to top]

Number of Participants With ≥ Grades 3-5 Non-hematologic Toxicity

Non-hematologic (i.e., not begin in bone marrow or blood) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.

,,
InterventionParticipants (Count of Participants)
Serious infectionNeurologic eventSyncopeConfusionMotor neuropathyVision disturbanceHyperglycemiaHypophosphatemiaHypocalcemiaHypokalemiaHyponatremiaDehydrationMucositis/StomatitisLiver test abnormalitiesPancreatitisDiarrheaConstipationSerious hemorrhageFatigueHeadacheBone painNauseaAnorexiaHypoxiaMyelodysplastic syndrome
Grade 317011014221116612152510000
Grade 40000100101000100010001140
Grade 50000000000000000000000011

[back to top]

1 Year Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)

"1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans.~PFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival." (NCT00006436)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Interim PET scan positive 1-year PFSInterim PET scan negative 1 year PFS
Arm 1-Combination Chemo and Biological Therapy61.589.3

[back to top]

Median Duration of Complete Response/Complete Response Unconfirmed

"Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy).~Complete response unconfirmed (CRu) is when a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by > 75% in sum of the products of the greatest diameters or are < 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR." (NCT00006436)
Timeframe: The participants were followed for duration of complete response or complete response unconfirmed for a median of 15.4 years.

Interventionyears (Median)
Arm 1-Combination Chemo and Biological Therapy13.9

[back to top]

Median Overall Survival

Overall survival is time from treatment start date until date of death or date last known alive. (NCT00006436)
Timeframe: The participants were followed for survival for a median of 15.4 years.

Interventionyears (Median)
Arm 1-Combination Chemo and Biological Therapy14.2

[back to top]

Median Progression Free Survival (PFS)

PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed. (NCT00006436)
Timeframe: The participants were followed for a median of 15.4 years.

Interventionyears (Median)
Arm 1-Combination Chemo and Biological Therapy13.8

[back to top]

Recovery of Human Immunodeficiency Virus (HIV) Viral Load

The HIV viral load is a measure of actively replicating virus in the blood. If no anti-retroviral therapy is given, then reduction of this HIV viral load to manageable levels might risk infection. In our study, the recovery of HIV viral load was measured the time from the initiation of antiretroviral therapy until the viral load was undetectable or < 50 copies. (NCT00006436)
Timeframe: Either following or concurrently with combination chemo and biological therapy, approximately every 6 to 8 weeks after therapy was completed up to 16 months

Interventionmonths (Median)
Arm 1-Combination Chemo and Biological Therapy2

[back to top] [back to top]

Progression-free Survival at 5 Years

Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00006721)
Timeframe: 0-5 years

Interventionpercentage of participants (Number)
CHOP + Rituximab60
CHOP + Tositumomab66

[back to top]

Progression-free Survival at 2 Years

Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00006721)
Timeframe: 0-2 years

Interventionpercentage of participants (Number)
CHOP + Rituximab76
CHOP + Tositumomab80

[back to top]

Overall Survival at 5 Years

Measured from date of registration to date of death due to any cause (NCT00006721)
Timeframe: 0-5 years

Interventionpercentage of participants (Number)
CHOP + Rituximab92
CHOP + Tositumomab86

[back to top]

Overall Survival at 2 Years

Measured from date of registration to date of death due to any cause (NCT00006721)
Timeframe: 0-2 years

Interventionpercentage of participants (Number)
CHOP + Rituximab97
CHOP + Tositumomab93

[back to top]

Objective Response (Confirmed and Unconfirmed Complete and Partial Responses)

Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. (NCT00006721)
Timeframe: Assessed 200 days and 365 days after initiation of therapy and then every 6 months until death

Interventionparticipants (Number)
CHOP + Rituximab224
CHOP + Tositumomab223

[back to top]

Overall Survival

Probability of overall survival which is defined as the time from study entry to death from any cause. Patients alive where censored at last contact. (NCT00025259)
Timeframe: 5 years

InterventionProbability of survival (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)0.93
Arm II (RER With CR [ABVE-PC, IFRT])0.98
Arm III (RER With CR [ABVE-PC])0.98
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])0.98
Arm VI (SER [DECA, ABVE-PC, IFRT])0.96
Arm VII (SER [ABVE-PC, IFRT])0.93

[back to top]

Event-free Survival

Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact. (NCT00025259)
Timeframe: 5 years

InterventionProbability of survival (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)0.89
Arm II (RER With CR [ABVE-PC, IFRT])0.87
Arm III (RER With CR [ABVE-PC])0.84
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])0.87
Arm V (RER With PD)0.70
Arm VI (SER [DECA, ABVE-PC, IFRT])0.79
Arm VII (SER [ABVE-PC, IFRT])0.74

[back to top]

Disease Response Assessed by Modified RECIST Criteria

Number of participants with complete response and very good partial response at the end of protocol therapy. (NCT00025259)
Timeframe: Protocol therapy: the overall duration of which is: (n=1527) an average of 137.1 days, median 133.0 days, interquartile range: 101.0, 164.0 days.

InterventionNumber of participants (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)5
Arm II (RER With CR [ABVE-PC, IFRT])370
Arm III (RER With CR [ABVE-PC])380
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])538
Arm V (RER With PD)29
Arm VI (SER [DECA, ABVE-PC, IFRT])105
Arm VII (SER [ABVE-PC, IFRT])100

[back to top]

Grade 3 or 4 Non-hematologic Toxicity

Occurrence of any grade 4 non-hematologic toxicity or grade 3 non-hematologic toxicity which doesn't respond to treatment within 7 days despite recommended therapy modification, or toxic death, which is any death primarily attributable to treatment. Grade 3 is defined to be severe or medically significant but not immediate life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 refers to toxicities with life-threatening consequences; urgent intervention indicated. (NCT00025259)
Timeframe: Protocol therapy: the overall duration of which is: (n=1684) an average of 137.3 days, median 133.0 days, interquartile range: 101.0, 164.0 days.

InterventionNumber of participants (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)10
Arm II (RER With CR [ABVE-PC, IFRT])153
Arm III (RER With CR [ABVE-PC])130
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])216
Arm V (RER With PD)11
Arm VI (SER [DECA, ABVE-PC, IFRT])62
Arm VII (SER [ABVE-PC, IFRT])45

[back to top]

Survival at 5 and 10 Years

Survival at 5 and 10 years is expressed at the percentage of subjects known to remain alive at those timepoints. (NCT00026208)
Timeframe: 5 and 10 years

,
InterventionParticipants (Count of Participants)
5 years10 years
Stanford V-C + Low-dose Radiotherapy6741
Stanford V-C Only33

[back to top]

Frequency of Complete Response

"The frequency of complete response (CR) is reported as the number (proportion) of subjects in complete response, as assessed during weeks 4 to 5 of chemotherapy. Per protocol, CR is defined as complete regression of all palpable and radiographic demonstrable disease by computed tomography (CT) scan or positron emission tomography-CT (PET-CT)." (NCT00026208)
Timeframe: 5 weeks

InterventionParticipants (Count of Participants)
Stanford V-C + Low-dose Radiotherapy31

[back to top] [back to top]

Overall Survival (OS)

Overall survival was assessed at up to 16 years from date of diagnosis, and reported as the median years of survival with standard deviation. (NCT00026208)
Timeframe: 16 years

Interventionyears (Median)
Stanford V-C + Low-dose Radiotherapy10.4
Stanford V-C Only13.2

[back to top]

Progression-free Survival (PFS)

Progression-free survival was assessed for 3 years from the completion of treatment. Progression-free survival was considered to mean the proportion of patients (percentage) still alive without disease recurrence or progression. (NCT00026208)
Timeframe: up to 3 years

Interventionpercentage of participants (Number)
Stanford V-C + Low-dose Radiotherapy89.7
Stanford V-C Only50

[back to top]

Second Hodgkin's Disease Progression

Second Hodgkin's disease progression is reported as the number of participants experiencing 2 instances of progression of the underlying Hodgkin's disease, assessed at up to 16 years from date of diagnosis. (NCT00026208)
Timeframe: 16 years

InterventionParticipants (Count of Participants)
Stanford V-C + Low-dose Radiotherapy3
Stanford V-C Only1

[back to top] [back to top]

Event-free Survival (EFS)

EFS between centrally reviewed differentiated ependymoma and anaplastic ependymoma for the patients who were treated with radiation therapy only. The event-free survival (EFS) defined as the time to disease progression, disease relapse, occurrence of a second neoplasm, or death from any cause, measured from the start of radiation therapy. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability at 5 years. (NCT00027846)
Timeframe: At 5 years since the time of radiation therapy

InterventionProbability of EFS at 5 years (Number)
Differentiated Ependymoma0.746
Anaplastic Ependymoma0.607

[back to top]

Overall Survival

Overall survival (OS) is measured from the date of study enrollment to the date to death. The product-limit (Kaplan-Meier) estimate is for estimation of OS probability at 5 years. (NCT00027846)
Timeframe: Up to 5 years after completion of study treatment

InterventionProbability of OS at 5 years (Number)
GTR1 Differentiated Histology Supratentorial (Group 1)1
Radiation (Group 2)0.862
Sub-Total Resection Any Histology or Location (STR) (Group 3)0.702

[back to top]

Rate of Gross-total or Near-total Resection and Second Surgery After Chemotherapy

The Rate Of Gross-Total or Near-Total Resection With Second Surgery After Chemotherapy Treatment. (NCT00027846)
Timeframe: At the time of second surgery

Interventionpercentage of participants (Number)
Sub-Total Resection Any Histology or Location (STR) (Group 3)76

[back to top]

Local Control and Patterns of Failure

Documented and analyzed qualitatively and quantitatively. (NCT00027846)
Timeframe: Up to 5 years after completion of study treatment

,,
InterventionParticipant (Number)
Local controlPattern of failure localPattern of failure MetastaticPattern of failure local & metastatic
GTR1 Differentiated Histology Supratentorial (Group 1)6401
Radiation (Group 2)21757267
Sub-Total Resection Any Histology or Location (STR) (Group 3)293154

[back to top]

Event-free Survival

Event-free survival is calculated from the date of study enrollment to the date of disease progression, disease relapse, occurrence of second neoplasm, or death from any cause. The product-limit (Kaplan-Meier) estimate is for estimation of Event -free survival (EFS) probability at 5 years. (NCT00027846)
Timeframe: Up to 5 years after completion of study treatment

InterventionProbability of EFS at 5 years (Number)
GTR1 Differentiated Histology Supratentorial (Group 1)0.614
Radiation (Group 2)0.685
Sub-Total Resection Any Histology or Location (STR) (Group 3)0.372

[back to top]

Event-free Survival (EFS)

EFS between centrally reviewed differentiated ependymoma and anaplastic ependymoma for the patients who had sub-total resection initially. The event-free survival (EFS) defined as the date of disease progression, disease relapse, occurrence of a second neoplasm, or death from any cause, measured from the start date of radiation therapy. The product-limit (Kaplan-Meier) estimate is for estimation of EFS probability. (NCT00027846)
Timeframe: At 5 years since the time of radiation therapy.

InterventionProbability of EFS at 5 years (Number)
Differentiated Ependymoma0.424
Anaplastic Ependymoma0.298

[back to top]

Long Term Survival

"Survival Endpoints:~Event free survival and overall survival were assessed at 5 years from time of study enrollment" (NCT00031590)
Timeframe: Up to 5 years from date of randomization until the date of first documented progression or date of death from any cause, whichever came first.

InterventionPercentage of participants (Number)
5 year Overall Survival (OS)5 year Event Free Survival (EFS)
Study Treatment87.570

[back to top]

Disease-Free Survival Rate at 2-year and 5-year.

Disease-Free Survival (DFS) was calculated from the time of complete remission until relapse or death due to any cause. (NCT00038610)
Timeframe: Baseline to 2-year and 5-year

Interventionpercentage of participants (Number)
2-year DFS rate5-year DFS rate
Hyper-CVAD + Imatinib4943

[back to top]

Overall Survival Rate at 2-year and 5-year.

Overall survival (OS) was calculated from the date of initiation of therapy until death. (NCT00038610)
Timeframe: Baseline to 2-year and 5-year

Interventionpercentage of participants (Number)
2-year OS rate5-year OS rate
Hyper-CVAD + Imatinib5743

[back to top]

Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate

"Complete Remission (CR): Defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count of 1.0 × 109/L or higher and a platelet count of 100 × 109/L and no extramedullary disease.~Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts.~Molecular CR: Same as for CR with RT-PCR negativity for bcr-abl.~Induction Death: Defined as death occurring after start of therapy without meeting the definition of CR or resistant disease." (NCT00038610)
Timeframe: Baseline to 6 months

Interventionparticipants (Number)
Complete RemissionPartial RemissionMolecular Complete RemissionInduction Death
Hyper-CVAD + Imatinib421171

[back to top]

2 Year Overall Survival

Percentage of participants who were alive at 2 years. The 2 year survival, with 95% confidence interval, was estimated using the Kaplan Meier method. (NCT00039130)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Rituximab With High Intensity Chemotherapy80

[back to top]

Complete Response Rate

Response is assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Complete response requires disappearance of all evidence of disease. (NCT00039130)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Rituximab With High Intensity Chemotherapy83

[back to top]

2 Year Event Free Survival

Percentage of patients who were event free at 2 years. The 2-year event free rate was estimated using the Kaplan Meier method. An event is defined as death, progression or treatment failure. (NCT00039130)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Rituximab With High Intensity Chemotherapy78

[back to top]

Progression Free Survival

Kaplan-Meier estimates will be used to verify the progression free survival. (NCT00039195)
Timeframe: 2 years

Interventionpercentage of patients progression free (Number)
Induction R-CHOPac Therapy79

[back to top]

5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups

Percentage of patients who achieved a complete remission (CR) and were alive and relapse free at 5 years. The 5-year progression free survival was estimated using the Kaplan Meier method. (NCT00039377)
Timeframe: 5 years from CR

Interventionpercentage of patients (Number)
Patients With HLA-matched Sibling Donor46
Patients Without HLA-matched Sibling Donors47

[back to top]

5 Year Overall Survival for Autologous & Allogeneic Transplant Groups

Percentage of patients who were alive at 5 years. The 5-year progression free survival was estimated using the Kaplan Meier method. (NCT00039377)
Timeframe: 5 years from registration

Interventionpercentage of patients (Number)
Patients With HLA-matched Sibling Donor53
Patients Without HLA-matched Sibling Donors51

[back to top]

Number of Participants Who Achieved a BCR-ABL Response at 12 Months

"BCR-ABL response is defined in two ways: complete molecular response (CMR) and major molecular response (MMR).~Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene~MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region [Bcr] gene and Abelson proto-oncogene [Abl] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction [RT-PCR] (performed centrally)." (NCT00039377)
Timeframe: 12 months

Interventionparticipants (Number)
Complete Molecular ResponseMajor Molecular Response
Entire Cohort94

[back to top]

Disease Free Survival

"Disease-free survival (DFS) was measured as the interval from achievement of complete remission (CR) until relapse or death, regardless of cause; patients alive and in CR were censored at last follow-up. DFS was estimated using the Kaplan Meier method.~A complete remission (CR) was defined as recovery of morphologically normal bone marrow and blood counts (i.e., neutrophils >= 1.5 x 10^9/L and platelets > 100 x 10^9/L) and no circulating leukemic blasts or evidence of extramedullary leukemia and persisting for at least one month." (NCT00039377)
Timeframe: Duration of treatment (up to 10 years)

Interventionyears (Median)
Entire Cohort1.7

[back to top]

Overall Survival

Overall survival (OS) as the interval from the on-study date until death. OS was estimated using the Kaplan Meier method. (NCT00039377)
Timeframe: Duration of study (up to 10 years)

Interventionyears (Median)
Entire Cohort3.6

[back to top]

Overall Survival

Overall Survival rate at 1 year. Time to death is from date of registration to date of death due to any cause. (NCT00041132)
Timeframe: assessed after cycle 4, after completion of treatment, then every 3 months for 2 years, then every 6 months thereafter until 5 years

Interventionpercentage of participants (Number)
Hyper-CVAD + MTX/Ara-C + Rituximab92

[back to top]

Progression-free Survival

Progression-Free Survival (PFS) rate at 1 year. PFS measured from date of registration to date of first observation of progressive disease or death due to any cause. Progressive disease is a 50% increase in the sum of products of greatest diameters (SPD) of target measurable lesions over the smallest sum observed if a complete response (confirmed, or unconfirmed) was not previously achieved; appearance of a new lesion/site; unequivocal progression of non-measurable disease; or death due to disease without prior documentation of progression. (NCT00041132)
Timeframe: assessed after cycle 4, after completion of treatment, then every 3 months until 1 year after registration

Interventionpercentage of participants (Number)
Hyper-CVAD + MTX/Ara-C + Rituximab90

[back to top]

Response

Complete (CR), complete unconfirmed (CRU) and partial responses (PR). CR is complete disappearance of all measurable and non-measurable disease with the exception of nodes; no new lesions; previously enlarged organs must have regressed in size; and if bone marrow positive at baseline, it must be negative. CRU is complete disappearance of all measurable and non-measurable disease; regressed, non-palpable organs; and one or more exceptions not qualifying for CR (see protocol section 10). PR applies to patients with at least one measurable lesion who do not qualify for CR or CRU. PR is a 50% decrease in sum of products of greatest diameters (SPD) for up to six identified dominant lesions identified at baseline; no new lesions; no increase in the size of liver, spleen or other nodes; and splenic and hepatic nodules must have regressed in size by at least 50% in SPD. (NCT00041132)
Timeframe: assessed after cycle 4 and after completion of treatment (168 days)

Interventionparticipants (Number)
Hyper-CVAD + MTX/Ara-C + Rituximab42

[back to top]

Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy

Site of radiotherapy (high energy radiation) and/or toxicity experienced by the participants post HSCT radiotherapy. Grading was preformed using the Modified Glucksberg Criteria. (NCT00043979)
Timeframe: up to 6 cycles or 168 days

InterventionParticipants (Count of Participants)
Chest wall; G2 skinAbdomen; G4 GIPancreas; G4 LFTs, G4 pancreatitisPleura, mediastinum; G4 LFTs, G2 mucositisChest wall; G4 skin, G3 mucositisSpine, skull; G2 nausea+vomiting, G2 fatiguePelvis; G4 enteritisPulmonary (cyberknife)Brain; B3 mucositisWhole lung; G3 mucositis, G3 skin, G5 lungL arm, R shoulder, B/L femur
Arm 2-Recipients11111111111

[back to top]

Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)

GVT is defined as tumor response after day 42 post-transplantation without cytotoxic therapy. (NCT00043979)
Timeframe: up to day 100

InterventionParticipants (Count of Participants)
Arm 2-Recipients0

[back to top]

Cluster of Differentiation 4 (CD4) Reconstitution

The median CD4 count with a range of 85-1565 (absolute count) was used to determine recovery and were considered recovered if in this range. The CD4 count was established by flow cytometry testing. (NCT00043979)
Timeframe: Day +28-42

Interventionmm(3) (Median)
Arm 2-Recipients284

[back to top]

Number of Participants to Complete Conversion to >95% Donor Chimerism

Participants who tolerated the transplantation regimen and accepted >95% of the donors blood, marrow, and/or tissue. (NCT00043979)
Timeframe: up to 30 days

InterventionParticipants (Count of Participants)
Day +14Day +28
Arm 2-Recipients2323

[back to top]

Early Post Transplantation Relapse

Participants who experienced recurrence or progression of disease following transplant. (NCT00043979)
Timeframe: up to 300 days

InterventionDays (Median)
Arm 2-Recipients100

[back to top]

Median Progression Free Survival

Progression free survival was based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months

InterventionMonths (Median)
Arm 2-Recipients15.9

[back to top]

Number of Participants With Acute and Chronic GVHD

Acute GVHD as by Modified Glucksberg Criteria occurring before day 100. Chronic GVHD as per Seattle criteria occurring after day 100. (NCT00043979)
Timeframe: up to 5 years or death

,
Interventionparticipants (Number)
acute GVHDchronic GVHD
Recipients -Cyclosporine GVHD Prophylaxis1212
Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis55

[back to top]

Median Time to Reach Absolute Neutrophil Count of 500/mm(3)

Days for participants to achieve a neutrophil count of 500/mm(3). (NCT00043979)
Timeframe: up to 12 days

InterventionDays (Median)
Arm 2-Recipients9

[back to top]

Number of Participants With Engraftment

Engraftment is defined as rapid conversion to complete donor chimerism and is assessed by blood counts and chimerism, >95% donor engraftment at day 100 in >75% of patients. (NCT00043979)
Timeframe: 100 days

InterventionParticipants (Number)
Arm 2-Recipients23

[back to top]

Toxicity

Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00043979)
Timeframe: 16.5 months

InterventionParticipants (Number)
Arm 2-Recipients30

[back to top]

Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)

Response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST). RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials. They presume that linear measures are an adequate substitute for 2-D (dimensional) methods and registers four response categories: Complete response (CR) is disappearance of all target lesions. Partial response (PR) is 30% increase in the sum of the longest diameter of target lesions. Progressive disease (PD) is 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) is small changes that do not meet above criteria. For the purposes of this study very good partial response ((VGPR) is >75% reduction in disease) was also employed. (NCT00043979)
Timeframe: up to 10 cycles of therapy or 280 days

InterventionParticipants (Count of Participants)
Complete Response (CR)Progressive Disease (PD)Partial Response (PR)Very Good Partial Response (VGPR)
Arm 2-Recipients2442

[back to top]

Median Survival From Date of Progression

Median survival from date of progression is based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months

InterventionMonths (Median)
Participants who did not receive a transplant(n=7)Participants who received a transplant (n=23)
Arm 2-Recipients3.319.1

[back to top]

Median Time to Reach a Platelet Count of 50,000/mm(3)

Days for participants to achieve a platelet count of 50,000/mm(3). (NCT00043979)
Timeframe: up to 43 days

InterventionDays (Median)
Arm 2-Recipients15

[back to top]

Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant

Participants who are alive at two years following Allo-Hematopoietic Stem Cell Transplant. (NCT00043979)
Timeframe: 2 years

Interventionpercentage of participants (Number)
From date of enrollmentFrom date of transplantation
Arm 2-Recipients39.134.8

[back to top]

Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment

Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma (NCT00049036)
Timeframe: 60 days

Interventionproportion (Number)
EPOCH + Concurrent Rituximab0.69
EPOCH Followed by Rituximab0.53

[back to top]

Median Time to Neutrophil Recovery

Neutrophil recovery is defined as a neutrophil count ≥5000 µl for three consecutive days. (NCT00051311)
Timeframe: Up to 2 months after stem cell transplant

InterventionDays (Median)
Recipient14

[back to top]

Median Cycles of Induction Chemotherapy With Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, and Prednisone Given to Recipients

Median cycles of induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone given to recipients. (NCT00051311)
Timeframe: Up to cycle 3

InterventionCycles (Median)
Recipient2

[back to top]

Percentage of Recipients Who Achieved Donor Chimerism at Day +14

Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy. (NCT00051311)
Timeframe: Day+14

Interventionpercentage of recipients (Number)
Recipient90

[back to top]

Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis

Here is the number of recipients who developed grades I-IV acute graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV acute GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV acute GVHD can occur in the skin, liver, and/or gut. Grade 1: rash < 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea >1500 ml/d. Grade 4: desquamation and bullae, total bilirubin >15 mg/dl, and pain +/- ileus. (NCT00051311)
Timeframe: At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)

InterventionParticipants (Count of Participants)
Grade I GVHDGrade II GVHDGrade III GVHDGrade IV GVHD
Recipient1760

[back to top]

Number of Recipients With a Response to Reduced-intensity Stem Cell Transplantation (RIST)

Complete remission (CR) is complete disappearance of all detectable signs and symptoms of lymphoma for a period of at least one month. Complete remission unconfirmed (CRu) is a residual lymph node mass > 1.5 cm in greatest transverse diameter will be considered CRu if it has regressed by more than 75% in the SPD, does not change over at least one month, is negative by PET or gallium, and is negative on any biopsies obtained (biopsy not required). Progressive disease (PD) is a 25% or greater increase in SPD of all measured lesions compared to the smallest previous measurements, or appearance of any new lesion(s). (NCT00051311)
Timeframe: At least 100 days after post reduced-intensity stem cell transplantation (RIST).

InterventionParticipants (Count of Participants)
Complete Remission or Complete Remission UnconfirmedProgressive Disease
Recipient1516

[back to top]

Median Time to Platelet Recovery

Platelet recovery is defined as >50,000 mm3 platelet cell count after transfusion. (NCT00051311)
Timeframe: Up to 2 months after stem cell transplant

InterventionDays (Median)
Recipient13

[back to top]

Number of Recipients Evaluable Who Achieved Full Donor Chimerism at Day+100

Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy. (NCT00051311)
Timeframe: Day+100

InterventionParticipants (Count of Participants)
Recipient29

[back to top]

Number of Recipients Who Developed Chronic Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis

Here is the number of recipients who developed chronic graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV chronic GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV chronic GVHD can occur in the skin, liver, and/or gut. Grade 1: rash < 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea >1500 ml/d. Grade 4: desquamation and bullae, total bilirubin >15 mg/dl, and pain +/- ileus. (NCT00051311)
Timeframe: At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)

InterventionParticipants (Count of Participants)
Recipient23

[back to top]

Number of Recipients With Non-serious Adverse Events

Here is the number of recipients with non-serious adverse events assessed by the Common Toxicity Criteria version 2.0. A non-serious adverse event is any untoward medical occurrence. (NCT00051311)
Timeframe: Date treatment consent signed to date off study, approximately 58 months and 13 days.

InterventionParticipants (Count of Participants)
Recipient31

[back to top]

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00054665)
Timeframe: 43 months

InterventionParticipants (Number)
Part A: PS-341 Alone23
Part B: PS-341 & EPOCH44

[back to top]

Clinical Response Rate

Clinical Response Rate is the number of participants with a partial and complete response assessed by the criteria for lymphoma. A complete response is complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy and normalization of those biochemical abnormalities. Partial response is a greater than or equal to 50% decrease in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease (NCT00054665)
Timeframe: 18 weeks

,
InterventionParticipants (Number)
Partial responseComplete response
Part A: PS-341 Alone10
Part B: PS-341 & EPOCH78

[back to top]

Response Rate

Response includes both complete and partial responses. Per protocol, complete Response is defined as the complete disappearance of all clinical evidence of disease by physical examination, by imaging studies, by bone marrow biopsy (where indicated), by CNS evaluation (where indicated) and by biopsy where there is a residual abnormality on an imaging study. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present. Partial response is defined as: at least a 50% reduction in the size of all measurable tumor areas. Each site is to be defined by the product of the maximum length, width and depth (3 dimensions). No lesion may progress. No new lesion may appear. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present.. (NCT00057811)
Timeframe: Up to 5 years

Interventionpercentage of participants analyzed (Number)
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)88
Group C (Chemotherapy, Monoclonal Antibody Therapy)83

[back to top]

Grade ≥ 3 Stomatitis

The incidence of grade ≥ 3 stomatitis. Grade 3 stomatitis: Confluent ulcerations or pseudomembranes; bleeding with minor trauma. Grade 4 stomatitis: Tissue necrosis; Significant spontaneous bleeding; life-threatening consequences (NCT00057811)
Timeframe: Up to 1 year

,
Interventionparticipants (Number)
Incidence of grade ≥ 3 stomatitisNo incidence of grade ≥ 3 stomatitis
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)441
Group C (Chemotherapy, Monoclonal Antibody Therapy)634

[back to top]

Toxic Death

Implementation of the toxic death rate stopping rule, a death must be possibly, probably or definitely attributable to Rituximab and/or chemotherapy to be considered a toxic death. (NCT00057811)
Timeframe: Up to 1 year

,
Interventionparticipants (Number)
Toxic deathNo toxic death
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)045
Group C (Chemotherapy, Monoclonal Antibody Therapy)238

[back to top]

Minimal Residual Disease

The presence or absence of tumor cells at the end of induction assessed by studying tissue and/or blood/marrow. Details of methods and criteria used can be found in Shiramizu at al. BJH 153:758-763, 2011 (full citation in the citation section). (NCT00057811)
Timeframe: Not Provided

Interventionpercentage of samples analyzed (Number)
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)22
Group C (Chemotherapy, Monoclonal Antibody Therapy)70

[back to top]

Incidence of Adverse Experiences

Determine the incidence of adverse experiences, hematologic toxicity (WBC, hemoglobin, and platelet nadirs; and transfusion requirements), cardiac toxicity (incidence of left ventricular dysfunction and cardiomyopathy by echocardiography), and the development of human antimouse antibody/human anti-chimeric antibody in patients treated with this regimen. (NCT00058422)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
R-CHOP and Ibritumomab Tiuxetan (Zevalin)65

[back to top]

Event-free Survival (EFS)

Percentage of EFS patients. This is measured as the time from study entry until disease progression, disease recurrence, occurrence of a second malignant neoplasm, or death from any cause. To measure Event Free Survival, repeated one-sided logrank tests will be performed The upper critical values are based on the one-sided alpha-spending functions of t2 (alpha=0.05) and the lower critical values are based on testing the alternative hypothesis at 0.005 level. (NCT00059839)
Timeframe: From first enrollment up to 3 years.

Interventionpercentage of participants (Number)
Standard (APO) With Vincristine (Arm I)74
Consolidation (Includes Vinblastine) (Arm II)79

[back to top]

Objective Response to Treatment

Objective response assessed using standard myeloma response criteria. Objective response is defined as a > 50% reduction in the quantitative IgM or M-Spike levels from baseline levels. Response must be documented by two measurements separated by at least 3 weeks. (NCT00060346)
Timeframe: Every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry

Interventionproportion of participants (Number)
Rituximab + CHOP0.938

[back to top]

Occurrence of Severe Toxicity

An incidence of severe toxicity is defined to be the occurrence of grade 3 or higher infection or grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy. If 12 or more patients experience grade 3 or higher infection or five or more patients experience grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy, the regimen will be flagged as being associated with an excessive rate of severe toxicity. (NCT00061893)
Timeframe: The first two cycles (6 weeks) of protocol chemotherapy

Interventionparticipants (Number)
Grade 3 or Higher InfectionGrade 3 or Higher Sensory Neuropathy
Combination Chemotherapy11

[back to top]

Event Free Survival

(NCT00061893)
Timeframe: 24 months after start of protocol therapy

Interventionpercentage of participants (Number)
Combination Chemotherapy35

[back to top]

Number of Participants Achieving Complete Remission

A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) > 1500/μl, no circulating blasts, platelets > 100,000/μl; bone marrow cellularity > 20% with trilineage hematopoiesis, and < 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement). (NCT00061945)
Timeframe: 9 years

Interventionparticipants (Number)
Phase I - Alemtuzumab and Combination Chemotherapy92
Phase II - Alemtuzumab and Combination Chemotherapy145

[back to top]

Disease-free Survival, for Only Complete Response Patients

Disease Free Survival (DFS) is defined as the time from a Complete Response (CR) until death or relapse. The date of last clinical assesment will be used as the censor date for patients with no death or relapse. The DFS will be estimated using the Kaplan-Meier method with confidence intervals presented. (NCT00061945)
Timeframe: 9 years 4 months

Interventionmonths (Median)
Phase I - Alemtuzumab and Combination Chemotherapy58.6
Phase II - Alemtuzumab and Combination Chemotherapy19.8

[back to top]

Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)

The maximum tolerated dose is defined as the highest alemtuzumab dose at which less than 40% of patients develop the dose limiting toxicity (DLT), where DLT is defined as the inability to proceed (due to medical complications) with the protocol treatment within six weeks of receiving the last dose of alemtuzumab. Groups of six patients will be enrolled into each cohort at the time of re-registration prior to starting Course IV. After a cohort has accrued 6 patients and at least 3 have completed the 2-6 week post alemtuzumab observation period without DLT, the incoming patients will be assigned to the next cohort in the table while the DLT and other toxicities continue to be assessed for the newly closed cohort. If less than 3 out of 6 enrolled patients in a cohort have completed the 2-6 week post alemtuzumab observation period without DLT, additional patients may continue to enroll in that same cohort, i.e., accrual will not be suspended while waiting for patient follow-up data. (NCT00061945)
Timeframe: 6 weeks

Interventionmg (Number)
Phase I - Alemtuzumab and Combination Chemotherapy30

[back to top]

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV. (NCT00061945)
Timeframe: 8 months

Interventionparticipants (Number)
Phase II - Alemtuzumab and Combination Chemotherapy30

[back to top]

Overall Survival

Overall Survival is defines as the time from registration to death due to any cause. It is estimated using the Kaplan-Meier method with confidence intervals presented. (NCT00061945)
Timeframe: 9 years 4 months

Interventionmonths (Median)
Phase I - Alemtuzumab and Combination Chemotherapy33.6
Phase II - Alemtuzumab and Combination Chemotherapy23.1

[back to top]

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Minimal Residual Disease measures the presence of of circulating leukemia cells in the body. Patients that report a Complete Response (CR) during treatment are further tested to determine the presence of small amounts of circulating leukemia cells. Here we report the number of patients who were MRD negative. (NCT00061945)
Timeframe: 9 years 4 months

InterventionParticipants (Count of Participants)
Phase II - Alemtuzumab and Combination Chemotherapy16

[back to top]

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00069238)
Timeframe: 67 months and 9 days

InterventionParticipants (Count of Participants)
All Participants31

[back to top]

Maximum Tolerated Dose (MTD) of Alemtuzumab

MTD was achieved by increasing doses of Alemtuzumab on three cohorts. Cohort 1 received 30mg of Alemtuzumab, cohort 2 received 60mg of Alemtuzumab, and cohort 3 received 90mg of Alemtuzumab intravenously up to 2 cycles. The MTD reflects the highest dose of Alemtuzumab in which no more than 1 of 6 participants entered at a specific dose level experienced a dose limiting toxicity (DLT). (NCT00069238)
Timeframe: up to 2 cycles of therapy, approximately 42 days

Interventionmg (Number)
All Participants30

[back to top]

Progression-free Survival

Measured from date of registration to date of first observation of progression or symptomatic deterioration. Progression is defined as one or more of the following must occur. Unequivocal progression of disease in the opinion of the treating physician (an explanation must be provided). Appearance of a new lesion/site. Death due to disease without documented progression or symptomatic deterioration. Symptomatic deterioration is defined as global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00070018)
Timeframe: at 6 weeks after treatment, then every 6 months for 2 years, then annually thereafter

Interventionpercentage of participants (Number)
CHOP + RT + Zevalin89

[back to top]

"Failure-free Survival (FFS) in Chemotherapy Plus Possible Surgery Arm"

Failure is defined as the occurrence of one of the following: disease progression, defined as at least a 20% increase in the disease measurement, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions; relapse (defined with same criteria as for disease progression) after response; or death as a first event. Data will be summarized as number of eligible patients in each of the following categories at the time of data cutoff for analyses of 5-year FFS: 1)Failed; 2)Failure-free through 5 years of follow-up; 3)Failure-free until data cutoff (if less than 5 years of follow-up); 4)Withdrew from study; 5)Lost to follow-up. NOTE: Reported data are through March 2008 (see Caveats section). (NCT00072280)
Timeframe: Study enrollment until failure, completion of follow-up, or completion of 5-year FFS analyses (up to 5 years)

Interventionparticipants (Number)
FailedFailure-free through 5 years of follow-upFailure-free at cutoff (if < 5 years follow-up)Withdrew from studyLost to follow-up
Chemotherapy Plus Possible Surgery10100

[back to top]

Patterns of Failure for Group C and Group D in Terms of Vitreous vs Patterns of Failure for Group C and Group D in Terms of Vitreous vs Retinal vs Both as Sites of Recurrence

Sites of disease recurrence for Group C and Group D eyes where treatment failure was detected (NCT00072384)
Timeframe: From the date of enrollment assessed up to 36 months

,
InterventionEyes (Number)
Retinal seeding and vitreal seedingRetinal seeding but no vitreal seedingVitreal seeding but no retinal seedingNeither retinal seeding nor vitreal seeding
Group C Eyes0100
Group D Eyes1714

[back to top]

Patterns of Treatment Failure vs. no Treatment Failure for Group C Eyes and Group D Eyes According to Initial Sites of Involvement

The association between the probability of experiencing treatment failure vs. no failure in a C eye and the presence of subretinal seeding (SRS), subretinal fluid (SRF), or vitreal seeding (VS) at the on study ophthalmological examination under anesthesia. The association between the probability of experiencing treatment failure vs. no failure in a D eye and the presence of subretinal seeding (SRS), subretinal fluid (SRF), or vitreal seeding (VS) at the on study ophthalmological examination under anesthesia. (NCT00072384)
Timeframe: From the date of enrollment assessed up to 12 months

,
InterventionEyes (Number)
Treatment failure- SRS, SRF, VSTreatment failure- SRS; no SRF; no VSTreatment failure- SRS and SRF; no VSTreatment failure- SRS and VS; no SRFTreatment failure- SRF; no SRS; no VSTreatment failure- SRF and VS; no SRSTreatment failure- VS; no SRS; no SRFTreatment failure- No SRS; no VS; no SRFNo treatment failure- SRS, SRF, VSNo treatment failure- SRS; no SRF; no VSNo treatment failure- SRS and SRF; no VSNo treatment failure- SRS and VS; no SRFNo treatment failure- SRF; no SRS; no VSNo treatment failure- SRF and VS; no SRSNo treatment failure- VS; no SRS; no SRFNo treatment failure- No SRS; no VS; no SRF
Group C Eyes0000100000001011
Group D Eyes3030232021222021

[back to top]

Event-free Survival (EFS)

Proportion of patients event free at 1 year following enrollment. Event free survival time is computed as the time to study entry until disease relapse/progression, secondary malignancy, or death. (NCT00072384)
Timeframe: One year after study enrollment

InterventionPercentage probability (Number)
Treatment (Chemotherapy, Surgery)45.45

[back to top]

Group C Eyes - Treatment Failure Within One Year

"Each Group C eye will be classified as experiencing failure within one year after start of treatment: yes or no. The method of Rosner et al. (Biometrics v. 38, 105-114, 1982) will be used to model possible dependence between eyes from the same patient. The point estimate of the probability of treatment failure is reported as the Mean measure type." (NCT00072384)
Timeframe: One year

InterventionProbability of treatment failure (Mean)
Treatment (Chemotherapy, Surgery)0.25

[back to top]

Group D Eyes - Treatment Failure Within One Year

"Each Group D eye will be classified as experiencing failure within one year after start of treatment: yes or no. The method of Rosner et al. (Biometrics v. 38, 105-114, 1982) will be used to model possible dependence between eyes from the same patient. The point estimate of the probability of treatment failure is reported as the Mean measure type." (NCT00072384)
Timeframe: One year

InterventionProbability of treatment failure (Mean)
Treatment (Chemotherapy, Surgery)0.52

[back to top]

Toxicity Associated With Chemotherapy

The number of patients that experience CTC Version 4 grade 3 or higher toxicities of any kind. (NCT00072384)
Timeframe: From date of enrollment until termination of protocol therapy assessed up to 72 weeks

InterventionPatients (Number)
Treatment (Chemotherapy, Surgery)10

[back to top]

Percentage of Patients With Opportunistic Infection

Participants are susceptible to opportunistic infections such as bacterial, fungal, viral, protozoan infections and more due to immune suppression from chemotherapy drugs used to treat their disease. (NCT00074490)
Timeframe: First 100 days post-transplant

Interventionpercentage of participants (Number)
Arm IVD Cohort 1 (Th2 DLI)0
Arm IVD Cohort 3 (Multiple Th2 DLI)11.11
Arm IVA (12-day Expanded Th2 DLI)7.50
Arm IVB (6-day Expanded Th2 DLI)9.09
Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus)11.90

[back to top]

Percentage of Patients With ≥ Grade 2 Acute Graft Versus Host Disease (GVHD)

GVHD of the skin, liver and gut were graded on a scale of 1, 2, 3, and 4 (e.g. the grades are not added together) using the National Institutes of Health Consensus Criteria. Grade 1 is minimal GVHD, Grade 2 is moderate GVHD, Grade 3 is severe GVHD and Grade 4 is very severe GVHD. Grade 4 is a worse outcome than Grade 1. (NCT00074490)
Timeframe: first 100 days post-transplant

Interventionpercentage of patients (Number)
Arm IVD Cohort 1 (Th2 DLI)0
Arm IVD Cohort 3 (Multiple Th2 DLI)11.11
Arm IVA (12-day Expanded Th2 DLI)10
Arm IVB (6-day Expanded Th2 DLI)40.91
Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus)40.48

[back to top]

Percentage of Patients to Receive T Cell Infusion

T cells administered by intravenous infusion after patient received transplant. (NCT00074490)
Timeframe: first 100 days post-transplant

Interventionpercentage of patients (Number)
Arm IVD Cohort 1 (Th2 DLI)100
Arm IVD Cohort 3 (Multiple Th2 DLI)100
Arm IVA (12-day Expanded Th2 DLI)100
Arm IVB (6-day Expanded Th2 DLI)100
Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus)100

[back to top]

Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00074490)
Timeframe: Date treatment consent signed to date off study, approximately 5 years

InterventionParticipants (Count of Participants)
Arm IVD Cohort 1 (Th2 DLI)1
Arm IVD Cohort 3 (Multiple Th2 DLI)27
Arm IVA (12-day Expanded Th2 DLI)40
Arm IVB (6-day Expanded Th2 DLI)44
Arm IVC (6-day Expanded Th2 DLI and High Dose Sirolimus)42

[back to top]

Percentage of Patients With Stage 1, Clinical Group IIB or C (Node Positive) or Stage 2 Failure Free at 5 Years Following Study Entry

Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years

InterventionEstimated percentage of participants (Number)
Regimen I (Chemotherapy, Radiotherapy)90

[back to top]

Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 2 Failure Free at 5 Years Following Study Entry

Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years

InterventionEstimated percentage of participants (Number)
Regimen II (Chemotherapy, Radiotherapy, Surgery)67

[back to top]

Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry

Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years

InterventionEstimated percentage of participants (Number)
Regimen I (Chemotherapy, Radiotherapy)87
Regimen II (Chemotherapy, Radiotherapy, Surgery)67

[back to top]

Percentage of Patients With Delayed Surgical Procedures

The decision to perform second-look surgery should be based on the physical examination and imaging studies at Week 12 and should only be considered if a reasonable functional and cosmetic result is anticipated. (NCT00075582)
Timeframe: At 13 weeks after induction

Interventionpercentage of participants (Number)
Regimen II (Stage I Group III Nonorbit or Stage III Group I/II0.49

[back to top]

Cumulative Incidence of Patients Who Receive Reduced Doses of Radiation Therapy

The local failure rate will be estimated using cumulative incidence curves. (NCT00075582)
Timeframe: From enrollment up to 5 years

Interventionstimated percentage of participants (Number)
Regimen I (Chemotherapy, Radiotherapy)0.081
Regimen II (Chemotherapy, Radiotherapy, Surgery)0.115

[back to top]

Cumulative Incidence of Group III Patients Who Received With Reduced Radiotherapy Dose

The local failure rate will be estimated using cumulative incidence curves for Group III patients who received reduced doses of radiation therapy after second look surgical resection. (NCT00075582)
Timeframe: From enrollment up to 20 weeks

InterventionEstimated percentage of participants (Number)
Regimen II (Stage I Group III Nonorbit or Stage III Group I/II0

[back to top]

Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions

Event Free Probability. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years83.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)81.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old69.1
Dexamethasone, High Dose Methotrexate (IM) < 10 Years91.2
Prednisone, Capizzi Methotrexate <10 Years82.1
Prednisone, Capezzi Methotrexate >= 10 Years73.5
Predisone and High Dose Methotrexate < 10 Yrs Old80.8
Prenisone and High Dose Methotrexate >=10 Years75.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years77.0
Prenisone, Capezzi Methotrexate (Down's Syndrome)61.8
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)44.4

[back to top]

Correlation of Early Marrow Response Status With MRD Positive.

Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29

Interventionparticipants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years26
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)12
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old43
Dexamethasone, High Dose Methotrexate (IM) < 10 Years14
Prednisone, Capizzi Methotrexate <10 Years16
Prednisone, Capezzi Methotrexate >= 10 Years95
Prednisone and High Dose Methotrexate < 10 Yrs Old17
Prednisone and High Dose Methotrexate >=10 Years98
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years39
Prednisone, Capezzi Methotrexate (Down's Syndrome)3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)3
Prednisone and High Dose Methotrexate (Non Randomly Assigned)3

[back to top]

Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).

Bone marrow MRD status is defined as negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years86.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)93.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old80.5
Dexamethasone, High Dose Methotrexate (IM) < 10 Years93.1
Prednisone, Capizzi Methotrexate <10 Years86.5
Prednisone, Capezzi Methotrexate >= 10 Years83.4
Prednisone and High Dose Methotrexate < 10 Yrs Old84.2
Prednisone and High Dose Methotrexate >=10 Years83.9
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years85.3
Prednisone, Capezzi Methotrexate (Down's Syndrome)74.4
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)25

[back to top]

Correlation of Early Marrow Response Status With MRD Negative.

Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29

Interventionparticipants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years182
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)72
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old198
Dexamethasone, High Dose Methotrexate (IM) < 10 Years188
Prednisone, Capizzi Methotrexate <10 Years195
Prednisone, Capezzi Methotrexate >= 10 Years471
Prednisone and High Dose Methotrexate < 10 Yrs Old190
Prednisone and High Dose Methotrexate >=10 Years479
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years208
Prednisone, Capezzi Methotrexate (Down's Syndrome)25
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)3
Prednisone and High Dose Methotrexate (Non Randomly Assigned)18

[back to top]

Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)

Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 Years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years79.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)69.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old65.6
Dexamethasone, High Dose Methotrexate (IM) < 10 Years86.2
Prednisone, Capizzi Methotrexate <10 Years93.8
Prednisone, Capizzi Methotrexate >= 10 Years63.1
Predisone and High Dose Methotrexate < 10 Yrs Old84.2
Prednisone and High Dose Methotrexate >=10 Years73.6
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years74.6

[back to top]

Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)

Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years66.5
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)43.3
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old35.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years80
Prednisone, Capizzi Methotrexate <10 Years34.7
Prednisone, Capizzi Methotrexate >= 10 Years39
Prednisone and High Dose Methotrexate < 10 Yrs Old55
Prednisone and High Dose Methotrexate >=10 Years47.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years49.4

[back to top]

Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).

Bone marrow MRD status is defined as negative with < .01 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years95.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)92.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old87.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years98.1
Prednisone, Capizzi Methotrexate <10 Years93.3
Prednisone, Capizzi Methotrexate >= 10 Years90.2
Prednisone and High Dose Methotrexate < 10 Yrs Old94.5
Prednisone and High Dose Methotrexate >=10 Years90.5
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years91.6
Prednisone, Capizzi Methotrexate (Down's Syndrome)78.3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)25.0

[back to top]

Long Term Feasibility Success

"Success is defined as the completion of induction plus four cycles of maintenance within 60 weeks of enrollment without more than a 25% reduction in either carboplatin or temozolomide dosage.~If the participant completes all therapy within 60 weeks the patient is a long-term feasibility success. As such, a patient who experiences short term feasibility failure can be classified as a long-term feasibility success." (NCT00077207)
Timeframe: 60 weeks

Interventionparticipants (Number)
Treatment (Carboplatin, Vincristine Sulfate, Temozolomide)41

[back to top]

Percent Probability of Progression-free Survival (PFS)

Percentage probability of being alive and without the occurrence of disease progression 3 years following enrollment. (NCT00077207)
Timeframe: 3 years

InterventionPercent probability PFS (Number)
Carboplatin, Vincristine Sulfate, Temozolomide)60.59

[back to top]

Percentage Probability of Event-free Survival (EFS)

Percentage probability of being alive and without the occurrence of disease progression or second malignant neoplasm 6 years following enrollment. (NCT00077207)
Timeframe: Six years

Interventionpercent probability EFS (Number)
Carboplatin, Vincristine Sulfate, Temozolomide)40.89

[back to top]

Number of Participants Who Experienced a Grade 3 or 4 Thrombocytopenia and/or Neutropenia.

Occurence of grade 3 or 4 thrombocytopenia or neutropenia while receiving protocol therapy. (NCT00077207)
Timeframe: Up to 18 months of protocol therapy

InterventionParticipants (Count of Participants)
Carboplatin, Vincristine Sulfate, Temozolomide)43

[back to top]

Number of Participants Who Experienced Toxic Death

Primary safety endpoints are (1) the occurrence of toxic death, which is death during treatment that is not primarily attributable to disease progression, and (2) the occurrence of grade 4 allergy to carboplatin. (NCT00077207)
Timeframe: Up to 6 years after the start of protocol therapy

InterventionParticipants (Count of Participants)
Carboplatin, Vincristine Sulfate, Temozolomide)0

[back to top]

Short Term Feasibility Success

"Success is defined as the completion of induction plus one cycle of maintenance within 24 weeks of enrollment without more than a 25% reduction in either carboplatin or temozolomide dosage.~Failure to complete the induction and one cycle of maintenance within 24 weeks counts as a short-term-feasibility failure." (NCT00077207)
Timeframe: 24 weeks

Interventionparticipants (Number)
Treatment (Carboplatin, Vincristine Sulfate, Temozolomide)25

[back to top]

Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0

Participants with Grade 3 and higher reported on protocol therapy (NCT00079417)
Timeframe: 6 months after enrollment

InterventionParticipants (Number)
Incidence of Catheter Related InfectionIncidence of Upper Respiratory InfectionIncidence of DehydrationIncidence of UrticariaIncidence of Neutrophils
Vincristine Sulfate and Carboplatin and Surgery11116

[back to top]

Response Rate (RR) at Patient Level After the First Course of Therapy

RR will be estimated. The response after 1 course of chemotherapy will be used to better define response to this neoadjuvant systemic chemotherapy, prior to the use of local ophthalmic therapy. Response to subsequent courses will help define response to combined systemic chemotherapy and local ophthalmic therapy. Number of patients with Type I, II, III or IV response after first course of therapy (NCT00079417)
Timeframe: 1 month after enrollment

InterventionProportion of participants (Number)
Vincristine Sulfate and Carboplatin and Surgery0.71

[back to top]

Response Rate (RR) at Eye Levels After the First Course of Therapy

RR will be estimated. The response after 1 course of chemotherapy will be used to better define response to this neoadjuvant systemic chemotherapy, prior to the use of local ophthalmic therapy. Response to subsequent courses will help define response to combined systemic chemotherapy and local ophthalmic therapy. Number eyes with Type I, II, III or IV response after first course of therapy (NCT00079417)
Timeframe: 1 month after enrollment

InterventionProportion of eyes (Number)
Vincristine Sulfate and Carboplatin and Surgery0.71

[back to top]

Event-free Survival

Proportion of patients with event free survival at 2 years. An event is defined as the need for non-protocol therapy, defined as additional on-protocol chemotherapy, enucleation or external beam radiation, among patients with Group B intraocular tumors with a schedule of neoadjuvant 2-agent (Vincristine/Carboplatin) chemotherapy (chemo-reduction) and standardized local ophthalmic therapy. (NCT00079417)
Timeframe: At 2 years

InterventionProportion of participants (Number)
Vincristine Sulfate and Carboplatin and Surgery0.65

[back to top]

Event-free Survival Rate (EFSR) Defined as the Need for Non-protocol Chemotherapy, Enucleation, or EBRT at the Patient Level

EFSR will be estimated for patients who respond to vincristine and carboplatin after an initial 1 cycle of chemoreduction (NCT00079417)
Timeframe: 2 years after enrollment

InterventionProportion of participants (Number)
Vincristine Sulfate and Carboplatin and Surgery0.60

[back to top]

Overall Survival

Overall Survival at six years after initiating protocol therapy (NCT00083551)
Timeframe: 6 Years

Interventionpercentage of participants (Number)
Thalidomide65
No Thalidomide58

[back to top]

Grade 3-4 Allergy/Immunology

All Grade 3-4 Allergy/Immunology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1

[back to top]

2-yr Overall Survival

Overall survival is defined as the time from date of diagnosis to death or date of last follow-up. 2-year overall survival is the probability of patients remaining alive at 2-years from study entry estimated using Kaplan-Meier (KM) methods which censors patients at date of last follow-up. Precision of this conditional probability estimate was measured in terms of standard error. Median OS, the original primary endpoint, was not estimable based on the Kaplan-Meier method because of insufficient follow-up. (NCT00084838)
Timeframe: Patients are followed for survival up to 5 yrs post-therapy completion or death; As of this analysis, median follow-up among survivors was 31 months with the longest follow-up being 40 months.

Interventionprobability (Number)
Multi-agent Intrathecal and Systemic CT With RT (Modified IRS0.70

[back to top]

Grade 3-4 Hepatic Events

All Grade 3-4 Hepatic events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Grade 3-4 Muscloskeletal Events

All Grade 3-4 Muscloskeletal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Pre-Radiation Therapy Chemotherapeutic Response

"Response pre-RT/post-CT was defined as follows with overall response defined as achieving PR or CR.~Complete Response (CR): Complete resolution of all initially demonstrable tumor on MRI or CT evaluation w/o appearance of any new areas of disease; negative CSF cytology. Partial Response (PR): >/= 50% decrease in the sum of the products of the maximum perpendicular diameters of the tumor (sum LD) relative to baseline w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Stable Disease (SD): <50% decrease in the sum LD w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Progressive Disease (PD): >/= 25% increase in the sum LD relative to baseline, or the appearance of any new areas of disease or appearance of positive cytology after two consecutive negative samples." (NCT00084838)
Timeframe: Assessed at study entry and pre-RT/post-CT at week 7.

Interventionproportion of evaluable patients (Number)
Multi-agent Intrathecal and Systemic CT With RT (Modified IRS0.58

[back to top]

Grade 3/4 Events

All Grade 3-4 events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1021

[back to top]

Grade 3-4 Renal/Genitourinary Events

All Grade 3-4 Renal/Genitourinary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)4

[back to top]

Grade 3-4 Pulmonary Events

All Grade 3-4 Pulmonary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)4

[back to top]

Grade 3-4 Pain Events

All Grade 3-4 Pain events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)31

[back to top]

Grade 3-4 Neurology Events

All Grade 3-4 Neurology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)45

[back to top]

Grade 3-4 Metabolic/Laboratory Events

All Grade 3-4 Metabolic/Laboratory events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)128

[back to top]

Grade 3-4 Infection/Febrile Neutropenia Events

All Grade 3-4 Infection/Febrile Neutropenia events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)49

[back to top]

Grade 3-4 Hemorrhage Events

All Grade 3-4 Hemorrhage events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1

[back to top]

Grade 3-4 Gastrointestinal Events

All Grade 3-4 Gastrointestinal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)139

[back to top]

Grade 3-4 Dermatology Events

All Grade 3-4 Dermatology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)3

[back to top]

Grade 3-4 Constitutional Events

All Grade 3-4 Constitutional events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)22

[back to top]

Grade 3-4 Cardiovascular Events

All Grade 3-4 Cardiovascular events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)6

[back to top]

Grade 3-4 Blood/Bone Marrow Events

"All Grade 3-4 Blood/Bone Marrow events based on CTCAEv2 as reported on case report forms.~Arm Name" (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)564

[back to top]

Grade 3-4 Auditory/Hearing Events

All Grade 3-4 Auditory/Hearing events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Associative Memory for Two Risk Group at Enrollment

Assessment of associative memory at enrollment. Associate memory score is a representative measurement of learning and recalling pictograph representations of words. It measures associative memory (Long-Term Retrieval). Mean=100, SD=15, Average Range 85-115. Higher is better. (NCT00085202)
Timeframe: At enrollment

Interventionscore on a scale (Mean)
Average Risk Group93.61
High Risk Group98.04

[back to top]

Perceptual Speed for Two Risk Group at Enrollment

Assessment of Perceptual Speed at enrollment. It measures rapidly locating and circling identical numbers from a set of numbers which reflects perceptual speed. Mean=100, SD=15, Average Range 85-115. Higher is better. (NCT00085202)
Timeframe: At enrollment

Interventionscore on a scale (Mean)
Average Risk Group82.06
High Risk Group90.04

[back to top]

Perceptual Speed for Two Risk Group at 5 Years After Enrollment

Assessment of Perceptual Speed at 5 years after enrollment. It measures rapidly locating and circling identical numbers from a set of numbers which reflects perceptual speed. Mean=100, SD=15, Average Range 85-115. Higher is better. (NCT00085202)
Timeframe: At 5 years after enrollment

Interventionscore on a scale (Mean)
Average Risk Group78.68
High Risk Group72.29

[back to top]

Reading Decoding Composite Scores in the Intervention and Standard of Care Groups

SOC is standard-of-Care control group. Patients randomly assigned to the control group received the current standard of care. RI is Reading Intervention Group. Patients randomly assigned to Reading Intervention Group which is with The Fast ForWord program. Assessment of reading decoding was completed using the Woodcock Johnson, Third Edition (WJIII) Tests of Achievement (Woodcock, McGraw, & Mather, 2001), with particular attention given to the reading and reading-related abilities. Two subtests were completed: (1) Letter-Word Identification, and (2) Word Attack, a test requiring the patient to read phonologically regular nonwords. The combination of these two subtests provided a standardized composite score of overall reading decoding ability with a population mean of 100 and a standard deviation of 15. Scores of 90-110 are considered to be in the average range, while those 80-89 are considered low-average (refer: Journal of Pediatric Psychology 39(4) pp. 450-458, 2014). (NCT00085202)
Timeframe: 5 years postdiagnosis

,
Interventionscore on a scale (Mean)
BaselineChange over time
Intervention104.1-1.51
Standard of Care102.4-1.17

[back to top]

Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors

The relationship between ERBB2 protein expression in tumors and progression-free survival was assessed in 122 participants with a diagnosis of medulloblastoma and with ERBB2 protein assessments. If the ERBB2 value was greater than zero, the ERBB2 was defined as positive for the participant. If the ERBB2 value was zero, the ERBB2 was defined as negative. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups. (NCT00085202)
Timeframe: 2 years after tumor cell analysis in 122 participants

,,
Interventionprobability of PFS at 2 years (Number)
Positive ERBB2Negative ERBB2
Average-Risk Group83.393.5
High-Risk Group69.671.4
Overall Study79.286.7

[back to top]

Processing Speed for Two Risk Group at Enrollment

Assessment of Processing Speed at enrollment. This score measure of Processing Speed based on Visual Matching and Decision Speed tests. Mean=100, SD=15, Average Range 85-115. Higher is better. (NCT00085202)
Timeframe: At enrollment

Interventionscore on a scale (Mean)
Average Risk Group83.98
High Risk Group87.29

[back to top]

Number of Average Risk Patients Whose Treatment Failure Included the Posterior Fossa

To monitor for treatment failure in the posterior fossa of patients whose tumor bed receives a reduced volume of radiation. (NCT00085202)
Timeframe: Annually for 6 years post irradiation

InterventionParticipants (Count of Participants)
Average-Risk Group6

[back to top]

Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.

122 participants with a diagnosis of medulloblastoma were grouped by ERBB2 positive/negative assessment and risk group into 4 groups. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups. (NCT00085202)
Timeframe: 2 years after tumor cell analysis in 122 participants

Interventionprobability of PFS at 2 years (Number)
ERBB2 Positive & Average Risk83.3
ERBB2 Positive & High Risk69.6
ERBB2 Negative & Average Risk93.5
ERBB2 Negative & High Risk71.4

[back to top]

Frequency of Mutations Associated With SHH and WNT Tumors

The frequency of mutations for the main genes associated with SHH and WNT tumors identified via targeted sequencing based on formalin fixed paraffin embedded material is provided. (NCT00085202)
Timeframe: within 3.5 years following completion of accrual

,,,,,,,
InterventionParticipants (Count of Participants)
PTCH1DDX3XTP53KMT2DSUFUCREBBPGLI2TCF4PTENKMT2CFBXW7GSE1CTNNB1SMARCA4PIK3CAAPCEPHA7ARID1AARID2ATMBRCA2
SHH Pathway - In/Del Germline000000000000000000001
SHH Pathway - In/Del Somatic700221000003000000000
SHH Pathway - SNV Germline000000000000000000000
SHH Pathway - SNV Somatic435000013210102001010
WNT Pathway - In/Del Germline000000000000000000000
WNT Pathway - In/Del Somatic000202000100000011000
WNT Pathway - SNV Germline000000000000000100000
WNT Pathway - SNV Somatic0730011001401841000100

[back to top]

Associative Memory for Two Risk Group at 5 Years After Enrollment

Assessment of associative memory at 5 years after enrollment. Assessment of associative memory score at enrollment. Associate memory score is a representative measurement of learning and recalling pictograph representations of words. It measures associative memory (Long-Term Retrieval). Mean=100, SD=15, Average Range 85-115. Higher is better. (NCT00085202)
Timeframe: At 5 years after enrollment

Interventionscore on a scale (Mean)
Average Risk Group98.73
High Risk Group93.58

[back to top]

Processing Speed for Two Risk Group at 5 Years After Enrollment

Assessment of Processing Speed at 5 years after enrollment. This score measure of Processing Speed based on Visual Matching and Decision Speed tests. Mean=100, SD=15, Average Range 85-115. Higher is better. (NCT00085202)
Timeframe: At 5 years after enrollment

Interventionscore on a scale (Mean)
Average Risk Group84.21
High Risk Group75.71

[back to top]

Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 49-72 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. (NCT00085735)
Timeframe: 49 - 72 months post diagnosis

InterventionScores on a scale (Mean)
Low-dose Craniospinal Radiation (LDSCI)90.5
Standard-dose Craniospinal Radiation (SDCSI)86.4

[back to top]

Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays

PFS was defined as the time interval from date of study entry to disease progression, relapse or death due to cancer or to last follow-up. Second malignancies and deaths from causes clearly not associated with tumor progression or recurrence were censored. PFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. (NCT00085735)
Timeframe: 3 years

InterventionPercentage probability of PFS (Number)
Group 3 Medulloblastoma70.6
Group 4 Medulloblastoma90.6
Sonic Hedgehog (SHH) Medulloblastoma90.4
Wingless (WNT) Medulloblastoma98.4

[back to top]

Event-free Survival (EFS)

EFS was defined as the time interval from date of study entry to date of disease progression, disease recurrence, second malignant neoplasm or death from any cause, whichever occurs first, or to the date of last follow-up for patients without events. EFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% confidence intervals (CI's). (NCT00085735)
Timeframe: Assessed at 3 years

,
Interventionprobability of 3 year EFS (Number)
IFRT vs PFRT
Involved Field Radiation (IFRT)85.8
Posterior Fossa Radiation (PFRT)85.8

[back to top]

Event-free Survival (EFS)

EFS was defined as the time interval from date of study entry to date of disease progression, disease recurrence, second malignant neoplasm or death from any cause, whichever occurs first, or to the date of last follow-up for patients without events. EFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% confidence intervals (CI's). (NCT00085735)
Timeframe: Assessed at 3 years

,
Interventionprobability of 3 year EFS (Number)
LDCSI vs SDCSI
Low-dose Craniospinal Radiation (LDSCI)76.3
Standard-dose Craniospinal Radiation (SDCSI)84.9

[back to top]

Overall Survival (OS)

OS was defined as the time interval from date of study entry to date of death from any cause or to the date of last follow-up for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. For purposes of this analysis, arms I, III and V (involved field radiation therapy [IFRT]) are combined and compared to arms II, IV and VI (posterior fossa irradiation [PFRT]). (NCT00085735)
Timeframe: 3 years

,
InterventionProbability of 3 yr OS rate (Number)
IFRT vs PFRT
Involved Field Radiation (IFRT)90.3
Posterior Fossa Radiation (PFRT)93.3

[back to top]

Overall Survival (OS)

OS was defined as the time interval from date of study entry to date of death from any cause or to the date of last follow-up for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. For purposes of this analysis, arms I, III and V (involved field radiation therapy [IFRT]) are combined and compared to arms II, IV and VI (posterior fossa irradiation [PFRT]). (NCT00085735)
Timeframe: 3 years

,
InterventionProbability of 3 yr OS rate (Number)
LDCSI vs SDCSI
Low-dose Craniospinal Radiation (LDSCI)85.5
Standard-dose Craniospinal Radiation (SDCSI)90.4

[back to top]

Incidence of Endocrine Dysfunction as Measured by Growth Hormone Stimulation Tests at the Time of Completion of Therapy by Radiotherapy (RT) Group

Endocrine dysfunction was assessed by growth hormone stimulation (GHS) tests. We report the percentage of patients with abnormal growth hormone stimulation tests. (NCT00085735)
Timeframe: Post-treatment up to 3 years

InterventionPercentage of patients (Number)
Involved Field Radiation (IFRT)0.0
Posterior Fossa Radiation (PFRT)50.0

[back to top]

Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 2 (27 - 48 Months Post Diagnosis)

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 27-48 months post diagnosis, only the assessments before progression date were reported. The range of FSIQ is 50 - 150. A higher FSIQ is better. (NCT00085735)
Timeframe: 27 - 48 months post diagnosis

InterventionScores on a scale (Mean)
Low-dose Craniospinal Radiation (LDSCI)92.2
Standard-dose Craniospinal Radiation (SDCSI)90.5

[back to top]

Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 1 (4-15 Months Post Diagnosis)

Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 4 - 15 months post diagnosis. (NCT00085735)
Timeframe: 4-15 months post diagnosis

InterventionPercentage of Participants (Number)
Eligible and Evaluable Patients58

[back to top]

Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 2 (27-48 Months Post Diagnosis)

Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 27 - 48 months post diagnosis. (NCT00085735)
Timeframe: 27-48 months post diagnosis

InterventionPercentage of Participants (Number)
Eligible and Evaluable Patients32

[back to top]

Incidence of Grade 3+ Hearing Loss at 1-year Post Treatment as Assessed by CTCAE v4

Proportions of patients with grade 3+ hearing impairment as assessed by CTCAE v4 at 1-year post treatment were calculated. (NCT00085735)
Timeframe: Up to 3 years

InterventionPercentage of pts with g3+ hearing loss (Number)
Involved Field Radiation (IFRT)8
Posterior Fossa Radiation (PFRT)8

[back to top]

Local Posterior Fossa (LPF) Failure Rate

LPF failure was defined as tumor recurrence/progression within the tumor bed. The cumulative incidence (CI) of LPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF) and with other events prior to LPF failure (e.g., death, second malignancy) were considered as having competing events. (NCT00085735)
Timeframe: 3 years

Interventionpercentage 3 yr cumulative incidence (Number)
Involved Field Radiation (IFRT)1.4
Posterior Fossa Radiation (PFRT)2.7

[back to top]

Non-local Posterior Fossa (NLPF) Failure Rate

NLPF failure was defined as tumor recurrence/progression outside the radiation therapy clinical target volume boost (CTV-boost) but within the posterior fossa CTV (CTV-PF). The cumulative incidence (CI) of NLPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF, LPF) and with other events prior to NLPF failure (e.g., death, second malignancy) were considered as having competing events. (NCT00085735)
Timeframe: 3 years

InterventionPercentage of 3 yr cumulative incidence (Number)
Involved Field Radiation (IFRT)6.9
Posterior Fossa Radiation (PFRT)2.7

[back to top]

Non-posterior Fossa (NPF) Failure Rate

NPF failure was defined as tumor recurrence within the neuroaxis but outside the radiation therapy clinical target volume (CTV). The cumulative incidence (CI) of NPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., LPF failure) and with other events prior to NPF failure (e.g., death, second malignancy) were considered as having competing events. (NCT00085735)
Timeframe: 3 years

InterventionPercentage of 3 yr cumulative incidence (Number)
Involved Field Radiation (IFRT)5.1
Posterior Fossa Radiation (PFRT)6.2

[back to top]

Overall Survival (OS) by Molecular Subgroup Based on Methylation Arrays

OS was defined as the time interval from date of study entry to date of death from any cause or to date of last contact for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. (NCT00085735)
Timeframe: 3 years

InterventionPercent probability of overall survival (Number)
Group 3 Medulloblastoma76.3
Group 4 Medulloblastoma97.3
Sonic Hedgehog (SHH) Medulloblastoma92.0
Wingless (WNT) Medulloblastoma98.3

[back to top]

Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 3 (49 - 72 Months Post Diagnosis)

Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 49 - 72 months post diagnosis. (NCT00085735)
Timeframe: 49 - 72 months post diagnosis

InterventionPercentage of Participants (Number)
Eligible and Evaluable Patients69

[back to top]

Post-treatment Endocrine Function by CSI Group

Post-treatment endocrine function was measured by laboratory assessment of the thyroid stimulating hormone (TSH). The mean TSH will be reported. (NCT00085735)
Timeframe: Up to 3 years

InterventionuU/ml (Mean)
Low-dose Craniospinal Radiation (LDSCI)5.3
Standard-dose Craniospinal Radiation (SDCSI)6.1

[back to top]

Post-treatment Grade 3+ Hearing Loss as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4

Proportions of patients with grade 3+ hearing loss after the completion of therapy will be calculated and reported separately for low dose craniospinal irradiation (LDCSI) versus (vs.) standard dose craniospinal irradiation (SDCSI) patients. Eligible and evaluable patients 3-7 years of age will be used. (NCT00085735)
Timeframe: Up to 3 years

InterventionPercentage of pts with g3+ hearing loss (Number)
Low-dose Craniospinal Radiation (LDSCI)11
Standard-dose Craniospinal Radiation (SDCSI)11

[back to top]

Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 1 (4-15 Months Post Diagnosis)

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. (NCT00085735)
Timeframe: 4 - 15 months post diagnosis

InterventionT-score (Mean)
Low-dose Craniospinal Radiation (LDSCI)50.7
Standard-dose Craniospinal Radiation (SDCSI)51.3

[back to top]

Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 2 (27-48 Months Post Diagnosis)

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. (NCT00085735)
Timeframe: 27-48 months post diagnosis

InterventionT-score (Mean)
Low-dose Craniospinal Radiation (LDSCI)51.4
Standard-dose Craniospinal Radiation (SDCSI)55.0

[back to top]

Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. (NCT00085735)
Timeframe: 49 - 72 months post diagnosis

InterventionT-score (Mean)
Low-dose Craniospinal Radiation (LDSCI)54.1
Standard-dose Craniospinal Radiation (SDCSI)58.6

[back to top]

Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 1 (4 - 15 Months Post Diagnosis).

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 4-15 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. (NCT00085735)
Timeframe: 4 -15 months post diagnosis

InterventionScores on a scale (Mean)
Low-dose Craniospinal Radiation (LDSCI)93.8
Standard-dose Craniospinal Radiation (SDCSI)96.2

[back to top]

Progression-Free Survival (PFS)

The time between the date of randomization and the date of the initial documentation of progressive/relapsed disease or death due to any cause. (NCT00088530)
Timeframe: 18 months after 6 cycles of treatment; approximately 24 months

Interventionmonths (Median)
Experimental Group5.3
Comparator Group2.6

[back to top]

Overall Survival

The time between the date of randomization and the date of death due to any cause. (NCT00088530)
Timeframe: 18 months after 6 cycles of treatment; approximately 24 months

InterventionMonths (Median)
Experimental Group10.2
Comparator Group7.6

[back to top]

Complete Response (CR) and Complete Response Unconfirmed (CRu)

Proportion of patients with a best response of complete response (CR) or Complete Response unconfirmed (CRu) in the End Of Treatment (EOT) or End Of Study (EOS) analyses by independent assessment in the Intent-to-treat (ITT) population through the End of Treatment (EOT) (NCT00088530)
Timeframe: EOT; approximately 6 months

,
Interventionpercentage of randomized patients (Number)
END OF TREATMENT: CR/CRu, n (%)END OF STUDY: CR/CRu, n (%)
Comparator Group5.77.1
Experimental Group20.024.3

[back to top]

Overall Response Rate (ORR) Lasting at Least 4 Months

The proportion of patients with Complete response or Partial Response with a difference from the first documented objective response to disease progression or death of at least 4 months. (NCT00088530)
Timeframe: approximately 24 months

Interventionparticipants (Number)
Experimental Group12
Comparator Group6

[back to top]

Functional CR in Patients Treated With R-CHOP Followed by 90-Yttrium -Zevalin™.

Patients will be considered a functional CR if they meet the criteria for a CR, or if they meet the criteria for a CRu or partial response (PR) by CT and are PET negative. Please see primary outcome #1 for the definition of CR and CRu. PR is defined as: A decrease of >50% in the SPD (sum of products of the diameters) of the six largest (or less) dominant nodes or extra-nodal masses. No increase in the size of the liver or the spleen. No unequivocal progression in any non-measurable or non-dominant site. Splenic and hepatic nodules must regress by >50% in SPD (sum of the products of the diameters). Bone marrow assessment is not relevant for determination of a PR because it is assessable and not measurable disease. No new sites of disease. (NCT00088881)
Timeframe: Assessed after 2 cycles of R-CHOP, after completion of R-CHOP, and at Week 12 After 90-Yttrium Zevalin

Interventionproportion of participants (Number)
Treatment0.89

[back to top]

Complete Response (CR) +Complete Response/Uncertain (CRu) in Patients Treated With R-CHOP Followed by 90-Yttrium -Zevalin™.

Response was assessed based upon the criteria from the International Workshop to Standardize Criteria for Non-Hodgkin's Lymphoma (Cheson, 1999). CR is defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease related B-symptoms if present prior to therapy, as well as normalization (normal limits of institutional labs) of those biochemical abnormalities (e.g., LDH) definitely attributed to NHL. CRu is defined as meeting the criteria of CR except one or more of the followings: A residual dominant node (or extra-nodal mass) that is currently > 1.5 cm in greatest diameter that has decreased by > 75% from baseline in the product of its diameters. Individual dominant nodes (or extra-nodal masses) that were previously confluent must have decreased by > 75% in SPD compared with the size of the original mass. Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). (NCT00088881)
Timeframe: Assessed after 2 cycles of R-CHOP, after completion of R-CHOP, and at Week 12 After 90-Yttrium Zevalin

Interventionproportion of participants (Number)
Treatment0.87

[back to top]

3-year Time to Treatment Failure (TTF) Rate

Time to treatment failure (TTF) is defined as the time from step 1 registration to disease progression or death. TTF is censored at last documented progression free for cases without progression. The 3-year TTF rate is defined as the probability of patients remaining free from treatment failure at 3 years. (NCT00088881)
Timeframe: Assessed every 3 months for one year; every 4 months for the second year; then every 6 months for 3 years; then annually to 10 years from patient entry.

Interventionprobability (Number)
Treatment0.92

[back to top]

3-year Overall Survival (OS) Rate

Overall survival (OS) is defined as the time from step 1 registration to death of any cause. OS is censored at the date last known alive for cases that are alive. The 3-year OS rate is defined as the probability of patients remaining alive at 3 years. (NCT00088881)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 years; then annually to 10 years from patient entry.

Interventionprobability (Number)
Treatment0.98

[back to top]

Event-free Survival

Monitoring of efficacy results will be performed in comparison with historical results. (NCT00096135)
Timeframe: 3 years

Interventionpercentage of participants (Number)
CNS Patients - Treatment (Combination Chemotherapy)64.9
Testicular Relapse Patients (Combination Chemotherapy)70

[back to top]

Pharmacokinetics

Mean trough serum concentration measured before final dose of epratuzumab. (NCT00098839)
Timeframe: Up to day 36

Interventionug/mL (Mean)
Twice Weekly Dosing Schedule501

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01%

Proportion of patients (evaluable and had MRD measured at the end of Block 1) who had MRD < 0.01%. (NCT00098839)
Timeframe: At the end of Block 1 of re-induction therapy (day 36)

InterventionProportion of participants (Number)
Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly.195
Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly.295

[back to top]

Event-free Survival Rate

Proportion of patients who were event free at 4 months (NCT00098839)
Timeframe: At 4 months after enrollment

InterventionProportion of participants (Number)
Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly.604
Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly.640

[back to top]

Remission Re-induction (CR2) Rate

The proportion of patients who achieved complete response at the end Block 1 of re-induction therapy. Complete Remission (CR) - Attainment of M1 bone marrow (<5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (ANC >1000/uL and platelet count >100,000/uL). Partial Remission (PR) - Complete disappearance of circulating blasts and achievement of M2 marrow status (5% or < 25% blast cells and adequate cellularity). Partial Remission Cytolytic (PRCL) - Complete disappearance of circulating blasts and achievement of at least 50% reduction from baseline in bone marrow blast count. Minimal Response Cytolytic (MRCL) - 50% reduction in the peripheral blast count with no increase in peripheral white blood cell count. (NCT00098839)
Timeframe: At the end of Block 1 of re-induction therapy (day 36)

Interventionproportion of participants (Number)
Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly.646
Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly.660

[back to top]

Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses

Response was defined as participants with a complete response (CR), unconfirmed complete response (CRu) or partial response (PR), based on International Workshop Criteria (IWG) for Tumor Response Criteria assessed with CT & FDG-PET scans at 4 cycles (12 weeks). CR defined as disappearance of all target and non-target lesions in liver & spleen, & all lymph node masses regressed to normal size. PR defined as ≥50% reduction in sum of product of diameters (SPD) for measured lymph nodes, splenic & liver lesions separately compared to baseline SPD. CRu does not qualify for CR above, due to a residual nodal mass or an indeterminate bone marrow. (NCT00101010)
Timeframe: Evaluation after 12 weeks (4 cycles of 21 days)

InterventionParticipants (Count of Participants)
Complete Response (CR)Uncomfirmed Complete Response (CRu)Partial Response (PD)
Rituximab - Combination Chemotherapy47814

[back to top]

Number of Participants Experienced Grade 3 or Higher Cardiac Toxicity After Treatment: Cardiac Toxicity as Measured by Left Ventricular Ejection Fraction (LVEF) on Echocardiogram (ECHO) After 8 Courses

Ejection fraction ( EF) refers to the amount, or percentage, of blood that is pumped (or ejected) out of the ventricles with each contraction. Cardiology evaluation performed before second dose of pegylated liposomal doxorubicin or before entry onto trial, re-evaluation by cardiologist obtained in asymptomatic patients after chemotherapy cycle 4 and again after completion of therapy, and more often if symptomatic. Severe cardiac toxicity considered to be both Grade 3 and 4, and are graded according to NCI common toxicity criteria, CTCAE version 3.0. (NCT00101010)
Timeframe: Up to 24 weeks (8 cycles of 21 days)

Interventionparticipants (Number)
Rituximab - Combination Chemotherapy10

[back to top]

Median Event Free Survival (EFS)

Vaccine Response - EFS among participants who received vaccination. Event free survival (EFS) was calculated from date of enrollment until progression or death from any cause. Progressive disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00101101)
Timeframe: 18 months

Interventionmonths (Median)
Vaccine and Conventional Therapy9

[back to top]

Rate of Immunological Response to Vaccination

"Immunological response to vaccination, as measured by in vitro testing of peripheral blood mononuclear cells (PBMCs) for interferon gamma secretion, delayed type hypersensitivity reaction (DTH) in response to irradiated autologous tumor cells, and lymphocyte accumulation at DTH and vaccine injection sites.~DTH Skin Testing was performed within 2 weeks prior to first vaccine, and again after fourth vaccine was administered. Aliquots containing 10^6 irradiated autologous tumor cells were re-suspended in 0.2 mL of Plasma-Lyte A and injected intradermally in the forearm and marked. 48 hours later, injection site was inspected for induration and erythema.~3mm punch biopsy of DTH injection site and vaccine site was obtained 48 hours after administration of irradiated tumor cells before and after the vaccine series. Vaccine site biopsy was obtained 2-5 days after the second vaccine had been given. Granulocytic and lymphocytic accumulation at these sites was graded by a pathologist." (NCT00101101)
Timeframe: 4 months per participant

Interventionparticipants (Number)
Clinical DTHIncrease in Interferon Gamma Secretion
Vaccine and Conventional Therapy015

[back to top] [back to top] [back to top]

Event-free Survival (EFS) for SR-High Patients.

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

Interventionpercent probability (Number)
Group 3-SR-high ALL, Combination Chemotherapy85.58

[back to top]

Early Marrow Status (EMS) by MRD Status End Induction (Day 29)

Early Marrow Status defined as M1 versus M2/M3 marrow is correlated with MRD (Positive vs. Negative) (NCT00103285)
Timeframe: Early Marrow Status at Day 15, MRD Status at Day 29 of therapy.

InterventionParticipants (Count of Participants)
All Patients for Induction, MRD Negative4378
All Patients for Induction, MRD Positive258

[back to top]

Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)

Event-free probability where EFS is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

InterventionPercent probability (Number)
Group 1-SR-low ALL, Arm I-combination Chemotherapy95.22
Group 2-SR-avg ALL, Arm I-combination Chemotherapy88.52

[back to top]

Event-free Survival (EFS) for SR-Average ALL Patients

EFS for SR-Average with standard and Intensified Consolidation. Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

,
Interventionpercent probability (Number)
Standard and Intensified therapyStandard therapy
Group 2-SR-avg ALL, Arm I-combination Chemotherapy83.8287.41
Group 2-SR-avg ALL, Arm II-combination Chemotherapy88.8988.29

[back to top]

Event-free Survival (EFS) for SR-Low Patients

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

InterventionPercent probability (Number)
SR-low ALL, Arm I-combination Chemotherapy95.22
SR-low ALL, Arm II-combination Chemotherapy93.96

[back to top]

Event-Free Survival Probability According to MRD Status End Induction (Day 29)

Event-Free survival by Day 29 MRD status (negative vs positive), Event Free Probability (time from study entry to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: MRD at Day 29 of therapy

InterventionPercent Probability (Number)
Induction Therapy, MRD Negative91.39
Induction Therapy, MRD Positive79.86

[back to top] [back to top]

Event-free Survival (EFS) for SR-Average ALL Patients

EFS for SR-Average with standard and Intensified Consolidation. Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

,
Interventionpercent probability (Number)
Standard and Intensified therapy
Group 2-SR-avg ALL, Arm III-combination Chemotherapy88.34
Group 2-SR-avg ALL, Arm IV-combination Chemotherapy90.51

[back to top]

Overall Survival Probability (OS) According to Induction Day 29 MRD Status

Overall survival by Day 29 MRD status (negative vs positive), Overall survival defined as time from study entry to death or date of last contact for patients who are alive. (NCT00103285)
Timeframe: Overall Survival Probability of 6 years

Interventionpercent probability (Number)
Induction Therapy, MRD Negative97.07
Induction Therapy, MRD Positive90.47

[back to top]

Cure by AV-PC x 3 or AV-PC x 3 + IFRT for Stage I Unresected, Stage I Resected Whose Disease Recurred, and Stage II Patients

To estimate the proportions of Stage I unresected, Stage I resected (whose disease has recurred after observation), and Stage II LPHD patients who can be cured with AV-PC x 3, with IFRT for those who are not in a CR after chemotherapy. (NCT00107198)
Timeframe: At 5 years

InterventionProbability participants (Number)
Surgery or Combination Chemotherapy, With/Without Radiotherapy0.89

[back to top]

Cure by Surgery Alone in Stage I Resected Patients

To estimate the proportion of Stage I patients (with a single involved lymph node that is totally resected) who can be cured with surgery alone. (NCT00107198)
Timeframe: At 2 years

InterventionProbability participants (Number)
Surgery or Combination Chemotherapy, With/Without Radiotherapy0.82

[back to top]

Failure-free Survival (FFS)

The time to a treatment (strategy) failure, where failure includes one of the following occurrences as a first event: disseminated disease (> Stage I/II) progression or recurrence at any time, local disease progression or recurrence anytime during or after treatment with AV-PC +/- IFRT, occurrence of a second malignant neoplasm, death from any cause. (NCT00107198)
Timeframe: At 5 years

InterventionProbability participants (Number)
Surgery or Combination Chemotherapy, With/Without Radiotherapy0.91

[back to top]

Event-free Survival

Failure includes one of the following occurrences as a first event: relapse/progression or second malignancy from enrollment. (NCT00107198)
Timeframe: At 5 years

InterventionProbability participants (Number)
Surgery or Combination Chemotherapy, With/Without Radiotherapy0.85

[back to top]

Grade 3 or 4 Toxicity

(NCT00107198)
Timeframe: Any time during chemoradiotherapy, up to the end of 3-cycles of AV-PC induction. Each cycle is 21 days.

InterventionParticipants (Number)
Surgery or Combination Chemotherapy, With/Without Radiotherapy26

[back to top]

Progression-free Survival (PFS) at 2 Years

Clinical responses were evaluated according to International Workshop NHL criteria (Cheson et al, 1999). Progression disease was defined as if a (CR, CRU) was not achieved at a previous assessment, a 50% increase in the SPD of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Appearance of a new lesion/site. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Death due to disease without prior documentation of progression. PFS is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. (NCT00107380)
Timeframe: 0-2 years

Interventionpercentage of participants (Number)
R-CHOP + I-131-tositumomab69

[back to top] [back to top]

Response Rate (Complete, Complete Unconfirmed, and Partial)

Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. (NCT00107380)
Timeframe: 6 months

Interventionparticipants (Number)
Partial ResponseConfirmed ResponseUnconfirmed ResponseNo Response
R-CHOP + I-131-tositumomab21411012

[back to top]

Toxicity

Number of patients with Grade 3-5 adverse events that are related to study drug by given type of adverse event (NCT00109837)
Timeframe: Patients were assessed for adverse events after the induction cycle

InterventionParticipants with a given type of AE (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST, SGOT (serum glut oxaloacetic transaminase)Albumin, serum-low (hypoalbuminemia)Alkaline phosphataseAnorexiaAscites (non-malignant)Bilirubin (hyperbilirubinemia)Calcium, serum-low (hypocalcemia)CholecystitisCholesterol, serum-high (hypercholesterolemia)Coagulation-Other (Specify)Colitis, infectious (e.g., Clostridium difficile)ConstipationDIC (disseminated intravascular coagulation)Death not assoc with CTCAE term-Multi-organ failEdema: limbFatigue (asthenia, lethargy, malaise)Febrile neutropeniaFever (in the abs of neutropenia)FibrinogenGlucose, serum-high (hyperglycemia)Glucose, serum-low (hypoglycemia)HemoglobinHypertensionHypotensionHypoxiaIleus, GI (functional obstruction of bowel)Infec(doc clin or mibio) w/ Gr 3/4 neut-AnalInfec(doc clin or mibio) w/ Gr 3/4 neut-BladderInfec(doc clin or mibio) w/ Gr 3/4 neut-BloodInfec(doc clin or mibio) w/ Gr 3/4 neut-BronchusIInfec(doc clin or mibio) w/ Gr 3/4 neut-CatheterInfec(doc clin or mibio) w/ Gr 3/4 neut-Eye NOSInfec(doc clin or mibio) w/ Gr 3/4 neut-LungInfec(doc clin or mibio) w/ Gr 3/4 neut-NoseInfec(doc clin or mibio) w/ Gr 3/4 neut-PharynxInfec(doc clin or mibio) w/ Gr 3/4 neut-Ur tractInfec with nor ANC or Gr 1/2 neut-Lung (pneumonia)Infection-Other (Specify)Leukocytes (total WBC)LipaseLiver dysfunction/failure (clinical)LymphopeniaMagnesium, serum-high (hypermagnesemia)Mucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (funct/symp) - Oral cavityMucositis/stomatitis (func/symp) - PharynxMuscle weak,gen spec area-Whole bodyNauseaNeuropathy: motorNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - BonePain - NeckPancreatic endocrine: glucose intolerancePancreatitisPhosphate, serum-low (hypophosphatemia)PlateletsPotassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)Rash/desquamationRenal failureSodium, serum-low (hyponatremia)Thrombosis/thrombus/embolismThrombotic microangiopathyTriglyceride, serum-high (hypertriglyceridemia)Tumor lysis syndromeTyphlitis (cecal inflammation)Uric acid, serum-high (hyperuricemia)Vomiting
Induction171332216712111211318111161332321111111111122143121912112314711111144171261215111

[back to top]

Continuous Complete Remission at 1 Year

A patient has a continuous complete remission at 1 year if they achieve a CR and are alive 365 days after registering to the study. (NCT00109837)
Timeframe: After induction, after consolidation, every 3 months during maintenance, and every three months after off treatment for up to a year

Interventionparticipants (Number)
Treatment21

[back to top]

Progression-Free Survival Rate at 2 and 5 Years

"Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse>~≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.>~Appearance of any new lesion during or after completion of therapy.>~PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.>~The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below." (NCT00118209)
Timeframe: Up to 5 years post-registration

,
Interventionpercentage of participants (Number)
2-year PFS5-year PFS
Arm A - R-CHOP75.566.0
Arm B - DA-EPOCH-R78.968.0

[back to top]

Overall Survival Rate at 2 and 5 Years

Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below. (NCT00118209)
Timeframe: Up to 5 years post-registration

,
Interventionpercentage of participants (Number)
2-year OS rate5-year OS rate
Arm A - R-CHOP85.778.5
Arm B - DA-EPOCH-R86.577.5

[back to top]

Response Rate

The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response) (NCT00118209)
Timeframe: Up to 5 years post-registration

Interventionpercentage of participants (Number)
Arm B - DA-EPOCH-R86.7
Arm A - R-CHOP88.0

[back to top]

Objective Response (Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR))

Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the SPD for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. (NCT00121199)
Timeframe: After Cycle 4 (Day 64) but prior to Cycle 5 (Day 85) and after Cycle 8 (Day 181). After completion of protocol treatment, every 6 months for 2 years, then annually for a maximum of five years.

Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Unconfirmed Complete Response (UCR)Unconfirmed Partial Response (UPR)No Response
CHOP + Rituximab + Bevacizumab22206115

[back to top] [back to top]

Progression-free Survival at 1 Year

Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00121199)
Timeframe: 0-1 year

Interventionpercentage of participants (Number)
CHOP + Rituximab + Bevacizumab77

[back to top]

Progression-free Survival at 2 Year

Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00121199)
Timeframe: 0-2 years

Interventionpercentage of participants (Number)
CHOP + Rituximab + Bevacizumab69

[back to top]

Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt

"Complete Response (CR): Disappearance of all measurable or evaluable disease confirmed.~Partial Response (PR): Reduction of 50% or greater in the sum of the products of the perpendicular diameters of all measurable.~Of 8 High Risk participants, 7 met the primary response outcome. 1 High Risk participant did not meet protocol defined primary outcome response and died two months following enrollment." (NCT00126191)
Timeframe: 3 years

Interventionparticipants (Number)
Low Risk2
High Risk7

[back to top]

Disease Free Survival

Participants are followed after completion of protocol therapy until disease progression to determine disease free survival. (NCT00126191)
Timeframe: Until disease progression up to 120 months

InterventionMonths (Mean)
Low Risk84
High Risk52

[back to top]

Event-free Survival

Percentage of participants alive without relapse at 1 year and 3 years. (NCT00133991)
Timeframe: 1 year and 3 years

Interventionpercentage of participants (Number)
1 year3 years
R-CVP + HiCy5252

[back to top]

Percentage of Participants Experiencing Grade 3-5 Toxicity

Percentage of participants experiencing at least one grade 3-5 adverse event (by CTCAE 3.0 criteria). (NCT00133991)
Timeframe: Up to 2 years

InterventionParticipants (Count of Participants)
R-CVP + HiCy21

[back to top]

Overall Response Rate

Number of participants who have a complete or partial remission (2007 International Working Group criteria). (NCT00133991)
Timeframe: Up to 3 months

InterventionParticipants (Count of Participants)
Complete remissionPartial remission
R-CVP + HiCy112

[back to top]

Overall Survival

Percentage of participants alive at 1 year and at 3 years. (NCT00133991)
Timeframe: 1 year and 3 years

Interventionpercentage of participants (Number)
1 year3 years
R-CVP + HiCy5757

[back to top]

Relapse Pattern

Percentage of participants experiencing central nervous system (CNS) and systemic relapse. (NCT00133991)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Systemic relapse onlySystemic and CNS relapse
R-CVP + HiCy32

[back to top]

Minimal Residual Disease (MRD).

Detection of Minimal Residual Disease following one course of chemotherapy where positive MRD was defined as one or more leukemic cell per 1000 mononuclear bone-marrow cells (>=0.1%). (NCT00136084)
Timeframe: Day 22 MRD measurement

,
Interventionparticipants (Number)
MRD PositiveMRD Negative
Arm 1: (HDAC)3168
Arm 2:(LDAC)4363

[back to top]

Relationship of Inhibition of DNA Synthesis and Clinical Response

Clinical response is defined as MRD (minimal residual disease) measured by flow cytometry at day 22. The MRD at day 22 is classified as positive (with MRD) or negative (no detectable MRD). The relation between inhibition of DNA synthesis and MRD was performed by logistic regression. In the model, logit of probability of MRD positive was regressed on inhibition of DNA synthesis. (NCT00136084)
Timeframe: Measurements were assessed in Induction I chemotherapy

InterventionPercent inhibition of DNA Synthesis (Mean)
Overall66.7

[back to top]

Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO

To estimate proportion of patients with MRD reduction after one course of Induction II (cytarabine + daunomycin + etoposide (ADE) + GO), who had no response to first course of induction therapy. (NCT00136084)
Timeframe: Induction II

InterventionParticipants (Number)
DecreaseIncrease or no change
Overall272

[back to top]

Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)

To estimate the proportion of minimal residual disease (MRD)+ patients who become MRD- after one course of gemtuzumab ozogamicin (GO) (NCT00136084)
Timeframe: Consolidation I

InterventionParticipants (Number)
NegativePositive
Overall114

[back to top]

To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy

Inhibition of DNA synthesis is defined as the percentage of DNA synthesis rate at 24-hour post-araC treatment over DNA synthesis rate pre-araC treatment. (NCT00136084)
Timeframe: Measurements were assessed in Induction I chemotherapy

InterventionPercent Inhibition of DNA Synthesis (Mean)
Arm 1: (HDAC)60.6
Arm 2:(LDAC)72.8

[back to top]

Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.

To estimate proportion of patients experiencing CTC Grade 3 or 4 toxicity during Induction II (Cytarabine + Daunomycin + Etoposide (ADE) + GO), who had no response to first course of induction therapy (NCT00136084)
Timeframe: Induction II

InterventionParticipants (Number)
Experienced Grade 3 or 4 toxicitiesDid not experience Grade 3 or 4 toxicities
Overall273

[back to top]

To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy

Overall event-free survival (EFS) was defined as the time from study enrollment to induction failure, relapse, secondary malignancy, death, or study withdrawal for any reason, with event-free patients censored on the date of the last follow-up (NCT00136084)
Timeframe: Five Year

InterventionPercentage of Participants (Number)
Overall62.4

[back to top]

Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy341.3447.9

[back to top]

Overall Event-free Survival (EFS)

EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years

InterventionPercentage of Participants (Number)
Total Therapy87.3

[back to top]

Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).

Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)

Interventionpmol/1,000,000,000 cells (Mean)
4 hr1688
24 hr2521

[back to top]

Continuous Complete Remission Since Week 56 Therapy.

CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years

InterventionPercentage of participants (Number)
Patients With High Risk of CNS Relapse92.2

[back to top]

Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy41.2110.7

[back to top]

Minimal Residual Disease (MRD)

Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)

Interventionparticipants (Number)
Negative <0.01%Positive >= 0.01%
Total Therapy390102

[back to top]

Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)

"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion

InterventionPercent change (Mean)
4 hr-44
24 hr-50

[back to top]

MTD of VSLI

Subjects had to receive at least 1 course consisting of 4 weekly infusions of VSLI at the assigned drug dose with a minimum 2 weeks of observation after the last VSLI dose to be included in the evaluation of the MTD. (NCT00144963)
Timeframe: 6 weeks

Interventionmg/m2 (Number)
VSLI2.25

[back to top]

Volume of Distribution

The PK profiles of total plasma VCR following a single intravenous infusion at a target dose of 1.0 mg/m2 for approximately 1 hour (NCT00145041)
Timeframe: cycle 1 day 1

InterventionmL/m2 (Mean)
Overall Study2722

[back to top]

Clearance

The pharmacokinetic profile of VCR on Day 1 of Cycle 1 Cl is mL/h/m2 (NCT00145041)
Timeframe: Day 1 of Cycle 1

Interventionml/h/m2 (Mean)
Overall Study193

[back to top]

T 1/2

The PK profiles of total plasma VCR following a single intravenous infusion at a target dose of 1.0 mg/m2 for approximately 1 hour every 2 weeks (one cycle) to three male and four female subjects with malignant melanoma and hepatic dysfunction secondary to metastases were measured. (NCT00145041)
Timeframe: cycle 1 day 1

Interventionhr (Mean)
Overall Study9.94

[back to top]

Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years

This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission. (NCT00176462)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Arm 2 High Risk64.9

[back to top]

Number of Patients With Serious Adverse Events as a Measure of Safety and Tolerability

Summary of grade 3 or higher toxicities (per Common Toxicity Criteria version 2.0) which generally is described as severe adverse reaction or symptom. (NCT00184002)
Timeframe: At end of every cycle

InterventionParticipants (Count of Participants)
DR-COP35

[back to top]

Percentage of Patients With Complete Response to the Combination Chemotherapy

"Initial disease response tests will be performed after cycle 4 on all patients. Subsequent assessments after cycles 6 and/or 8 will depend on response. If after 4 cycles of therapy complete response or partial response has been documented, therapy will continue. If stable or progressive disease has been documented, the patient will be withdrawn from the study.~Response to the study treatment will be determined according to the criteria proposed in the Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas by Cheson et al (23)." (NCT00184002)
Timeframe: At completion of cycle 4, 6, and 8

InterventionPercentage of participants (Number)
Complete ResponsePartial Response
DR-COP75.023.0

[back to top]

Overall Survival (OS)

OS is measured from the start of on-study to the date of death or to the last date of follow-up. Measurement is determined by Kaplan-Meyer estimate. The probability of survival at 5 years after diagnosis is given. (NCT00186875)
Timeframe: 2 years after last patient completes therapy (approximately 4 years after enrollment)

Interventionprobability (Mean)
Standard Risk0.654
High Risk0.357

[back to top]

Response Rate

"The response rate is defined as the proportion of participants who attain morphological complete remission after the re-induction Block C, inclusive of all patients who begin re-induction. Morphological complete remission was defined as <5% blasts in bone marrow by morphology." (NCT00186875)
Timeframe: End of re-induction Block C (approximately 1 month after the start of therapy)

,
Interventionproportion of participants (Number)
Complete remissionFailure to reach complete remission
High Risk0.7860.214
Standard Risk0.8460.154

[back to top]

Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)

The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is >=0.01%. The prevalence of MRD after Block C is defined as the proportion of MRD positives. (NCT00186875)
Timeframe: End of Block Block C therapy (Day 46)

,,
InterventionParticipants (Count of Participants)
Negative <0.01%Positive ≥0.01%
High Risk18
Standard Risk119
TOTXV Participants390102

[back to top]

Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)

The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is >=0.01%. The prevalence of MRD after Block B is defined as the proportion of MRD positives. (NCT00186875)
Timeframe: End of Block B therapy (Day 19)

,,
InterventionParticipants (Count of Participants)
Negative <0.01%Positive ≥0.01%
High Risk210
Standard Risk1111
TOTXV Participants191297

[back to top] [back to top]

Ocular Survival of Eyes in Stratum A and Stratum B Patients Based on IC Classification

"To describe the 5-year ocular survival of eyes outcome of intraocular retinoblastoma with respect to the new International Classification (IC) for Intraocular Retinoblastoma and the AJCC.~Patients were re-classified into 2 groups of early (IC groups A and B) and advanced (IC groups C, D, and E) retinoblastoma. Analysis was done at eye level since each eye in the same patient could be a different group. Patients from stratum A and B were analyzed separately.~Three eyes (2 patients) in stratum B received external beam radiation therapy (EBRT) and were also coincident with enucleation surgery, so their event status was not changed. Although the 3 eyes had shorter EFS interval because EBRT occurred (less than 2 years) before the surgery, it did not change the 5-year survival probability." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum A-Early Disease0.839
Stratum A-Advanced Disease0.667
Stratum B-Early Disease1.0
Stratum B-Advanced Disease0.743

[back to top]

Event-free Survival of Eyes in Stratum A and Stratum B Patients Based on IC Classification

"To describe the 5-year event-free survival of the eyes outcome of intraocular retinoblastoma with respect to the new International Classification (IC) for Intraocular Retinoblastoma and the AJCC.~Patients were re-classified into 2 groups of early (IC groups A and B) and advanced (IC groups C, D, and E) retinoblastoma. Analysis was done at eye level since each eye in the same patient could be a different group. Patients from stratum A and B were analyzed separately.~Three eyes (2 patients) in stratum B received external beam radiation therapy (EBRT) and were also coincident with enucleation surgery, so their event status was not changed. Although the 3 eyes had shorter EFS interval because EBRT occurred (less than 2 years) before the surgery, it did not change the 5-year survival probability." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum A-Early Disease0.839
Stratum A-Advanced Disease0.667
Stratum B-Early Disease1.0
Stratum B-Advanced Disease0.743

[back to top]

Event-free Survival of Eyes in Stratum B Patients Responding to Window Treatment

"To estimate the 5-year event-free survival (EFS) of eyes of bilateral disease patients with advanced intraocular retinoblastoma in either eye (R-E IV-V) responding to the vincristine/topotecan window, with alternating cycles of vincristine and carboplatin with vincristine, topotecan, and periocular carboplatin, with intensive focal treatments.~Event-free survival of eye will be defined per eye as the time interval from date on study to date of first event (an event includes external beam radiation or enucleation) or to last follow-up date for eyes without events. Event-free survival of eye will be estimated using the method of Kaplan and Meier. Standard error is 5-year EFS." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum B0.763

[back to top]

Event-free Survival of Eyes of Stratum B Patients

"To estimate the 5-year event-free survival of early stage eyes (R-E I-III) of patients with contralateral advanced disease treated with vincristine and topotecan.~Event-free survival of eye will be defined per eye as the time interval from date on study to date of first event (an event includes external beam radiation or enucleation) or to last follow-up date for eyes without events. Event-free survival of eye will be estimated using the method of Kaplan and Meier." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum B1.0

[back to top]

Event-free Survival of Stratum A Patients

"To estimate the 5-year event-free survival of patients with early stage intraocular retinoblastoma (R-E I-III) with vincristine and carboplatin with intensive focal treatments.~Event-free survival will be defined per patient as follows: for patients with one advanced stage eye, the time interval from date on study to date of first event (an event includes external beam radiation or enucleation) of advanced stage eyes, time to first event will be used for the analysis. Event-free survival will be estimated using the method of Kaplan and Meier." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum A0.688

[back to top]

Event-free Survival of Stratum B Patients Responding to Window Treatment

"To estimate the 5-year event-free (EFS) survival of bilateral disease patients with advanced intraocular retinoblastoma in either eye (R-E IV-V) responding to the vincristine/topotecan window, with alternating cycles of vincristine and carboplatin with vincristine, topotecan, and periocular carboplatin, with intensive focal treatments.~Event-free survival will be defined per patient as follows: for patients with one advanced stage eye, the time interval from date on study to date of first event (an event includes external beam radiation or enucleation) of advanced stage eyes, time to first event will be used for the analysis. Event-free survival will be estimated using the method of Kaplan and Meier." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum B0.667

[back to top]

Relationship Between Topotecan Clearance (CL) and CYP3A4/5 Genotype in Stratum B Participants.

Blood samples for pharmacokinetic studies were collected at 0 hour (pre-dose), 5 minutes, 1.5 and 2.5 hours after the end of topotecan dose on Course 1 Day 1, Course 2 Day 1, and if further studies were needed, Course 5 Day 1 and Course 8 Day 1. A blood sample for pharmacogenetic studies was collected during the course of therapy on protocol. (NCT00186888)
Timeframe: Courses 1, 2, 5, and 8

InterventionLiters/hour/m^2 (Median)
Stratum B18.8

[back to top]

Mean Primary Visual Cortex Function: Cluster Size

"Functional magnetic resonance imagining (fMRI) was used to investigate primary visual cortex (V1) response to visual stimulation in 105 children being treated for intraocular retinoblastoma. Primary visual cortex activity was assessed in each subject using blood oxygenation level-dependent (BOLD) signal. The BOLD signal was analyzed via a general linear model using Statistical Parametric Mapping software (SPM, Wellcome Institute of Neuology, London).~Voxel volume/peak BOLD response is a measurement of the volume of activation of the cortex. There is no known association with visual outcome at this time." (NCT00186888)
Timeframe: At diagnosis through 6 years after last patient enrollment

Interventionnumber activated voxels (negative BOLD) (Mean)
Stratum A2372
Stratum B1080
Stratum C2105

[back to top]

Event-free Survival Per Eye in Stratum A and Stratum B Patients Based on AJCC Classification

"To describe the 5-year event-free survival of eyes outcome of intraocular retinoblastoma with respect to the new classification of the American Joint Committee on Cancer (AJCC).~For AJCC staging, the patients were re-classified into 2 groups of early (AJCC=1, 1a or 1b) and advanced (AJCC=2, 2a, 2b, 3, 3a, 3b) retinoblastoma. The analysis was done at eye level since each eye in the same patient could be a different group. Patients from stratum A and B were analyzed separately" (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum A-Early Disease0.857
Stratum A-Advanced Disease0.500
Stratum B-Early Disease1.0
Stratum B-Advanced Disease0.719

[back to top]

Mean Primary Visual Cortex Function: Maximum T-value

"Functional magnetic resonance imagining (fMRI) was used to investigate primary visual cortex (V1) response to visual stimulation in 105 children being treated for intraocular retinoblastoma. Primary visual cortex activity was assessed in each subject using blood oxygenation level-dependent (BOLD) signal. The BOLD signal was analyzed via a general linear model using Statistical Parametric Mapping software (SPM, Wellcome Institute of Neurology, London). The maximum t-statistic in activated cluster (negative BOLD) is provided.~Voxel volume/peak BOLD response is a measurement of the volume of activation of the cortex. There is no known association with visual outcome at this time." (NCT00186888)
Timeframe: At diagnosis through 6 years after last patient enrollment

InterventionMaximum t-statistic (negative BOLD) (Mean)
Stratum A7.9
Stratum B6.2
Stratum C8.8

[back to top]

Relationship Between Topotecan Clearance (CL) and ABCG2/B1 Genotype in Stratum B Participants.

Blood samples for pharmacokinetic studies were collected at 0 hour (pre-dose), 5 minutes, 1.5 and 2.5 hours after the end of topotecan dose on Course 1 Day 1, Course 2 Day 1, and if further studies were needed, Course 5 Day 1 and Course 8 Day 1. A blood sample for pharmacogenetic studies was collected during the course of therapy on protocol. (NCT00186888)
Timeframe: Courses 1, 2, 5, and 8

InterventionLiters/hour/m^2 (Median)
Stratum B18.8

[back to top]

Ocular Survival Per Eye in Stratum A and Stratum B Patients Based on AJCC Classification

"To describe the 5-year ocular survival of eyes outcome of intraocular retinoblastoma with respect to the new classification of the American Joint Committee on Cancer (AJCC).~For AJCC staging, the patients were classified into 2 groups of early (AJCC=1, 1a or 1b) and advanced (AJCC=2, 2a, 2b, 3, 3a, 3b) retinoblastoma . The analysis was done at eye level since each eye in the same patient could be a different group. Patients from stratum A and B were analyzed separately" (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum A-Early Disease0.857
Stratum A-Advanced Disease0.500
Stratum B-Early Disease1.0
Stratum B-Advanced Disease0.719

[back to top]

Ocular Survival of Stratum B Patients Responding to Window Treatment

"To estimate the 5-year ocular survival of bilateral disease patients with advanced intraocular retinoblastoma in either eye (R-E IV-V) responding to the vincristine/topotecan window, with alternating cycles of vincristine and carboplatin with vincristine, topotecan, and periocular carboplatin, with intensive focal treatments.~Ocular survival will be defined per patient as follows: for patients with one advanced stage eye, the time interval from date on study to date of enucleation of advanced stage eye or date of last follow-up, for patients with two advanced stage eyes, the time to the first enucleation will be used for analysis. Ocular survival will be estimated using the method of Kaplan and Meier. Standard error is 5-year ocular survival" (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum B0.667

[back to top]

Ocular Survival of Stratum A Patients

"To estimate the 5-year ocular survival of patients with early stage intraocular retinoblastoma (R-E I-III) with vincristine and carboplatin with intensive focal treatments.~Ocular survival will be defined per patient as follows: for patients with one advanced stage eye, the time interval from date on study to date of enucleation of advanced stage eye or date of last follow-up, for patients with two advanced stage eyes, the time to the first enucleation will be used for analysis. Ocular survival will be estimated using the method of Kaplan and Meier." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum A0.688

[back to top]

Ocular Survival of Eyes of Stratum B Patients

"To estimate the 5-year ocular survival of early stage eyes (R-E I-III) of patients with contralateral advanced disease treated with vincristine and topotecan.~Ocular survival will be defined per patient as follows: for patients with one advanced stage eye, the time interval from date on study to date of enucleation of advanced stage eye or date of last follow-up, for patients with two advanced stage eyes, the time to the first enucleation will be used for analysis. Ocular survival will be estimated using the method of Kaplan and Meier." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum B1.0

[back to top]

Ocular Survival of Eyes in Stratum B Patients Responding to Window Treatment

"To estimate the 5-year ocular survival of eye of bilateral disease patients with advanced intraocular retinoblastoma in either eye (R-E IV-V) responding to the vincristine/topotecan window, with alternating cycles of vincristine and carboplatin with vincristine, topotecan, and periocular carboplatin, with intensive focal treatments.~Ocular survival of eye will be defined per eye as the time interval from date on study to date of enucleation or date of last follow-up. Ocular survival of eye will be estimated using the method of Kaplan and Meier. Standard error is 5-year ocular survival." (NCT00186888)
Timeframe: From date on-study to an event or last follow-up

Interventionprobability (Number)
Stratum B0.763

[back to top]

Change in Distortion Product Otoacoustic Emissions (DPOAEs)

For DP_amplitude to be considered valid, a baseline DP_SNR (Distortion Product for Signal-to-noise ratio) for each frequency (1000-8000 Hz) and for each ear (left and right) must be = 6 dB. Any ear with invalid amplitude at baseline for each frequency should be excluded. The DPOAEs amplitude levels were averaged across the right and left ears at each frequency in the patients exhibiting valid DPOAE amplitudes in both ears, resulting in mean DPOAE levels. Subsequently, comparisons between baseline and most recent evaluation (collapsed across ears) for each frequency were made to evaluate if a significant decrease in DPOAE amplitude exists between the two time points. (NCT00186888)
Timeframe: From Diagnosis through 5 years after completion of therapy

,,
InterventiondB (Mean)
1000 Hz1400 Hz2000 Hz2800 Hz4000 Hz6000 Hz8000 Hz
Additional Evaluation4.58.211.08.43.45.7-9.9
Baseline17.716.615.111.615.313.35.0
Interim Evaluation5.59.413.012.211.312.9-2.0

[back to top]

Change in Parenting Stress Index (PSI)

The PSI is a commonly used measure of parenting stress. In 101 questions, the PSI delineates between stress as a function of child characteristics (e.g., adaptability, demandingness, mood; Child Domain) and stress as a function of parent characteristics (e.g., depression, sense of competence, social isolation; Parent Domain), as well as an overall stress score (Total Stress). Raw scores are calculated (normative means: Child Doman = 98.4; Parent Domain = 122.7; Total Stress Score = 221.1). This measure was given at all time points. Scores range from 131-320 for Total Stress, 69-188 for Parent Domain, and 50-145 for Child Domain, with higher scores indicative of greater stress (Total: >260; Parent: >153, Child: >122). (NCT00186888)
Timeframe: Baseline (at study entry), 6 months, 1 year, 2 years, 3 years, and 5 years

,,,,,
Interventionunits on a scale (Mean)
Child DomainParent DomainOverall Total Stress
1 Year93.27105.84200.51
2 Years92.77105.84198.61
3 Years94.60105.92200.23
5 Years92.49102.74194.68
6 Months93.08101.56194.84
Baseline96.76109.38207.25

[back to top]

Stratum B Response to Window Therapy

The primary outcome is to estimate the proportion of stratum B patients responding to 2 courses of window therapy consisting of vincristine and topotecan. Complete Response is the complete regression of all apparent tumor masses in the funduscopic examination and by MRI and ultrasound (US). Partial Response is defined as greater than 50% (but less than 100%) reduction of the tumor masses in the funduscopic examination and by US and MRI, without the appearance of any new lesions. The response must persist for at least 4 weeks. Stratum A and C did not receive window therapy. (NCT00186888)
Timeframe: Six weeks post window therapy

InterventionParticipants (Number)
Partial responseProgressive Disease or New LesionFailure due to Toxicity
Stratum B2421

[back to top]

Stratum B Response Rate of Early Stage Eyes to Window Therapy

To estimate the proportion of early stage eyes defined as Reese-Ellsworth Group I, II, or III eyes, that responded to 2 courses of window therapy which consisted of vincristine and topotecan (NCT00186888)
Timeframe: Six weeks post window therapy.

InterventionParticipants (Number)
Partial responseProgressive Disease / New lesionFailure due to Toxicity
Stratum B1101

[back to top]

Number of Participants With Development of Pineal Cysts

The MRI reports from bilateral patients were reviewed and data abstracted regarding pineal gland measurement and information about pineal cysts. The number of participants with change in primary visual cortex function from diagnosis through 6 years after last patient enrollment is reported here. (NCT00186888)
Timeframe: At diagnosis through 6 years after last patient enrollment

InterventionParticipants (Count of Participants)
Developed new solitary cyst(s)Developed multiple new cystsGrowth of pineal cystDecrease in size (resolution) of pineal cystNo change
Participants With Bilateral Retinoblastoma12155111

[back to top]

Number of Participants With Change in Size of Pineal Gland

The MRI reports from bilateral patients were reviewed and data abstracted regarding pineal gland measurement and information about pineal cysts. The number of participants with change in pineal gland size is reported here. (NCT00186888)
Timeframe: From diagnosis through 6 years after last patient enrollment

InterventionParticipants (Count of Participants)
Prominent or mildly enlarged pineal glandsPineal growth over timeNo change in pineal gland size
Participants With Bilateral Retinoblastoma12823

[back to top]

Assessment of School Readiness

The Bracken Basic Concepts Scale was used to assess school readiness. It is an examiner-administered measure that assesses per-academic skills including letter and number recognition, shapes, colors, and understanding of sizes and comparisons. Raw scores are converted into age-normed scaled scores (normative mean = 10, SD = 3) for the School Readiness Composite. Higher scores are indicative of stronger pre-academic skills, with scores from 7 to 13 within the Average range. (NCT00186888)
Timeframe: Patients were assessed at 5 years of age

Interventionunits on a scale (Mean)
5 Years8.96

[back to top]

Change in Cognitive Functioning

The Early Learning Composite was assessed with Mullen Scales of Early Learning, a measure of developmental functioning appropriate for use with children from birth through age 5. It is an examiner-administered instrument that uses toys, games, pictures, and other objects to elicit information about a child's language, fine and gross motor skills, and overall early learning capabilities. Raw scores are converted to an age-normed standard score (normative mean = 100, SD = 15) for the overall Early Learning Composite. This measure was given at all time points. Higher scores are indicative of better functioning, with scores from 85-115 in the average range. (NCT00186888)
Timeframe: Baseline (at study entry) and at ages 6 months, 1 year, 2 years, 3 years and 5 years

Interventionunits on a scale (Mean)
Baseline91.61
6 Months90.96
1 Year95.91
2 Years88.40
3 Years82.12
5 Years86.00

[back to top]

Change in Parent Report of Social-Emotional Factors

This outcome was measured using the Ages and Stages Questionnaire which is a parent-completed measure of a child's social-emotional functioning. Raw scores are calculated and compared to cut-off points by age (6 months = 45; 1 year = 48; 2 years = 50; 3 years = 59; 5 years =70). Higher scores are indicative of more problems with scores above the cut-off indicating significant concerns warranting additional follow-up. Possible scores range from 0 to 200+, depending on the number of items administered, which varies by the age of the child (19 to 33 items). However, the primary use of this tool is as a screener. Thus, typically, scores are interpreted as they compare to the identified cut-offs, with children who score above the cut-off referred for further evaluation. This measure was given at all time points. (NCT00186888)
Timeframe: Baseline (at study entry), 6 months, 1 year, 2 years, 3 years, and 5 years

Interventionunits on a scale (Mean)
Baseline40
6 Months19.42
1 Year26.28
2 Years29.67
3 Years40.61
5 Years39.93

[back to top]

Change in Relevant Daily Living Skills

The Adaptive Behavior composite was measured using the Vineland Scales of Adaptive Behavior (VABS) which is an examiner-administered semi-structured interview that assesses adaptive functioning from birth through adulthood. Subscales including motor skills, communication, socialization, and daily living skills combine into an overall adaptive behavior composite which is an age-normed standard score (normative mean = 100, SD = 15). This measure was given at all time points. Higher scores are indicative of better functioning, with scores from 85-115 in the average range. (NCT00186888)
Timeframe: Baseline (at study entry), 6 months, 1 year, 2 years, 3 years, and 5 years

Interventionunits on a scale (Mean)
Baseline97.48
6 Months104.73
1 Year106.06
2 Years94.22
3 Years96.45
5 Years93.03

[back to top]

Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193479)
Timeframe: 18 Months

Interventionpercentage of patients (Number)
CNOP (CVP)/Rituximab/Pegfilgrastim Followed by Rituximab81

[back to top] [back to top] [back to top] [back to top]

Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants

An adverse event (AE) was any medical occurrence in a participant who was administered denileukin diftitox and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and did not necessarily have a causal relationship with this treatment. An AE included any side effect, injury, toxicity, sensitivity reaction, or any undesirable clinical or laboratory event that was not normally observed in the participant. Safety was assessed for all participants who received at least one dose of study medication and was monitored throughout the study. Safety evaluations were based on the incidence, intensity, and type of AE, and clinically significant changes in the participant's medical history, physical examination findings, vital signs, and clinical laboratory results. Participants also notified the study staff of any problems that occurred between visits by telephone, and if necessary, were evaluated by the investigator or study staff at an unscheduled interim visit. (NCT00211185)
Timeframe: From date of first dose up to approximately 4 weeks after discontinuation of denileukin diftitox and CHOP, or after early withdrawal for any reason, up to approximately 5 years 9 months

InterventionPercentage of participants (Number)
FatigueNauseaHemoglobinNeuropathy-sensoryAlanine transaminaseHyperglycemiaHypoalbuminemiaLeukocytesFeverHypocalcemiaLymphopeniaAspartate transaminaseDyspneaPlateletsAlopeciaNeutrophilsConstipationEdema-limbHyponatremia
Denileukin Diftitox in Combination With CHOP63.346.940.840.834.734.734.734.732.730.630.628.628.628.626.526.524.520.420.4

[back to top]

Overall Response in the Intent To Treat (ITT) Population

Response rate was defined as the percentage of the ITT population who achieved a Complete Response (CR), Unconfirmed Complete Response (CRu), or Partial Response (PR). The International Working Group recommendations on non-Hodgkin's lymphoma response criteria were used to determine response to therapy. Largely, the protocol defined the response criteria as: 1) CR, loss of all detectable clinical and radiographic evidence of disease and disease-related symptoms if present before therapy; 2) CRu, CR with the caveats, response to therapy was accompanied with a 75% reduction in measurable lesion size and/or an indeterminate bone marrow biopsy (if initially positive); and 3) PR, less than or equal to 50% decrease in the sum of the measurements of tumor diameters, no increase in the size of other nodes, liver, or spleen, hepatic or spleen nodules regressed by at least 50%, and/or no new sites of disease. (NCT00211185)
Timeframe: From the start of the treatment to the date of participant's death assessed up to 5 years 9 months

InterventionPercentage of participants (Number)
Confirmed complete responseUnconfirmed complete responsePartial responseStable diseaseDisease progressionEarly deathInadequate assessment
Denileukin Diftitox in Combination With CHOP51.04.110.26.14.14.120.4

[back to top]

Overall Response in the Efficacy Analyzable (EA) Population

Response rate was defined as the percentage of the EA population who achieved a CR, CRu, or PR. The International Working Group recommendations on non-Hodgkin's lymphoma response criteria were used to determine response to therapy. Largely, the protocol defined the response criteria as: 1) CR, loss of all detectable clinical and radiographic evidence of disease and disease-related symptoms if present before therapy; 2) CRu, CR with the caveats, response to therapy was accompanied with a 75% reduction in measurable lesion size and/or an indeterminate bone marrow biopsy (if initially positive); and 3) PR, less than or equal to 50% decrease in the sum of the measurements of tumor diameters, no increase in the size of other nodes, liver, or spleen, hepatic or spleen nodules regressed by at least 50%, and/or no new sites of disease. (NCT00211185)
Timeframe: From the start of the treatment to the date of the participant's death assessed up to 5 years 9 months

InterventionPercentage of participants (Number)
Confirmed complete responseUnconfirmed complete responsePartial responseStable diseaseDisease progressionEarly deathInadequate assessment
Denileukin Diftitox in Combination With CHOP67.65.413.58.15.40.00.0

[back to top]

Progression-Free Survival

PFS was defined as the period of time from treatment start to the first documentation of PD, recurrence, or death. PD was defined as a greater than or equal to 50% increase from baseline in the sum of the products of the greatest diameters of any previously identified abnormal node for PRs or non-responders, or the appearance of any new lesions during or at the end of therapy. PFS was censored at the last date for which the response assessment resulted in the absence of PD for participants who did not demonstrate objective progression or recurrence. Participants who withdrew prior to evidence of disease progression or recurrence, PFS was censored at the last date assessment showed an absence of PD. (NCT00211185)
Timeframe: From the date of first dose of study drug until date of first documentation of PD, recurrence, or death from any cause, assessed up to 5 years 9 months

InterventionWeeks (Mean)
Denileukin Diftitox in Combination With CHOP12.4

[back to top]

Percentage of Participants With Overall Survival

Overall Survival (OS) was defined as the time from the date of registration to the date of the participant's death. OS was determined by reviewing all participant's records every 6 months until the study was administratively closed or all participants died, whichever occurred first. Participants who were lost to follow-up but were still alive at the date of last contact were censored at the date of last contact. Participants who did not have a recorded date of death were censored for OS at the last date at which they were known to be alive. (NCT00211185)
Timeframe: From date of randomization until death, or administrative close of study, whichever came first, assessed up to 5 years 9 months

InterventionPercentage of participants (Number)
Denileukin Diftitox in Combination With CHOP63.3

[back to top]

Duration of Response

Duration of response was defined as the length of time from the first date at which the response criteria were met (taking the earliest date at which a PR, CRu, or the confirmed CR occurred) until the date that recurrent or PD or death was accurately documented, per the criteria defined for progression-free survival (PFS). All participants within the EA population who achieved a response per the criteria defined were included in the duration of the response analysis. Participants lost to follow-up prior to PD or death were censored at the date they were last known to still be responding to treatment. Duration of response was estimated using the Kaplan-Meier method with the median duration of response summarized. (NCT00211185)
Timeframe: From the date of the first documented CR (confirmed or unconfirmed) or PR until the date of first documentation of recurrent or PD or death, assessed up to 5 years 9 months

InterventionMonths (Median)
Denileukin Diftitox in Combination With CHOP29.7

[back to top]

Number of Participants With Adverse Events, by Group

Number of participants with toxicities of Thalidomide/Dexamethasone vs. VAD as induction regimens in newly diagnosed multiple myeloma (MM). (NCT00215943)
Timeframe: 4 Years, 7 Months

,
Interventionparticipants (Number)
Serious Adverse Events (SAEs)Adverse Events (AEs)
Active Comparator: Thalidomide and Dexamethasone Treatment137
Active Comparator: VAD Treatment036

[back to top]

Number of Participants With Progression Free Survival (PFS), by Treatment Arm

"Number of participants with PFS for thalidomide/Dexamethasone vs. VAD with respect to progression free survival in newly diagnosed MM. Progressive Disease (PD): (for patients not in CR) Requires one or more of the following; > 25% increase in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation.~> 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg and confirmed on a repeat investigation.~>25% increase in plasma cells in a bone marrow aspirate, which also must be an absolute increase of at least 10%. Definite increase in the size of existing lytic lesions or plasmacytomas. Development of new bone lesions or plasmacytomas (except compression fractures). Development of hypercalcemia (corrected calcium > 11.5 mg/dL not attributable to other causes)." (NCT00215943)
Timeframe: 4 Months

Interventionparticipants (Number)
Active Comparator: VAD Treatment2
Active Comparator: Thalidomide and Dexamethasone Treatment1

[back to top]

Overall Survival (OS), by Treatment Arm

"Median OS for thalidomide/Dexamethasone participants vs. VAD participants. Months from On Study to Expired/Last Date Known Alive.~Investigators had planned to accrue 176 participants to calculate median overall survival." (NCT00215943)
Timeframe: Up to 10 Years

Interventionmonths (Median)
Active Comparator: VAD Treatment57
Active Comparator: Thalidomide and Dexamethasone Treatment56.5

[back to top]

Response Rates of VAD vs. Thalidomide/Dexamethasone

Blade (15) criteria for remission in multiple myeloma was used to assess response. Complete Response (CR)includes: Disappearance of the original monoclonal protein from the blood and urine on at least two determinations for a minimum of 6 weeks by immunofixation studies. Partial Response (PR) includes: At least a 50% reduction in the level of serum monoclonal protein for at least two determinations 6 weeks apart. Minimal Response (MR)includes: At least a 25% to 49% reduction in the level of serum monoclonal protein for at least 2 determinations 2 weeks apart. (NCT00215943)
Timeframe: End of Cycle 4 - 4 Months per Participant

,
Interventionparticipants (Number)
Complete ResponsePartial ResponseMinimal Response
Active Comparator: Thalidomide and Dexamethasone Treatment1162
Active Comparator: VAD Treatment196

[back to top]

12-Month Progression-Free Survival (PFS)

12-month progression-free survival is defined as the probability of patients remaining alive and progression-free at 12 months from study entry. (NCT00217425)
Timeframe: Assessed every 3 months the first 2 years from study entry and every 6 months 3-5 years from study entry.

Interventionprobability (Number)
Treatment (A-CHOP Followed by MA)0.44

[back to top]

3-Year Overall Survival

3-year overall survival is defined as the probability of patients surviving at 3 years from study entry. (NCT00217425)
Timeframe: Assessed every 3 months the first 2 years from study entry and every 6 months 3-5 years from study entry.

Interventionprobability (Number)
Treatment (A-CHOP Followed by MA)0.39

[back to top]

Overall Response Rate

Overall response rate is defined as proportion of patients who achieve complete remission [CR, unconfirmed CR (CRu) or Functional CR] or partial remission. Response is assessed using the criteria from the International Workshop to Standardize Criteria for Non-Hodgkin's Lymphoma (Chesen, 1999). (NCT00217425)
Timeframe: Assessed after cycle 3, cycle 6, and cycle 8 (if given).

Interventionproportion (Number)
Treatment (A-CHOP Followed by MA)0.90

[back to top]

Overall Survival

Time from registration to death from any cause. Patients alive were censored at follow up. (NCT00262925)
Timeframe: assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry

Interventionmonths (Median)
Treatment (Chemotherapy, Enzyme Inhibitor Therapy)5.2

[back to top]

Complete Response Rate

"Complete response requires that all of the following be present for at least four weeks.~1. Peripheral Blood Counts: Neutrophil count >= 1.0 x 109/L, Platelet count >= 100 x 109/L, Reduced hemoglobin concentration or hematocrit has no bearing on remission status, Leukemic blasts must not be present in the peripheral blood.~2 .Bone Marrow Aspirate and Biopsy: Cellularity of bone marrow biopsy must be > 20% with maturation of all cell lines, <= 5% blasts.~3. Extramedullary leukemia, such as CNS or soft tissue involvement, must not be present." (NCT00262925)
Timeframe: assessed before the first consolidation cycle and first cytoreduction cycle, before the first and after the last maintenance cycle; after discontinuing treatment, assessed every 3 months if < 2 years and every 6 months if 2-5 years from study entry

Interventionpercentage of participants (Number)
Treatment (Chemotherapy, Enzyme Inhibitor Therapy)33

[back to top]

Cumulative Incidence Rate of Oral Mucositis

"Cumulative incidence of World Health Organization (WHO) grade 2 or > mucositis (moderate to severe) in participants completing up to 6 blinded cycles. Rate defined as participants who had Grade 2 or > divided by total number of participants who completed up to 6 blinded cycles.~WHO Criteria of Grade 1: possible buccal mucosal scalloping with/without erythema; No ulcers; swallows solid diet. Grade 2: ulcers with or without erythema; swallow solid diet. Grade 3: ulcers with/without (extensive) erythema; swallow liquid, not solid diet. Grade 4: mucositis to extent alimentation not possible." (NCT00267046)
Timeframe: Within 6 blinded cycles (3-week cycles), up to 18 weeks.

,
InterventionPercentage of Participants (Mean)
Cumulative incidence of WHO grade 2 or higher mucoCumulative Incidence of WHO Grade 3 or 4 Mucositis
Palifermin4413
Placebo8851

[back to top]

Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles

Median maximum score (0 to 10, with 10 being the worst) for participant-reported outcomes in the first 2 blinded cycles for Mouth Pain, Overall Mouth and Throat Soreness, and Rectal Soreness while median maximum score for Swallowing, Drinking and Eating Difficulty (0 to 4, with 4 being the difficult). (NCT00267046)
Timeframe: Within the first 2 blinded cycles (3-week cycles), up to 6 weeks.

,
InterventionUnits on a scale (Median)
Mouth PainOverall Mouth and Throat SorenessRectal SorenessDrinking DifficultyEating DifficultySwallowing Difficulty
Palifermin110000
Placebo55.541.522

[back to top]

2-year Progression-Free Survival (PFS)

2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS. (NCT00274924)
Timeframe: Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.

Interventionprobability (Number)
Group I (PET Negative)0.76
Group II (PET Positive)0.42

[back to top]

5-year Overall Survival

5-year overall survival is defined as the probability of patients who remain alive at 5 years from study entry. The method of Kaplan and Meier (1958) was used to estimate overall survival. (NCT00274924)
Timeframe: Every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.

Interventionprobability (Number)
Group I (PET Negative)0.77
Group II (PET Positive)0.69

[back to top]

3 Year Progression-Free Survival Rate

Percentage of participants out of total treated alive with disease progression 3 years following registration. Progression-free survival (PFS) was measured from the date of study registration to the date of documented disease progression or death of any cause. (NCT00290433)
Timeframe: From registration to disease progression or death, up to 3 years

Interventionpercentage of participants (Number)
HCVIDDOXIL Regimen30

[back to top]

Response Rate R-HCVAD vs. R-CHOP

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00290498)
Timeframe: 3 years

,
InterventionParticipants (Count of Participants)
Complete RemissionInevaluableProgressive DiseasePartial RemissionComplete Remission Unconfirmed
R-CHOP71101
R-HCVAD402142

[back to top]

Progression Free Survival (Rate)

Progression free survival (PFS) for three years following therapy with Rituxan-HCVAD alternating with Rituximab with high -dose methotrexate/ara-C and standard R-CHOP in patients with newly diagnosed B-cell aggressive non-Hodgkin's lymphomas younger than 60 years old and with adjusted IPI 2 or higher adverse prognostic features. (NCT00290498)
Timeframe: 3 years post-therapy

InterventionParticipants (Count of Participants)
R-HCVAD/MA35
R-CHOP7

[back to top]

Days Platelets Count of < 100K/μL

The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir < 25K/μL) in the absence of platelet transfusion in the blinded study cycle. (NCT00299182)
Timeframe: Prior to start of treatment and then at least 2 times a week during treatment until end of cycle 2 (1 cycle = 21 days)

Interventiondays (Mean)
Arm A 1mcg/kg5.5
Arm A 3mcg/kg5.3
Arm A 10mcg/kg8.3
Arm B 1mcg/kg6.8
Arm B 3mcg/kg8
Arm B 10mcg/kg9.3
Placebo9.8

[back to top]

Platelet (PLT) Nadir

Blood counts were performed at least two times a week and when clinically indicated during the study and daily when PLT count is < 50K/μL until recovery (two consecutive counts showing upward trend). The optimal biologic dose was defined as the dose of AMG 531 at which the greatest proportion of patients avoided grade 4 thrombocytopenia (Platelet nadir < 25K/μL) in the absence of platelet transfusion in the blinded study cycle. (NCT00299182)
Timeframe: Prior to start of treatment and then at least 2 times a week during treatment until end of cycle 2 (1 cycle = 21 days)

InterventionK/μL (Mean)
Arm A 1mcg/kg20.3
ARM A 3mcg/kg26.3
Arm A 10mcg/kg24.8
Arm B 1mcg/kg22.5
Arm B 3mcg/kg18.3
Arm B 10mcg/kg8
Placebo11.3

[back to top]

Overall Survival

Percentage of participants alive at different time points (NCT00301821)
Timeframe: time from study entry to 36 months

Interventionpercentage of Participants (Number)
Overall Survival at 12 monthsOverall Survival at 24 monthsOverall Survival at 36 months
Epratuzumab + Rituximab + CHOP898180

[back to top]

Progression-free Survival (PFS)

Percentage of participants Progression-free at different time points. Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: the time from study entry to 36 months

Interventionpercentage of participants (Number)
Progression Free Survival at 12 monthsProgression Free Survival at 24 monthsProgression Free Survival at 36 months
Epratuzumab + Rituximab + CHOP857776

[back to top]

Overall Response Rate (ORR)

Overall response rate will be estimated by the number of patients with objective status of partial response (PR), unconfirmed complete response (CRu), or complete response (CR) during the first 6 cycles of treatment divided by number of evaluable patients (met eligibility criteria, signed consent form, and started treatment). Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: Baseline to first 6 cycles of treatment

Interventionpercentage of participants (Number)
Epratuzumab + Rituximab + CHOP95

[back to top]

Event-free Survival After 12 Months

The primary endpoint of the trial was the percentage of the eligible patients who were alive and event-free 12 months after enrollment to the study (EFS12). (NCT00301821)
Timeframe: From Baseline to 12 months

Interventionpercentage of participants (Number)
Epratuzumab + Rituximab + CHOP78

[back to top]

Event Free Survival (EFS)

Survival is defined as the minimum time from study entry to a relapse of any kind, death from any cause, or occurrence of a second malignant neoplasm. Patients without report of such events where censored at last contact. This will be used to compute event free survival (EFS). (NCT00302003)
Timeframe: At 60 months

InterventionProbability of survival (Number)
Group 10.79

[back to top]

Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).

Survival is defined as the minimum time from study entry to requirement for additional chemotherapy and IFRT for retrieval, occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact. Patients who achieve less than CR after 3 cycles of AV-PC will require IFRT and hence will satisfy this definition at the time of response evaluation. Patients who achieve a CR but who relapse will receive addition chemotherapy and IFRT or intense retrieval and hence will satisfy this definition at the time of the first relapse of Hodgkin disease. This endpoint will be used to compute event free survival without receiving radiation therapy (EFSnoRT). (NCT00302003)
Timeframe: At 60 months

InterventionProbability of survival (Number)
Group 10.49

[back to top]

Overall Survival

Survival is defined as time from study entry to death due to any cause. Patients alive at last contact where censored at last contact. (NCT00302003)
Timeframe: At 60 months

InterventionProbability of survival (Number)
Group 10.99

[back to top]

Intensive Therapy Free Survival (ITFS).

Survival is defined as the minimum time from study entry to a relapse of higher risk at any time, any relapse following treatment with protocol mandated IFRT, death from any cause, or the occurrence of a second malignant neoplasm. This will be used to compute intensive therapy free survival (ITFS). Patients without report of such events where censored at last contact. This differs from traditional EFS in that relapse after AVPC* x3 therapy alone that does not place the patient in a higher risk category is not considered a treatment failure. In this definition, higher-risk relapse refers to relapse involving sites and extent of disease that place the patient in the current COG definition of intermediate or high-risk disease. If a patient with CR who experiences a LR relapse is not retreated with protocol-mandated chemotherapy and IFRT, subsequent disease relapses will nevertheless be counted in the analysis of the treatment strategy. (NCT00302003)
Timeframe: At 60 months

InterventionProbability of survival (Number)
Group 10.89

[back to top]

Complete Response Rate - Locally Reviewed

"Assessed by the ECOG-ACRIN data manager based upon local review of images and data sent by the local sites.~Treatment response was determined by calculating the sum of the maximal cross section in 2 separate axes using enhancing lesion(s) on CT or MRI imaging. The same imaging modality was to be used throughout assessment. Complete response was defined as the disappearance of all contrast enhancing tumor size on CT or MRI, patient was off all glucocorticoids, and resolution of all meningeal and vitreous involvement if present. Response must have lasted at least 4 weeks." (NCT00335140)
Timeframe: For the primary endpoint, complete response will be based on disease status at three weeks post the end of therapy (week 17).

Interventionpercentage of participants (Number)
Rituximab + Standard Chemotherapy64

[back to top]

Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors

The outcome of these patients will be compared with a fixed outcome based on that seen for similar patients treated with NWTS-5 regimen (NCT00002610). (NCT00335556)
Timeframe: 4 years

InterventionPercentage of 4-year OS (Number)
UH-138.9

[back to top]

Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)

Compare the outcome of patients treated with alternating CyCE/VDCy chemotherapy (with or without vincristine/irinotecan cycles) to a fixed outcome based on that seen for similar patients treated with NWTS-5 (NCT00002610). (NCT00335556)
Timeframe: 4 years

InterventionPercentage of 4-year OS (Number)
UH-176.1
Window/UH-125.0
UH-287.5

[back to top]

Event Free Survival Probability

Event-free survival will be informally compared to that seem for similar patients treated on NWTS-5 (NCT00002610). (NCT00335556)
Timeframe: 4 years

InterventionPercent Probability 4 Year EFS (Number)
Regimen DD-4A100.0

[back to top]

Toxicity Rate

Percentage of participants with Grade 4 cardiac toxicities, Grade 4 Sinusoidal Obstruction Syndrome (SOS), and treatment-related deaths determined using CTCAE v4. (NCT00335556)
Timeframe: Up to 4 years

InterventionPercentage of patients (Number)
Cardiac toxicitiesTreatment-related deathsSinusoidal Obstruction Syndrome
Combined UH-2, UH-1, Window/UH-14.94.90

[back to top]

Response Rate

Criteria for response assessed by three-dimensional measurement: Complete Response (CR), Disappearance of all index lesions and non-index lesions. No new lesions; Partial Response (PR), At least a 65% decrease in the sum of the volumes of the index lesions. No new lesions; Response rate (RR) = CR+PR of patients who received window therapy. (NCT00335556)
Timeframe: Up to 2 months

InterventionPercentage of participants (Number)
Combined Window/UH-1 and UH-271

[back to top]

Number of Patients With INI1 Mutations in Renal and Extrarenal Malignant Rhabdoid Tumor by Fluorescent in Situ Hybridization

(NCT00335556)
Timeframe: At baseline

InterventionCount participants (Number)
UH-123
Window/UH-11

[back to top]

Pathological Features Present At Diagnosis - Iris Infiltration (II)

Proportion of patients who had iris infiltration at enrollment. (NCT00335738)
Timeframe: At enrollment

InterventionProportion of patients with II (Number)
All Patients0.029

[back to top]

Pathological Features Present at Diagnosis - Scleral Invasion (SI)

Proportion of patients that had scleral invasion at enrollment. (NCT00335738)
Timeframe: At enrollment

InterventionProportion of patients with SI (Number)
All Patients0.016

[back to top]

Overall Survival (OS)

OS distributions will be estimated by the Kaplan-Meier method for patients with high risk features according to central review and treated with adjuvant chemotherapy and separately for subjects with central review recommendation of enucleation alone. (NCT00335738)
Timeframe: At 2 Years

InterventionEstimated Probability (Number)
Group 1 (Identified by Central Review as High Risk)0.9628
Group 2 (Identified by Central Review as Not High Risk)1

[back to top]

Pathological Features Present At Diagnosis - Anterior Chamber Seeding (ACS)

Proportion of patients who had anterior chamber seeding at enrollment. (NCT00335738)
Timeframe: At enrollment

InterventionProportion of patients with ACS (Number)
All Patients0.045

[back to top]

Event-free Survival (EFS)

EFS distributions will be estimated by the Kaplan-Meier method for patients with high risk features according to central review and treated with adjuvant chemotherapy and separately for subjects with central review recommendation of enucleation alone. (NCT00335738)
Timeframe: At 2 years

InterventionEstimated Probability (Number)
Group 1 (Identified by Central Review as High Risk)0.9394
Group 2 (Identified by Central Review as Not High Risk)0.9953

[back to top]

Pathological Features Present At Diagnosis - Ciliary Body Infiltration (CBI)

Proportion of patients who had ciliary body infiltration at enrollment. (NCT00335738)
Timeframe: At Enrollment

InterventionProportion of patients with CBI (Number)
All Patients0.019

[back to top]

Pathological Features Present At Diagnosis - Tumor Involving the Optic Nerve Posterior to the Lamina Cribrosa (LC) as an Independent Finding

Proportion of patients with tumor involving the optic nerve posterior to the lamina cribrosa as an independent. (NCT00335738)
Timeframe: At enrollment

InterventionProportion of patients with LC (Number)
All Patients0.16

[back to top]

Toxicity As Assessed By the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

Number of patients assigned chemotherapy who experienced grade 3 or higher CTC AE toxicity. (NCT00335738)
Timeframe: During planned six cycles of chemotherapy

Interventionparticipants (Number)
Group 1 (Identified by Central Review as High Risk)19

[back to top]

Pathological Features Present At Diagnosis - Posterior Uveal Invasion (PVI)

Proportion of patients who had posterior uveal invasion at enrollment. (NCT00335738)
Timeframe: At enrollment

InterventionProportion of patients with PVI (Number)
All Patients0.24

[back to top]

Rates of Nutritional Toxicities

Rates of nutritional toxicities reported as Adverse Events during therapy for each cycle will be summarized using standard descriptive methods (such as number of patients). The difference in number of patients with nutritional toxicities between the two treatment regimens will be compared using a Chi-square test. (NCT00336024)
Timeframe: Beginning of treatment to the end of consolidation

,
InterventionParticipants (Count of Participants)
Nutritional Disorders Induction Cycle INo Nutritional Disorders Induction Cycle INutritional Disorders Induction Cycle IINo Nutritional Disorders Induction Cycle IINutritional Disorders Induction Cycle IIINo Nutritional Disorders Induction Cycle IIINutritional Disorders Consolidation Cycle INo Nutritional Disorders Consolidation Cycle INutritional Disorders Consolidation Cycle IINo Nutritional Disorders Consolidation Cycle IINutritional Disorders Consolidation Cycle IIINo Nutritional Disorders Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))1029132673212279301029
Arm II (Patients Treated With MTX)172113251226830533533

[back to top]

Percentage of Participants With Event Free Survival (EFS)

EFS was defined as time from enrollment to the occurrence of first event (disease progression/relapse, secondary malignancy, death from any cause) or date of last contact for patients who are event-free. The percentage of participants with EFS and 90% confidence interval were provided. The difference in incidence for the two treatment regimens were compared using a one-sided log-rank test with a significance level of 0.1. (NCT00336024)
Timeframe: Baseline to up to 5 years

Interventionpercentage of participants with EFS (Number)
Arm I (Patients Treated Without Methotrexate (MTX))43.6
Arm II (Patients Treated With MTX)54.9

[back to top]

Percentage of Participants With Any Acute Adverse Events

Event is defined as the first occurrence of any acute toxicity. Estimates will be obtained using life-table methods. Patients who have progression or recurrence of disease will be censored in this analysis. Difference in incidence for the two treatment regimens will be compared using log-rank test. (NCT00336024)
Timeframe: Beginning of treatment to the end of consolidation

Interventionpercentage of participants (Number)
Arm I (Patients Treated Without Methotrexate (MTX))97.4
Arm II (Patients Treated With MTX)97.2

[back to top]

Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism

"Thyroid function was assessed as per ACNS0334 Endocrine Guidelines. Normal and Abnormal are defined at each institution by the laboratory standards where the blood tests are run. Primary Hypothyroidism/Subclinical Compensatory Hypothyroidism is defined as patients with Free T4 level less than Institutional Normal or equal to Institutional Normal with TSH level greater than Institutional Normal." (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))3
Arm II (Patients Treated With MTX)5

[back to top]

Number of Participants With Secondary Malignancies

The number of patients who had secondary malignancy will be reported for this analysis due to small numbers. (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))1
Arm II (Patients Treated With MTX)0

[back to top]

Rates of Gastrointestinal Toxicities

Rates of gastrointestinal toxicities reported as Adverse Events during therapy for each cycle will be summarized using standard descriptive methods (such as number of patients). The difference in number of patients with gastrointestinal toxicities between the two treatment regimens will be compared using a Chi-square test. (NCT00336024)
Timeframe: Beginning of treatment to the end of consolidation

,
InterventionParticipants (Count of Participants)
GI Tox Induction Cycle INo GI Tox Induction Cycle IGI Tox Induction Cycle IINo GI Tox Induction Cycle IIGI Tox Induction Cycle IIINo GI Tox Induction Cycle IIIGI Tox Consolidation Cycle INo GI Tox Consolidation Cycle IGI Tox Consolidation Cycle IINo GI Tox Consolidation Phase IIGI Tox Consolidation Cycle IIINo GI Tox Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))8314354351128732534
Arm II (Patients Treated With MTX)1226102883014241028632

[back to top]

Number of Participants With Chronic Central Hypothyroidism

"Thyroid function was assessed as per ACNS0334 Endocrine Guidelines. Normal and Abnormal are defined at each institution by the laboratory standards where the blood tests are run. Central Hypothyroidism is defined as Free T4 level less than Institutional Normal with TSH less than or equal to Institutional Normal." (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))1
Arm II (Patients Treated With MTX)1

[back to top]

Number of Participants With Chronic Diabetes Insipidus

"The number of patients who had Diabetes Insipidus and on DDAVP will be reported for this analysis due to small numbers.." (NCT00336024)
Timeframe: Beginning of off-treatment to up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))1
Arm II (Patients Treated With MTX)1

[back to top]

Number of Participants With Chronic Low Somatomedin C

Low Somatomedin C is defined as patients with somatomedin C value less than institutional normal. As numbers are too small, descriptive statistics such as number will be reported for this analysis. Growth hormone function was assessed as per ACNS0334 Endocrine Guidelines. Low Somatomedin C levels are defined at each institution by the laboratory standards where the blood tests are run. (NCT00336024)
Timeframe: Off-treatment up to 9 years

InterventionParticipants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))2
Arm II (Patients Treated With MTX)5

[back to top]

Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).

"Three tools are used to assess intelligence (IQ) depending on age. The range of IQ scores is 40-160 (mean=100, SD=15); range for the Processing Speed Index (PSI)=45-155. Higher scores represent better functioning. (1) Wechsler Preschool and Primary Scale of Intelligence-4th Edition (WPPSI-IV) is used for ages 2.5 to 6 years. Bug Search and Cancellation subtests are summed to calculate PSI. (2) Wechsler Intelligence Scales for Children-5th Edition (WISC-V) is used for ages 6 - 16 years. Symbol Search and Coding subtests are summed to calculate PSI. (3) Wechsler Adult Intelligence Scales-4th Edition (WAIS-IV) is used for ages 16 and older. Symbol Search and Coding subtests are summed to calculate PSI.~The Pediatric Quality of Life Inventory Version 4 (PedsQL) measures health-related quality of life (QOL). Parents complete the measure for children ages 2-17, and patients > 18 complete a self-report version. Total scores range from 0-100, with higher scores representing better QOL." (NCT00336024)
Timeframe: 60 months (+/- 3 months)

,
Interventionscores on a scale (Median)
Total Quality of Life ScoreIntelligence QuotientProcessing Speed Index
Arm I (Patients Treated Without Methotrexate (MTX))60.577.082.0
Arm II (Patients Treated With MTX)56.578.589.0

[back to top]

Number of Patients That Achieved a Complete Response or a Partial Response (PR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT00337987)
Timeframe: After 4 years

Interventionparticipants (Number)
Denileukin Diftitox/CHOP Administration32

[back to top]

Number of Patients That Achieved a Complete Response (CR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT00337987)
Timeframe: After 4 years

Interventionparticipants (Number)
Denileukin Diftitox/CHOP Administration27

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Social Functioning

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy86.1
Week 883.0
Week 1280.7
After Radiation85.1
Off-therapy89.1

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Total Score

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy77.6
Week 869.1
Week 1272.3
After Radiation77.8
Off-therapy83.5

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Cognitive Problems

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 879.1
Week 1278.2
After Radiation87.0
Off-therapy82.0

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Communication

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 880.7
Week 1283.0
After Radiation87.2
Off-therapy89.0

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Nausea

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 862.7
Week 1260.1
After Radiation76.7
Off-therapy81.6

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Pain and Hurt

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 863.9
Week 1271.5
After Radiation79.9
Off-therapy88.0

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Perceived Physical Appearance

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 877.6
Week 1281.3
After Radiation81.4
Off-therapy84.7

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Procedural Anxiety

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 871.8
Week 1270.9
After Radiation68.1
Off-therapy80.1

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Total Score

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 874.1
Week 1274.2
After Radiation81.7
Off-therapy83.5

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Treatment Anxiety

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 889.2
Week 1282
After Radiation89.4
Off-therapy87.3

[back to top]

Patient Quality of Life (QoL), PedsQL v.3.0: Worry

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 871.2
Week 1272.2
After Radiation74.5
Off-therapy76.0

[back to top]

Patient Quality of Life (QoL), PedsQL v.4.0: Emotional Functioning

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy72.6
Week 875.3
Week 1275.7
After Radiation84.5
Off-therapy81.6

[back to top]

Patient Quality of Life (QoL), PedsQl v.4.0: Physical Functioning

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy83.2
Week 868.4
Week 1269.1
After Radiation80.8
Off-therapy85.2

[back to top]

Patient Quality of Life (QoL), PedsQL v.4.0: Psychosocial Health

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy79.3
Week 877.6
Week 1278.6
After Radiation84.3
Off-therapy84.3

[back to top]

Patient Quality of Life (QoL), PedsQL v.4.0: School Functioning

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy73.1
Week 869.5
Week 1272.6
After Radiation78.4
Off-therapy81.3

[back to top]

Patient Quality of Life (QoL), PedsQL v.4.0: Total Score

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy80.9
Week 874.4
Week 1275.3
After Radiation83.1
Off-therapy84.5

[back to top]

Patient Quality of Life (QoL), PedsQL v.4.0:Social Functioning

"Patient QOL will be measured at multiple time points to assess the patient's functioning.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy90.9
Week 888.6
Week 1288.0
After Radiation90.1
Off-therapy91.1

[back to top]

Patient Quality of Life (QoL), Symptom Distress Scale

"The patient's degree of discomfort from specific treatment-related symptoms across multiple time points.~Instrument interpretation: SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy17.3
Week 819.6
Week 1218.1
After Radiation15.1
Off-therapy14.3

[back to top]

Prognostic Factors for Treatment Failure: Age

Age was examined for the association with event-free survival (EFS) which was defined as the interval between date on study and date of relapse/disease progression, second malignant tumor, death, or last contact, whichever came first. Given only 11 events, the investigators used univariate Cox model with Score test to compute the p value for the statistical significance. (NCT00352027)
Timeframe: 5.5 (years) median follow-up with minimum 0.3 to maximum 9.4 years follow-up

Interventionevents (Number)
Stanford V Chemotherapy11

[back to top]

Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: (Echocardiogram)

Echocardiograms will be carried out on the patient at 1, 2, 5, and 10 years after therapy. Outcomes will be categorized. (NCT00352027)
Timeframe: 1, 2, 5, and 10 years post therapy

,,,
InterventionParticipants (Count of Participants)
NormalAbnormal
Year 1 Off Therapy680
Year 10 Off Therapy151
Year 2 Off Therapy571
Year 5 Off Therapy362

[back to top]

Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: (Electrocardiogram)

Electrocardiograms (EKGs) will be conducted on the patient at 1, 2, 5, and 10 years after therapy. Results will be categorized as either normal or abnormal, determined by the test outcome. (NCT00352027)
Timeframe: 1, 2, 5, and 10 years post therapy

,,,
InterventionParticipants (Count of Participants)
NormalAbnormal
Year 1 Off Therapy515
Year 10 Off Therapy106
Year 2 Off Therapy448
Year 5 Off Therapy244

[back to top]

Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: (Pulmonary Function)

Patient pulmonary function will undergo assessment at 1, 2, 5, and 10 years after therapy. Results will be categorized as either normal or abnormal, depending on the test results. (NCT00352027)
Timeframe: 1, 2, 5, and 10 years post therapy

,,,
InterventionParticipants (Count of Participants)
NormalAbnormal
Year 1 Off Therapy4620
Year 10 Off Therapy91
Year 2 Off Therapy4120
Year 5 Off Therapy2511

[back to top]

Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy: Thyroid (TSH)

For patients that received cervical radiation, TSH laboratory testing will be conducted at 1, 2, 5 and 10 years. TSH results will be categorized as Normal, Hypothyroid, Hyperthyroid, or Thyroid Nodule, depending on the test's findings. (NCT00352027)
Timeframe: 1, 2, 5, and 10 years post therapy

,,,
InterventionParticipants (Count of Participants)
NormalHypothyroidHyperthyroidThyroid Nodule
Year 1 Off Therapy60820
Year 10 Off Therapy20300
Year 2 Off Therapy541110
Year 5 Off Therapy37810

[back to top]

Local and Distant Failure for Children Treated With Tailored-field Radiation

The cumulative incidence of local and distant failure will be estimated. Effect of competing risks will be taken into account. Local failure is defined as in-field, and distant failure is defined as out-of-field. (NCT00352027)
Timeframe: from first enrollment date up to 3 years follow-up

Interventionprobability that the event occurs (Number)
Cumulative incidence of distant failure at 3 yearsCumulative incidence of local failure at 3 years
Stanford V Chemotherapy0.03750.1127

[back to top]

Prognostic Factors for Treatment Failure: Gender

Event-free survival (EFS) was calculated for the 80 eligible patients. EFS was defined as the interval between on study to relapse, second malignant tumor, or last contact (all alive) whichever came first. For those who had multiple relapses, the first one was counted. Given only 11 events, we examined individually age, gender, histology and stage for its association with EFS using Cox model. P values from Score test were computed for the statistical significance. (NCT00352027)
Timeframe: 3 years follow-up

Interventionevents (Number)
MaleFemale
Stanford V Chemotherapy56

[back to top]

Prognostic Factors for Treatment Failure: Histology

Event-free survival (EFS) was calculated for the 80 eligible patients. EFS was defined as the interval between on study to relapse, second malignant tumor, or last contact (all alive) whichever came first. For those who had multiple relapses, the first one was counted. Given only 11 events, we examined individually age, gender, histology and stage for its association with EFS using Cox model. P values from Score test were computed for the statistical significance. (NCT00352027)
Timeframe: 3 years follow-up

Interventionevents (Number)
Classical, Nodular SclerosingOther
Stanford V Chemotherapy101

[back to top]

Prognostic Factors for Treatment Failure: Stage

Ann Arbor staging classification was used to stage all patients. Stage was examined (I/II versus III) for the association with event-free survival (EFS), defined as the interval between date on study and of relapse/disease progression, second malignancy, death, or last contact, whichever came first. Given only 11 events, the investigators used univariate Cox model with Score test to compute the p value for the statistical significance. Stage NCT00352027)
Timeframe: 5.5 (years) median follow-up with minimum 0.3 to maximum 9.4 years follow-up

Interventionevents (Number)
Stage Stage ≥III
Stanford V Chemotherapy83

[back to top]

Toxicities With Grade >1

Comparison of the toxicities of intermediate risk patients treated with Stanford V chemotherapy low dose tailored-field radiation (current HOD05 protocol) to those patients on HOD99 (NCT00145600). Grading of toxicities for HOD05 and HOD99 used the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. (NCT00352027)
Timeframe: 3 years

,,,,,,,
Interventionadverse events (Number)
Alanine transaminase (ALT)Aspartate transaminase (AST)Allergic reaction/hypersensitivityConstipationFebrile neutropeniaFever (in the absence of neutropenia)GlucoseGGT (gamma-Glutamyltranspeptidase)HemoglobinHypoxiaIleus, GI (functional obstruction of bowel)Infection with Grade 3 or 4 neutrophilsInfection - OtherInfection with normal ANC or Grade 1-2 neutrophilsInfection with unknown ANCInsomniaLeukocytes (total WBC)LymphopeniaMucositis/stomatitis (functional/symptomatic)NauseaNeuropathy: motorNeuropathy: sensoryNeutrophils/granulocytes (ANC/AGC)PainPhosphatePlateletsPotassiumSodiumSyndromes - OtherThrombosis/embolism (vascular access-related)Thrombosis/thrombus/embolismVomiting
HOD05 - Grade 200000000000000000000000000000000
HOD05 - Grade 3114072012611213014122010124510211202
HOD05 - Grade 40000100060000000157000032000000010
HOD05 - Grade 500000000000000000000000000000000
HOD99 - Grade 200000000000000000000000000000001
HOD99 - Grade 3000150002002011019012119103000004
HOD99 - Grade 4000020100000000050000030100000000
HOD99 - Grade 500000000000000000000000000000000

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Physical Functioning

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Pre-therapy-2.9
Parent and Patient Scores at Week 8-2.3
Parent and Patient Scores at Week 12-1.9
Parent and Patient Scores at After Radiation-5.4
Parent and Patient Scores at Off-therapy-2

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Total Score

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 871.7
Week 1269.3
After Radiation74.5
Off-therapy80.0

[back to top]

3-year Event-free Survival (EFS) Probability

Comparison of thee-year EFS probability along with the whole EFS distributions of intermediate risk patients treated with Stanford V chemotherapy low dose tailored-field radiation to those patients on HOD99. (NCT00352027)
Timeframe: 3 years

Interventionprobability (Number)
HOD05 Participants0.887
HOD99 Participants0.844

[back to top]

3-year Event-Free Survival Probability

The survival probability for the time interval from treatment start to the time of the first failure (disease recurrence, second malignancy or death) within a 3-year time frame. (NCT00352027)
Timeframe: 3 years

Interventionprobability (Number)
Stanford V Chemotherapy0.887

[back to top]

3-year Local Failure-free Survival Probability

Comparison of the 3-year local failure-free survival probability along with the whole local failure-free survival distributions of intermediate risk patients treated with Stanford V chemotherapy low dose tailored-field radiation to those patients on HOD99. (NCT00352027)
Timeframe: 3 years

Interventionprobability (Number)
HOD05 Participants0.887
HOD99 Participants0.932

[back to top]

3-year Overall Survival (OS) Probability

Comparison of the 3-year OS probability along with the whole OS distributions of intermediate risk patients treated with Stanford V chemotherapy low dose tailored-field radiation to those patients on HOD99. (NCT00352027)
Timeframe: 3-years

Interventionprobability (Number)
HOD05 Participants1.00
HOD99 Participants0.978

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Cognitive Problems

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.46

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Communication

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.35

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Nausea

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-2.31

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Pain and Hurt

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-2.52

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Perceived Physical Appearance

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.20

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Procedural Anxiety

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-0.87

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Total Score

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.41

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Treatment Anxiety

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-0.96

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Worry

"Relationship between quality of life and symptom distress across multiple time points [completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.3.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.06

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Emotional Functioning

"Relationship between quality of life and symptom distress instruments aggregated across multiple time points [At diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.56

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Physical Functioning

"Relationship between quality of life and symptom distress instruments aggregated across multiple time points [At diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.9

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Psychosocial Health

"Relationship between quality of life and symptom distress instruments aggregated across multiple time points [At diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-0.92

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: School Functioning

"Relationship between quality of life and symptom distress instruments aggregated across multiple time points [At diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.21

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Social Functioning

"Relationship between quality of life and symptom distress instruments aggregated across multiple time points [At diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-0.79

[back to top]

Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Total Score

"Relationship between quality of life and symptom distress instruments aggregated across multiple time points [At diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy]. Generalized estimating equations (GEE) were used to examine the association between symptoms distress and QoL scores.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. SDS, higher scores indicate higher overall symptom distress with a range of 10-50." (NCT00352027)
Timeframe: 6 months after the completion of therapy

Interventionbeta coefficient (Number)
QoL Participants-1.46

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Cognitive Problems

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-1.0
Parent and Patient Scores at Week 120.14
Parent and Patient Scores at After Radiation-8.0
Parent and Patient Scores at Off-therapy-4.0

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Communication

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-0.3
Parent and Patient Scores at Week 12-3.6
Parent and Patient Scores at After Radiation-7.4
Parent and Patient Scores at Off-therapy-6.3

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Nausea

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-1.2
Parent and Patient Scores at Week 12-3.4
Parent and Patient Scores at After Radiation-3.0
Parent and Patient Scores at Off-therapy-1.1

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Pain and Hurt

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-2.0
Parent and Patient Scores at Week 12-9.5
Parent and Patient Scores at After Radiation-5.6
Parent and Patient Scores at Off-therapy-5.4

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Perceived Physical Appearance

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-2.5
Parent and Patient Scores at Week 12-9.5
Parent and Patient Scores at After Radiation-5.9
Parent and Patient Scores at Off-therapy-9.3

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Procedural Anxiety

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-0.2
Parent and Patient Scores at Week 12-9.3
Parent and Patient Scores at After Radiation-2.2
Parent and Patient Scores at Off-therapy-8.7

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Total Score

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-1.5
Parent and Patient Scores at Week 12-5.2
Parent and Patient Scores at After Radiation-4.5
Parent and Patient Scores at Off-therapy-5

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Treatment Anxiety

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-6.1
Parent and Patient Scores at Week 12-8.8
Parent and Patient Scores at After Radiation-7.9
Parent and Patient Scores at Off-therapy-6.6

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Worry

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Week 8-0.7
Parent and Patient Scores at Week 12-3.9
Parent and Patient Scores at After Radiation-2.7
Parent and Patient Scores at Off-therapy-0.5

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Emotional Functioning

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Pre-therapy-4.9
Parent and Patient Scores at Week 8-9.4
Parent and Patient Scores at Week 12-8.0
Parent and Patient Scores at After Radiation-10.8
Parent and Patient Scores at Off-therapy-1.7

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Psychosocial Health

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Pre-therapy-2.8
Parent and Patient Scores at Week 8-6.4
Parent and Patient Scores at Week 12-6.3
Parent and Patient Scores at After Radiation-5.6
Parent and Patient Scores at Off-therapy-3.3

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: School Functioning

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Pre-therapy1.3
Parent and Patient Scores at Week 8-5.3
Parent and Patient Scores at Week 12-4.1
Parent and Patient Scores at After Radiation-3.4
Parent and Patient Scores at Off-therapy-4.3

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Social Functioning

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Pre-therapy-5.3
Parent and Patient Scores at Week 8-5.7
Parent and Patient Scores at Week 12-7.4
Parent and Patient Scores at After Radiation-5.0
Parent and Patient Scores at Off-therapy-3.3

[back to top]

Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Total Score

"Assess and compare the patient reported and parent proxy quality of life across multiple time points. Reported mean differences were calculated as parent score minus patient score.~Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. Reported mean differences were calculated as: parent score - patient score." (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Parent and Patient Scores at Pre-therapy-2.9
Parent and Patient Scores at Week 8-4.8
Parent and Patient Scores at Week 12-4.8
Parent and Patient Scores at After Radiation-5
Parent and Patient Scores at Off-therapy-2.9

[back to top]

Disease Failure Rate Within Radiation Fields

Defined as disease that recurs in the initially involved nodal region within the field of irradiation. The disease failure rate within the radiation fields will be estimated with a 95% confidence interval using appropriate methods (e.g., estimate cumulative incidence in the presence of competing risks). (NCT00352027)
Timeframe: 3 years

Interventionproportion of participants (Number)
Stanford V Chemotherapy0.1125

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Cognitive Problems

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 877.6
Week 1279.5
After Radiation78.6
Off-therapy79.9

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Communication

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 879.2
Week 1280.4
After Radiation80.3
Off-therapy84.3

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Nausea

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 861.2
Week 1257.4
After Radiation72.2
Off-therapy83.2

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Pain and Hurt

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 861.2
Week 1261.8
After Radiation73.1
Off-therapy82.7

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Perceived Physical Appearance

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 874.9
Week 1272.2
After Radiation73.7
Off-therapy76.3

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Procedural Anxiety

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 870.0
Week 1260.0
After Radiation63.1
Off-therapy73.8

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Treatment Anxiety

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 881.9
Week 1272.6
After Radiation78.5
Off-therapy81.8

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Worry

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.3.0, higher scores indicate lower problems with a range of 0-100. (NCT00352027)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Week 870
Week 1269.2
After Radiation71.9
Off-therapy78.7

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Emotional Functioning

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy67.7
Week 865.4
Week 1268.1
After Radiation73.0
Off-therapy82.0

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Physical Functioning

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy79.8
Week 865.3
Week 1267.3
After Radiation73.6
Off-therapy84.6

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Psychosocial Health

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy76.2
Week 871.0
Week 1274.1
After Radiation79.0
Off-therapy88.0

[back to top]

Parent Proxy Quality of Life (QoL), PedsQL v.4.0: School Functioning

Parent's assessment of child's functioning over multiple time points. Instrument interpretation: PedsQL v.4.0, higher scores indicate better HRQOL with a range of 0-100. (NCT00352027)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), completion of radiation (T4), and 3-6 months (T5) after the completion of therapy

Interventionunits on a scale (Mean)
Pre-therapy74.4
Week 862.8
Week 1270.8
After Radiation75.6
Off-therapy78.9

[back to top]

Event Free Survival Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00352534)
Timeframe: 4 years

InterventionProbability (Number)
Very Low Risk0.88
Standard Risk, Stage I or II, With LOH0.87
Standard Risk, Stage III0.88

[back to top]

Incidence of Contralateral Kidney Lesions

Number of contralateral kidney lesions during follow-up. (NCT00352534)
Timeframe: During follow-up

InterventionLesions (Number)
Very Low Risk1

[back to top]

Incidence of Renal Failure

Number of renal failures defined as requiring dialysis or renal transplant as determined by low GFR during follow-up (NCT00352534)
Timeframe: During follow-up

InterventionIncidents (Number)
Very Low Risk0

[back to top]

Overall Survival (OS) Probability

Probability of being alive after 4 years in the study. (NCT00352534)
Timeframe: 4 years

InterventionProbability (Number)
Very Low Risk1.00
Standard Risk, Stage I or II, With LOH1.00
Standard Risk, Stage III0.97

[back to top]

Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy

Adverse events are reported for patients receiving concurrent irinotecan hydrochloride and radiotherapy. (NCT00354744)
Timeframe: From enrollment to up to 2 years

Interventionpercentage of patients (Number)
Course 1Course 2Course 3Course 4
High_Risk_Rhabdomyosarcoma53.368.479.355.7

[back to top]

Percentage of Patients Event Free at 4 Years Following Study Entry

Event-free survival: Time to recurrence, second malignancy, or death as a first event, estimated from a Kaplan Meier curve (NCT00354744)
Timeframe: 4 years

InterventionPercentage of patients (Number)
High_Risk_Rhabdomyosarcoma36

[back to top]

Number of Patients With Complete or Partial Response Assessed by RECIST Criteria

"Volumetric measurements of the primary tumor using an elliptical model (0.5 x the product of the 3 largest perpendicular diameters) to assess response to neoadjuvant therapy. The RECIST (Response Evaluation Criteria in Solid Tumors) from the NCI will be used for assessment of the size of measurable metastases, including nodal metastases. Primary Tumor Measurement: Technical guidelines for cross-sectional imaging computed tomography (CT) slice thickness should be 5mm or less and the diameter of the measurable mass should be at least twice the reconstructed slice thickness. Smaller masses are considered detectable, but will be counted as non-measurable. Complete Response (CR): Complete disappearance of the tumor confirmed at >4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Progressive Disease (PD): At least 40% increase in tumor volume compared to the smallest volume obtained since the beginning." (NCT00354744)
Timeframe: Protocol week 6 evaluation

Interventionpercentage of participants (Number)
High_Risk_Rhabdomyosarcoma63

[back to top]

Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15

4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study) (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
% Change in SUVmax From Baseline to Week 15 < 40%0.6667
% Change in SUVmax From Baseline to Week 15 >= 40%0.5686

[back to top]

Acute and Late Effects of VAC as Delivered on This Study to D9803 VAC

The toxicity rates will be estimated for each phase and course of treatment, and will be compared to the fixed rates under D9803 using one-sided lower confidence intervals for a single proportion without adjustment for multiple comparisons. (NCT00354835)
Timeframe: Up to 43 weeks

,
Interventionparticipants (Number)
AnemiaFebrile NeutropeniaNausea or HepatopathyPlatelet Count DecreasedVomiting
VAC (Weeks 1-15)58306279
VAC (Weeks 31 - 43)54171632

[back to top] [back to top]

Incidence of Toxicity

Grade 3 or 4 nausea, diarrhea, dehydration, radiation dermatitis, mucositis due to radiation. Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3. (NCT00354835)
Timeframe: Up to 15 weeks

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.2072
VAC Alternating With Vincristine, Irinotecan (VI)0.3673

[back to top]

Incidence of Bladder Dysfunction

Number of patients with a summary score greater than 8.5 (NCT00354835)
Timeframe: 3-6 years after enrollment

InterventionParticipant (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)2
VAC Alternating With Vincristine, Irinotecan (VI)1

[back to top]

Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison

Compare 4-year EFS using eligible participants only to the historical rate of 0.65 with IRSI-V. The 4-year EFS is probability of no relapse, secondary malignancy, or death after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.65. (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6255

[back to top]

Event Free Survival (EFS) by PAX Status

(NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
PAX30.51
PAX70.66

[back to top]

Event Free Survival (EFS)

Probability of no relapse, secondary malignancy, or death after 4 year in the study (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6255
VAC Alternating With Vincristine, Irinotecan (VI)0.5874

[back to top]

Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 4

4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study). (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
% Change in SUVmax From Baseline to Week 4 < 40%0.2857
% Change in SUVmax From Baseline to Week 4 >= 40%0.6364

[back to top]

Response Rate (RR)

Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at > 4 weeks; Partial Response (PR): At least 64% decrease in volume compared to the baseline; Overall Response (OR) = CR + PR. (NCT00354835)
Timeframe: Reporting Period 1 (Weeks 1 - 15)

InterventionProportion (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6667
VAC Alternating With Vincristine, Irinotecan (VI)0.6726

[back to top]

Overall Survival (OS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison

Compare 4-year OS using eligible participants only to the historical rate of 0.70 with IRSI-V. The 4-year OS is probability of being alive after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.70. (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.7293

[back to top]

Overall Survival (OS)

Probability of being alive after 4 years in the study. (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.7293
VAC Alternating With Vincristine, Irinotecan (VI)0.7223

[back to top]

Local Failure

Compare 2-year local failure rate to the historical rate of 0.13 with IRSI-V. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.13. (NCT00354835)
Timeframe: 2 years

InterventionProportion of participants (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.1757

[back to top]

Objective Response Rate (ORR)

Objective response rate (ORR) defined as the proportion of participants experiencing a Complete Response (CR) or Partial Response to a regimen of SGN-3- + CHOP using International Workshop Response Criteria (IWG) for Non-Hodgkin's Lymphomas (NHL). The IWG criteria (Cheson et al 2007) for a CR is a complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. A PR is at least a 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses, no increase should be observed in the size of other nodes, liver or spleen, and no new sites of disease should be observed. (NCT00365274)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
Complete ResponsePartial Response
SGN-30 + Combination Chemotherapy8317

[back to top]

Response Rate in Patients Treated With Rituximab-CHOPbortezomib Induction Therapy (R-CHOP-V) Followed by Bortezomib Maintenance Therapy(VM).

Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. (NCT00376961)
Timeframe: At the time of restaging (between Cycles 6 and 7), every 6 months during Cycles 7-14, and at the end of protocol treatment

Interventionparticipants (Number)
Complete ResponsePartial ResponseUnconfirmed Complete ResponseUnconfirmed Partial ResponseNo ResponseAssessment Inadequate
R-CHOP-V Followed by VM1716131414

[back to top]

2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM)

Measured from date of registration to date of first observation of relapsed or progressive disease, or death due to any cause. (NCT00376961)
Timeframe: 0-2 years

Interventionpercentage of participants (Number)
R-CHOP-V Followed by VM62

[back to top] [back to top]

2-year Overall Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM)

Measured from date of registration to date of death due to any cause or last contact (NCT00376961)
Timeframe: 0-2 years

Interventionpercentage of participants (Number)
R-CHOP-V Followed by VM85

[back to top]

Event Free Survival Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study (NCT00379340)
Timeframe: At 4 years

InterventionProbability of EFS at 4 years (Number)
Stage III/IV With LOH 1p and 16q Treated With Regimen M0.90
Stage IV With Non-lung Disease Treated With Regimen M0.73

[back to top]

Event Free Survival Associated With the Burden of Pulmonary Metastatic Disease

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: At 4 years

InterventionProbability (Number)
Lung Mets <= 1cm0.88
Lung Mets > 1cm0.82

[back to top]

Event Free Survival (EFS) Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: At 4 years

InterventionProbability of EFS at 4 years (Number)
Stage IV and Slow Incomplete Response (SIR) of Lung Metastases0.89

[back to top]

Event Free Survival Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: 4 years

InterventionProbability (Number)
Stage IV and Rapid Complete Response (RCR) of Lung Metastases0.79

[back to top]

Number of Patients Who Experienced Adverse Events

(NCT00379574)
Timeframe: 6 months

Interventionparticipants (Number)
Bortezomib + CHOP Every 2 Weeks49

[back to top]

Number of Patients Who Achieved Complete Response

All patients,9 patients of phase I study and 40 patietns in phase II stuay, were assessed with International Working Group response criteria assessed by CT; Complete Response (CR), Disappearance of all detectable clinical and radiographic evidence of disease and diappearance of all disease-related symptoms. (NCT00379574)
Timeframe: 14 weeks

Interventionparticipants (Number)
Bortezomib + CHOP Every 2 Weeks32

[back to top]

Adjusted Event Free Survival

Adjusted percentage of patients who were event free at 3 years. For patients who received matched donor SCT, EFS was adjusted to start from the actual SCT date. For patients who did not undergo SCT, EFS was adjusted to start from median time to SCT based on patients who received matched related SCT (where patients who had events prior to SCT date were excluded from the calculation of median time to SCT). (NCT00381680)
Timeframe: 3 years

Interventionadjusted percentage of participants (Number)
Received SCTDid not receive SCT
Regimen A: Standard Vincristine Dosing82.264.2

[back to top]

Frequency and Severity of Adverse Effects

Percentage of patients who developed at least 1 episode of grade 2 to 4 neuropathy. (NCT00381680)
Timeframe: Up to 107 weeks

Interventionpercentage of participants (Number)
CC or CT genotypeHigh-risk CEP72 genotype (TT at rs924607)
All Patients17.344.4

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1

Percentage of patients who had minimal residual disease (MRD) < 0.01% among those with isolated BM or combined BM relapse >= 36 months and had successful MRD determinations at End Block 1 (NCT00381680)
Timeframe: End of Block 1 (35 days) of Induction therapy

Interventionpercentage of participants (Number)
Regimen A50.8
Regimen B41.5

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3

Percentage of patients who had minimal residual disease (MRD) < 0.01% among those with isolated BM or combined BM relapse >= 36 months and had successful MRD determinations at End Block 3. (NCT00381680)
Timeframe: End of Block 3 (105 days) of Induction therapy

Interventionpercentage of participants (Number)
Regimen A81.4
Regimen B88.9

[back to top]

Event Free Survival (EFS)

Percentage of patients who were event free at 3 years among those with isolated BM or combined BM relapse >= 36 months. (NCT00381680)
Timeframe: 3 years

,
Interventionpercentage of participants (Number)
MRD < 0.01% BL1MRD >= 0.01% BL1MRD < 0.01% BL3MRD >= 0.01% BL3
Regimen A88.560.083.861.5
Regimen B77.346.283.333.3

[back to top]

Event Free Survival. EFS

Percentage of patients who were event free at 3 years among those on Standard VCR dosing who did not undergo Hematopoietic Stem Cell Transplant (SCT). (NCT00381680)
Timeframe: 3 years after enrollment

Interventionpercentage of participants EFS at 3 yrs3 (Number)
Regimen A: Standard Vincristine Dosing66.0

[back to top]

Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .

(NCT00389818)
Timeframe: After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation

Interventionproportion of patients (Number)
DR-COP0.475

[back to top]

The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 9+/-3 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported. (NCT00392327)
Timeframe: 6 - 12 months post diagnosis

InterventionScore on a scale (Mean)
Regimen A (Medulloblastoma Patients)96.6
Regimen B (Medulloblastoma Patients)89.1
Regimen C (Medulloblastoma Patients)83.5
Regimen D (Medulloblastoma Patients)94.8

[back to top]

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 30+/-6 Months Post Diagnosis for SPNET Patients

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. Mean and standard deviation of MI were calculated and reported. (NCT00392327)
Timeframe: 24 - 36 months post diagnosis

InterventionT-Score (Mean)
Regimen A (SPNET Patients)53.5
Regimen B (SPNET Patients)75.5
Regimen C (SPNET Patients)64.5
Regimen D (SPNET Patients)53.5

[back to top]

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 60+/-12 Months Post Diagnosis for SPNET Patients

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. Mean and standard deviation of MI were calculated and reported. (NCT00392327)
Timeframe: 48 - 72 months post diagnosis

InterventionT-Score (Mean)
Regimen A (SPNET Patients)56.0
Regimen B (SPNET Patients)64.0
Regimen C (SPNET Patients)71.5
Regimen D (SPNET Patients)53.7

[back to top]

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. Mean and standard deviation of MI were calculated and reported. (NCT00392327)
Timeframe: 6 - 12 months post diagnosis

InterventionT-Score (Mean)
Regimen A (Medulloblastoma Patients)50.9
Regimen B (Medulloblastoma Patients)50.2
Regimen C (Medulloblastoma Patients)50.8
Regimen D (Medulloblastoma Patients)47.5

[back to top]

Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for SPNET Patients

Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction. Mean and standard deviation of MI were calculated and reported. (NCT00392327)
Timeframe: 6 - 12 months post diagnosis

InterventionT-Score (Mean)
Regimen A (SPNET Patients)53.8
Regimen B (SPNET Patients)66.7
Regimen C (SPNET Patients)46.1
Regimen D (SPNET Patients)64.3

[back to top]

Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma

The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals. Data below represents all molecular subgroups combined. (NCT00392327)
Timeframe: Up to 5 years

InterventionPercent Probability (Number)
Regimen A (Medulloblastoma Patients)57.5
Regimen B (Medulloblastoma Patients)65.3
Regimen C (Medulloblastoma Patients)60.3
Regimen D (Medulloblastoma Patients)70.9

[back to top]

Percent Probability of Event-free Survival (EFS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)

The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals. (NCT00392327)
Timeframe: Up to 5 years

InterventionPercent Probability (Number)
Regimen A (SPNET Patients)52.2
Regimen B (SPNET Patients)52.6
Regimen C (SPNET Patients)19
Regimen D (SPNET Patients)63

[back to top]

Percent Probability of Overall Survival (OS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)

The Kaplan-Meier method will be used to estimate 5-year OS, defined as the time from study enrollment to death from any cause, or to date of last contact. (NCT00392327)
Timeframe: Up to 5 years

InterventionPercent Probability (Number)
Regimen A (SPNET Patients)60.9
Regimen B (SPNET Patients)57.9
Regimen C (SPNET Patients)35.3
Regimen D (SPNET Patients)77.0

[back to top]

The Estimated Full-scale IQ (FSIQ) at 30+/-6 Months Post Diagnosis for SPNET Patients

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 30+/-6 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported. (NCT00392327)
Timeframe: 24 - 36 months post diagnosis

InterventionScore on a scale (Mean)
Regimen A (SPNET Patients)83.3
Regimen B (SPNET Patients)57.5
Regimen C (SPNET Patients)83.7
Regimen D (SPNET Patients)88.5

[back to top]

Tumor Response to Radiation Therapy for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)

Percentages of patients with responses after radiation therapy (induction therapy) are reported with 95% confidence intervals. Complete and partial responses were considered responses. SPNET is no longer recognized by WHO (World Health Organization) as a disease entity. Additional trial information can be found under PubMed® # 30332335. (NCT00392327)
Timeframe: 12 weeks after treatment initiation

Interventionpercentage of patients (Number)
Regimen A (SPNET Patients)69.9
Regimen B (SPNET Patients)83.3
Regimen C (SPNET Patients)66.7
Regimen D (SPNET Patients)73.7

[back to top]

The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for SPNET Patients

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 9+/-3 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported. (NCT00392327)
Timeframe: 6 - 12 months post diagnosis

InterventionScore on a scale (Mean)
Regimen A (SPNET Patients)84.6
Regimen B (SPNET Patients)80.3
Regimen C (SPNET Patients)99.3
Regimen D (SPNET Patients)90.6

[back to top]

Tumor Response to Radiation Therapy for Patients With Medulloblastoma

Percentages of patients with responses after radiation therapy (induction therapy) are reported with 95% confidence intervals. Complete and partial responses were considered responses. (NCT00392327)
Timeframe: 12 weeks after treatment initiation

Interventionpercentage of patients (Number)
Regimen A (Medulloblastoma Patients)75.9
Regimen B (Medulloblastoma Patients)78.8
Regimen C (Medulloblastoma Patients)72.9
Regimen D (Medulloblastoma Patients)81.8

[back to top]

Percent Probability of Overall Survival (OS) for Patients With Medulloblastoma

The Kaplan-Meier method will be used to estimate 5-year OS, defined as the time from study enrollment to death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals. Data below represents all molecular subgroups combined. (NCT00392327)
Timeframe: Up to 5 years

InterventionPercent Probability (Number)
Regimen A (Medulloblastoma Patients)66.0
Regimen B (Medulloblastoma Patients)75.9
Regimen C (Medulloblastoma Patients)69.9
Regimen D (Medulloblastoma Patients)81.6

[back to top]

The Estimated Full-scale IQ (FSIQ) at 60+/-12 Months Post Diagnosis for SPNET Patients

Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 60+/-12 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported. (NCT00392327)
Timeframe: 48 - 72 months post diagnosis

Interventionscore on a scale (Mean)
Regimen A (SPNET Patients)94.8
Regimen B (SPNET Patients)48.0
Regimen C (SPNET Patients)87.0
Regimen D (SPNET Patients)79.7

[back to top]

Overall Survival (OS) at 1 Year

(NCT00392834)
Timeframe: 1 year post treatment

InterventionCumulative proportion surviving at 1 yr (Number)
Regimen A (R-CODOX-M Chemotherapy)1.0
Regimen B (Rituximab and IVAC Chemotherapy)0.82

[back to top]

Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

Overall Survival (OS) of patients with Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen. OS is defined from the first dose of study drug to the time of death for any reason. (NCT00392990)
Timeframe: At 2 years from treatment initiation Median follow up 34 months (range 15-45)

Interventionpercentage of patients alive (Number)
High Risk - Treated With Alternating R-CODOX-M/R-IVAC81
Low Risk - Treatment With 3 Cycles of R-CODOX-M100

[back to top]

Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate)

"Adverse events (AE) graded as either 3 or 4 and determined to be at least possibly related to study treatment will be collected in patients Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen to assess the safety and toxicity profile of the addition of rituximab, subsitution of adriamycin for doxil and lower dose of methotrexate. AEs will be assessed as follows at the following time points: At the end of each cycle or monthly whichever is less frequent and 30 days post last dose of study treatment for a maximum of 3 cycles for regimen A and 4 cycles for regimen B and up to 12 months.~In general AEs will be assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v 3.0). In general adverse events (AEs) will be graded according to the following:~Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE" (NCT00392990)
Timeframe: After each cycle or monthly (whichever is less frequent), 30 days post last dose. Treatment duration was at a median of 13 weeks (range 11-20) for high-risk patients and 10 weeks (range 9-12) for low-risk patients.

,
Interventionparticipants (Number)
Anemia : Grade 3Anemia : Grade 4Neutropenia : Grade 3Neutropenia : Grade 4Thrombocytopenia : Grade 3Thrombocytopenia : Grade 4Mucositis : Grade 3Mucositis : Grade 4Infection : Grade 3Infection : Grade 4Elevated Transaminases : Grade 3Elevated Transaminases : Grade 4Fever (Neutropenic) : Grade 3Fever (Neutropenic) : Grade 4Low Phosphate : Grade 3Low Phosphate : Grade 4Sodium Abnormalities : Grade 3Sodium Abnormalities : Grade 4Hyperglycemia : Grade 3Hyperglycemia : Grade 4Hypoalbuminemia : Grade 3Hypoalbuminemia : Grade 4Hypokalemia : Grade 3Hypokalemia : Grade 4Cardiac : Grade 3Cardiac : Grade 4Diarrhea : Grade 3Diarrhea : Grade 4Elevated Creatinine : Grade 3Elevated Creatinine : Grade 4Nausea/Vomiting : Grade 3Nausea/Vomiting : Grade 4Low Blood Pressure : Grade 3Low Blood Pressure : Grade 4Rash : Grade 3Rash : Grade 4Edema : Grade 3Edema : Grade 4Low Magnesium : Grade 3Low Magnesium : Grade 4
High Risk - Treated With Alternating R-CODOX-M/R-IVAC131561137380604050401540103020201010101010
Low Risk - Treatment With 3 Cycles of R-CODOX-M3022122010203010203000200000000000000000

[back to top]

Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

"Response Rate is defined as combined number of patients with Complete Remission (CR) Complete Remission undetermined (Cru) and Partial Remission (PR) for patients with Burkitt's and Burkitt-like Lymphoma/Leukemia. Response will be measured by CT scans following treatment completion and assessed using Response Criteria for Non-Hodgkin's Lymphoma where:~CR=complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms.~CRu=same as above but allowing for 75% decrease in lymph node masses and indeterminate or normal bone marrow.~PR=50% decrease in SPD of the six largest dominant nodes or nodal masses with no increase in size or other nodes, liver, spleen and no new sites of disease." (NCT00392990)
Timeframe: After two cycles of treatment and at completion of treatment (4 cycles for high risk and 3 cycles for low risk) up to approximately 20 weeks.

,
Interventionpercentage of patients (Number)
ORR after two cycles of treatmentORR at completion of treatment
High Risk - Treated With Alternating R-CODOX-M/R-IVAC100100
Low Risk - Treatment With 3 Cycles of R-CODOX-M100100

[back to top]

Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

Progression Free Survival (PFS) will be defined from the first dose of study drug to the first documentation of progressive disease or death for any reason. Patients that are lost to follow-up before progression will be censored at the point of last documentation of not experiencing the event. (NCT00392990)
Timeframe: At 2 years from treatment initiation. Median follow up 34 months (range 15-45)

Interventionpercentage of patients progression free (Number)
High Risk - Treated With Alternating R-CODOX-M/R-IVAC76
Low Risk - Treatment With 3 Cycles of R-CODOX-M100

[back to top]

Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.

Interventionpercentage of participants (Number)
Intramuscular Native E Coli L-asparaginase (IM-EC)71
Intravenous PEG-asparaginase (IV-PEG)99

[back to top]

Induction Infection Toxicity Rate

Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy. (NCT00400946)
Timeframe: Assessed daily during remission induction days 4-32.

Interventionpercentage of participants (Number)
Overall26

[back to top]

5-Year Disease-Free Survival by Bone Marrow Day 18 Status

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
M1 Day 18 Bone Marrow Status.89
M2/M3 Day 18 Bone Marrow Status.78
Hypocellular Day 18 Bone Marrow Status.88

[back to top]

Post-Induction Nadir Serum Asparaginase Activity Level

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.

,
InterventionIU/mL (Mean)
Week 5 NSAA LevelWeek 11 NSAA LevelWeek 17 NSAA LevelWeek 23 NSAA LevelWeek 29 NSAA Level
Intramuscular Native E Coli L-asparaginase (IM-EC)0.1290.1430.1590.1800.123
Intravenous PEG-asparaginase (IV-PEG)0.7260.7730.7870.7570.806

[back to top]

Induction Therapeutic Nadir Serum Asparaginase Activity Rate

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.

Interventionpercentage of participants (Number)
Day 4 NSAA RateDay 11 NSAA RateDay 18 NSAA RateDay 25 NSAA Rate
Overall97968712

[back to top]

Induction Serum Asparaginase Activity Level

Serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.

InterventionIU/mL (Median)
Day 4 NSAA LevelDay 11 NSAA LevelDay 18 NSAA LevelDay 25 NSAA Level
Overall.694.505.211.048

[back to top]

5-Year Disease-Free Survival

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
Intramuscular Native E Coli L-asparaginase (IM-EC).89
Intravenous PEG-asparaginase (IV-PEG).90

[back to top] [back to top]

5-Year Disease-Free Survival by MRD Day 32 Status

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
Low Day 32 MRD Level.79
High Day 32 MRD Level.90

[back to top]

5-year Disease-Free Survival by CNS Directed Treatment Group

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
CNS-1.89
CNS-2.89
CNS-31.00
Traumatic Tap With Blasts.84
Traumatic Tap Without Blasts.87

[back to top]

Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction

Interventionpercent probability (Number)
Standard RiskHigh Risk
ARM I (Combination Chemotherapy)87.485.1

[back to top]

Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction

Interventionpercent probability (Number)
High RiskInduction Failure
ARM II (Combination Chemotherapy)85.0100

[back to top]

Cumulative Incidence of CNS Relapse for T-ALL by Risk Group

Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

,
Interventionpercent probability (Number)
Low RiskIntermediate RiskHigh Risk
ARM I (Combination Chemotherapy)1.851.163.64
ARM III (Combination Chemotherapy)1.929.16.52

[back to top]

Cumulative Incidence of CNS Relapse for T-ALL by Risk Group

Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

,
Interventionpercent probability (Number)
Intermediate RiskHigh Risk
ARM II (Combination Chemotherapy)1.080
ARM IV (Combination Chemotherapy)0.853.45

[back to top]

Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I (Combination Chemotherapy)89.01
ARM II (Combination Chemotherapy)90.53
ARM III (Combination Chemotherapy)78.07
ARM IV (Combination Chemotherapy)86.46

[back to top]

Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I and ARM III (Combination Chemotherapy)82.96
ARM II and ARM IV (Combination Chemotherapy)88.30

[back to top]

Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I and ARM II (Combination Chemotherapy)91.45
ARM III and ARM IV (Combination Chemotherapy)85.78

[back to top]

Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)

Disease-free survival defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, remission death) or date of last contact for those who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I (Combination Chemotherapy)91.76
ARM II (Combination Chemotherapy)90.53
ARM III (Combination Chemotherapy)86.06
ARM IV (Combination Chemotherapy)84.89

[back to top]

Palonosetron Response Rate in the 10 Day Study Cycle

Number of participants with dose of palonosetron who experienced response (no emesis) during acute and delayed time period of the study (10 days) divided by number of participants. Complete response defined as no emesis and no rescue medicines in 10 days from the start of chemotherapy in the first chemotherapy cycle. (NCT00410488)
Timeframe: 10 days

Interventionpercentage of participants (Number)
Palonosetron - 1 Dose31.25
Palonosetron - 3 Doses50

[back to top]

2-year Progression-free Survival (PFS)

PFS for patients who received maintenance rituximab or ASCT after VcR-CVAD induction is defined as time from start of maintenance rituximab or ASCT to earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored. (NCT00433537)
Timeframe: Assessed every 6 months for 5 years, and then yearly thereafter.

Interventionprobability (Number)
VcR-CVAD Induction Followed by Maintenance Rituximab0.79
VcR-CVAD Induction Followed by ASCT0.76

[back to top]

3-year Overall Survival (OS)

OS for patients who received maintenance rituximab or ASCT after VcR-CVAD induction is defined as time from start of maintenance rituximab or ASCT to death. Patients alive at last follow-up were censored. (NCT00433537)
Timeframe: Assessed every 6 months for 5 years, and then yearly thereafter.

Interventionprobability (Number)
VcR-CVAD Induction Followed by Maintenance Rituximab0.91
VcR-CVAD Induction Followed by ASCT0.96

[back to top]

Complete Response (CR) Rate

Number of eligible, treated participants who achieve complete response. Response criteria are based upon the criteria from the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Complete response is defined as complete disappearance of all detectable clinical evidence of disease, and disease-related symptoms if present prior to therapy. (NCT00433537)
Timeframe: Assessed after VcR-CVAD cycles 2, 4, and 6.

Interventionproportion (Number)
VcR-CVAD Induction0.68

[back to top]

Best Confirmed Disease Response

The primary efficacy analysis was based on the best response obtained during the treatment period according to the European Group for Blood and Marrow Transplantation (EBMT) criteria as assessed by the investigator. The best confirmed response was defined as 2 separate and consecutive evaluations of response, at least 6 weeks apart (for progressive disease [PD], 1 to 3 weeks apart). The ordering of the responses was: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and PD. CR was the best response and the poorest response was PD. (NCT00441168)
Timeframe: every 28 days during treatment period for up to 6 to 8 cycles

,
Interventionparticipants (Number)
CRPRResponse Rate (CR + PR)MROverall Response (CR + PR + MR)NCPDUnknown/Unable to Assess
PAD Treatment16707114
VAD Treatment05527314

[back to top]

Best Reported Disease Response

The primary efficacy analysis was based on the best response obtained during the treatment period according to the EBMT criteria as assessed by the investigator. The ordering of the responses was: CR, PR, MR, NC and PD. CR was the best response and the poorest response was PD. (NCT00441168)
Timeframe: every 28 days during treatment period for up to 6 to 8 cycles

,
Interventionparticipants (Number)
CRPRResponse Rate (CR + PR)MROverall Response (CR + PR + MR)NCPDUnknown/Unable to Assess
PAD Treatment347310300
VAD Treatment16729501

[back to top]

Duration of Response (DOR)

DOR was defined as the duration from the date of the best confirmed response for subjects who achieved CR or PR to the date of first documented evidence of PD (or relapse for subjects who experienced CR) over the duration of the study. DOR = ([Date of PD or date of censoring - Date of best response]+1)/30.44. (NCT00441168)
Timeframe: every 28 days during treatment period for up to 6 to 8 cycles

,
Interventionmonths (Number)
patient 1patient 2patient 3patient 4patient 5patient 6
PAD Treatment2.837.695.526.574.967.42
VAD Treatment1.686.183.715.424.73NA

[back to top]

Number of Participants From Whom Fixed Tissue Samples Were Collected for Future Studies.

Number of participants from whom paraffin-embedded DLBCL tissue samples were collected for future studies. (NCT00450385)
Timeframe: Baseline

InterventionParticipants (Count of Participants)
R-CHOP57

[back to top]

Progression-free Survival Rate

Percentage of participants achieving progression-free survival at 1, 3 and 5 years after the start of protocol therapy, based upon the International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL). Progression is defined as a ≥ 50% increase from nadir in the product of the two largest perpendicular diameters (PPD-size) of any previously identified abnormal node, or appearance of any new lesion. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
1 year progression-free survival3 year progression-free survival5-year progression-free survival
R-MACLO-IVAM-T917869

[back to top]

Response Rate

Percentage of participants achieving complete response (CR) to protocol therapy according to International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL) using the CT imaging method. Patients were classified by best tumor response; CR was defined as normalization of the lactate dehydrogenase (LDH), complete disappearance of disease-related symptoms and lymph nodes, and clearance of lymphoma from involved organs; complete response unconfirmed (CRu) as a residual lymph node greater than 1.5 cm in greatest transverse diameter that had regressed by more than 75% or an indeterminate bone marrow examination; partial response (PR) as greater than 50% reduction in the involved lymph nodes, or disappearance of the involved lymph nodes but persistent bone marrow involvement; relapse/progression as new or increased lymph nodes, organomegaly, or reappearance of bone marrow involvement. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
R-MACLO-IVAM-T100

[back to top]

Number of Patients Experiencing Adverse Events.

Number of patients experiencing adverse events during the course of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years

Interventionparticipants (Number)
R-MACLO Cycles22
R-IVAM Cycles22
Thalidomide Therapy19

[back to top]

Overall Survival Rate

Percentage of participants who are alive up to five years after receipt of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
1-year rate overall survival Rate2-year overall survival Rate3-year overall survival rate4-year overall survival rate5-year overall survival rate
R-MACLO-IVAM-T9696968787

[back to top]

Overall Survival (OS)

OS is the elapsed time from the date of study enrollment (baseline) to the date of death from any cause. For participants not known to have died as of the data cutoff date, OS was censored at the last contact date or last date known to be alive, whichever was later. (NCT00451178)
Timeframe: Baseline to death from any cause (up to 55 months)

Interventionmonths (Median)
R-CHOP and EnzastaurinNA
R-CHOPNA

[back to top]

Event-Free Survival (EFS)

EFS is the elapsed time from the date of randomization to the first date of objectively-determined PD, institution of a new anticancer treatment (other than maintenance therapy), or death from any cause. PD was assessed according to International Working Group recommendations (Cheson et al. 1999). PD: Enlarging liver/spleen nodules, new or increased lymph nodes/masses and reappearance of bone marrow infiltrate. For participants not known to have died as of the data cut-off date, who did not have objectively determined disease progression, and who were not treated with a new anticancer treatment, EFS was censored at the date of the last objectively determined disease-free assessment. (NCT00451178)
Timeframe: Randomization to measured PD, start of new therapy, or death from any cause (up to 55 months)

Interventionmonths (Median)
R-CHOP and Enzastaurin36.2
R-CHOP22.6

[back to top]

Percentage of Participants With Complete Response (CR/CRu) and/or Post-Baseline PET-Negative Scan (Concordance Between Response and PET Scan)

Lesion response was assessed according to International Working Group recommendations (Cheson et al. 1999). CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow must be negative if positive at baseline. Normalization of markers. CRu does not qualify for CR above, due to a residual nodal mass or an indeterminate bone marrow. Percentage of participants with CR/CRu and/or PET-negative scan=(Number of participants with complete response and/or PET-negative scan at Cycle 6)/(Number of participants with a PET-positive scan at baseline)*100. (NCT00451178)
Timeframe: Cycle 6 (21 days/cycle)

,
Interventionpercentage of participants (Number)
CR/CRu and PET-Negative Post-BaselineCR/CRu or PET-Negative Post-Baseline
R-CHOP25.643.6
R-CHOP and Enzastaurin26.853.6

[back to top]

PFS of Participants With High or Low Expression of Protein Biomarkers and Correlation of Biomarkers to PFS

Reported is PFS of participants (pts) with high or low biomarker expression levels. PFS: time from randomization to first date of PD/death from any cause. PD assessed according to International Working Group recommendations (Cheson et al. 1999). PD: Enlarging liver/spleen nodules, new/increased lymph node/masses and reappearance of bone marrow infiltrate. For pts who had subsequent anticancer therapy, PFS censored at date of last assessment prior to subsequent therapy. Biomarkers and number of pts censored: EIF4EBP1 Cytoplasm (C) 4,3,7,3; EIF4EBP1 Nucleus (N) 0,2,11,4; EIF4E C 5,2,6,4; EIF4E N 0,0,11,6; HDAC2 N 5,1,5,5; PCREB N 5,3,6,4; PEIF3746 C 4,2,7,4; PEIF3746 N 5,2,6,4; PEIFS209 C 5,2,5,4; PEIFS65 N 7,2,4,4; PEIFT70 C 5,2,6,4; PEIFT70 N 6,4,5,2; P GSK3B C 7,3,4,3; PKCb2 C 4,3,7,3; PS6 C 9,4,1,1; PTEN C 5,2,6,4; PTEN N 3,0,8,6. Correlation of biomarkers with PFS (statistical analyses) reported if high expression groups combined and low expression groups combined each had ≥10 pts. (NCT00451178)
Timeframe: Randomization to measured PD or death from any cause (up to 55 months)]

,,
Interventionmonths (Median)
Marker: EIF4EBP1 CytoplasmMarker: EIF4EBP1 NucleusMarker: EIF4E CytoplasmMarker: EIF4E NucleusMarker: HDAC2 NucleusMarker: PCREB NucleusMarker: PEIF3746 CytoplasmMarker: PEIF3746 NucleusMarker: PEIFS209 CytoplasmMarker: PEIFS65 NucleusMarker: PEIFT70 CytoplasmMarker: PEIFT70 NucleusMarker: P GSK3B CytoplasmMarker: PKCb2 CytoplasmMarker: PS6 CytoplasmMarker: PTEN CytoplasmMarker: PTEN Nucleus
High Biomarker Expression (R-CHOP)9.49NA21.424.5010.5510.5520.90NA9.20NANA32.3021.4210.5510.0221.426.34
Low Biomarker Expression (R-CHOP and Enzastaurin)27.96NA27.96NANANANANA27.9627.9627.9627.96NANA16.57NANA
Low Biomarker Expression (R-CHOP)32.3010.55NA32.30NANANA32.30NA32.3010.55NA9.4920.90NA9.4932.30

[back to top]

Duration of Complete Response (CR or CRu)

Duration of response (DOR) either CR or CRu: Elapsed time from date CR or CRu criteria met to first objectively-determined PD. For responding participants (pts) who died without PD and pts not known to have died as of data cut-off date, who did not have PD, DOR censored at date of last objective progression-free disease assessment. For responding pts who received subsequent systemic anticancer therapy (other than enzastaurin maintenance therapy) prior to PD, DOR was censored at date of last objective progression-free disease assessment prior to subsequent therapy. CR and CRu defined using International Working Group recommendations (Cheson et al. 1999). CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. CRu does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. (NCT00451178)
Timeframe: Time of response to PD (up to 55 months)

Interventiondays (Median)
R-CHOP and EnzastaurinNA
R-CHOPNA

[back to top]

PFS of Participants With High or Low Expression of Protein Biomarkers and Correlation of Biomarkers to PFS

Reported is PFS of participants (pts) with high or low biomarker expression levels. PFS: time from randomization to first date of PD/death from any cause. PD assessed according to International Working Group recommendations (Cheson et al. 1999). PD: Enlarging liver/spleen nodules, new/increased lymph node/masses and reappearance of bone marrow infiltrate. For pts who had subsequent anticancer therapy, PFS censored at date of last assessment prior to subsequent therapy. Biomarkers and number of pts censored: EIF4EBP1 Cytoplasm (C) 4,3,7,3; EIF4EBP1 Nucleus (N) 0,2,11,4; EIF4E C 5,2,6,4; EIF4E N 0,0,11,6; HDAC2 N 5,1,5,5; PCREB N 5,3,6,4; PEIF3746 C 4,2,7,4; PEIF3746 N 5,2,6,4; PEIFS209 C 5,2,5,4; PEIFS65 N 7,2,4,4; PEIFT70 C 5,2,6,4; PEIFT70 N 6,4,5,2; P GSK3B C 7,3,4,3; PKCb2 C 4,3,7,3; PS6 C 9,4,1,1; PTEN C 5,2,6,4; PTEN N 3,0,8,6. Correlation of biomarkers with PFS (statistical analyses) reported if high expression groups combined and low expression groups combined each had ≥10 pts. (NCT00451178)
Timeframe: Randomization to measured PD or death from any cause (up to 55 months)]

Interventionmonths (Median)
Marker: EIF4EBP1 CytoplasmMarker: EIF4E CytoplasmMarker: HDAC2 NucleusMarker: PCREB NucleusMarker: PEIF3746 CytoplasmMarker: PEIF3746 NucleusMarker: PEIFS209 CytoplasmMarker: PEIFS65 NucleusMarker: PEIFT70 CytoplasmMarker: PEIFT70 NucleusMarker: P GSK3B CytoplasmMarker: PKCb2 CytoplasmMarker: PS6 CytoplasmMarker: PTEN CytoplasmMarker: PTEN Nucleus
High Biomarker Expression (R-CHOP and Enzastaurin)NANA27.9624.1027.96NANANANANA27.9627.96NA27.9627.96

[back to top]

Percentage of Participants With Complete Response (CR and CRu) and Objective Response [CR, CRu, and Partial Response (PR)] (Overall Response Rate)

CR, CRu, and PR were defined using International Working Group recommendations (Cheson et al. 1999). CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow must be negative if positive at baseline. Normalization of markers. CRu does not qualify for CR above, due to a residual nodal mass or an indeterminate bone marrow. PR is a 50% decrease in the sum of the products of diameters for up to 6 identified dominant lesions, including splenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. The percentage of participants with complete response (CR/CRu) and objective response (Cr/CRu/PR)=(Number of participants whose best overall response was CR/CRu or Cr/CRu/PR)/(Number of participants treated)*100. (NCT00451178)
Timeframe: Baseline through long-term follow-up (up to 2 years post last dose)

,
Interventionpercentage of participants (Number)
Complete ResponseObjective Response
R-CHOP42.985.7
R-CHOP and Enzastaurin51.883.9

[back to top]

Participants Who Had Treatment-Emergent Adverse Events (TEAEs) or Died (Evaluate Toxicity and Tolerability of R-CHOP Plus Enzastaurin)

Data presented are the number of participants who experienced at least 1 TEAE, Grade 3 or 4 Common Terminology Criteria for Adverse Events (CTCAE), serious adverse event (SAE), as well as the number of participants who discontinued due to an adverse event (AE) or SAE, who died on therapy, died within 30 days post treatment or within 60 days of first dose. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. (NCT00451178)
Timeframe: First dose through 30 days post study treatment discontinuation (up to 56 months)

,
InterventionParticipants (Count of Participants)
At Least 1 TEAEAt Least 1 Grade 3/4 CTCAEAt Least 1 SAEDiscontinued due to AEDiscontinued due to SAEDied on Therapy (all causes)Died within 30 days post treatment discontinuationDied within 60 days of first dose
R-CHOP43301863332
R-CHOP and Enzastaurin565035104563

[back to top]

Progression-Free Survival (PFS) Time

PFS time is the elapsed time from the date of randomization to the first date of objectively-determined PD or death from any cause. PD was assessed according to International Working Group recommendations (Cheson et al. 1999). PD: Enlarging liver/spleen nodules, new or increased lymph nodes/masses and reappearance of bone marrow infiltrate. For participants not known to have died as of the data cut-off date and who did not have objective PD, PFS was censored at the date of the last objective progression-free disease assessment. For participants who received subsequent anticancer therapy (other than enzastaurin maintenance therapy) prior to objectively determined disease progression or death, PFS was censored at the date of the last objective progression-free disease assessment prior to the date of subsequent therapy. (NCT00451178)
Timeframe: Randomization to measured PD or death from any cause (up to 55 months)

Interventionmonths (Median)
R-CHOP and Enzastaurin36.2
R-CHOP22.6

[back to top]

Percentage of Participants With a PET-Negative Scan (PET-Negative Rate)

The percentage of participants with a PET-negative scan=(Number of participants who had a PET-negative scan at Cycle 6)/(Number of participants who had a PET-positive scan at baseline)*100. (NCT00451178)
Timeframe: Cycle 6 (21 days/cycle)

Interventionpercentage of participants (Number)
R-CHOP and Enzastaurin44.6
R-CHOP41.0

[back to top]

Percentage of Participants Alive Progression-Free at Year 2 (2-Year PFS Rate)

PD was assessed according to International Working Group recommendations (Cheson et al. 1999). PD: Enlarging liver/spleen nodules, new or increased lymph nodes/masses and reappearance of bone marrow infiltrate. Percentage of participants alive progression-free at Year 2=(Number of participants alive progression free at Year 2)/(Number of participants assessed)*100. (NCT00451178)
Timeframe: Randomization to measured PD (up to Year 2)

Interventionpercentage of participants (Number)
R-CHOP and Enzastaurin59
R-CHOP49

[back to top]

Number of Patients Reaching Complete Hematological Response After Induction Therapy

(NCT00458848)
Timeframe: At the end of induction, day +50

Interventionparticipants (Number)
Philadelphia Positive, Imatinib Only in Induction Therapy49

[back to top]

Percentage of Participants Reaching Disease Free Survival

(NCT00458848)
Timeframe: At 60 months

Interventionpercentage of participants (Number)
Philadelphia Positive, Imatinib Only in Induction Therapy45.8

[back to top]

Percentage of Participants Reaching Overall Survival

Overall survival from diagnosis (NCT00458848)
Timeframe: At 60 months

Interventionpercentage of patients (Number)
Philadelphia Positive, Imatinib Only in Induction Therapy48.8

[back to top]

Maximum Tolerated Dose of Bortezomib (Phase I)

Determine the safety and the maximum tolerated dose (MTD) of bortezomib when added to the combination of rituximab, methotrexate, and cytarabine alternating with bortezomib, rituximab-hyperCVAD in patients with untreated aggressive mantle cell lymphoma. (NCT00477412)
Timeframe: Cycle 1 Day 1 - End of Cycle 2 up to 60 days.

Interventionmg/m^2 (Number)
Phase 1 Maximum Tolerated Dose (MTD)1.3

[back to top]

Number of Participants With Overall Response Rate

Response rate is determined by CT scans of the chest, abdomen, and pelvis, unilateral BM biopsy and aspirate with lymphoma markers (if initially positive) and colonoscopy/endoscopy if applicable. (NCT00477412)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
Phase II- Treatment (Combination Chemotherapy)87

[back to top]

Overall Survival

Overall survival is the time in number of months from start of study treatment to date of death due to any cause. (NCT00477412)
Timeframe: Date of diagnosis to last known date of survival, up to 5 years

Interventionmonths (Median)
Phase II- Treatment (Combination Chemotherapy)44

[back to top]

Time to Failure (Phase II)

Failure will be defined as recurrence/progression of disease or death from either disease or toxicity. Bayesian toxicity monitoring schema will be used to monitor severe toxicity profile in combined therapy. Severe toxicity is defined as at least two episodes of neutropenic fever during treatment courses. (NCT00477412)
Timeframe: First date of diagnosis up to 5 years

Interventionmonths (Median)
Phase II- Treatment (Combination Chemotherapy)55

[back to top]

Time to New Anti-follicular Lymphoma (FL) Therapy

Time to new FL therapy is defined as the time from randomization until the time of first administration of the new FL therapy other than ofatumumab. Time to new FL therapy will be censored if participants are lost to follow-up. The censoring date in such cases will be the date of the last attended visit at which the endpoint was assessed. (NCT00494780)
Timeframe: Followed up to 5 years

Interventionmonths (Median)
500 mg Ofatumumab + CHOP47.2
1000 mg Ofatumumab + CHOPNA

[back to top]

Progression-Free Survival (PFS)

PFS is defined as the time from randomization until progression or death. (NCT00494780)
Timeframe: Followed up to 5 years

Interventionmonths (Median)
500 mg Ofatumumab + CHOP27.6
1000 mg Ofatumumab + CHOPNA

[back to top]

Vss at the Sixth Infusion (Week 15, Visit 22)

Vss is defined as the volume of distribution at steady state of ofatumumab. (NCT00494780)
Timeframe: Week 15 (Visit 22)

InterventionLiters (Geometric Mean)
500 mg Ofatumumab + CHOP5.15
1000 mg Ofatumumab + CHOP5.32

[back to top]

AUC(0-inf) and AUC(0-504) After the Sixth Infusion (Week 15, Visit 22)

AUC is defined as the area under the ofatumumab concentration-time curve as a measure of drug exposure. AUC(0-504) is AUC from the start of infusion to 504 hours after the start of the infusion; AUC(0-inf) is AUC from the start of infusion extrapolated to infinity. (NCT00494780)
Timeframe: Week 15 (Visit 22)

,
InterventionMilligrams * hours/liter (mg.h/L) (Geometric Mean)
AUC(0-inf), n=20, 28AUC(0-504), n=24, 28
1000 mg Ofatumumab + CHOP399676168866
500 mg Ofatumumab + CHOP17713379500

[back to top]

Cmax and Ctrough at the Sixth Infusion (Week 15, Visit 22)

Cmax is defined as the maximum concentration of drug in plasma samples. Ctrough is defined as the trough plasma concentration (measured concentration at the end of a dosing interval [taken directly before next administration]). (NCT00494780)
Timeframe: Week 15 (Visit 22)

,
Interventionmilligrams per liter (mg/L) (Geometric Mean)
CmaxCtrough
1000 mg Ofatumumab + CHOP497188
500 mg Ofatumumab + CHOP23278.5

[back to top]

Median Percent Change From Visit 1 (Screening, Week -2) in Tumor Size at Visit 33 (24 Months After the Last Infusion of Ofatumumab)

The tumor size for a participant was computed as the sum of product of diameters (SPD) for the indicator lesions. Reduction in tumor size was calculated as percent change from Visit 1 until Visit 33, separately by radiologist 1 and radiologist 2. Percent change from Visit 1 (Screening, Week -2) = (value at Visit 33 minus value at Visit 1 divided by value at Visit 1) * 100. (NCT00494780)
Timeframe: Maximum of 24 months after the last infusion of Ofatumumab (Visit 33; median of 33.8 months)

,
InterventionPercent change in tumor size (Median)
Radiologist 1Radiologist 2
1000 mg Ofatumumab + CHOP-100-100
500 mg Ofatumumab + CHOP-100-100

[back to top]

Percent Change From Visit 1 (Screening) in Peripheral CD19+ and CD20+ Cell Counts at Visit 33 (24 Months After the Last Infusion of Ofatumumab)

The peripheral blood for each participant was collected and analyzed for CD19+ and CD20+ cell counts. CD19+ and CD20+ are B-cell types which are used as an index of a participant's response to treatment. (NCT00494780)
Timeframe: Maximum of 24 months after the last infusion of Ofatumumab (Visit 33; median of 33.8 months)

,
InterventionPercent change in cell counts (Median)
CD19+CD20+
1000 mg Ofatumumab + CHOP307.9307.9
500 mg Ofatumumab + CHOP154.1154.1

[back to top]

Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Visits 1, 28, and 33

HAHA are indicators of immunogenicity to ofatumumab. Blood samples were drawn from participants at Visits 1, 28, and 33 for analysis of HAHA. (NCT00494780)
Timeframe: Visits 1 (Screening), 28 (9 months after last dose), and 33 (24 months after last dose)

,
Interventionparticipants (Number)
Visit 1, n=29, 29Visit 28, n=18, 21Visit 33, n=16, 16
1000 mg Ofatumumab + CHOP000
500 mg Ofatumumab + CHOP000

[back to top]

CL After the Sixth Infusion (Week 15, Visit 22)

CL is the clearance of drug from plasma, which is defined as the volume of plasma from which the drug is cleared per unit time. (NCT00494780)
Timeframe: Week 15 (Visit 22)

InterventionMilliliters per hour (mL/h) (Geometric Mean)
500 mg Ofatumumab + CHOP6.29
1000 mg Ofatumumab + CHOP5.92

[back to top]

Duration of Response

The duration of response is defined as the time from the initial response (the first visit at which response was observed) to progression or death. (NCT00494780)
Timeframe: Followed up to 5 years

Interventionmonths (Median)
500 mg Ofatumumab + CHOP21.0
1000 mg Ofatumumab + CHOP25.0

[back to top]

Half Life (t1/2) of Ofatumumab at the Sixth Infusion (Week 15, Visit 22)

Half life is defined as the period of time required for the amount of drug in the body to be reduced by half. (NCT00494780)
Timeframe: Week 15 (Visit 22)

Interventionhours (Geometric Mean)
500 mg Ofatumumab + CHOP652
1000 mg Ofatumumab + CHOP644

[back to top]

Median Percent Change From Visit 1 (Screening) in Serum Complement (CH50) Levels at Visit 22

The peripheral blood for each participant was collected and analyzed for serum complement CH50 levels. Cluster of Differentiation index 50 (CD50) is a human gene which is used as an index of immune response. CD50Percent change from Visit 1 (Screening, Week -2) = (value at Visit 22 minus value at Visit 1 divided by value at Visit 1) * 100. (NCT00494780)
Timeframe: Visit 1 (Screening, Week -2) and Visit 22 (Week 15)

InterventionPercent change in serum complement CH50 (Median)
500 mg Ofatumumab + CHOP42.0
1000 mg Ofatumumab + CHOP23.2

[back to top]

Number of Participants Who Experienced Any Adverse Event (AEs) From First Treatment to Visit 33 (24 Months After Last Infusion)

An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. A list of AEs experienced in the study with a frequency threshold of 5% can be found in the AE section. (NCT00494780)
Timeframe: Up to 22 months after study start

Interventionparticipants (Number)
500 mg Ofatumumab + CHOP29
1000 mg Ofatumumab + CHOP29

[back to top]

Number of Participants With Complete Remission (CR) at Visit 26

Participants were evaluated for response by an Independent Endpoint Review Committee in accordance with the standardized response criteria for NHL. Participants with CR were defined as those with the complete disappearance of all detectable clinical and radiographic evidence of disease. (NCT00494780)
Timeframe: Maximum of 23 months after the start of treatment

Interventionparticipants (Number)
500 mg Ofatumumab + CHOP6
1000 mg Ofatumumab + CHOP9

[back to top]

Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab)

Based on standardized response criteria for NHL, responders included participants with CR (complete disappearance of all detectable clinical and radiographic evidence of disease), CRu (more than a 75% decrease in LN size compared to baseline), and PR (>=50% decrease in LN size and evidence of new lesions). Non-responders included participants with stable disease (SD; <50% decrease in LN size from baseline) and progressive disease (PD; >=50% increase in LN size and evidence of new lesions). (NCT00494780)
Timeframe: Maximum of 23 months after the start of treatment

,
Interventionparticipants (Number)
Responder, CRResponder, CRuResponder, PRNon-Responder, SDNon-Responder, PD
1000 mg Ofatumumab + CHOP971300
500 mg Ofatumumab + CHOP6101021

[back to top]

Overall Survival

Time, in days, from informed consent date until the date of death or date of last contact (NCT00495079)
Timeframe: unlimited

Interventiondays (Median)
Marqibo56

[back to top]

Clinical Response Assessment Per Independent Response Review Committee (IRRC) Evaluation

Number of subjects who achieved Complete Remission (CR)as assessed by the IRRC. CR is defined as no evidence of ALL. ANC>=1X10^9/L or Platelet count>=100x10^9/L, absence of blasts in blood and morrow (<5%), resolution of all sites of extramedullary disease (EMD). CR with incomplete blood count recovery(CRi)is defined as per CR but platelet count <100x10^9/L or ANC<1x10^9/L. (NCT00495079)
Timeframe: Response assessment at the end of each 28 days course

Interventionparticipants (Number)
Marqibo11

[back to top]

Complete Remission Plus Complete Remission Without Full Platelet Recovery (CR + CRi)

CR is defined as no evidence of ALL: ANC>or=1x10^9/L or platelet count>100x10^9/L, absence of leukemia blast cells in blood and marrow (<5% blasts), resolution of all sites of extramedullary disease (EMD). CR with incomplete blood count recovery (CRi): As per CR but platelet count< 100x10^9/L or ANC< 1x10^9/L. Partial remission(PR):CR with>5-25% abnormal cells in the marrow or 50% decrease in bone marrow blasts. Reduction in EMD by at least 50%. Hematologic Improvement. Bone marrow blast(BMB) response: BMB<5% in the absence of HI. Stable disease(SD):No significant hematological and extramedullary change from baseline. (NCT00495079)
Timeframe: Response assessment performed at the end of each 28 day course.

Interventionparticipants (Number)
Marqibo13

[back to top]

Duration of CR + CRi

Duration of response for those subjects who achieved CR or CRi (NCT00495079)
Timeframe: CR + CRi duration was calculated from the date the subject first met the definition of CR or CRi until the date of relapse

Interventiondays (Median)
Marqibo28

[back to top]

Disease Control Rate

Proportion of patients whose best overall response is complete response (CR), partial response (PR), or stable disease (SD) (NCT00506142)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Cohort 118
Cohort 28

[back to top]

The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient.

Limiting toxicity defined as Any Grade IV hematological toxicities lasting longer than 7 days, myelosuppression causing delays > 14 days in delivery of therapy, > Grade 3 thromboembolic events, > Grade 3 bleeding events, > Grade 2 hypertension, > Grade 2 proteinuria. (NCT00516295)
Timeframe: First 2 courses (42 days) of therapy

Interventionnumber of toxicities (Number)
Arm I (Feasibility Assessment of VTCB)0

[back to top]

Time to Disease Progression in Patients Receiving VTC With or Without Bevacizumab

Time from enrollment to disease progression, death, second malignant neoplasm, or last patient follow-up whichever occurs first. Patients who experience disease progression, death or second malignant neoplasm will be considered to have experienced an event; otherwise the patient will be considered censored at last follow-up. (NCT00516295)
Timeframe: Maximum of 5 years after enrollment

Interventiondays of event free survival (Median)
Arm I (Feasibility Assessment of VTCB)442

[back to top]

Probability of CNS Relapse

To assess whether intensification of CNS-directed intrathecal and systemic chemotherapy will improve outcome in patients at high-risk of CNS relapse. (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 35000.8
TOTXVI PEG 25001.8
TOTXVI Not Randomized2.7
All Eligible Patients in TOTXV5.7

[back to top]

Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.

"The primary objective of this study is to compare the distributions of continuous complete remission of patients randomized on the first day of the continuation phase to receive a higher dose of PEG-asparaginase or to receive the conventional dose (2,500 units/m2).~The randomization will occur on the starting day of the continuation phase, at which time all information necessary for performing the randomization should be available. In the rare case that immunophenotype and/or Day-15 MRD is not available, we will make the following assumptions: If immunophenotype is unknown at the time the randomization is to be executed, then it will be assumed B-lineage. If Day-15 MRD is unknown at the time of randomization, then it will be assumed negative (<0.01%). Past experience indicate that few patients will fall into these unknown categories." (NCT00549848)
Timeframe: 3.5 years after the last enrollment up to 12.5 years

InterventionPercentage of participants (Number)
PEG 3500 Units/m^291.6
PEG 2500 Units/m^290.7

[back to top]

Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%

To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. (NCT00549848)
Timeframe: Middle of remission induction, Day 15 in Total XVI and Day 19 in Total XV

InterventionParticipants (Count of Participants)
TOTXVI PEG 350022
TOTXVI PEG 250026
TOTXVI Not Randomized31
All Eligible Patients in TOTXV55

[back to top]

Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%

To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. (NCT00549848)
Timeframe: End of remission induction; day 42 in Total XVI and day 46 in Total XV

InterventionParticipants (Count of Participants)
TOTXVI PEG 35007
TOTXVI PEG 250012
TOTXVI Not Randomized20
All Eligible Patients in TOTXV44

[back to top]

Probability of Overall Survival

To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV. (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 350097.5
TOTXVI PEG 250095.6
TOTVI Not Randomized90.8
All Eligible Patients in TOTXV93.5

[back to top]

Probability of Event-free Survival

"To estimate the event-free survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV (NCT00137111).~EFS will be measured from the date of complete response to the date of initial failure for patients who fail. Failure includes the traditional endpoints of failure to achieve a complete remission, relapse in any site, secondary malignancy, and death during induction or remission. EFS time will be measured to the date of last contact for patients who are failure free at the time of analysis. The EFS time is defined to be zero (0) for patients who die during induction therapy or fail to achieve a complete remission." (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 350092.4
TOTXVI PEG 250091.1
TOTXVI Not Randomized86.3
All Eligible Patients in TOTXV87.1

[back to top]

Percentage of Participants With Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Grade 3 and higher toxicities will be descriptively summarized. (NCT00554788)
Timeframe: Up to 30 days after completion of study treatment

,,
Interventionpercentage of participants (Number)
Abdominal painAcute kidney injuryAlanine aminotransferase increasedAnemiaAnorexiaApneaAspartate aminotransferase increasedCatheter related infectionDehydrationDepressed level of consciousnessDiarrheaEncephalopathyEnterocolitisEnterocolitis infectiousEsophagitisFebrile neutropeniaFeverGGT increasedGastric hemorrhageHearing impairedHypermagnesemiaHypertensionHypoalbuminemiaHypocalcemiaHypoglycemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypotensionHypoxiaInfections and infestations - Other, specifyLower gastrointestinal hemorrhageLung infectionLymphocyte count decreasedMucositis oralNauseaNervous system disorders - Other, specifyNeutrophil count decreasedOral painPainPeripheral motor neuropathyPharyngeal mucositisPlatelet count decreasedPneumonitisRectal painSeizureSepsisSinus tachycardiaSinusitisSkin infectionUpper respiratory infectionVomitingWhite blood cell decreased
Stage 2/3 Patients000011.10011.1005.6005.6055.611.10011.15.6005.6027.85.611.122.20027.8016.705.616.705.6005.605.65.6000011.1011.111.15.6
Stage 4a Patients5.65.616.7033.3011.1011.1016.705.611.15.655.605.65.65.605.605.6016.75.60011.12.633.35.60027.811.1005.65.605.6005.6011.15.605.65.622.20
Stage 4b Patients005.35.315.85.35.3010.55.305.305.3036.85.3005.3005.310.55.321.110.515.810.50021.1005.35.35.310.55.300005.3005.30005.305.35.3

[back to top]

Response Rate to the Induction Phase of the Regimen

This study used a modified version of the international criteria for neuroblastoma response. The response rate to the induction phase of the regimen and a corresponding 95% confidence interval will be calculated for all strata combined. (NCT00554788)
Timeframe: 12 weeks after participant received the first dose

Interventionpercentage of participants (Number)
All Eligible Patients68

[back to top]

Event-free Survival (EFS)

The probability of surviving patients who did not experience events at 1 year following enrollment. An event is defined as relapse, second malignancy, or death from any cause. (NCT00554788)
Timeframe: At 1 year

InterventionProbability (Number)
Stage 2/3 Patients88
Stage 4a Patients83
Stage 4b Patients28

[back to top]

Toxicity to Medications

"Adverse events were closely monitored and recorded at weekly visits during treatment period and for two years after treatment ceased. Laboratory values were taken every other week during the treatment period.~Please see Adverse Events module for more details." (NCT00555464)
Timeframe: Initial visit, 2, 4, 6, 10 and 12 weeks of therapy

,
Interventionparticipants (Number)
Patients with Serious Adverse EventsPatients with Other Adverse Events
Oral Steroid Treatment Group00
Vincristine Treatment Group03

[back to top]

Response of Hemangioma (IH) to Treatment

"Response of IH not confined to the dermis will be coded using the following criteria: Progressive disease: >40% increase in volume by MRI, Partial response: >65% reduction in volume by MRI, Complete response: no visual or radiographic evidence of disease, Stable disease: none of the above or <40% increase or <65% decrease in volume by MRI.~Response of superficial IH will be coded using the following criteria (based on RECIST): Progressive disease: >30% increase in IH size, Partial response: >30% reduction in size, Complete response: no evidence of disease, Stable disease: none of the above.~Our first 3 patients showed limits to using MRI volume to measure IH size/response to therapy. Unlike other solid tumors, the superficial distribution of some IH made getting volume by MRI difficult, resulting in smaller tumor estimation compared to clinical assessment. Based on these observations, we amended the protocol to report response based on RECIST criteria instead of change in IH volume." (NCT00555464)
Timeframe: 6 weeks

,
Interventionparticipants (Number)
Progressive DiseasePartial ResponseComplete ResponseStable Disease
Oral Steroid Treatment Group1002
Vincristine Treatment Group0202

[back to top]

Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years.

Interventionpercent probability (Number)
Arm B (IR/HR MLL-R Chemotherapy)38.89
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)35.82

[back to top] [back to top]

Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm

Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status. (NCT00557193)
Timeframe: 3 Years from end of Induction)

Interventionpercent probability (Number)
Arm A (MRD Negative)86.05
Arm A (MRD Positive)87.5
Arm B (MRD Negative)47.37
Arm B (MRD Positive)22.73
Arm C (MRD Negative)51.85
Arm C (MRD Positive)27.03

[back to top]

Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in samples which have acquired resistance to lestaurtinib (NCT00557193)
Timeframe: At relapse (up to 3 years)

InterventionProportion of cells that are viable (Mean)
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)0.69

[back to top]

Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in samples which have primary resistance to lestaurtinib (NCT00557193)
Timeframe: Sampled at the start of induction

InterventionProportion of cells that are viable (Median)
Arm A (Standard Risk MLL-G)0.75
Arm B (IR/HR MLL-R Chemotherapy)0.48
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)0.47

[back to top]

Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy

Summarized with mean and standard deviation for those with available data in Arm C (NCT00557193)
Timeframe: Sampled between weeks 6-12 from start of induction

InterventionActivity percentage (Mean)
Arm C (Safety/Efficacy Dose Level 2)69.00

[back to top]

Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)

EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years

Interventionpercentage probability (Number)
Arm C (Safety/Efficacy Dose Level 2)35.82

[back to top]

Percent Probability for Event-free Survival (EFS) for Patients on Arm A

EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years

Interventionpercentage probability (Number)
Arm A (Standard Risk MLL-G)86.67

[back to top]

Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts

Described via mean and standard deviation by group. (NCT00557193)
Timeframe: Sampled at the start of induction

InterventionqPCR fold expression ratio (Mean)
Arm A (Standard Risk MLL-G)1.25
Arm B (IR/HR MLL-R Chemotherapy)7.85
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)5.83

[back to top]

Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in available Arm C relapse samples (NCT00557193)
Timeframe: At relapse (up to 3 years)

InterventionqPCR fold expression ratio (Mean)
Arm C (Safety/Efficacy Dose Level 2)5.73

[back to top]

Complete Response Rate

Complete response rate is defined as the percentage of patients who achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) at the end of induction therapy. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionpercentage of patients (Number)
Treatment (Pediatric Regimen)89

[back to top]

Disease-free Survival

DFS was defined as time from bone marrow response in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionmonths (Median)
Treatment (Pediatric Regimen)81.7

[back to top]

Event-free Survival

EFS was defined as time from registration in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionmonths (Median)
Treatment (Pediatric Regimen)78.1

[back to top] [back to top]

Overall Survival

OS was defined from registration to death resulting from any cause. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionmonths (Median)
Treatment (Pediatric Regimen)NA

[back to top]

Number of Participants With Clinically Significant Change From Baseline in Laboratory Findings

Criteria for laboratory test abnormality: Blood Chemistry (alkaline phosphatase [greater than{>}5*upper limit of normal {ULN}, calcium [less than {<}1.75 millimole per liter {mmol/L}, creatinine [>3*ULN], glucose [>13.9 mmol/L], phosphorous [<0.6 mmol/L], potassium [<3 mmol/L], aspartate transaminase [>5.0*ULN], total bilirubin [>3*ULN]), Coagulation (international normalized ratio [>2*ULN]), Hematology (hemoglobin [<80 grams/Liter], lymphocytes [<0.5*10^9/L], absolute neutrophil count [<1*10^9/L], platelet count [<50*10^9/L], WBC [<2.0*10^9/L]). (NCT00562965)
Timeframe: Baseline up to 42 days post-treatment, disease follow up (every 12 weeks for a minimum of 1 year and up to 2 years)

,
Interventionparticipants (Number)
Baseline up to 42 days post-treatmentDisease follow up
Control Regimens R-CVP + R-FND127
Rituximab + Inotuzumab Ozogamicin118

[back to top]

Number of Participants With Grade 3 or 4 Treatment Emergent Adverse Events (TEAEs)

AE=any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. TEAE=between first dose of study drug and up to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state. (NCT00562965)
Timeframe: Baseline up to 42 days post-treatment

Interventionparticipants (Number)
Rituximab + Inotuzumab Ozogamicin12
Control Regimens R-CVP + R-FND13

[back to top]

Percentage of Participants With Objective Response (OR)

OR was based on assessment of complete response(CR),unconfirmed CR(Cru),partial response(PR) as per International Response Criteria for Non-Hodgkin's Lymphoma.Confirmed response=response persists on repeat imaging at least 4 weeks after initial response.CR=complete disappearance of all detectable clinical/radiographic evidence of disease,lymph nodes regressed to normal size [at least 1.5 centimeter(cm) or less],spleen regressed,not palpable on physical examination,bone marrow infiltrate cleared on repeat aspiration/biopsy.PR=at least 50 percent (%) decrease in sum of product diameters of 6 greatest dominant nodes,no increase in other nodes,liver/spleen,no new sites of disease. CRu=residual lymph node greater than 1.5 cm in transverse diameter that has regressed more than 75% in product diameter.Individual nodes previously confluent,regressed more than 75% in product diameters.Indeterminate bone marrow (increased number/size of lymph aggregates without cytologic/architectural atypia). (NCT00562965)
Timeframe: Baseline, every 6 to 12 weeks during treatment period, end of treatment (EOT) (42 days after last dose), every 12 weeks during follow-up for up to 1 year after the last dose of study drug

Interventionpercentage of participants (Number)
Rituximab + Inotuzumab Ozogamicin93.3
Control Regimens R-CVP + R-FND64.3

[back to top]

Progression-Free Survival (PFS)

PFS was defined as the time from randomization to disease progression or death due to any cause, whichever occurred first, censored at the last tumor evaluation date. PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.44. (NCT00562965)
Timeframe: Baseline until disease progression or death or up to 1 year after last dose of study drug

Interventionmonths (Median)
Rituximab + Inotuzumab OzogamicinNA
Control Regimens R-CVP + R-FND16.4

[back to top]

Number of Participants With Clinically Significant Change From Baseline in QT Interval Findings

Assessments of QT interval was performed only in rituximab + inotuzumab ozogamicinin group. QT interval corrected using Fridericia's formula (QTcF) and Bazett's formula (QTcB) was analyzed as per common terminology criteria for adverse events (CTCAE) version 3.0, where Grade 1 = mild AE, Grade 2 = moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening or disabling AE, Grade 5 = death related to AE. Number of participants with change in CTCAE grading at post-baseline time point compared to the baseline were presented. The post-baseline value was defined as the maximum grade after the first dose date on or before the end of treatment. (NCT00562965)
Timeframe: Baseline up to 42 days post-treatment

Interventionparticipants (Number)
QTcB: BL normal, post-BL normalQTcB: BL normal, post-BL Grade 1QTcB: BL normal, post-BL Grade 2QTcF: BL normal, post-BL normalQTcF: BL normal, post-BL Grade 1
Rituximab + Inotuzumab Ozogamicin42363

[back to top]

Number of Participants With Clinically Significant Change From Baseline in Vital Signs

Criteria for determining significant change from baseline in vital signs abnormalities: heart rate value of <40 beats per minute and value >150 beats per minute, systolic blood pressure (SBP) of <80 or >210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of <40 or >130 mmHg, temperature <32 or >40 degree centigrade, and body weight>=10% increase or decrease of body weight in kilogram (kg). (NCT00562965)
Timeframe: Baseline up to 42 days post-treatment, disease follow up (every 12 weeks for a minimum of 1 year and up to 2 years)

,
Interventionparticipants (Number)
Baseline up to 42 days post-treatmentDisease follow up
Control Regimens R-CVP + R-FND12
Rituximab + Inotuzumab Ozogamicin03

[back to top]

Overall Survival Probability at Months 6, 12 and 24

Overall survival was defined as the time from randomization to death due to any cause, censoring at the date of last contact or the end of the study. Participants who withdrew or lost to follow-up from study without having death documented were censored at the date of last contact. Kaplan-Meier estimates of the probability of survival at 6, 12 and 24 months was used to estimate the survival function. (NCT00562965)
Timeframe: Baseline up to Month 6, 12, 24

,
Interventionpercent chance of survival (Number)
Overall Survival: Baseline up to Month 6Overall Survival: Baseline up to Month 12Overall Survival: Baseline up to Month 24
Control Regimens R-CVP + R-FND92.383.967.1
Rituximab + Inotuzumab Ozogamicin100.086.786.7

[back to top]

Event-free Survival Rate

Comparison of EFS curves, starting from the time of randomization, by treatment group (single CEM vs. tandem CEM) (NCT00567567)
Timeframe: Three years, from time of randomization

Interventionpercent probability (Number)
Single HST (CEM)48.8
Tandem HST (CEM), Randomly Assigned61.8

[back to top]

EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content & Pts>547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).

Kaplan-Meier curves of EFS will be plotted, and the proportion of responders to induction therapy will be tabulated. (NCT00567567)
Timeframe: Up to 3 years

Interventionpercent probability (Number)
Single HST (CEM)73.1

[back to top]

Duration of Greater Than or Equal to Grade 3 Thrombocytopenia

A logistic regression model will be used to test the ability of the number of days of thrombocytopenia to predict the presence of a polymorphism. (NCT00567567)
Timeframe: Through completion of a participant's first cycle during induction, including treatment delays, assessed up to 46 days

InterventionDays (Median)
Single HST (CEM)4
Tandem HST (CEM), Randomly Assigned4
Not Assigned4

[back to top]

Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells

A descriptive comparison of the median number of T-cells (CD3, CD4, CD8) between treatment arms (single vs. tandem myeloablative regimens) will be performed. (NCT00567567)
Timeframe: Up to 6 months after completion of assigned myeloablation therapy

,
Interventioncells/mm^3 (Median)
CD3CD4CD8
Single HST (CEM)20073104
Tandem HST (CEM), Randomly Assigned255.581151

[back to top]

Proportion of Patients With a Polymorphism

A chi-square test will be used to test whether the response rate after two cycles of induction therapy and the presence of a polymorphism are independent in the study population. (NCT00567567)
Timeframe: Through completion of a participant's first two cycles during induction, including treatment delays, assessed up to 69 days

InterventionProportion of patients (Number)
Single HST (CEM)0.96
Tandem HST (CEM), Randomly Assigned0.96
Not Assigned0.97

[back to top]

Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies

Median peak serum concentration level of isotretinoin for patients enrolled on ANBL0532 (NCT00567567)
Timeframe: Day 1 of each course

InterventionMicromolar (Median)
Single HST (CEM)1.00
Tandem HST (CEM), Randomly Assigned1.36
Not Assigned1.26

[back to top]

Response After Induction Therapy

Per the International Response Criteria: measurable tumor defined as product of longest x widest perpendicular diameter. Elevated catecholamine levels, tumor cell invasion of bone marrow also considered measurable tumor. Complete Response (CR)-no evidence of primary tumor or metastases. Very Good Partial Response (VGPR)->90% reduction of primary tumor; no metastases; no new bone lesions, all pre-existing lesions improved. Partial Response (PR)-50-90% reduction of primary tumor; >50% reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by >50%. Mixed Response (MR)->50% reduction of any measurable lesion (primary or metastases) with <50% reduction in other sites; no new lesions; <25% increase in any existing lesion. No Response (NR)-no new lesions; <50% reduction but <25% increase in any existing legions. Progressive Disease (PD)-any new/increased measurable lesion by >25%; previous negative marrow positive. (NCT00567567)
Timeframe: Study enrollment to the end of induction therapy

InterventionProportion participants that responded (Number)
Single HST (CEM)0.54
Tandem HST (CEM), Randomly Assigned0.48
Not Assigned0.35

[back to top]

Surgical Response

Percentage of patients who achieved a surgical complete resection (NCT00567567)
Timeframe: Up to 3 years

InterventionPercentage of patients (Number)
Single HST (CEM)83.98
Tandem HST (CEM), Randomly Assigned84.09
Not Assigned58.89

[back to top]

Duration of Greater Than or Equal to Grade 3 Neutropenia

A logistic regression model will be used to test the ability of the number of days of neutropenia to predict the presence of a polymorphism. (NCT00567567)
Timeframe: Through completion of a participant's first cycle during induction, including treatment delays, assessed up to 39 days

InterventionDays (Median)
Single HST (CEM)7
Tandem HST (CEM), Randomly Assigned7
Not Assigned7

[back to top]

Topotecan Systemic Clearance

Median topotecan systemic clearance for courses 1 and 2. (NCT00567567)
Timeframe: Day 1 of courses 1-2

InterventionL/h/m2 (Median)
Single HST (CEM)28.1
Tandem HST (CEM), Randomly Assigned28.1
Not Assigned28.5

[back to top]

Type of Surgical or Radiotherapy Complication

The Percentage of patients who experienced surgical or radiotherapy complications will be calculated. The complications are: bowel obstruction, chylous leaf, renal injury/atrophy/loss and diarrhea. (NCT00567567)
Timeframe: Up to 3 years

InterventionPercentage of patients (Number)
Single HST (CEM)13.11
Tandem HST (CEM), Randomly Assigned12.50
Not Assigned11.85

[back to top]

OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology

Kaplan-Meier curves of OS will be plotted, and the proportion of responders to induction therapy will be tabulated. (NCT00567567)
Timeframe: Up to 3 years

Interventionpercent probability (Number)
Single HST (CEM)81.0

[back to top]

Intraspinal Extension

Percentage of patients with primary tumors with intraspinal extension. (NCT00567567)
Timeframe: Up to 5 years

InterventionPercentage of patients (Number)
Single HST (CEM)8.25
Tandem HST (CEM), Randomly Assigned9.66
Not Assigned7.78

[back to top]

Incidence Rate of Local Recurrence

Cumulative incidence rate of local recurrence comparison between ANBL0532 patients randomized or assigned to receive single CEM transplant and boost radiation versus the historical A3973 patients who were transplanted and received boost radiation. (NCT00567567)
Timeframe: Up to 3 years

InterventionPercentage 3-year cumulative incidence (Number)
Single HST (CEM)15.7

[back to top]

Disease Relapse or Progression as Measured by CT Scan or PET

(NCT00574496)
Timeframe: 3 years

Interventionmonths (Median)
High-Risk or Relapsed Hodgkin Lymphoma34.3

[back to top]

Overall Survival

(NCT00574496)
Timeframe: up to 8 years

Interventionmonths (Median)
High-Risk or Relapsed Hodgkin Lymphoma70.3

[back to top]

Progression-free Survival at 1 Year

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT00574496)
Timeframe: 1 year

Interventionproportion of progression-free pts (Number)
High-Risk or Relapsed Hodgkin Lymphoma33.3

[back to top]

Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)

Hemoglobin Levels were measured at baseline, before peripheral blood stem cell transplantation (PBSCT), during PBSCT and at hospital discharge. (NCT00577096)
Timeframe: up to 30 weeks

,
Interventiong/dl (Mean)
BaselineBefore TransplantationDuring TransplanationAt Discharge
Exercise11.712.010.811.0
Usual Care11.512.010.810.9

[back to top]

Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)

Hemoglobin Levels were measured at baseline, before peripheral blood stem cell transplantation (PBSCT), During PBSCT and at hospital discharge. (NCT00577096)
Timeframe: up to 15 weeks

,
Interventiong/dl (Mean)
BaselineBefore transplantationDuring transplantationAt discharge
Exercise11.611.010.410.6
Usual Care12.110.810.110.6

[back to top]

Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)

(NCT00577096)
Timeframe: up to 15 weeks

InterventionPlatelet transfusions (Mean)
Usual Care3.1
Exercise2.3

[back to top]

Number of Stem Cell Collection Attempts (Long Term)

(NCT00577096)
Timeframe: up to 30 weeks

InterventionStem Cell Collection Attempts (Mean)
Usual Care1.3
Exercise1.1

[back to top]

Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)

(NCT00577096)
Timeframe: up to 30 weeks

InterventionPlatelet Transfusions (Mean)
Usual Care3.6
Exercise2.0

[back to top]

Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)

The targeted hemoglobin level for each participant was 10-12 g/dl. This is the number of red blood cell (RBC) transfusions administered to participants, as part of the investigational therapy algorithm, in an attempt to alleviate the anemia caused by multiple myeloma and high-dose chemotherapy. The numbers of RBC and platelet transfusions were obtained from the University of Arkansas for Medical Sciences blood bank. (NCT00577096)
Timeframe: up to 30 weeks

InterventionRBC Transfusions (Mean)
Usual Care1.8
Exercise1.0

[back to top]

Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)

The targeted hemoglobin level for each participant was 10-12 g/dl. This is the number of red blood cell (RBC) transfusions administered to participants, as part of the investigational therapy algorithm, in an attempt to alleviate the anemia caused by multiple myeloma and high-dose chemotherapy. The numbers of RBC and platelet transfusions were obtained from the University of Arkansas for Medical Sciences blood bank. (NCT00577096)
Timeframe: up to 15 weeks

InterventionRBC Transfusions (Mean)
Usual Care2.3
Exercise1.8

[back to top]

Number of Stem Cell Collection Attempts (Short Term)

(NCT00577096)
Timeframe: up to 15 weeks

InterventionStem Cell Collection Attempts (Mean)
Usual Care1.4
Exercise1.1

[back to top]

Total Number of Days of Stem Cell Collection (Long Term)

(NCT00577096)
Timeframe: up to 30 weeks

InterventionDays (Mean)
Usual Care4.9
Exercise4.5

[back to top]

Total Number of Days of Stem Cell Collection (Short Term)

(NCT00577096)
Timeframe: up to 15 weeks

InterventionDays (Mean)
Usual Care5.3
Exercise4.0

[back to top]

Number of Participants With Overall Survival (10 Years) by Treatment

Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years. (NCT00577993)
Timeframe: 10 Years

InterventionParticipants (Count of Participants)
Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab59
Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)58

[back to top]

Number of Participants With Progression Free Survival (10 Years) by Treatment

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00577993)
Timeframe: 10 years

InterventionParticipants (Count of Participants)
Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab59
Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)58

[back to top]

3 Year Overall Survival (OS)

This is the percent of participants who were still alive at 3 years after study entry. (NCT00581776)
Timeframe: 36 months

InterventionPercent of participants (Number)
VCR-CVAD With Rituximab Maintenance86

[back to top]

3 Year Progression Free Survival

This is the percent of subjects who had not had any recurrence or relapse of disease as of 3 years after enrollment in the study. (NCT00581776)
Timeframe: 36 months

Interventionpercent of participants (Number)
VCR-CVAD With Rituximab Maintenance63

[back to top]

Complete Response Rate (CR) at the End of Induction Chemotherapy

Complete Response Rate (CRR) as defined by 1999 International Working Group criteria, is defined as patients with complete disappearance of disease, or regression of all lymph nodes to 1.5 cm in greatest diameter or less. All subjects who had completed 2 cycles of therapy and had at least one disease evaluation, or had completed 1 cycle of therapy with progressive disease, were considered evaluable. (NCT00581776)
Timeframe: at 21 weeks

Interventionpercent of participants (Number)
VCR-CVAD With Rituximab Maintenance77

[back to top]

Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR).

"Patients were considered evaluable for response if they completed at least 2 cycles of therapy and had undergone an initial response evaluation, or had disease progression after 1 cycle of therapy.~1999 International Working Group criteria defines a CR as patients with complete disappearance of disease, or regression of all lymph nodes to 1.5 cm in greatest diameter or less. Partial Response indicates patients responded to treatment with a reduction in the amount of tumor (50 percent or more). Overall response rate is the percent of complete responses plus the percent of partial responses." (NCT00581776)
Timeframe: At completion of induction therapy (21 weeks)

InterventionPercent of participants (Number)
VCR-CVAD With Rituximab Maintenance90

[back to top] [back to top]

Progression Free Survival

Overall Progression Free Survival at 2 years (NCT00594815)
Timeframe: 2 Years

Interventionpercentage of participants (Number)
Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma57

[back to top]

Feasibility and Toxicity of Administering Consolidation Therapy Including Cyclophosphamide and Pharmacokinetically Targeted Topotecan to Patients With Metastatic Disease Based on the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity

For the subset of patients with metastatic disease (high-risk group patients), during consolidation, we will calculate the number and proportion of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity. Patients were to received 2 courses of consolidation chemotherapy and then maintenance therapy. (NCT00602667)
Timeframe: At completion of consolidation therapy (up to 6 months after on-study date)

InterventionPercentage of courses delayed (Number)
High-Risk Group2.6

[back to top]

Feasibility and Toxicity of Administering Oral Maintenance Therapy in Children <3 Years of Age as Measured by the Percentage of Total Scheduled Maintenance Doses Received

These data are based on patient diaries. For children <3 years of age, we will calculate the percentage of total scheduled doses each patient received per course for each of the oral maintenance courses and report the overall average number percentage of doses received per course across patients. If patients received all planned doses, their percentage would be 100%. If the average percentage was less than 75%, then feasibility would be in question. (NCT00602667)
Timeframe: From start of oral maintenance therapy (approximately 6 months after on-study date) to completion of oral maintenance therapy (up to 1 year after on-study date)

InterventionPercentage of scheduled doses received (Mean)
Low-Risk Group96
Intermediate-Risk Group91
High-Risk Group98

[back to top]

Feasibility and Toxicity of Administering Vinblastine With Induction Chemotherapy for Patients With Metastatic Disease as Measured by the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity

For the subset of patients with metastatic disease (high-risk group patients), during induction, the proportion percentage of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity will be calculated. Patients were to receive 4 courses of induction and then consolidation chemotherapy. (NCT00602667)
Timeframe: From on-study date up to 4 months after on-study date

InterventionPercentage of courses delayed (Number)
High-Risk Group3.8

[back to top]

Methotrexate AUC0-66h in Induction Cycle 1

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

Interventionµmol·h/L (Median)
Low-Risk Group1797
Intermediate-Risk Group1813
High-Risk Group1821

[back to top]

Methotrexate AUC0-66h in Induction Cycle 2

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

Interventionµmol·h/L (Median)
Low-Risk Group1900
Intermediate-Risk Group1902
High-Risk Group1879

[back to top]

Methotrexate AUC0-66h in Induction Cycle 3

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

Interventionµmol·h/L (Median)
Low-Risk Group1872
Intermediate-Risk Group1879
High-Risk Group1831

[back to top]

Methotrexate AUC0-66h in Induction Cycle 4

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate AUC0-66h (area under concentration curve from time 0 to 66 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

Interventionµmol·h/L (Median)
Low-Risk Group1804
Intermediate-Risk Group1841
High-Risk Group1886

[back to top]

Methotrexate Clearance in Induction Cycle 1

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of Methotrexate (MTX)

InterventionL/h/m^2 (Median)
Low-Risk Group5.69
Intermediate-Risk Group6.06
High-Risk Group5.65

[back to top]

Methotrexate Clearance in Induction Cycle 2

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

InterventionL/h/m^2 (Median)
Low-Risk Group5.47
Intermediate-Risk Group5.70
High-Risk Group5.70

[back to top]

Methotrexate Clearance in Induction Cycle 3

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

InterventionL/h/m^2 (Median)
Low-Risk Group5.68
Intermediate-Risk Group5.78
High-Risk Group5.81

[back to top]

Methotrexate Clearance in Induction Cycle 4

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

InterventionL/h/m^2 (Median)
Low-Risk Group5.75
Intermediate-Risk Group5.89
High-Risk Group5.79

[back to top]

Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis. (NCT00602667)
Timeframe: 42 hours from start of MTX

Interventionµmol/L (Median)
Low-Risk Group0.49
Intermediate-Risk Group0.57
High-Risk Group0.61

[back to top]

Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 2

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis. (NCT00602667)
Timeframe: 42 hours from start of MTX

Interventionµmol/L (Median)
Low-Risk Group0.75
Intermediate-Risk Group0.72
High-Risk Group0.69

[back to top]

Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 3

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis. (NCT00602667)
Timeframe: 42 hours from start of MTX

Interventionµmol/L (Median)
Low-Risk Group0.65
Intermediate-Risk Group0.70
High-Risk Group0.58

[back to top]

Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 4

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate concentration at 42 hours post-dose are obtained using post hoc analysis. (NCT00602667)
Timeframe: 42 hours from start of MTX

Interventionµmol/L (Median)
Low-Risk Group0.64
Intermediate-Risk Group0.64
High-Risk Group0.55

[back to top]

Methotrexate Volume of Central Compartment in Induction Cycle 1

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 1. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

InterventionL/m^2 (Median)
Low-Risk Group11.63
Intermediate-Risk Group13.70
High-Risk Group13.25

[back to top]

Methotrexate Volume of Central Compartment in Induction Cycle 2

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 2. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

InterventionL/m^2 (Median)
Low-Risk Group13.77
Intermediate-Risk Group13.73
High-Risk Group13.62

[back to top]

Methotrexate Volume of Central Compartment in Induction Cycle 3

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 3. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

InterventionL/m^2 (Median)
Low-Risk Group12.70
Intermediate-Risk Group13.55
High-Risk Group13.87

[back to top]

Methotrexate Volume of Central Compartment in Induction Cycle 4

Methotrexate plasma concentration-time data are collected after the start of methotrexate infusion in induction cycle 4. Population parameters and inter-subject variability are estimated. Individual estimates of methotrexate volume of central compartment are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion and 6, 23, 42, 66 hours from start of MTX

InterventionL/m^2 (Median)
Low-Risk Group12.64
Intermediate-Risk Group13.31
High-Risk Group13.68

[back to top]

OSI-420 AUC0-24h

Erlotinib metabolite OSI-420 plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of OSI-420 AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 1, 2, 4, 8, and 24 hours post-dose

Interventionµmol·h/L (Median)
Low-Risk Group2.17
Intermediate-Risk Group1.81
High-Risk Group1.62

[back to top]

Overall Survival (OS) Compared to Historical Controls

OS was measured from the date of initial treatment to date of death or to date of last contact for survivors. 1-year OS estimates were reported by risk group. OS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals. (NCT00602667)
Timeframe: 1 year after treatment initiation of last patient

InterventionPercent probability (Number)
SJYC07 Low-risk Medulloblastoma Patients100
SJYC07 Intermediate-risk Medulloblastoma Patients84.4
SJYC07 High-risk Medulloblastoma Patients61.5

[back to top]

Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan

Number of participants who successfully achieve target systemic exposure of intravenous topotecan after an empiric dosage during consolidation phase of therapy are reported. (NCT00602667)
Timeframe: Pre-infusion, 5 min., 1, and 3 hours from end of infusion

Interventionparticipants (Number)
Intermediate-Risk Group0
High-Risk Group8

[back to top]

Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan

Number of participants who successfully achieve target systemic exposure of intravenous topotecan after a pharmacokinetic-guided dosage adjustment during consolidation phase of therapy are reported. (NCT00602667)
Timeframe: Pre-infusion, 5 min., 1, and 3 hours from end of infusion

Interventionparticipants (Number)
Intermediate-Risk Group1
High-Risk Group20

[back to top]

Percent of Patients With Sustained Objective Responses Rate After Consolidation

For patients enrolled on the high-risk arm with measurable residual disease after induction treated with consolidation therapy, we will estimate the objective response (complete response (CR)/partial response (PR)) rate after consolidation therapy with a 95% confidence interval. Objective responses must be sustained for at least eight weeks. All patients who receive at least 1 dose of cyclophosphamide or topotecan during consolidation are evaluable for response. (NCT00602667)
Timeframe: 8 weeks after completion of consolidation therapy (up to 8 months after on-study date)

Interventionpercentage of participants (Number)
High-Risk Group13.2

[back to top]

Percent of PET Scans With Loss of Signal Intensity

Measures will be analyzed for intermediate risk participants who receive proton beam therapy (PBT) and who consent. This objective aims to assess the feasibility of using post-proton beam therapy (PBT) positron emission tomography (PET) as an in-vivo dosimetric and distal edge verification system in this patient population. To quantify the decay in signal, 134 scans from 53 patients were analyzed by recording the mean activation value (MAV), the average recorded PET signal from activation, within the target volume. With each patient being given the same dose, the percent standard deviation in the MAV can serve as a quantitative representation of signal loss due to radioactive decay. (NCT00602667)
Timeframe: Up to 3 times during RT consolidation

Interventionmean activation value (MAV) (Mean)
Intermediate Risk Group60

[back to top]

Percent Probability of Event-free Survival (EFS) for Medulloblastoma Patients

Defined as the time interval from date on treatment until the date of first progression, second malignancy or death due to any cause; or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis. (NCT00602667)
Timeframe: From date on treatment to date of first progression, relapse, second malignancy or death from any cause or to date of last contact, estimated at 1 year after

InterventionPercent Probability (Number)
Low-Risk Group73.9
Intermediate-Risk Group46.9
High-Risk Group30.8

[back to top]

Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients

Progression was defined as 25% increase in the size of any measurable lesion; the appearance of a new lesion; or the conversion of negative cerebrospinal fluid (CSF) cytology to positive. Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis. (NCT00602667)
Timeframe: From date on treatment until date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment

InterventionPercent Probability (Number)
Low-Risk Group73.9
Intermediate-Risk Group46.9
High-Risk Group30.8

[back to top]

Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup

Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. Eligible medulloblastoma patients who received any methotrexate and had molecularly confirmed medulloblastoma are included in this analysis. Five patients were excluded as 3 had no archival tissue available and 2 were found to not be medulloblastoma by methylation profile. (NCT00602667)
Timeframe: From date on treatment to date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment

InterventionPercent Probability (Number)
Low-risk SHH Patients73.9
Intermediate-risk SHH Patients50.0
High-risk SHH Patients54.5
Intermediate-risk Group 3 Patients30.8
High-risk Group 3 Patients9.1
Intermediate-risk Group 4 Patients62.5
High-risk Group 4 Patients50.0

[back to top]

Percentage of Patients With Objective Responses Rate to Induction Chemotherapy

For patients treated in the intermediate and high risk strata with residual or metastatic disease we will estimate the stratum-specific objective response rate (complete response (CR) or partial response [ PR]). All patients who receive at least 1 -dose of methotrexate are evaluable for response. Objective responses must be sustained for at least eight weeks. (NCT00602667)
Timeframe: From on-study date to 2 months after completion of induction chemotherapy (up to 4 months after on-study date)

InterventionPercentage of patients (Number)
Intermediate-Risk Group58.3
High-Risk Group21.1

[back to top]

Rate of Distant Disease Progression

Distant failure was defined as the interval from end of RT to date of distant failure (or combined local + distant failure). Competing events were local failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval. (NCT00602667)
Timeframe: 1 year after completion of radiation therapy for last patient

Interventionpercentage of participants (Number)
Intermediate-risk Patients Who Received Focal Radiation25.6

[back to top]

Rate of Local Disease Progression

Local failure was defined as the interval from end of RT to date of local failure (or combined local + distant failure). Competing events were distant failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval. (NCT00602667)
Timeframe: 1 year after completion of radiation therapy for last patient

InterventionPercentage of participants (Number)
Intermediate-risk Patients Who Received Focal Radiation13.2

[back to top]

Topotecan Apparent Oral Clearance in Maintenance Chemotherapy

Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan apparent oral clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 0.25, 1.5 and 6 hours post-dose

InterventionL/h (Median)
Low-Risk Group41.4
Intermediate-Risk Group41.0
High-Risk Group44.6

[back to top]

Topotecan AUC0-24h in Consolidation Chemotherapy

Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, 5 min., 1, 3, and 24 hours from end of infusion

Interventionµg·h/L (Median)
Intermediate-Risk Group117
High-Risk Group116

[back to top]

Topotecan AUC0-24h in Maintenance Chemotherapy

Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 0.25, 1.5, 6, and 24 hours post-dose

Interventionµg·h/L (Median)
Low-Risk Group10.90
Intermediate-Risk Group11.60
High-Risk Group10.33

[back to top]

Topotecan Clearance in Consolidation Chemotherapy

Topotecan plasma concentration-time data are collected on day 1 of consolidation cycle 1 after a single IV dose. Individual estimates of topotecan clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, 5 min., 1, and 3 hours from end of infusion

InterventionL/h/m^2 (Median)
Intermediate-Risk Group30.3
High-Risk Group26.40

[back to top]

Concentration of Cerebrospinal Fluid Neurotransmitters

Concentrations of various neurotransmitters in cerebrospinal fluid were measured at 5 timepoints. The median concentration of each neurotransmitter at each time point was calculated and provided with a full range. (NCT00602667)
Timeframe: Baseline, at the completion of therapy, and every 12 months up to 36 months after off therapy date

Interventionng/ml (Median)
Dopamine concentration at baselineDopamine concentration at completion of treatmentDopamine concentration at 12 months off treatmentDopamine concentration at 24 months off treatmentDopamine concentration at 36 months off treatment3,4-dihydroxyphenylacetic acid concentration at baseline3,4-dihydroxyphenylacetic acid concentration at completion of treatment3,4-dihydroxyphenylacetic acid concentration at 12 months off treatment3,4-dihydroxyphenylacetic acid concentration at 24 months off treatment3,4-dihydroxyphenylacetic acid concentration at 36 months off treatmentHydroxytryptamine concentration at baselineHydroxytryptamine concentration at completion of treatmentHydroxytryptamine concentration at 12 months off treatmentHydroxytryptamine concentration at 24 months off treatmentHydroxytryptamine concentration at 36 months off treatmentHydroxyindoleacetic acid concentration at baselineHydroxyindoleacetic acid concentration at completion of treatmentHydroxyindoleacetic acid concentration at 12 months off treatmentHydroxyindoleacetic acid concentration at 24 months off treatmentHydroxyindoleacetic acid concentration at 36 months off treatmentHomovanillic acid concentration at baselineHomovanillic acid concentration at completion of treatmentHomovanillic acid concentration at 12 months off treatmentHomovanillic acid concentration at 24 months off treatmentHomovanillic acid concentration at 36 months off treatment
Patients With Neurotransmitter Studies3.163.706.434.464.052.561.621.041.521.002.382.012.002.441.6252.0352.7235.7233.9831.5682.44114.1368.2888.2779.78

[back to top]

Number and Type of Genetic Polymorphisms

Types of genetic polymorphisms of neurotransmitters were examined. We studied 3 genetic polymorphisms; these were types of genetic polymorphisms involved in dopamine metabolism. They were as follows: rs6323, rs4680, and rs6280. (NCT00602667)
Timeframe: At study enrollment (Day 0)

InterventionParticipants (Count of Participants)
rs6323rs4680rs6280
Number of Patients With Neurotransmitter Studies171717

[back to top]

Number of Participants With Chromosomal Abnormalities

Amplifications and deletions (gains and losses) for chromosomes of interest are shown in the table of measured values. (NCT00602667)
Timeframe: Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment

,,
InterventionParticipants (Count of Participants)
chr2p gain/amplificationchr2p loss/deletionchr2q gain/amplificationchr2q loss/deletionchr6p gain/amplificationchr6p loss/deletionchr6q gain/amplificationchr6q loss/deletionchr8p gain/amplificationchr8p loss/deletionchr8q gain/amplificationchr8q loss/deletionchr9p gain/amplificationchr9p loss/deletionchr9q gain/amplificationchr9q loss/deletionchr10p gain/amplificationchr10p loss/deletionchr10q gain/amplificationchr10q loss/deletionchr20p gain/amplificationchr20p loss/deletionchr20q gain/amplificationchr20q loss/deletion
High-Risk Group606032320807331507090505
Intermediate-Risk Group121230302635601505070403
Low-Risk Group505010101010442600030201

[back to top]

Number of Successful Collections for Frozen and Fixed Tumor Samples

Successful collections will be defined as the number of patients who have frozen/fixed tumor samples available. (NCT00602667)
Timeframe: Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment

,,
InterventionParticipants (Count of Participants)
Number with frozen tumor tissueNumber with fixed tumor tissue
High-Risk Group3271
Intermediate-Risk Group73153
Low-Risk Group2754

[back to top]

Numbers of Patients With Gene Alterations

Gene alterations, which include single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations are shown for specific genes of interest in the results table. (NCT00602667)
Timeframe: Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment

,,
InterventionParticipants (Count of Participants)
PTCH1 alterationSUFU alterationKMT2D alterationSMO alterationBCOR alterationPTEN alterationBRCA2 alterationGLI2 alterationSMARCA4 alterationTP53 alterationMYCN alteration
High-Risk Group31310000001
Intermediate-Risk Group41100000101
Low-Risk Group76521100200

[back to top]

Numbers of Patients With Molecular Abnormalities by Tumor Type

Alterations included single nucleotide variants (SNPs), amplifications, deletions, translocations, indels, and germline alterations. Cytogenetic information shows gains and losses as specified in the table of measured values. (NCT00602667)
Timeframe: Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment

,,,,,,
InterventionParticipants (Count of Participants)
PTCH1 alterationSUFU alterationKMT2D alterationSMO alterationBCOR alterationPTEN alterationBRCA2 alterationGLI2 alterationSMARCA4 alterationTP53 alterationMYCN amplificationchr2p gain/amplificationchr2p loss/deletionchr2q gain/amplificationchr2q loss/deletionchr6p gain/amplificationchr6p loss/deletionchr6q gain/amplificationchr6q loss/deletionchr8p gain/amplificationchr8p loss/deletionchr8q gain/amplificationchr8q loss/deletionchr9p gain/amplificationchr9p loss/deletionchr9q gain/amplificationchr9q loss/deletionchr10p gain/amplificationchr10p loss/deletionchr10q gain/amplificationchr10q loss/deletionchr20p gain/amplificationchr20p loss/deletionchr20q gain/amplificationchr20q loss/deletion
High-risk Group 3 Patients00000000001101032320706030307080404
High-risk Group 4 Patients00000000000000000000101000000000000
High-risk SHH Patients31310000000404000000000301200010101
Intermediate-risk Group 3 Patients00000000100010120201221100005050303
Intermediate-risk Group 4 Patients00000000000010110100404101000000000
Intermediate-risk SHH Patients41100000001000000000000400500020100
Low-risk SHH Patients76521100200505010101010442600030201

[back to top]

Pharmacogenetic Variation on Central Nervous System Transmitters

Frequencies of genetic polymorphisms were reported. (NCT00602667)
Timeframe: At study enrollment (Day 0)

InterventionParticipants (Count of Participants)
Genetic Polymorphisms for monoamine oxidase A (MAOA) rs632372067969Genetic Polymorphisms for catecholamine-O-methyltransferase (COMT) rs468072067969Genetic Polymorphisms for dopamine receptor D (DRD3) rs628072067969
AGCCTCTTGGAATG
Patients With Neurotransmitter Studies2
Patients With Neurotransmitter Studies13
Patients With Neurotransmitter Studies7
Patients With Neurotransmitter Studies5
Patients With Neurotransmitter Studies0
Patients With Neurotransmitter Studies6
Patients With Neurotransmitter Studies4

[back to top]

Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1

Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide AUC0-24h are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose

Interventionµmol·h/L (Median)
Low-Risk Group39.9
Intermediate-Risk Group38.7
High-Risk Group42.2

[back to top]

Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 1

Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

InterventionL/h/m^2 (Median)
Low-Risk Group2.39
Intermediate-Risk Group2.08
High-Risk Group2.43

[back to top]

4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2

4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group95.9
Intermediate-Risk Group49.5
High-Risk Group43.5

[back to top]

4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1

4-OH cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group96.8
Intermediate-Risk Group48.7
High-Risk Group39.8

[back to top]

Cyclophosphamide Clearance in Induction Chemotherapy

Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

InterventionL/h/m^2 (Median)
Low-Risk Group2.40
Intermediate-Risk Group2.23
High-Risk Group2.25

[back to top]

Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 2

Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

InterventionL/h/m^2 (Median)
Low-Risk Group2.48
Intermediate-Risk Group2.55
High-Risk Group2.37

[back to top]

Erlotinib Apparent Oral Clearance

Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent oral clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 1, 2, 4, 8, and 24 hours post-dose

InterventionL/h/m^2 (Median)
Low-Risk Group6.53
Intermediate-Risk Group7.79
High-Risk Group8.40

[back to top]

Erlotinib Apparent Volume of Central Compartment

Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib apparent volume of central compartment are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 1, 2, 4, 8, and 24 hours post-dose

InterventionL/m^2 (Median)
Low-Risk Group72.9
Intermediate-Risk Group61.7
High-Risk Group104.8

[back to top]

Erlotinib AUC0-24h

Erlotinib plasma concentration-time data are collected on day 1 of maintenance cycle B2. Individual estimates of erlotinib AUC0-24h (area under concentration curve from 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 1, 2, 4, 8, and 24 hours post-dose

Interventionµmol·h/L (Median)
Low-Risk Group31.0
Intermediate-Risk Group23.5
High-Risk Group22.0

[back to top]

Event-free Survival (EFS) Compared to Historical Controls

EFS was measured from the date of initial treatment to the earliest date of disease progression, second malignancy or death for patients who fail; and to the date of last contact for patients who remain at risk for failure. 1-year EFS estimates are reported by risk group. EFS was compared to St. Jude historical cohorts by risk group using hazard ratios with 95% confidence intervals. (NCT00602667)
Timeframe: From date on treatment until date of first event (progression, second malignancy or death) or until date of last contact, assessed up to 10 years

InterventionPercent probability (Number)
SJYC07 Low-risk Medulloblastoma Patients73.9
SJYC07 Intermediate-risk Medulloblastoma Patients46.9
SJYC07 High-risk Medulloblastoma Patients30.8

[back to top]

4-OH Cyclophosphamide AUC0-24h in Induction Chemotherapy

4-OH cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group116.4
Intermediate-Risk Group111.3
High-Risk Group109.1

[back to top]

4-OH Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1

4-OH cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of 4-OH cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose

Interventionµmol·h/L (Median)
Low-Risk Group1.98
Intermediate-Risk Group1.96
High-Risk Group1.82

[back to top]

CEPM AUC0-24h in Consolidation Chemotherapy Cycle 1

Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group128.9
Intermediate-Risk Group62.2
High-Risk Group51.8

[back to top]

CEPM AUC0-24h in Consolidation Chemotherapy Cycle 2

Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group132.7
Intermediate-Risk Group46.8
High-Risk Group44.0

[back to top]

CEPM AUC0-24h in Induction Chemotherapy

Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 9 in one induction cycle. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group140.2
Intermediate-Risk Group137.8
High-Risk Group135.3

[back to top]

CEPM AUC0-24h in Maintenance Chemotherapy Cycle A1

Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 0.5, 1.75, 3, 6, and 24 hours post-dose

Interventionµmol·h/L (Median)
Low-Risk Group1.59
Intermediate-Risk Group1.65
High-Risk Group1.41

[back to top]

Cyclophosphamide Apparent Oral Clearance in Maintenance Chemotherapy Cycle A1

Cyclophosphamide plasma concentration-time data are collected on day 1 of maintenance cycle A1. Individual estimates of cyclophosphamide apparent oral clearance are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-dose, 0.5, 1.75, 3 and 6 hours post-dose

InterventionL/h/m^2 (Median)
Low-Risk Group2.95
Intermediate-Risk Group2.83
High-Risk Group2.74

[back to top]

Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1

Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group1968
Intermediate-Risk Group1504
High-Risk Group868

[back to top]

Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2

Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group1966
Intermediate-Risk Group799
High-Risk Group899

[back to top]

Cyclophosphamide AUC0-24h in Induction Chemotherapy

Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis. (NCT00602667)
Timeframe: Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion

Interventionµmol·h/L (Median)
Low-Risk Group2070
Intermediate-Risk Group2150
High-Risk Group2105

[back to top]

Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 13 to Week 22

The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks. (NCT00618813)
Timeframe: Week 13 to week 22

Interventionparticipants (Number)
Treatment (Combination Chemotherapy)9

[back to top]

Incidence of Death

Incidence of death from complications of therapy while the patient is on protocol therapy or within one month of terminating protocol therapy (NCT00618813)
Timeframe: Length of protocol therapy (up to 37 weeks) plus 30 days

Interventionparticipants (Number)
Treatment (Combination Chemotherapy)0

[back to top]

Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Enrollment to Week 12

The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks. (NCT00618813)
Timeframe: Enrollment to week 12

Interventionparticipants (Number)
Treatment (Combination Chemotherapy)12

[back to top]

Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 29 to Week 37

The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks. (NCT00618813)
Timeframe: Week 29 to week 37

Interventionparticipants (Number)
Treatment (Combination Chemotherapy)14

[back to top]

Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 23 to Week 28

The incidence rate of DLT while on protocol therapy where DLT is defined as (1) Grade 3 or greater nonhematological adverse event that is possibly, probably, or likely related to therapy with the specific exception of Grade 3 or greater nausea or vomiting controlled by standard supportive care measures, Grade 3 infection and Grade 3 alopecia; or (2) Grade 4 or higher hematological AE that delays the administration of therapy at least 2 weeks. (NCT00618813)
Timeframe: Week 23 to week 28

Interventionparticipants (Number)
Treatment (Combination Chemotherapy)9

[back to top]

Median Time to Response

The time to response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started) in months. (NCT00632827)
Timeframe: Up to 2 years

Interventionmonths (Median)
Treatment Plan3.0

[back to top]

Overall Survival Rate

Overall Survival will be defined the percentage of participants alive at median follow up of 25 months. If the patient is lost to follow-up, survival will be censored on the last date the patient was known to be alive. The analysis is expected to occur up to 60 months after the first patient is entered the trial. (NCT00632827)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
Treatment Plan75

[back to top]

Complete Response Rate

The complete response rate will be defined as the total number of patients who have defined complete response using study regimen (intensive induction therapy/progressive chemotherapy/stem cell rescue), divided by the number of patients entered in the trial using response-evaluable patients. (NCT00632827)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment Plan14

[back to top]

Progression Free Survival

Progression-Free Survival will be defined the percentage of participants alive and progression-free at median follow up of 25 months. Patients will be routinely followed for disease progression and those who die without a reported prior progression will be considered to have progressed on the day of their death. Patients who did not progress or die will be censored at the day of their last treatment assessment. Patients who have not received study regimen or did not have on-study treatment assessments will be censored on the day they entered the trial. Patients who receive chemotherapy for reasons other than documented progression of disease or clinical progression without documented progression will be censored on the earliest date of subsequent therapy (NCT00632827)
Timeframe: Up to 3 years

Interventionpercentage of partcipants (Number)
Treatment Plan65

[back to top]

An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria

Response was assessed by computerized tomography (CT) after every 2 cycles of induction therapy, one time at least 4 weeks after completing induction (i.e., prior to maintenance), and then every 3 months while on maintenance therapy. At the conclusion of maintenance therapy, patients underwent one post-treatment scan, with further scans completed at the discretion of the treating physician. Positron emission tomography was permitted but only CT measurements were used to determine response. (NCT00634179)
Timeframe: Following completion of therapy, up to 2 years

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Overall Response Rate (ORR)
Phase I: Induction13619
Phase II: Maintenance191029

[back to top]

Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)

INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression. (NCT00634179)
Timeframe: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks

Interventionmg/m^2 (Number)
MTD of Bortezomib With Vincristine Capped at 1.5 mg1.62

[back to top]

Geometric Mean Area Under Curve (AUC) of Analyte, 2-dechloro-cyclophosphamide(2-deCI-CP), in Aprepitant Treatment and Control Group

Pharmacokinetic (PK) blood sampling to determine the geometric mean AUC of 2-deCI-CP, during & post chemotherapy infusion, baseline, at 30, 60, 75, 90 minutes, and 2 , 4, 6, 8, and 24 hours from start of cyclophosphamide infusion. The absence of PK drug interactions was determined if the 90% Confidence Intervals (CI) of the geometric mean AUC ratio between 2 groups is within 0.80 to 1.25. Measurements reported as concentrate times the time, i.e. micrograms (ug)/milliliters (mL) times hour (hr). (NCT00651755)
Timeframe: Time points over 24 hours of cyclophosphamide infusion for both cycles (21 day cycle)

Interventionug/mL*hr (Geometric Mean)
Aprepitant4.5
Control6.0

[back to top]

Geometric Mean Area Under Curve (AUC) of Analyte, 4-hydroxy-cyclophosphamide (4-OH-CP), in Aprepitant Treatment and Control Group

Pharmacokinetic (PK) blood sampling to determine the geometric mean AUC of 4-hydroxy-cyclophosphamide (4-OH-CP), during & post chemotherapy infusion, baseline, at 30, 60, 75, 90 minutes, and 2 , 4, 6, 8, and 24 hours from start of cyclophosphamide infusion. The absence of PK drug interactions was determined if the 90% Confidence Intervals (CI) of the geometric mean AUC ratio between 2 groups is within 0.80 to 1.25. Measurements reported as concentrate times the time, i.e. micrograms (ug)/milliliters (mL) times hour (hr). (NCT00651755)
Timeframe: Time points over 24 hours of cyclophosphamide infusion for both cycles (21 day cycle)

Interventionug/mL*hr (Geometric Mean)
Aprepitant3.9
Control4.0

[back to top]

Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group

Pharmacokinetic (PK) blood sampling to determine the geometric mean AUC of Cyclophosphamide (CP) during & post chemotherapy infusion, baseline, at 30, 60, 75, 90 minutes, and 2 , 4, 6, 8, and 24 hours from start of cyclophosphamide infusion. The absence of PK drug interactions was determined if the 90% Confidence Intervals (CI) of the geometric mean AUC ratio between 2 groups is within 0.80 to 1.25. Measurements reported as concentrate times the time, i.e. micrograms (ug)/milliliters (mL) times hour (hr). (NCT00651755)
Timeframe: Time points over 24 hours of cyclophosphamide infusion for both cycles (21 day cycle)

Interventionug/mL*hr (Geometric Mean)
Aprepitant300
Control Group250

[back to top]

Geometric Mean Area Under Curve (AUC) of Analyte, Prednisolone (PL), in Aprepitant Treatment and Control Group

Pharmacokinetic (PK) blood sampling to determine the geometric mean AUC of PL, during & post chemotherapy infusion, baseline, at 30, 60, 75, 90 minutes, and 2 , 4, 6, 8, and 24 hours from start of cyclophosphamide infusion. The absence of PK drug interactions was determined if the 90% Confidence Intervals (CI) of the geometric mean AUC ratio between 2 groups is within 0.80 to 1.25. Measurements reported as concentrate times the time, i.e. nanograms (ng)/milliliters (mL) times hour (hr). (NCT00651755)
Timeframe: Time points over 8 hours of cyclophosphamide infusion for both cycles (21 day cycle)

Interventionng/mL*hr (Geometric Mean)
Aprepitant4416
Control3817

[back to top]

Geometric Mean Area Under Curve (AUC) of Analyte, Vincristine (VC), in Aprepitant Treatment and Control Group

Pharmacokinetic (PK) blood sampling to determine the geometric mean AUC of VC, during & post chemotherapy infusion, baseline, at 30, 60, 75, 90 minutes, and 2 , 4, 6, 8, and 24 hours from start of cyclophosphamide infusion. The absence of PK drug interactions was determined if the 90% Confidence Intervals (CI) of the geometric mean AUC ratio between 2 groups is within 0.80 to 1.25. Measurements reported as concentrate times the time, i.e. nanograms (ng)/milliliters (mL) times hour (hr). (NCT00651755)
Timeframe: Time points over 24 hours of cyclophosphamide infusion for both cycles (21 day cycle)

Interventionng/mL*hr (Geometric Mean)
Aprepitant41
Control39

[back to top]

Geometric Mean Area Under Curve (AUC) of Analyte,Prednisone (PR), in Aprepitant Treatment and Control Group

Pharmacokinetic (PK) blood sampling to determine the geometric mean AUC of PR, during & post chemotherapy infusion, baseline, at 30, 60, 75, 90 minutes, and 2 , 4, 6, 8, and 24 hours from start of cyclophosphamide infusion. The absence of PK drug interactions was determined if the 90% Confidence Intervals (CI) of the geometric mean AUC ratio between 2 groups is within 0.80 to 1.25. Measurements reported as concentrate times the time, i.e. nanograms (ng)/milliliters (mL) times hour (hr). (NCT00651755)
Timeframe: Time points over 8 hours of cyclophosphamide infusion for both cycles (21 day cycle)

Interventionng/mL*hr (Geometric Mean)
Aprepitant287
Control265

[back to top]

Overall Survival (OS)

Estimated 4-year survival, where survival is calculated as the time from study enrollment to death from any cause or last follow-up alive whichever occurs first. Kaplan-Meier method is used for estimation. Patients alive at last contact are censored. (NCT00653068)
Timeframe: Up to 4 years after study enrollment

InterventionEstimated Probability (Number)
Stratum I0.3888
Stratum III0.5486

[back to top]

Toxic Death

The number of patients who experience death that is considered to be primarily attributable to complications of treatment. (NCT00653068)
Timeframe: During and after completion of study treatment up to 1 year after enrollment.

InterventionParticipants (Count of Participants)
Stratum I3
Stratum III1

[back to top]

Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy

Number of Participants with Nonhematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy. (NCT00653068)
Timeframe: During protocol therapy up to 1 year after enrollment.

InterventionParticipants (Count of Participants)
AcidosisAcute kidney injuryApneaAdult respiratory distress syndromeAspirationAtelectasisCatheter related infectionCentral nervous system necrosisDehydrationDiarrheaDissmeminated intravascular coagulation (DIC)EnterocolitisFebrile neutropeniaHearing impairmentHematuriaHydrocephalusHypernatremiaHypoalbuminemiaHypocalcemiaHypoglycemiaHypokalemiaHyponatremiaHypophosphatemiaHypotensionHypoxiaIncreased Alanine aminotransferaseIncreased Aspartate aminotransferaseIncreased LipaseIntracranial hemorrhagentraoperative venous injuryLaryngospasmLeft ventricular systolic dysfunctionLung infectionMulti-organ failureMucositis oralPoisoning and procedural complicationsOther gastrointestinal disordersOther infectionPneumonitisProductive coughPulmonary edemaRecurrent laryngeal nerve palsyRenal calculiRespiratory failureSeizureSepsisSinus tachycardiaStridorUpper respiratory infectionVascular access complicationVoice alterationVomitingWeight loss
All Patients11213121111161111132922465412111313117211113262211111

[back to top]

Event-free Survival

Estimated 4-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact. (NCT00653068)
Timeframe: Up to 4 years after study enrollment

InterventionEstimated probability (Number)
Stratum I0.3401
Stratum III0.4500

[back to top]

Neurotoxicity Assessment at Cycle 4

Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 16 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to fill out at completion of cycle 4 of their chemotherapy treatment and the mean total score for all patients is reported. (NCT00659269)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Taxane Group: Multivitamin (MV) Arm14.5
Multivitamin + Vitamin B12 + Vitamin B614.5
Heavy Metals Group: Multivitamin (MV) Arm8.71
Heavy Metals Group: MV + Vitamin B12 + Vitamin B6 Arm7.05
Vinca Alkaloids Group: Multivitamin (MV) Arm17.5
Vinca Alkaloids Group: MV + Vitamin B12 + Vitamin B6 Arm9.22

[back to top]

Neurotoxicity Assessment at Cycle 2

Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 11 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to complete at completion of cycle 2 of chemotherapy treatment and the mean total score for all patients is reported. (NCT00659269)
Timeframe: 2 weeks

Interventionunits on a scale (Mean)
Taxane Group: Multivitamin (MV) Arm13.0
Taxane Group: MV + Vitamin B12 + Vitamin B612.0
Heavy Metals Group: Multivitamin (MV) Arm9.7
Heavy Metals Group: MV + Vitamin B12 + Vitamin B6 Arm8.4
Vinca Alkaloids Group: Multivitamin (MV) Arm14.56
Vinca Alkaloids Group: MV + Vitamin B12 + Vitamin B6 Arm5.6

[back to top]

Neurotoxicity Assessment at Baseline

Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 11 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to fill out at baseline (prior to chemotherapy treatment) and the mean total score for all patients is reported. (NCT00659269)
Timeframe: At study start; prior to treatment (week 0)

Interventionunits on a scale (Mean)
Taxane Group: Multivitamin (MV) Arm8.5
Taxane Group: MV + Vitamin B12 + Vitamin B67.3
Heavy Metals Group: Multivitamin (MV) Arm5.23
Heavy Metals Group: MV + Vitamin B12 + Vitamin B6 Arm4.58
Vinca Alkaloids Group: Multivitamin (MV) Arm6.80
Vinca Alkaloids Group: MV + Vitamin B12 + Vitamin B6 Arm2.08

[back to top]

Change in Neurotoxicity Assessment Between Cycle 4 and Baseline

Neurotoxicity is evaluated using The Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) questionnaire. FACT-Tax is a validated, self-reported instrument. The questionnaire consists of 11 questions and possible scores for each question range from 0 (no neurotoxicity symptoms) to 4 (worst possible neurotoxicity symptoms). The total score for any patient can therefore range from 0 to 44. The questionnaire is given to patients to fill out at baseline, cycle 2, and cycle 4 of their chemotherapy treatment. Change in neurotoxicity scores from baseline to the completion of 4 cycles are reported as the mean total score for all patients. (NCT00659269)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Taxane Group: Multivitamin (MV) Arm7.0
Taxane Group: MV + Vitamin B12 + Vitamin B67.2
Heavy Metals Group: Multivitamin (MV) Arm3.9
Heavy Metals Group: MV + Vitamin B12 + Vitamin B6 Arm4.7
Vinca Alkaloids Group: Multivitamin (MV) Arm11.8
Vinca Alkaloids Group: MV + Vitamin B12 + Vitamin B6 Arm7

[back to top]

Overall Response Rate: Percentage of Participants With Complete Remission (CR) or Partial Remission (PR)

Complete Remission (CR) was defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count ≥1.0 × 10^9/L, a platelet count ≥100 × 10^9/L, and no extramedullary disease. Complete recovery except platelets (CRp) was defined as for CR, except for recovery of platelet count to <100 × 10^9/L. Partial remission (PR) was defined as a bone marrow with >5% and <25% blasts with a granulocyte count of ≥1.0 × 109/L and a platelet count of ≥100 × 10^9/L. Relapse was defined by recurrence of more than 5% lymphoblasts in the bone marrow aspirate or by the presence of extramedullary disease after achieving CR. (NCT00669877)
Timeframe: After two 21-day courses, response to treatment checked for Complete Remission (CR)

Interventionpercentage of participants (Number)
Hyper-CVAD89

[back to top]

Complete Remission Rate: Percentage of Participants With Complete Remission (CR)

Complete Remission (CR) was defined as the presence of 5% or less blasts in the bone marrow, with a granulocyte count ≥1.0 × 10^9/L, a platelet count ≥100 × 10^9/L, and no extramedullary disease. Complete recovery except platelets (CRp) was defined as for CR, except for recovery of platelet count to <100 × 10^9/L. Partial remission (PR) was defined as a bone marrow with >5% and <25% blasts with a granulocyte count of ≥1.0 × 109/L and a platelet count of ≥100 × 10^9/L. Relapse was defined by recurrence of more than 5% lymphoblasts in the bone marrow aspirate or by the presence of extramedullary disease after achieving CR. (NCT00669877)
Timeframe: After two 21-day courses, response to treatment checked for Complete Remission (CR)

Interventionpercentage of participants (Number)
Hyper-CVAD85

[back to top]

Event-free > Survival at 12 Months (Phase 2, DLBCL/Mixed Dose Level 3)

Other Phase II Cohorts were not evaluable for event-free survival analysis. (NCT00670358)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Ph II, DLBCL/Mixed44

[back to top]

Progression-free > Survival at 24 Months (Phase 2, Transformed/Composite)

"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions~Other Phase II Cohorts were not evaluable for progression-free survival analysis." (NCT00670358)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Ph II, Transformed/Composite27

[back to top]

Toxicity as Assessed by NCI CTCAE v3.0 (Phase I)

(NCT00670358)
Timeframe: 5 years

,,
InterventionParticipants (Count of Participants)
Grade 3+ Adverse EventGrade 4+ Adverse EventGrade 3+ Hem Adverse EventGrade 4+ Hem Adverse EventGrade 3+ Non-Hem Adverse Event
Ph 1, DL 132321
Ph1, DL 231311
Ph1, DL 354542

[back to top]

Percentage of Participants With Event-free Survival (EFS)

Percentage of participants who were event free. Event Free Probability defined as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignant neoplasm, remission death) or date of last contact for subjects who are event-free. (NCT00671034)
Timeframe: 5 Years

InterventionPercentage of participants (Number)
Arm I (Calaspargase Pegol 2100)72.35
Arm II (Calaspargase Pegol 2500)80.8
Arm III (Pegaspargase 2500)79.34

[back to top]

Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction

Percentage of participants with Negative MRD (MRD<0.01%). (NCT00671034)
Timeframe: End of induction (Day 29)

InterventionPercentage of participants (Number)
Arm I (Calaspargase Pegol 2100)65.2
Arm II (Calaspargase Pegol 2500)81
Arm III (Pegaspargase 2500)72.5

[back to top]

Asparaginase Level

The proportion of patients with an asparaginase level of at least 0.1 IU/mL and the proportion with at least 0.4 IU/mL on Days 4, 15, 22 and 29 of Induction compared to Oncaspar (NCT00671034)
Timeframe: Days 4, 15, 22 and 29 of Induction

,,
Interventionpercentage of patients (Number)
Level at least 0.1 IU/mL day 4Level at least 0.1 IU/mL day 15Level at least 0.1 IU/mL day 22Level at least 0.1 IU/mL day 29Level at least 0.4 IU/mL day 4Level at least 0.4 IU/mL day 15Level at least 0.4 IU/mL day 22Level at least 0.4 IU/mL day 29
Arm I (Calaspargase Pegol 2100)098.498.294.9075.837.513.6
Arm II (Calaspargase Pegol 2500)010010095.0095.062.527.5
Arm III (Pegaspargase 2500)010095.128.6093.014.60

[back to top]

Pharmacodynamics (PD)

Plasma Asparaginase Concentration During consolidation and induction. (NCT00671034)
Timeframe: Day 29 of consolidation and induction

,,
InterventionmIU/mL (Median)
Plasma Asparaginase Concentration- ConsolidationPlasma Asparaginase Concentration- Induction
Arm I (Calaspargase Pegol 2100)575.9271.6
Arm II (Calaspargase Pegol 2500)617.2339.6
Arm III (Pegaspargase 2500)562.172.8

[back to top]

Plasma and CSF Concentrations of Asparagine in ug/ml

The plasma and CSF concentrations of asparagine in ug/ml after administration of EZN-2285 compared to Oncaspar. (NCT00671034)
Timeframe: 25 Days Post-dose (Day 29)

,,
Interventionug/mL (Mean)
CSF asparagine concentration (ug/mL)Plasma asparagine concentration (ug/mL)
Arm I (Calaspargase Pegol 2100)0.20.2
Arm II (Calaspargase Pegol 2500)0.190.25
Arm III (Pegaspargase 2500)0.260.83

[back to top]

Toxicities During Post Induction Intensification Therapy (All Grades)

The calculation of AE incidence will be based on the number of patients per AE category. For each patient who has multiple AEs classified to the same category, that patient will be tabulated under the worst toxicity grade for that AE category. The incidence of AEs will be tabulated by treatment arm and by organ class. Special attention will be paid to hypersensitivity, pancreatitis, coagulopathy, infection, neurologic dysfunction and thromboembolic events. (NCT00671034)
Timeframe: Up to 5 years

,,
InterventionPercentage of participants (Number)
Alergic Reaction - ConsolidationAlergic Reaction - Delayed Intensification IAlergic Reaction - Interim Maintenance ICNS - ConsolidationCNS - Delayed Intensification ICNS - Interim Maintenance IHyperbilirubinemia - ConsolidationHyperbilirubinemia - Delayed Intensification IHyperbilirubinemia - Interim Maintenance IHyperglycemia - ConsolidationHyperglycemia - Delayed Intensification IHyperglycemia - Interim Maintenance IHyperlipidemia - ConsolidationHyperlipidemia - Delayed Intensification IHyperlipidemia - Interim Maintenance I% patients w/INR increase - Consolidation% pts w/INR increase - Delayed Intensification I% patients w/INR increase - Interim Maintenance IPancreatitis - ConsolidationPancreatitis -Delayed Intensification IPancreatitis - Interim Maintenance I% pts w/prolongation of APT time - Consolidation% pts w/prolongation APT time -Delayed Intension I%pts w/prolongation APT time-Interim maintenance IThrombosis - ConsolidationThrombosis - Delayed Intensification IThrombosis - Interim Maintenance I
Arm I (Calaspargase Pegol 2100)20.44.40.00.00.00.053.128.941.344.944.434.82.02.22.26.16.72.210.22.22.28.28.96.50.02.20.0
Arm II (Calaspargase Pegol 2500)27.30.00.00.03.80.045.538.527.642.461.544.83.00.03.43.03.80.06.17.73.49.126.96.90.00.00.0
Arm III (Pegaspargase 2500)23.30.02.10.02.60.030.210.533.346.536.833.37.00.02.67.00.02.67.00.02.67.018.47.72.30.00.0

[back to top]

Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)

Mean half-life of plasma asparaginase during consolidation and Induction; half-life is defined as the time taken for drug concentration to decrease by half. (NCT00671034)
Timeframe: Post Day 29 of Induction and Post Day 22 of Consolidation

,,
Interventionhours (Mean)
Asparaginase half-life during ConsolidationAsparaginase half-life during Induction
Arm I (Calaspargase Pegol 2100)415.8305.1
Arm II ( Calaspargase Pegol 2500)355.9321.5
Arm III (Pegaspargase 2500)117.2126.9

[back to top]

Immunogenicity

Number of Patients with Positive Immunogenicity tests (NCT00671034)
Timeframe: 25 Days Post-dose (Day 29)

InterventionParticipants (Count of Participants)
Arm I (Calaspargase Pegol 2100)2
Arm II (Calaspargase Pegol 2500)2
Arm III (Pegaspargase 2500)4

[back to top]

Percentage of Participants With Complete Remission at the End of Induction

Complete Remission (CR) rate; where CR is defined as M1 marrow (< 5% lymphoblasts in the bone marrow) (NCT00671034)
Timeframe: End of induction (Day 29)

InterventionPercentage of participants (Number)
Arm I (Calaspargase Pegol 2100)92.4
Arm II (Calaspargase Pegol 2500)97.6
Arm III (Pegaspargase 2500)94.1

[back to top]

Number of Participants With a Response

Response - Complete remission (CR): Normalization peripheral blood & bone marrow 5% or & platelet count >100x10^9/L; CR with incomplete platelet recovery (CRp): CR but platelet count <100x10^9/L. CR with incomplete recovery (CRi): CR but platelet count <100x10^9/L or absolute neutrophil count < 1x10^9/L. Partial response (PR): As above except for presence of 6-25% marrow blasts. Lymphoblastic lymphoma (& ALL subtypes with extramedullary disease): CR - disappearance all known disease. PR - >50% decrease in tumor size using sum of product, includes 50% volume decrease in lesions measurable in 3 dimensions. No Response (NR) - No significant change (includes stable disease). Lesions decreased size but <50% or lesions with slight enlargement <25% increase in size. Progressive Disease (PD): Appearance new lesions, 25% or > increase in size existing lesions (>50% if 1 lesion & <2). (NCT00671658)
Timeframe: Response assessed following first 21 day course up to end of treatment with 8 cycles, up to 210 days

InterventionParticipants (Number)
Complete Response (CR)Complete Response without Platelet RecoveryPartial Response (PR)
HYPER-CVAD19834

[back to top]

Duration of Rituximab Infusion Including Dose Interruption Times

The median duration of the rituximab infusion on Day 1 of each cycle, including the duration of dose interruptions, is reported. (NCT00719472)
Timeframe: Day 1 of each of Cycles 1 to 6 or 8

InterventionMinutes (Median)
Cycle 1 (n=362)Cycle 2 (n=363)Cycle 3 (n=344)Cycle 4 (n=329)Cycle 5 (n=312)Cycle 6 (n=303)Cycle 7 (n=59)Cycle 8 (n=59)
Rituximab 375 mg/m^224591919191919191

[back to top]

Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)

(NCT00719472)
Timeframe: Cycle 2 through Cycle 6 or 8 (end of study)

InterventionPercentage of participants (Number)
Rituximab 375 mg/m^298.6

[back to top] [back to top]

Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1

(NCT00719472)
Timeframe: Cycle 1

InterventionPercentage of participants (Number)
Rituximab 375 mg/m^291.8

[back to top]

Percentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)

Serum samples for measurement of CD19+ lymphocytes were taken pre-dose (within 15 minutes before rituximab infusion). CD19+ lymphocyte counts were measured by flow cytometry using a fluorescent-activated cell sorter (FACS). (NCT00719472)
Timeframe: Day 1 of Cycle 2 and either Cycle 6 or 8 (last cycle)

InterventionPercentage of participants (Number)
Cycle 2 (n=338)Cycle 6 (n=240)Cycle 8 (n=32)
Rituximab 375 mg/m^250.568.387.5

[back to top]

Maximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)

Serum samples for rituximab pharmacokinetic analysis were taken pre-dose (within 15 minutes before rituximab infusion) and post-dose (within 15 minutes after the end of the rituximab infusion) after the first faster infusion (Cycle 2) and after the last infusion (either Cycle 6 or 8). An enzyme-linked immunosorbent assay (ELISA) was used to measure rituximab levels in the serum samples. (NCT00719472)
Timeframe: Day 1 of Cycles 2 and either 6 or 8 (last cycle)

Interventionµg/mL (Mean)
Cycle 2 (n=335)Cycle 6 (n=238)Cycle 8 (n=36)
Rituximab 375 mg/m^2228.0275.0299.0

[back to top]

Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events

Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay) (NCT00720109)
Timeframe: Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1)

InterventionPts with DLTs (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)1

[back to top]

Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)

An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death. (NCT00720109)
Timeframe: From the time entry on study to first event or date of last follow-up, assessed up to 7 years

Interventionpercentage of patients (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation

A 1-sample Z-test of proportions (alpha=5%, 1-sided test) will be used. (NCT00720109)
Timeframe: At end of consolidation (at 11 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)10.5
Standard-risk0
High-risk66.7

[back to top]

Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy

Percent of patients MRD Positive (MRD > 0.01%) at End of Induction. (NCT00720109)
Timeframe: At the end of induction therapy (at 5 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)40.7
Standard-risk29.2
High-risk100.0

[back to top]

Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy

Event-Free Survival (EFS) curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed. (NCT00720109)
Timeframe: At 3 years

InterventionPercent probability (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

Overall Response Rate (ORR)

ORR was defined as complete response (CR) + complete response, unconfirmed (CRu) + partial response (PR) as determined by the Independent Review Committee. Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death. (NCT00722137)
Timeframe: Median duration of follow-up of 40 months

InterventionParticipants (Number)
R-CHOP204
VcR-CAP211

[back to top]

18-Month Survival

18-month survival was defined as the estimated probability of survival at 18 months (Kaplan-Meier estimate). (NCT00722137)
Timeframe: Up to month 18 from the time of randomization

InterventionPercentage of Participants (Mean)
R-CHOP83.8
VcR-CAP84.9

[back to top]

Number of Participants Experiencing an Adverse Event (AE)

An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related. AEs were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 8 cycles (24 weeks) and AEs were collected for up to 30 days following the last dose of study drug. (NCT00722137)
Timeframe: Up to 107.4 months

InterventionParticipants (Number)
R-CHOP239
VcR-CAP240

[back to top]

Time to Progression (TTP)

Time to progression was defined as the duration from the date of randomization until the date of first documented evidence of progressive disease (PD) or date of relapse for subjects who experienced complete response (CR) or complete response, unconfirmed (CRu). PD and response were based on the assessment of an Independent Review Committee. (NCT00722137)
Timeframe: Median duration of follow-up of 40 months

InterventionDays (Median)
R-CHOP490.0
VcR-CAP929.0

[back to top]

Overall Survival (OS)

OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive. (NCT00722137)
Timeframe: Median duration of follow-up of 40 months

InterventionDays (Median)
R-CHOP1714.0
VcR-CAPNA

[back to top]

Overall Survival (OS) in Long Term Follow-up Period

OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive. (NCT00722137)
Timeframe: Up to 107.4 months

InterventionDays (Median)
R-CHOP1695.0
VcR-CAP2760.0

[back to top]

Progression Free Survival (PFS)

PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee. (NCT00722137)
Timeframe: Median duration of follow-up of 40 months

InterventionDays (Median)
R-CHOP437.0
VcR-CAP751.0

[back to top] [back to top]

Treatment-free Interval (TFI)

The TFI was defined as the duration from the date of last dose plus 1 day to the start date of the new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, treatment-free interval was censored at the date of death or the last date known to be alive. (NCT00722137)
Timeframe: Median duration of follow-up of 40 months

InterventionDays (Median)
R-CHOP624.0
VcR-CAP1236.0

[back to top]

Overall Complete Response (CR + CRu)

Overall complete response was defined as the number of participants with complete response (CR) and those with unconfirmed complete response (CRu). Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death. (NCT00722137)
Timeframe: Median duration of follow-up of 40 months

,
InterventionParticipants (Number)
Overall complete responseCRCRu
R-CHOP957916
VcR-CAP12210616

[back to top]

Duration of Response

The duration of treatment response was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR, CRu, or PR as determined by the Independent Review Committee. The duration of response for complete responders was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR or CRu verified by bone marrow and lactate dehydrogenase (LDH). (NCT00722137)
Timeframe: Median duration of follow-up of 40 months

,
InterventionDays (Median)
Duration of responseDuration for Complete responders
R-CHOP459.0563.0
VcR-CAP1110.01282.0

[back to top]

Number of Participants With Microarray Testing Results Are Completed Within 7 Days.

(NCT00736450)
Timeframe: Upto 7 days

InterventionParticipants (Count of Participants)
results within 7 days or lessresults in more than 7 days
Arm I112

[back to top]

Time to Perform Microarray Study After Receipt of Tissue

The time from tissue harvest to release of microarray test and IHC assay results will be noted in days. (NCT00736450)
Timeframe: Upto 14 days

Interventiondays (Mean)
Arm I4.4

[back to top]

5-year Overall Survival

Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact. (NCT00770224)
Timeframe: 0-5 years

Interventionpercentage of participants (Number)
R-CHOP+I-131 Tositumomab Followed by Rituximab Maintenance94

[back to top]

5-year Progression-free Survival

Measured from date of registration to date of first observation of progressive disease or death due to any cause. Progressive disease is ≥ 50% increase in the sum of products of greatest diameters (SPD) of target measurable nodal lesions over the smallest sum observed (over baseline if no decrease during therapy), or ≥ 50% increase in the greatest transverse diameter (GTD) of any node > 1 cm in shortest axis, or ≥ 50% increase in the SPD of other target measurable lesions (e.g., splenic or hepatic nodules) over the smallest sum observed. Appearance of any new bone marrow involvement; appearance of a new lesion/site; lymph nodes with the long axis is > 1.5 cm, or if the both the long and short axes are > 1 cm; in patients with no pretreatment PET scan or when the PET scan was positive before therapy, lesions should be PET positive; or death due to disease without prior documentation of progression. (NCT00770224)
Timeframe: 0-5 years

Interventionpercentage of participants (Number)
R-CHOP+I-131 Tositumomab Followed by Rituximab Maintenance85

[back to top]

Percentage of Participants With 3-year Progression-free Survival (PFS)

Measured from date of registration to date of first observation of progressive disease or death due to any cause. Progressive disease is ≥ 50% increase in the sum of products of greatest diameters (SPD) of target measurable nodal lesions over the smallest sum observed (over baseline if no decrease during therapy), or ≥ 50% increase in the greatest transverse diameter (GTD) of any node > 1 cm in shortest axis, or ≥ 50% increase in the SPD of other target measurable lesions (e.g., splenic or hepatic nodules) over the smallest sum observed. Appearance of any new bone marrow involvement; appearance of a new lesion/site; lymph nodes with the long axis is > 1.5 cm, or if the both the long and short axes are > 1 cm; in patients with no pretreatment PET scan or when the PET scan was positive before therapy, lesions should be PET positive; or death due to disease without prior documentation of progression. (NCT00770224)
Timeframe: 0-3 years

Interventionpercentage of participants (Number)
R-CHOP+I-131 Tositumomab Followed by Rituximab Maintenance90

[back to top] [back to top]

Relative Efficacy of the 2 Groups

The goal is to see if there are major differences between the two arms for each group in term of efficacy and of toxicity both overall and in comparison to the previous responses to rituximab alone. The comparisons are for level of response eg CR (>100k) vs PR (230-100k) vs NR (<30k) and for duration of response-----duration of response is controlled by comparison to duration of response from initial rituximab infusions (NCT00774202)
Timeframe: 2 years

,
Interventionnumber of responders (Number)
CRPRresponse longer than previous response
High Dose Rituximab400
Rituximab, C, V, P410

[back to top]

Number of Participants With SAEs

How many participants had SAEs among those receiving R-CVP or among those receiving double dose rituximab and did participants in one arm have substantially more SAEs than those in the other arm (NCT00774202)
Timeframe: 2 years

Interventionnumber of patients with SAEs (Number)
Rituximab + CVP0
Double Dose Rituximab1

[back to top]

Phase II MTD of Vorinostat

MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle). (NCT00787527)
Timeframe: 21 Days

Interventionmg/three times daily (Number)
Schedule B - Vorinostat Three Times Daily300

[back to top]

Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat

MTD of Vorinostat defined as highest dose level in which 6 patients have been treated with less than 2 instances of DLT. Continual reassessment during each 21-day cycle to assess DLT. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle. The dose of Vorinostat escalated in successive 3+3 cohorts of participants to determine the MTD. (NCT00787527)
Timeframe: 21 Days

Interventionparticipants (Number)
Schedule A - Vorinostat Once Daily1
Schedule A - Vorinostat Twice Daily2

[back to top]

Phase I Maximum Tolerated Dose (MTD) of Vorinostat

MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); and for Phase II Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle). (NCT00787527)
Timeframe: 21 Days

Interventionmg/day (Number)
Schedule A - Vorinostat Once or Twice Daily300

[back to top]

Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation

Will be estimated using the method of Kaplan-Meier. (NCT00792948)
Timeframe: 12 months

InterventionProbability of 12-month RFS (Number)
Treatment0.83

[back to top]

Overall Survival (OS)

OS will be estimated using the method of Kaplan-Meier. (NCT00792948)
Timeframe: From the date of initial registration on the study until death from any cause, assessed up to 5 years

InterventionProbability of surviving 12 months (Number)
Treatment0.88

[back to top]

Continuous Complete Remission (CCR) Rate

Will be testing using an exact binomial test (NCT00792948)
Timeframe: 18 months

Interventionpercentage of participants (Number)
Treatment57

[back to top]

Percentage of HIV-positive Patients With 2-year Progression-free Survival (PFS) Treated With Initial 2 Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.

Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is >1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. (NCT00822120)
Timeframe: 2 years

Interventionpercentage of patients (Number)
HIV-positive: 2 Cycles of ABVD Followed by PET-directed Therap83

[back to top]

Percentage of HIV-positive Patients With 5-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging.

Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact. (NCT00822120)
Timeframe: 5 years

Interventionpercentage of participants (Number)
HIV-positive: 2 Cycles of ABVD Followed by PET-directed Therap89

[back to top] [back to top]

Percentage of HIV-negative Patients Who Are PET-positive After 2 Cycles of ABVD With 2-year PFS

Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is > 1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. (NCT00822120)
Timeframe: 2 years

Interventionpercentage of participants (Number)
HIV-negative: 2 Cycles of ABVD Followed by Escalated BEACOPP64

[back to top]

Complete and Partial Response Rates for HIV-negative Patients Treated With Response- Adapted Therapy Based on FDG-PET Imaging After 2 Cycles of ABVD

Complete Response (CR) is a complete disappearance of all disease with the exception of the following. If no PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted if it is PET negative. If the PET scan was negative before therapy, all nodal masses at baseline must have regressed. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. If PET scan or when the PET scan was positive before therapy, PET should be positive in at least one previously involved site. (NCT00822120)
Timeframe: 7 months after registration

Interventionpercentage of patients (Number)
PET-negative: Continued ABVD After 2 Cycles of ABVD100
PET-positive: BEACOPP Escalated After 2 Cycles of ABVD93

[back to top] [back to top]

Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine (ABVD) Followed by Response-adapted Therapy Based on Interim FDG-PET Imaging.

Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is > 1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. (NCT00822120)
Timeframe: 2 years

Interventionpercentage of participants (Number)
HIV-negative: 2 Cycles of ABVD Followed by PET-directed Therap79

[back to top]

Percentage of HIV-negative Patients With 2-year Overall Survival (OS) Treated With 2 Initial Cycles of ABVD Followed by Response-Adapted Therapy Based on Interim FDG-PET Imaging

Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact. (NCT00822120)
Timeframe: 2 years

Interventionpercentage of participants (Number)
HIV-negative:2 Cycles of ABVD Followed by PET-directed Therapy98

[back to top]

At Least 50% Shrinkage in Tumor Measurements by Physical Examination

(NCT00846430)
Timeframe: Monthly physical exam first three months and then every three months after, for up to 36 months

InterventionParticipants (Count of Participants)
Open-Label Intervention7

[back to top]

Improvement of Symptoms and Pain

Subjects will be evaluated for pain and Quality of Life scores (NCT00846430)
Timeframe: Monthly physical exam first three months and then every three months after, for up to 36 months

InterventionParticipants (Count of Participants)
Open-Label Intervention9

[back to top]

No Reported Psychological Toxicity Based Upon Psychological Evaluations

Psychological toxicity defined as suicidal ideation (NCT00846430)
Timeframe: Psychological evaluation at 24 months

InterventionParticipants (Count of Participants)
Open-Label Intervention8

[back to top]

Response by MRI Measurements

partial response by RICST criteria is defined as >50% tumor shrinkage (NCT00846430)
Timeframe: evaluated 6, 12 and 24 months compared to baseline

Interventionparticipants (Number)
Partial Response at 6 monthsComplete Response at 6 monthsLess than Partial Response at 6 monthsPartial Response at 12 monthsComplete Response at 12 monthsLess than Partial Response at 12 monthsPartial Response at 24 monthsComplete Response at 24 monthsLess than Partial Response at 24 monthsno longer participating at 24 months
Open-Label Intervention0182164113

[back to top]

AALL08P1 Feasibility Outcome

Percentage of Group B (High Risk-High) patients that tolerate at least 8 of the 12-14 total doses of pegaspargase during Consolidation, Interim Maintenance, and Delayed Intensification periods. Only Grp B analyzed since this is prespecified in protocol. (NCT00866307)
Timeframe: Consolidation through Delayed Intensification

Interventionpercentage of participants (Number)
Group B (High Risk-High)53.3

[back to top]

AALL08P1 Safety Outcome

Percentage of Group B (High Risk-High) patients taking less than 49 weeks from day 1 of consolidation to day 1 of maintenance therapy. Only Group B analyzed since this is prespecified in protocol. (NCT00866307)
Timeframe: Consolidation through Delayed Intensification

Interventionpercentage of participants (Number)
Group B (High Risk-High)50.0

[back to top]

3-Year Event-Free Survival (EFS)

3-year EFS was calculated based on the participants with a complete response (CR). Study regimen considered successful if it exhibits a 3-year EFS rate greater than 60% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%. (NCT00866749)
Timeframe: 3 Years

InterventionParticipants (Count of Participants)
Augmented BFM Therapy68

[back to top]

Overall Survival

Overall Survival defined: Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT00866749)
Timeframe: Up to 12 years

InterventionMonths (Median)
Augmented BFM Therapy121

[back to top]

Participants Achieving Negative Minimal Residual Disease (MRD)

To evaluate the prognostic significance of minimal residual disease (MRD) in bone marrow samples of participants who achieved a complete response (CR) at the end of induction (day 29) and at the end of consolidation (day 84) in this group of patients. (NCT00866749)
Timeframe: up to 3 months

Interventionparticipants (Number)
Participants with CR and MRD negative on Day 29Participants with CR and MRD negative on day 84
Augmented BFM Therapy6087

[back to top]

Participants With a Complete Response (CR)

Complete Response defined as: Bone Marrow blasts /= 100 and an Absolute Neutrophil Count (ANC) >/= 1000 (NCT00866749)
Timeframe: Up to 1 year

Interventionparticipants (Number)
Augmented BFM Therapy108

[back to top]

Toxic Death Rate

The proportion of toxic death rate among all eligible patients. (NCT00873093)
Timeframe: 4 months

Interventionpercentage of participants (Number)
Overall2.1

[back to top]

Severe Adverse Events (SAE) Rate.

The proportion of SAE rate among all eligible patients (NCT00873093)
Timeframe: 4 months

Interventionpercentage of participants (Number)
Overall8.2

[back to top]

Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy

The percentage of eligible and evaluable patients who have achieved complete response at the end Block 1 of re-induction therapy. (NCT00873093)
Timeframe: The outcome is measured the end of Block 1 (Day 36 of Block 1) of re-induction therapy.

InterventionPercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs72.2
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs63

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3

Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 3. (NCT00873093)
Timeframe: End of Block 3 (Day 36 of Block 3) of re-induction therapy

InterventionPercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs80
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs63.6

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2

Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 2. (NCT00873093)
Timeframe: End of Block 2 (Day 36 of Block 2) of re-induction therapy

Interventionpercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs66.7
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs42.1

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1

Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 1. (NCT00873093)
Timeframe: End of Block 1 (Day 36 of Block 1) of re-induction therapy

Interventionpercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs35.4
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs25

[back to top]

Event Free Survival

Percentage of patients who were event free at 4 months (NCT00873093)
Timeframe: 4 months after enrollment

InterventionPercentage of participants (Number)
Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs68.5
Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs37.8

[back to top]

Kaplan-Meier Estimate for Duration of Response (DOR)

DOR was defined as the time from first response (CR or PR) to disease progression or relapse, or death due to any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Interventionmonths (Median)
Bendamustine and Rituximab (BR)26.5
R-CHOP/R-CVP32.1

[back to top]

Change From Baseline to End of Treatment in the Global Health Status Score of the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30)

EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). This outcome reports the global health status on a scale of 0-100 with a high score for the global health status/QOL represents a high quality of life. (NCT00877006)
Timeframe: Day 1 (prior to treatment), 32 weeks

Interventionunits on a scale (Mean)
Bendamustine and Rituximab (BR)3.6
R-CHOP/R-CVP-5.1

[back to top]

Worst Overall CTCAE Grade for Hematology Laboratory Test Results

Hematology test data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for hematology test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and hematology test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, weekly during treatment, and at the end-of-treatment visit)

,
Interventionparticipants (Number)
Absolute Neutrophil Count: Grade 1Absolute Neutrophil Count: Grade 2Absolute Neutrophil Count: Grade 3Absolute Neutrophil Count: Grade 4Absolute Neutrophil Count: Grades 1-4Hemoglobin: Grade 1Hemoglobin: Grade 2Hemoglobin: Grade 3Hemoglobin: Grade 4Hemoglobin: Grades 1-4Lymphocytes Absolute: Grade 1Lymphocytes Absolute: Grade 2Lymphocytes Absolute: Grade 3Lymphocytes Absolute: Grade 4Lymphocytes Absolute: Grades 1-4Platelets: Grade 1Platelets: Grade 2Platelets: Grade 3Platelets: Grade 4Platelets: Grades 1-4White Blood Cells: Grade 1White Blood Cells: Grade 2White Blood Cells: Grade 3White Blood Cells: Grade 4White Blood Cells: Grades 1-4
Bendamustine and Rituximab (BR)225148501711294251177155483143106149713641796519204
R-CHOP/R-CVP142047104185129517218965555912572147810122498927187

[back to top]

Worst Overall Common Terminology Criteria for Adverse Events (CTCAE) Grades for Serum Chemistry Laboratory Test Results

Clinical laboratory data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for serum chemistry test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and laboratory test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)

,
Interventionparticipants (Number)
Albumin: Grade 1Albumin: Grade 2Albumin: Grade 3Albumin: Grade 4Albumin: Grades 1-4Alkaline Phosphatase: Grade 1Alkaline Phosphatase: Grade 2Alkaline Phosphatase: Grade 3Alkaline Phosphatase: Grade 4Alkaline Phosphatase: Grades 1-4Creatinine: Grade 1Creatinine: Grade 2Creatinine: Grade 3Creatinine: Grade 4Creatinine: Grades 1-4Gamma-glutamyl transferase: Grade 1Gamma-glutamyl transferase: Grade 2Gamma-glutamyl transferase: Grade 3Gamma-glutamyl transferase: Grade 4Gamma-glutamyl transferase: Grades 1-4Hypercalcemia: Grade 1Hypercalcemia: Grade 2Hypercalcemia: Grade 3Hypercalcemia: Grade 4Hypercalcemia: Grades 1-4Hyperglycemia: Grade 1Hyperglycemia: Grade 2Hyperglycemia: Grade 3Hyperglycemia: Grade 4Hyperglycemia: Grades 1-4Hyperkalemia: Grade 1Hyperkalemia: Grade 2Hyperkalemia: Grade 3Hyperkalemia: Grade 4Hyperkalemia: Grades 1-4Hypernatremia: Grade 1Hypernatremia: Grade 2Hypernatremia: Grade 3Hypernatremia: Grade 4Hypernatremia: Grades 1-4Hypocalcemia: Grade 1Hypocalcemia: Grade 2Hypocalcemia: Grade 3Hypocalcemia: Grade 4Hypocalcemia: Grades 1-4Hypoglycemia: Grade 1Hypoglycemia: Grade 2Hypoglycemia: Grade 3Hypoglycemia: Grade 4Hypoglycemia: Grades 1-4Hypokalemia: Grade 1Hypokalemia: Grade 2Hypokalemia: Grade 3Hypokalemia: Grade 4Hypokalemia: Grades 1-4Hyponatremia: Grade 1Hyponatremia: Grade 2Hyponatremia: Grade 3Hyponatremia: Grade 4Hyponatremia: Grades 1-4Magnesium: Grade 1Magnesium: Grade 2Magnesium: Grade 3Magnesium: Grade 4Magnesium: Grades 1-4Phosphorus: Grade 1Phosphorus: Grade 2Phosphorus: Grade 3Phosphorus: Grade 4Phosphorus: Grades 1-4Aspartate Aminotransferase: Grade 1Aspartate Aminotransferase: Grade 2Aspartate Aminotransferase: Grade 3Aspartate Aminotransferase: Grade 4Aspartate Aminotransferase: Grades 1-4Alanine Aminotransferase: Grade 1Alanine Aminotransferase: Grade 2Alanine Aminotransferase: Grade 3Alanine Aminotransferase: Grade 4Alanine Aminotransferase: Grades 1-4Total Bilirubin: Grade 1Total Bilirubin: Grade 2Total Bilirubin: Grade 3Total Bilirubin: Grade 4Total Bilirubin: Grades 1-4Uric Acid: Grade 1Uric Acid: Grade 2Uric Acid: Grade 3Uric Acid: Grade 4Uric Acid: Grades 1-4
Bendamustine and Rituximab (BR)331430504110042193102331183052601079420150129731011800083681348151001618000184000040460004672530354221045466205414100154100142
R-CHOP/R-CVP44130057253002825100263710605360006743415112481009100001028600341000010160101728050334411046522313132210353831042700074200042

[back to top]

Therapeutic Classification of Prior Medications

(NCT00877006)
Timeframe: prior to start of treatment

,
Interventionparticipants (Number)
PsycholepticsSex Hormones and Modulators of the Genital SystemStomatological PreparationsThroat PreparationsThyroid TherapyTopical Products for Join and Muscular PainUnspecified HerbalUrologicalsVaccinesVasoprotectivesVitamins
Bendamustine and Rituximab (BR)57110016110202070
R-CHOP/R-CVP59120017010117061

[back to top]

Therapeutic Classification of Concomitant Medications

(NCT00877006)
Timeframe: 32 weeks

,
Interventionparticipants (Number)
PsycholepticsSex Hormones and Modulators of the Genital SystemStomatological PreparationsThroat PreparationsThyroid TherapyTopical Preparations for Join and Muscular PainUnspecified HerbalUrologicalsVaccinesVasoprotectivesVitamins
Bendamustine and Rituximab (BR)696233313511116
R-CHOP/R-CVP744292125411821

[back to top]

Potentially Clinically Significant Abnormal Weight

Participants were weighed at Baseline and at Endpoint (Week 32); those participants with an increase or decrease of >=10% were considered potentially clinically significant. (NCT00877006)
Timeframe: Baseline, Week 32

,
Interventionparticipants (Number)
Increase >=10%Decrease >=10%
Bendamustine and Rituximab (BR)818
R-CHOP/R-CVP58

[back to top]

Participants Who Died At the End of the Treatment Period or the Long-Term Follow-up Period

Death is due to any cause. Data are broken out by patients who died within 30 days of the last dose of study medications, and those who died greater than 30 days of the last dose of study medications. (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period

,
InterventionParticipants (Count of Participants)
All DeathsDeaths within 30 days of study treatmentDeaths greater than 30 days of study treatment
Bendamustine and Rituximab (BR)40238
R-CHOP/R-CVP32131

[back to top]

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period

AE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. An AE can, therefore, be any unfavorable and unintended physical sign, symptom, or laboratory parameter that develops or worsens in severity during the course of the study, or significant worsening of the disease under study (or any concurrent disease), whether or not considered related to the study drug. AEs were graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). SAE=an adverse event occurring at any dose that results in: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity (a substantial disruption of one's ability to conduct normal life functions), a congenital anomaly/birth defect, or other important medical event. (NCT00877006)
Timeframe: 32 weeks

,
Interventionparticipants (Number)
Any AESevere AEs (grades 3, 4, 5)Treatment-related AEsDeathsSAEsWithdrawn due to AEs
Bendamustine and Rituximab (BR)221130209126010
R-CHOP/R-CVP213127NA9493

[back to top]

Eastern Cooperative Oncology Group (ECOG) Performance Status at the End of Treatment Period

Participants' ECOG Performance Status was evaluated at the end of treatment as improved, stayed the same, or worsened from baseline (see Baseline Characteristics for ECOG Performance Status). (NCT00877006)
Timeframe: Week 32

,
Interventionparticipants (Number)
ImprovedStayed the SameWorsened
Bendamustine/Rituximab3215334
R-CHOP/R-CVP2814142

[back to top]

Clinically Significant Abnormal Vital Signs

(NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)

,
Interventionparticipants (Number)
Heart Rate >=120 and ↑ >=15 bpmHeart Rate <=50 and ↓ >=15 bpmSystolic Blood Pressure(BP) >=180 and ↑ >=20 mm HgSystolic BP <=90 and ↓ >=20 mm HgDiastolic BP >=105 and ↑ from Baseline >=15 mm HgDiastolic BP <=50 and ↓ from Baseline >=15 mm Hg
Bendamustine and Rituximab (BR)022612
R-CHOP/R-CVP122222

[back to top]

Percentage of Participants With Overall Response at End of Treatment Period

Overall Response=participants with Complete Remission (CR) + those with Partial Remission (PR). CR=see Outcome Measure 1 for details. PR= at least a 50% decrease in the sum of the product of the greatest diameters (SPD) of up to 6 of the largest dominant nodes/masses; at least a 50% decrease in the SPD of hepatic and splenic nodules in their greatest transverse diameter; no increase in the size of the liver, spleen, and other nodes; no measurable disease in organs other than the liver or spleen; no new sites of disease; protocol-specified PET scan and bone marrow criteria. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)

Interventionpercentage of participants (Number)
Bendamustine and Rituximab (BR)97
R-CHOP/R-CVP91

[back to top]

Percentage of Participants With Complete Response (CR) at End of Treatment Period

CR=complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, if present pretherapy; protocol-specified positron emission tomography (PET) scan assessment criteria; (if the spleen and/or liver were enlarged on the basis of physical examination and/or anatomic imaging before treatment) the liver and/or spleen were considered normal size on physical examination and by anatomic imaging after therapy, with disappearance of all nodules related to lymphoma; (if the bone marrow was involved by lymphoma before treatment) the infiltrate must have cleared on subsequent bone marrow biopsies. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)

Interventionpercentage of participants (Number)
Bendamustine and Rituximab (BR)31
R-CHOP/R-CVP25

[back to top]

Participants With Disease Progression, Relapse or Death At the End of the Treatment Period or the Long-Term Follow-up Period

"Relapsed disease (after CR) and progressive disease (PD) (after PR or SD):~Lymph nodes were considered abnormal if the long axis was greater than 1.5 cm. Lymph nodes with a long axis of 1.1 to 1.5 cm were considered abnormal if its short axis was greater than 1.0 cm.~In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT require histologic confirmation.~>= 50% increase from nadir in sum of the products of the greatest diameters (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must have increased by 2: 50% and to a size of 1.5 cm by 1.5 cm, or more than 1.5 cm in the long axis~other conditions as specified in the protocol" (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period

InterventionParticipants (Count of Participants)
Bendamustine and Rituximab (BR)36
R-CHOP/R-CVP30

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to death from any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Interventionmonths (Median)
Bendamustine and Rituximab (BR)65.0
R-CHOP/R-CVP64.1

[back to top]

Kaplan-Meier Estimate for Progression-free Survival (PFS)

PFS was defined as the time from randomization to disease progression or relapse, or death from any cause, whichever occurred first. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Interventionmonths (Median)
Bendamustine and Rituximab (BR)31.8
R-CHOP/R-CVP33.4

[back to top]

Kaplan-Meier Estimate for Event-free Survival (EFS)

"EFS was defined as the time from randomization to treatment failure, disease progression or relapse, other malignancies, or death from any cause, whichever occurred first.~Treatment failure was defined as failure to achieve a CR or PR after 6 cycles of treatment. If a patient failed to achieve CR or PR by the time of data analysis or early withdrawal, the treatment failure date was set at 126 days (6 cycles of treatment) after randomization or the new anticancer treatment date, whichever is earlier." (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Interventionmonths (Median)
Bendamustine and Rituximab (BR)31.8
R-CHOP/R-CVP32.6

[back to top]

Level of Methylation

the percentage of methylated DNA (NCT00882206)
Timeframe: Day 0

Interventionpercentage of DNA (Mean)
Decitabine / Vorinostat84.98

[back to top]

Level of Methylation

the percentage of methylated DNA (NCT00882206)
Timeframe: Day 33

Interventionpercentage of DNA (Mean)
Decitabine / Vorinostat86.1

[back to top]

Level of Methylation

the percentage of methylated DNA (NCT00882206)
Timeframe: Day 5

Interventionpercentage of DNA (Mean)
Decitabine / Vorinostat79.82

[back to top]

Response to Treatment

Response includes both complete remission (defined as <5% leukemic blasts in the bone marrow) and partial remission (defined as a greater than 35% reduction in the bone marrow leukemia blast percentage at day 33) (NCT00882206)
Timeframe: Day 33

Interventionparticipants (Number)
Decitabine / Vorinostat6

[back to top]

Number of Participants With Complete Remission

Complete remission (CR) required a marrow with ≤ 5% blasts in a normo- or hypercellular marrow with an absolute neutrophil count (ANC) of ≥ 1 * 10^9/L and a platelet count of ≥ 100 * 10^9/L with complete resolution of all sites of extramedullary disease required. (NCT00890656)
Timeframe: Response evaluated following first course at 14 -21 days and 1-2 weeks later to confirm response status (or at the time of hematologic recovery) and with visits every 2-3 courses.

InterventionParticipants (Number)
Augmented Hyper-CVAD41

[back to top]

Complete Response (CR) Rate

Rate calculated as number of participants with CR. Complete Remission (CR) defined as Normalization of peripheral blood and bone marrow with 5% or less blasts in a normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above and platelet count of 100 x 10^9/L or above. Complete resolution of all sites of extramedullary disease is required for CR. (NCT00905034)
Timeframe: 6 cycles (cycle = 28 days)

Interventionpercentage of participants (Number)
MOAD28

[back to top]

Number of Participants in Complete Remission 6 Months After Randomization

"Complete remission [CR] is defined according to Cheson criteria. CR requires the following:~Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities.~All lymph nodes and nodal masses must have regressed to normal size. Previously involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must have decreased to ≤1 cm in their greatest transverse diameter after treatment, or by more than 75% in the sum of the products of the greatest diameters (SPD).~The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination.~If the bone marrow was involved by lymphoma before treatment, the infiltrate must be cleared on repeat bone marrow aspirate and biopsy of the same site." (NCT00911183)
Timeframe: 6 months after randomization

InterventionParticipants (Count of Participants)
Arm I (R-COP Regimen)14
Arm II (R-COPY Regimen)9

[back to top]

Overall Survival Time

OS is defined as the delay between the date of randomization and the date of death (NCT00911183)
Timeframe: from randomization, up to 5 years

Interventionmonths (Median)
Arm I (R-COP Regimen)20.1
Arm II (R-COPY Regimen)25.4

[back to top]

Number of Participants With Severe Toxicity

"Severe toxicity, defined as febrile neutropenia or toxic death. Febrile neutropenia is defined in the International CTC toxicity scale as fever of unknown origin without clinically or microbiologically documented infection: neutrophils < 1.0 x 109/l and fever ≥ 38.5° C.~Toxic death is defined as any death which occur during treatment (from day 1 of the first cycle of chemotherapy up to day 30 of the last cycle) and is not related to lymphoma." (NCT00911183)
Timeframe: 6 months after randomization

InterventionParticipants (Count of Participants)
Arm I (R-COP Regimen)10
Arm II (R-COPY Regimen)8

[back to top]

Progression-free Survival Time

Delay between the date of randomization and the date of progression or death. Progression is defined according to the Cheson criteria. (NCT00911183)
Timeframe: from randomization, up to 5 years

Interventionmonths (Median)
Arm I (R-COP Regimen)10.4
Arm II (R-COPY Regimen)18.0

[back to top]

Occurrence of a Dose-Limiting Toxicity

The MTD in each stratum will be the highest dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy. (NCT00928200)
Timeframe: Beginning with the first dose of investigational product until 30 days following the last dose of Erwinase

InterventionParticipants (Count of Participants)
Single Arm0

[back to top]

Complete Response Rate

Complete Response Rate is defined as the percentage of participants with the best response of Complete Response (CR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease. (NCT00931918)
Timeframe: End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]

,
Interventionpercentage of participants (Number)
End of Cycle 2End of Treatment (Cycle 6)Best Complete Response Rate
RCHOP234549
Vc-RCHOP165656

[back to top]

Overall Response Rate (ORR)

ORR is defined as the percentage of participants with the best overall response complete response (CR) + partial response (PR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites. (NCT00931918)
Timeframe: End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]

,
Interventionpercentage of participants (Number)
End of Cycle 2End of Treatment (Cycle 6)Best Overall Response Rate
RCHOP938898
Vc-RCHOP908496

[back to top]

Percentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher

Percentage of participants who shifted from a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 0, 1, or 2 at Baseline to a Grade 3 or higher on study (worst post-baseline grade). Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=Life-threatening consequences and 5=Death related to AE. (NCT00931918)
Timeframe: Days 1, 4 and 10 of each cycle and end of treatment visit (Median of 16 weeks on treatment)

,
Interventionpercentage of participants (Number)
LymphocytesWBC CountNeutrophilsPlateletsHemoglobinHyperglycemiaHypokalemiaHypophosphatemiaHyponatremiaAlanine aminotransferase (ALT) increasedAspartate aminotransferase (AST) increased
RCHOP706865181014137421
Vc-RCHOP866970391591410312

[back to top]

Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category

Percentage of participants in the following categories: • At least 1 TEAE • Drug-related, TEAEs • Grade 3 or higher TEAEs. Grade 3 are AEs of Severe Intensity • Grade 3 or higher drug-related, TEAEs • TEAEs resulting in study drug discontinuation • Serious TEAEs An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. (NCT00931918)
Timeframe: First dose of study drug through 30 days after the last dose of study drug (Up to 26 Weeks)

,
Interventionpercentage of participants (Number)
At Least 1 TEAEDrug-related, TEAEsGrade 3 or higher TEAEsGrade 3 or Higher Drug-related, TEAEsTEAEs Resulting in Study Drug DiscontinuationSerious TEAEs
RCHOP100887155431
Vc-RCHOP99957968634

[back to top]

Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate

FDG-PET negative rate is defined as the percentage of participants FDG-PET negative at the given time-point. (NCT00931918)
Timeframe: End of Cycle 2 and End of Treatment (Cycle 6) [Median of 16 weeks on treatment]

,
Interventionpercentage of participants (Number)
End of Cycle 2End of Treatment (Cycle 6)
RCHOP4253
Vc-RCHOP3759

[back to top]

Duration of Response

Duration of response is defined as the time (in months) from the date of first documentation of confirmed complete response (CR) or partial response (PR) to the date of first documentation of progressive disease (PD), relapse from CR or death related to disease. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), duration of response is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using IWG-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites and PD= any new lesion or increase by > 50% of previously involved sites from nadir. (NCT00931918)
Timeframe: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

Interventionmonths (Median)
RCHOPNA
Vc-RCHOPNA

[back to top]

Overall Survival

Overall survival is defined as the time from the date of randomization to the date of death from any cause. A participant who is alive at the end of his/her study follow-up is censored at the date of last contact. (NCT00931918)
Timeframe: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

Interventionmonths (Median)
RCHOPNA
Vc-RCHOPNA

[back to top]

Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)

PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by > 50% of previously involved sites from nadir. (NCT00931918)
Timeframe: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

Interventionmonths (Median)
RCHOPNA
Vc-RCHOPNA

[back to top]

Progression-Free Survival Rate

PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by > 50% of previously involved sites from nadir. The progression-free survival rate is defined as the Kaplan-Meier (KM) estimate of progression-free survival at 2 years. (NCT00931918)
Timeframe: 2 Years (Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm)

Interventionpercentage of participants (Number)
RCHOP78
Vc-RCHOP82

[back to top]

Time to Progression (TTP)

TTP is defined as the time from the date of randomization to the date of first documentation of progressive disease, relapse from CR, or death related to disease under study if participant did not have any documentation of disease progression prior to death caused by lymphoma or complications thereof. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), TTP is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by > 50% of previously involved sites from nadir. (NCT00931918)
Timeframe: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm

Interventionmonths (Median)
RCHOPNA
Vc-RCHOPNA

[back to top]

Event-Free Survival (EFS)

Probability of no relapse, secondary malignancy, or death whichever occurs first (NCT00945009)
Timeframe: 4 years from study enrollment

InterventionProbability (Mean)
Arm 1 (Bilateral Wilms Tumors)0.82

[back to top]

Kidney Preservation After Preoperative Chemotherapy

Prevention of complete removal of at least one kidney in 50% of patients with bilateral Wilms tumor (BWT). (NCT00945009)
Timeframe: 12 weeks from study entry

InterventionPercentage of patients (Number)
Arm 1 (Bilateral Wilms Tumors)39

[back to top]

Number of Patients Without Complete Removal of at Least One Kidney

To evaluate the efficacy of chemotherapy in preserving renal units in children with diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) and preventing Wilms tumor development. (NCT00945009)
Timeframe: 12 weeks from the study entry

InterventionParticipants (Count of Participants)
Arm 3 (DHPLN)7

[back to top]

Percentage of Patients Who Had Definitive Surgical Treatment

Percentage of Bilateral Wilms Tumor (BWT) patients who undergo definitive surgery by week 12 after initiation of chemotherapy. (NCT00945009)
Timeframe: 12 weeks from study entry

Interventionpercentage of participants (Number)
Arm 1 (Bilateral Wilms Tumors)85

[back to top]

Percentage of Patients Who Experienced Partial Nephrectomy After Preoperative Chemotherapy

Percentage of patients who experienced partial nephrectomy in lieu of nephrectomy in 25% of children with unilateral tumors and aniridia, Beckwith-Wiedemann syndrome (BWS), hemihypertrophy or other overgrowth syndromes, by using prenephrectomy 2-drug chemotherapy induction with vincristine and dactinomycin. (NCT00945009)
Timeframe: 12 weeks from study entry

Interventionpercentage of patients (Number)
Arm 2 (Unilateral High Risk Tumors Bilaterally Predisposed)57

[back to top]

Best Overall Response Based on Response Evaluation Criteria in Solid Tumors (RECIST)

All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs were to be identified as target lesions. Data were to be collected at Screening, every 6 weeks and at 30 days after the final dose of robatumumab or the standard treatment assigned (whichever was last). The best overall response was to be the best response recorded from the start of the treatment until disease progression/recurrence. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): >30% decrease in the sum of the longest diameter (LD) of target lesions; Progressive Disease (PD): >20% increase in the sum of the LD of target lesions or the appearance of one or more new lesions; or Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00960063)
Timeframe: Screening, every 6 weeks and at ~30 days after last dose of study drug (Up to ~10.3 months)

,
InterventionParticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)
Ifosfamide+Etoposide+Robatumumab0201
Temozolomide+Irinotecan+Robatumumab0100

[back to top]

Number of Participants With Dose Limiting Toxicities

Dose-limiting toxicity was defined by the following adverse events (AEs) that were considered possibly or probably related to either robatumumab or to its interaction with the chemotherapy regimen assigned: neutropenia (Grade 4 for >1 week that did not resolve prior to Day 1 of the next cycle; Grade 3-4 neutropenia with Grade ≥2 fever lasting 3 days; neutropenic infection; failure to recover to study entry/eligibility criteria laboratory requirement levels that resulted in a delay of 14 days between treatment cycles), thrombocytopenia (Grade 4 for >1 week that did not resolve prior to Day 1 of the next cycle; Grade 3-4 requiring a platelet transfusion on 2 separate days within a cycle) or all other AEs (Grade ≥3 [any duration] not ameliorable by supportive or symptomatic measures). The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4.0) was to be used to grade AEs. (NCT00960063)
Timeframe: Up to ~30 days after last dose of study drug (Up to ~10.3 months)

InterventionParticipants (Number)
Temozolomide+Irinotecan+Robatumumab1
Ifosfamide+Etoposide+Robatumumab3

[back to top]

Number of Participants Who Developed Anti-robatumumab Antibodies

The incidence of anti-robatumumab antibodies was to be assessed. Only participants who had a negative pre-treatment sample and a post-treatment sample were considered to be evaluable. If a participant had a single sample considered positive in the anti-robatumumab antibody assay (with the exception of pre-treatment positive participants), then they would be counted as positive in the immunogenicity assessment. (NCT00960063)
Timeframe: Prior to 1st and 8th doses of robatumumab, ~30 days after last dose of study drug, and 4 months after last dose of study drug (Up to ~13.3 months)

InterventionParticipants (Number)
Temozolomide+Irinotecan+Robatumumab0
Ifosfamide+Etoposide+Robatumumab0

[back to top]

Overall Response Rate (OR) Where OR = CR + CRp + CRi

Number of participants out of total treated who experienced a complete response response according to RECIST criteria either (CR + CRp) CR Without Platelet Recovery. Response (CR + CRp) defined as Complete remission (CR): Disappearance of all clinical and/or radiologic evidence of disease. Neutrophil count > 1.0 x10^9/L, platelet count > 100 x10^9/L, and blasts < 5% in a normocellular or hypercellular marrow. Complete remission without platelet recovery (CRp): Peripheral blood and marrow parameters as for CR, but with platelet count > 20 x 10^9/L and < 100 x 10^9/L in the absence of platelet transfusions. CR with incomplete blood count recovery (CRi): Same as CR but platelets ≤ 100,000/mcl and/or neutrophils ≤ 1,000/mcl. (NCT00968253)
Timeframe: 8 courses of treatment, up to 24 weeks

Interventionpercentage of participants (Number)
Phase I: RAD001 5 mg + Combination Chemo33
Phase I: RAD001 10 mg + Combination Chemo33
Phase II: MTD RAD001 + Combination Chemo33

[back to top]

Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT)

"The Maximum tolerated dose (MTD) was the highest dose level at which fewer than 2 of 6 patients developed a dose limiting toxicity (DLT) in the first two cycles of therapy. A 3 by 3 design was used for dose escalation in the phase I portion of the study.~A dose-limiting toxic effect (DLT) was defined as a clinically significant adverse event or abnormal laboratory value directly attributable to everolimus and assessed as unrelated to disease progression, intercurrent illness, or concomitant medications, occurring during the first or second cycle of therapy, that met any of the following criteria: CTCAE version 3.0 grade 3 increased AST or ALT for 7 days, CTCAE grade 4 increased AST or ALT of any duration, or any other clinically significant CTCAE grade 3 or 4 toxic effect. Electrolyte abnormalities (changes in glucose, chemistries, liver enzymes, pancreatic enzymes) correctable by optimal therapy and without clinical impact were not considered DLTs." (NCT00968253)
Timeframe: Following first two dose cycles (21 days/each), up to 42 days

InterventionParticipants (Count of Participants)
Phase I: RAD001 5 mg + Combination Chemo0
Phase I: RAD001 10 mg + Combination Chemo1

[back to top]

Participant Responses by Daily Dose Level Assignment (RAD001 5 mg, 10 mg and MTD 5 mg)

Response defined as Complete remission (CR): Disappearance of all clinical and/or radiologic evidence of disease. Neutrophil count > 1.0 x10^9/L, platelet count > 100 x10^9/L, and blasts < 5% in a normocellular or hypercellular marrow. Complete remission without platelet recovery (CRp): Peripheral blood and marrow parameters as for CR, but with platelet count > 20 x 10^9/L and < 100 x 10^9/L in the absence of platelet transfusions. CR with incomplete blood count recovery (CRi): Same as CR but platelets ≤ 100,000/mcl and/or neutrophils ≤ 1,000/mcl. Partial remission (PR): Peripheral blood count recovery as for CR, with decrease in marrow blasts by > 50% from pretreatment values with no more than 25% leukemia/lymphoma cells in the marrow. Nonresponder, Other: All other responses will be considered failures. (NCT00968253)
Timeframe: Up to 20 cycles of study drugs (21 day cycles) or till disease progression

,,
Interventionparticipants (Number)
Complete RemissionComplete Remission without platelet recoveryCR with incomplete blood count recoveryPartial RemissionNonresponder
Phase I: RAD001 10 mg + Combination Chemo20115
Phase I: RAD001 5 mg + Combination Chemo10011
Phase II: MTD RAD001 + Combination Chemo31008

[back to top]

Response Rate (Complete Response [CR]+Partial Response [PR]) (Phase II)

Objective disease status is evaluated according to the 2007 revised Cheson et al. criteria. Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. (NCT00972478)
Timeframe: Up to week 26

Interventionpercentage of participants (Number)
Ph II: R-CHOP+Vorinostat81

[back to top]

Safe Dose of Vorinostat to be Used in Combination With R-CHOP Assessed by CTCAE Version 4.0 (Phase I)

Safe dose of Vorinostat (in combination with R-CHOP) at which 3/10 or fewer patients have doselimiting toxicities (DLT). Toxicities graded according to the NCI Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0). DLT apply only during cycle 1 and should be drug-related (possible, probable, or definite). (NCT00972478)
Timeframe: 21 days

Interventionmg PO Once daily Days 1-9 (Number)
Ph I: R-CHOP+Vorinostat (400mg D1-9)400

[back to top]

Overall Survival (Phase II)

From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00972478)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Ph II: R-CHOP+Vorinostat86

[back to top]

Progression-free Survival (Phase II)

From date of registration to date of first documentation of progressive disease, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. (NCT00972478)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Ph II: R-CHOP+Vorinostat73

[back to top]

Toxicity of Vorinostat-R-CHOP in Patients With Newly Diagnosed DLBCL

Incidence of toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. (NCT00972478)
Timeframe: Up to week 26

,
InterventionParticipants (Number)
Abdominal painAcute kidney injuryAlanine aminotransferase increasedAnemiaAnorexiaAspartate aminotransferase increasedAtrial fibrillationBladder spasmBronchial infectionCD4 lymphocytes decreasedCPK increasedCarbon monoxide diffusing capacity decreasedColitisCreatinine increasedCystitis noninfectiveDehydrationDepressionDiarrheaDisseminated intravascular coagulationDizzinessDuodenal perforationDysphagiaDyspneaElectrocardiogram QT corrected interval prolongedFatigueFebrile neutropeniaFecal incontinenceGastrointestinal disorders - Other, specifyGeneralized muscle weaknessHematuriaHiccupsHyperglycemiaHypoalbuminemiaHypocalcemiaHypokalemiaHyponatremiaHypophosphatemiaHypotensionInfections and infestations - Other, specifyJejunal perforationLeft ventricular systolic dysfunctionLeukocytosisLung infectionLymphocyte count decreasedMucosal infectionMucositis oralMulti-organ failureMyalgiaMyocardial infarctionNauseaNeutrophil count decreasedObstruction gastricPainParonychiaPeripheral motor neuropathyPlatelet count decreasedPneumonitisRecurrent laryngeal nerve palsyRespiratory failureSepsisSinus tachycardiaSinusitisSmall intestinal obstructionStoma site infectionSyncopeUrinary tract infectionUrinary tract painUrine output decreasedVasovagal reactionVisceral arterial ischemiaVomitingWeight lossWhite blood cell decreased
Ph I: R-CHOP+Vorinostat (400mg D1-9)1004100000001102121100013300210011201010000401110180001400030000000101007
Ph II: R-CHOP+Vorinostat31122211111110014020011119241120143086233111420130223371110221111111114320102332

[back to top]

Overall Survival at One Year

The number of participants alive one year after baseline. (NCT00973752)
Timeframe: 1 years

InterventionParticipants (Count of Participants)
Experimental19

[back to top]

Event-free Survival

Estimated 5-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact. (NCT00980460)
Timeframe: Time from patient enrollment to progression, treatment failure, death from any cause, diagnosis of a second malignant neoplasm, or last follow-up, assessed up to 5 years

InterventionPercent Probability (Number)
Very Low-risk Group100
Low-risk Group (Regimen T)87.21
Intermediate-risk Group (Regimen F)87.03
High-risk Group (Regimen W)43.61
High-risk Group (Regimen H)46.38

[back to top]

Number of Cycles on Which Grade 3 or Higher Adverse Events Coded According to CTC AE Version 5 Were Observed

All grade 3 or 4 or greater non-hematological toxicities. The frequency of each toxicity type will be quantified as the number of reporting periods on which the toxicity of the relevant grade is reported. This measure does not apply to patients enrolled in the VERY LOW RISK group. (NCT00980460)
Timeframe: During protocol therapy up to 1 year after enrollment

,,,
InterventionCycles (Number)
Hearing impairedDiarrheaEnterocolitisNauseaSmall intestinal obstructionVomitingAbdominal distensionAbdominal painColitisAnal mucositisAscitesMalabsorptionMucositis oralConstipationDental cariesTyphlitisDuodenal obstructionEsophageal hemorrhageGastritisIlleusOral painSmall intestinal mucositisColonic hemorrhageDysphagiaEsophagitisGastroparesisGastric fistulaGastrointestinal disorders - Other, specifyObstruction gastricRectal mucositisFeverGeneral disorders and administration site conditions - Other, specifyPainMulti-organ failureIrritabilityInfusion related reactionHypothermiaCatheter related infectionInfections and infestations - Other, specifyMucosal infectionOtitis mediaUrinary tract infectionBiliary tract infectionAbdominal infectionBladder infectionEnterocolitis infectiousDuodenal infectionUpper respiratory infectionEye infectionWound infectionSepsisLung infectionPeritoneal infectionSkin infectionSmall intestine infectionPeriorbital infectionAlanine aminotransferase increasedAspartate aminotransferase increasedActivated partial thromboplastin time prolongedAlkaline phosphatase increasedBlood bilirubin increasedCreatinine increasedGGT increasedWeight lossFibronogen decreasedEjection fraction decreasedInvestigations - Other, specifyWhite blood cell decreasedINR increasedCPK increasedCholesterol highElectrocardiogram QT corrected interval prolongedLipase increasedSerum amylase increasedAnorexiaDehydrationHyperglycemiaHyperkalemiaHypermagnesemiaHypernatremiaHypokalemiaHyponatremiaAcidosisAlkalosisHypocalcemiaHypoalbuminemiaHypomagnesemiaHypophosphatemiaTumor lysis syndromeHypercalcemiaHypoglycemiaHypertriglyceridemiaMetabolism and nutrition disorders - Other, specifyPeripheral sensory neuropathyOculomotor nerve disorderAbducens nerve disorderPeripheral motor neuropathySyncopeDysphasiaDepressed level of consciousnessSeizureApneaAtelectasisDyspneaBronchospasmHypoxiaPleural effusionPulmonary edemaStridorRespiratory failureEpistaxisWheezingHypertensionHematomaHypotensionVascular disorders - Other, specifyThromboembolic eventLeft ventricular systolic dysfunctionCardiac arrestRight ventricular dysfunctionVentricular tachycardiaCardiac disorders - Other, specifySinus tachycardiaHeart failureMyocardial infarctionBiliary fistulaHepatobiliary disorders - Other, specifyHepatic hemorrhagePortal vein thrombosisPortal hypertensionBiliary anastomotic leakPostoperative hemorrhageGastrointestinal anastomotic leakIntraoperative hemorrhageArthralgiaGeneralized muscle weaknessBack painBone painMuscle weakness lower limbAgitationHallucinationsInsomniaAcute kidney injuryRenal and urinary disorders - Other, specifyRenal calculiProteinuriaErythema multiformeSkin and subcutaneous tissue disorders - Other, specifyRash maculo-papularEye disorders - Other, specifySurgical and medical procedures - Other, specifyTumor painAllergic reactionAnaphylaxisImmune system disorders - Other, specify
High-risk Group (Regimen H)4151305061000600100000000001111904211109003000502003107016191151661100011111171210503291013212190014110020011003061001114050100000410011000001000000010001012000221
High-risk Group (Regimen W)415010013391000810200141011110000101000012711000040200000100910302014000110000020353001260043370110020230100001022000202131113001111001011120000001000100001001000
Intermediate-risk Group (Regimen F)20150101241103111442121113410000000091610008380031128141152111028372173762110000000301315124148224173112120000531710000221102112006132011210000112101100121114109310123110000
Low-risk Group (Regimen T)14111200000000000000000000000010000001411100000000000000110000000000000000132222410000000000020000000100000000003000000000000000000000000000000000000000000

[back to top]

Disease Status at the End of 2 Courses of Therapy

RECIST v 1.1 and serum alphafetoprotein responses are evaluated separately. RECIST v 1.1 complete response (CR) is defined as disappearance of all target lesions and partial response (PR) is defined as reduction of at last 30% in the sum of the longest dimension of all target lesions (CR and PR measured by CT or MRI) between enrollment. Serum alphafetoprotein response is a decrease of at least 90% from the last serum alphafetoprotein measurement from the baseline prior to the start of chemotherapy to the end of cycle 2. This is calculated for HIGH RISK regimen W and HIGH RISK regimen H only. (NCT00980460)
Timeframe: First two cycles of therapy- up to 42 days after enrollment

,
Interventionparticipants (Number)
RECIST PR, no AFP responseAFP response, no RECIST responseRECIST response, AFP responseno AFP response, no RECIST response
High-risk Group (Regimen H)310418
High-risk Group (Regimen W)35616

[back to top]

Number of Deaths

Number of patients who experience on-protocol-therapy death possibly, probably or likely related to systemic chemotherapy. This outcome measure applies to INTERMEDIATE RISK patients only. (NCT00980460)
Timeframe: During protocol therapy or within 30 days of the termination of protocol therapy up to 1 year after enrollment

InterventionParticipants (Count of Participants)
Intermediate-risk Group (Regimen F)1

[back to top]

Feasibility of Referral for Liver Transplantation

A patient for whom referral is considered appropriate who receives a consultation after enrollment will be considered a success with respect to feasibility. (NCT00980460)
Timeframe: 3 cycles of therapy - up to 3 months after enrollment

InterventionParticipants (Count of Participants)
Intermediate-risk Group (Regimen F)37
High-risk Group (Regimen H)16

[back to top]

Dose Limiting Toxicity

Number of participants with dose limiting toxicity events (NCT00993044)
Timeframe: 2 years

Interventionparticipants (Number)
Single Arm2

[back to top]

Time to Progression

-The progression definitions used for this study are from the 2007 Cheson criteria. (NCT01000285)
Timeframe: Up to 4 years following completion of therapy

Interventiondays (Median)
Best response of complete responseBest response of partial responseBest response of stable diseaseAll participants
EPOCH Chemotherapy & Bortezomib19914388127

[back to top]

Effects of HTLV-1 Integration Sites After Treatment

(NCT01000285)
Timeframe: 6 months

Interventionnumber of integration sites (Mean)
BaselineStudy completion
EPOCH Chemotherapy & Bortezomib1.311.00

[back to top]

Relation of NFκB Gene Expression Profile on Response

Standard error represents the standard error of the fold expression of protein coding transcripts for each gene indicated. (NCT01000285)
Timeframe: 6 months

,,,,,,,
Interventionfold expression (Mean)
BLKCADMICD25CD4CD45
Patient A (Responder) Post-Therapy0.1780.0110.0351.3801.718
Patient A (Responder) Pre-Therapy1.0001.0001.0001.0001.000
Patient B (Responder) Post-Therapy0.1720.0070.0150.6070.959
Patient B (Responder) Pre-Therapy0.8890.6230.3031.4372.049
Patient C (Non-responder) Post-Therapy77.5901.8160.6911.9231.640
Patient C (Non-responder) Pre-Therapy68.8561.4940.8621.3191.163
Patient D (Non-responder) Post-Therapy46.8010.4700.5120.6480.714
Patient D (Non-responder) Pre-Therapy233.1792.0132.8973.0570.594

[back to top]

Effects of HTLV-1 RNA Load After Treatment as Measured by Hbz Messenger RNA

(NCT01000285)
Timeframe: 6 months

,
Interventioncopies/peripheral blood mononuclear cell (Mean)
BaselineStudy completion
Non-responders41.935.7
Responders37.07.33

[back to top]

Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events

The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. (NCT01000285)
Timeframe: Up to 30 days after completion of treatment

Interventionparticipants (Number)
FatigueVomitingSpontaneous bacterial peritonitisAbdominal distensionHemoglobinLeukocytes (WBC)LymphopeniaNeutrophilsPlateletsInfection without neutropeniaInfection with neutropeniaOmaya port infectionIV port infectionSepsisNeutropenic feverHypoglycemiaHyperglycemiaMagnesiumHypokalemiaHypertriglyceridemiaConfusionHeadacheEncephalitisAbdominal painCoughDyspnea
EPOCH Chemotherapy & Bortezomib11126716611112312111111111

[back to top]

Effects of HTLV-1 Integrase Gene Sequence After Treatment as Measured by Nucleotide Divergence

(NCT01000285)
Timeframe: 6 months

Interventionpercentage of nucleotide divergence (Mean)
BaselineStudy completion
EPOCH Chemotherapy & Bortezomib0.490.52

[back to top]

Effects of on HTLV-1 DNA After Treatment as Measured by Proviral Loads

(NCT01000285)
Timeframe: 6 months

,
Interventioncopies/peripheral blood mononuclear cell (Mean)
BaselineStudy completion
Non-responders0.4170.033
Responders0.3720.0128

[back to top]

Efficacy of Treatment as Measured by Best Overall Response

-The response definitions used for this study are the 2007 Cheson criteria. (NCT01000285)
Timeframe: Up to 4 years following completion of therapy

Interventionparticipants (Number)
Progressive DiseaseStable diseasePartial responseComplete response
EPOCH Chemotherapy & Bortezomib3393

[back to top]

Complete Response

Complete Response (NCT01004991)
Timeframe: 13 months

InterventionParticipants (Count of Participants)
All Patients11

[back to top]

Overall Survival

Survival from enrollment to death. (NCT01026220)
Timeframe: At 3 years from enrollment

InterventionProbability of survival (Number)
Group 10.97
Group 20.97
Group 30.97

[back to top]

Grade 3 and 4 Non-hematologic Toxicities During Protocol Therapy

The number of patients that experience Common Terminology Criteria (CTC) Version 4 grade 3 or higher non-hematologic toxicity at any time during protocol therapy. (NCT01026220)
Timeframe: During and after completion of study treatment.

Interventionparticipants (Number)
Group 172

[back to top]

Relapse-free Survival

A description, survival to relapse, of patterns of relapse after Doxorubicin, Bleomycin, Vincristine, Etoposide - Prednisone, Cyclophosphamide (ABVE-PC) and risk-adapted radiotherapy. (NCT01026220)
Timeframe: 3 years from enrollment

InterventionProbability of survival (Number)
Group 10.82
Group 60.83
Group 70.79

[back to top]

Event-free Survival for Rapid Early Response (RER) Positron Emission Tomography(PET)-1 Positive, RER PET-1 Negative

To investigate whether very early response assessment measured by Fluorodeoxyglucose-PET after 1 cycle of chemotherapy identifies a subject cohort that can be studied in future trials and that is distinguishable from currently defined RER after 2 cycles. (NCT01026220)
Timeframe: 3 years from enrollment

InterventionProbability of survival (Number)
Group 10.84
Group 40.82
Group 50.90

[back to top]

Event Free Survival

Survival from enrollment to first event: relapse/progression, second malignancy, or death. (NCT01026220)
Timeframe: At 3 years from enrollment

InterventionProbability of survival (Number)
Group 10.81
Group 20.83
Group 30.78

[back to top]

Second-event-free Survival

Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event. (NCT01026220)
Timeframe: At 4 years from enrollment

,
InterventionProbability of survival (Number)
Group 10.91
Group 20.94
Group 30.88

[back to top]

Safety Analysis and Monitoring of Toxic Death

The primary endpoint for safety analysis and monitoring is toxic death, which is death primarily attributable to treatment. (NCT01026220)
Timeframe: Within 30 days of protocol treatment at median follow-up of 48 months (range: 1 to 70 months).

Interventionparticipants (Number)
Group 10

[back to top]

Clinical Response on Study and at Relapse After Dose Adjusted - Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Rituximab (DA-EPOCH-RC)

Clinical response was assessed by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphomas. Complete remission is complete disappearance of all detectable clinical and radiographic evidence of disease. Complete response unconfirmed is as per complete remission except that if a residual node is greater than 1.5cm, it must have decreased by greater than 75% in the sum of the products of the perpendicular diameters (SPD). Partial response is ≥50% decreased in the SPD of 6 largest dominant nodes or nodal masses. Relapsed disease is appearance of any new lesion or increase by ≥50% in the size of the previously involved sites. Stable disease is defined as less than a partial response but not progressive disease. Progression is ≥50% increase from nadir in the SPD of diameters of any previously identified abnormal node for partial response or non-responders; and an appearance of any new lesion during or at the end of therapy. (NCT01030900)
Timeframe: On study and at relapse after study treatment, approximately 10 months

InterventionParticipants (Count of Participants)
Complete remissionComplete response unconfirmedPartial responseStable diseaseRelapsed diseaseProgressive disease
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin + Rituximab + Campath170132014

[back to top]

Progression Free Survival (PFS)

PFS is the time interval from start of treatment to documented evidence of disease progression estimated using a Kaplan Meier curve. Progression was assessed by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphomas and is defined as ≥50% increase from nadir in the sum of the products of diameters of any previously identified abnormal node for partial response or non-responders. And an appearance of any new lesion during or at the end of therapy. (NCT01030900)
Timeframe: Time of progression or death, approximately 10 months

Interventionmonths (Median)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin + Rituximab + Campath6.6

[back to top]

Overall Survival (OS)

OS is from enrollment to the day of death estimated using the Kaplan-Meier curve. (NCT01030900)
Timeframe: Median overall survival from enrollment to the day of death, approximately 17.9 months

Interventionmonths (Median)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin + Rituximab + Campath17.9

[back to top]

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01030900)
Timeframe: Date treatment consent signed to date off study, approximately 58 months and 18 days.

InterventionParticipants (Count of Participants)
Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin + Rituximab + Campath48

[back to top]

Complete Response (CR) Rate

"Complete response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.~Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.~PET scan was negative.~The spleen and/or liver, if enlarged before therapy on the basis of physical examination or CT scan, was not palpable on physical examination and was considered normal size by imaging studies; all splenic and hepatic nodules related to lymphomas disappeared.~If bone marrow was involved before treatment, the infiltrate cleared on repeated bone marrow biopsy.~No new sites of disease were detected." (NCT01040871)
Timeframe: 6 cycles

Interventionpercentage of participants (Number)
VR-CAP64.5
R-CHOP63.5

[back to top]

Overall Response Rate

"Overall response = Complete Response (CR) + Partial Response (PR) Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.~Complete Response: see primary endpoint Partial Response: At least a 50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses." (NCT01040871)
Timeframe: 6 cycles

Interventionpercentage of participants (Number)
VR-CAP93.4
R-CHOP98.6

[back to top]

Progression-free Survival (PFS)Rate at 1-year

Kaplan-meier estimate of progression-free survival at 1-year. Progression-free survival was defined as the interval between the date of randomization and the date of first documented evidence of disease progression or death. (NCT01040871)
Timeframe: 1 year

Interventionpercentage of partipants (Number)
VR-CAP78.9
R-CHOP83.9

[back to top]

Rate of Durable Complete Response

Proportion of subjects who achieved a CR with duration of at least 6 months (NCT01040871)
Timeframe: Median follow up approx 12 months

Interventionpercentage of participants (Number)
VR-CAP44.7
R-CHOP47.3

[back to top]

Rate of Durable Response

Proportion of subjects who achieved a CR or PR with duration of at least 6 months. Duration of response (CR or PR) was calculated from the date of initial documentation of a response to the date of first documented evidence of disease progression or death due to disease progression. Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. (NCT01040871)
Timeframe: Median follow up approx. 12 months

Interventionpercentage of participants (Number)
VR-CAP53.9
R-CHOP67.6

[back to top]

Subsequent Anti-lymphoma Therapy Rate at 1-year

Kaplan-meier estimate of subsequent anti-lymphoma therapy at 1-year. Time to subsequent anti-lymphoma therapy was measured from the date of randomization to the start date of new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti-lymphoma treatment was censored at the date of death or the last date known to be alive. (NCT01040871)
Timeframe: 1 year

Interventionpercentage of participants (Number)
VR-CAP71.1
R-CHOP80.2

[back to top]

Overall Survival Rate at 1-year

Kaplan-meier estimate of overall survival at 1-year measured from date of randomization. (NCT01040871)
Timeframe: 1 year

Interventionpercentage of partipants (Number)
VR-CAP94.1
R-CHOP84.2

[back to top]

Feasibility of the Addition of Temozolomide to Chemotherapy Determined by Patient Enrollment

Proportion of no Grade 4+ non-hematologic toxicity. (NCT01055314)
Timeframe: From start to week 26 of therapy

InterventionProportion of Participants (Number)
Temozolomide0.7097

[back to top]

Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment

Proportion of no Grade 3+ cardiac toxicity. (NCT01055314)
Timeframe: From start to week 26 of therapy

InterventionProportion of Participants (Number)
IMC-A120.9390

[back to top]

Event-Free Survival

Probability of no relapse, secondary malignancy, or death after 3 years in the study. (NCT01055314)
Timeframe: 3 years

InterventionProbability (Number)
IMC-A120.1627
Temozolomide0.1919

[back to top]

Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0

Number of patients with grade 3+ adverse events (AE) during therapy. (Grade 3+) = (Grade 3 + Grade 4 + Grade 5) . Grade 3: Severe and undesirable AE; Grade 4: Life threatening or disabling AE; Grade 5: Death related to AE. (NCT01055314)
Timeframe: Up to 54 weeks

InterventionParticipants (Number)
IMC-A1289
Temozolomide61

[back to top]

Response Rate (CR + PR)

Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at > 4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment; Overall Response (OR) = CR + PR. (NCT01055314)
Timeframe: From the start of treatment until a maximum of 2 cycles (21 days per cycle) of treatment in the absence of disease progression or unacceptable toxicities

InterventionProportion of Participants (Number)
IMC-A120.7667
Temozolomide0.7846

[back to top]

Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period

InterventionMonths (Median)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab OzogamicinNA
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab OzogamicinNA

[back to top]

Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts

OR was evaluated according to the International Response Criteria for NHLs. CR was defined as complete disappearance of all lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their GTD for nodes >1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the SPD of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or GTD (for single nodules). With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks.

InterventionPercentage of participants (Number)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin81.3
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin51.9

[back to top]

Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy

"The following parameters were analyzed for hematology: lymphocytes, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, monocytes, neutrophils, platelets, prothrombin international normalized ratio, prothrombin time, fibrinogen, and activated partial thromboplastin time. Laboratory test results were graded using the NCI CTCAE v3.0 where CTCAE Grade 3 equals severe and CTCAE Grade 4 equals life threatening or disabling." (NCT01055496)
Timeframe: Within 3 days prior to the start of each cycle, Day 8 of each cycle, Day 15 of Cycles 1, 2, and 3, and the end-of-treatment visit. Each Cycle is 21 Days.

InterventionPercentage of Participants (Number)
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin91.7
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin96.4

[back to top]

Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts

OR was evaluated according to the International Response Criteria for NHLs. CR was defined as complete disappearance of all lesions and disease-related symptoms; all nodes must have decreased to normal (less than or equal to [≤]1.5 centimeters [cm] in their greatest transverse diameter (GTD) for nodes >1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the sum of the product diameters (SPD) of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or GTD (for single nodules). With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks.

InterventionPercentage of participants (Number)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin81.3
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin53.6

[back to top]

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts

Measure includes death from any cause, PD (including symptomatic deterioration) during and after treatment or initiation of new anticancer therapy for the lymphoma. PD was defined as symptomatic deterioration and according to the International Response Criteria for NHL: 1) appearance of any new lesion >1.5 cm in any axis during or at EOT, even if other lesions are decreasing, 2) at least a 50% increase from nadir in the SPD of any previously involved or single involved nodes, or the size of other lesions (splenic or hepatic). Lymph nodes with a short axis diameter of <1.0 cm must increase by ≥50% and to a size of 1.5x1.5 cm or >1.5 cm in the long axis, 3) 50% increase in the longest diameter of any single previously identified node >1 cm in its short axis. PD was defined as clinical PD, new non-nodal lesions or new nodal lesion ≥1.5 cm in GTD, progression of existing non-index lesions or bone marrow that was negative and now positive. (NCT01055496)
Timeframe: 6, 12 and 24 months

,
InterventionPercent Probability (Number)
6 months12 months24 months
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin80.0066.6722.22
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin60.9847.9233.54

[back to top]

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.

Measure includes death from any cause, PD (including symptomatic deterioration) during and after treatment or initiation of new anticancer therapy for the lymphoma. PD was defined as symptomatic deterioration and according to the International Response Criteria for NHL: 1) appearance of any new lesion >1.5 cm in any axis during or at EOT, even if other lesions are decreasing, 2) at least a 50% increase from nadir in the SPD of any previously involved or single involved nodes, or the size of other lesions (splenic or hepatic). Lymph nodes with a short axis diameter of <1.0 cm must increase by ≥50% and to a size of 1.5x1.5 cm or >1.5 cm in the long axis, 3) 50% increase in the longest diameter of any single previously identified node >1 cm in its short axis. PD was defined as clinical PD, new non-nodal lesions or new nodal lesion ≥1.5 cm in GTD, progression of existing non-index lesions or bone marrow that was negative and now positive. (NCT01055496)
Timeframe: 6, 12, and 24 months

,
InterventionPercent Probability (Number)
6 months12 months24 months
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin61.8551.5444.67
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin54.7424.88NA

[back to top]

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: 6, 12, and 24 months

,
InterventionPercent Probability (Number)
6 months12 months24 months
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin100.0080.0080.00
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin74.0762.9655.09

[back to top]

Mean Inotuzumab Ozogamicin Serum Concentrations

Pharmacokinetic (PK) samples were required for participants enrolled in the confirmatory and preliminary efficacy MTD cohorts only (Parts 2 and 3). Concentrations of inotuzumab ozogamicin in serum were determined using appropriate, validated unconjugated (also known as free) bioanalytical assays. (NCT01055496)
Timeframe: Pre-dose on Cycle 1, Day 2; Pre-dose, 1 and 3 hours post-dose on Cycle 3, Day 2; 24 hours post-dose on Cycle 3, Day 3 and 168 hours post-dose on Cycle 3, Day 8.

,,,
Interventionng/mL (Mean)
Cycle 1 Day 2, 0h
Cohort 1, Arm 2NA
Cohort 3b, Arm 2NA
Cohort 4, Arm 1NA
Cohort 4, Arm 2NA

[back to top]

Mean Inotuzumab Ozogamicin Serum Concentrations

Pharmacokinetic (PK) samples were required for participants enrolled in the confirmatory and preliminary efficacy MTD cohorts only (Parts 2 and 3). Concentrations of inotuzumab ozogamicin in serum were determined using appropriate, validated unconjugated (also known as free) bioanalytical assays. (NCT01055496)
Timeframe: Pre-dose on Cycle 1, Day 2; Pre-dose, 1 and 3 hours post-dose on Cycle 3, Day 2; 24 hours post-dose on Cycle 3, Day 3 and 168 hours post-dose on Cycle 3, Day 8.

,
Interventionng/mL (Mean)
Cycle 1 Day 2, 0hCycle 3 Day 2, 0hCycle 3 Day 2, 1hCycle 3 Day 2, 3hCycle 3 Day 3, 24hCycle 3 Day 8, 168h
Cohort 2b/MTD/EE Arm 2: (R-GDP) Plus Inotuzumab OzogamicinNA25.00283.27280.33154.25NA
Cohort 3/MTD/EE Arm 1: (R-CVP) Plus Inotuzumab OzogamicinNANA189.74213.95110.39NA

[back to top]

Percentage of Participants With a Treatment Emergent AE

An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event may not necessarily have had a causal relationship with the treatment or usage. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as those occurring on or after the first study drug dose day through and including 56 days post last dose of study drug. The severity of all AEs was graded by the investigator using the National Cancer Institute Common Terminology Criteria for AE Version 3.0 (NCI CTCAE v3.0). (NCT01055496)
Timeframe: SAEs were assessed from informed consent through and including the end of treatment visit (at least 28 calendar days after last study drug administration). Non-SAEs were recorded from time of the first dose of study drug through last participant visit.

,
InterventionPercentage of Participants (Number)
Subjects with AEsSubjects with SAEsSubjects with Grade 3 or 4 AEsSubjects with Grade 5 AEsSubjects discontinued due to AEsSubjects with dose reduced due to AEsSubjects with temporary discontinuation due to AEs
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin10031.389.64.227.116.754.2
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin10045.596.45.536.432.767.3

[back to top]

Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy

"The following parameters were analyzed for blood chemistry: blood urea nitrogen (or urea), creatinine, glucose, calcium, sodium, potassium, phosphorus, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, total bilirubin (and direct bilirubin, if total bilirubin was elevated), alkaline phosphatase, uric acid (or urate), albumin and total protein. Laboratory test results were graded using the NCI CTCAE v3.0 where CTCAE Grade 3 equals severe and CTCAE Grade 4 equals life threatening or disabling." (NCT01055496)
Timeframe: Within 3 days prior to the start of each cycle, on Day 8 of each cycle, on Day 15 of Cycles 1, 2, and 3, and the end-of-treatment visit. Each Cycle is 21 Days.

InterventionPercentage of Participants (Number)
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin21.3
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin36.4

[back to top]

Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1

DLT was defined as: febrile neutropenia, Grade (Gr) 4 neutropenia ≥7 days, Gr 4 thrombocytopenia ≥7 days, Gr 3/4 thrombocytopenia associated with bleeding requiring a transfusion, Gr 3/4 non-hematologic toxicity (except alopecia) ≥7 days or treatment-related and clinically significant irrespective of duration, ≥Gr 3 QTc prolongation, Gr 4 alanine or aspartate aminotransferase, Gr 2 hyperbilirubinemia (greater than (>)1.5 x upper normal limit) >7 days, delayed recovery from a treatment-related toxicity that prevented re-dosing by >7 days, or Granulocyte-colony stimulating factor treatment during the first cycle. (NCT01055496)
Timeframe: From the first dose of study medication (Study Day 1) to the completion of the first 21-day cycle.

InterventionParticipants (Count of Participants)
Cohort 1, Arm 10
Cohort 2, Arm 10
Cohort 3, Arm 11
Cohort 4, Arm 12
MTD Confirmation Cohort, Arm 12

[back to top]

Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2

DLT was defined as: febrile neutropenia, Grade (Gr) 4 neutropenia ≥7 days, Gr 4 thrombocytopenia ≥7 days, Gr 3/4 thrombocytopenia associated with bleeding requiring a transfusion, Gr 3/4 non-hematologic toxicity (except alopecia) ≥7 days or treatment-related and clinically significant irrespective of duration, ≥Gr 3 QTc prolongation, Gr 4 alanine or aspartate aminotransferase, Gr 2 hyperbilirubinemia (greater than (>)1.5 x upper normal limit) >7 days, delayed recovery from a treatment-related toxicity that prevented re-dosing by >7 days, or Granulocyte-colony stimulating factor treatment during the first cycle. (NCT01055496)
Timeframe: From the first dose of study medication (Study Day 1) to the completion of the first 21-day cycle.

InterventionParticipants (Count of Participants)
Cohort 1, Arm 20
Cohort 2a, Arm 22
Cohort 2b, Arm 21
Cohort 3b, Arm 22
Cohort 4, Arm 20
MTD Confirmation Cohort, Arm 23

[back to top]

Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts

PFS was defined as time from date of first dose to the earlier date of progression (including symptomatic deterioration), date of death from any cause, or initiation of new anticancer therapy for the lymphoma. Participants without an event were censored at the date of the last valid tumour assessment. A valid tumour assessment visit was defined as the tumour assessment visit with overall response of CR, PR, stable disease (SD), or disease progression (PD), but not 'Not Done' or 'Unknown'. Participants without a post-baseline tumour assessment and without a PFS event were censored on the date of first dose. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks

InterventionMonths (Median)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin16.36
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin10.12

[back to top]

Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts

PFS was defined as time from date of first dose to the earlier date of progression (including symptomatic deterioration), date of death from any cause, or initiation of new anticancer therapy for the lymphoma. Participants without an event were censored at the date of the last valid tumour assessment. A valid tumour assessment visit was defined as the tumour assessment visit with OR of CR, PR, SD, or PD, but not 'Not Done' or 'Unknown'. Participants without a post-baseline tumour assessment and without a PFS event were censored on the date of first dose. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks

InterventionMonths (Median)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin14.36
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin6.14

[back to top]

Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period

InterventionMonths (Median)
DE Arm 1: (R-CVP) Plus Inotuzumab OzogamicinNA
DE Arm 2: (R-GDP) Plus Inotuzumab OzogamicinNA

[back to top]

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: 6, 12, and 24 Months

,
InterventionPercent Probability (Number)
6 months12 months24 months
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin84.3878.1371.61
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin88.0059.1153.74

[back to top]

Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval

PFS is the time interval from start of treatment to documented evidence of disease progression. Disease progression was measured by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: Time of progression or death at 4 years

Interventionpercentage of participants (Number)
Group A - Low-risk Burkitt Lymphoma (BL)100
Group B - High-Risk Burkitt Lymphoma (BL)82.1
Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL)71.0

[back to top]

Percentage of Participants With Kaplan-Meier Curve Event Free Survival (EFS) Constructed With an 95% Confidence Interval

EFS was determined from the date of enrolment in the study until the date of progression, last documentation of disease at or after the last treatment cycle, death, or last follow-up (whichever occurred first). Disease progression was measured by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: At 4 years

Interventionpercentage of participants (Number)
Group A - Low-risk Burkitt Lymphoma (BL)100
Group B - High-Risk Burkitt Lymphoma (BL)82.1
Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL)71.0

[back to top]

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01092182)
Timeframe: Date treatment consent signed to date off study, approximately 102 months and 25 days for Group A, 125 months and 28 days for Group B and 117 months and 29 days for group C.

InterventionParticipants (Count of Participants)
Group A - Low-risk Burkitt Lymphoma (BL)13
Group B - High-Risk Burkitt Lymphoma (BL)87
Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL)72

[back to top]

Kaplan-Meier Progression Free Survival (PFS) Constructed With an 95% Confidence Interval in Participants Who Underwent Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) and/or Computed Tomography (CT) Scans After Cycle 2

The predictive value of early FDG-PET/CT scans on PFS was assessed after cycle 2. PFS is the time interval from start of treatment to documented evidence of disease progression, assessed by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: After 2 cycles of therapy and prior to cycle 3

Interventionpercentage of participants (Number)
Group A - Low-risk Burkitt Lymphoma (BL)100
Group B - High-Risk Burkitt Lymphoma (BL)90.0
Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL)78.7

[back to top]

Percentage of Participants Kaplan-Meier Curve Overall Survival (OS) Constructed With an 95% Confidence Interval

OS was calculated from the enrolment date until date of death or last follow-up using the Kaplan Meier. Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: At 4 years

Interventionpercentage of participants (Number)
Group A - Low-risk Burkitt Lymphoma (BL)100
Group B - High-Risk Burkitt Lymphoma (BL)84.9
Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL)76.7

[back to top]

EFS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy

The Kaplan-Meier estimate of EFS is calculated from enrollment date to first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of EFS are presented.

Interventionpercentage of participants (Number)
Arm IV: Nonrandomly Assigned to Arm II Treatment33.6

[back to top]

EFS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation

The Kaplan-Meier estimate of EFS is calculated from enrollment date to first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of EFS are presented.

Interventionpercentage of participants (Number)
Arm I: Observation66.9

[back to top]

EFS With Incomplete Resection After Initial Surgery, Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only

Kaplan-Meier estimates of EFS are calculated from randomization date to first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause. The comparison between randomized arms (post-radiation maintenance chemotherapy versus post-radiation observation only) for this stratum is conveyed by the hazard ratio and 95% Wald confidence interval. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of EFS are presented.

Interventionpercentage of participants (Number)
Arm II: Randomized to Radiation With Maintenance Chemotherapy in Stratum 241.7
Arm III: Randomized to Radiation Only in Stratum 267.5

[back to top]

EFS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only

Kaplan-Meier estimates of EFS are calculated from randomization date to first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause. The comparison between randomized arms (post-radiation maintenance chemotherapy versus post-radiation observation only) for this stratum is conveyed by the hazard ratio and 95% Wald confidence interval. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of EFS are presented.

Interventionpercentage of participants (Number)
Arm II: Randomized to Radiation With Maintenance Chemotherapy in Stratum 172.7
Arm III: Randomized to Radiation Only in Stratum 162.9

[back to top]

Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only

Kaplan-Meier estimates of EFS are calculated from randomization date to first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause. The comparison between randomized arms (post-radiation maintenance chemotherapy versus post-radiation observation only) is conveyed by the hazard ratio and 90.46% stagewise adjusted Wald confidence interval. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of EFS are presented

Interventionpercentage of participants (Number)
Arm II: Randomized to Radiation With Maintenance Chemotherapy69.2
Arm III: Randomized to Radiation Only63.7

[back to top]

OS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only.

Kaplan-Meier estimates of OS are calculated from randomization date to death from any cause. The comparison between randomized arms (post-radiation maintenance chemotherapy versus post-radiation observation only) for this stratum is conveyed by the hazard ratio and 95% Wald confidence interval. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of OS are presented.

Interventionpercentage of participants (Number)
Arm II: Randomized to Radiation With Maintenance Chemotherapy in Stratum 190.7
Arm III: Randomized to Radiation Only in Stratum 186.4

[back to top]

OS in Children With Incomplete Resection After Initial Surgery Who Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only

Kaplan-Meier estimates of OS are calculated from randomization date to death from any cause. The comparison between randomized arms (post-radiation maintenance chemotherapy versus post-radiation observation only) for this stratum is conveyed by the hazard ratio and 95% Wald confidence interval. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of OS are presented.

Interventionpercentage of participants (Number)
Arm II: Randomized to Radiation With Maintenance Chemotherapy in Stratum 269.2
Arm III: Randomized to Radiation Only in Stratum 289.5

[back to top]

OS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy

The Kaplan-Meier estimate of OS is calculated from enrollment date to death from any cause. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of OS are presented.

Interventionpercentage of participants (Number)
Arm IV: Nonrandomly Assigned to Arm II Treatment74.0

[back to top]

OS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation

The Kaplan-Meier estimate of OS is calculated from enrollment date to death from any cause. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of OS are presented.

Interventionpercentage of participants (Number)
Arm I: Observation100

[back to top]

Overall Survival (OS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only

Kaplan-Meier estimates of OS are calculated from randomization date to death from any cause. The comparison between randomized arms (post-radiation maintenance chemotherapy versus post-radiation observation only) is conveyed by the hazard ratio and 90.46% stagewise adjusted Wald confidence interval. (NCT01096368)
Timeframe: Up to 10 years after enrollment. 5-year estimates of OS are presented.

Interventionpercentage of participants (Number)
Arm II: Randomized to Radiation With Maintenance Chemotherapy88.3
Arm III: Randomized to Radiation Only86.9

[back to top]

Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131

Number of MIBG avid patients who receive 131I-MIBG divided by the number of patients evaluable for the feasibility of MIBG endpoint x 100%. (NCT01175356)
Timeframe: Up to 6 weeks after course 5 of induction

InterventionPercentage of participants (Number)
Treatment (131I-MIBG, Chemotherapy)86.8

[back to top]

Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy

Number of MIBG avid patients who receive 131I-MIBG and Bu/Mel divided by the number of patients evaluable for the feasibility of MIBG and Bu/Mel consolidation endpoint x 100%. (NCT01175356)
Timeframe: Up to day -6 of conditioning

InterventionPercentage of participants (Number)
Treatment (131I-MIBG, Chemotherapy)82.2

[back to top]

Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG

Number of patients who had an unacceptable toxicity or experienced SOS. Unacceptable toxicity was defined as CTC Grade 4-5 Pulmonary/Respiratory. (NCT01175356)
Timeframe: Up to 6 weeks after course 5 of induction

InterventionParticipants (Count of Participants)
Treatment (131I-MIBG, Chemotherapy)3

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.42

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical

Age and gender standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-1.44

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-1.21

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.27
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.34

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.64
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.67

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.72
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.77

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.16
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.25

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.62
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.64

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.80
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.89

[back to top]

Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.7 years

Interventionpercent probability (Number)
B-ALL Average Risk: MTX 20 mg/m^2/Week Starting Dose95.05
B-ALL Average Risk: MTX 40 mg/m^2/Week Starting Dose94.17

[back to top]

DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens

DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.1 years

Interventionpercent probability (Number)
B-ALL Low Risk Arm I (LR-M)98.75
B-ALL Low Risk Arm II (LR-C)98.50

[back to top]

DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.7 years

Interventionpercent probability (Number)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks94.10
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks95.13

[back to top]

DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care

DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5.1 years

Interventionpercent probability (Number)
Standard Risk With Down Syndrome89.77

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for each randomization group will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-1.12
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.02

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for each randomization group will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-1.19
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks0.21

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.27

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.28

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.39

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.36

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.87

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.84

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 4.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-1.12

[back to top]

Sample Collection of Central Path Review Slides in B-LLy Patients

Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported. (NCT01190930)
Timeframe: Up to 1 month

Interventionpercentage of patients (Number)
B-LLy89.7

[back to top]

Overall Survival (OS) for B-LLy Patients

OS is calculated as the time from study enrollment to death or date of last contact. The 5-year OS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5 years

Interventionpercent probability (Number)
B-LLy93.97

[back to top]

Event Free Survival (EFS) for B-LLy Patients

EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5 years

Interventionpercent probability (Number)
B-LLy94.54

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 4.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-1.19

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning

Age standardized Quality of life, measured by the Social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.40

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.67

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Genetic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.62

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.46
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.33

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.85
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.47

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.71
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.51

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.30

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.66

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.5 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.74

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.20

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.63

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.84

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.19

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.59

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.86

[back to top]

Changes in Human Immunodeficiency Virus (HIV) Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months

,
Interventionmedian change in copies per mL (Median)
End of Cycle 2At treatment discontinuation6-month follow-up12-month follow-up
Phase II: DA-R-EPOCH-25-22.5-18-20
Phase II: VR-DA-EPOCH-20-87-200

[back to top]

Changes in Human Herpes Virus (HHV)-8 Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Interventioncopies per 100uL (Median)
12-month follow-up
Phase II: VR-DA-EPOCH0

[back to top]

Changes in Epstein-Barr Virus (EBV) Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

,,,
InterventionIU/mL (Median)
End of Cycle 2At treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-DA-EPOCH, Dose Level 10000
Phase I: VR-DA-EPOCH, Dose Level 2-2436.1-1.92-1.92-1.15
Phase II, DA-R-EPOCH0-0.280-2.7
Phase II, VR-DA-EPOCH-0.61-2.9-1.55-0.56

[back to top]

Event-free Survival (EFS) (Phase II)

The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Phase II: VR-DA-EPOCH75.6
Phase II: DA-R-EPOCH82.2

[back to top]

Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)

Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months

,,
Interventioncopies per milliliter (Median)
End of cycle 2Treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-CHOP, Dose Level 128000
Phase I: VR-DA-EPOCH, Dose Level 1-14518-4517-551160
Phase I: VR-DA-EPOCH, Dose Level 2-12.5000

[back to top]

Change in CD8 Cell Counts (Phase I)

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

,,
Interventioncells/mm^3 (Median)
End of cycle 2Treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-CHOP, Dose Level 1-172-81-16128
Phase I: VR-DA-EPOCH, Dose Level 135.5-164.5-56604
Phase I: VR-DA-EPOCH, Dose Level 2-115211275154

[back to top] [back to top]

Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)

"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months

Interventionpercentage of participants (Number)
Phase II: VR-DA-EPOCH67.5
Phase II: DA-R-EPOCH76.2

[back to top]

Changes in Absolute CD4 Cell Counts (Phase I)

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

,,
Interventioncell/mm^3 (Median)
End of cycle 2Treatment discontinuation6-month follow-up12-month follow-up
Phase I: VR-CHOP, Dose Level 1-218-190-175-84
Phase I: VR-DA-EPOCH, Dose Level 192-3976169
Phase I: VR-DA-EPOCH, Dose Level 2-9-293131

[back to top]

Tumor Response (Phase I)

The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment

,,
Interventionpercentage of participants (Number)
Complete responsePartial Response
Phase I: Arm C (VR-CHOP) Dose Level 11000
Phase I: VR-DA-EPOCH, Dose Level 183.316.7
Phase I: VR-DA-EPOCH, Dose Level 283.316.7

[back to top]

Pharmacokinetic Clearance (Phase I)

Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion

,
InterventionLiter/hour (Mean)
DoxorubicinEtoposideVincristine
Phase I: VR-DA-EPOCH, Dose Level 178.63.022.4
Phase I: VR-DA-EPOCH, Dose Level 276.02.416.8

[back to top]

Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)

The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years

,
Interventionpercentage of participants (Number)
DeathLife-threateningSevereModerateMild
Phase II: DA-R-EPOCH20.028.931.117.80
Phase II: VR-DA-EPOCH28.937.820.08.92.2

[back to top]

Overall Survival (OS) (Phase II)

The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Phase II: VR-DA-EPOCH77.6
Phase II: DA-R-EPOCH86.7

[back to top]

Changes in Human Herpes Virus (HHV)-8 Viral Load

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Interventioncopies per 100uL (Median)
At treatment discontinuation6-month follow-up12-month follow-up
Phase II: DA-R-EPOCH000

[back to top]

Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs) to Rituximab

Levels of HACA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 & 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 [up to 6 years]) (NCT01200758)
Timeframe: Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)

,
Interventionpercentage of participants (Number)
Baseline (n=208, 191)Post-Baseline (n=206, 197)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)5.81.5
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)2.62.0

[back to top]

Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle

Stage I and II (maintenance): D29 of Cy8 (induction; 1 Cy=4 weeks), predose (within 2 hr) on D1 of Cy9 to 19 (maintenance Cy1 to 12 [1 Cy=8 weeks]; up to data cutoff of 11 Jan 2016 [up to 6 years]) (NCT01200758)
Timeframe: Stage I and II (maintenance): Predose (within 2hr) up to data cutoff of 11 Jan 2016 [up to 6 years]) (See detailed timeframe in Outcome Measure description)

,
Interventionmcg/mL (Geometric Mean)
Cycle 8 (n = 174, 170)Cycle 9 (n = 171, 168)Cycle 10 (n = 164, 160)Cycle 11 (n = 164, 157)Cycle 12 (n = 160, 150)Cycle 13 (n = 157, 150)Cycle 14 (n = 153, 147)Cycle 15 (n = 148, 143)Cycle 16 (n = 150, 145)Cycle 17 (n = 149, 143)Cycle 18 (n = 143, 132)Cycle 19 (n = 138, 131)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)37.6930.3528.4428.7728.8028.8428.0928.1928.0528.2428.5927.75
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)61.3149.4747.2746.7044.7244.3243.3244.1142.9642.8244.7943.69

[back to top]

Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

Interventionpercentage of participants (Number)
Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)25.0
Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)42.9

[back to top]

Stage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab

AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Predose (within 2 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy 7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 [up to 26 months]) (NCT01200758)
Timeframe: Stage I (Induction): Predose (within 2 hour [hr]) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)

Interventionmcg*day/mL (Geometric Mean)
Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)2734.21
Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)3778.93

[back to top]

Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab

Predose (within 2 hr) and 24 hrs postdose on Cy7 (D1,3,7,15), predose (0 hr) on Cy8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 [up to 26 months]) (NCT01200758)
Timeframe: Stage I (Induction): Predose (within 2hr) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)

Interventionmcg/mL (Geometric Mean)
Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)250.63
Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)236.82

[back to top]

Stage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHL

PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node >1 cm in its short axis or in the SPD of more than one node. PFS analysis was performed using Kaplan - Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 & 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 [up to 6 years]) (NCT01200758)
Timeframe: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

Interventiondays (Median)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)NA
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)NA

[back to top]

Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL

Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)

Interventionpercentage of participants (Number)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)78.1
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)77.9

[back to top]

Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death

Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node >1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 & 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 [up to 6 years]) (NCT01200758)
Timeframe: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

Interventionpercentage of participants (Number)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)34.6
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)31.7

[back to top]

Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

Interventionpercentage of participants (Number)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)84.9
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)84.4

[back to top]

Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL

Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node >1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 & 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 [up to 6 years]) (NCT01200758)
Timeframe: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

Interventionpercentage of participants (Number)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)36.1
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)35.1

[back to top]

Stage I and II (Pooled): Percentage of Responses Showing Time Saved of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20

All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (<) 1 hr, at least 1 hr but <2 hrs, at least 2 hrs but <3 hrs, at least 3 hrs but <4 hrs, >/=4 hrs. Staff were asked not to consider the time needed for the first IV administration. Analysis was done in all participants to show a comparison on the time saved by staffs when administered via SC and IV. (NCT01200758)
Timeframe: After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)

Interventionpercentage of responses (Number)
After Cy8: <1 hour (n=166)After Cy8: ≥1 to <2 hours (n=166)After Cy8: ≥2 to <3 hours (n=166)After Cy8: ≥3 to <4 hours (n=166)After Cy8: ≥4 hours (n=166)After Cy15: <1 hour (n=130)After Cy15: ≥1 to <2 hours (n=130)After Cy15: ≥2 to <3 hours (n=126)After Cy15: ≥3 to <4 hours (n=130)After Cy15: ≥4 hours (n=130)After Cy20: <1 hour (n=126)After Cy20: ≥1 to <2 hours (n=126)After Cy20: ≥2 to <3 hours (n=126)After Cy20: ≥3 to <4 hours (n=126)After Cy20: ≥4 hours (n=126)
All Participants112035181613173414221432211319

[back to top]

Stage I and II (Pooled): Ctrough of Rituximab at Each Induction Treatment Cycle

Stage I and II (Induction): Rituximab IV: Predose (within 2 hr) on D1 of Cy1-8 (1 Cy=3 weeks & 4 weeks for Cy8); Rituximab SC: Predose (within 2 hr) on D1 of Cy1 & Cy3-8 (1 Cy=3 weeks and 4 weeks for Cy8), predose (within 2 hr) on D0 of Cy2 (up to data cutoff of 31 Oct 2013 [up to 32 months]) (NCT01200758)
Timeframe: Stage I and II (Pooled): Predose (within 2hr) up to data cutoff of 31 Oct 2013 [up to 32 months]) (See detailed timeframe in Outcome Measure description)

,
Interventionmcg/mL (Geometric Mean)
Cycle 1 (n = 198, 193)Cycle 2 (n = 197, 190)Cycle 3 (n = 192, 190)Cycle 4 (n = 186, 185)Cycle 5 (n = 185, 185)Cycle 6 (n = 187, 180)Cycle 7 (n = 183, 172)Cycle 8 (n = 52, 54)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)14.0030.1345.2554.0664.6871.0278.3177.60
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)12.8840.0063.8381.7198.00109.56120.75131.48

[back to top]

Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)

Interventionpercentage of participants (Number)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)57.9
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)50.6

[back to top]

Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

Interventionpercentage of participants (Number)
Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)82.8
Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)90.5

[back to top]

Percentage of Responses Who Showed Rituximab SC Formulation Convenient as Compared to Rituximab IV Formulation as Assessed by Physician/Nurse Opinion

"All investigator physicians and nurses involved in this study were asked to complete question i.e. Which formulation of rituximab (SC or IV) do you think is more convenient? based on their experience with the rituximab SC and IV formulations across all participants and presented as rituximab SC is much more convenient; rituximab SC is a little more convenient; both formulations are equally convenient; rituximab IV is a little more convenient; and rituximab IV is much more convenient." (NCT01200758)
Timeframe: After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)

Interventionpercentage of responses (Number)
Cy8: Rituximab SC much more convenient (n=166)Cy8: Rituximab SC little more convenient (n=166)Cy8: Both formulations equally convenient (n=166)Cy8: Rituximab IV little more convenient (n=166)Cy8: Rituximab IV much more convenient (n=166)Cy15: Rituximab SC much more convenient (n=130)Cy15: Rituximab SC little more convenient (n=130)Cy15: Both formulations equally convenient (n=130)Cy15: Rituximab IV little more convenient (n=130)Cy15: Rituximab IV much more convenient (n=130)Cy20: Rituximab SC much more convenient (n=126)Cy20: Rituximab SC little more convenient (n=126)Cy20: Both formulations equally convenient (n=126)Cy20: Rituximab IV little more convenient (n=126)Cy20: Rituximab IV much more convenient (n=126)
All Participants8113240887500889210

[back to top]

Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

Interventionpercentage of participants (Number)
Stage II: Rituximab IV + Chemotherapy (CHOP/CVP)34.8
Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)28.2

[back to top]

Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)

Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

Interventionpercentage of participants (Number)
Stage II: Rituximab IV + Chemotherapy (CHOP/CVP)85.1
Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)80.3

[back to top]

Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase

Depletion is defined as a cluster of differentiation (CD) 19 value <80 cells per cubic millimeter (cells/mm^3). (NCT01200758)
Timeframe: Stage I and II (induction): for rituximab IV - D1 of Cy 1 to 8 (1 Cy=3 weeks); for rituximab SC - D1 of Cy 1 and Cy 3 to 8, D0 of Cy 2

,
Interventionpercentage of participants (Number)
Cycle 1 Day 1 - Baseline (n=188, 168)Cycle 2 Day 0 (n=183, 180)Cycle 3 Day 1 (n=175, 175)Cycle 4 Day 1 (n=178, 180)Cycle 5 Day 1 (n=179, 176)Cycle 6 Day 1 (n=173, 175)Cycle 7 Day 1 (n=178, 173)Cycle 8 Day 1 (n=175, 174)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)51.695.199.499.4100.0100.0100.0100.0
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)54.895.099.4100.0100.0100.0100.0100.0

[back to top]

Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase

Depletion is defined as a CD19 value <80 cells/mm^3. (NCT01200758)
Timeframe: Stage I and II (maintenance): D1 of Cy 9 to 20 (1 Cy=8 weeks) (up to data cutoff of 11 Jan 2016 [up to 6 years])

,
Interventionpercentage of participants (Number)
Cycle 9 Day 1 (n=170, 161)Cycle 10 Day 1 (n=165, 164)Cycle 11 Day 1 (n=158, 158)Cycle 12 Day 1 (n=151, 146)Cycle 13 Day 1 (n=149, 143)Cycle 14 Day 1 (n=152, 143)Cycle 15 Day 1 (n=149, 140)Cycle 16 Day 1 (n=142, 141)Cycle 17 Day 1 (n=145, 142)Cycle 18 Day 1 (n=141, 140)Cycle 19 Day 1 (n=140, 138)Cycle 20 Day 1 (n=139, 134)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)99.499.499.4100.0100.0100.0100.0100.0100.0100.0100.0100.0
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

[back to top]

Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper. (NCT01200758)
Timeframe: Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

Interventionpercentage of participants (Number)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)31.7
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)32.2

[back to top]

Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL

Event-free survival was defined as the time from randomization to disease progression/relapse, death or initiation of new NHL therapy. If the specified event (progression/relapse, death or new anti-lymphoma treatment) did not occur, event-free survival was censored at the last tumor assessment date either during treatment or follow up. Event-free survival analysis was performed using Kaplan-Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 & 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 [up to 6 years]) (NCT01200758)
Timeframe: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

Interventiondays (Median)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)NA
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)NA

[back to top]

Percentage of Participants Who Died

(NCT01200758)
Timeframe: Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])

Interventionpercentage of participants (Number)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)12.7
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)8.8

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Participants without event were censored at the time of last follow-up information for survival, ie, at the last time known to be alive. (NCT01200758)
Timeframe: Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])

Interventiondays (Median)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)NA
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)NA

[back to top]

Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration

(NCT01200758)
Timeframe: 12 weeks, 24 weeks, and 36 weeks after the last rituximab administration (up to data cutoff of 11 Jan 2016 [up to 6 years])

,
Interventionmcg/mL (Median)
Week 12: Follow-up Visit 1 (n = 117, 118)Week 24: Follow-up Visit 2 (n = 88, 96)Week 36: Follow-up Visit 3 (n = 38, 53)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)15.602.891.08
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)22.355.192.02

[back to top]

Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab

(NCT01200758)
Timeframe: Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours predose on Cy8) of induction treatment (1 Cy=3 weeks)

Interventionmicrograms per milliliter (mcg/mL) (Geometric Mean)
Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)83.1
Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)134.6

[back to top]

Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Human Antibodies (HAHAs) to Rituximab

Levels of HAHA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 & 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 [up to 6 years]) (NCT01200758)
Timeframe: Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)

,
Interventionpercentage of participants (Number)
Baseline (n=68, 188)Post-Baseline (n=66, 197)
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)10.37.6
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)11.213.2

[back to top]

Event-Free Survival

Estimated 5-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact. (NCT01231906)
Timeframe: 5 years after enrollment

InterventionPercent Probability (Number)
Arm A (Combination Chemotherapy)77.64
Arm B (Combination Chemotherapy, Topotecan Hydrochloride)78.79

[back to top]

Response

Proportion of patients reaching a CR. A CR requires the following: an absolute neutrophil count (segs and bands) >1000/μL, no circulating blasts, platelets >100,000/μL; adequate bone marrow cellularity with trilineage hematopoiesis, and <5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement). (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant).9846

[back to top]

Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant)0.667

[back to top]

Overall Survival (OS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)55.9

[back to top]

Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy, Transplant)5

[back to top]

Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: At 3 years after CR

Interventionpercentage of patients (Number)
Treatment (Chemotherapy, Transplant)52.6

[back to top]

Disease Free Survival (DFS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)29.7

[back to top]

Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores

The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)

Interventionscore on a scale (Mean)
BaselineChange Baseline, Cycle 3 Day 1Change Baseline, Study CompletionChange Baseline, Follow-Up Month 12Change Baseline, Follow-Up Month 24Change Baseline, Follow-Up Month 36Change Baseline, Follow-Up Month 48Change Baseline, Follow-Up Completion
Rituximab+Chemotherapy59.816.379.8412.6714.7415.0116.628.74

[back to top] [back to top]

Percentage of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)

Interventionpercentage of participants (Number)
Rituximab+Chemotherapy95.3
Obinutuzumab+Chemotherapy98.1

[back to top]

Overall Response Rate (ORR), Investigator-Assessed

Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)

,
Interventionpercentage of participants (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy81.477.1
Rituximab+Chemotherapy80.177.6

[back to top]

Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed

Kaplan Meier estimate of median PFS was defined as time at which half of participants have progressed (progressive disease [PD]). Progression-free survival was defined as time from randomization until first documented day of disease progression or relapse, using a modified version of Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 cm or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with diameter 1.5 cm. Tumor measurements were obtained by CT or MRI. This outcome measure used data from primary analysis which included all 1418 participants. (NCT01287741)
Timeframe: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)

Interventionmonths (Median)
Rituximab+ChemotherapyNA
Obinutuzumab+ChemotherapyNA

[back to top]

Median Time to Overall Survival (OS)

Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)

Interventionmonths (Median)
Rituximab+ChemotherapyNA
Obinutuzumab+ChemotherapyNA

[back to top]

Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab. (NCT01287741)
Timeframe: C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)

Interventionmicrograms per milliliter (μg/mL) (Geometric Mean)
Cycle 1, Day 8 pre-infusionCycle 1, Day 15 pre-infusionCycle 2, Day 1 pre-infusionCycle 4, Day 1 pre-infusionCycle 6, Day 1 pre-infusionCycle 8, Day 1 pre-infusionCycle 1, Day 1 post-infusionCycle 1, Day 1 20-28 hours after end of infusionCycle 1, Day 1 66-80 hours after end of infusionCycle 1, Day 8 post-infusionCycle 1, Day 15 post-infusionCycle 2, Day 1 post-infusionCycle 4, Day 1 post-infusionCycle 6, Day 1 post-infusionCycle 8, Day 1 post-infusion
Obinutuzumab+Chemotherapy174320431352378478435259219578718938817813881

[back to top]

Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab

The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants. (NCT01287741)
Timeframe: Pre-dose (Hour 0) on Cycle (C) 4 Day (D) 1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)

Interventionpercentage of participants (Number)
ScreeningCycle 4 Day 1Study Completion / Early DiscontinuationFollow-Up Month 6Follow-Up Month 12Follow-Up Month 18Follow-Up Month 24Follow-Up Month 30Follow-Up Completion/ Early DiscontinuationUnscheduled
Obinutuzumab+Chemotherapy2.0000000000

[back to top]

Overall Response Rate (ORR), IRC-Assessed

Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. This outcome measure used data from primary analysis which included all 1418 participants. (NCT01287741)
Timeframe: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)

,
Interventionpercentage of participants (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy82.382.1
Rituximab+Chemotherapy80.281.1

[back to top]

Complete Response (CR) at the End of Treatment, IRC-Assessed

Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. This outcome measure used data from primary analysis which included all 1418 participants. (NCT01287741)
Timeframe: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)

,
Interventionpercentage of participants (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy39.166.7
Rituximab+Chemotherapy34.465.3

[back to top]

Median Time to Event-Free Survival (EFS), Investigator-Assessed

Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed. Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. (NCT01287741)
Timeframe: Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, approximately 6.5 years (up to 31 January 2018)

Interventionmonths (Mean)
Rituximab+Chemotherapy74.5
Obinutuzumab+Chemotherapy68.3

[back to top]

Median Time to Disease-Free Survival (DFS), Investigator-Assessed

Kaplan Meier estimate of median DFS was defined as time at which half of participants have disease progression/relapse or death from any cause. Disease-free survival was defined as time from date of the first occurrence of a documented CR to date of disease progression/relapse or death from any cause on basis of investigator assessments with use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. (NCT01287741)
Timeframe: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)

Interventionmonths (Median)
Rituximab+ChemotherapyNA
Obinutuzumab+Chemotherapy65.4

[back to top]

Duration of Response (DOR), Investigator-Assessed

DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression >/= 50%. Progression/relapse: at least 50% increase in nodal lesions or >/=50% increase in any node > 1 cm or >/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%. (NCT01287741)
Timeframe: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)

Interventionmonths (Median)
Rituximab+Chemotherapy71.9
Obinutuzumab+ChemotherapyNA

[back to top]

Complete Response (CR) at the End of Treatment, Investigator-Assessed

Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)

,
Interventionpercentage of participants (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy35.456.5
Rituximab+Chemotherapy33.959.1

[back to top]

Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score

The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)

Interventionscore on a scale (Mean)
BaselineScore Change, Cycle 3 Day 1Score Change, Study Compl./Discont.Score Change, Follow-Up Month 12Score Change, Follow-Up Month 24Score Change, Follow-Up Month 30Score Change, Follow-Up Month 36Score Change, Follow-Up Month 48Score Change, Follow-Up Term./Compl.
Obinutuzumab+Chemotherapy45.183.704.356.186.6625.007.317.375.55

[back to top]

Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score

The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)

Interventionscore on a scale (Mean)
BaselineScore Change, Cycle 3 Day 1Score Change, Study Compl./Discont.Score Change, Follow-Up Month 12Score Change, Follow-Up Month 24Score Change, Follow-Up Month 36Score Change, Follow-Up Month 48Score Change, Follow-Up Term./Compl.
Rituximab+Chemotherapy45.343.835.036.377.077.578.225.51

[back to top]

Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores

The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)

Interventionscore on a scale (Mean)
BaselineChange Baseline, Cycle 3 Day 1Change Baseline, Study CompletionChange Baseline, Follow-Up Month 12Change Baseline, Follow-Up Month 24Change Baseline, Follow-Up Month 30Change Baseline, Follow-Up Month 36Change Baseline, Follow-Up Month 48Change Baseline, Follow-Up Completion
Obinutuzumab+Chemotherapy58.557.5110.2213.8415.8158.3317.9917.538.46

[back to top]

Median Time to Progression-Free Survival (PFS), Investigator-Assessed

Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI). (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)

Interventionmonths (Median)
Rituximab+Chemotherapy74.5
Obinutuzumab+Chemotherapy68.3

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. Survival will be measured by the estimated median survival computed by Kaplan-Meier (K-M) analysis, which is the time point at which the cumulative survival drops below 50%, if present. If not present then the median Overall Survival is not reached and not available (NA) as there are an insufficient number of participants with events. In either case ranges are provided for observed survival intervals used in the K-M analysis. (NCT01319981)
Timeframe: Up to 7 years, 8 months

InterventionMonths (Median)
Hyper-CMAD + RituximabNA
Hyper-CMADNA

[back to top]

Number of Patients With Complete Remission at One Year

The complete remission (CR) is the total number of patients who are in CR at one year divided by the total number of patients who received at least one dose of HCVAD with liposomal vincristine. CR was defined as the presence of 1x10^9/L neutrophils, >100x10^9/L platelets in the perpherial blood, and no extramedullary disease. (NCT01319981)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Hyper-CMAD + Rituximab12
Hyper-CMAD13

[back to top]

Complete Response Duration

The complete remission (CR) is the total number of patients who are in CR at one year divided by the total number of patients who received at least one dose of HCVAD with liposomal vincristine. CR was defined as the presence of 1x10^9/L neutrophils, >100x10^9/L platelets in the perpherial blood, and no extramedullary disease. Response date to loss of response or last follow up. Remission duration will be measured by the estimated median remission duration computed by Kaplan-Meier (K-M) analysis, which is the time point at which the cumulative remission duration drops below 50%, if present. If not present then median remission duration is not reached and not available (NA) as there are an insufficient number of participants with events. In either case ranges are provided for observed survival intervals used in the K-M analysis.. (NCT01319981)
Timeframe: Up to 7 years, 8 months

InterventionMonths (Median)
Hyper-CMAD + RituximabNA
Hyper-CMADNA

[back to top]

Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)

The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

,
Interventionunits on a scale (Mean)
Lymphoma, BaselineLymphoma Change, Cycle 3 Day 1Lymphoma Change, End InductionLymphoma Change, Maint Month 2Lymphoma Change, Maint Month 12Lymphoma Change, End Maint
Obinutuzumab+Chemotherapy45.542.713.014.524.274.57
Rituximab+Chemotherapy45.012.042.994.804.934.31

[back to top]

Overall Response (Follicular Lymphoma Population), IRC-Assessed

Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy91.388.6
Rituximab+Chemotherapy88.085.2

[back to top]

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

,
Interventionunits on a scale (Mean)
Change Baseline, Maint/Obs Month 2Change Baseline, Maint/Obs Month 12Change Baseline, Maint/Obs Completion
Obinutuzumab+Chemotherapy0.040.060.05
Rituximab+Chemotherapy0.040.060.03

[back to top]

Disease-Free Survival (Follicular Lymphoma Population)

Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy27.9
Obinutuzumab+Chemotherapy26.3

[back to top]

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

Interventionunits on a scale (Mean)
Baseline InductionChange Baseline, Cycle 3 Day 1Change Baseline, Induction ComplChange Baseline, Maint/Obs Month 2Change from Baseline, Maint/Obs Month 12
Rituximab+Chemotherapy0.800.030.040.050.00

[back to top]

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 after Day 1 of last induction cycle, Follow-up: every year for up to data cut-off (up to 5 years and 2 months)

,
Interventionunits on a scale (Mean)
Change Baseline, Follow-Up Month 36Change Baseline, Follow-Up Month 48
Obinutuzumab+Chemotherapy0.060.06
Rituximab+Chemotherapy0.050.05

[back to top]

Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)

FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

,
Interventionunits on a scale (Mean)
Physical Well-being (PW), BaselinePW Change, Cycle 3, Day 1PW Change, End InductionPW Change, Maint Month 2PW Change, Maint Month 12PW Change, End MaintSocial/Family Well-being , BaselineS/FW Change, Cycle 3 Day 1S/FW Change, End InductionS/FW Change, Maint Month 2S/FW Change, Maint Month 12S/FW Change, End MaintEmotional Well-being (EW), BaselineEW Change, Cycle 3 Day 1EW Change, End InductionEW Change, Maint Month 2EW Change, Maint Month 12EW Change, End MaintFunctional Well-being (FW), BaselineFW Change, Cycle 3 Day 1FW Change, End InductionFW Change, Maint Month 2FW Change, Maint Month 12FW Change, End Maint
Obinutuzumab+Chemotherapy23.14-0.210.561.421.341.3323.28-0.67-0.56-0.67-0.97-0.7117.871.351.141.491.461.4918.76-0.070.931.251.651.72
Rituximab+Chemotherapy23.36-0.91-0.060.831.140.8822.84-0.52-0.46-0.39-0.61-0.9317.641.491.161.771.451.4318.66-0.300.441.041.841.40

[back to top] [back to top]

Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI). (NCT01332968)
Timeframe: Baseline up to final analysis (up to 10 years)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy40.6
Obinutuzumab+Chemotherapy34.3

[back to top]

Complete Response (Overall Study Population), IRC-Assessed

Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)]

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy27.169.5
Rituximab+Chemotherapy26.359.4

[back to top]

Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)

The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

,
Interventionunits on a scale (Mean)
Total Score, BaselineTotal Score Change, Cycle 3 Day 1Total Score Change, End InductionTotal Score Change, Maint Month 2Total Score Change, Maint Month 12Total Score Change, End Maint
Obinutuzumab+Chemotherapy128.423.215.108.137.908.80
Rituximab+Chemotherapy127.401.984.188.408.877.43

[back to top]

Complete Response (Overall Study Population), Investigator-Assessed

Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy18.461.1
Rituximab+Chemotherapy23.357.0

[back to top]

Complete Response (Follicular Lymphoma Population), IRC-Assessed

Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy28.571.4
Rituximab+Chemotherapy26.859.7

[back to top]

Complete Response (Follicular Lymphoma Population), Investigator-Assessed

Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy18.662.0
Rituximab+Chemotherapy24.156.7

[back to top]

Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase

The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs. (NCT01332968)
Timeframe: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)

Interventionunits on a scale (Mean)
Baseline InductionChange Baseline, Cycle 3 Day 1Change Baseline, Induction ComplChange Baseline, Maint/Obs Month 2Change from Baseline, Maint/Obs Month 12Change Baseline, Maint/Obs Completion
Obinutuzumab+Chemotherapy0.810.030.030.06-0.20-0.10

[back to top]

Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed

Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI). (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 4 years and 7 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy24.0
Obinutuzumab+Chemotherapy16.8

[back to top]

Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)

Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy24.6
Obinutuzumab+Chemotherapy18.4

[back to top]

Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed

Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy23.5
Obinutuzumab+Chemotherapy18.0

[back to top]

Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01332968)
Timeframe: Baseline up to 10 years

Interventionpercentage of participants (Number)
Rituximab+Chemotherapy99.6
Obinutuzumab+Chemotherapy99.9

[back to top]

Progression-Free Survival in the Overall Study Population, Investigator-Assessed

Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy41.5
Obinutuzumab+Chemotherapy34.8

[back to top]

Overall Survival (Follicular Lymphoma Population)

Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: Baseline up to 10 years

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy14.3
Obinutuzumab+Chemotherapy12.6

[back to top]

Overall Response (Overall Study Population), IRC-Assessed

Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%; Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy89.987.2
Rituximab+Chemotherapy86.783.3

[back to top]

Disease-Free Survival (Overall Study Population)

Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy14.9
Obinutuzumab+Chemotherapy11.2

[back to top]

Overall Response (Follicular Lymphoma Population), Investigator-Assessed

Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy88.285.5
Rituximab+Chemotherapy86.481.2

[back to top]

Overall Response (Overall Study Population), Investigator-Assessed

Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%; Overall Response (OR) = CR + PR. (NCT01332968)
Timeframe: Baseline up to end of induction period (up to approximately 7 months)

,
Interventionpercentage of participants with event (Number)
Without PETWith PET
Obinutuzumab+Chemotherapy87.385.4
Rituximab+Chemotherapy85.781.8

[back to top]

Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed

DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. (NCT01332968)
Timeframe: From first occurrence of documented CR or PR to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy39.3
Obinutuzumab+Chemotherapy33.3

[back to top] [back to top]

Duration of Response (DOR) (Overall Study Population), Investigator-Assessed

DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. (NCT01332968)
Timeframe: From first occurrence of documented CR or PR to data cut-off (up to approximately 4 years and 7 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy25.5
Obinutuzumab+Chemotherapy18.7

[back to top]

Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)

The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. (NCT01332968)
Timeframe: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)

,
Interventionunits on a scale (Mean)
TOI Score, BaselineTOI Score Change, Cycle 3 Day 1TOI Score Change, End InductionTOI Score Change, Maint M2TOI Score Change, Maint M12TOI Score Change, End Maint
Obinutuzumab+Chemotherapy86.942.184.577.177.207.44
Rituximab+Chemotherapy86.610.462.916.227.616.23

[back to top]

Event-Free Survival (Overall Study Population)

Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy30.6
Obinutuzumab+Chemotherapy22.6

[back to top]

Event-Free Survival (Follicular Lymphoma Population)

Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event. (NCT01332968)
Timeframe: Baseline up to 10 years

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy42.9
Obinutuzumab+Chemotherapy35.8

[back to top]

Overall Survival (Overall Study Population)

Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event. (NCT01332968)
Timeframe: Baseline up to data cut-off (up to approximately 5 years and 2 months)

Interventionpercentage of participants with event (Number)
Rituximab+Chemotherapy10.2
Obinutuzumab+Chemotherapy8.4

[back to top]

Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment

"Complete Response Rate (CR) was reported at the end of the CEOP-P (6 courses for patients not receiving transplant and 4-6 courses for patients receiving transplant). Response assessment was performed by computerized tomography (CT) or positron emission tomography (PET)/CT based on the investigator's preference after cycles 2, 4 and 6. Response was assessed by the treating physician according to the Cheson Revised response criteria (Cheson et al,, 2007) or International Harmonization Project criteria (Cheson, 2007), based on imaging modality used.~Complete Response Definition: Disappearance of all evidence of disease Nodal Masses: (a) [18F]fluorodeoxyglucose(FDG)-avid or PET positive prior to therapy; mass of any size permitted if PETnegative (b) Variably FDG-avid or PET negative; regression to normal size on CT Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative" (NCT01336933)
Timeframe: 168 days - 252 days (4-6 courses; 42 days per course)

Interventionpercentage of participants analyzed (Number)
Treatment (Chemotherapy and Enzyme Inhibitor Therapy)52

[back to top]

Event Free Survival (EFS)

Estimated 2-year Event Free Survival (EFS), as well as plots of EFS, will be produced using the method of Kaplan-Meier, along with 95% confidence intervals for EFS. Event-free survival is defined as time from therapy until relapse, progression, or death from any cause. (NCT01336933)
Timeframe: 2 years

Interventionpercentage of participants analyzed (Number)
Treatment (Chemotherapy and Enzyme Inhibitor Therapy)39

[back to top]

Overall Response Rates (ORR)= (Complete Response Rates (CR) + Partial Response Rates (PR))

"Every patient who fulfills all aspects of patient eligibility who receives at least 2 complete courses of chemotherapy will be evaluable for the response endpoint. Response rates will be descriptively summarized using percentages and 95% confidence intervals.~Complete Response Definition: Defined in Primary Objective Partial Response Definition: Regression of measurable disease and no new sites, Nodal Masses: > 50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes~FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site~Variably FDG-avid or PET negative; regression on CT Spleen, Liver:> 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified" (NCT01336933)
Timeframe: 2 years

Interventionpercentage of participants analyzed (Number)
Treatment (Chemotherapy and Enzyme Inhibitor Therapy)70

[back to top]

To Evaluate the Safety and Tolerability of the Regimen by the Percent of Participants With Indicated Adverse Events

Adverse events will be summarized using patient level incidence rates so that a patient contributes once to any adverse event. The number and percentage of patients with any adverse event will be summarized for each course. Serious adverse events will be analyzed similarly. (NCT01336933)
Timeframe: 22 months

Interventionpercentage of participants (Number)
Grade 3-4 anaemiaGrade 3-4 thrombocoytopeniaGrade 3-4 febrile neutropeniaGrade 3-4 mucositisGrade 3-4 sepsisGrade 3-4 increased creatinineGrade 3-4 liver transaminases
Treatment (Chemotherapy and Enzyme Inhibitor Therapy)27121818151212

[back to top]

Percent of Patients Who Proceeded With Transplant

Percentage of patients who received consolidation with high dose therapy and autologous stem cell rescue (HDT/SCR). (NCT01336933)
Timeframe: 168-252 days (4 courses up to 6 courses of treatment)

InterventionParticipants (Count of Participants)
Treatment15

[back to top]

Overall Survival (OS)

Estimated 2-year Overall Survival (OS), as well as plots of OS, will be produced using the method of Kaplan-Meier, along with 95% confidence intervals for OS. Overall survival is defined as time from the first chemotherapy administered on trial until death from any cause. (NCT01336933)
Timeframe: 2 years

Interventionpercentage of participants analyzed (Number)
Treatment (Chemotherapy and Enzyme Inhibitor Therapy)60

[back to top] [back to top]

Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)

"Measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive without report of progression or relapse are censored at date of last contact.~Progressions is defined using the 2007 revised Cheson et. Al. criteria, as ≥50% increase in the sum of the products of diameters (SPD) of target measurable lesions, appearance of any new bone marrow involvement, or appearance of any new lesion >1.5 cm in the longest axis." (NCT01359592)
Timeframe: up to 5 years

Interventionpercentage of participants (Number)
R-CHOP x 3 Followed by PET-directed Therapy87

[back to top]

Progression-free Survival (PFS) Within the PET+ and PET- Subgroups of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)

Measured from date of interim positron emission tomography (PET)/computed tomography scan to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive without report of progression or relapse are censored at date of last contact. (NCT01359592)
Timeframe: up to 5 years

Interventionpercentage of participants (Number)
Interim PET-negative89
Interim PET-positive86

[back to top]

Overall Survival of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)

Measured from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT01359592)
Timeframe: up to 5 years

Interventionpercentage of participants (Number)
R-CHOP x 3 Followed by PET-directed Therapy89

[back to top]

Number of Participants With Complete Remission (CR)

Complete Remission is Normalization of the peripheral blood and bone marrow with 5% or less blasts in marrow with a granulocyte count of 1 x 109/L or above and a platelet count of 100x 109/L or above. Complete resolution of all sites of extramedullary disease is required for CR. (NCT01363128)
Timeframe: Up to 8 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Ofatumumab)68

[back to top]

4-Year Overall Survival

Overall Survival is defined as time from date of treatment start until date of death due to any cause or last Follow-up. For continuous data, summary statistics including n, mean, standard deviation, median, minimum and maximum will be computed. The posterior median time to event and it 95% credible interval will be estimated. Kaplan-Meier method, Log rank test and Cox proportional hazards regression modeling will be utilized to analyze survival at 4 years. (NCT01363128)
Timeframe: Up to 4 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Ofatumumab)47

[back to top]

4-year Event Free Survival

Event Free Survival defined as the time from the start of therapy to time of primary refractory disease, relapse from CR, death from any cause or last follow-up. Kaplan-Meier method will be utilized to analyze event free survival for the 4 year percent alive and in CR. (NCT01363128)
Timeframe: Up to 4 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Ofatumumab)41

[back to top]

Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy

An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. (NCT01370694)
Timeframe: From first dose of combination therapy up to 24 weeks

InterventionParticipants (Number)
MK-8808 Combination Therapy6

[back to top]

Clinical Response of Tumor to MK-8808/CVP Combination Therapy

The response of the tumor to MK-8808/CVP combination therapy was radiographically assessed using Response Criteria Evaluation in Solid Tumors (RECIST). Response categories of partial response (PR), complete resonse (CR), and uncomfirmed (CRu) central review. (NCT01370694)
Timeframe: Up to 2 years

InterventionParticipants (Number)
PRCRCRu
MK-8808 Combination Therapy600

[back to top]

Proportion of Patients Who Are PET Negative After Induction Treatment

(NCT01390584)
Timeframe: Assessed at end of Cycle 2

Interventionproportion of participants (Number)
Step 1: Induction Tx0.8

[back to top]

Overall Survival

Overall survival is defined as the time from study entry to death or date last known alive. (NCT01390584)
Timeframe: Assessed at 36 months

Interventionmonths (Median)
ABVD + INRTNA
ABVD + BEACOPP + INRTNA

[back to top]

Complete Response (CR) Rate After Induction Treatment

Complete response (CR) is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy. (NCT01390584)
Timeframe: Assessed at end of Cycle 2

Interventionproportion of participants (Number)
Step 1: Induction Tx1.0

[back to top]

Progression-free Survival at 36 Months Among Patients Who Are PET Positive After Induction Treatment

Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis. (NCT01390584)
Timeframe: Assessed at 36 months

Interventionproportion of participants (Number)
ABVD + BEACOPP + INRTNA

[back to top]

Progression-free Survival Rate

Progression-free survival is defined as the time from study entry to lymphoma progression or death from any cause. Proportion of patients who are progression-free and alive at 36 months will be reported. Progression is defined as appearance of any new lesions more than 1.5 cm in any axis, at least a 50% increase from nadir in sum of the product of the diameters (SPD) of any previously involved nodes or extranodal masses or the size of other lesions, or at least 50% increase in the longest diameter of any single previously identified node or extranodal mass more than 1 cm in its short axis. (NCT01390584)
Timeframe: Assessed at 36 months

Interventionproportion of participants (Number)
ABVD + INRTNA
ABVD + BEACOPP + INRTNA

[back to top]

AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine

(NCT01397825)
Timeframe: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

,
Interventionng/mL*hr (Mean)
Cycle 1, Day 1Cycle 2, Day 1
Dose Escalation, Alisertib 30 mg77.969.0
Dose Escalation, Alisertib 40 mg84.882.7

[back to top]

AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine

(NCT01397825)
Timeframe: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

Interventionng/mL*hr (Mean)
Cycle 1, Day 1
Dose Escalation, Alisertib 50 mg116.8

[back to top]

Overall Response Rate as Assessed by the Investigator [Phase 1]

Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites. (NCT01397825)
Timeframe: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

Interventionpercentage of participants (Number)
Safety Lead-in25
Dose Escalation, Alisertib 30 mg33
Dose Escalation, Alisertib 40 mg45
Dose Escalation, Alisertib 50 mg50

[back to top]

Number of Participants With Treatment-Emergent Adverse Events [Phase 1]

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. (NCT01397825)
Timeframe: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

Interventionparticipants (Number)
Safety Lead-in13
Dose Escalation, Alisertib 30 mg4
Dose Escalation, Alisertib 40 mg25
Dose Escalation, Alisertib 50 mg3

[back to top]

Tmax: Time to First Occurrence of Cmax fo Alisertib

(NCT01397825)
Timeframe: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose

,,,
Interventionhours (hr) (Median)
Day 1Day 7
Dose Escalation, Alisertib 30 mg3.53.1
Dose Escalation, Alisertib 40 mg3.03.1
Dose Escalation, Alisertib 50 mg6.12.5
Safety Lead-in3.02.0

[back to top]

Cmax: Maximum Plasma Concentration for Alisertib

(NCT01397825)
Timeframe: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose

,,,
InterventionnanoMolar (nM) (Mean)
Day 1Day 7
Dose Escalation, Alisertib 30 mg893.31672.5
Dose Escalation, Alisertib 40 mg1159.72223.3
Dose Escalation, Alisertib 50 mg1746.73670.0
Safety Lead-in1624.12915.8

[back to top]

T1/2: Terminal Disposition Phase Half-life for Vincristine

(NCT01397825)
Timeframe: Cycles 1 and 2 on Day prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

Interventionnanogram/milliliter (ng/mL) (Mean)
Cycle 1, Day 1
Dose Escalation, Alisertib 50 mg25.6

[back to top] [back to top]

Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]

Abnormal Physical Examination findings determined by the investigator to be clinically significant were reported as Adverse Events. (NCT01397825)
Timeframe: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

Interventionparticipants (Number)
Safety Lead-in0
Dose Escalation, Alisertib 30 mg0
Dose Escalation, Alisertib 40 mg2
Dose Escalation, Alisertib 50 mg2

[back to top]

Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]

Abnormal changes in MUGA and ECHO findings determined by the investigator to be clinically significant were reported as adverse events. (NCT01397825)
Timeframe: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

Interventionparticipants (Number)
Safety Lead-in0
Dose Escalation, Alisertib 30 mg0
Dose Escalation, Alisertib 40 mg0
Dose Escalation, Alisertib 50 mg0

[back to top]

Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]

Abnormal treatment-emergent Chemistry and Hematology Laboratory values determined by the investigator to be clinically significant were reported as adverse events. (NCT01397825)
Timeframe: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

,,,
Interventionparticipants (Number)
AnaemiaNeutropeniaFebrile neutropeniaLeukopeniaLymphopeniaThrombocytopeniaHypokalaemiaHyperkalaemiaHypomagnesaemiaHypermagnesaemiaHypocalcaemiaHypercalcaemiaHyperglycaemiaHypoalbuminaemiaHyponatraemiaHypernatraemiaHypophosphataemiaNeutrophil count decreasedLymphocyte count decreasedWhite blood cell count decreasedAspartate aminotransferase increasedAlanine aminotransferase increasedBlood bilirubin increasedPlatelet count decreased
Dose Escalation, Alisertib 30 mg320221000000100000000000
Dose Escalation, Alisertib 40 mg14114917615012200113001001
Dose Escalation, Alisertib 50 mg223313201110121011012201
Safety Lead-in670827502021132011100011

[back to top]

Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]

Abnormal ECGs findings determined by the investigator to be clinically significant were reported as adverse events. (NCT01397825)
Timeframe: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

Interventionparticipants (Number)
Safety Lead-in0
Dose Escalation, Alisertib 30 mg0
Dose Escalation, Alisertib 40 mg0
Dose Escalation, Alisertib 50 mg0

[back to top]

Cmax: Maximum Plasma Concentration for Vincristine

(NCT01397825)
Timeframe: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 2, Day 1
Dose Escalation, Alisertib 30 mg132.2113.9
Dose Escalation, Alisertib 40 mg105.4124.4
Dose Escalation, Alisertib 50 mg158.4122.3

[back to top]

AUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine

(NCT01397825)
Timeframe: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

,,
Interventionng/mL*hr (Mean)
Cycle 1, Day 1Cycle 2, Day 1
Dose Escalation, Alisertib 30 mg69.860.8
Dose Escalation, Alisertib 40 mg69.172.8
Dose Escalation, Alisertib 50 mg104.172.2

[back to top]

AUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib

(NCT01397825)
Timeframe: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose

,,,
Interventionnanomoles/liter*hour (nmol/L*hr) (Mean)
Day 1Day 7
Dose Escalation, Alisertib 30 mg5817.512227.5
Dose Escalation, Alisertib 40 mg8005.917996.0
Dose Escalation, Alisertib 50 mg13096.733800.0
Safety Lead-in10116.721812.5

[back to top]

T1/2: Terminal Disposition Phase Half-life for Vincristine

(NCT01397825)
Timeframe: Cycles 1 and 2 on Day prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

,
Interventionnanogram/milliliter (ng/mL) (Mean)
Cycle 1, Day 1Cycle 2, Day 1
Dose Escalation, Alisertib 30 mg20.219.9
Dose Escalation, Alisertib 40 mg20.020.2

[back to top]

Percentage of Participants With Neurocognitive Failure

Neurocognitive failure is defined as cognitive failure on two or more of the following tests: Hopkins Verbal Learning Test - Revised (HVLT-R) Free Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test Part A, Trail Making Test Part B, and Controlled Oral Word Association. Cognitive failure for each test is defined as a change from baseline in raw score (post baseline score - baseline score) at or exceeding the minimally important difference reported in the literature [determined by the reliable change index (RCI) method] of -5, -3, -2,12, 26, and -12, respectively, indicating a worsening of neurocognitive function. Time to neurocognitive failure is defined as time from randomization to date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rates are estimated using the cumulative incidence method and the distributions of failure times are compared between the arms. Two-year estimates are provided here. (NCT01399372)
Timeframe: Neurocognitive function tests were administered at baseline, after cycle 4 of treatment (4 months), then every six months after end of treatment (7 months) for five years. Two-year rates are provided here.

Interventionpercentage of participants (Number)
Chemotherapy31.6
Chemotherapy + Low-Dose WBRT17.9

[back to top]

Overall Survival

Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. (NCT01399372)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years.

Interventionyears (Median)
ChemotherapyNA
Chemotherapy + Low-Dose WBRTNA

[back to top]

Global Heath Status (GHS) Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

"Global Health Status is calculated from two questions on the EORTC QLQ-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Data through five years after end of protocol treatment is included in the analysis, while summary data is provided only through three years due to very few participants after that timepoint." (NCT01399372)
Timeframe: EORTC QLQ-C30 was administered at baseline, after cycle 4 of treatment (4 months), then every six months after end of treatment (7 months) for five years.

,
Interventionscore on a scale (Mean)
BaselineEnd of cycle 46 Months Post-Treatment12 Months Post-Treatment18 Months Post-Treatment24 Months Post-Treatment30 Months Post-Treatment36 Months Post-Treatment42 Months Post-Treatment48 Months Post-Treatment54 Months Post-Treatment60 Months Post-Treatment
Chemotherapy62.7867.6774.5478.4776.7970.8377.0875.0075.0079.7670.2480.56
Chemotherapy + Low-Dose WBRT54.9064.5875.3578.9976.6783.3379.6385.0077.5684.3891.6783.33

[back to top]

Progression-free Survival

Progression is defined as any of the following: more than 25% increase in the contrast-enhancing lesion seen on magnetic resonance imaging (MRI) compared with baseline or best response; new site of disease (central nervous system or systemic); recurrent or new ocular disease; recurrent or positive cerebrospinal fluid (CSF) cytology. Progression-free survival time is defined as time from randomization to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. (NCT01399372)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years.

Interventionyears (Median)
Chemotherapy2.1
Chemotherapy + Low-Dose WBRTNA

[back to top]

Percentage of Participants Experiencing Partial Response or Complete Response

Response was evaluated using the international criteria proposed by the International Primary Central Nervous System Lymphoma (PCNSL) Study Group criteria. Complete Response was defined as no contrast brain enhancement on magnetic resonance imaging (MRI), no corticosteroid use for at least 2 weeks, a normal eye exam, and negative CSF cytology. Partial response was defined as at least 50% decrease in enhancing tumor on MRI compared with baseline imaging, no or minor retinal pigment epithelium (RPE) abnormality, and negative CSF cytology. (NCT01399372)
Timeframe: After 4th cycle of chemotherapy, approximately 4 months after randomization.

Interventionpercentage of participants (Number)
Chemotherapy83.3
Chemotherapy + Low-Dose WBRT80.6

[back to top]

Progression-Free Survival (PFS) at 2 Years

Disease progression is defined using the 2007 revised Cheson et al. criteria that is at least 50% increase in sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed, or >= 50% increase in greatest transverse diameter (GTD) of any nodal > 1 cm in shortest axis, or >= 50% increase in the SPD of other target measurable lesions over the smallest sum observed, any new bone marrow involvement, any new lesion, lymph node with long axis is > 1.5 cm or if both long and short axes are > 1 cm, PET positive if patients with no pretreatment PET scan or when PET scan was positive before therapy. Progression-free survival is measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact. (NCT01412879)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Arm 1: R-HCVAD/MTX/Ara-C (Induction Therapy)82
Arm 2: R-Bendamustine (Induction Therapy)81

[back to top] [back to top]

Response Rate (Complete and Partial Response)

Complete Response (CR) is a complete disappearance of all disease with the exception of the following. If no PET scan or when the PET scan was positive before therapy, a post-treatment residual mass of any size is permitted if it is PET negative. If the PET scan was negative before therapy, all nodal masses at baseline must have regressed. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response (PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. If PET scan or when the PET scan was positive before therapy, PET should be positive in at least one previously involved site. (NCT01412879)
Timeframe: Up to 9 months

Interventionpercentage of participants (Number)
Arm 1: R-HCVAD/MTX/Ara-C (Induction Therapy)94.1
Arm 2: R-Bendamustine (Induction Therapy)82.9

[back to top]

5-year Overall Survival (OS)

Measured from date of registration to date of death due to any cause. Patients last known to be alive and are censored at date of last contact. (NCT01412879)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
Arm 1: R-HCVAD/MTX/Ara-C (Induction Therapy)81
Arm 2: R-Bendamustine (Induction Therapy)79

[back to top]

Duration of Response (DOR)

DOR is defined as first occurrence of documented response (CR or PR) until the first occurrence of relapse or progression or death of any cause. CR: disappearance of all evidence of disease. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. (NCT01414855)
Timeframe: From the response assessment to relapse, progression, or death (up to 64 months)

Interventionmonths (Median)
Obinutuzumab + CHOP45.6

[back to top]

Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment

Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, FDG-PET and computed tomography (CT). CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

Interventionpercentage of participants (Number)
Obinutuzumab + CHOP82.0

[back to top]

Pharmacokinetics: Volume of Distribution (V) for Obinutuzumab

V is the apparent volume in which a drug is distributed in the body. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters (mL). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

InterventionmL (Mean)
Cycle 1 (n = 54)Cycle 8 (n = 37)
Obinutuzumab + CHOP45809210

[back to top]

Pharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab

T1/2 is the time required for the concentration of the drug to reach half of its original value. Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in days (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

Interventiondays (Mean)
Cycle 1 (n = 37)Cycle 8 (n = 21)
Obinutuzumab + CHOP6.0423

[back to top]

Pharmacokinetics: Clearance (Cl) for Obinutuzumab

Cl is the volume of serum cleared of the drug per unit of time. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters/day (mL/day). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

InterventionmL/day (Mean)
Cycle 1 (n = 54)Cycle 8 (n = 37)
Obinutuzumab + CHOP456143

[back to top]

Pharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)

Blood was collected for PK parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in in day times micrograms per milliliter (day*μg/mL). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

Interventionday*μg/mL (Mean)
Cycle 1 (n = 59)Cycle 8 (n = 74)
Obinutuzumab + CHOP13203300

[back to top]

Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment

Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

Interventionpercentage of participants (Number)
Obinutuzumab + CHOP75.0

[back to top]

Percentage of Participants With Adverse Events as a Measure of Safety

An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug or other protocol-imposed intervention. Preexisting conditions that worsened during the study were reported as adverse events. (NCT01414855)
Timeframe: From the first dose of study treatment to end of study (up to 5 years 4 months)

Interventionpercentage of participants (Number)
Obinutuzumab + CHOP100.0

[back to top]

Progression-Free Survival (PFS) as Assessed by the Investigator

PFS was defined as the time from the date of the first dose of study treatment until the date of disease progression, relapse, or death from any cause. (NCT01414855)
Timeframe: From the first dose of study treatment to PFS assessment (up to 64 months)

Interventionmonths (Median)
Obinutuzumab + CHOP48.3

[back to top]

Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab

Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12

Interventionμg/mL (Mean)
Cycle 1Cycle 8 (n = 85)
Obinutuzumab + CHOP297574

[back to top] [back to top]

Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment

Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

Interventionpercentage of participants (Number)
Obinutuzumab + CHOP58.0

[back to top]

Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment

Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). CR is the disappearance of all evidence of disease. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

Interventionpercentage of participants (Number)
Obinutuzumab + CHOP55.0

[back to top]

Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2

IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA >=1000 copies/mL at week 12 to week 24 or RNA >=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 2 treatment arm. (NCT01435018)
Timeframe: From Step 2 study entry to Step 2 discontinuation, up to 144 weeks

,,
InterventionParticipants (Count of Participants)
With IERC-confirmed KS progressionWith dose-limiting toxicityDiedWith AIDS-defining eventsWith virologic failureWith objective response
BV+ART101127
ET+ART100010
PTX+ART105015

[back to top]

Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART

Baseline CD4 lymphocyte cell count is the mean of screening and Step 1 entry CD4 values. Absolute change in CD4+ lymphocyte cell count was calculated as value at a given visit minus the baseline CD4 lymphocyte cell count. (NCT01435018)
Timeframe: Baseline, weeks 12, 24, 48

,
Interventioncells/mm^3 (Median)
Week 12 CD4 changeWeek 24 CD4 changeWeek 48 CD4 change
BV+ART2143112
PTX+ART3765105

[back to top]

Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART

Baseline CD4 lymphocyte cell count is the mean of screening and Step 1 entry CD4 values. Absolute change in CD4+ lymphocyte cell count was calculated as value at a given visit minus the baseline CD4 lymphocyte cell count. (NCT01435018)
Timeframe: Baseline, weeks 12, 24, 48

,
Interventioncells/mm^3 (Median)
Week 12 CD4 changeWeek 24 CD4 changeWeek 48 CD4 change
ET+ART3710669
PTX+ART4795157

[back to top]

Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3

IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA >=1000 copies/mL at week 12 to week 24 or RNA >=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 3 treatment arm. (NCT01435018)
Timeframe: From Step 3 study entry to Step 3 discontinuation, up to 144 weeks

,,
InterventionParticipants (Count of Participants)
With IERC-confirmed KS progressionWith dose-limiting toxicityDiedWith AIDS-defining eventsWith virologic failureWith objective response
BV+ART6035218
ET+ART200025
PTX+ART8077129

[back to top]

Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4

IERC-confirmed KS progression refers to KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Virologic failure is defined as two successive measurements of plasma HIV-1 RNA >=1000 copies/mL at week 12 to week 24 or RNA >=400 copies/mL at week 24 or later. Objective response refers to complete response or partial response as best overall KS response. Results are presented by Step 4 treatment arm. (NCT01435018)
Timeframe: From Step 4 study entry to Step 4 discontinuation, up to 96 weeks

,
InterventionParticipants (Count of Participants)
With IERC-confirmed KS progressionWith dose-limiting toxicityDiedWith AIDS-defining eventsWith virologic failureWith objective response
BV+ART203013
PTX+ART302003

[back to top]

Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of AIDS-defining events by week 48. AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Time to event was computed as the number of weeks from study entry to the first AIDS-defining event. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART15.2
PTX+ART28.6

[back to top]

Number of Participants With Peripheral Neuropathy (PN)

Presence of PN is defined as having all of the following results: presence of symptomatic PN, abnormal perception of vibrations, and absent or hypoactive deep tendon reflexes. (NCT01435018)
Timeframe: Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of PN for ET+ART was only done at screening, weeks 9 and 21.

,,
InterventionParticipants (Count of Participants)
ScreeningWeek 3Week 6Week 9Week 12Week 15Week 18Week 21
BV+ART71133265
ET+ART10000000
PTX+ART00224312

[back to top]

Number of Participants With Symptomatic Peripheral Neuropathy (SPN)

"SPN consists of three assessments: (1) pain, aching or burning in feet, legs, (2) pins and needles in feet, legs, and (3) numbness (lack of feeling) in feet, legs. SPN is graded on a severity scale from 0 (not present), 1 (mild) to 10 (severe). Presence of SPN is defined as having grade >=1 in at least one of the three assessments." (NCT01435018)
Timeframe: Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of SPN for ET+ART was only done at screening, weeks 9 and 21.

,,
InterventionParticipants (Count of Participants)
ScreeningWeek 3Week 6Week 9Week 12Week 15Week 18Week 21
BV+ART7662464036262530
ET+ART2400140004
PTX+ART5934322723161520

[back to top] [back to top]

Self-reported Adherence to ART Therapy

ART adherence is based on participant's recall of the number of missed ART doses for the past month. Perfect adherence is defined as having zero missed ART doses. (NCT01435018)
Timeframe: At Weeks 6, 12, 18, 30 and 48

,,
InterventionParticipants (Count of Participants)
Week 6 Perfect AdherenceWeek 12 Perfect AdherenceWeek 18 Perfect adherenceWeek 30 Perfect adherenceWeek 48 Perfect adherence
BV+ART101101856613
ET+ART433629130
PTX+ART106103978520

[back to top]

Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, or virologic failure by week 48 (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART60.9
PTX+ART42.0

[back to top]

Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of change in KS treatment by week 48. Change in KS treatment was defined as stopping Step 1 randomized chemotherapy and initiating a different chemotherapy. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART32.5
PTX+ART18.9

[back to top]

Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of change in KS treatment by week 48. Change in KS treatment was defined as stopping Step 1 randomized chemotherapy and initiating a different chemotherapy. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART59.5
PTX+ART26.0

[back to top]

Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of death by week 48. Time to death was computed as the number of weeks from study entry to the death date. For participants who did have the event, time to death was censored at the week of last contact with the participant. Time to death above 48 were censored at week 48. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART18.5
PTX+ART10.3

[back to top]

Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of death by week 48. Time to death was computed as the number of weeks from study entry to date of death. For participants who did have the event, time to death was censored at the week of last contact with the participant. Time to death above 48 were censored at week 48. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART25.6
PTX+ART10.7

[back to top]

Cumulative Rate of Death for BV+ART vs PTX+ART

The Kaplan-Meier estimate of the cumulative rate of death. Time to death was computed as the number of weeks between study entry and date of death. For participants who did not have the event, time to death was censored at the week of last contact with the participant or at the participant's off study week, whichever is later. (NCT01435018)
Timeframe: From study entry to week 240

InterventionCumulative events per 100 persons (Number)
BV+ART18.5
PTX+ART10.3

[back to top]

Cumulative Rate of Death for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of death. Time to death was computed as the number of weeks between study entry and date of death. For participants who did not have the event, time to death was censored at the week of last contact with the participant or at the participant's off study week, whichever is later. (NCT01435018)
Timeframe: From study entry to week 240

InterventionCumulative events per 100 persons (Number)
ET+ART25.6
PTX+ART10.7

[back to top]

Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART

Virologic failure is defined as two successive measurements of plasma HIV-1 RNA >=1000 copies/mL at week 12 to week 24 or RNA >=400 copies/mL at week 24 or later. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART7.4
PTX+ART1.8

[back to top]

Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART

Virologic failure is defined as two successive measurements of plasma HIV-1 RNA >=1000 copies/mL at week 12 to week 24 or RNA >=400 copies/mL at week 24 or later. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART7.8
PTX+ART0.0

[back to top]

Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of IERC-confirmed KS progression by week 48. IERC-confirmed KS progression was defined as KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART43.9
PTX+ART25.7

[back to top]

Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of IERC-confirmed KS progression by week 48. IERC-confirmed KS progression was defined as KS disease progression confirmed by the IERC based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART69.8
PTX+ART41.2

[back to top]

Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of AIDS-defining events by week 48. AIDS-defining events refer to non-KS AIDS-defining diagnosis (WHO Stage 4 (2007), plus microsporidiosis, cyclospora gastroenteritis, Chagas disease and visceral leishmaniasis). Time to event was computed as the number of weeks from study entry to the first AIDS-defining event. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART17.9
PTX+ART19.6

[back to top]

Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, or virologic failure by week 48 (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART77.5
PTX+ART54.6

[back to top]

Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART54.5
PTX+ART36.2

[back to top]

Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of KS progression, death, AIDS defining event, virologic failure, or KS-IRIS. (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART57.6
PTX+ART33.9

[back to top]

Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of KS progression, death, or AIDS defining event by week 48 (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART56.7
PTX+ART42.1

[back to top]

Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART

The Kaplan-Meier estimate of the cumulative rate of KS progression, death, or AIDS defining event by week 48 (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART72.4
PTX+ART54.6

[back to top]

Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART

Progression-free survival (PFS) by week 48 is defined as a lack of the following events: (a) Independent Endpoint Review Committee (IERC)-confirmed KS progression, (b) death, (c) entry into an additional step, or (d) loss to follow-up, prior to week 48. PFS rate was estimated by the Kaplan-Meier survival probability at week 48. Time to event was computed as the number of weeks from study entry to the first among these events. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. Overall KS outcome status (complete response, partial response, stable, disease progression) was based on comparing follow-up to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
BV+ART44.1
PTX+ART64.2

[back to top]

Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART

Progression-free survival (PFS) by week 48 is defined as a lack of the following events: (a) Independent Endpoint Review Committee (IERC)-confirmed KS progression, (b) death, (c) entry into an additional step, or (d) loss to follow-up, prior to week 48. PFS rate was estimated by the Kaplan-Meier survival probability at week 48. Time to event was computed as the number of weeks from study entry to the first among these events. For participants who did not have any of the events, event time was censored at the week of last contact with the participant. Follow-up time beyond 48 was censored at week 48. Overall KS outcome status (complete response, partial response, stable, disease progression) was based on comparing follow-up to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). (NCT01435018)
Timeframe: From study entry to week 48

InterventionCumulative events per 100 persons (Number)
ET+ART19.7
PTX+ART49.8

[back to top]

Duration of Objective Response for BV+ART vs. PTX+ART

Duration of objective response is the number of weeks from first complete or partial response to the earliest among progression, death or off study week. The 25th percentile duration is presented. (NCT01435018)
Timeframe: From study entry up to week 144

Interventionweeks (Number)
ET+ART21.0
PTX+ART45.7

[back to top]

Duration of Objective Response for ET+ART vs. PTX+ART

Duration of objective response is the number of weeks from first complete or partial response to the earliest among progression, death or off study week. The 25th percentile duration is presented. (NCT01435018)
Timeframe: From study entry up to week 144

Interventionweeks (Number)
ET+ART10.1
PTX+ART19.9

[back to top]

Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART

KS-IRIS is defined as any IERC-confirmed KS-progression that occurs within 12 weeks of ART-initiation that is associated with an increase in CD4 cell count of at least 50 cells/mm^3 above the study entry value and/or a decrease in the HIV-1 RNA level by at least 0.5 log below the study entry value prior to or at the time of documented KS progression. (NCT01435018)
Timeframe: From study entry to week 12

InterventionParticipants (Count of Participants)
BV+ART2
PTX+ART0

[back to top]

Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART

KS-IRIS is defined as any IERC-confirmed KS-progression that occurs within 12 weeks of ART-initiation that is associated with an increase in CD4 cell count of at least 50 cells/mm^3 above the study entry value and/or a decrease in the HIV-1 RNA level by at least 0.5 log below the study entry value prior to or at the time of documented KS progression. (NCT01435018)
Timeframe: From study entry to week 12

InterventionParticipants (Count of Participants)
ET+ART6
PTX+ART0

[back to top]

Number of Participants With Objective Response for BV+ART vs. PTX+ART

The number of participants with objective response (complete response or partial response) as best overall KS response in Step 1. Overall KS response status (complete response, partial response, stable, disease progression) was based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). (NCT01435018)
Timeframe: From study entry up to week 144

InterventionParticipants (Count of Participants)
BV+ART80
PTX+ART91

[back to top]

Number of Participants With Objective Response for ET+ART vs. PTX+ART

The number of participants with objective response (complete response or partial response) as best overall KS response in Step 1. Overall KS response status (complete response, partial response, stable, disease progression) was based on comparing follow-up KS response to study entry or best KS response with respect to clinical assessment of KS cutaneous lesions (count, character and marker lesion area), oral KS, visceral KS and tumor-associated edema and as described in the publications (Krown et al 1989, Cianfrocca et al 2002). (NCT01435018)
Timeframe: From study entry up to week 144

InterventionParticipants (Count of Participants)
ET+ART18
PTX+ART34

[back to top]

Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART

Time to IERC-confirmed KS progression or death was computed as the number of weeks between study entry and the earlier between date of IERC-confirmed KS progression or date of death. For participants who did not have the event, event time was censored at the week of last contact with the participant or at the participant's off study week, whichever is later.The 25-th percentile and hazard ratio are presented. (NCT01435018)
Timeframe: From study entry to week 240

Interventionweeks (Number)
BV+ART24.7
PTX+ART38.6

[back to top]

Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART

Time to IERC-confirmed KS progression or death was computed as the number of weeks between study entry and the earlier between date of IERC-confirmed KS progression or date of death. For participants who did not have the event, event time was censored at the week of last contact with the participant or the participant's off study week, whichever is later. The 25-th percentile and hazard ratio are presented. (NCT01435018)
Timeframe: From study entry to week 240

Interventionweeks (Number)
ET+ART17.9
PTX+ART30.0

[back to top]

Number of Dose-Limiting Toxicities (DLT)

DLTs for siplizumab was defined as infusional grade 3 non-hematologic toxicity lasting longer than 6 hours after the infusion, any grade 4 non-hematologic toxicity, or the development of an EBV-related lymphoproliferative disorder (LPD). Expected toxicities of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) and grade 3 laboratory AEs were not considered to be DLTs. (NCT01445535)
Timeframe: First 30 days after treatment initiation.

InterventionDose Limiting Toxicities (Number)
Cohort 1 - 3.4 mg/kg0
Cohort 2 - 4.8 mg/kg0
Cohort 3 - 8.5 mg/kg0
Cohort 4 - 15 mg/kg0

[back to top]

Number of Participants With Serious and Non-serious Adverse Events

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01445535)
Timeframe: Date treatment consent signed until 30 days after removal from study treatment or until off study, whichever comes first, approximately 22 weeks.

InterventionParticipants (Count of Participants)
Cohort 1 - 3.4 mg/kg3
Cohort 2 - 4.8 mg/kg3
Cohort 3 - 8.5 mg/kg3
Cohort 4 - 15 mg/kg5

[back to top]

Overall Progression Free Survival (PFS)

Progression was assessed by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma. Progression is defined as ≥50% increase from nadir in the sum of the products of the perpendicular diameters (SPD) of any previously identified abnormal nodes for Partial Response's or non-responders. Progression-free survival (PFS) was determined from the on-study date until date of progression or last follow-up. The probability of PFS as a function of time was estimated by the Kaplan-Meier method. (NCT01445535)
Timeframe: On-study date until date of progression or last follow up, approximately 7 months.

InterventionMonths (Median)
All Participants6.8

[back to top]

Number of Participants With a Response to Therapy

Response was assessed by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma. Complete Remission was defined as the disappearance of all detectable clinical and radiographic evidence of disease, disappearance of all disease related symptoms if present before therapy, and normalization of those biochemical abnormalities (for example lactate dehydrogenase (LDH)) definitely assignable to the lymphoma. Complete response unconfirmed was defined as a residual node greater than 1.5 cm, with a decrease by greater than 75 percent in the sum of the products of the perpendicular diameters (SPD) of all measured lymph nodes. Partial Response was defined as a ≥ 50% decreased in SPD of 6 largest dominant nodes or nodal masses. Relapsed disease was defined as the appearance of any new lesion or increase by ≥50% in the size of the previously identified sites. Progressive disease was defined as a ≥50% increase from nadir in the SPD. (NCT01445535)
Timeframe: Response assessments were performed after the fourth and sixth cycle of therapy, at therapy completion, and every 3 months for year 1, four months for year 2, 6 months for years 3-5, and annually thereafter, up to 5 years.

,,,
InterventionParticipants (Count of Participants)
Complete RemissionComplete Response UnconfirmedPartial ResponseRelapsed DiseaseProgressive DiseaseStable DiseaseNot Evaluable
Cohort 1 - 3.4 mg/kg1010100
Cohort 2 - 4.8 mg/kg2010000
Cohort 3 - 8.5 mg/kg1010100
Cohort 4 - 15 mg/kg4000002

[back to top]

Maximum Tolerated Dose (MTD) of Siplizumab

A classic 3+3 dose-escalation design was used to assess the MTD of siplizumab in combination with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R). If 2 of 6 patients experienced a dose-limiting toxicity (DLT) at a particular dose level, the MTD has been exceeded. The preceding dose level will be the MTD, provided 6 patients have been entered at this level and no more than one has experienced a DLT. DLTs for siplizumab was defined as infusional grade 3 non-hematologic toxicity lasting longer than 6 hours after the infusion, any grade 4 non-hematologic toxicity, or the development of an Epstein Barr Virus (EBV)-related lymphoproliferative disorder (LPD). Expected toxicities of dose-adjusted EPOCH-R and grade 3 laboratory adverse events (AEs) were not considered to be DLTs. (NCT01445535)
Timeframe: First 30 days after treatment initiation.

Interventionmg/kg (Number)
All Participants15

[back to top]

Overall Survival (OS)

Overall survival was determined from the on-study date until date of progression or last follow up. The probability of OS as a function of time was estimated by the Kaplan-Meier method. (NCT01445535)
Timeframe: On study date until date of death or last follow up, approximately 12 months.

InterventionMonths (Median)
All Participants12.1

[back to top]

Probability of Overall Survival (OS)

"For OS, only deaths are considered failures for OS. Kaplan-Meier estimates of the OS curves are computed along with estimates of standard errors by Peto's method.~Please note the unit of measurement of probabilities are percentages." (NCT01451515)
Timeframe: Two years post therapy.

Interventionpercentage of patients alive (Number)
Stratum 191.7
Stratum 271.4
Stratum 3100
All Enrollments86.96

[back to top]

Minimal Disseminated Disease (MDD)

Detectable disease in bone marrow or blood: A binary measure, positive (detectable), negative (non-detectable) (NCT01451515)
Timeframe: At Diagnosis

,,
Interventionparticipants (Number)
NegativePositive
Stratum 141
Stratum 223
Stratum 304

[back to top]

Minimal Residual Disease (MRD)

Detectable disease in bone marrow or blood: A binary measure, positive (detectable), negative (non-detectable) (NCT01451515)
Timeframe: Day 8

,,
Interventionparticipants (Number)
NegativePositive
Stratum 180
Stratum 241
Stratum 304

[back to top]

Probability of Event-free Survival (EFS)

"For EFS, relapse and second malignancies are considered as failures in addition to death in complete remission. The time to EFS will be set to 0 for patients who fail to achieve complete remission. Kaplan-Meier estimates of the OS and EFS curves are computed, along with estimates of standard errors by Peto's method.~Please note the unit of measurement of probabilities are percentages." (NCT01451515)
Timeframe: Two years post therapy.

Interventionpercentage of event-free patients (Number)
Stratum 191.7
Stratum 271.4
Stratum 3100
All Enrollments86.96

[back to top]

Number of Participants Who Experienced a Dose Limiting Toxicity (DLT).

To evaluate the side effects of giving decitabine and vorinostat before and during chemotherapy using the standard drugs vincristine, dexamethasone, PEG-asparaginase and mitoxantrone. (NCT01483690)
Timeframe: 6 weeks

,
InterventionParticipants (Count of Participants)
# of patients with DLT# of patients without DLT# of patients not evaluable
Initial Dose Level221
Modified Dose Level1125

[back to top]

Disease Response Rate After Treatment.

Bone marrow evaluation was performed on Day 35 of study to evaluate treatment response. CR defined as attaining M1 marrow (<5% blasts) with no evidence of circulating blasts or extramedullary disease in addition to recovery of peripheral blood counts (ANC >750/uL and platelet count >75,000/uL). CRp was defined as attaining an M1 marrow with no evidence of circulating blasts or extramedullary disease in addition to recovery of ANC but insufficient recovery of platelets. CRi was attaining M1 marrow with no evidence of circulating blasts or extramedullary disease but insufficient recovery of ANC with or without sufficient recovery of platelets. PR was defined as no evidence of circulating blasts and achievement of M2 marrow (5-25% blasts) without new sites of disease and with recovery of ANC. SD is for patients who did not meet the criteria for PR, CR, CRp, or CRi. PD is an increase of at least 25% in the absolute number of leukemia cells or development of new sites. (NCT01483690)
Timeframe: 6 weeks

,
InterventionParticipants (Count of Participants)
complete response (CR)complete response without platelet recovery (CRp)complete remission with incomplete recovery (CRi)stable disease (SD)patient not evaluable for response
Initial Dose Level01112
Modified Dose Level13347

[back to top]

Complete Response

Complete response (CR) defined as: No emetic episodes and no rescue medications. This is a cross-over designed study, the outcomes by single dose, two doses and control cycles were evaluated by combining the results from both cycle 1 and cycle 2 according to the treatment received. (NCT01490060)
Timeframe: From Day 1 to Day 5 in two 21-days cycles (Cycle 1 and Cycle 2).

Interventionpercentage of participants (Number)
Control Cycle (Arm A/Arm B)17
Arm A: Single Dose, Day 110
Arm B: Two Doses, Day 1 + Day 450

[back to top]

Change From Baseline in Percentage of Cells Positive for Ki67

Mean change from baseline in Percentage of Cells Positive for Ki67 by patient response. (NCT01527149)
Timeframe: Baseline and up to 3 years

Interventionpercentage of cells positive for Ki-67 (Mean)
Not CRCR
Treatment (Monoclonal Antibody and Combination Chemotherapy)-2.5NA

[back to top]

Proportion of Patients Who Experience Complete Remission as Assessed by HSFCM

Established when all CR criteria are met and negative flow cytometry examination of peripheral blood and bone marrow biopsy/aspiration collected at baseline, before courses 3 and 5, within 3 weeks after course 6, on day 100 (if HDC-ASCT eligible), and then every 6 months for 3 years. (NCT01527149)
Timeframe: Up to 3 years

InterventionProportion of participants (Number)
Treatment (Monoclonal Antibody and Combination Chemotherapy).84

[back to top]

Median of Serum Complement CD20 Levels

Median serum C20 MFI (mean fluorescence intensity) (NCT01527149)
Timeframe: Baseline

Interventionmean fluorescence intensity (Median)
Treatment (Monoclonal Antibody and Combination Chemotherapy)186.8

[back to top]

Proportion of Patients Experiencing a Complete Response

"Evaluated according to the International Working Group Response criteria as reported by Cheson et al. and the revised Cheson criteria.~Complete response is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Typically FDG-avid lymphoma: in patients with PET scan positive before therapy, a posttreatment residual mass of any size is permitted as long as it is PET negative. Variably FDG-avid lymphomas/FDG avidity unknown: in patients with a negative pretreatment PET scan, all lymph nodes and nodal masses must have regressed on CT to normal size (1.5 cm in their greatest transverse diameter for nodes 1.5 cm before therapy). Previously involved nodes that were 1.1 cm to 1.5 cm in their long axis and more than 1)" (NCT01527149)
Timeframe: 22 weeks

InterventionProportion of participants (Number)
Treatment (Monoclonal Antibody and Combination Chemotherapy).62

[back to top]

Median Overall Survival (OS)

Estimated distributions obtained using the Kaplan-Meier method. Estimates of quantities such as median survival will be obtained. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed. (NCT01527149)
Timeframe: From baseline through study completion, an average of 5 years

Interventionmonths (Median)
Treatment (Monoclonal Antibody and Combination Chemotherapy)56.0

[back to top]

Median Progression-free Survival (PFS)

Estimated distributions obtained using the Kaplan-Meier method. Estimates of quantities such as median survival will be obtained. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed. (NCT01527149)
Timeframe: From baseline through study completion, an average of 5 years

Interventionmonths (Median)
Treatment (Monoclonal Antibody and Combination Chemotherapy)45.5

[back to top]

Number of Participants With at Least One Serious Adverse Event

Evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. (NCT01527149)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment (Monoclonal Antibody and Combination Chemotherapy)19

[back to top]

Percentage of Participants With Autologous Stem Cell Transplantation

Estimated using simple relative frequencies. The corresponding 95% confidence intervals will be computed using the method proposed in Clopper and Pearson. (NCT01527149)
Timeframe: Up to 6 weeks after the last dose of ofatumumab-chemotherapy, an average of 4 month

Interventionpercentage of participants (Number)
Treatment (Monoclonal Antibody and Combination Chemotherapy)73

[back to top]

Time-to-tumor Progression (TTP) at 3 Years

Estimated percentage of patients that progressed at 3 years. Time to Progression distributions obtained using the Kaplan-Meier method. Corresponding confidence intervals using the methodology of Brookmeyer and Crowley will be computed. (NCT01527149)
Timeframe: From baseline until objective tumor progression, as assessed up to 3 years

Interventionpercentage of participants (Number)
Treatment (Monoclonal Antibody and Combination Chemotherapy)76

[back to top]

Event-free Survival

MRIs of the head and spine. Number of participants with event free survival at 60 months is reported. (NCT01542736)
Timeframe: Up to 60 months.

InterventionParticipants (Count of Participants)
Reduced Radiation With Concurrent Chemotherapy7

[back to top]

Intellectual Competence Measured by IQ Score: Month 24

Neuropsychological testing will be performed after radiation in completed. IQ score is reported. The Wechsler Intelligence Scale for Children, 5th edition (WISC-V) measures intellectual competence in Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed. The average score for the scale is fixed at 100, with a standard deviation of 15. Higher scores indicate higher levels of intellectual competence and a better outcome. (NCT01542736)
Timeframe: Month 24

Interventionscore on a scale (Mean)
Reduced Radiation With Concurrent Chemotherapy96.83

[back to top]

Intellectual Competence Measured by IQ Score: Month 60

Neuropsychological testing will be performed after radiation in completed. IQ score is reported. The Wechsler Intelligence Scale for Children, 5th edition (WISC-V) measures intellectual competence in Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed. The average score for the scale is fixed at 100, with a standard deviation of 15. Higher scores indicate higher levels of intellectual competence and a better outcome. (NCT01542736)
Timeframe: Month 60

Interventionscore on a scale (Mean)
Reduced Radiation With Concurrent Chemotherapy79

[back to top]

Intellectual Competence Measured by IQ Score: Week 8

Neuropsychological testing will be performed after radiation in completed. The Wechsler Intelligence Scale for Children, 5th edition (WISC-V) measures intellectual competence in Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed. The average score for the scale is fixed at 100, with a standard deviation of 15. Higher scores indicate higher levels of intellectual competence and a better outcome. (NCT01542736)
Timeframe: Week 8

Interventionscore on a scale (Mean)
Reduced Radiation With Concurrent Chemotherapy102.4

[back to top]

Overall Survival

Overall Survival will be measured at the end of study. number of surviving participants is reported. (NCT01542736)
Timeframe: up to 5 years

InterventionParticipants (Count of Participants)
Reduced Radiation With Concurrent Chemotherapy7

[back to top]

3-year Overall Survival Rate of Patients With Relapsed ALL

Estimate the 3-year survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy. (NCT01700946)
Timeframe: 3 years of follow-up since the on-study date

Interventionpercentage of participants (Number)
STANDARD RISK94.4
HIGH RISK55.5
All Patients Enrolled on the Study72.63

[back to top]

3-year Event-free Survival Rates in Patients With Relapsed ALL

Estimate the 3-year event-free survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy. (NCT01700946)
Timeframe: 3 years of follow-up since the on-study date

Interventionpercentage of participants (Number)
STANDARD RISK83.3
HIGH RISK55.7
All Patients Enrolled on the Study67.83

[back to top]

Mean of CD20 Expression Levels

To estimate mean levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block I of remission induction therapy for relapsed precursor B-cell ALL. (NCT01700946)
Timeframe: Baseline and at the end of Block I (approximately 5 weeks after the on-study date)

,,
Interventionpercentage of CD20 Antigen (Mean)
At BaselineAt Block I
All Patients Enrolled on the Study36.2319.43
HIGH RISK39.8220.10
STANDARD RISK31.1018.54

[back to top]

Median CD20 Expression Levels

To estimate median levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block I of remission induction therapy for relapsed precursor B-cell ALL. (NCT01700946)
Timeframe: Baseline and at the end of Block I (approximately 5 weeks after the on-study date)

,,
Interventionpercentage of CD20 Antigen (Median)
At BaselineAt Block 1
All Patients Enrolled on the Study22.015.58
HIGH RISK23.1319.58
STANDARD RISK16.4011.83

[back to top]

Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8

Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing Cycle 8. (NCT01724021)
Timeframe: Cycle 8 (Up to 32 weeks)

Interventionpercentage of participants (Number)
Arm A77.1
Arm B84.2

[back to top]

Summary of Observed Serum Rituximab Concentration

(NCT01724021)
Timeframe: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)

,
Interventionmicrogram per milliter (Mean)
Cycle 1Cycle 2Cycle 3Cycle 4Interim stagingCycle 5Cycle 6Cycle 7Cycle 8Final stagingFollow-up, 6 monthsFollow-up, 12 monthsEnd of study/early treatment termination
Arm A3355.925053.162977.087956.6117273.6108030.9100927.795614.0104873.086806.67802.92380.19302.0
Arm B970.124541.146093.959485.577665.370387.398679.7117172.0137048.1120995.78042.91685.39553.9

[back to top]

Rituximab Administration Satisfaction Questionnaire (RASQ) Score

The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. (NCT01724021)
Timeframe: During Cycle 4, 8 of treatment (Up to 32 weeks)

,
Interventionunits on a scale (Mean)
Physical impact domainPsychological Impact domainImpact on activitiesf daily livingConvenience domainSatisfaction domain
Rituximab Intravenous (IV)82.1477.7359.4959.0574.88
Rituximab Subcutaneous (SC)82.0884.0081.8681.0587.26

[back to top]

Percentage of Participants With Anti-Rituximab Antibodies Over Time

(NCT01724021)
Timeframe: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)

,
Interventionpercentage of participants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Interim stagingCycle 5Cycle 6Cycle 7Cycle 8Final stagingFollow-up, 6 monthsFollow-up, 12 monthsEnd of study/early treatment termination
Arm A2.02.10.300000001.82.10.6
Arm B3.02.20.90.300000000.60.6

[back to top]

Disease-free Survival (DFS)

DFS was defined as the period from the data of the initial CR/CRu until the date of relapse or death from any cause, whichever occurred first. (NCT01724021)
Timeframe: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

Interventionmonths (Median)
Arm ANA
Arm BNA

[back to top]

Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time

(NCT01724021)
Timeframe: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)

,
Interventionpercentage of participants (Number)
Cycle 1Cycle 2Cycle 3Cycle 4Interim stagingCycle 5Cycle 6Cycle 7Cycle 8Final stagingFollow-up, 6 monthsFollow-up, 12 monthsEnd of study/early treatment termination
Arm A11.47.07.17.09.012.516.023.813.310.06.57.73.5
Arm B15.618.223.514.79.710.211.610.911.012.613.48.76.3

[back to top]

Cancer Therapy Satisfaction Questionnaire (CTSQ) Score

CTSQ is a validated 16-item questionnaire that measures three domains related to participants' satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. (NCT01724021)
Timeframe: During Cycle 4, 8 of treatment (Up to 32 weeks)

,
Interventionunits on a scale (Mean)
Expectations of therapy domainFeelings about side effects domainSatisfaction with therapy domain
Rituximab Intravenous (IV)80.8860.6384.59
Rituximab Subcutaneous (SC)82.0761.6485.42

[back to top]

Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])

Administration time was defined as the time from start to end of the SC injection or from start to end of the IV infusion (NCT01724021)
Timeframe: Cycle 1-4, Cycle 5-8 for both SC and IV (Up to 32 weeks)

Interventionminutes (Median)
Rituximab Intravenous (IV)840
Rituximab Subcutaneous (SC)22

[back to top]

Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6

Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6. (NCT01724021)
Timeframe: Cycle 6 (Up to 24 weeks)

Interventionpercentage of participants (Number)
Arm A79.1
Arm B80.6

[back to top]

Progression-free Survival (PFS)

PFS was defined as the time from randomization to the first occurrence of progression or relapse, according to the IWG response criteria. IWG criteria is defined criteria using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; PR: At least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses; SD: participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD; PD: Lymph nodes considered abnormal if the long axis is more than 1.5 cm regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes <= 1.0 × <= 1.0 cm would not be considered as abnormal for PD. (NCT01724021)
Timeframe: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

Interventionmonths (Median)
Arm ANA
Arm BNA

[back to top]

Number of Participants With Treatment Emergent Adverse Events (AEs)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT01724021)
Timeframe: Randomization of first participant to clinical cutoff date (Up to 4 years)

Interventionparticipants (Number)
Arm A352
Arm B347

[back to top]

Event-free Survival (EFS)

EFS was defined as the time from randomization to first occurrence of progression or relapse according to IWG response criteria. IWG criteria is defined using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; partial response (PR): At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; stable disease (SD): participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (PD); PD: Lymph nodes considered abnormal if the long axis is more than 1.5 centimeter (cm) regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes less than or equal to (<=) 1.0 × <= 1.0 cm would not be considered as abnormal for PD. (NCT01724021)
Timeframe: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

Interventionmonths (Median)
Arm ANA
Arm BNA

[back to top]

Complete Response (CR) Rate

CR rate was assessed according to the International Working Group (IWG) Response Criteria (CHESON ET AL. 1999) and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by > 75 % but still >1.5 cm in size, and indeterminate bone marrow assessment. Tumor assessments were based on computed tomography (CT) scans with contrast of the neck, chest, and abdomen (if detectable by these techniques) or other diagnostic means, if applicable. Other methods (e.g., MRI) were acceptable for participants in whom contrast CT scans were contraindicated. Due to the limited availability of FDG-PET scanners, an FDG-PET scan was not mandated in the study. (NCT01724021)
Timeframe: 28 days (± 3 days) after Day 1 of the last dose of induction treatment

Interventionpercentage of participants (Number)
Arm A49.2
Arm B52.7

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to death from any cause. (NCT01724021)
Timeframe: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

Interventionmonths (Median)
Arm ANA
Arm BNA

[back to top]

Induction Response

Induction response is the defined as the proportion of patients who achieve complete remission (CR) or partial remission (PR) during 6 cycles of induction therapy. Response was assessed was using a combination of CT scans and PET scans. Partial and complete response were categorized according to standard lymphoma response criteria, specifically the Revised Response Criteria (Cheson 2007). Given the cycle length of 3 weeks, induction duration per protocol was 18 weeks. (NCT01746173)
Timeframe: Disease was re-staged at cycles 3 and 6 during induction. Median duration of induction therapy in this study cohort was 6 cycles/18 weeks (range 2-6 cycles).

Interventionproportion of patients (Number)
CHOEP + High Dose Therapy + Auto SCT.60

[back to top]

24-month Progression-Free Survival Rate

24-month progression-free survival rate is defined as the proportion of patients remaining alive and progression-free at 24 months from start of induction therapy. Disease progression was assessed using a combination of CT scans and PET scans. Progression was categorized according to standard lymphoma response criteria, specifically the Revised Response Criteria (Cheson 2007). (NCT01746173)
Timeframe: Disease was re-staged at cycles 3 and 6 during induction, at day 100 post-ASCT, and in long-term follow-up at months 12, 18, 24 and 36. All patients were evaluable up to month 24.

Interventionproportion of patients (Number)
CHOEP + High Dose Therapy + Auto SCT0.0

[back to top] [back to top]

Response Rate (RR)

"Response Rate (RR) was determined as the sum of complete response (CR) and partial response (PR). Due to overlap, complete response rate without platelet recovery (CRp) is not included in Response Rate (RR). The outcome is reported as the total number without dispersion.~CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) > 1,000/microliter; platelets > 100,000/microliter; < 5% blasts in bone marrow.~CRp = Meets all criteria for CR except platelet count.~PR = Meets all criteria for CR except bone marrow contains 5 to 25% leukemia cells." (NCT01769209)
Timeframe: Day 29

InterventionParticipants (Count of Participants)
Bortezomib + Chemotherapy11

[back to top]

Progression-free Survival (PFS)

"Progression-free survival (PFS) was assessed as survival without progression at 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression.~Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease." (NCT01769209)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Bortezomib + Chemotherapy3

[back to top]

Complete Response Without Platelet Recovery (CRp)

"Complete response without platelet recovery (CR) was determined as the number of participants who achieved CRp by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. The outcome reflects only those subjects that meet all complete response (CR) criteria except platelet count; participants that meet all criteria including platelet count are not included in this outcome. CR and CRp are defined below.~CR =.No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) > 1,000/microliter; platelets > 100,000/microliter; < 5% blasts in bone marrow.~CRp = Meets all criteria for CR except platelet count." (NCT01769209)
Timeframe: Day 29

InterventionParticipants (Count of Participants)
Bortezomib + Chemotherapy1

[back to top]

Complete Response (CR)

"Complete response (CR) was determined the number of participants who achieved CR by Day 29 after induction treatment. The outcome is reported as the total number without dispersion. CR is defined as:~CR = No circulating blasts or extramedullary disease; trilineage hematopoiesis; absolute neutrophil count (ANC) > 1,000/microliter; platelets > 100,000/microliter; < 5% blasts in bone marrow.~Not CR = All statuses and conditions if less than or not as defined." (NCT01769209)
Timeframe: Day 29

InterventionParticipants (Count of Participants)
Bortezomib + Chemotherapy11

[back to top]

Failure-free Survival (FFS)

"Failure-free survival (FFS) was assessed as survival without progression or the addition of another systemic therapy, at or within 2 years. The outcome is reported as the number (without dispersion) of the participants alive without progression. Progression is defined below.~Progression = More than 25% increase in circulating and/or bone marrow blasts, or the development of extramedullary disease." (NCT01769209)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Bortezomib + Chemotherapy3

[back to top]

Overall Survival (OS)

Overall survival (OS) was assessed as participants remaining alive 2 years after induction therapy. The outcome is reported as the number of participants (without dispersion). (NCT01769209)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Bortezomib + Chemotherapy5

[back to top]

Number of Patients Who Complete Treatment

Number of patients who complete chemotherapy treatment. (NCT01775475)
Timeframe: Up to 18 weeks

InterventionParticipants (Count of Participants)
Arm I (CHOP)3
Arm II (Oral Chemotherapy)1

[back to top]

Overall Response Rate

Overall response is complete or partial response as defined by response definitions of the 2014 International Conference on Malignant Lymphoma Imaging Working Group (i.e. Lugano classification). Complete response is the disappearance of all lesions with no new lesions detected. Partial response is >=50% decrease in the sum of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites and no new sites of disease. (NCT01775475)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
Arm I (CHOP)3
Arm II (Oral Chemotherapy)1

[back to top]

Overall Survival

Proportion of participants who survived 2 years (NCT01775475)
Timeframe: Up to 24 months

InterventionProportion of participants (Number)
Arm I (CHOP)0
Arm II (Oral Chemotherapy)0

[back to top]

Participants Who Experienced an Adverse Event

Number of participants who experienced an adverse event (NCT01775475)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
Arm I (CHOP)4
Arm II (Oral Chemotherapy)3

[back to top]

Change in Absolute CD4 Count From Baseline to Post-treatment

Change in absolute CD4 count from baseline to post-treatment (visit 6) (NCT01775475)
Timeframe: From baseline to 18 weeks

Interventioncells per mm^3 (Mean)
Arm I (CHOP)-41.3
Arm II (Oral Chemotherapy)203.3

[back to top]

Progression-free Survival

Proportion of participants who survived without disease progression at 2 years (NCT01775475)
Timeframe: Up to 24 months

Interventionproportion (Number)
Arm I (CHOP)0
Arm II (Oral Chemotherapy)0

[back to top]

Proportion of Patients Who Are Adherent to Antiretroviral Therapy

Number of patients who did not miss any of their doses of antiretroviral therapy (NCT01775475)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
Arm I (CHOP)3
Arm II (Oral Chemotherapy)3

[back to top]

Proportion of Patients Who Are Adherent to Chemotherapy

Patients who did not miss any doses of chemotherapy (NCT01775475)
Timeframe: Up to 18 weeks

InterventionParticipants (Count of Participants)
Arm I (CHOP)4
Arm II (Oral Chemotherapy)3

[back to top]

Progression-free Survival Per Independent Review Facility (IRF)

The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first. (NCT01777152)
Timeframe: Up to 60 months

Interventionmonths (Median)
A+CHP48.20
CHOP20.80

[back to top]

Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)

The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first. (NCT01777152)
Timeframe: Up to 60 months

Interventionmonths (Median)
A+CHP55.66
CHOP32.03

[back to top]

Incidence of Adverse Events (AEs)

Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment. (NCT01777152)
Timeframe: Up to 8.28 months

,
InterventionParticipants (Count of Participants)
Any treatment-emergent AEBlinded study treatment-related AECHP treatment-related AEAny serious adverse event (SAE)Blinded study treatment-related SAECHP treatment-related SAETreatment discontinuations due to AETreatment discontinuations due to blinded study treatment-related AETreatment discontinuations due to CHP treatment-related AE
A+CHP22120119887586214108
CHOP22119320587455315107

[back to top]

Incidence of Laboratory Abnormalities

Number of participants who experienced a Grade 3 or higher laboratory toxicity. (NCT01777152)
Timeframe: Up to 8.28 months

,
InterventionParticipants (Count of Participants)
Any Chemistry TestAlanine Aminotransferase HighAlbumin LowAlkaline Phosphatase HighCalcium LowGlucose HighPhosphate LowPotassium HighPotassium LowSodium HighSodium LowUrate HighAny Hematology TestAbsolute Neutrophil Count LowHemoglobin HighHemoglobin LowLeukocytes LowLymphocytes HighLymphocytes LowNeutrophils LowPlatelets Low
A+CHP253211840314568171912052171
CHOP2313016322062781901321161191

[back to top]

Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)

The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma. (NCT01777152)
Timeframe: Up to 8.34 months

InterventionParticipants (Count of Participants)
A+CHP153
CHOP126

[back to top]

Overall Survival (OS)

The time from randomization to death due to any cause. (NCT01777152)
Timeframe: Up to 90 months

InterventionMonths (Median)
A+CHPNA
CHOPNA

[back to top]

Objective Response Rate (ORR) Per IRF at End of Treatment

The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma. (NCT01777152)
Timeframe: Up to 8.34 months

InterventionParticipants (Count of Participants)
A+CHP188
CHOP163

[back to top]

The Tolerability of BuMel Regimen

Number of patients who experience one or more unacceptable toxicities (severe sinusoidal obstruction syndrome [SOS] or Grade 4-5 pulmonary toxicity per Common Toxicity Criteria [CTC] v.4.0) during the Consolidation phase of therapy. (NCT01798004)
Timeframe: Up to 28 days post-consolidation therapy, up to 1 year

Interventionparticipants (Number)
All Patients9

[back to top]

Percentage of Participants Who Achieved Complete Response (CR)

Percentage of participants with measurable disease who achieved CR were reported. CR: disappearance of all evidence of disease. CR Criteria: Complete disappearance of all disease-related symptoms; all lymph nodes and nodal masses regressed to normal size (less than or equal to [<=]1.5 cm in greatest transverse diameter [GTD] for nodes greater than [>]1.5 cm before therapy). Previous nodes of 1.1 to 1.5 cm in long axis and greater than (>)1.0 cm in short axis before treatment decreased to <=1.0 cm in short axis after treatment. Disappearance of all splenic and hepatic nodules and other extranodal disease; a negative positron emission tomography (PET) scan. A posttreatment residual mass of any size but PET-negative; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to approximately 4.5 years

InterventionPercentage of participants (Number)
Treatment Arm B: Ibrutinib+R-CHOP67.3
Treatment Arm A: Placebo+R-CHOP68.0

[back to top]

Overall Survival

Overall survival was defined as the duration from the date of randomization to the date of the participant's death. Median Overall Survival was estimated by using the Kaplan-Meier method. (NCT01855750)
Timeframe: Up to 5.5 years

InterventionMonths (Median)
Treatment Arm B: Ibrutinib+R-CHOPNA
Treatment Arm A: Placebo+R-CHOPNA

[back to top]

Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population

EFS: duration from randomization date to disease progression(PD) date, relapse from complete response(CR) assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either positron emission tomography(PET)-positive/ biopsy-proven residual disease upon completion of >=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in sum of product of diameters(SPD) of >1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to 5.5 years

InterventionMonths (Median)
Treatment Arm B: Ibrutinib+R-CHOP49.64
Treatment Arm A: Placebo+R-CHOP54.77

[back to top]

Event-Free Survival (EFS) - Activated B-Cell (ABC) Population

EFS: duration from randomization date to PD date, relapse from CR assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either PET-positive/ biopsy-proven residual disease upon completion of >=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in SPD of >1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to approximately 4.5 years

InterventionMonths (Median)
Treatment Arm B: Ibrutinib+R-CHOP48.56
Treatment Arm A: Placebo+R-CHOP48.16

[back to top]

Time to Worsening in the Lymphoma Subscale of Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)

Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life. (NCT01855750)
Timeframe: Up to approximately 4.5 years

InterventionMonths (Median)
Treatment Arm B: Ibrutinib+R-CHOP11.7
Treatment Arm A: Placebo+R-CHOP35.0

[back to top]

Progression-Free Survival (PFS)

PFS was defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. Progressive Disease (PD): any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 centimeter (cm) in any axis, 50% increase in SPD of >1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to approximately 4.5 years

InterventionMonths (Median)
Treatment Arm B: Ibrutinib+R-CHOP48.56
Treatment Arm A: Placebo+R-CHOPNA

[back to top]

Proportion of Patients With Complete Response

Complete response is defined as complete disappearance of all detectable clinical evidence of disease, and disease-related symptoms if present prior to therapy. (NCT01856192)
Timeframe: Assessed every 3 months for 2 years, every 6 months for year 3, and then annually for years 4-10

Interventionproportion of participants (Number)
Arm A (R2CHOP)0.73
Arm B (RCHOP)0.68

[back to top]

Overall Survival Rate at 3 Years

Overall survival is defined as time from randomization to death or date last known alive. Overall survival rate at 3 years was calculated using the method of Kaplan Meier. (NCT01856192)
Timeframe: Assessed every 3 months for 2 years, every 6 months for year 3, and then annually for years 4-10

Interventionproportion of participants (Number)
Arm A (R2CHOP)0.826
Arm B (RCHOP)0.751

[back to top]

3-year Progression-free Survival Rate

"Progression-free survival is defined as the time from randomization to disease progression, new primary of the same type or death, whichever occurs first. Progressive disease is defined as:~Appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size.~>= 50% increase from nadir in the sum of the product of the diameters of any previously involved nodes or extranodal masses, or in a single involved node or extranodal mass, or the size of other lesions.~>= 50% increase in the longest diameter of any single previously identified node or extranodal mass > 1 cm in its short axis.~Lesions should be PET positive unless the lesion is too small to be detected with current PET systems.~Measurable extranodal disease should be assessed in a manner similar to that for nodal disease.~3-year progression-free survival rate was calculated using Kaplan-Meier method." (NCT01856192)
Timeframe: Assessed every 3 months for 2 years, every 6 months for year 3, and then annually for years 4-10, 3-year PFS rate reported

Interventionproportion of participants (Number)
Arm A (R2CHOP)0.727
Arm B (RCHOP)0.615

[back to top]

Proportion of Patients With Response

"Response is defined as complete response (CR) or partial response (PR) CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms~PR:~>=50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses~No increase in the size of other nodes, liver or spleen~Bone marrow assessment is irrelevant for determination of a PR if the sample was positive prior to treatment. However, if positive, the cell type should be specified~No new sites of disease~The post-treatment PET should be positive at any previously involved sites~For variably FDG-avid lymphomas/FDG-avidity unknown, without a pretreatment PET scan, or if a pretreatment PET scan was negative, CT scan criteria should be used~Patients with a CR and persistent morphologic bone marrow involvement~Patients with bone marrow involved before therapy and a clinical CR but no bone marrow assessment after treatment" (NCT01856192)
Timeframe: Assessed every 3 months for 2 years, every 6 months for year 3, and then annually for years 4-10

Interventionproportion of participants (Number)
Arm A (R2CHOP)0.97
Arm B (RCHOP)0.92

[back to top]

Local Failure Rate and Pattern of Failure

Local failure is defined as relapse or progression of disease at the primary site. The cumulative incidence of local failure will be estimated; competing events will include distant failure or death prior to local failure. (NCT01857934)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
NB2012 Therapy (Including Induction, Consolidation, and MRD) Antibody Antibody (hu14.18K322A)1.56

[back to top]

Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)]

Per the 1993 INRC: measurable tumor defined as product of the longest x widest perpendicular diameter, elevated catecholamine levels and tumor cels in bone marrow. Complete Response (CR)-no evidence of primary tumor or metastases. Very Good Partial Response (VGPR)->90% reduction of primary tumor; no metastases; no new bone lesions, all pre-existing lesions improved. Partial Response (PR)-50-90% reduction of primary tumor; >50% reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by >50%. Mixed Response (MR)->50% reduction of any measurable lesion with <50% reduction in other sites; no new lesions; <25% increase in any existing lesion. No Response (NR)-no new lesions; <50% reduction but <25% increase in an any existing lesion. No Response (NR)-no new lesions; <50% reduction but <25% increase in any existing legions. Progressive Disease (PD)-any new/increased measurable lesion by >25%; previous negative marrow positive. (NCT01857934)
Timeframe: After two initial courses of chemotherapy (approximately 6 weeks after enrollment)

InterventionParticipants (Count of Participants)
NB2012 Therapy (Including Induction, Consolidation, and MRD) Antibody (hu14.18K322A)42

[back to top]

Event-free Survival (EFS)

EFS was estimated as time to relapse, progressive disease, secondary neoplasm, or death from any cause from enrollment. The EFS was estimated by Kaplan-Meier method (NCT01857934)
Timeframe: 3 years, from time of enrollment

Interventionpercent of probability (Number)
NB2012 Therapy (Including Induction, Consolidation, and MRD) Plus Antibody (hu14.18K322A)73.7

[back to top]

Dose Limiting Toxicity (DLT)

Number of patients who experience an unacceptable dose limiting toxicity (per CTCAE v 4.0) including the following toxicities: 1) Toxicity requiring the use of pressors, including Grade 4 acute capillary leak syndrome or Grade 3 and 4 hypotension; 2) Toxicity requiring ventilation support, including Grade 4 respiratory toxicity; 3) Grade 3 or 4 neurotoxicity with MRI evidence of new CNS thrombi, infarction or bleeding. (NCT01857934)
Timeframe: During MRD treatment cycle (approximately 8-12 months after enrollment)

InterventionParticipants (Count of Participants)
NB2012 Therapy (Including Induction, Consolidation, and MRD) Plus Antibody (hu14.18K322A)1

[back to top]

Feasibility of Delivering hu14.18K322A to 6 Cycles of Induction Therapy

"The study is designed to monitor the feasibility of delivering hu14.18K332A to 6 cycles of Induction chemotherapy. The feasibility of Induction therapy for this study will be to target no worse than 75%. A patient was considered as a failure for the 6 cycles of Induction therapy if the patient failed to complete Induction therapy within 155 days since treatment initiation due to toxicity or disease progression, unless the delay was a result of non-medical issues (e.g. not due to protocol toxicity). The proportion of patients who successfully received hu14.18K322A with 6 cycles of induction chemotherapy was estimated together with a 95% confidence interval. The response rate (CR + VGPR + PR) to 6 cycles of Induction chemoimmunotherapy was estimated together with the 95% confidence intervals" (NCT01857934)
Timeframe: After 6 cycles of induction therapy (approximately 24 weeks after enrollment)

Interventionpercentage of participants (Number)
NB2012 Therapy (Including Induction, Consolidation, and MRD) Plus Antibody (hu14.18K322A)96.8

[back to top]

Dose Limiting Toxicity (DLT) or Severe (Grade 3 or 4) VOD With hu14.18K322A With Allogeneic NK Cells in Consolidation

Number of patients who experience an unacceptable dose limiting toxicity (per CTCAE v 4.0) including the following toxicities: 1) toxicity requiring the use of pressors, including Grade 4 acute capillary leak syndrome or Grade3 and 4 hypotension; 2) Toxicity requiring ventilation support, including Grade 4 respiratory toxicity; 3) Grade 3 or 4 neurotoxicity with MRI evidence of new CNS thrombi, infarction or bleeding in any subject receiving the hu14.18K322A with NK cell combination; 4) Failure of recovery of ANC > 500/mm3 by day 35 after PBSC infusion. Number of patients who experience Grade 3 or Grade 4 (per Common Toxicity Criteria v 4.0) veno occlusive disease (VOD). (NCT01857934)
Timeframe: During the recovery phase after busulfan/melphalan and PBSC rescue (approximately 24-26 weeks after enrollment)

InterventionParticipants (Count of Participants)
NB2012 Therapy (Including Induction, Consolidation, and MRD) Plus Antibody (hu14.18K322A)0

[back to top]

Adverse Events.

Safety, tolerability will be assessed by counting the number of participants experiencing adverse events at 8 weeks post treatment. (NCT01887587)
Timeframe: Baseline to 30 days post treatment; approximately 8 weeks

Interventionparticipants (Number)
(Modified VXLD) Plus MLN97085

[back to top]

Optimal Dose of MLN9708

This measure will be the maximum tolerated dose (MTD) at which no more than 1 Dose Limiting Toxicity (DLT) is observed. The starting dose of MLN9708 will be 2.3 mg orally on days 1, 8 and 15. If no DLT is seen in the first 3 patients, the dose will be increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation. (NCT01887587)
Timeframe: 8 Weeks

Interventionmg (Number)
Modified VXLD Plus MLN97082.3

[back to top]

DLBCL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Cycle 2 PredoseCycle 3 PredoseCycle 4 PredoseCycle 5 PredoseBaselineCycle 7 PredoseCycle 8 Predose
Diffuse Large B-Cell Lymphoma (DLBCL)53.97101.79110.50121.67109.40157.93132.57

[back to top]

DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionmcg*hr/mL (Mean)
Diffuse Large B-Cell Lymphoma (DLBCL)NA

[back to top]

DLBCL: Apparent Total Clearance (CL/F) of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionliter per hour (L/h) (Mean)
Diffuse Large B-Cell Lymphoma (DLBCL)NA

[back to top]

Percentage of Participants With Overall Survival (OS)

OS was defined as the time from first dose of rituximab to death from any cause. (NCT01889069)
Timeframe: Day 1 until death (up to maximum 54 months)

InterventionPercentage of Participants (Number)
Diffuse Large B-Cell Lymphoma (DLBCL)19.4
Follicular Lymphoma (FL)4.7
Subcutaneous (SC) Rituximab11.4

[back to top]

Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria

EFS was defined as the time from first dose of rituximab to first occurrence of progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurred first. (NCT01889069)
Timeframe: Day 1 up to first occurrence of progression or relapse, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first (up to maximum 54 months)

InterventionPercentage of Participants (Number)
Diffuse Large B-Cell Lymphoma (DLBCL)29.2
Follicular Lymphoma (FL)22.1
Subcutaneous (SC) Rituximab25.3

[back to top]

Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria

DFS assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occured first. (NCT01889069)
Timeframe: From 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occurs first (up to maximum 54 months) (end of Induction period = up to 8 months)

InterventionPercentage of Participants (Number)
Diffuse Large B-Cell Lymphoma (DLBCL)21.7
Follicular Lymphoma (FL)25.6
Subcutaneous (SC) Rituximab23.5

[back to top]

Percentage of Participants With Complete Response (CR) According to IWG Response Criteria

Complete response required: 1) the complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities, 2) all lymph nodes and nodal masses had regressed to normal size, 3) the spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and not be palpable on physical examination and 4) if the bone marrow was involved by lymphoma before treatment, the infiltrate was cleared on repeat bone marrow aspirate and biopsy of the same site. CR/unconfirmed (CRu) included those patients who fulfilled criteria 1 and 3 above as well as 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that regressed by more than 75% in the SPD and 2) indeterminate bone marrow. Response was assessed according to the IWG response criteria. (NCT01889069)
Timeframe: At 4 to 8 weeks after end of Induction period (end of Induction period = up to 8 months)

InterventionPercentage of Participants (Number)
Diffuse Large B-Cell Lymphoma (DLBCL)65.2
Follicular Lymphoma (FL)67.9
Subcutaneous (SC) Rituximab66.4

[back to top]

FL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)

FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days. (NCT01889069)
Timeframe: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Cycle 2 PredoseCycle 3 PredoseCycle 4 PredoseCycle 5 PredoseBaselineCycle 8 Predose
Follicular Lymphoma (FL)48.86156.33200.337.6097.90284.08

[back to top]

Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores

Patient-assessed satisfaction was evaluated using RASQ. Participants were asked questions regarding convenience and satisfaction for rituximab SC. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. DLBCL participants could be enrolled at cycle 2, cycle 3, or cycle 4. FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must be able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Each Cycle is 21 days for DLBCL. Each Cycle 21 days during the Induction phase and 2 months during Maintenance phase for FL. (NCT01889069)
Timeframe: DLBCL: Cycle (C) 2, C3, C4, C5, C6, End of C8; FL: Induction: C3, C4, C5, C6, C8, Maintenance: C2, C3, C4, C5, C6, C7, C8, C10, C12, End of treatment (4-8 weeks after last dose)

InterventionUnits on a Scale (Mean)
Convenience domain Cycle 3 InductionConvenience domain Cycle 4 InductionConvenience domain Cycle 5 InductionConvenience domain Cycle 6 InductionConvenience domain Cycle 8 InductionConvenience domain Cycle 2 MaintenanceConvenience domain Cycle 3 MaintenanceConvenience domain Cycle 4 MaintenanceConvenience domain Cycle 5 MaintenanceConvenience domain Cycle 6 MaintenanceConvenience domain Cycle 7 MaintenanceConvenience domain Cycle 8 MaintenanceConvenience domain Cycle 10 MaintenanceConvenience domain Cycle 12 MaintenanceConvenience domain End of TreatmentSatisfaction domain Cycle 3 InductionSatisfaction domain Cycle 4 InductionSatisfaction domain Cycle 5 InductionSatisfaction domain Cycle 6 InductionSatisfaction domain Cycle 8 InductionSatisfaction domain Cycle 2 MaintenanceSatisfaction domain Cycle 3 MaintenanceSatisfaction domain Cycle 4 MaintenanceSatisfaction domain Cycle 5 MaintenanceSatisfaction domain Cycle 6 MaintenanceSatisfaction domain Cycle 7 MaintenanceSatisfaction domain Cycle 8 MaintenanceSatisfaction domain Cycle 10 MaintenanceSatisfaction domain Cycle 12 MaintenanceSatisfaction domain End of Treatment
Follicular Lymphoma (FL)81.876.579.695.883.183.687.5100.080.283.382.793.891.786.375.089.484.191.793.891.392.079.2100.079.787.594.293.850.091.075.0

[back to top]

Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores

Patient-assessed satisfaction was evaluated using RASQ. Participants were asked questions regarding convenience and satisfaction for rituximab SC. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. DLBCL participants could be enrolled at cycle 2, cycle 3, or cycle 4. FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must be able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Each Cycle is 21 days for DLBCL. Each Cycle 21 days during the Induction phase and 2 months during Maintenance phase for FL. (NCT01889069)
Timeframe: DLBCL: Cycle (C) 2, C3, C4, C5, C6, End of C8; FL: Induction: C3, C4, C5, C6, C8, Maintenance: C2, C3, C4, C5, C6, C7, C8, C10, C12, End of treatment (4-8 weeks after last dose)

InterventionUnits on a Scale (Mean)
Convenience domain Cycle 2 TreatmentConvenience domain Cycle 3 TreatmentConvenience domain Cycle 4 TreatmentConvenience domain Cycle 5 TreatmentConvenience domain Cycle 6 TreatmentConvenience domain Cycle 8 TreatmentSatisfaction domain Cycle 2 TreatmentSatisfaction domain Cycle 3 TreatmentSatisfaction domain Cycle 4 TreatmentSatisfaction domain Cycle 5 TreatmentSatisfaction domain Cycle 6 TreatmentSatisfaction domain Cycle 8 Treatment
Diffuse Large B-Cell Lymphoma (DLBCL)75.081.982.183.380.883.887.583.385.683.384.691.2

[back to top]

Percentage of Participants With Administration-Associated Reactions (AAR)

AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. (NCT01889069)
Timeframe: Baseline up to 54 months

,,
InterventionPercentage of Participants (Number)
At least One AARAt Least One AAR Grade ≥3Cutaneous and Soft Tissue AARs (Localized)Cutaneous and Soft Tissue AARs (Non-Localized)
Diffuse Large B-Cell Lymphoma (DLBCL)4.201.42.8
Follicular Lymphoma (FL)8.108.10
Subcutaneous (SC) Rituximab6.305.11.3

[back to top]

FL: Plasma Trough Concentrations of Rituximab

FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Pharmacokinetic (PK) data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days. (NCT01889069)
Timeframe: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Cycle 2 PredoseCycle 3 PredoseCycle 4 PredoseCycle 5 PredoseBaselineCycle 8 Predose
Follicular Lymphoma (FL)55.49119.50157.257.6090.88201.56

[back to top]

Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the CTCAE, version 4.0. (NCT01889069)
Timeframe: Baseline up to 54 months

InterventionPercentage of Participants (Number)
Diffuse Large B-Cell Lymphoma (DLBCL)51.4
Follicular Lymphoma (FL)43.0
Subcutaneous (SC) Rituximab46.8

[back to top]

DLBCL: Plasma Trough Concentrations of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 pre-dose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Cycle 2 PredoseCycle 3 PredoseCycle 4 PredoseCycle 5 PredoseBaselineCycle 7 PredoseCycle 8 Predose
Diffuse Large B-Cell Lymphoma (DLBCL)42.5388.92110.50100.2092.92141.44117.61

[back to top]

Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events

SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here. (NCT01889069)
Timeframe: Baseline up to 54 months

InterventionPercentage of Participants (Number)
Diffuse Large B-Cell Lymphoma (DLBCL)36.1
Follicular Lymphoma (FL)26.7
Subcutaneous (SC) Rituximab31.0

[back to top]

DLBCL: Plasma Concentrations of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Cycle 2 PredoseCycle 3 PredoseCycle 4 PredoseCycle 5 PredoseBaselineCycle 7 PredoseCycle 7 Day 7Cycle 7 Day 14Cycle 8 Predose
Diffuse Large B-Cell Lymphoma (DLBCL)42.5388.92110.50100.2092.92141.44348.81226.40117.61

[back to top]

DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21

Plasma concentrations of rituximab in participants with DLBCL by chemotherapy regimen cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 14 days (R-CHOP-14) or cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 21 days (R-CHOP-21) in the PK) population.DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Cycle 2 PredoseCycle 3 PredoseCycle 4 PredoseCycle 5 PredoseBaselineCycle 7 PredoseCycle 7 Day 7Cycle 7 Day 14Cycle 8 Predose
Diffuse Large B-Cell Lymphoma (DLBCL) R-CHOP-2128.3788.92110.5094.0074.25150.13398.76272.50123.76

[back to top]

DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21

Plasma concentrations of rituximab in participants with DLBCL by chemotherapy regimen cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 14 days (R-CHOP-14) or cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 21 days (R-CHOP-21) in the PK) population.DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Cycle 2 PredoseCycle 5 PredoseBaselineCycle 7 PredoseCycle 7 Day 7Cycle 7 Day 14Cycle 8 Predose
Diffuse Large B-Cell Lymphoma (DLBCL) R-CHOP-14170.00125.00214.2593.5071.5542.0078.50

[back to top]

Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria

PFS was defined as the time from first dose of rituximab to the first occurrence of disease progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or death from any cause, whichever occurred first. (NCT01889069)
Timeframe: Day 1 up to first occurrence of progression or relapse, or death, whichever occurs first (up to maximum 54 months)

InterventionPercentage of Participants (Number)
Diffuse Large B-Cell Lymphoma (DLBCL)29.2
Follicular Lymphoma (FL)22.1
Subcutaneous (SC) Rituximab25.3

[back to top] [back to top]

FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab

FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days. (NCT01889069)
Timeframe: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Geometric Least Squares Mean)
Follicular Lymphoma (FL)61.01

[back to top]

DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Geometric Least Squares Mean)
Diffuse Large B-Cell Lymphoma (DLBCL)70.50

[back to top]

DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days. (NCT01889069)
Timeframe: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

Interventionmicrograms per millilitre (ug/mL) (Mean)
Diffuse Large B-Cell Lymphoma (DLBCL)NA

[back to top]

Response Rate (CR+CRi) Among Expansion Cohort

The response rate (CR + CRi) is defined as the rate of complete remission (CR) + complete remission with incomplete count recovery (CRi). Complete remission (CR) is defined as < 5% marrow aspirate blasts, neutrophils ≥ 1000/uL, platelets > 100,000/uL, no blasts in peripheral blood, and C1 Extramedullary disease status. C1 Extramedullary disease status is characterized by complete disappearance of all measurable and non-measurable extramedullary disease with the exception of lesions for which the following must be true: for participants with at least one measurable lesion, all lesions must have reduced by 75% in sum of products of greatest diameters (SPD), have no new lesions, and the spleen and other previously enlarged organs must have regressed in size. Complete remission with incomplete platelet recovery (CRi) is defined the same as CR, except absolute neutrophil count may be <1000/uL and/or platelet count may be ≤ 100,000/uL. (NCT01925131)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
CVP + Inotuzumab MTD83.33

[back to top]

Frequency and Severity of Toxicities

Number of participants with Grade 3-5 adverse events that are possibly, probably or definitely related to study drug are reported by given type of adverse event. (NCT01925131)
Timeframe: Up to 3 years

,,,,,
InterventionParticipants (Number)
AnemiaAscitesDysphagiaEncephalopathyEnterocolitisFatigueFebrile neutropeniaFeverGastric hemorrhageGastrointestinal disorders - Other, specifyHeadacheHyperglycemiaHypertensionHypoalbuminemiaHypocalcemiaHypokalemiaInfections and infestations - Other, specifyIntracranial hemorrhageLipase increasedLung infectionLymphocyte count decreasedMucositis oralNeutrophil count decreasedPlatelet count decreasedRenal and urinary disorders - Other, specifySepsisSkin infectionWhite blood cell decreased
CVP + Inotuzumab Dose Level 12000000120000000010020320003
CVP + Inotuzumab Dose Level 22000002101100000000010320004
CVP + Inotuzumab Dose Level 370110121000411100000319700110
CVP + Inotuzumab Dose Level 43000003000041001000230440005
CVP + Inotuzumab Dose Level 55100101000020000100060850007
CVP + Inotuzumab MTD51000171000010004010618101209

[back to top]

MTD of Inotuzumab Ozogamicin With CVP for Patients With Relapsed or Refractory CD22+ Acute Leukemia

To determine the maximum tolerated dose (MTD) of inotuzumab ozogamicin in this regimen for patients with relapsed or refractory CD22+ acute leukemia (B-cell acute lymphoblastic leukemia [B-ALL], mixed phenotype, and Burkitt's). The MTD is defined as the highest dose studied in which the incidence of dose-limiting toxicities is < 33% using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. (NCT01925131)
Timeframe: 28 days

Interventionmg/m^2 (Number)
Day 1 DoseDay 8 DoseDay 15 Dose
CVP + Inotuzumab0.80.50.5

[back to top]

Progression-free Survival

Median progression-free survival (in months) and observed minimum-maximum range. (NCT01925612)
Timeframe: Up to approximately 4 years

InterventionMonths (Median)
Part 1: BV(1.2 mg/kg) + RCHOPNA
Part 1: BV(1.8 mg/kg) + RCHOPNA
Part 2: BV(1.8 mg/kg) + RCHPNA
Part 3: BV(1.8 mg/kg) + RCHPNA
Part 3: RCHOPNA

[back to top]

Incidence of Laboratory Abnormalities

Number (count) of participants that experienced a Grade 3 or higher maximum post-baseline laboratory toxicity (hematology and chemistry). Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), v4.03. Grade 1 = mild, no intervention needed; Grade 2 = moderate, minimal intervention needed; Grade 3 = severe or medically significant, hospitalization is required; Grade 4 = life-threatening, urgent intervention needed; Grade 5 = death related to adverse event. (NCT01925612)
Timeframe: Up to 6 months

,,,,
InterventionParticipants (Count of Participants)
Any Hematology TestLymphocytes (x10^3/uL)Absolute Neutrophil Count (x10^3/uL)Neutrophils (x10^3/uL)Leukocytes (x10^3/uL)Hemoglobin (x10^3/uL)Platelets (x10^3/uL)Any Chemistry TestGlucose (mg/dL)Potassium (mEq)/LCalcium (mg/dL)Sodium (mEq/L)Alanine Aminotransferase (IU/L)
Part 1: BV(1.2 mg/kg) + RCHOP10844301430100
Part 1: BV(1.8 mg/kg) + RCHOP161544211752120
Part 2: BV(1.8 mg/kg) + RCHP4311100201001
Part 3: BV(1.8 mg/kg) + RCHP6422110101000
Part 3: RCHOP4400100312000

[back to top]

Objective Response Rate

Number (count) of participants that achieved complete or partial remission at the end of treatment according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007) (NCT01925612)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Part 1: BV(1.2 mg/kg) + RCHOP23
Part 1: BV(1.8 mg/kg) + RCHOP19
Part 2: BV(1.8 mg/kg) + RCHP10
Part 3: BV(1.8 mg/kg) + RCHP10
Part 3: RCHOP9

[back to top]

Complete Remission Rate

Number (count) of participants that achieved remission according to the Revised Response Criteria for Malignant Lymphoma (Cheson 2007). (NCT01925612)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Part 1: BV(1.2 mg/kg) + RCHOP20
Part 1: BV(1.8 mg/kg) + RCHOP16
Part 2: BV(1.8 mg/kg) + RCHP9
Part 3: BV(1.8 mg/kg) + RCHP6
Part 3: RCHOP8

[back to top]

Incidence of Adverse Events

Number (count) of participants that experienced at least 1 adverse event. (NCT01925612)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Part 1: BV(1.2 mg/kg) + RCHOP29
Part 1: BV(1.8 mg/kg) + RCHOP22
Part 2: BV(1.8 mg/kg) + RCHP11
Part 3: BV(1.8 mg/kg) + RCHP11
Part 3: RCHOP12

[back to top]

Overall Survival

Median overall survival (in months) and observed minimum-maximum range. (NCT01925612)
Timeframe: Up to approximately 4 years

InterventionMonths (Median)
Part 1: BV(1.2 mg/kg) + RCHOPNA
Part 1: BV(1.8 mg/kg) + RCHOPNA
Part 2: BV(1.8 mg/kg) + RCHPNA
Part 3: BV(1.8 mg/kg) + RCHPNA
Part 3: RCHOPNA

[back to top]

Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants

Response rate will be defined as the proportion of patients who achieved complete response or partial response (CR+PR) using the World Health Organization (WHO) criteria evaluated after two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high risk Ewing Sarcoma Family of Tumor (ESFT). Participants who are treated in Group B with Desmoplastic Small Round Cell Tumor (DSRCT) or those who do not receive window therapy will not be included in this analysis. (NCT01946529)
Timeframe: at 6 weeks after start of therapy (after 2 initial courses)

Interventionparticipants (Number)
Partial Response (PR)Stable disease (no response) (NR)Progressive Disease (PD)
Group B (High Risk) - ESFT381

[back to top]

Supplementary Analysis: Number of Participants With TEAEs: Participants With MZL

Number of MZL participants with TEAEs were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication. (NCT01974440)
Timeframe: Up to 8 years

InterventionParticipants (Count of Participants)
Placebo + Chemoimmunotherapy (CIT)28
Ibrutinib + CIT28

[back to top]

Supplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL

ORR in MZL participants was defined as the percentage of participants who achieved a CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: >=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL. (NCT01974440)
Timeframe: Up to 8 years

Interventionpercentage of participants (Number)
Placebo + Chemoimmunotherapy (CIT)82.1
Ibrutinib + CIT89.3

[back to top]

Supplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZL

OS in MZL participants was defined as the interval (in months) between the date of randomization and the date of the participant's death due to any cause. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)NA
Ibrutinib + CITNA

[back to top]

Primary Analysis: Progression Free Survival (PFS): Stratified Analysis

PFS was defined as duration (in months) from the date of randomization to the date of disease progression or relapse from complete response (CR) or death, whichever was first reported. PFS was assessed by the investigator based on the 2007 Revised Response Criteria for Malignant Lymphoma. Disease progression was defined as any new lesion or increase by greater than or equal to (>=) 50 percent (%) of previously involved sites from nadir disease progression criteria: Appearance of new nodal lesion 1.5 centimeters (cm) in any axis, 50% increase in sum of product of diameters (SPD) of greater than (>) 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)23.75
Ibrutinib + CIT40.51

[back to top]

Primary Analysis: Overall Survival (OS): Stratified Analysis

OS was defined as the interval (in months) between the date of randomization and the date of the participant's death due to any cause. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)NA
Ibrutinib + CITNA

[back to top]

Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)

PFS in MZL participants was defined as duration (in months) from the date of randomization to the date of disease progression or relapse from CR or death, whichever was first reported. PFS was assessed by the investigator based on the 2007 Revised Response Criteria for Malignant Lymphoma. Disease progression was defined as any new lesion or increase by >=50% of previously involved sites from nadir disease progression criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in SPD of >1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. Participants who were progression-free and alive or had unknown status were censored at the last tumor assessment. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)91.63
Ibrutinib + CITNA

[back to top]

Primary Analysis: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. Adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication. (NCT01974440)
Timeframe: Up to 8 years

InterventionParticipants (Count of Participants)
Placebo + Chemoimmunotherapy (CIT)197
Ibrutinib + CIT199

[back to top]

Primary Analysis: Duration of Response (DOR): Stratified Analysis

DOR was defined as the interval (in months) between the date of initial documentation of response (CR or PR) and the date of first documented evidence of progressive disease (or relapse for participants who experienced CR during the study) or death, whichever occurred first. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: >=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)21.68
Ibrutinib + CIT44.32

[back to top]

Primary Analysis: Complete Response Rate (CRR): Stratified Analysis

CRR was defined as the percentage of participants who achieved a complete response (CR); (based on investigator assessment) on or prior to the initiation of subsequent antilymphoma therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis. (NCT01974440)
Timeframe: Up to 8 years

Interventionpercentage of participants (Number)
Placebo + Chemoimmunotherapy (CIT)50.2
Ibrutinib + CIT55

[back to top]

Supplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL

TTW in MZL participants in the Lymphoma subscale of the FACT-Lym was defined as the time (in months) from the date of randomization to the start date of the worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline in participant symptoms. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (0 = not at all, 1 = a little bit, 2 = some what, 3 = quite a bit and 4 = very much, where the higher score indicated worse condition). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)36.83
Ibrutinib + CIT58.91

[back to top]

Primary Analysis: Overall Response Rate (ORR): Stratified Analysis

ORR was defined as the percentage of participants who achieved a CR or partial response (PR). Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: >=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. Stratification factors were used for the analysis. (NCT01974440)
Timeframe: Up to 8 years

Interventionpercentage of participants (Number)
Placebo + Chemoimmunotherapy (CIT)90.5
Ibrutinib + CIT91.6

[back to top]

Primary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire

Time-to-worsening in the Lymphoma subscale of the FACT-Lym was defined as the time (in months) from the date of randomization to the start date of the worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline in participant symptoms. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (0 = not at all, 1 = a little bit, 2 = some what, 3 = quite a bit and 4 = very much, where the higher score indicated worse condition). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)37.03
Ibrutinib + CIT24.84

[back to top]

Supplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL

CRR in MZL participants was defined as the percentage of participants who achieved a CR (based on investigator assessment) on or prior to the initiation of subsequent antilymphoma therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL. (NCT01974440)
Timeframe: Up to 8 years

Interventionpercentage of participants (Number)
Placebo + Chemoimmunotherapy (CIT)60.7
Ibrutinib + CIT64.3

[back to top]

Supplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL

DOR in MZL participants was defined as the interval (in months) between the date of initial documentation of response (CR or PR) and the date of first documented evidence of progressive disease (or relapse for participants who experienced CR during the study) or death, whichever occurred first. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy and no new sites of disease detected during assessment. Criteria for PR: >=50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. Kaplan-Meier method was used for the analysis. For this outcome measure, unstratified analysis was performed on participants with MZL. (NCT01974440)
Timeframe: Up to 8 years

Interventionmonths (Median)
Placebo + Chemoimmunotherapy (CIT)89.17
Ibrutinib + CITNA

[back to top]

Event-free Survival (EFS)

Event-free survival (EFS) is defined as the time from diagnosis to the earliest of disease progression/recurrence, second malignancy or death from any cause, or to the date of last follow-up for patients without events. EFS was estimated using the method of Kaplan and Meier. 2-year estimates are reported with 95% CI's. (NCT02017964)
Timeframe: 2 years from diagnosis

Interventionpercent probability (Number)
All Eligible Patients (Combination Chemotherapy)52.0

[back to top]

Percentage of Patients With Responses at 189 Days

The percentage of patients with complete response (CR) at the end of induction (~189 days) was reported and presented with the associated exact 95% confidence interval. (NCT02017964)
Timeframe: 189 days from start of treatment

InterventionPercentage of patients (Number)
All Eligible Patients (Combination Chemotherapy)92.0

[back to top]

Overall Survival (OS)

Overall Survival (OS) is defined as the time from diagnosis to death from any cause, or to the date of last follow-up for survivors. OS was estimated using the method of Kaplan and Meier. 2-year estimates are reported with 95% CI's, as the data are not mature to 72 months. (NCT02017964)
Timeframe: Assessed up to 72 months, reported at 2 years from diagnosis

Interventionpercent probability (Number)
All Eligible Patients (Combination Chemotherapy)92.0

[back to top]

Progression-free Survival (PFS)

Progression-free survival (PFS) is defined as the time interval from diagnosis to the earliest of disease progression/recurrence or death from any cause, or to the date of last follow-up for patients without events. PFS was estimated using the method of Kaplan and Meier. 2-year estimates are reported with 95% CI's. (NCT02017964)
Timeframe: 2 years from diagnosis

Interventionpercent probability (Number)
All Eligible Patients (Combination Chemotherapy)52.0

[back to top]

Percentage of Patients With Responses at 273 Days

The percentage of patients with complete response (CR) at the end of therapy (~273 days) was reported and presented with the associated exact 95% confidence interval. (NCT02017964)
Timeframe: 273 days from start of treatment

InterventionPercentage of patients (Number)
All Eligible Patients (Combination Chemotherapy)88.0

[back to top]

Number of Participants With Grade 3 or Greater Non-hematologic Toxicities

Compare toxicity profiles for grade 3 or greater toxicities associated with each of 131I-MIBG treatment regimens; single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG (NCT02035137)
Timeframe: All toxicities from enrollment through 30 days following end of protocol therapy, an average of 6 months

InterventionParticipants (Count of Participants)
Single-Agent 131I-MIBG7
131I-MIBG With Vincristine/Irinotecan17
131I-MIBG With Vorinostat12

[back to top]

Objective Tumor Response After One Course of Therapy

To identify the MIBG treatment regimen associated with the highest overall response rate after one course of treatment on the three arms. The response evaluation was based on central review (intent to treat analysis). Responders defined as meeting CR/MRD/PR criteria. Response was based on NANT response criteria v1.2 (https://doi.org/10.1002/pbc.26940). RECST 1.1 criteria was used for measurable tumors with PR criteria > 30% decrease in target tumor size. Curie score was used with PR criteria > 50% decrease in Curie score. Complete Response- disappearance of all target lesions, Curie score of 0 and no detectable bone marrow disease. Overall Response (OR)=CR+PR. (NCT02035137)
Timeframe: 43-50 days from study day 1

InterventionParticipants (Count of Participants)
Single-Agent 131I-MIBG5
131I-MIBG With Vincristine/Irinotecan5
131I-MIBG With Vorinostat11

[back to top]

Doxorubicin PK: Cmax

Cmax was determined using the post-dose Doxorubicin plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

Interventionmcg/mL (Mean)
Venetoclax PK Popluation1260

[back to top]

Obinutuzumab PK: Cmax

Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

Interventionmcg/mL (Mean)
Venetoclax 800 mg326

[back to top]

Percentage of Participants Who Are Alive and Without Disease Progression at Month 12

Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: >/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions. (NCT02055820)
Timeframe: Month 12

InterventionPercentage of Participants (Number)
Venetoclax 200 mg + R-CHOP85.71
Venetoclax 400 mg + R-CHOP100.00
Venetoclax 600 mg + R-CHOP87.50
Venetoclax 800mg + R-CHOP66.67
Venetoclax + R-CHOP 800 mg Phase II88.99
Venetoclax 200mg + G-CHOP100.00
Venetoclax 400mg + G-CHOP75.00
Venetoclax 600mg + G-CHOP100.00
Venetoclax 800 mg + G-CHOP A100.00
Venetoclax 800 mg + G-CHOP B100.00

[back to top]

Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification

CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to NCT02055820)
Timeframe: Baseline up to end of treatment (approx. 6 months)

InterventionPercentage of Participants (Number)
Venetoclax + R-CHOP 800 mg Phase II37.4

[back to top]

Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC

CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)

InterventionPercentage of participants (Number)
Venetoclax + R-CHOP 800 mg Phase II66.7

[back to top]

Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC

"Objective Response defined as PR (partial response) or CR (complete response) at end of treatment.~CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.~PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR" (NCT02055820)
Timeframe: Baseline to end of treatment (up to approximately 6 months)

InterventionPercentage of Participants (Number)
Venetoclax + R-CHOP 800 mg Phase II81.5

[back to top]

Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)

CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)

InterventionPercentage of participants (Number)
Venetoclax + R-CHOP 800 mg Phase II68.2

[back to top]

Rituximab PK: Cmax

Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

Interventionmcg/mL (Mean)
Venetoclax 800 mg173

[back to top]

Rituximab PK: Cmin Within the Dosing Interval

Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2. (NCT02055820)
Timeframe: Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)

Interventionmcg/mL (Mean)
Venetoclax 800 mg26.1

[back to top]

Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)

DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade >/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs. (NCT02055820)
Timeframe: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)

InterventionParticipants (Number)
Venetoclax 200 mg + R-CHOP1
Venetoclax 400 mg + R-CHOP0
Venetoclax 600 mg + R-CHOP1
Venetoclax 800mg + R-CHOP0
Venetoclax 200mg + G-CHOP2
Venetoclax 400mg + G-CHOP1
Venetoclax 600mg + G-CHOP1
Venetoclax 800 mg + G-CHOP A0
Venetoclax 800 mg + G-CHOP B0

[back to top]

Safety: Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02055820)
Timeframe: Baseline up to approximately 36 months

InterventionPercentage of Participants (Number)
Venetoclax 200 mg + R-CHOP100.00
Venetoclax 400 mg + R-CHOP100.00
Venetoclax 600 mg + R-CHOP100.00
Venetoclax 800mg + R-CHOP100.00
Venetoclax + R-CHOP 800 mg Phase II99.0
Venetoclax 200mg + G-CHOP100.00
Venetoclax 400mg + G-CHOP100.00
Venetoclax 600mg + G-CHOP100.00
Venetoclax 800 mg + G-CHOP A100.00
Venetoclax 800 mg + G-CHOP B100.00

[back to top]

Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)

"AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as hour*micrograms per milliliter (hr*mcg/mL)" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)

Interventionhr*mcg/mL (Mean)
Venetoclax 800mg + R-CHOP.66
Venetoclax 200 mg + R-CHOP2.51
Venetoclax 400 mg + R-CHOP3.87
Venetoclax 600 mg + R-CHOP3.70
Venetoclax + R-CHOP 800 mg4.51
Venetoclax 200mg + G-CHOP2.55
Venetoclax 400mg + G-CHOP4.33
Venetoclax 600mg + G-CHOP5.13
Venetoclax + G-CHOP 800mg6.20

[back to top]

Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)

"Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as micrograms per milliliter" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

InterventionUg/ML (Mean)
Venetoclax + R-CHOP 100 mg.09
Venetoclax 200 mg + R-CHOP.58
Venetoclax 400 mg + R-CHOP.92
Venetoclax 600 mg + R-CHOP.85
Venetoclax 800mg + R-CHOP1.15
Venetoclax 200mg + G-CHOP.52
Venetoclax 400mg + G-CHOP1.26
Venetoclax 600mg + G-CHOP1.00
Venetoclax + G-CHOP 800 mg1.54

[back to top]

Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval

Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

Interventionmcg/mL (Mean)
Venetoclax + R-CHOP 100 mg0.0714
Venetoclax 200 mg + R-CHOP0.522
Venetoclax 400 mg + R-CHOP0.253
Venetoclax 600 mg + R-CHOP0.387
Venetoclax 800mg + R-CHOP0.640
Venetoclax 200mg + G-CHOP0.134
Venetoclax 400mg + G-CHOP0.395
Venetoclax 600mg + G-CHOP0.612
Venetoclax + G-CHOP 800 mg0.628

[back to top]

Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)

Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

InterventionHour (Mean)
Venetoclax + R-CHOP 100 mg4.0
Venetoclax 200 mg + R-CHOP4.59
Venetoclax 400 mg + R-CHOP6.50
Venetoclax 600 mg + R-CHOP5.52
Venetoclax 800mg + R-CHOP5.53
Venetoclax 200mg + G-CHOP5.72
Venetoclax 400mg + G-CHOP6.56
Venetoclax 600mg + G-CHOP5.30
Venetoclax + G-CHOP 800 mg5.79

[back to top]

Vincristine PK: Cmax

Cmax was determined using the post-dose Vincristine plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

Interventionmcg/mL (Mean)
Venetoclax PK Popluation54.0

[back to top]

Prednisone Plasma PK: AUC

AUC was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

Interventionhr*mcg/mL (Mean)
Cycle 1, Day 1Cycle 2, Day 1
Venetoclax PK Popluation195184

[back to top]

Prednisone Plasma PK: Tmax

Tmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

InterventionHour (Mean)
Cycle 1, Day 1Cycle 2, Day 1
Venetoclax PK Popluation2.193.80

[back to top]

Relative Dose Intensity of Venetoclax

Dose intensity was categorized as < 80%, 80% to < 85%, 85% to < 90%, or >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)

,,,,,,,,,
InterventionPercentage of Partcipants (Number)
<80%80-<85%85-<90%>=90%
Venetoclax + G-CHOP 800 mg83.30.0016.70.00
Venetoclax + G-CHOP 800mg B100.00.000.000.00
Venetoclax + R-CHOP 800 mg Phase II26.03.42.967.6
Venetoclax 200 mg + R-CHOP71.40.000.0028.6
Venetoclax 200mg + G-CHOP100.000.000.000.00
Venetoclax 400 mg + R-CHOP0.000.000.00100.00
Venetoclax 400mg + G-CHOP14.314.30.0071.4
Venetoclax 600 mg + R-CHOP12.512.512.562.5
Venetoclax 600mg + G-CHOP50.016.70.0033.3
Venetoclax 800mg + R-CHOP0.000.000.00100.00

[back to top]

Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy

Maintenance of relative dose intensity was defined as a dose intensity of >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)

,
InterventionPercentage of participants (Number)
CyclophosphamideDoxorubicinVincristinePrednisone
Venetoclax + R-CHOP Arm89.588.686.687.4
Venetoclax 600mg + G-CHOP77.477.478.181.3

[back to top]

Prednisone Plasma PK: Cmax

Cmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

InterventionNg/ML (Mean)
Cycle 1, Day 1Cycle 2, Day 1
Venetoclax PK Popluation49.943.2

[back to top]

Cyclophosphamide PK: Cmax

Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

Interventionmcg/mL (Mean)
Venetoclax PK Popluation32.1

[back to top]

Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients

DFS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization

Interventionpercentage of participants (Number)
Arm A (HR and IR Control)39.04
Arm B (HR and IR Blinatumomab)54.44

[back to top]

Overall Survival (OS) of LR Relapse Patients

OS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Three-year OS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization

Interventionpercentage of participants (Number)
Arm C (LR Control)88.29
Arm D (LR Blinatumomab)90.37

[back to top]

Overall Survival (OS) of HR and IR Relapse Patients

OS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Two-year OS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization

Interventionpercentage of participants (Number)
Arm A (HR and IR Control)58.40
Arm B (HR and IR Blinatumomab)71.33

[back to top]

Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients

DFS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization

Interventionpercentage of participants (Number)
Arm C (LR Control)58.94
Arm D (LR Blinatumomab)67.00

[back to top]

Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients

EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. Three-year EFS rates will be calculated for both groups. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
Arm A (Combination Chemotherapy)81.7
Arm B (Combination Chemotherapy, Bortezomib)85.1

[back to top]

EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)

EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
AALL1231 T-ALL Patients88.3
AALL0434 T-ALL Patients88.8

[back to top]

EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3

EFS will be calculated as time from the end of the three high-risk blocks of therapy to first event (relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
VHR T-ALL MRD Undetectable25.0
VHR T-ALL MRD Detectable88.9

[back to top]

EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond

EFS for very high risk (VHR) T-LLy patients treated with HR Berlin-Frankfurt-Munster (BFM) intensification blocks who have complete or partial remission and those who do not respond (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
VHR T-LLy (CR/PR)0

[back to top]

Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase

Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (NCT02112916)
Timeframe: 3 years from start of therapy by patient

InterventionPercentage of participants (Number)
Total Patients78.0

[back to top]

Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)

Cumulative incidence of isolated CNS relapse adjusting for competing risks using the method of: Gray R, A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1141:1154, 1988 (NCT02112916)
Timeframe: 3 years

,
InterventionPercentage of participants (Number)
Isolated CNS RelapseIsolated Bone Marrow RelapseCombined Bone Marrow Relapse
AALL0434 T-ALL Patients2.23.01.8
AALL1231 T-ALL Patients3.61.41.3

[back to top] [back to top]

Minimal Residual Disease Negativity

To estimate in each cohort the rate of minimal residual disease (MRD) negativity. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)

,
InterventionParticipants (Count of Participants)
MRD-MRD+
Cohort I (Ph-)121
Cohort II (Ph+/Ph-like)79

[back to top]

Complete Response Rate (Cohort I)

Complete response rate is measured by the number of participants achieving complete remission (CR) or complete remission with incomplete platelet recovery (CRi) rate. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)

InterventionParticipants (Count of Participants)
CR or CRiNo CR or CRi
Cohort I (Ph-)1910

[back to top]

Overall Survival Rate (Cohort I)

To evaluate the 3-year overall survival rate in elderly participants with newly diagnosed Ph-negative ALL treated with blinatumomab followed by POMP maintenance. Overall (NCT02143414)
Timeframe: From the day of registration on study until death from any cause, assessed at 3 years

Interventionpercentage of participants (Number)
Cohort I (Ph-)34

[back to top]

Incidence of Dose-limiting Toxicity (Cohort II)

Defined as any grade 4 or higher treatment-related, non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only participants with Ph-positive ALL or Ph-like DSMKF ALL were evaluated. (NCT02143414)
Timeframe: Up to day 42 of post-remission therapy

InterventionParticipants (Count of Participants)
Cohort II (Ph+/Ph-like)0

[back to top]

Disease-free Survival (Cohort II)

An estimate of disease free survival in Ph-positive ALL and Ph-like DSMKF ALL (Cohort II). Disease free survival is measured by the number of years between the date the patient first achieves complete remission (CR) or complete remission with incomplete platelet recovery (CRi) until relapse from CR/CRi or death from any cause. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Duration of treatment and follow up until death or date of primary analysis (about 7.5 years)

Interventionyears (Median)
Cohort II (Ph+/Ph-like)5.3

[back to top]

Maximum Serum Concentration at Steady State (Cmax,ss)

"Cmax,ss: Maximum concentration of drug in plasma at steady state on administering a fixed dose at equal dosing intervals.~PK sampling was done at pre-dose and 1 hour after the end of infusion (EOI) at Core Cycles 1-3 and 5-8. At Core Cycle 4 (i.e. steady state), intensive PK samplings were done as follows: predose, EOI, 1 hour after EOI, 24 hour after EOI, 168 hour after EOI, 336 hour after EOI, 504 hour after EOI. Lastly, one sample at any time of the end of treatment (EOT) 1 visit was obtained." (NCT02162771)
Timeframe: Core Cycle 4 (Week 12)

Interventionug/mL (Geometric Mean)
CT-P10256.19
Rituxan254.49

[back to top]

Overall Response Rate (ORR) According to the 1999 International Working Group (IWG) Criteria

"ORR was defined as the proportion of patients with the best response of complete response (CR), unconfirmed complete response (CRu), or partial response (PR) by central review.~Per 1999 IWG criteria, the disease status was assessed by using contrasted CT, and CR, CRu, and PR were defined as followings; CR=Disappearance of all clinical/radiographic evidence of disease: regression of lymph nodes to normal size, absence of B-symptoms, bone marrow involvement, and organomegaly, and normal LDH level; CRu=Regression of measurable disease: >=75% decrease in SPD of target lesions and in each target lesions. no increase in the size of non-target lesions, neither new lesion nor organomegaly measured; PR=Regression of measurable disease: >=50% decrease in SPD of target lesions and no evidence of disease progression." (NCT02162771)
Timeframe: During the Core Study Period (up to 8 cycles; Week 24)

InterventionParticipants (Count of Participants)
CT-P1064
Rituxan63

[back to top]

B-cell Kinetics (B-cell Depletion and Recovery)

B-cell kinetics were demonstrated by median values of B-cell counts (Lower limit of quantification was 20 cells/uL). (NCT02162771)
Timeframe: Cycles 1 to 8 during the Core Study Period

,
Interventioncells/uL (Median)
Core Cycle 1 (Predose)Core Cycle 1 (1 hour after the end of infusion)Core Cycle 2 (Predose)Core Cycle 3 (Predose)Core Cycle 4 (Predose)Core Cycle 5 (Predose)Core Cycle 6 (Predose)Core Cycle 7 (Predose)Core Cycle 8 (Predose)
CT-P1092.520.020.020.020.020.020.020.020.0
Rituxan62.020.020.020.020.020.020.020.020.0

[back to top]

Area Under the Serum Concentration-time Curve at Steady State (AUCtau)

"AUCtau: Area under the plasma drug concentration-time curve within a dosing interval at steady state.~PK sampling was done at pre-dose and 1 hour after the end of infusion (EOI) at Core Cycles 1-3 and 5-8. At Core Cycle 4 (i.e. steady state), intensive PK samplings were done as follows: predose, EOI, 1 hour after EOI, 24 hour after EOI, 168 hour after EOI, 336 hour after EOI, 504 hour after EOI. Lastly, one sample at any time of the end of treatment (EOT) 1 visit was obtained." (NCT02162771)
Timeframe: Core Cycle 4 (Week 12)

Interventionh*ug/mL (Geometric Mean)
CT-P1041002.43
Rituxan40099.08

[back to top]

Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale

"The percentages of patients experiencing grade 3+ peripheral neuropathy assessed by the treating clinician using the modified Balis scale. The Modified Balis scale of Pediatric Neuropathy allows clinicians to assign a score for sensory or motor neuropathy symptoms separately. Scores range from 1 to 4 with 1 being the least symptomatic state and 4 indicating a severe debility. The percentages of patients (with a score >/=3) will be compared between the 2 arms by two-sample Z test at 1-sided alpha level of 0.05." (NCT02166463)
Timeframe: From the enrollment of the patient to the time of analysis or the last follow-up; an average of 3.6 years.

InterventionPercentage of patients (Number)
Arm I (ABVE-PC)5.5
ARM II (Bv-AVEPC)6.7

[back to top]

Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death

Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle. Progression is defined as an ≥50% increase of in the product of the perpendicular diameters of any of the involved nodes or nodal masses or focal organ lesions in sites that were persistently PET positive; or recurrent PET positive lesions (Deauville 4, 5) in sites that had previously been PET negative regardless of change of size, as was the development of new PET avid measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Relapse is defined in patients who achieved a prior CR but subsequently has an increase of ≥50% of the PPD in prior nodal or extranodal sites in a recurrently PET positive lesion(s), or the development of new measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Second malignancy is defined based on report of a cancer that is not considered to be classic Hodgkin Lymphoma. (NCT02166463)
Timeframe: Up to 48 months after the last enrollment

Interventionpercentage of participants (Number)
Arm I (ABVE-PC)82.5
ARM II (Bv-AVEPC)92.1

[back to top]

Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review

The percentages of patients (with available PET scan) with no SRL and no PD will be compared between the two randomized arms to see if brentuximab vedotin in the chemotherapy backbone of doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) arm has a higher rate of early response compared to doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide (ABVE-PC) arm. Two-sample Z test of proportions at 1-sided alpha level of 0.05 will be used for these comparisons. (NCT02166463)
Timeframe: After 42 days of chemotherapy

InterventionPercentage of patients (Number)
Arm I (ABVE-PC)80.7
ARM II (Bv-AVEPC)81.2

[back to top]

Complete Response Rate

The number of patients achieving complete response during treatment on study (NCT02257242)
Timeframe: Up to 6 cycles of treatment (approximately 6 months)

InterventionParticipants (Count of Participants)
Vincristine Sulfate Liposome Injection 1.8 mg/m^21
Vincristine Sulfate Liposome Injection 1.95 mg/m^20
Vincristine Sulfate Liposome Injection 1.98 mg/m^20
Vincristine Sulfate Liposome Injection 2.04 mg/m^21
Vincristine Sulfate Liposome Injection 2.10 mg/m^20
Vincristine Sulfate Liposome Injection 2.14 mg/m^21
Vincristine Sulfate Liposome Injection 2.19 mg/m^20
Vincristine Sulfate Liposome Injection 2.22 mg/m^21
Vincristine Sulfate Liposome Injection 2.24 mg/m^21

[back to top]

Maximum Tolerated Dose

Determined as the median of the marginal posterior distribution using data from all available patients (NCT02257242)
Timeframe: Up to 6 cycles of treatment (approximately 6 months)

Interventionmg/m^2 (Number)
Dose-escalation Cohort2.24

[back to top]

Number of Participants Who Completed Six Cycles of Study Treatment

(NCT02257242)
Timeframe: Up to 6 cycles of treatment (approximately 6 months)

InterventionParticipants (Count of Participants)
Vincristine Sulfate Liposome Injection: 1.8 mg/m^21
Vincristine Sulfate Liposome Injection: 1.95 mg/m^20
Vincristine Sulfate Liposome Injection: 1.98 mg/m^21
Vincristine Sulfate Liposome Injection: 2.04 mg/m^21
Vincristine Sulfate Liposome Injection: 2.10 mg/m^21
Vincristine Sulfate Liposome Injection: 2.14 mg/m^21
Vincristine Sulfate Liposome Injection: 2.19 mg/m^21
Vincristine Sulfate Liposome Injection: 2.22 mg/m^21
Vincristine Sulfate Liposome Injection: 2.24 mg/m^21

[back to top]

Kaplan-Meier (K-M) Estimate of Event Free Survival (EFS)

EFS was defined as the time (months) from randomization until occurrence of one of the following events, whichever occurred first: • Disease progression • Initiation of subsequent systemic anti-lymphoma therapy • Death due to any cause The assessment of EFS was conducted by the IRAC using the International Working Group (IWG) criteria for NHL. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as an EFS event (initiation of subsequent systemic anti-lymphoma therapy) if the decision to treat and the location to be treated was determined prior to randomization. Participants who did not experience any of the events defined in the categories above before the clinical data cutoff date were censored at date last known alive. (NCT02285062)
Timeframe: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up was 24.5 months

InterventionMonths (Median)
Lenalidomide Plus R-CHOP (R2-CHOP)NA
Placebo Plus R-CHOPNA

[back to top]

Kaplan-Meier Estimate of Progression Free Survival (PFS)

Progression free survival was defined as the time (months) from the date of randomization to the date of disease progression or death (any cause), whichever occurred earlier and was assessed by the Independent Response Adjudication Committee (IRAC). Relapse from complete response (CR) was considered as disease progression throughout the study. Disease progression was determined based on the Revised Response Criteria for Malignant Lymphoma. The PFS analysis was based on the censoring rules using the Food and Drug Administration (FDA) Guidance. Participants who did not experience disease progression and who did not die before the clinical data cutoff date were censored at the date of last adequate response assessment. (NCT02285062)
Timeframe: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months

Interventionmonths (Median)
Lenalidomide Plus R-CHOP (R2-CHOP)NA
Placebo Plus R-CHOPNA

[back to top]

Percentage of Participants Who Achieved a Complete Response (CR)

The percentage of participants who achieved a CR after initiation of the study treatment and prior to initiation of subsequent systemic antilymphoma therapy as assessed by the IRAC. A CR = complete metabolic response; target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow per International Working Group (IWG) 2014 for Non-Hodgkin's Lymphoma (NHL). Participants who did not have any adequate response assessments during this period were not considered as responders. (NCT02285062)
Timeframe: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months

InterventionPercentage of Participants (Number)
Lenalidomide Plus R-CHOP (R2-CHOP)69.1
Placebo Plus R-CHOP64.9

[back to top]

Percentage of Participants Who Achieved an Objective Response

An objective response = percentage of participants who achieved a complete response or partial response after initiation of the treatment and prior to initiation of subsequent systemic anti-lymphoma therapy. A CR = complete metabolic response; Target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter; no new lesions. Participants who did not have any adequate response assessments during this period were not considered as responders. (NCT02285062)
Timeframe: From randomization date up to the data cut off date of 15 March 2019; median total treatment duration was 18.10 weeks for both treatment arms; range = 1.6 to 29.0 weeks for R2-CHOP arm and 0.3 to 22.9 weeks for placebo-R-CHOP arm

InterventionPercentage of Participants (Number)
Lenalidomide Plus R-CHOP (R2-CHOP)90.9
Placebo Plus R-CHOP90.9

[back to top]

Mean Change From Baseline in the EQ-5D-3L Visual Analogue Scale (VAS)

"The EQ-5D-3L questionnaire includes a visual analogue scale which records the respondent's self-rated health on a vertical, 0-100 scale where 100 = Best imaginable health state and 0 = Worst imaginable health state. Higher scores again indicate better HRQoL and positive change scores indicate that post screening values were higher than those observed at screening. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to no problems, some problems and extreme problems." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

,
InterventionUnits on a Scale (Mean)
MidcycleC6 D1EoT = 3-4 weeks after C6Follow-Up Period: Week 34
Lenalidomide Plus R-CHOP (R2-CHOP)4.06.08.012.0
Placebo Plus R-CHOP3.09.06.09

[back to top]

Mean Change From Baseline in the Euroqol 5-Dimension 3-Level (EQ-5D-3L) Index Score

"The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to no problems, some problems and extreme problems. The instrument is scored as a single summary index using one of the available EQ-5D-3L value sets; in this study the UK scoring weights 9 were used. The UK index ranges from -0.594 to 1, where 0 equates to death and 1 equates to full health (-0.594 is considered 'worse than death')." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

,
InterventionUnits on a Scale (Mean)
MidcycleC6 D1EoT = 3-4 weeks after C6Follow-Up Period: Week 34
Lenalidomide Plus R-CHOP (R2-CHOP)0.080.100.100.15
Placebo Plus R-CHOP0.080.140.060.09

[back to top]

Mean Change From Baseline in the FACT-Lym Additional Concerns Subscale

"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms such as pain, itching, night sweats,trouble sleeping, fatigue and trouble concentrating and concerns regarding lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The Additional Concerns subscale ranges from 0 to 60, where higher scores reflect better HRQoL." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

,
InterventionUnits on a Scale (Mean)
MidcycleC6 D1EoT = 3-4 weeks after C6Follow-Up Period: Week 34
Lenalidomide Plus R-CHOP (R2-CHOP)3.85.86.68.3
Placebo Plus R-CHOP4.15.24.56.5

[back to top]

Mean Change From Baseline in the FACT-Lym Physical Well-Being Subscale

"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The physical well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

,
InterventionUnits on a Scale (Mean)
MidcycleC6 D1EoT = 3-4 weeks after C6Follow-Up Period: Week 34
Lenalidomide Plus R-CHOP (R2-CHOP)-0.7-0.01.52.8
Placebo Plus R-CHOP0.20.90.72.6

[back to top]

Mean Change From Baseline in the FACT-Lym Trial Outcome Index (TOI)

"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The FACT-Lym TOI is calculated by summing the Physical Well-being, Functional Well-being and Additional Concerns scores and has a range of 0 to 116. Higher scores reflect better HRQoL or fewer symptoms." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

,
InterventionUnits on a Scale (Mean)
MidcycleC6 D1EoT = 3-4 weeks after C6Follow-Up Period: Week 34
Lenalidomide Plus R-CHOP (R2-CHOP)2.65.99.113.5
Placebo Plus R-CHOP4.67.55.812.2

[back to top] [back to top]

Percentage of Participants Who Completed the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire

The completion rate for FACT-Lym assessments was judged by looking at the number of completed FACT-Lym assessments at each time point. The FACT-Lym was considered completed if at least 1 calculable score was present. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The FACT-Lym is a health related quality of life (HRQoL) questionnaire targeted to the management of chronic illness, predominantly within oncology and is considered an extension of the FACT-General questionnaire. (NCT02285062)
Timeframe: Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

,
InterventionPercentage of Participants (Number)
ScreeningMidcycle = After Cycle 3, but before Cycle 4End of Treatment (EoT) = 3-4 weeks after C6Follow-Up Period: Week 34
Lenalidomide Plus R-CHOP (R2-CHOP)98.687.076.167.7
Placebo Plus R-CHOP98.286.379.669.5

[back to top] [back to top]

Mean Change From Baseline in the FACT-Lym Functional Well-Being Subscale

"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The functional well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34

,
InterventionUnits on a Scale (Mean)
MidcycleC6 D1EoT = 3-4 weeks after C6Follow-Up Period: Week 34
Lenalidomide Plus R-CHOP (R2-CHOP)-0.50.01.02.3
Placebo Plus R-CHOP0.51.40.73.1

[back to top]

K-M Estimate of Overall Survival (OS)

Overall survival was assessed by the Independent Response Adjudication Committee (IRAC) and defined as time from randomization until death due to any cause. Participants who withdrew consent were censored at the time of withdrawal. Participants who were still alive before the clinical data cutoff date and participants who were lost to follow-up were censored at date last known alive. (NCT02285062)
Timeframe: From randomization until death due to any cause (up to approximately 86 months)

InterventionMonths (Median)
Lenalidomide Plus R-CHOP (R2-CHOP)NA
Placebo Plus R-CHOPNA

[back to top]

K-M Estimate of Duration of Complete Response

Duration of complete response was calculated for complete responders only and was defined as the time from documented initial complete response prior to initiation of subsequent systemic antilymphoma therapy until documented disease progression or death, whichever occurred earlier. Participants who had not progressed or died at the time of the analysis were censored at the date of last response assessment demonstrating no disease progression. Participants who changed treatment without evidence of disease progression were censored at the last assessment showing no progression prior to treatment change. (NCT02285062)
Timeframe: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months.

InterventionMonths (Median)
Lenalidomide Plus R-CHOP (R2-CHOP)NA
Placebo Plus R-CHOPNA

[back to top]

Overall Survival

Time from study enrollment to death or last patient contact. (NCT02306161)
Timeframe: 5 years after enrollment

InterventionPercent Probability (Number)
Regimen A (VDC/IE)44.93
Regimen B (VDC/IE + Ganitumab)48.19

[back to top]

Frequency of Toxicity-events

The number of induction or consolidation reporting periods in which a CTC version 4 codeable grade 4 or greater non-hematological adverse event, grade 3 or greater left ventricular systolic dysfunction or the reporting period is terminated because of a CTC codeable event. (NCT02306161)
Timeframe: Up to 202 days

InterventionReporting Periods (Number)
Regimen A (VDC/IE)10
Regimen B (VDC/IE + Ganitumab)27

[back to top]

Event-free Survival

Estimated 5-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact. (NCT02306161)
Timeframe: 5 years after enrollment

Interventionpercent probability of participants (Number)
Regimen A (VDC/IE)30.88
Regimen B (VDC/IE + Ganitumab)30.4

[back to top]

Event Free Survival Rate

measure the event free survival rate for the patients at 18 months: patients that without tumor relapse or metastasis (NCT02319486)
Timeframe: 18 months

Interventionparticipants (Number)
CEV With/Without Carboplatin- Stage 27
CEV With/Without Carboplatin - Stage 34

[back to top]

Number of Participants Able to Complete Two or More Courses of Therapy Regardless of Dose Modifications

(NCT02337478)
Timeframe: Up to 56 days

InterventionParticipants (Count of Participants)
Treatment (Vincristine Sulfate Liposome)0

[back to top]

Overall Survival

Kaplan-Meier estimation will be used to analyze overall survival. (NCT02337478)
Timeframe: Up to 6 months after completion of therapy

Interventionmonths (Mean)
Treatment (Vincristine Sulfate Liposome)1.5

[back to top]

Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)

"The occurrence of any of the following toxicities during Lead-in/Cycle 1 (Day -7 through Day 28) was considered a DLT if judged by the investigator to be possibly, probably, or definitely related to the administration of any drug in the treatment regimen (ENTO, VCR, DEX, institutional standard CNS prophylaxis):~Grade 4 (or higher) non-hematologic toxicity~Grade 3 non-hematologic toxicity lasting ≥ 7 days despite optimal supportive care~Any Grade 3 non-hematologic laboratory value if:~Medical intervention was required to treat, or~The abnormality led to hospitalization, or~The abnormality persisted for > 1 week~Grade 4 Neutropenia (absolute neutrophil count [ANC] < 500 /μL) persistent for greater than 14 days or associated with febrile neutropenia~Grade 4 thrombocytopenia (platelets < 25,000/μL) persisting for greater than 14 days (or greater than 25,000 /μL, but requiring prophylactic platelet transfusion to maintain this level)" (NCT02404220)
Timeframe: ENTO Lead-in and Cycle 1 (Day -7 through Day 28)

Interventionpercentage of participants (Number)
ENTO 200 mg + VCR 0.5 mg33.3
ENTO 400 mg + VCR 0.5 mg0
ENTO 400 mg + VCR 1.0 mg16.7
ENTO 400 mg + VCR 2.0 mg0

[back to top]

Percentage of Participants With Complete Remission (CR) at the End of Induction

"Assessment of clinical response was made according to National Comprehensive Cancer Network (NCCN) guidelines on acute lymphoblastic leukemia (ALL) Version 2, 2016. CR required all of the following:~No circulating blasts or extramedullary disease (no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement).~Trilineage hematopoiesis (TLH) and < 5% blasts in bone marrow aspirate.~ANC > 1000/μL.~Platelets > 100,000/μL." (NCT02404220)
Timeframe: End of Induction (Cycle 2, Day 28)

Interventionpercentage of participants (Number)
ENTO 200 mg + VCR 0.5 mg20.0
ENTO 400 mg + VCR 0.5 mg33.3
ENTO 400 mg + VCR 1.0 mg14.3
ENTO 400 mg + VCR 2.0 mg0

[back to top]

Percentage of Participants With Overall Response at the End of Induction

"Overall response included CR, CRi, and PR. CR required all of the following:~No circulating blasts or extramedullary disease (no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement).~TLH and < 5% blasts in bone marrow aspirate.~ANC > 1000/μL.~Platelets > 100,000/μL.~CRi required all criteria for CR except platelet count and/or ANC:~Platelets ≤ 100,000/μL and/or ANC is ≤ 1000/μL~PR required all criteria for CR except for bone marrow blasts:~bone marrow may contain ≥ 5% but less than 25% blast morphology" (NCT02404220)
Timeframe: End of Induction (Cycle 2, Day 28)

Interventionpercentage of participants (Number)
ENTO 200 mg + VCR 0.5 mg20.0
ENTO 400 mg + VCR 0.5 mg33.3
ENTO 400 mg + VCR 1.0 mg28.6
ENTO 400 mg + VCR 2.0 mg10.0

[back to top]

Percentage of Participants With Overall Remission at the End of Induction

"Assessment of clinical response was made according to NCCN guidelines on ALL Version 2, 2016. Overall remission included CR and complete remission with incomplete hematologic recovery (CRi). CR required all of the following:~No circulating blasts or extramedullary disease (no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement).~TLH and < 5% blasts in bone marrow aspirate.~ANC > 1000/μL.~Platelets > 100,000/μL.~CRi required all criteria for CR except platelet count and/or ANC:~Platelets ≤ 100,000/μL and/or ANC is ≤ 1000/μL" (NCT02404220)
Timeframe: End of Induction (Cycle 2, Day 28)

Interventionpercentage of participants (Number)
ENTO 200 mg + VCR 0.5 mg20.0
ENTO 400 mg + VCR 0.5 mg33.3
ENTO 400 mg + VCR 1.0 mg14.3
ENTO 400 mg + VCR 2.0 mg0.0

[back to top]

Percentage of Participants With Partial Response (PR) at the End of Induction

"PR required all of the following:~No circulating blasts or extramedullary disease (no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement).~TLH and bone marrow may contain ≥ 5% but less than 25% blast morphology.~ANC > 1000/μL.~Platelets > 100,000/μL." (NCT02404220)
Timeframe: End of Induction (Cycle 2, Day 28)

Interventionpercentage of participants (Number)
ENTO 200 mg + VCR 0.5 mg0.0
ENTO 400 mg + VCR 0.5 mg0.0
ENTO 400 mg + VCR 1.0 mg14.3
ENTO 400 mg + VCR 2.0 mg10.0

[back to top]

Event Free Survival (EFS)

Event free survival defined as the time from treatment to relapse of leukemia or death for any reason or lost to follow-up. Study regimen considered successful if it exhibits a 3-year EFS rate greater than 65% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%. (NCT02419469)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Ofatumumab Plus ChemotherapyNA

[back to top]

Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)

The method of Thall, Simon and Estey will be used for toxicity monitoring for this study. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 whenever possible. Safety data will be summarized by category, severity and frequency. (NCT02420717)
Timeframe: 42 days

InterventionMilligrams (mg) (Number)
Phase I Ruxolitinib 15mg25

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg4.8
Phase I Ruxolitinib 20mg5.4
Phase I Ruxolitinib 25mg38.5

[back to top]

Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)

Complete Response (CR) is disappearance of all clinical and/or radiologic evidence of disease, Neutrophil count ≥ 1.0 x 10^9/L, Platelet count ≥ 100 x 10^9/L, Normal bone marrow differential (≤ 5% blasts), No extra-medullary leukemia. Complete Remission with Incomplete Blood Count Recovery (CRi) is CR except for ANC < 1.0 x 10^9/L and/or platelets < 100 x 10^9/L. (NCT02420717)
Timeframe: 42 days

InterventionParticipants (Count of Participants)
Phase I Ruxolitinib 15mg0
Phase I Ruxolitinib 20mg1
Phase I Ruxolitinib 25mg0

[back to top]

Progression-free Survival

Time from date of treatment start until the date of first objective documentation of disease-relapse. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg2.3
Phase I Ruxolitinib 20mg1.8
Phase I Ruxolitinib 25mg1.9

[back to top]

12-month PFS (Progression Free Survival) of Treatment With Ixazomib in Combination With DA-EPOCH-R (Phase II)

12-month PFS will be defined as the percentage of patients alive and progression free 12 months from start of therapy. Patients lost to follow up will be censored from last point of contact. PFS was calculated using a Kplan-meier estimation with the probability of patients being progression free at 12 months, presented as the percentage based on this probability. (NCT02481310)
Timeframe: Up to 12 months from initiation of treatment

Interventionprobability (%) of patients alive (Number)
Treatment (Combination Chemotherapy, Rituximab, Ixazomib)75.84

[back to top] [back to top]

Percentage of Participants Who Were Alive

Percentage of participants with survival was calculated 41 months after the first dose of study treatment. (NCT02486952)
Timeframe: Up to 41 months

Interventionpercentage of participants (Number)
Diffuse Large B-Cell Lymphoma74.4

[back to top]

Probability of Event Free Survival (EFS)

EFS was calculated as the time from randomization to the date of first reported event. Events were defined as disease progression or relapse, institution of a new anticancer treatment, or death from any cause without progression. (NCT02486952)
Timeframe: Up to 41 months

Interventionprobability of EFS (Number)
Diffuse Large B-Cell Lymphoma0.695

[back to top]

2-year Overall Survival Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.

(NCT02535806)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Treatment Arm1

[back to top]

Number of Subject With Adverse Events

Toxicities were assessed and graded according to CTCAE v 4.0. (NCT02535806)
Timeframe: 36 days

InterventionParticipants (Count of Participants)
Treatment Arm1

[back to top]

Remission Rate Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.

Number of patients with bone marrow blast percentage <5% after treatment (NCT02535806)
Timeframe: 36 days

InterventionParticipants (Count of Participants)
Treatment Arm2

[back to top]

Post-induction Level of Minimal Residual Disease Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.

Percent of Cells Positive for Minimal residual disease measured by multiparameter flow cytometry (NCT02535806)
Timeframe: 36 days

InterventionPercentage of Cells Positive for MRD (Mean)
Treatment Arm0.65

[back to top]

Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

The Primary Outcome measures toxicity, with particular attention to Events of Clinical Interest when adding MK-3475 to standard RCHOP therapy. The sample size of 30 patients will permit the estimation of a 40% incidence of grade 3-5 clinically relevant toxicity. (NCT02541565)
Timeframe: Up to 90 days after completion of study treatment

InterventionParticipants (Count of Participants)
Treatment (Pembrolizumab, Combination Chemotherapy)13

[back to top] [back to top]

Complete Response Rate (Phase II)

A success is defined to be an objective status of CR after completion of 6 cycles of treatment. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. A 95% confidence interval for the true overall CR rate will be calculated according to the method of Duffy and Santner. (NCT02561273)
Timeframe: Up to the completion of course 6 (18 weeks)

Interventionpercentage of participants (Number)
Treatment (Combination Chemotherapy, Lenalidomide)49

[back to top]

Number of Participants With Adverse Events Graded According to CTC (Phase II)

"The toxicity profile will be further assessed based on phase II patients. Overall toxicity incidence of maximum tolerated dose level of the Intent to treat (ITT) group of subjects is summarized.~39 subjects were dosed with 10 mg dose of Lenalidamide as the ITT group." (NCT02561273)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
grade 3,4 neutropeniagrade 3, 4 leukopeniagrade 3, 4 anemiagrade 3, 4 thrombocytopeniagrade 3, 4 lymphopeniagrade 3, 4 febrile neutropeniagrade 3, 4 diarrheagrade 3, 4 Peripheral sensory neuropathygrade 3, 4 fatiguegrade 3, 4 nauseagrade 3, 4 anorexiagrade 3, 4 vomitinggrade 3, 4 mucositis oralgrade 3, 4 Rash maculo-papulargrade 3, 4 hypotensiongrade 3, 4 back pain
Treatment (Combination Chemotherapy, Lenalidomide)2725171718153211111111

[back to top]

Progression-free Survival

The distribution of PFS will be estimated using the method of Kaplan-Meier. The PFS rate at 2 years will be estimated. A 2-year PFS rate of 60% will be considered of interest. (NCT02561273)
Timeframe: Time from registration to progression or death due to any cause, assessed up to 2 years

Interventionpercentage of participants (Number)
Treatment (Combination Chemotherapy, Lenalidomide)55

[back to top]

Overall Survival

The distribution of overall survival will be estimated using the method of Kaplan-Meier. (NCT02561273)
Timeframe: Time from registration to death due to any cause, assessed up to 1 year

Interventionpercentage of participants (Number)
Treatment (Combination Chemotherapy, Lenalidomide)89

[back to top]

Overall Response Rate

The ORR will be estimated by the total number of patients who achieve a PR or CR at the end of six cycles of treatment divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true ORR will be calculated. (NCT02561273)
Timeframe: Up to the completion of course 6 (18 weeks)

Interventionpercentage of participants (Number)
Treatment (Combination Chemotherapy, Lenalidomide)69

[back to top]

Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP

MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I) within the first cycle of study treatment. (NCT02561273)
Timeframe: 21 days

Interventionmilligrams (Number)
Treatment (Combination Chemotherapy, Lenalidomide)10

[back to top]

Number of Participants With Adverse Events Graded According to Common Toxicity Criteria (CTC) (Phase I)

Non-hematologic toxicities will be evaluated via the ordinal CTC standard toxicity grading. Hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTC standard toxicity grading. Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. (NCT02561273)
Timeframe: Up to 6 cycles of treatment (approximately 5 months)

,
InterventionParticipants (Count of Participants)
grade 3,4 neutropeniagrade 3, 4 anemiagrade 3, 4 thrombocytopeniagrade 3,4 neutropenia fevergrade 3, 4 diarrheagrade 3, 4 hyperglycemiagrade 3, 4 hypokalemiagrade 3, 4 hypotensiongrade 3, 4 hyperbilirubinemiagrade 3, 4 mucositisgrade 3,4 nauseagrade 3,4 vomiting
10 mg Lenalidomide Participants532400000000
15 mg Lenalidomide Participants433022111221

[back to top]

Overall Survival (OS)

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin8.6
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine7.6

[back to top]

Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline

"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin33.0
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine30.7

[back to top]

Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days

"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin37.0
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine35.1

[back to top]

Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days

"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin20.2
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine18.8

[back to top]

Overall Response Rate in Patients With Central Nervous System Involvement at Baseline

"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin23.9
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine24.5

[back to top]

Duration of Response in Patients Without Central Nervous System Involvement at Baseline

"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin5.7
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine4.0

[back to top]

Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin10.3
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine8.7

[back to top]

Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days

"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin6.9
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine4.0

[back to top]

Duration of Response in Patients With Chemotherapy-free Interval <90 Days

"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin3.0
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine2.8

[back to top]

Duration of Response in Patients With Central Nervous System Involvement at Baseline

"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin1.5
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine2.7

[back to top]

Duration of Response by Independent Review Committee

"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin5.7
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine3.8

[back to top]

Overall Response Rate by Independent Review Committee

"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.~CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown" (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin31.6
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine29.7

[back to top]

Progression-free Survival Rate at 6 Months by Independent Review Committee

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy. (NCT02566993)
Timeframe: At 6 months

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin31.3
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine24.4

[back to top]

Progression-free Survival Rate at 12 Months by Independent Review Committee

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy. (NCT02566993)
Timeframe: at 12 months

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin10.8
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine4.4

[back to top]

Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: At 12 months

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin29.6
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine24.4

[back to top]

Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: At 24 months

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin8.6
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine8.7

[back to top]

Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: At 18 months

Interventionpercentage of participants (Number)
Lurbinectedin/Doxorubicin13.9
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine15.9

[back to top]

Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy. (NCT02566993)
Timeframe: Every six weeks up to progression disease, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin4.2
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine4.1

[back to top]

Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy. (NCT02566993)
Timeframe: Every six weeks up to progression disease, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin4.8
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine4.4

[back to top]

Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy. (NCT02566993)
Timeframe: Every six weeks up to progression disease, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin1.6
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine2.8

[back to top]

Progression-free Survival in Patients With Central Nervous System Involvement at Baseline

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy. (NCT02566993)
Timeframe: Every six weeks up to progression disease, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin1.9
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine2.8

[back to top]

Progression-free Survival (PFS) by Independent Review Committee

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy. (NCT02566993)
Timeframe: Every six weeks up to progression disease, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin4.0
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine4.0

[back to top]

Overall Survival in Patients Without Central Nervous System Involvement at Baseline

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin9.1
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine7.7

[back to top]

Overall Survival in Patients With Chemotherapy-free Interval < 90 Days

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin5.7
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine5.3

[back to top]

Overall Survival in Patients With Central Nervous System Involvement at Baseline

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date). (NCT02566993)
Timeframe: Every three months up to death or study termination, a period of approximately 3.5 years

Interventionmonths (Median)
Lurbinectedin/Doxorubicin4.6
Topotecan or Cyclophosphamide/Doxorubicin/Vincristine6.6

[back to top]

Number of Participants With AEs and Lab Abnormalities Not Defined as DLTs in Participants With Relapsed or Refractory B-cell NHL: Dose Escalation Stage

The number of participants with AEs and lab abnormalities not defined as DLTs in participants in the dose escalation stage with relapsed or refractory B-cell NHL are presented. (NCT02568683)
Timeframe: Cycle 1 (28-day cycle)

,
InterventionParticipants (Count of Participants)
AEs not defined as DLTsLab abnormalities not defined as DLTs
ENTO 200 mg65
ENTO 400 mg44

[back to top]

Number of VCR Doses

(NCT02568683)
Timeframe: Baseline to end of study (maximum: 24 weeks)

Interventiondoses (Mean)
ENTO 200 mg8.7
ENTO 400 mg2.3

[back to top]

Duration of Exposure to ENTO

(NCT02568683)
Timeframe: Baseline to end of study (maximum: 24 weeks)

Interventionweeks (Mean)
ENTO 200 mg17.7
ENTO 400 mg4.3

[back to top]

Number of Participants With Adverse Events (AEs) and Laboratory (Lab) Abnormalities Defined as Dose Limiting Toxicities (DLTs) in Participants With Relapsed or Refractory B-cell NHL: Dose Escalation Stage

"Occurrence of any of the following toxicities during Cycle 1 was considered DLT if judged by the Investigator to be possibly, probably, or definitely related to the administration of any drug in the treatment regimen:~Grade 4 (or higher) non-hematologic toxicity~Grade 3 non-hematologic toxicity lasting ≥ 7 days despite optimal supportive care~Note: Grade 3 or higher neuropathy was considered DLT if occurring during Cycle 1 regardless of duration.~Any Grade 3 non-hematologic laboratory value if:~Medical intervention was required to treat the patient, or~Abnormality led to hospitalization, or~Abnormality persisted for > 1 week~Grade 4 Neutropenia (absolute neutrophil count [ANC] < 500 /μL) persisting for > 14 days or associated with febrile neutropenia~Grade 4 thrombocytopenia (platelets < 25,000 cells/μL) persisting for > 14 days (or > 25,000 cells/μL, but requiring prophylactic platelet transfusion to maintain this level)" (NCT02568683)
Timeframe: Cycle 1 (28-day cycle)

InterventionParticipants (Count of Participants)
ENTO 200 mg0
ENTO 400 mg2

[back to top]

Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab

"Atezo-G-CHOP: Induction: Predose on D1 of Cy2,3,5,6 (1 Cy: 21 days); Maintenance: Predose on D1 of Month 1,2,4,7,15,23; at 120 days and 1 year of last atezolizumab dose or at treatment discontinuation (up to 4 years); Atezo-R-CHOP: Predose on D1 of Cy 2,3,5,8,16,25 (1 Cy: 21 days); at 120 days and 1 year of last atezolizumab dose or at treatment discontinuation (up to 4 years). Predose time point was any time prior to dose for Cycles 2,3,5,6,8 during induction phase, for Cycles 16,25 during consolidation treatment, and for Months 1 to 24 during maintenance phase. Atezo-G-Benda: Induction: Predose on D1 of Cy2,3,5,6 (1Cy: 28 days), Cy3D15: Predose; ; Maintenance: Predose on D1 of Month 1,4,7,15,23; at 120 days and 1 year of last atezolizumab dose or at treatment discontinuation (up to 4 years). The percentage of participants with positive results for ATAs to atezolizumab at baseline and at post-baseline time points are reported." (NCT02596971)
Timeframe: Baseline up to approximately 4 years

Interventionpercentage of participants (Number)
BaselineInduction Cycle 2 Day 1Consolidation Cycle 16Atezolizumab Day 120 Follow upAtezo PK and Immunogenicity Follow Up (1YR)
Atezo-R-CHOP Cohort (Expansion Phase)14.32.65.99.15.6

[back to top]

Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab

Induction: Predose (any time prior to dose) on D1 of Cy1,5,8 (1Cy: 21 days); Maintenance: at 120 days and 1 year of last rituximab dose or at treatment discontinuation (up to 4 years) (NCT02596971)
Timeframe: Baseline up to approximately 4 years

Interventionpercentage of participants (Number)
BaselineInduction Cycle 1 Day 1Induction Cycle 5 Day 1Induction Cycle 8 Day 1Rituximab Day 120 Follow upRituximab 1 Year Follow upStudy Drug Completion or Early Discontinuation
Atezo-R-CHOP Cohort (Expansion Phase)14.3000000

[back to top]

Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab

Induction: Predose (any time prior to dose) on D1 of Cy1,5,6 (1Cy: 21/28 days); Maintenance: Predose (any time prior to dose) on D1 of Month 1; at 120 days and 1 year of last obinutuzumab dose or at treatment discontinuation (up to 4 years) (NCT02596971)
Timeframe: Baseline up to approximately 4 years

Interventionpercentage of participants (Number)
Induction Cycle 1 Day 1Induction Cycle 5 Day 1Induction Cycle 6 Day 1Maintenance Month 1Study Drug Completion or Early DiscontinuationObinutuzumab Day 120 Follow up
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)2.400000

[back to top]

Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02596971)
Timeframe: Baseline up to approximately 4 years

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)100
Atezo-G-CHOP Cohort (Safety Run-In Phase)100
Atezo-R-CHOP Cohort (Expansion Phase)100

[back to top]

Percentage of Participants With Best Response of CR or PR During Study, as Determined by Investigator Using Modified Cheson 2007 Criteria

CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. Only Atezo-G-Benda and Atezo-R-Chop cohorts were evaluated for efficacy. (NCT02596971)
Timeframe: Baseline up to approximately 4 years (assessed at Baseline, 6 to 8 weeks after Day [D] 1 of Cycle [Cy] 6 or 8 (1Cy: 21 or 28 days), then every 2 months up to 24 months, at 35 days of last dose, and at every 3 months post-treatment follow-up [up 4 years])

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)80.0
Atezo-R-CHOP Cohort (Expansion Phase)75.0

[back to top]

Percentage of Participants With Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria

Primary end point was positron emission tomography (PET) CR at EOI by IRC according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake less than or equal to [NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)75
Atezo-R-CHOP Cohort (Expansion Phase)77.5

[back to top]

Percentage of Participants With CR at EOI, as Determined by the Investigator Using Lugano 2014 Criteria

Tumor response assessment was performed by the investigator according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)87.5
Atezo-R-CHOP Cohort (Expansion Phase)77.5

[back to top]

Percentage of Participants With CR at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria

Complete response according to modified Cheson 2007 criteria using PET/CT scan: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If bone marrow was involved by lymphoma prior to treatment, infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. All PET evaluable 1L FL and 1L DLBCL patients with at least one dose of atezolizumab were included in efficacy population. Only Atezo-G-Benda and Atezo-R-Chop cohorts were evaluated for efficacy. (NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)80.0
Atezo-R-CHOP Cohort (Expansion Phase)75.0

[back to top]

Percentage of Participants With CR at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria

Complete response according to the modified Cheson 2007 criteria using PET/CT scan: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. Partial Response (PR): at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. All PET evaluable 1L FL and 1L DLBCL patients with at least one dose of atezolizumab were included in efficacy population. (NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)75.0
Atezo-R-CHOP Cohort (Expansion Phase)77.5

[back to top]

Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria

Objective response: having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. All positron emission tomography (PET) evaluable 1L FL and 1L DLBCL patients with at least one dose of atezolizumab were included in efficacy population. (NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)95.0
Atezo-R-CHOP Cohort (Expansion Phase)87.5

[back to top]

Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Lugano 2014 Criteria

Tumor response assessment was performed by IRC according to modified Lugano classification using PET/CT scan. OR defined as a response of CR or PR. CR: a score of 1 (no uptake above background), 2 (uptake ] liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. All positron emission tomography (PET) evaluable 1L FL and 1L DLBCL patients with at least one dose of atezolizumab were included in efficacy population. (NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)90.0
Atezo-R-CHOP Cohort (Expansion Phase)87.5

[back to top]

Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria

Objective response: having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. All positron emission tomography (PET) evaluable 1L FL and 1L DLBCL patients with at least one dose of atezolizumab were included in efficacy population. (NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)90.0
Atezo-R-CHOP Cohort (Expansion Phase)90.0

[back to top]

Observed Serum Atezolizumab Concentration

"Atezo-G-Benda: Induction:Predose on D1 of Cy5,6 & D1,15 of Cy2,3 (1Cy:21/28 days), Cy2D1:0.5h postinfusion; Maintenance:Predose on D1 of Month 1,2,4,7,15,23, Month 2 D1: 0.5h postinfusion; 120 days & 1 year of last dose or at treatment discontinuation (up to 4 years); Atezo-G-CHOP: Induction:Predose on D1 of Cy2,3,5,6 (1Cy:21 days), Cy2D1:0.5h postinfusion; Maintenance:Predose on D1 of Month 1,2,3,4,7,15,23, Month 2 D1: 0.5h postinfusion; 120 days & 1 year of last dose or at treatment discontinuation (up to 4 years). Predose time point was within 5 hour prior to dose for Cy2,3,5,6 during induction phase and for Months 1 to 24 during maintenance phase. infusion length: 30-60 minutes." (NCT02596971)
Timeframe: Atezo-R-CHOP: Predose on D1 of Cy2,3,5,8,9,10,11,12,16,20,25 (1Cy:21 days), 0.5h postinfusion of D1 of Cy2,9; at 120 days & 1 year of last dose or at treatment discontinuation (up to 4 years)

,
Interventionug/mL (Median)
Cycle 2 - Cmax after 1st infusionC2 - Cmin before 2nd infusionC6 - Cmin after 6th infusion
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)27583256
Atezo-G-CHOP Cohort (Safety Run-In Phase)42494195

[back to top]

Observed Serum Atezolizumab Concentration

"Atezo-G-Benda: Induction:Predose on D1 of Cy5,6 & D1,15 of Cy2,3 (1Cy:21/28 days), Cy2D1:0.5h postinfusion; Maintenance:Predose on D1 of Month 1,2,4,7,15,23, Month 2 D1: 0.5h postinfusion; 120 days & 1 year of last dose or at treatment discontinuation (up to 4 years); Atezo-G-CHOP: Induction:Predose on D1 of Cy2,3,5,6 (1Cy:21 days), Cy2D1:0.5h postinfusion; Maintenance:Predose on D1 of Month 1,2,3,4,7,15,23, Month 2 D1: 0.5h postinfusion; 120 days & 1 year of last dose or at treatment discontinuation (up to 4 years). Predose time point was within 5 hour prior to dose for Cy2,3,5,6 during induction phase and for Months 1 to 24 during maintenance phase. infusion length: 30-60 minutes." (NCT02596971)
Timeframe: Atezo-R-CHOP: Predose on D1 of Cy2,3,5,8,9,10,11,12,16,20,25 (1Cy:21 days), 0.5h postinfusion of D1 of Cy2,9; at 120 days & 1 year of last dose or at treatment discontinuation (up to 4 years)

Interventionug/mL (Median)
Cycle 2 - Cmax after 1st infusionC2 - Cmin before 2nd infusionC8 - Cmax after 7th infusionC8 - Cmin before 8th infusion
Atezo-R-CHOP Cohort (Expansion Phase)33282.1486.5184

[back to top]

Observed Serum Obinutuzumab Concentration

"Predose time point was any time prior to dose for Cycle (Cy) 1 and within 5 hour prior to dose for other cycles (Cy 2,5,6) and for Months 1 to 24 during maintenance phase. Infusion duration for administration of first infusion should begin at an initial rate of 50 milligrams per hour (mg/hour). If no reaction occurs, increase the infusion rate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour." (NCT02596971)
Timeframe: Induction: Predose, 0.5 hour (h) postinfusion on Day (D) 1 of Cy1,2,5,6 (1Cy: 21/28 days); Maintenance: Predose, 0.5h postinfusion on Day 1 of Month 1,3,7,15,23; 120 days & 1 year of last dose or at treatment discontinuation (up to 4 years)

,
Interventionug/mL (Median)
C1 Cmax after 1st infusionC1 Cmin after the last infusion on C1C6 - Cmax after last dosing of inductionC6 - Cmin after last dosing of induction
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)329322544203
Atezo-G-CHOP Cohort (Safety Run-In Phase)400399659245

[back to top]

Observed Serum Rituximab Concentration

"Predose time point was any time prior to dose for Cycle 1 and within 5 hour prior to dose for other cycles (Cycles 2,5,8) during induction phase and for Months 1 to 24 during maintenance phase. Infusion duration for administration of first infusion should begin at an initial rate of 50 mg/hour. If no infusion-related or hypersensitivity reaction occurs, increase the infusion rate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour. If no reaction occurs, increase the infusion rate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour." (NCT02596971)
Timeframe: Predose, 0.5h postinfusion on D1 of Cy1,2,5,8 (1Cy: 21 days); at 120 days and 1 year after last rituximab dose or at treatment discontinuation (up to 4 years)

Interventionug/mL (Median)
C1 - Cmax after dosing C1C1 - Ctrough after dosing C1C8 - Cmax after dosing C8C8 - Ctrough after dosing C8
Atezo-R-CHOP Cohort (Expansion Phase)15926.1229105.5

[back to top]

Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab

"Atezo-G-CHOP: Induction: Predose on D1 of Cy2,3,5,6 (1 Cy: 21 days); Maintenance: Predose on D1 of Month 1,2,4,7,15,23; at 120 days and 1 year of last atezolizumab dose or at treatment discontinuation (up to 4 years); Atezo-R-CHOP: Predose on D1 of Cy 2,3,5,8,16,25 (1 Cy: 21 days); at 120 days and 1 year of last atezolizumab dose or at treatment discontinuation (up to 4 years). Predose time point was any time prior to dose for Cycles 2,3,5,6,8 during induction phase, for Cycles 16,25 during consolidation treatment, and for Months 1 to 24 during maintenance phase. Atezo-G-Benda: Induction: Predose on D1 of Cy2,3,5,6 (1Cy: 28 days), Cy3D15: Predose; ; Maintenance: Predose on D1 of Month 1,4,7,15,23; at 120 days and 1 year of last atezolizumab dose or at treatment discontinuation (up to 4 years). The percentage of participants with positive results for ATAs to atezolizumab at baseline and at post-baseline time points are reported." (NCT02596971)
Timeframe: Baseline up to approximately 4 years

,
Interventionpercentage of participants (Number)
BaselineInduction Cycle 2 Day 1Atezolizumab Day 120 Follow upAtezo PK and Immunogenicity Follow Up (1YR)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)2.4000
Atezo-G-CHOP Cohort (Safety Run-In Phase)0000

[back to top]

Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Lugano 2014 Criteria

Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT scan. OR: a response of CR or PR. CR: a score of 1 (no uptake above background), 2 (uptake ] liver) or 5 (uptake markedly >liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. All positron emission tomography (PET) evaluable 1L FL and 1L DLBCL patients with at least one dose of atezolizumab were included in efficacy population. (NCT02596971)
Timeframe: Up to approximately 6 months

Interventionpercentage of participants (Number)
Atezo-G-Benda Cohort (Safety Run-In and Expansion Phases)95.0
Atezo-R-CHOP Cohort (Expansion Phase)87.5

[back to top]

Cmax (Post 5th and 8th Infusion)

Maximum serum drug concentration (Cmax) at steady state after the 5th and 8th infusions. (NCT02617485)
Timeframe: Week 13 (5th infusion) and Week 22 (8th infusion)

,
Interventionμg/mL (Mean)
5th infusion8th infusion
MabionCD20273.356296.784
MabThera266.439296.462

[back to top]

CLss (Post 5th and 8th Infusions)

Clearance at steady state after the 5th and 8th infusions. (NCT02617485)
Timeframe: Week 13 to Week 16 and Week 22 to Week 26

,
InterventionmL/day (Mean)
5th infusion8th infusion
MabionCD20198.701179.168
MabThera206.905191.272

[back to top]

Adverse Events

Percentage of patients with at least one AE in a given category. Data from the entire follow-up are included (Period 1 and Period 2). (NCT02617485)
Timeframe: from baseline to Week 46

,
Interventionpercent (Number)
all AEsTEAEsTESAEssevere TEAEsrelated TEAEsrelated severe TEAEsrelated TESAEsTEAEs leading to deathrelated TEAEs leading to death
MabionCD2071.071.019.040.053.029.013.08.02.0
MabThera67.565.012.522.542.522.55.000

[back to top]

AUC (W1-W26) B-cell

Area under the serum concentration-time curve of CD19+ B cell counts, measured from the first administration to the final time point at Week 26 (AUC(1-26) B-cell). (NCT02617485)
Timeframe: baseline to Week 26

Interventioncells*days/mL blood (Mean)
MabionCD203395.82
MabThera10476.2

[back to top]

AUC (W1-W26)

Area under the serum concentration-time curve measured after the first administration (Week 1) until Week 26 (AUC(1-26)) (NCT02617485)
Timeframe: Week 1 until Week 26

Intervention(μg*day)/mL (Mean)
MabionCD2028413.6
MabThera26955.3

[back to top]

Area Under the Serum Concentration-time Curve From Week 13 to Week 26 (AUC[W13-W26])

Area under the serum concentration-time curve from time zero to final time point measured from Week 13 until Week 26 (AUC[W13-W26]). PK blood samples for this endpoint were drawn at Day 85 ± 4 (before and after completion of the fifth infusion), Day 106 ± 4 (before and after completion of sixth infusion), Day 127 ± 4 (before and after completion of the seventh infusion), Day 148 ± 4 (before and after completion of the eight infusion), Day 155 ± 4 (one week after last infusion) and Day 176 ± 4 (one month after last infusion). (NCT02617485)
Timeframe: Week 13 to Week 26

Intervention(μg*day)/mL (Mean)
MabionCD2016498.9
MabThera15647.4

[back to top]

Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4])

Area under the serum concentration-time curve from time zero (Day 1) to final time point measured after the first administration (Week 1) until Week 4 (AUC(W1-W4)). PK blood samples for this endpoint were drawn at Day 1 (before and after the first infusion), Day 8 ± 1 (7 days after first infusion), Day 15 ± 1 (14 days after first infusion), Day 22 ± 2 (before and after completion of the second infusion). (NCT02617485)
Timeframe: Baseline to Week 4

Intervention(μg*day)/mL (Mean)
MabionCD201559.51
MabThera1509.79

[back to top]

Ctrough (Before 8th Infusion)

Trough serum concentration measured at the end of a dosing interval at steady state, taken directly before eighth infusion. (NCT02617485)
Timeframe: Week 22

Interventionμg/mL (Mean)
MabionCD20102.246
MabThera90.61

[back to top]

T1/2 (Post 5th and 8th Infusions)

Elimination half-life at steady state after the 5th and 8th infusions. (NCT02617485)
Timeframe: Week 13 to Week 16 and Week 22 to Week 26

,
Interventiondays (Mean)
5th infusion8th infusion
MabionCD2014.80118.301
MabThera15.21716.997

[back to top]

Kel (Post 5th and 8th Infusions)

Elimination Rate Constant at steady stade after the 5th and 8th infusions. (NCT02617485)
Timeframe: Week 13 (5th infusion) and Week 22 (8th infusion)

,
Intervention1/day (Mean)
5th infusion8th infusion
MabionCD200.056630.04335
MabThera0.054180.04379

[back to top]

Immunogenicity

Percentage of patients with positive ADA or NAb results in a given category. Data pertain to the entire follow-up period (from Baseline to Week 46). (NCT02617485)
Timeframe: from baseline to Week 46

,
Interventionparticipants (Number)
Treatment-induced ADAPersistent ADATransient ADATreatment-boosted ADANAb positive
MabionCD2064200
MabThera11000

[back to top]

Efficacy Assessment at Week 26

An efficacy assessment was made after 8 treatment cycles (at Week 26) based on tumour responses classified according to the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (Cheson et al. 1999). Response was assessed based on clinical, radiologic (CT scan) and pathologic (bone marrow) criteria. Possible efficacy responses were: complete response, partial response, stable disease, and progressive disease. Efficacy reported here includes all patients included in the ITT set. (NCT02617485)
Timeframe: Week 26

,
InterventionParticipants (Count of Participants)
CompletePartialStable diseaseProgressive diseaseMissing
MabionCD20344210104
MabThera1418422

[back to top]

Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)

A dose limiting toxicity (DLT) was defined as an adverse event (AE) during the first 21 days that was possibly related to the study drug and fulfilled any of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0: CTCAE Grade 3 nonhematologic toxicity, grade 4 neutropenia that lasted longer than 2 weeks, grade ≥3 thrombocytopenia complicated by hemorrhage, and any hematologic toxicity that caused a cycle delay of >14 days. (NCT02677116)
Timeframe: Parts A and B: Cycle 1 through Cycle 2 in each arm (21-day cycle); Part C: Cycle 1 only (21-day cycle)

InterventionParticipants (Count of Participants)
Olaratumab + Vincristine + Irinotecan (Part A)0
Olaratumab + Ifosfamide (Part A)1
Olaratumab + Doxorubicin (Part A)0
Olaratumab + Vincristine + Irinotecan (Part B)1
Olaratumab + Ifosfamide (Part B)0
Olaratumab + Doxorubicin (Part B)1
Olaratumab + Vincristine + Irinotecan (Part C)1
Olaratumab + Ifosfamide (Part C)0
Olaratumab + Doxorubicin (Part C)0

[back to top]

PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part C

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25. (NCT02677116)
Timeframe: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

,,
Interventionμg/mL (Geometric Mean)
Cycle 1, Day 8Cycle 2, Day 8Cycle 3-25, Day 8
Olaratumab + Doxorubicin (Part C)90.3141156
Olaratumab + Ifosfamide (Part C)124NANA
Olaratumab + Vincristine + Irinotecan (Part C)83.713483.7

[back to top]

PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part B

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25. (NCT02677116)
Timeframe: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

,
Interventionμg/mL (Geometric Mean)
Cycle 1, Day 8Cycle 2, Day 8Cycle 3-25, Day 8
Olaratumab + Ifosfamide (Part B)125199289
Olaratumab +Vincristine + Irinotecan (Part B)99.1230348

[back to top]

PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25. (NCT02677116)
Timeframe: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

,
Interventionμg/mL (Geometric Mean)
Cycle 1, Day 8Cycle 2, Day 8Cycle 3-25, Day 8
Olaratumab + Ifosfamide (Part A)46.311488.2
Olaratumab + Vincristine + Irinotecan (Part A)97.837.795.1

[back to top]

PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25. (NCT02677116)
Timeframe: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

Interventionμg/mL (Geometric Mean)
Cycle 2, Day 8Cycle 3-25, Day 8
Olaratumab + Doxorubicin (Part A)38.594.4

[back to top]

PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A

PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25. (NCT02677116)
Timeframe: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose

Interventionμg/mL (Geometric Mean)
Cycle 1, Day 8
Olaratumab Alone (Part A)73

[back to top]

PK: Maximum Concentration (Cmax) of Olaratumab Part C

Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data. (NCT02677116)
Timeframe: Cycle 1, Days 1 and 8; Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

,
Interventionmicrogram/milliliter (μg/mL) (Geometric Mean)
Cycle 1, Day 1Cycle 1, Day 8Cycle 2, Day 8
Olaratumab + Ifosfamide (Part C)363498567
Olaratumab + Vincristine + Irinotecan (Part C)548695707

[back to top]

PK: Maximum Concentration (Cmax) of Olaratumab Part C

Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data. (NCT02677116)
Timeframe: Cycle 1, Days 1 and 8; Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

Interventionmicrogram/milliliter (μg/mL) (Geometric Mean)
Cycle 1, Day 1Cycle 1, Day 8
Olaratumab + Doxorubicin Cycle 1 (Part C)406493

[back to top]

PK: Maximum Concentration (Cmax) of Olaratumab Part C

Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data. (NCT02677116)
Timeframe: Cycle 1, Days 1 and 8; Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

Interventionmicrogram/milliliter (μg/mL) (Geometric Mean)
Cycle 2, Day 8
Olaratumab + Doxorubicin (Part C)502

[back to top]

PK: Maximum Concentration (Cmax) of Olaratumab Part B

PK: Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data. (NCT02677116)
Timeframe: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

,
Interventionmicrogram/milliliter (μg/mL) (Geometric Mean)
Cycle 2, Day 1Cycle 2, Day 8
Olaratumab +Vincristine + Irinotecan (Part B)585647
Olaratumab + Ifosfamide (Part B)629696

[back to top]

PK: Maximum Concentration (Cmax) of Olaratumab Part B

PK: Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data. (NCT02677116)
Timeframe: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

Interventionmicrogram/milliliter (μg/mL) (Geometric Mean)
Cycle 1, Day 8
Olaratumab Alone (Part B)639

[back to top]

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A

Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data. (NCT02677116)
Timeframe: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

,,
Interventionmicrogram/milliliter (μg/mL) (Geometric Mean)
Cycle 2, Day 1Cycle 2, Day 8
Olaratumab + Doxorubicin (Part A)406422
Olaratumab + Ifosfamide (Part A)396398
Olaratumab + Vincristine + Irinotecan (Part A)437523

[back to top]

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A

Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data. (NCT02677116)
Timeframe: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose

Interventionmicrogram/milliliter (μg/mL) (Geometric Mean)
Cycle 1, Day 8
Olaratumab Alone (Part A)439

[back to top]

Progression Free Survival (PFS)

Progression-free survival (PFS) is defined as the time from baseline to the first date of radiological disease progression or death due to any cause. Progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression. If participant started new treatment before PD, the participant was censored at the date of last tumor assessment prior to new therapy. If treatment was discontinued for reasons other than PD and no further assessment, censoring occurred at last tumor assessment. (NCT02677116)
Timeframe: Baseline to radiological disease progression or death from any cause (Up to 2 Years)

InterventionMonths (Median)
Olaratumab + Vincristine + Irinotecan (Part A)1.54
Olaratumab + Ifosfamide (Part A)1.38
Olaratumab + Doxorubicin (Part A)1.26
Olaratumab + Vincristine + Irinotecan (Part B)1.28
Olaratumab + Ifosfamide (Part B)1.25
Olaratumab + Doxorubicin (Part B)NA
Olaratumab + Vincristine + Irinotecan (Part C)4.07
Olaratumab + Ifosfamide (Part C)4.88
Olaratumab + Doxorubicin (Part C)5.52

[back to top]

Percentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies

Percentage of participants with a TE positive anti-olaratumab antibodies defined as a participant with a 4-fold (2 dilutions) increase over a positive baseline antibody titer. (NCT02677116)
Timeframe: From Baseline to Study Completion (Up to 33 Months)

Interventionpercentage of participants (Number)
Olaratumab + Vincristine + Irinotecan (Part A)0
Olaratumab + Ifosfamide (Part A)0
Olaratumab + Doxorubicin (Part A)0
Olaratumab + Vincristine + Irinotecan (Part B)0
Olaratumab + Ifosfamide (Part B)0
Olaratumab + Doxorubicin (Part B)0
Olaratumab + Vincristine + Irinotecan (Part C)0
Olaratumab + Ifosfamide (Part C)0
Olaratumab + Doxorubicin (Part C)0

[back to top]

Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

Objective Response Rate (ORR) is the percentage of participants achieving a confirmed best overall tumor response of CR or PR. According to RECIST v1.1, PR defined as a >30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; CR was defined as the disappearance of all target and non-target lesions. (NCT02677116)
Timeframe: Baseline to objective progression or start of new anti-cancer therapy (Up to 7 months)

Interventionpercentage of participants (Number)
Olaratumab + Vincristine + Irinotecan (Part A)0
Olaratumab + Ifosfamide (Part A)0
Olaratumab + Doxorubicin (Part A)9.1
Olaratumab + Vincristine + Irinotecan (Part B)20.0
Olaratumab + Ifosfamide (Part B)0
Olaratumab + Doxorubicin (Part B)0
Olaratumab + Vincristine + Irinotecan (Part C)0
Olaratumab + Ifosfamide (Part C)0
Olaratumab + Doxorubicin (Part C)25.0

[back to top]

LGG Cohort: Kaplan-Meier Estimates of Time to Response (TTR) as Per Investigator Assessment Using RANO Criteria

"Time from randomization to first documented response of CR or PR as per investigator assessment using RANO criteria. CIs were estimated using the Brookmeyer Crowley method. Patients without an event were censored either at the maximum follow-up time (if they experienced disease progression or death), or at their last tumor assessment date.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 4.2 years

InterventionMonths (Median)
LGG Cohort: Dabrafenib and Trametinib7.4
LGG Cohort: Carboplatin and VincristineNA

[back to top]

LGG Cohort: Kaplan-Meier Estimates of Time to Response (TTR) as Per Central Independent Assessment Using RANO Criteria

"Time from randomization to first documented response of CR or PR as per central independent assessment using RANO criteria. CIs were estimated using the Brookmeyer Crowley method. Patients without an event were censored either at the maximum follow-up time (if they experienced disease progression or death), or at their last tumor assessment date.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically (NCT02684058)
Timeframe: Up to approx. 4.2 years

InterventionMonths (Median)
LGG Cohort: Dabrafenib and Trametinib11.0
LGG Cohort: Carboplatin and VincristineNA

[back to top]

LGG Cohort: Kaplan-Meier Estimates of Overall Survival (OS)

Time from first dose to death due to any cause in the LGG cohort. Confidence Intervals were estimated using the Brookmeyer Crowley method. If a patient was not known to have died at the time of analysis cut-off, OS was censored at the date of last contact. (NCT02684058)
Timeframe: Up to 4.6 years

InterventionMonths (Median)
LGG Cohort: Dabrafenib and TrametinibNA
LGG Cohort: Carboplatin and VincristineNA

[back to top]

LGG Cohort: Clinical Benefit Rate (CBR) by Investigator Assessment Using RANO Criteria

"Percentage of participants with a best overall response of CR or PR, or stable disease (SD) which lasts for 24 weeks or longer.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.~SD: Partient did not qualify for CR, PR, or progressive disease and has stable nonenhancing (T2/FLAIR) lesions on same or lower doses of corticosteroids compared with baseline scan and clinically stable status." (NCT02684058)
Timeframe: Up to approx. 4.2 years

InterventionPercentage of participants (Number)
LGG Cohort: Dabrafenib and Trametinib91.8
LGG Cohort: Carboplatin and Vincristine56.8

[back to top]

LGG Cohort: Clinical Benefit Rate (CBR) by Central Independent Assessment Using RANO Criteria

"Percentage of participants with a best overall response of CR or PR, or stable disease (SD) which lasts for 24 weeks or longer.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.~SD: Partient did not qualify for CR, PR, or progressive disease and has stable nonenhancing (T2/FLAIR) lesions on same or lower doses of corticosteroids compared with baseline scan and clinically stable status." (NCT02684058)
Timeframe: Up to approx. 4.2 years

InterventionPercentage of participants (Number)
LGG Cohort: Dabrafenib and Trametinib86.3
LGG Cohort: Carboplatin and Vincristine43.2

[back to top]

LGG Cohort: 2-year OS Estimate

OS was defined as the time from the first dose to death due to any cause in the LGG cohort. The 2-year Kaplan-Meier OS estimate represented the estimated percentage of participants remaining free from OS events for up to 2 years. If a patient was not known to have died at the time of analysis cut-off, OS was censored at the date of last contact (NCT02684058)
Timeframe: 2 years from first dose

InterventionPercentage of participants (Number)
LGG Cohort: Dabrafenib and Trametinib100.0
LGG Cohort: Carboplatin and Vincristine96.9

[back to top]

HGG Cohort: Time to Response (TTR) as Per Investigator Assessment Using RANO Criteria

"Time from start of treatment to first documented response of CR or PR as per investigator assessment using RANO criteria. CIs were estimated using the Brookmeyer Crowley method. Patients without an event were censored either at the maximum follow-up time (if they experienced disease progression or death), or at their last tumor assessment date.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 4.8 years

InterventionMonths (Median)
HGG Cohort: Dabrafenib and Trametinib3.4

[back to top]

HGG Cohort: Time to Response (TTR) as Per Central Independent Assessment Using RANO Criteria

"Time from start of treatment to first documented response of CR or PR as per independent assessment using RANO criteria. CIs were estimated using the Brookmeyer Crowley method. Patients without an event were censored either at the maximum follow-up time (if they experienced disease progression or death), or at their last tumor assessment date.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 4.8 years

InterventionMonths (Median)
HGG Cohort: Dabrafenib and Trametinib8.5

[back to top]

HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: Immediate Reaction Once the Medication Was Placed Into the Mouth

Participants who received the trametinib oral solution completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on the immediate reaction once the medication was placed into their mouth, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456174Week 172456173Week 572456173Week 572456174
BadVery BadUnable to answer questionMissingVery good, good, and neither good nor bad
LGG Cohort: Dabrafenib and Trametinib15
HGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib4
HGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib2
HGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib11
HGG Cohort: Dabrafenib and Trametinib5
LGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib13

[back to top]

HGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria

"Percentage of participants in the HGG cohort with a best overall confirmed CR or PR as assessed per RANO criteria by central independent assessment. The 95% CIs were computed using two-sided exact binomial method.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 3.2 years

InterventionPercentage of participants (Number)
HGG Cohort: Dabrafenib and Trametinib56.1

[back to top]

HGG Cohort: Kaplan-Meier Estimates of Progression Free Survival (PFS) as Per Investigatort Assessment Using RANO Criteria

Time from the date of first dose of study treatment to the date of first documented disease progression as per investigator assessment using RANO criteria or death due to any cause. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation. (NCT02684058)
Timeframe: Up to approx. 4.8 years

InterventionMonths (Median)
HGG Cohort: Dabrafenib and Trametinib24.0

[back to top]

HGG Cohort: Kaplan-Meier Estimates of Progression Free Survival (PFS) as Per Central Independent Assessment Using RANO Criteria

Time from the date of first dose of study treatment to the date of first documented disease progression as per central independent review assessment using RANO criteria or death due to any cause. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation. (NCT02684058)
Timeframe: Up to approx. 4.8 years

InterventionMonths (Median)
HGG Cohort: Dabrafenib and Trametinib9.0

[back to top]

HGG Cohort: Kaplan-Meier Estimates of Overall Survival (OS)

Time from first dose to death due to any cause in the LGG cohort. Confidence Intervals were estimated using the Brookmeyer Crowley method. If a patient was not known to have died at the time of analysis cut-off, OS was censored at the date of last contact. (NCT02684058)
Timeframe: Up to 5.1 years

InterventionMonths (Median)
HGG Cohort: Dabrafenib and TrametinibNA

[back to top]

HGG Cohort: Clinical Benefit Rate (CBR) as Per Investigator Assessment Using RANO Criteria

"Percentage of participants with a best overall response of CR or PR, or stable disease (SD) which lasts for 24 weeks or longer.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.~SD: Partient did not qualify for CR, PR, or progressive disease and has stable nonenhancing (T2/FLAIR) lesions on same or lower doses of corticosteroids compared with baseline scan and clinically stable status." (NCT02684058)
Timeframe: Up to approx. 4.8 years

InterventionPercentage of participants (Number)
HGG Cohort: Dabrafenib and Trametinib75.6

[back to top]

HGG Cohort: Clinical Benefit Rate (CBR) as Per Central Independent Assessment Using RANO Criteria

"Percentage of participants with a best overall response of CR or PR, or stable disease (SD) which lasts for 24 weeks or longer.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.~SD: Partient did not qualify for CR, PR, or progressive disease and has stable nonenhancing (T2/FLAIR) lesions on same or lower doses of corticosteroids compared with baseline scan and clinically stable status." (NCT02684058)
Timeframe: Up to approx. 4.8 years

InterventionPercentage of participants (Number)
HGG Cohort: Dabrafenib and Trametinib65.9

[back to top]

Ctrough for Trametinib

PK parameters were calculated by standard non-compartmental analysis. Ctrough is the pre-dose plasma concentration (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose

Interventionng/ml (Geometric Mean)
HGG Cohort: Dabrafenib and Trametinib8.73
LGG Cohort: Dabrafenib and Trametinib9.82

[back to top]

Cmax for Trametinib

PK parameters were calculated by standard non-compartmental analysis. Cmax is the maximum plasma drug concentration after single dose administration (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

Interventionng/mL (Geometric Mean)
HGG Cohort: Dabrafenib and Trametinib21.3
LGG Cohort: Dabrafenib and Trametinib22.7

[back to top]

AUCtau for Trametinib

PK parameters were calculated by standard non-compartmental analysis. AUCtau is the AUC calculated to the end of a dosing interval (tau) at steady-state (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

Interventionhr * ng/mL (Geometric Mean)
HGG Cohort: Dabrafenib and Trametinib307
LGG Cohort: Dabrafenib and Trametinib339

[back to top]

LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Central Independent Assessment Using RANO Criteria

Time from the date of randomization to the date of first documented disease progression as per central independent review assessment using RANO criteria or death due to any cause. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation. (NCT02684058)
Timeframe: Up to approx. 3 years and up to approx 4.2 years

,
InterventionMonths (Median)
Up to approx. 3 yearsUp to approx 4.2 years
LGG Cohort: Carboplatin and Vincristine7.47.2
LGG Cohort: Dabrafenib and Trametinib20.124.9

[back to top]

LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Fatigue Score

"The PROMIS Parent Proxy Global Health 7+2 was used to evaluate the quality of life of participants. The questionnaire included 1 item measuring the fatigue interference of the participants. Fatigue item used a 5-level Likert scale with 1= never and 5= almost always, higher scores indicate worsening fatigue. Raw scores were then converted into T-scores, standardized with a mean of 50 and a standard deviation of 10. Higher T-scores indicated a greater level of reported fatigue.~Participants who discontinued treatment for reasons other than disease progression entered the post-treatment efficacy follow-up phase, where the PROMIS Parent Proxy Global 7+2 Health questionnaire was performed every 16 weeks until disease progression, withdrawal of consent by patient or a parental/legal guardian, or lost to follow-up." (NCT02684058)
Timeframe: Baseline, and Day 1 of Week 5, 8, 16, 24, 32, 49, 48 and 56, and thereafter every 16 weeks until end of treatment (EOT), EOT, and every 16 weeks in the post-treatment efficacy follow-up phase until disease progression (assessed up to 4.6 years)

InterventionScore on a Scale (Mean)
BaselineWeek 5 Day 1Week 8 Day 1Week 16 Day 1Week 24 Day 1Week 32 Day 1Week 40 Day 1Week 48 Day 1Week 56 Day 1Week 72 Day 1Week 88 Day 1Week 104 Day 1Week 120 Day 1Week 136 Day 1Week 152 Day 1Week 168 Day 1EOTPost Treatment Follow-Up 1Post Treatment Follow-Up 2Post Treatment Follow-Up 3Post Treatment Follow-Up 4Post Treatment Follow-Up 5
LGG Cohort: Dabrafenib and Trametinib53.3053.9652.6851.2251.0452.4952.2751.6550.5149.9350.5251.1150.4050.9747.7148.2152.3548.9462.6248.9456.0762.62

[back to top]

LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Global Health Score

"The PROMIS Parent Proxy Global Health 7+2 was used to evaluate the quality of life of participants. The questionnaire included 7 items measuring the global health of the patient. 4 items used a 5-level Likert scale with 1=poor and 5=excellent; 1 item used a 5-level Likert scale with 1=never and 5=always; and 2 items used a 5-level Likert scale with 1=never and 5=almost always. The total raw global health score, ranging from 7 to 35, was computed by summing item values, with higher scores indicating better overall well-being. Raw scores were then transformed into T-scores, standardized with a mean of 50 and a standard deviation of 10. Higher T-scores reflected better global health status.~Participants who discontinued treatment for reasons other than disease progression entered the post-treatment efficacy follow-up phase, where the questionnaire was performed every 16 weeks until disease progression, withdrawal of consent by patient or a parental/legal guardian, or lost to follow-up." (NCT02684058)
Timeframe: Baseline, and Day 1 of Week 5, 8, 16, 24, 32, 49, 48 and 56, and thereafter every 16 weeks until end of treatment (EOT), EOT, and every 16 weeks in the post-treatment efficacy follow-up phase until disease progression (assessed up to 4.6 years)

InterventionScore on a Scale (Mean)
BaselineWeek 5 Day 1Week 8 Day 1Week 16 Day 1Week 24 Day 1Week 32 Day 1Week 40 Day 1Week 48 Day 1Week 56 Day 1EOTPost Treatment Follow-Up 1Post Treatment Follow-Up 2Post Treatment Follow-Up 3Post Treatment Follow-Up 4Post Treatment Follow-Up 5Post Treatment Follow-Up 6Post Treatment Follow-Up 8
LGG Cohort: Carboplatin and Vincristine42.8939.0638.3641.1136.5740.9638.8441.5638.6639.6945.5339.7034.6043.6037.9036.4537.90

[back to top]

LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Global Health Score

"The PROMIS Parent Proxy Global Health 7+2 was used to evaluate the quality of life of participants. The questionnaire included 7 items measuring the global health of the patient. 4 items used a 5-level Likert scale with 1=poor and 5=excellent; 1 item used a 5-level Likert scale with 1=never and 5=always; and 2 items used a 5-level Likert scale with 1=never and 5=almost always. The total raw global health score, ranging from 7 to 35, was computed by summing item values, with higher scores indicating better overall well-being. Raw scores were then transformed into T-scores, standardized with a mean of 50 and a standard deviation of 10. Higher T-scores reflected better global health status.~Participants who discontinued treatment for reasons other than disease progression entered the post-treatment efficacy follow-up phase, where the questionnaire was performed every 16 weeks until disease progression, withdrawal of consent by patient or a parental/legal guardian, or lost to follow-up." (NCT02684058)
Timeframe: Baseline, and Day 1 of Week 5, 8, 16, 24, 32, 49, 48 and 56, and thereafter every 16 weeks until end of treatment (EOT), EOT, and every 16 weeks in the post-treatment efficacy follow-up phase until disease progression (assessed up to 4.6 years)

InterventionScore on a Scale (Mean)
BaselineWeek 5 Day 1Week 8 Day 1Week 16 Day 1Week 24 Day 1Week 32 Day 1Week 40 Day 1Week 48 Day 1Week 56 Day 1Week 72 Day 1Week 88 Day 1Week 104 Day 1Week 120 Day 1Week 136 Day 1Week 152 Day 1Week 168 Day 1EOTPost Treatment Follow-Up 1Post Treatment Follow-Up 2Post Treatment Follow-Up 3Post Treatment Follow-Up 4Post Treatment Follow-Up 5
LGG Cohort: Dabrafenib and Trametinib42.6742.1443.8344.6845.2745.4645.3744.8344.5444.2144.9145.6044.4144.4547.8846.4844.9845.4027.7043.6031.2029.40

[back to top]

LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Pain Score

"The PROMIS Parent Proxy Global Health 7+2 was used to evaluate the quality of life of participants. The questionnaire included 1 item measuring the pain of the participants. Pain item used a 5-level Likert scale with 1= never and 5= almost always, higher scores indicate worsening pain. Raw scores were then converted into T-scores, standardized with a mean of 50 and a standard deviation of 10. Higher T-scores indicated more severe pain experiences.~Participants who discontinued treatment for reasons other than disease progression entered the post-treatment efficacy follow-up phase, where the PROMIS Parent Proxy Global 7+2 Health questionnaire was performed every 16 weeks until disease progression, withdrawal of consent by patient or a parental/legal guardian, or lost to follow-up." (NCT02684058)
Timeframe: Baseline, and Day 1 of Week 5, 8, 16, 24, 32, 49, 48 and 56, and thereafter every 16 weeks until end of treatment (EOT), EOT, and every 16 weeks in the post-treatment efficacy follow-up phase until disease progression (assessed up to 4.6 years)

InterventionScore on a Scale (Mean)
BaselineWeek 5 Day 1Week 8 Day 1Week 16 Day 1Week 24 Day 1Week 32 Day 1Week 40 Day 1Week 48 Day 1Week 56 Day 1EOTPost Treatment Follow-Up 1Post Treatment Follow-Up 2Post Treatment Follow-Up 3Post Treatment Follow-Up 4Post Treatment Follow-Up 5Post Treatment Follow-Up 6Post Treatment Follow-Up 8
LGG Cohort: Carboplatin and Vincristine52.6450.9751.0051.7551.8149.5952.5251.2053.9952.8750.6043.2543.2543.2543.2550.8843.25

[back to top]

LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Pain Score

"The PROMIS Parent Proxy Global Health 7+2 was used to evaluate the quality of life of participants. The questionnaire included 1 item measuring the pain of the participants. Pain item used a 5-level Likert scale with 1= never and 5= almost always, higher scores indicate worsening pain. Raw scores were then converted into T-scores, standardized with a mean of 50 and a standard deviation of 10. Higher T-scores indicated more severe pain experiences.~Participants who discontinued treatment for reasons other than disease progression entered the post-treatment efficacy follow-up phase, where the PROMIS Parent Proxy Global 7+2 Health questionnaire was performed every 16 weeks until disease progression, withdrawal of consent by patient or a parental/legal guardian, or lost to follow-up." (NCT02684058)
Timeframe: Baseline, and Day 1 of Week 5, 8, 16, 24, 32, 49, 48 and 56, and thereafter every 16 weeks until end of treatment (EOT), EOT, and every 16 weeks in the post-treatment efficacy follow-up phase until disease progression (assessed up to 4.6 years)

InterventionScore on a Scale (Mean)
BaselineWeek 5 Day 1Week 8 Day 1Week 16 Day 1Week 24 Day 1Week 32 Day 1Week 40 Day 1Week 48 Day 1Week 56 Day 1Week 72 Day 1Week 88 Day 1Week 104 Day 1Week 120 Day 1Week 136 Day 1Week 152 Day 1Week 168 Day 1EOTPost Treatment Follow-Up 1Post Treatment Follow-Up 2Post Treatment Follow-Up 3Post Treatment Follow-Up 4Post Treatment Follow-Up 5
LGG Cohort: Dabrafenib and Trametinib52.1450.1149.9349.7250.6548.7749.8749.8948.1449.4647.8248.7448.5646.1647.4248.6151.4653.0558.5153.0558.5158.51

[back to top]

T1/2 for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)

PK parameters were calculated by standard non-compartmental analysis. T1/2 is the elimination half-life (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

,
Interventionhr (Geometric Mean)
DabrafenibCarboxy-dabrafenibDesmethyl-dabrafenibHydroxy-dabrafenib
HGG Cohort: Dabrafenib and Trametinib2.487.127.062.66
LGG Cohort: Dabrafenib and Trametinib3.096.5916.13.52

[back to top]

Tmax for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)

PK parameters were calculated by standard non-compartmental analysis. Tmax is the time to reach maximum plasma concentration. Actual recorded sampling times were considered for the calculations. (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

,
Interventionhr (Geometric Mean)
DabrafenibCarboxy-dabrafenibDesmethyl-dabrafenibHydroxy-dabrafenib
HGG Cohort: Dabrafenib and Trametinib1.473.372.211.97
LGG Cohort: Dabrafenib and Trametinib1.473.662.291.68

[back to top]

HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: After- Taste Once the Medication Was Swallowed

Participants who received the trametinib oral solution completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on the after-taste of the medication after the medication was swallowed, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456173Week 172456174Week 572456174Week 572456173
Unable to answer questionMissingVery good, good, and neither good nor badBadVery bad
HGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib15
LGG Cohort: Dabrafenib and Trametinib5
HGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib11
HGG Cohort: Dabrafenib and Trametinib5
LGG Cohort: Dabrafenib and Trametinib16
LGG Cohort: Dabrafenib and Trametinib3
HGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib13

[back to top]

HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Assessment: After- Taste Once the Medication Was Swallowed

Participants who received the dabrafenib dispersible tablets for oral suspension completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on the after-taste of the medication after the medication was swallowed, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456173Week 172456174Week 572456174Week 572456173
BadVery badUnable to answer questionVery good, good, and neither good nor badMissing
HGG Cohort: Dabrafenib and Trametinib4
LGG Cohort: Dabrafenib and Trametinib13
HGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib6
LGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib10
HGG Cohort: Dabrafenib and Trametinib5
LGG Cohort: Dabrafenib and Trametinib16
LGG Cohort: Dabrafenib and Trametinib2
HGG Cohort: Dabrafenib and Trametinib0
HGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib11

[back to top]

HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Immediate Reaction Once the Medication Was Placed Into the Mouth

Participants who received the dabrafenib dispersible tablets for oral suspension completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on the immediate reaction once the medication was placed into their mouth, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456173Week 172456174Week 572456173Week 572456174
Very good, good, and neither good nor badBadVery badUnable to answer questionMissing
HGG Cohort: Dabrafenib and Trametinib4
LGG Cohort: Dabrafenib and Trametinib13
HGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib5
HGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib3
HGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib10
HGG Cohort: Dabrafenib and Trametinib5
LGG Cohort: Dabrafenib and Trametinib18
LGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib11

[back to top]

HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Taste of the Medication Before Rinsing the Mouth

Participants who received the dabrafenib dispersible tablets for oral suspension completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on how it tasted before rinsing with water, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456173Week 172456174Week 572456174Week 572456173
Very good, good, and neither good nor badBadVery badUnable to answer questionMissing
HGG Cohort: Dabrafenib and Trametinib5
LGG Cohort: Dabrafenib and Trametinib18
LGG Cohort: Dabrafenib and Trametinib4
HGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib5
HGG Cohort: Dabrafenib and Trametinib1
HGG Cohort: Dabrafenib and Trametinib6
LGG Cohort: Dabrafenib and Trametinib20
LGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib2
HGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib8

[back to top]

HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: Remaining After-taste Once Rinsing the Mouth With Water

Participants who received the trametinib oral solution completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on the after-taste of the medication after rinsing with water, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456173Week 172456174Week 572456173Week 572456174
Very good, good, and neither good nor badBadUnable to answer questionVery BadMissing
LGG Cohort: Dabrafenib and Trametinib15
HGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib6
LGG Cohort: Dabrafenib and Trametinib9
HGG Cohort: Dabrafenib and Trametinib4
HGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib2
HGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib3
HGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib14

[back to top]

Cmax for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)

PK parameters were calculated by standard non-compartmental analysis. Cmax is the maximum plasma drug concentration after single dose administration (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

,
Interventionng/ml (Geometric Mean)
DabrafenibCarboxy-dabrafenibDesmethyl-dabrafenibHydroxy-dabrafenib
HGG Cohort: Dabrafenib and Trametinib15209050388801
LGG Cohort: Dabrafenib and Trametinib13307210377687

[back to top]

HGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria (Longer Follow-up Time)

Percentage of participants with a best overall confirmed CR or PR as assessed per RANO criteria by central independent assessment. The 95% CIs were computed using two-sided exact binomial method. CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses. PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically. This analysis was conducted at the end of the trial (after the primary endpoint analysis cut-off date) and includes a longer follow-up time (NCT02684058)
Timeframe: Up to approx 4.8 years

InterventionPercentage of participants (Number)
HGG Cohort: Dabrafenib and Trametinib56.1

[back to top]

HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Questionnaire Item: Taste of the Medication Before Rinsing the Mouth

Participants who received the trametinib oral solution completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on how it tasted before rinsing with water, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456173Week 172456174Week 572456174Week 572456173
Very good, good, and neither good nor badUnable to answer questionMissingBadVery bad
HGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib15
LGG Cohort: Dabrafenib and Trametinib5
HGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib4
LGG Cohort: Dabrafenib and Trametinib9
HGG Cohort: Dabrafenib and Trametinib5
LGG Cohort: Dabrafenib and Trametinib12
LGG Cohort: Dabrafenib and Trametinib6
LGG Cohort: Dabrafenib and Trametinib2
HGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib1
HGG Cohort: Dabrafenib and Trametinib3
LGG Cohort: Dabrafenib and Trametinib14

[back to top]

HGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria

"Time from first documented response (PR or CR) until disease progression or death as per central independent assessment using RANO criteria. CIs were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 3.2 years and up to approx. 4.8 years

InterventionMonths (Median)
Up to approx. 3.2 yearsUp to approx. 4.8 years
HGG Cohort: Dabrafenib and Trametinib22.227.4

[back to top]

HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Remaining After-taste Once Rinsing the Mouth With Water

Participants who received the dabrafenib dispersible tablets for oral suspension completed a questionnaire to evaluate the palatability of the pediatric formulation. After taking the medication, participants provided feedback on the after-taste of the medication after rinsing with water, rating their experience as very good, good, neither good nor bad, bad or very bad. The ratings of very good, good, and neither good nor bad were grouped together for reporting purposes. (NCT02684058)
Timeframe: Week 1 and Week 5

InterventionParticipants (Count of Participants)
Week 172456173Week 172456174Week 572456173Week 572456174
Very badUnable to answer questionMissingVery good, good, and neither good nor badBad
HGG Cohort: Dabrafenib and Trametinib4
LGG Cohort: Dabrafenib and Trametinib15
HGG Cohort: Dabrafenib and Trametinib0
LGG Cohort: Dabrafenib and Trametinib0
HGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib7
LGG Cohort: Dabrafenib and Trametinib5
HGG Cohort: Dabrafenib and Trametinib6
LGG Cohort: Dabrafenib and Trametinib17
LGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib1
LGG Cohort: Dabrafenib and Trametinib4
HGG Cohort: Dabrafenib and Trametinib2
LGG Cohort: Dabrafenib and Trametinib8

[back to top]

HGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Investigator Assessment Using RANO Criteria

"Time from first documented response (PR or CR) until disease progression or death as per investigator assessment using RANO criteria. CIs were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 3.2 years and up to approx. 4.8 years

InterventionMonths (Median)
Up to approx. 3.2 yearsUp to approx. 4.8 years
HGG Cohort: Dabrafenib and Trametinib26.632.7

[back to top]

HGG Cohort: ORR by Investigator Assessment Using RANO Criteria

"ORR in the HGG cohort defined as the percentage of participants in the HGG cohort with a best overall confirmed CR or PR as assessed per RANO criteria by investigator assessment. The 95% CIs were computed using two-sided exact binomial method.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 3.2 years and up to approx. 4.8 years

InterventionPercentage of participants (Number)
Up to approx. 3.2 yearsUp to approx. 4.8 years
HGG Cohort: Dabrafenib and Trametinib58.561.0

[back to top]

LGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria

"Time from first documented response (PR or CR) until disease progression or death as per RANO criteria. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy, were censored at the date of the last adequate tumor evaluation.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 3 years and up to approx 4.2 years

,
InterventionMonths (Median)
Up to approx. 3 yearsUp to approx 4.2 years
LGG Cohort: Carboplatin and VincristineNA19.4
LGG Cohort: Dabrafenib and Trametinib20.330.0

[back to top]

LGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Investigator Assessment Using RANO Criteria

"Time from first documented response (PR or CR) until disease progression or death as per RANO criteria. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy, were censored at the date of the last adequate tumor evaluation.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 3 years and up to approx 4.2 years

,
InterventionMonths (Median)
Up to approx. 3 yearsUp to approx 4.2 years
LGG Cohort: Carboplatin and VincristineNA22.5
LGG Cohort: Dabrafenib and TrametinibNA44.4

[back to top]

LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Investigator Assessment Using RANO Criteria

Time from the date of randomization to the date of first documented disease progression as per investigator assessment using RANO criteria or death due to any cause. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation. (NCT02684058)
Timeframe: Up to approx. 3 years and up to approx 4.2 years

,
InterventionMonths (Median)
Up to approx. 3 yearsUp to approx 4.2 years
LGG Cohort: Carboplatin and VincristineNA30.8
LGG Cohort: Dabrafenib and TrametinibNA46.0

[back to top]

Ctrough for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)

PK parameters were calculated by standard non-compartmental analysis. Ctrough is the pre-dose plasma concentration (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose

,
Interventionng/ml (Geometric Mean)
DabrafenibCarboxy-dabrafenibDesmethyl-dabrafenibHydroxy-dabrafenib
HGG Cohort: Dabrafenib and Trametinib38.0398027541.8
LGG Cohort: Dabrafenib and Trametinib46.0319031044.3

[back to top]

AUCtau for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)

PK parameters were calculated by standard non-compartmental analysis. AUCtau is the AUC calculated to the end of a dosing interval (tau) at steady-state (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

,
Interventionhr * ng/ml (Geometric Mean)
DabrafenibCarboxy-dabrafenibDesmethyl-dabrafenibHydroxy-dabrafenib
HGG Cohort: Dabrafenib and Trametinib43007120033602840
LGG Cohort: Dabrafenib and Trametinib49106070036602960

[back to top]

AUClast for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)

PK parameters were calculated by standard non-compartmental analysis. AUClast is the area under the curve (AUC) from time zero to the last measurable concentration sampling time (tlast). (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

,
Interventionhr * ng/ml (Geometric Mean)
DabrafenibCarboxy-dabrafenibDesmethyl-dabrafenibHydroxy-dabrafenib
HGG Cohort: Dabrafenib and Trametinib43307340035202810
LGG Cohort: Dabrafenib and Trametinib48706420038702980

[back to top]

AUClast for Trametinib

Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. AUClast is the area under the curve (AUC) from time zero to the last measurable concentration sampling time (tlast). (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

Interventionhour (hr) * nanogram (ng)/mililiter (mL) (Geometric Mean)
HGG Cohort: Dabrafenib and Trametinib282
LGG Cohort: Dabrafenib and Trametinib328

[back to top]

All-collected Deaths

On-treatment deaths were collected from 1st dose to 30 days after last dose of treatment (or start of crossover treatment), up to 4.2 years (LGG) and 4.1 years (HGG). Post- treatment (efficacy/survival) follow-up deaths were collected from 31 days post-treatment to end of study (or start of crossover treatment), up to 4.6 years (LGG) and 5.1 years (HGG). For participants in the LGG cohort who crossed over to dabrafenib and trametinib, on-treatment deaths were collected from 1st dose to 30 days after last dose of crossover treatment, up to 4.2 years. None of the patients who crossed-over were included in the crossover post-treatment efficacy/survival follow-up. (NCT02684058)
Timeframe: On-treatment: Up to 4.2 years (LGG) and 4.1 years (HGG). Post- treatment: Up to 4.6 years (LGG) and 5.1 years (HGG).Crossover arm: on-treatment: up to 4.2 years

,
InterventionParticipants (Count of Participants)
On- treatment deathsPost-treatment efficacy/survival follow-up deathsCrossover post-treatment efficacy/survival follow-up deathsAll deaths
HGG Cohort: Dabrafenib and Trametinib611017
LGG Cohort: Dabrafenib and Trametinib0000

[back to top]

LGG Cohort: ORR by Investigator Assessment Using RANO Criteria

"Percentage of participants in the LGG cohort with a best overall confirmed CR or PR as assessed per RANO criteria by investigator assessment. The 95% CIs were computed using two-sided exact binomial method.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approx. 3 years and up to approx 4.2 years

,
InterventionPercentage of participants (Number)
Up to approx. 3 yearsUp to approx. 4.2 years
LGG Cohort: Carboplatin and Vincristine13.518.9
LGG Cohort: Dabrafenib and Trametinib54.858.9

[back to top]

LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Fatigue Score

"The PROMIS Parent Proxy Global Health 7+2 was used to evaluate the quality of life of participants. The questionnaire included 1 item measuring the fatigue interference of the participants. Fatigue item used a 5-level Likert scale with 1= never and 5= almost always, higher scores indicate worsening fatigue. Raw scores were then converted into T-scores, standardized with a mean of 50 and a standard deviation of 10. Higher T-scores indicated a greater level of reported fatigue.~Participants who discontinued treatment for reasons other than disease progression entered the post-treatment efficacy follow-up phase, where the PROMIS Parent Proxy Global 7+2 Health questionnaire was performed every 16 weeks until disease progression, withdrawal of consent by patient or a parental/legal guardian, or lost to follow-up." (NCT02684058)
Timeframe: Baseline, and Day 1 of Week 5, 8, 16, 24, 32, 49, 48 and 56, and thereafter every 16 weeks until end of treatment (EOT), EOT, and every 16 weeks in the post-treatment efficacy follow-up phase until disease progression (assessed up to 4.6 years)

InterventionScore on a Scale (Mean)
BaselineWeek 5 Day 1Week 8 Day 1Week 16 Day 1Week 24 Day 1Week 32 Day 1Week 40 Day 1Week 48 Day 1Week 56 Day 1EOTPost Treatment Follow-Up 1Post Treatment Follow-Up 2Post Treatment Follow-Up 3Post Treatment Follow-Up 4Post Treatment Follow-Up 5Post Treatment Follow-Up 6Post Treatment Follow-Up 8
LGG Cohort: Carboplatin and Vincristine54.3756.8858.1057.8155.0257.6658.4953.4857.6356.8852.3662.6248.9448.9448.9455.7848.94

[back to top]

Tmax for Trametinib

PK parameters were calculated by standard non-compartmental analysis. Tmax is the time to reach maximum plasma concentration. Actual recorded sampling times were considered for the calculations. (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

Interventionhour (Geometric Mean)
HGG Cohort: Dabrafenib and Trametinib1.67
LGG Cohort: Dabrafenib and Trametinib1.53

[back to top]

T1/2 for Trametinib

PK parameters were calculated by standard non-compartmental analysis. T1/2 is the elimination half-life (NCT02684058)
Timeframe: Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose

Interventionhour (Geometric Mean)
HGG Cohort: Dabrafenib and Trametinib26.7
LGG Cohort: Dabrafenib and Trametinib25.7

[back to top]

LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using Response Assessment in Neuro-Oncology (RANO) Criteria

"Percentage of participants in the LGG cohort with a best overall confirmed Complete Response (CR) or Partial Response (PR) as assessed per RANO criteria by central independent assessment. The 95% confidence intervals (CIs) were computed using two-sided exact binomial method.~CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.~PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically." (NCT02684058)
Timeframe: Up to approximately (approx.) 3 years

InterventionPercentage of participants (Number)
LGG Cohort: Dabrafenib and Trametinib46.6
LGG Cohort: Carboplatin and Vincristine10.8

[back to top]

LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria (Longer Follow-up Time)

Percentage of participants with a best overall confirmed CR or PR as assessed per RANO criteria by central independent assessment. The 95% CIs were computed using two-sided exact binomial method. CR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses. PR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically. This analysis was conducted at the end of the trial (after the primary endpoint analysis cut-off date) and includes a longer follow-up time (NCT02684058)
Timeframe: Up to approx 4.2 years

InterventionPercentage of participants (Number)
LGG Cohort: Dabrafenib and Trametinib54.8
LGG Cohort: Carboplatin and Vincristine16.2

[back to top]

All-collected Deaths

On-treatment deaths were collected from 1st dose to 30 days after last dose of treatment (or start of crossover treatment), up to 4.2 years (LGG) and 4.1 years (HGG). Post- treatment (efficacy/survival) follow-up deaths were collected from 31 days post-treatment to end of study (or start of crossover treatment), up to 4.6 years (LGG) and 5.1 years (HGG). For participants in the LGG cohort who crossed over to dabrafenib and trametinib, on-treatment deaths were collected from 1st dose to 30 days after last dose of crossover treatment, up to 4.2 years. None of the patients who crossed-over were included in the crossover post-treatment efficacy/survival follow-up. (NCT02684058)
Timeframe: On-treatment: Up to 4.2 years (LGG) and 4.1 years (HGG). Post- treatment: Up to 4.6 years (LGG) and 5.1 years (HGG).Crossover arm: on-treatment: up to 4.2 years

InterventionParticipants (Count of Participants)
On- treatment deathsPost-treatment efficacy/survival follow-up deathsCrossover on-treatment deathsCrossover post-treatment efficacy/survival follow-up deathsAll deaths
LGG Cohort: Carboplatin and Vincristine00101

[back to top]

Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

InterventionmL/h (Median)
1-5 years6-11 years
Part 2: Ibrutinib: 440 mg/m^21110856

[back to top]

Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

InterventionmL/h (Median)
12-17 years
Part 2: Ibrutinib: 240 mg/m^21730

[back to top]

Part 2: Time to Response

Time to response was defined as the time interval from the first dose of ibrutinib to the first documented response for those participants who responded. Time to response was summarized for participants who achieved either CR (including CRb and CRu) or PR. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells. (NCT02703272)
Timeframe: Up to 4 Years and 4 months

InterventionMonths (Median)
Part 2: Ibrutinib+CIT (RICE or RVICI)0.89
Part 2: Chemoimmunotherapy0.82

[back to top]

Part 2: Tumor Volume Reduction Rate at Day 14

The tumor volume reduction rate was defined as percent decrease in the sum of the products of the lesion diameters at Day 14. It was measured as the mean change in the sum of the products of the lesion diameters (SPD) at Day 14. (NCT02703272)
Timeframe: At Day 14

InterventionPercent change (Least Squares Mean)
Part 2: Ibrutinib+CIT (RICE or RVICI)-49.7
Part 2: Chemoimmunotherapy-58.60

[back to top]

Part 1 and Part 2: Gene Expression Evaluated by Disease-specific Biomarkers at Baseline

"Tumor formalin-fixed paraffin-embedded (FFPE) samples were taken to evaluate the baseline gene expression by disease-specific biomarkers such as BCL-2L1 (BCL-xl), BIRC2 (cIAP1), Caspase 3 (CASP3), STAT3, and SYK. Transcripts per million (TPM) is a normalization method for RNA-sequencing, which means for every 1,000,000 RNA molecules in the RNA-sequencing tumor FFPE sample, x came from this gene/transcript." (NCT02703272)
Timeframe: Baseline

,
InterventionTranscripts per million (Mean)
BCL-2L1 (BCL-xl)BIRC2 (cIAP1)Caspase 3 (CASP3)STAT3SYK
Part 2: Chemoimmunotherapy74.3079040.0171647.61412526.35308618.36324
Part 2: Ibrutinib+CIT (RICE or RVICI)58.0934647.2078751.14711540.02256705.29909

[back to top]

Part 1 and Part 2: Visual Analog Scale (VAS) Score for Palatability

Palatability of ibrutinib was measured by using a VAS. The scale is a 5-point visual analog scale incorporating a facial hedonic scale designed to span pediatric ages and levels of participant comprehension with a score range of 1 to 5, where 1 represents best score and 5 is worst palatability. (NCT02703272)
Timeframe: Day 1 of Cycle 1 and Cycle 3

,,
InterventionUnits on a scale (Mean)
Cycle 1 Day 1Cycle 3 Day 1
Part 1: Ibrutinib+RICE2.63.3
Part 1: Ibrutinib+RVICI3.22.3
Part 2: Ibrutinib+CIT (RICE or RVICI)2.42.6

[back to top]

Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 1 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionmilliliter per hour (mL/h) (Median)
1-5 years6-11 years
Part 1: Ibrutinib: 440 mg/m^212001300

[back to top]

Part 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 1 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

,
Interventionmilliliter per hour (mL/h) (Median)
1-5 years6-11 years12-17 years
Part 1: Ibrutinib: 240 mg/m^212201450348
Part 1: Ibrutinib: 329 mg/m^2508805729

[back to top]

Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionliter(s) (Median)
1-5 years6-11 years
Part 1: Ibrutinib: 440 mg/m^27.6319

[back to top]

Part 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

,
Interventionliter(s) (Median)
1-5 years6-11 years12-17 years
Part 1: Ibrutinib: 240 mg/m^211.1183.63
Part 1: Ibrutinib: 329 mg/m^25.187.5511.3

[back to top]

Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

AUC is defined as area under the plasma concentration-time curve. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 milligrams per meter square [mg/m^2], 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionhours*nanogram per milliliter (h*ng/mL) (Median)
1-5 years6-11 years
Part 1: Ibrutinib: 440 mg/m^2310324

[back to top]

Part 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

AUC is defined as area under the plasma concentration-time curve. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 milligrams per meter square [mg/m^2], 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

,
Interventionhours*nanogram per milliliter (h*ng/mL) (Median)
1-5 years6-11 years12-17 years
Part 1: Ibrutinib: 240 mg/m^21431451210
Part 1: Ibrutinib: 329 mg/m^2386349661

[back to top]

Part 2: Number of Participants With CD79B, CARD11, and MYD Mutations

Number of participants with CD79B, CARD11, and MYD mutations were reported. Blood samples were taken to evaluate the levels of biomarkers such as CD79B, CARD11, and MYD mutations. (NCT02703272)
Timeframe: Up to 4 year and 4 months

,
InterventionParticipants (Count of Participants)
CD79BCARD11MYD mutation
Part 2: Chemoimmunotherapy000
Part 2: Ibrutinib+CIT (RICE or RVICI)110

[back to top]

Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionnanograms per milliliter (ng/mL) (Median)
1-5 years6-11 years
Part 1: Ibrutinib: 440 mg/m^25.073.88

[back to top]

Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

,
Interventionnanograms per milliliter (ng/mL) (Median)
1-5 years6-11 years12-17 years
Part 1: Ibrutinib: 240 mg/m^23.863.464.88
Part 1: Ibrutinib: 329 mg/m^24.483.644.73

[back to top]

Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionng/mL (Median)
1-5 years6-11 years
Part 2: Ibrutinib: 440 mg/m^23.794.15

[back to top]

Part 1 and Part 2: Overall Response Rate (ORR)

ORR was defined as the percentage of participants achieving a best overall response of either complete response (CR) (including CR biopsy-negative [CRb] and unconfirmed CR [CRu]) or partial response (PR) as evaluated by International Pediatric non-Hodgkin lymphoma (NHL) response criteria. CR=disappearance of all disease; CRb=residual mass has no morphologic evidence of disease from limited or core biopsy, with no new lesions by imaging examination; bone marrow (BM) and CSF morphologically free of disease; no new or PD elsewhere, CRu=Residual mass is negative by FDG-PET; no new lesions by imaging examination; BM and CSF morphologically free of disease; no new or PD elsewhere, PR=50% decrease in SPD on CT or MRI; FDG-PET may be positive (deauville score or 4 or 5 with reduced lesional uptake compared with baseline); no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells. (NCT02703272)
Timeframe: Up to 4 year and 4 months

InterventionPercentage of participants (Number)
Part 1: Ibrutinib+RICE81.8
Part 1: Ibrutinib+RVICI50.0
Part 2: Ibrutinib+CIT (RICE or RVICI)68.6
Part 2: Chemoimmunotherapy81.3

[back to top]

Part 1 and Part 2: Number of Participants With Greater Than (>) 90% Bruton's Tyrosine Kinase (BTK) Occupancy

Number of participants with >90% BTK occupancy were reported. Blood samples were collected to assess BTK occupancy. (NCT02703272)
Timeframe: Up to 3 months

InterventionParticipants (Count of Participants)
Part 1: Ibrutinib5
Part 2: Ibrutinib5

[back to top]

Part 1 and Part 2: Number of Participants With Adverse Events as Measure of Safety and Tolerability

An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. (NCT02703272)
Timeframe: Up to 4 year and 4 months

InterventionParticipants (Count of Participants)
Part 1: Ibrutinib+RICE11
Part 1: Ibrutinib+RVICI10
Part 2: Ibrutinib+CIT (RICE or RVICI)35
Part 2: Chemoimmunotherapy15

[back to top]

Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionng/mL (Median)
12-17 years
Part 2: Ibrutinib: 240 mg/m^22.93

[back to top]

Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

AUC is defined as area under the plasma concentration-time curve. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionh*ng/mL (Mean)
12-17 years18+ years
Part 2: Ibrutinib: 329 mg/m^2499423

[back to top]

Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

AUC is defined as area under the plasma concentration-time curve. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionh*ng/mL (Mean)
1-5 years6-11 years
Part 2: Ibrutinib: 440 mg/m^2298655

[back to top]

Part 2: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib

AUC is defined as area under the plasma concentration-time curve. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionh*ng/mL (Mean)
12-17 years
Part 2: Ibrutinib: 240 mg/m^2:215

[back to top]

Part 2: Event Free Survival (EFS) Between the 2 Treatment Groups

EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the Independent Review Committee (IRC). CR was defined as computed tomography (CT) or magnetic resonance imaging (MRI) reveals no residual disease or new lesions, resected residual mass that was pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50 percent (%) decrease in sum of the products of the lesion diameters (SPD) on CT or MRI; fluorodeoxyglucose (FDG)-positron emission tomography (PET) may be positive, no new or progressive disease (PD); morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells. (NCT02703272)
Timeframe: Time from Randomization to death, disease progression, or lack of CR or PR after 3 cycles of treatment (up to 4 year and 4 months)

InterventionMonths (Median)
Part 2: Ibrutinib+CIT (RICE or RVICI)6.05
Part 2: Chemoimmunotherapy6.97

[back to top]

Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation

Number of participants who proceeded to stem cell transplantation were reported. (NCT02703272)
Timeframe: Up to end of the study (Up to 4 year and 4 months)

InterventionParticipants (Count of Participants)
Part 2: Ibrutinib+CIT (RICE or RVICI)13
Part 2: Chemoimmunotherapy7

[back to top]

Part 2: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionng/mL (Median)
12-17 years18+ years
Part 2: Ibrutinib: 329 mg/m^24.863.7

[back to top]

Part 2: Number of Participants With c-MYC Gene Rearrangement

Number of participants with c-MYC gene rearrangement were reported. Blood samples were taken to evaluate the levels of biomarker such as c-MYC Gene rearrangement. (NCT02703272)
Timeframe: At baseline (Cycle 1 Day 1)

InterventionParticipants (Count of Participants)
Part 2: Ibrutinib+CIT (RICE or RVICI)1
Part 2: Chemoimmunotherapy1

[back to top]

Part 2: Overall Survival

Overall survival was defined as duration from the date of randomization to the date of the participant's death. (NCT02703272)
Timeframe: Up to 4 year and 4 months

InterventionMonths (Median)
Part 2: Ibrutinib+CIT (RICE or RVICI)14.13
Part 2: Chemoimmunotherapy11.07

[back to top]

Part 2: Percentage of Participants Who Achieved Complete Response (CR)

Complete response rate was defined as the percentage of participants who achieved complete response or complete response with an incomplete marrow recovery (CRi) on or prior to initiation of subsequent anti-leukemic therapy per the IRC assessment. (NCT02703272)
Timeframe: Up to 4 year and 4 months

InterventionPercentage of Participants (Number)
Part 2: Ibrutinib+CIT (RICE or RVICI)17.1
Part 2: Chemoimmunotherapy18.8

[back to top]

Part 2: Percentage of Participants Who Achieved Partial Response (PR)

Percentage of participants who achieved PR were assessed. PR was defined as 50% decrease in SPD on computed tomography (CT) or magnetic resonance imaging (MRI); FDG-PET may be positive; no new or PD; morphologic evidence of disease may be present in BM or cerebrospinal fluid (CSF) if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells. (NCT02703272)
Timeframe: Up to 4 year and 4 months

Interventionpercentage of participants (Number)
Part 2: Ibrutinib+CIT (RICE or RVICI)51.4
Part 2: Chemoimmunotherapy62.5

[back to top]

Part 2: Percentage of Participants With EFS at 2 Years

EFS was the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurred first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells. (NCT02703272)
Timeframe: At 2 years

InterventionPercentage of participants (Number)
Part 2: Ibrutinib+CIT (RICE or RVICI)14.3
Part 2: Chemoimmunotherapy12.5

[back to top]

Part 2: Percentage of Participants With EFS at 3 Years

EFS is the time interval from randomization to death, disease progression, or lack of complete response (CR) or partial response (PR) after 3 cycles of treatment, whichever occurs first based on blinded independent event review by the IRC. CR was defined as CT or MRI reveals no residual disease or new lesions, resected residual mass that is pathologically (morphologically) negative for disease, BM and CSF morphologically free of disease with no new lesions by imaging examination. PR was defined as 50% decrease in um of the products of the SPD on CT or MRI; FDG-PET may be positive, no new or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis; however, there should be 50% reduction in percentage of lymphoma cells. (NCT02703272)
Timeframe: At 3 years

InterventionPercentage of participants (Number)
Part 2: Ibrutinib+CIT (RICE or RVICI)8.6
Part 2: Chemoimmunotherapy12.5

[back to top]

Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionliter(s) (Median)
12-17 years18+ years
Part 2: Ibrutinib: 329 mg/m^24.149.29

[back to top]

Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionliter(s) (Median)
1-5 years6-11 years
Part 2: Ibrutinib: 440 mg/m^21.686.18

[back to top]

Part 2: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent (oral) volume of distribution of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

Interventionliter(s) (Median)
12-17 years
Part 2: Ibrutinib: 240 mg/m^29.9

[back to top]

Part 2: Duration of Response

Duration of response was defined as the duration from date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (PD) or death, whichever occurred first. PD: >25% increase in SPD of residual lesions (calculated from nadir) on CT or MRI; Deauville score 4 or 5 on FDG-PET with increase in lesional uptake from baseline; documentation of new lesions or development of new morphologic evidence of disease in BM or CSF. (NCT02703272)
Timeframe: Up to 4 year and 4 months

InterventionMonths (Median)
Part 2: Ibrutinib+CIT (RICE or RVICI)6.01
Part 2: Chemoimmunotherapy6.51

[back to top]

Part 2: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent plasma clearance of ibrutinib. As per planned analyses, PK parameters for Part 2 were presented per dose group (240 mg/m^2, 329 mg/m^2 and 440 mg/m^2) and age group (1-5, 6-11, 12-17 and >18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age. (NCT02703272)
Timeframe: Up to Cycle 3 (each cycle of 21 or 28 days)

InterventionmL/h (Median)
12-17 years18+ years
Part 2: Ibrutinib: 329 mg/m^29821510

[back to top]

Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose

Complete response (CR) no emetic episodes and no rescue medications. (NCT02732015)
Timeframe: Days 1-10

InterventionParticipants (Count of Participants)
Cohort 10
Cohort 25

[back to top]

Delay in Chemotherapy Administration Due to Prolonged Neutrophil Recovery

incidence of delay in chemotherapy administration due to prolonged neutrophil recovery (NCT02786719)
Timeframe: through study completion, approximately 5 months

Interventionchemotherapy cycles (Number)
High Risk Neuroblastoma Patients9

[back to top]

Incidence of Infection

Incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors (NCT02786719)
Timeframe: through study completion, approximately 5 months

Interventioninfections (Number)
High Risk Neuroblastoma Patients6

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients after the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 5 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged75.54

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients after the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 5 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged74.52

[back to top]

Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)

Proportion of KMT2A-Rearranged patients treated with azacitidine with Dose Limiting Toxicities (DLTs) from the first course of azacitidine administration up to fourth course of azacitidine administration. (NCT02828358)
Timeframe: 6 months

Interventionpercentage of participants (Number)
KMT2A-Rearranged6.45

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients before the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 1 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged78.17

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients before the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 1 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged76.5

[back to top]

Part A and Part B Outcome Measure: Incidence of Adverse Events

Part A data only; study did not progress to Part B. (NCT02855359)
Timeframe: 54.7 weeks

,
InterventionParticipants (Count of Participants)
Any Treatment-emergent adverse event (TEAE)Any Grade 3-5 TEAEAny Treatment-related Adverse Event (AE)Any DM treatment-related AEAny RCHOP/RCHP treatment-related AEAny AE with Outcome of DeathAny Serious Adverse Event (SAE)Any Treatment-Related SAEAny DM Treatment-Related SAE
Denintuzumab Mafodotin + RCHOP13121313131432
Denintuzumab Mafodotin + RCHP1111109102542

[back to top]

Part A and Part B Outcome Measure: Incidence of Laboratory Abnormalities

Part A data reported; study did not progress to Part B. Laboratory abnormalities Grade 1+ are reported. (NCT02855359)
Timeframe: Up to 183 days

,
InterventionParticipants (Count of Participants)
Alanine aminotransferase increasedHypoalbuminemiaAlkaline phosphatase increasedAspartate aminotransferase increasedBlood bilirubin increasedHypercalcemiaHypocalcemiaHyperglycemiaHypoglycemiaHypermagnesemiaHypomagnesemiaHypophosphatemiaHypokalemiaHypernatremiaHyponatremiaHyperuricemiaAnemiaLeukopeniaLymphopeniaNeutropeniaThrombocytopenia
Denintuzumab Mafodotin + RCHOP4489405114445711211213131113
Denintuzumab Mafodotin + RCHP335503581045614010109910

[back to top]

Participants With Treatment Emergent Adverse Events (TEAE)

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03): - Grade 1 = Mild (no limitation in activity or intervention); - Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); - Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); - Grade 4 = Life-threatening; - Grade 5 = Death. Relation to IP is determined by the investigator. (NCT03003520)
Timeframe: From the date of the first dose of study drug to within 90 days after the last dose of durvalumab or 28 days after the last dose of any investigational product (IP) whichever is greater. (Up to approximately 72 weeks)

InterventionParticipants (Count of Participants)
>= 1 Treatment-emergent adverse event (TEAE)>=1 TEAE related to durvalumab>=1 TEAE related to R-CHOP>=1 TEAE related to durvalumab or any other IP>=1 TEAE severity grade 3-4>=1 TEAE severity grade 3-4 related to durvalumab>=1 TEAE severity grade 3-4 related to R-CHOP>=1 TEAE severity grade 3-4 related to any IP>=1 TEAE severity grade 5>=1 TEAE severity grade 5 related to any IP>=1 serious TEAE>=1 serious TEAE related to durvalumab>=1 serious TEAE related to R-CHOP>=1 serious TEAE related to any IP>=1 leading to discontinuation of durvalumab>=1 leading to discontinuation of R-CHOP>=1 leading to discontinuation of any IP>=1 leading to interruption of durvalumab>=1 leading to interruption of R-CHOP>=1 leading to interruption of any IP>=1 leading to infusion interruption of durvalumab>=1 leading to dose reduction of vincristine
DUR + R-CHOP433340413718273130231010141341315121824

[back to top]

Percentage of Participants Who Responded During Induction and Continued Into Consolidation Therapy (Database Cutoff Date: 02-Aug-2018)

The percentage of participants who achieved a partial response (PR) or complete response (CR) at the end of Induction and continued into consolidation period in the efficacy evaluable population in a comparative manner against historical control. The response to treatment was assessed according to the 2014 International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) (Cheson, 2014). CR was defined in outcome #1. PR was defined as a partial metabolic response and radiographic evidence showing ≥ 50% decrease in sum of perpendicular diameters (SPD) of up to 6 target measurable nodes and extranodal sites, no new lesions, spleen must have regressed > 50% in length beyond normal, and residual bone marrow involvement improved from baseline. Clopper-Pearson two-sided 95% confidence interval is reported. Null hypothesis was rejected if the lower limit of the confidence interval for the rate of subjects who continue consolidation therapy out of all subjects. (NCT03003520)
Timeframe: From first dose of study drug to completion of at least one cycle in the Consolidation Period (Day 1 up to Week 52)

Interventionpercentage of participants (Number)
DUR + R-CHOP67.6
DUR + R2-CHOP66.7

[back to top]

Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy

The primary efficacy analysis evaluated the complete response rate (CRR) at the end of the induction therapy in the efficacy evaluable population in a comparative manner against historical control. The response to treatment was assessed according to the 2014 International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) (Cheson, 2014). CR was defined as a complete metabolic response and radiographic evidence showing target nodes/nodal masses regressed to ≤ 1.5 cm in longest diameter, no new lesions, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. Clopper-Pearson two-sided 95% confidence interval is reported. Null hypothesis for the primary endpoint was rejected if the lower limit of the confidence interval for the complete response rate at the completion of the induction therapy in the efficacy evaluable population is above 55%. (NCT03003520)
Timeframe: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

Interventionpercentage of participants (Number)
DUR + R-CHOP54.1
DUR + R2-CHOP66.7

[back to top]

Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for the Interferon Gamma Score (IFNG-Score) From Ribonucleic Acid (RNA)-Sequencing Data

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome. (NCT03003520)
Timeframe: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

Interventionpercentage of participants (Number)
High Group for RNA IFN Gamma Score43
Low Group for RNA IFN Gamma Score60

[back to top]

Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Total Percentage

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome. (NCT03003520)
Timeframe: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

Interventionpercentage of participants (Number)
High Group for PDL1 % of Total Cells75
Low Group for PDL1 % of Total Cells20

[back to top]

Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Percentage of Tumor Cells

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome. (NCT03003520)
Timeframe: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

Interventionpercentage of participants (Number)
High Group for PDL1 % of Tumor Cells64
Low Group for PDL1 % of Tumor Cells56

[back to top]

Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) CD8 T-Cell Density

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome. (NCT03003520)
Timeframe: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

Interventionpercentage of participants (Number)
High Group for CD8 Density67
Low Group for CD8 Density64

[back to top]

Participants With Treatment Emergent Adverse Events (TEAE)

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03): - Grade 1 = Mild (no limitation in activity or intervention); - Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); - Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); - Grade 4 = Life-threatening; - Grade 5 = Death. Relation to IP is determined by the investigator. (NCT03003520)
Timeframe: From the date of the first dose of study drug to within 90 days after the last dose of durvalumab or 28 days after the last dose of any investigational product (IP) whichever is greater. (Up to approximately 72 weeks)

InterventionParticipants (Count of Participants)
>= 1 Treatment-emergent adverse event (TEAE)>=1 TEAE related to durvalumab>=1 TEAE related to R-CHOP>=1 TEAE related to lenalidomide>=1 TEAE related to durvalumab or any other IP>=1 TEAE severity grade 3-4>=1 TEAE severity grade 3-4 related to durvalumab>=1 TEAE severity grade 3-4 related to R-CHOP>=1 TEAE severity grade 3-4 related to lenalidomid>=1 TEAE severity grade 3-4 related to any IP>=1 TEAE severity grade 5>=1 TEAE severity grade 5 related to any IP>=1 serious TEAE>=1 serious TEAE related to durvalumab>=1 serious TEAE related to R-CHOP>=1 serious TEAE related to lenalidomide>=1 serious TEAE related to any IP>=1 leading to discontinuation of durvalumab>=1 leading to discontinuation of R-CHOP>=1 leading to discontinuation of lenalidomide>=1 leading to discontinuation of any IP>=1 leading to interruption of durvalumab>=1 leading to interruption of R-CHOP>=1 leading to interruption of lenalidomide>=1 leading to interruption of any IP>=1 leading to infusion interruption of durvalumab>=1 leading to dose reduction of vincristine>=1 leading to dose reduction of lenalidomide
DUR + R2-CHOP3333331323001111100002123011

[back to top]

Number of Participants With Adverse Events

Grade 1 or higher non-hematologic adverse events will be assessed by Common Terminology Criteria for Adverse Events version 5.0. (NCT03023046)
Timeframe: Within 28 days of the last dose of the study drugs

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy)44

[back to top]

Number of Participants With Morphological Complete Response Rate

Morphological complete remission (CR) was determined by bone marrow aspirate morphology and defined as <5% blasts by morphology, absolute neutrophil count >1000/uL, and platelet count >100,000/uL. (NCT03023046)
Timeframe: Within 4 cycles of study therapy

InterventionParticipants (Count of Participants)
Ph+ Subjects27
Ph- Subjects20

[back to top]

Overall Survival

Alive at 2 years after enrollment (NCT03023046)
Timeframe: Up to 2 years

InterventionPercentage of Participants (Number)
Treatment (Chemotherapy)70

[back to top]

Event-free Survival

Events were defined as any of the following: (1) unable to achieve either morphologic complete remission (CR) or MRD- by MFC, (2) relapse after CR, (3) MRD recurrence after achieving MRD-, or (4) death from any cause. (NCT03023046)
Timeframe: Up to 2 years

InterventionPercentage of Participants (Number)
Treatment (Chemotherapy)32

[back to top]

Number of Participants With Complete Measurable Residual Disease (MRD) Response Rate

"Response was determined by having no detectable disease by multiparameter flow cytometry (MFC-). For Ph+ subjects, complete molecular response (CMR) by BCR-ABL RT-PCR was assigned when MFC was undetectable.~When no measurable residual disease was detected by MFC (MFC-) per EuroFlow criteria, high-throughput sequencing-based MRD testing (HTS; ClonoSEQ) was performed." (NCT03023046)
Timeframe: Within 4 cycles of study therapy

InterventionParticipants (Count of Participants)Participants (Count of Participants)
MFC-72545885MFC-72545886CMR72545885HTS-72545885HTS-72545886
Achieve within 4 cyclesNot achieved within 4 cycles
Ph+ Subjects20
Ph- Subjects9
Ph+ Subjects11
Ph+ Subjects17
Ph+ Subjects8
Ph- Subjects6
Ph+ Subjects16
Ph- Subjects16

[back to top]

Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Percentage of participants who received an allogeneic HSCT after treatment with daratumumab were reported. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)14.3
Cohort 2: T-Cell ALL (1-17 Years)75.0
Cohort 2: T-Cell ALL (18-30 Years)60.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)30.0

[back to top]

Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL

Complete response based on the modified NCCN criteria was defined as: less than 5% blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets >100*10^9 cells/L and ANC >1.0*10^9 cells/L. This outcome measure was planned to be analyzed for specified arms only. (NCT03384654)
Timeframe: End of Cycle 1 (that is, up to 28 days)

InterventionPercentage of participants (Number)
Cohort 2: T-Cell ALL (1-17 Years)41.7
Cohort 2: T-Cell ALL (18-30 Years)60.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)30.0

[back to top]

Event-free Survival (EFS)

EFS was defined as the time (in months) from the date of first treatment to the first documented treatment failure (that is [ie], disease progression) or date of relapse from CR or death due to any cause, whichever occurred first. Per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or >5% blasts in the bone marrow; reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in the absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for the analysis. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionMonths (Median)
Cohort 1: B-cell ALL (1-17 Years)1.1
Cohort 2: T-Cell ALL (1-17 Years)8.9
Cohort 2: T-Cell ALL (18-30 Years)10.3
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)2.9

[back to top]

Maximum Observed Serum Concentration (Cmax) of Daratumumab

Cmax was defined as maximum observed serum concentration of daratumumab. (NCT03384654)
Timeframe: Cohort 1: B-cell ALL: End of infusion (EOI) on Day 1 of Cycle 2; Cohort 2: T-cell ALL (1-17 years): EOI on Day 22 of Cycle 2; Cohort 2: T-cell ALL (18-30 years): EOI on Day 1 of Cycle 2; Cohort 2: T-cell LL (1-30 years): EOI on Day 22 of Cycle 2

InterventionMicrograms per milliliter (mcg/mL) (Mean)
Cohort 1: B-cell ALL (1-17 Years)494
Cohort 2: T-Cell ALL (1-17 Years)763
Cohort 2: T-Cell ALL (18-30 Years)501
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)758

[back to top]

Minimal Residual Disease (MRD) Negative Rate

MRD negative rate was defined as the percentage of participants who were considered MRD negative after MRD testing by bone marrow aspirate at any timepoint after first study treatment administration and before disease progression or starting subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant (HSCT). MRD negative was defined as less than (<) 0.01% abnormal population counts to nucleated mononuclear cells when measured by flow cytometry. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)0
Cohort 2: T-Cell ALL (1-17 Years)45.8
Cohort 2: T-Cell ALL (18-30 Years)20.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)50.0

[back to top]

Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)

Complete response based on the modified National Comprehensive Cancer Network (NCCN) criteria was defined as: less than 5 percent (%) blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets greater than (>)100*10^9 cells/liter (L) and absolute neutrophil count (ANC) >1.0*10^9 cells/L. This outcome measure was planned to be analyzed for specified arm only. (NCT03384654)
Timeframe: Up to 2 cycles, that is, up to 56 days (each cycle of 28-days)

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)0

[back to top]

Overall Response Rate (ORR)

For ALL participants, ORR was defined as percentage of participants who achieved CR or CR with only partial hematological recovery(CRi) as per NCCN criteria. CR for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets >100*10^9 cells/L and ANC >1.0*10^9 cells/L. CRi for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; partial recovery of peripheral blood counts not meeting criteria for CR. For LL participants, ORR was defined as percentage of participants who had CR or PR during or after treatment administration but prior to start of subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant(HSCT). CR for LL: disappearance of all evidence of disease from all sites. PR for LL: decrease of >=50% in sum of products of diameter of lesions of up to 6 of largest dominant nodes or nodal masses with no new lesions. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)14.3
Cohort 2: T-Cell ALL (1-17 Years)83.3
Cohort 2: T-Cell ALL (18-30 Years)80.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)50.0

[back to top]

Overall Survival (OS)

OS was defined as the time (in months) from the date of first study drug administration to the date of death due to any cause. Kaplan-Meier method was used for the analysis. Participants who died after consent withdrawal were considered as having an OS event. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionMonths (Median)
Cohort 1: B-cell ALL (1-17 Years)3.2
Cohort 2: T-Cell ALL (1-17 Years)10.9
Cohort 2: T-Cell ALL (18-30 Years)12.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)4.2

[back to top]

Minimum Observed Serum Concentration (Cmin) of Daratumumab

Cmin was defined as minimum observed serum concentration of daratumumab. (NCT03384654)
Timeframe: Cohort 1: B-cell ALL: Predose on Day 1 of Cycle 2; Cohort 2: T-cell ALL (1-17 years): Predose on Day 22 of Cycle 2; Cohort 2: T-cell ALL (18-30 years): Predose on Day 1 of Cycle 2; Cohort 2: T-cell LL (1-30 years): Predose on Day 22 of Cycle 2

Interventionmcg/mL (Mean)
Cohort 1: B-cell ALL (1-17 Years)172
Cohort 2: T-Cell ALL (1-17 Years)369
Cohort 2: T-Cell ALL (18-30 Years)172
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)365

[back to top]

Relapse-free Survival (RFS)

RFS was defined as the time (in months) from CR to relapse from CR, or disease progression or death due to any cause, whichever occurred first. For ALL, as per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or >5% blasts in the bone marrow, or reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for analysis. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionMonths (Median)
Cohort 2: T-Cell ALL (1-17 Years)19.4
Cohort 2: T-Cell ALL (18-30 Years)9.4
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)NA

[back to top]

Concentration of Daratumumab in Cerebrospinal Fluid (CSF)

Concentration of daratumumab in CSF was reported. '0' in the number analyzed field signifies that none of the participants were available for the analysis at the specified time points. (NCT03384654)
Timeframe: Pre-dose on Cohort 1: Cycles 1 and 2: Day 1; Cohort 2: Cycle 1 Day 1 and Day 15 and Cycle 2 Day 2 and Day 15

Interventionmcg/mL (Mean)
Cycle 1 Day 1 predoseCycle 2 Day 1 predose
Cohort 1: B-cell ALL (1-17 Years)NA0.573

[back to top]

Concentration of Daratumumab in Cerebrospinal Fluid (CSF)

Concentration of daratumumab in CSF was reported. '0' in the number analyzed field signifies that none of the participants were available for the analysis at the specified time points. (NCT03384654)
Timeframe: Pre-dose on Cohort 1: Cycles 1 and 2: Day 1; Cohort 2: Cycle 1 Day 1 and Day 15 and Cycle 2 Day 2 and Day 15

,,
Interventionmcg/mL (Mean)
Cycle 1 Day 1 predoseCycle 1 Day 15 predoseCycle 2 Day 2 predoseCycle 2 Day 15 predose
Cohort 2: T-Cell ALL (1-17 Years)NA0.9070.9150.934
Cohort 2: T-Cell ALL (18-30 Years)NA0.3190.2960.163
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)NA0.4561.231.06

[back to top]

Number of Participants With Anti-daratumumab Antibodies

Number of participants with anti-daratumumab antibodies was reported. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionParticipants (Count of Participants)
Cohort 1: B-cell ALL (1-17 Years)0
Cohort 2: T-Cell ALL (1-17 Years)0
Cohort 2: T-Cell ALL (18-30 Years)0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)0

[back to top]

Number of Participants With Adverse Events

For the purpose of toxicity monitoring, toxicities are defined as any treatment -related grade 3 or 4 non-hematologic AEs occurred any time during the trial.NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 utilized for adverse event reporting. (NCT03488225)
Timeframe: Start of treatment up to 30 days after last dose received.

InterventionParticipants (Count of Participants)
Neutropenic FeverPeripheral Sensory NeuropathyAllergic ReactionMuscle Weakness
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)2111

[back to top]

Participants to Achieve Complete Remission (CR):

Complete Remission (CR) is defined as - Normalization of the peripheral blood and bone marrow blasts /= 100X10^9/L and complete resolution of all sites of extramedullary disease. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)4

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionMonths (Median)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)24

[back to top]

Number of Participants With Minimal Residual Disease (MRD) Negativity

MRD levels continuously assessed during induction and consolidation therapy by 6-color multiparameter flow. MRD negativity defined by a value of at least 10-4 and confirmed on a second bone marrow aspiration/biopsy performed after a subsequent cycle. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)4

[back to top]

Event-Free Survival

Event-free survival defined as the time interval from date of treatment start until the date of death, disease progression or relapse. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionMonths (Median)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)24

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)16.7

[back to top]

Participants With a Response

"defined as the percentage of patients achieving complete response (CR) or CR with inadequate count recovery (CRi). Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L)." (NCT03518112)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment (Blinatumomab, Combination Chemotherapy)4

[back to top]

Number of Participants Negative for Minimal Residual Disease (MRD)

Minimal Residual Disease (MRD) was assessed by flow cytometry. MRD negativity: Absence of detectable leukemia using multiparameter flow cytometry with a sensitivity of NCT03518112)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment (Blinatumomab, Combination Chemotherapy)4

[back to top]

Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death

"Time from date of treatment start until the date of first objective documentation of disease-relapse. Relapse and resistant disease will be defined based on morphological assessment of bone marrow and peripheral blood.~Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L).~Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts." (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)5.7

[back to top]

Duration of Response

"Response date to loss of response or last follow up. Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L).~Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts." (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)4.4

[back to top]

Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase

MRD-negative CR was achieved when a participant met the criteria for both MRD negativity and CR. MRD-negativity: ≤0.01 % breakpoint cluster region-Abelson (BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in complementary deoxyribonucleic acid (cDNA) with ≥ 10,000 ABL1 transcripts. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and less than (<) 5% blasts in the bone marrow (BM). 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (central nervous system [CNS] involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. Absolute neutrophil count (ANC) > 1000 per microliter (/mcL) (or >1.0*10^9/L). 5. Platelets >100,000/mcL (or >100*10^9/L). (NCT03589326)
Timeframe: From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length = 28 days)

InterventionParticipants (Count of Participants)
Cohort A: Ponatinib 30 mg53
Cohort B: Imatinib 600 mg13

[back to top]

Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire

"The four domains of the FACT-G questionnaire will be determined for each questionnaire: physical well-being, social/family well-being, emotional well-being, and functional well-being. Each of these four domains is scored on a subset of 6-7 statements with a 0-4 scale. The domain is scored by summing up the responses to these statements. The ranges for the domains are as follows: physical well-being 0-28, social/family well-being 0-28, emotional well-being 0-24, and functional well-being 0-28. Using general estimating equations, changes in these domains with time will be explored. Logistic regression analyses will be used to correlate changes in quality of life domains with clinical response.~The overall score is the sum of all the subscales and ranges from 0 to 108. Higher scores reflect better quality of life outcomes.~The FACT-G Total Score at 3 months is reported here" (NCT03596918)
Timeframe: Up to 3 months after treatment completion

Interventionscore on a scale (Mean)
Supportive Care (Vincristine Sulfate, Bleomycin Sulfate)56.9

[back to top]

"Percentage of Participants Who Are Feasibility Failure"

"Feasibility failures were defined as patients that did not receive >= 75% of the planned dinutuximab doses during Induction cycles 3-5. Assessed by estimation of the feasibility failure rate together with a 95% confidence interval." (NCT03786783)
Timeframe: Up to the first 5 cycles of treatment

InterventionPercentage of patients (Number)
Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT)0.0

[back to top]

Event-free Survival

Per the revised INRC, progressive disease is: 1) > 20% increase in the longest diameter of the primary tumor, taking as reference the smallest sum and ¬> increase of 5 mm in longest dimension, 2) Any new soft tissue lesion detected by CT/MRI that is MIBG avid or FDG-PET avid, 3) Any new soft tissue lesion seen on CT/MRI that is biopsied and found to be neuroblastoma or ganglioneuroblastoma, 4) Any new bone site that is MIBG avid, 5) Any new bone site that is FDG-PET avid and has CT/MRI findings of tumor or is histologically neuroblastoma or ganglioneuroblastoma 6) A metastatic soft tissue site with > 20% increase in longest diameter, taking as reference the smallest sum on study, and with > 5mm in sum of diameters of target soft tissue lesions, 7) A relative MIBG score ¬> 1.2, 8) Bone marrow without tumor infiltration that becomes >5% tumor infiltration, 9) Bone marrow with tumor infiltration that increases by > 2-fold and has > 20% tumor infiltration on reassessment. (NCT03786783)
Timeframe: Up to 1 year

InterventionPercent Probability (Number)
Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT)82.6

[back to top]

Percentage of Participants With Unacceptable Toxicity

Assessed with National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Assessed by estimation of the combined toxic death and unacceptable toxicity rate during Induction cycles 3-5 together with a 95% confidence interval. (NCT03786783)
Timeframe: Up to the first 5 cycles of treatment

Interventionpercentage of patients (Number)
Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT)0.0

[back to top]

Response Rate

Per the revised INRC, response is comprised by responses in 3 components: primary tumor, soft tissue and bone metastases, and bone marrow. Primary and metastatic soft tissue sites were assessed using Response Evaluation Criteria in Solid Tumors and MIBG scans or FDG-PET scans if the tumor was MIBG non-avid. Bone marrow was assessed by histology or immunohistochemistry and cytology or immunocytology. Complete response (CR) - All components meet criteria for CR. Partial response (PR) - PR in at least one component and all other components are either CR, minimal disease (in bone marrow), PR (soft tissue or bone) or not involved (NI; no component with progressive disease (PD). Minor response (MR) - PR or CR in at least one component but at least one other component with stable disease; no component with PD. Stable disease (SD) - Stable disease in one component with no better than SD or NI in any other component; no component with PD. Progressive disease (PD) - Any component with PD. (NCT03786783)
Timeframe: Up to the first 5 cycles of treatment

InterventionPercentage of patients (Number)
Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT)78.6

[back to top]

Overall Survival

Kaplan-Meier method was used to estimate overall survival (OS). OS was defined as the time from study enrollment to death. 1-year OS is provided. (NCT03786783)
Timeframe: Up to 1 year

InterventionPercent Probability (Number)
Treatment(Chemotherapy, Dinutuximab, Sargramostim, ASCT, EBRT)95.0

[back to top]

Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle

(NCT03817853)
Timeframe: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)

InterventionPercentage of Participants (Number)
Cycle (C) 5- HypertensionC5 - Renal failureC5 - Weight increased
All Participants33.333.333.3

[back to top]

Time to IRR From Infusion to Onset of the IRR During Cycle 2

Time to IRR (of any grade) in Cycle 2 was defined as the time from the start of infusion (i.e., start date/time of infusion of the first component of study treatment) in Cycle 2 to the onset of the IRR (of any grade) during Cycle 2. (NCT03817853)
Timeframe: From infusion to onset of IRR during Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected)

InterventionHours (Mean)
All Participants11.800

[back to top]

Duration (In Minutes) of Obinutuzumab Administration by Cycle

The duration of obinutuzumab administration (in minutes) by cycle was defined as the difference between the end time and the start time of obinutuzumab administration. (NCT03817853)
Timeframe: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)

InterventionMinutes (Mean)
Cycle(C) 1 Day(D) 1C1D8C1D15C2C3C4C5C6C7C8Maintenance Week 1Maintenance Week 9Maintenance Week 17Maintenance Week 25Maintenance Week 33Maintenance Week 41
All Participants295.96215.97207.52101.48102.9798.3398.2699.4999.5694.54101.4897.2197.6493.8392.5090.00

[back to top]

Objective Response Rate (ORR) at the End of Induction (EOI) Therapy

ORR at EOI therapy was defined as the percentage of particpants with either a CR, CR unconfirmed or PR at the EOI visit, as determined by the investigator and according to the guidelines used at the site. (NCT03817853)
Timeframe: Baseline up to end of induction therapy (up to approximately 6 months)

InterventionPercentage of Participants (Number)
Complete ResponsePartial Response
All Participants72.119.1

[back to top]

Percentage of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product, regardless of causal attribution. An AE was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study, recurrence of an intermittent medical condition, deterioration in a laboratory value or other clinical test or were related to a protocol-mandated intervention were also considered AEs. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. (NCT03817853)
Timeframe: Baseline up to clinical cut off date (up to approximately 1.5 years)

InterventionPercentage of Participants (Number)
All Participants99.1
Maintenance: Obinutuzumab41.1
Follow-up35.3

[back to top]

Percentage of IRRs Regardless of Grade by Cycle

IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator. (NCT03817853)
Timeframe: Within 24 hours from the end of study treatment infusion in all cycles, including maintenance ((1 cycle: 21 or 28 days depending on the chemotherapy selected); up to approximately 2.5 years)

InterventionPercentage of Participants (Number)
Cycle 1 Day 1Cycle 1 Day 2Cycle 1 Day 8Cycle 1 Day 15Cycle 2Cycle 3Cycle 4Cycle 5Cycle 6Cycle 7
All Participants49.67.84.54.511.88.34.96.23.64.4

[back to top]

Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle

The duration, in minutes, of IRRs during all cycles, where obinutuzumab was administered as an SDI. (NCT03817853)
Timeframe: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)

InterventionMinutes (Mean)
All Participants165.0

[back to top] [back to top]

Cluster of Differentiation (CD)38 Receptor Density

"Blood samples were collected to assess CD38 receptor density as a predictive biomarker. It was assessed across complete responders and non-complete responders. The Antibody Binding Capacity (ABC) was calculated using the following equation: ABC = 10^(Logarithm(Mean Fluorescence Intensity)*a+b) where a was the slope and b was the Y-intercept of the calibration curve equation. Specific and absolute quantitative values (specific antibody-binding capacity [sABC]) of binding of the selected antibodies were calculated after subtraction of the negative isotypic immunoglobulin G (IgG) control." (NCT03860844)
Timeframe: Pre-dose on Day 1

,,
InterventionsABC (Mean)
Blood blast cells: CR/CRiBlood blast cells: Non CR/CRi;Blood immune cells (Natural Killer [NK] cells): CR/CRiBlood immune cells (NK cells): Non CR/CRi
Acute Myeloid Leukemia (AML)19502.09815.011220.322530.0
B-cell Acute Lymphoblastic Leukemia (B-ALL)20345.631080.013506.216650.0
T-cell Acute Lymphoblastic Leukemia (T-ALL)12780.022952.022639.033859.0

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration until the last dose plus 30 days, or until the start of hematological recovery period or a new anti-leukemia/lymphoma therapy, whichever occurred first. (NCT03860844)
Timeframe: From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)

,,
InterventionParticipants (Count of Participants)
Any TEAEAny TESAE
Acute Myeloid Leukemia (AML)2616
B-cell Acute Lymphoblastic Leukemia (B-ALL)2719
T-cell Acute Lymphoblastic Leukemia (T-ALL)1312

[back to top]

B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab

Plasma samples were collected at specified timepoints to determine the AUC of isatuximab. (NCT03860844)
Timeframe: From Week 0 to Week 1, Week 0 to Week 5, and Week 0 to Week 10

,
Interventionmg*hour (h)/Liter (L) (Mean)
Week 0 to Week 1Week 0 to Week 5Week 0 to Week 10
B-cell Acute Lymphoblastic Leukemia (B-ALL)31703299071582686
T-cell Acute Lymphoblastic Leukemia (T-ALL)29057289167540375

[back to top] [back to top]

AML: Ceoi of Isatuximab

Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab. (NCT03860844)
Timeframe: At end of infusion on Cycle 1 Days 1 and 15

Interventionmcg/mL (Mean)
Cycle 1: Day 1Cycle 1: Day 15
Acute Myeloid Leukemia (AML)363562

[back to top]

CD38 Receptor Occupancy

Blood samples were collected to assess CD38 receptor occupancy as a pharmacodynamics marker. It was assessed across complete responders and non-complete responders. Multicolor flow cytometry assay was validated for CD38 receptor occupancy (CD38RO) quantification, based on the use of two murine monoclonal antibodies (MAbs), one competing with SAR650984 to determine the number of free CD38 receptors (MAb1) and one recognizing a different binding epitope on CD38 to measure the total number of receptors (MAb2) at the cell surface of the cancer cells. Cells were tagged with either MAb1 (Tube #1) or MAb2 (Tube #2). The percentage RO was calculated using the following equation: % CD38RO = [(sABC MAb2 - sABC MAb1)/sABC MAb2] X 100. (NCT03860844)
Timeframe: Pre-dose on Day 15

Interventionpercent receptor occupancy (Mean)
Blood plasma cells: CR/CRiBlood plasma cells: Non CR/CRi;Blood NK cells: CR/CRiBlood NK cells: Non CR/CRi
T-cell Acute Lymphoblastic Leukemia (T-ALL)40.555.066.770.0

[back to top]

AML: AUC of Isatuximab

Plasma samples were collected at specified timepoints to determine the AUC of isatuximab. (NCT03860844)
Timeframe: From Week 0 to Week 1, Week 0 to Week 3, and Week 0 to Week 8

Interventionmg*h/L (Mean)
Week 0 to Week 1Week 0 to Week 3Week 0 to Week 8
Acute Myeloid Leukemia (AML)28592130862291962

[back to top]

Percentage of Participants With Complete Response (CR) Rate

The complete response rate (CR + CRi [complete response with incomplete peripheral recovery]) was defined as the percentage of participants achieving complete response (CR + CRi) assessed by the investigator per National Comprehensive Cancer Network (NCCN) guidelines version 1.2018 criteria. CR was defined as <5% blasts in a bone marrow aspirate (BMA) with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL); Absolute neutrophil count (ANC) >=1000/microliter (mcL); platelets >100000/mcL; red blood cell transfusion independence. If the physician documented transfusion dependency related to study treatment and not to the participant's underlying disease, CRi was reported. CRi met the same criteria as for CR, except neutrophils and/or platelets recovery (ANC <1000/mcL or platelets <100000/mcL). (NCT03860844)
Timeframe: From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks

Interventionpercentage of participants (Number)
B-cell Acute Lymphoblastic Leukemia (B-ALL)52.0
T-cell Acute Lymphoblastic Leukemia (T-ALL)45.5
Acute Myeloid Leukemia (AML)60.9

[back to top]

Overall Response Rate (ORR)

ORR:Percentage of participants with CR/CRi or partial response (PR) for blood and bone marrow disease based on NCCN guideline. CR: <5% blasts in BMA with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL);ANC >=1000/mcL; platelets >100000/mcL; RBC transfusion independence. If the physician documented transfusion dependency related to study treatment;not to participant's underlying disease, CRi was reported. CRi met the same criteria as CR, except neutrophils and/or platelets recovery (ANC <1000/mcL or platelets <100000/mcL). PR: >50% decrease in the sum of the product of the greatest perpendicular diameters of the mediastinal enlargement. For participants with a previous positive positron emission tomography (PET) scan, a post-treatment PET was to be positive in at least 1 previously involved site. (NCT03860844)
Timeframe: From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks

Interventionpercentage of participants (Number)
B-cell Acute Lymphoblastic Leukemia (B-ALL)52.0
T-cell Acute Lymphoblastic Leukemia (T-ALL)54.5
Acute Myeloid Leukemia (AML)65.2

[back to top]

Number of Participants With Infusion Reactions (IRs)

An IR was an AE related to isatuximab typically with onset within 24 hours from the start of the isatuximab infusion and was reported by the investigator. (NCT03860844)
Timeframe: From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)

InterventionParticipants (Count of Participants)
B-cell Acute Lymphoblastic Leukemia (B-ALL)9
T-cell Acute Lymphoblastic Leukemia (T-ALL)5
Acute Myeloid Leukemia (AML)15

[back to top]

CD38 Receptor Occupancy

Blood samples were collected to assess CD38 receptor occupancy as a pharmacodynamics marker. It was assessed across complete responders and non-complete responders. Multicolor flow cytometry assay was validated for CD38 receptor occupancy (CD38RO) quantification, based on the use of two murine monoclonal antibodies (MAbs), one competing with SAR650984 to determine the number of free CD38 receptors (MAb1) and one recognizing a different binding epitope on CD38 to measure the total number of receptors (MAb2) at the cell surface of the cancer cells. Cells were tagged with either MAb1 (Tube #1) or MAb2 (Tube #2). The percentage RO was calculated using the following equation: % CD38RO = [(sABC MAb2 - sABC MAb1)/sABC MAb2] X 100. (NCT03860844)
Timeframe: Pre-dose on Day 15

Interventionpercent receptor occupancy (Mean)
Blood plasma cells: Non CR/CRi;Blood NK cells: CR/CRiBlood NK cells: Non CR/CRi
B-cell Acute Lymphoblastic Leukemia (B-ALL)44.055.661.3

[back to top]

B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab

Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab. (NCT03860844)
Timeframe: At end of infusion on Cycle 1 Days 1 and 29

,
Interventionmcg/mL (Mean)
Cycle 1: Day 1Cycle 1: Day 29
B-cell Acute Lymphoblastic Leukemia (B-ALL)452835
T-cell Acute Lymphoblastic Leukemia (T-ALL)259745

[back to top] [back to top]

Observed SC and IV Rituximab Area Under the Curve (AUCsc and AUCiv)

The area under the curve (AUC) for serum rituximab concentration versus time after dosage was measured for SC and IV administrations during Cycle 7. Geometric mean ratio and 90% confidence interval were estimated based on an ANCOVA model adjusted for tumor load at baseline and are reported in the statistical analysis. (NCT04660799)
Timeframe: During Cycle 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

Interventionday*mcg/mL (Geometric Mean)
Rituximab IV+CHOP3050.7
Rituximab SC+CHOP3806.7

[back to top]

Subcutaneous Serum Rituximab Trough Concentration (Ctrough SC) and Intravenous Serum Rituximab Trough Concentration (Ctrough IV)

For this pharmacokinetics (PK) primary outcome measure the serum rituximab Ctrough for SC and IV administrations were measured at Cycle 7, 21 days after study treatment administration for Cycle 7 (pre-dose of Cycle 8). Geometric mean ratio and 90% confidence interval were estimated based on an ANCOVA model adjusted for tumor load at baseline and are reported in the statistical analysis. (NCT04660799)
Timeframe: At Cycle 7 (one cycle=21 days), 21 days after study treatment administration, up to 21 weeks

Interventionmicrograms/milliliter (mcg/mL) (Geometric Mean)
Rituximab IV+CHOP90.7
Rituximab SC+CHOP137.4

[back to top]

Area Under the Curve (AUC) of Rituximab

AUC is the area under the serum concentration curve over the dosing interval of 21 days during Cycle 2 and Cycle 7. (NCT04660799)
Timeframe: During Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

,
Interventionday*mcg/mL (Geometric Mean)
Cycle 2Cycle 7
Rituximab IV+CHOP17303050
Rituximab SC+CHOP21303810

[back to top]

Maximum Observed Serum Concentration (Cmax) of Rituximab

(NCT04660799)
Timeframe: At Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

,
Interventionmicrograms per milliliter (mcg/mL) (Geometric Mean)
Cycle 2Cycle 7
Rituximab IV+CHOP200255
Rituximab SC+CHOP144228

[back to top]

Number of Participants Positive for Anti-drug Antibodies (ADAs) to Rituximab

Reported here is the number of participants who had a positive ADA assay result at baseline or post-baseline. The post-baseline results are divided in treatment-enhanced ADAs and treatment-induced ADAs. Treatment-enhanced ADAs are participants with a positive ADA result at baseline who had one or more post-baseline titer results that was at least 0.60 titer unit greater than the baseline titer result. Treatment-induced ADAs include participants with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. (NCT04660799)
Timeframe: From baseline up to 6 months after the last dose of study treatment (up to approximately 1 year)

,
InterventionParticipants (Count of Participants)
BaselinePost-baseline: Treatment-enhancedPost-baseline: Treatment-induced
Rituximab IV+CHOP211
Rituximab SC+CHOP101

[back to top]

Number of Participants Positive for Anti-rHuPH20 Antibodies

Reported here is the number of participants who had a positive anti-rHuPH20 antibody assay result at baseline or post-baseline. The post-baseline results are divided in treatment-enhanced anti-rHuPH20 antibodies and treatment-induced anti-rHuPH20 antibodies. Treatment-enhanced anti-rHuPH20 antibodies are participants with a positive anti-rHuPH20 antibody result at baseline who had one or more post-baseline titer results that was at least 0.60 titer unit greater than the baseline titer result. Treatment-induced anti-rHuPH20 antibodies include participants with negative or missing baseline anti-rHuPH20 antibody result(s) and at least one positive post-baseline anti-rHuPH20 antibody result. (NCT04660799)
Timeframe: From baseline up to 6 months after the last dose of study treatment (up to approximately 1 year)

InterventionParticipants (Count of Participants)
BaselinePost-baseline: Treatment-enhancedPost-baseline: Treatment-induced
Rituximab SC+CHOP211

[back to top]

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a subject administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. New disease, exacerbation of existing disease, recurrence of an intermittent medical condition not present at baseline, any deterioration in a laboratory value or other clinical test associated with symptoms or leading to a change in study/concomitant treatment or discontinuation from study drug as well as events related to protocol-mandated interventions are considered AEs. SAEs: any event that met any of these criteria: fatal, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, medically significant or required intervention to prevent any of the outcomes listed here. (NCT04660799)
Timeframe: AEs were reported up to 28 days after the last dose (up to approximately 7 months), and SAEs were reported up to 6 months after the last dose of study treatment (up to approximately 1 year)

,
InterventionParticipants (Count of Participants)
AEsSAEs
Rituximab IV+CHOP2411
Rituximab SC+CHOP268

[back to top]

Objective Response Rate (ORR), Complete Response (CR) or Partial Response (PR), as Determined by Investigator and IRC Using Lugano Response Criteria (LRC) for Malignant Lymphoma

ORR=CR+PR. Per LRC: CR by PET-CT: complete MR in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass; no new lesions, no FDG-avid disease in bone marrow; CR by CT: complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi, no extralymphatic disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow; PR by PET-CT: partial MR in lymph nodes and extralymphatic sites with a score of 4 or 5 with reduced uptake compared with baseline + residual masses of any size; no new lesions, residual uptake higher than in normal bone marrow but reduced compared with baseline; PR by CT: ≥ 50% decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target nodes and extranodal sites; non-measured lesion absent/normal, regressed, but no increase; spleen regressed by >50 % in length beyond normal; no new lesions. (NCT04660799)
Timeframe: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

,
Interventionpercentage of participants (Number)
InvestigatorIRC
Rituximab IV+CHOP70.866.7
Rituximab SC+CHOP88.580.8

[back to top]

Time to Cmax (Tmax) of Rituximab

(NCT04660799)
Timeframe: At Cycles 2 and 7 (one cycle=21 days): pre-dose, within 15 minutes of end of infusion, 24 hours post-dose, Days 3, 7, 15, 21, up to 21 weeks

,
Interventionday (Median)
Cycle 2Cycle 7
Rituximab IV+CHOP0.140.16
Rituximab SC+CHOP5.421.99

[back to top]

Trough Serum Concentration (Ctrough) of Rituximab

Ctrough was measured at Cycle 2 and Cycle 7, 21 days after study treatment administration for each cycle (pre-dose of Cycle 3 and Cycle 8, respectively). (NCT04660799)
Timeframe: At Cycles 2 and 7 (one cycle=21 days), 21 days after study treatment administration, up to 21 weeks

,
Interventionmcg/mL (Geometric Mean)
Cycle 2Cycle 7
Rituximab IV+CHOP43.290.7
Rituximab SC+CHOP63.5137

[back to top]

CRR, as Determined by the Investigator Using Lugano Response Criteria for Malignant Lymphoma

Per LRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake > mediastinum but ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Per LRC, CR based on CT was defined as complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 centimeters (cm) in longest transverse diameter (LDi) and no extralymphatic sites of disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. (NCT04660799)
Timeframe: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

Interventionpercentage of participants (Number)
Rituximab IV+CHOP58.3
Rituximab SC+CHOP76.9

[back to top]

Complete Response Rate (CRR) as Determined by the Independent Review Committee (IRC) Using Lugano Response Criteria (LRC) for Malignant Lymphoma

Per LRC, CR based on positron emission tomography- computed tomography (PET-CT) was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS), where, 1= no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake > mediastinum but ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Per LRC, CR based on CT was defined as complete radiologic response in lymph nodes and extralymphatic sites with target nodes/nodal masses regressing to ≤ 1.5 centimeters (cm) in longest transverse diameter (LDi) and no extralymphatic sites of disease; absence of non-measured lesion; organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, immunohistochemistry (IHC) negative. (NCT04660799)
Timeframe: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

Interventionpercentage of participants (Number)
Rituximab IV+CHOP62.5
Rituximab SC+CHOP80.8

[back to top] [back to top]

CRR, as Determined by IRC Using International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) 1999 Guidelines

CRR was assessed according to the IWG Response Criteria for NHL 1999 guidelines and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by > 75 % but still >1.5 cm in size, and indeterminate bone marrow assessment. (NCT04660799)
Timeframe: 6-8 weeks after the last dose of study treatment or 4-8 weeks after last dose of study treatment for early discontinuation (up to approximately 32 weeks)

Interventionpercentage of participants (Number)
Rituximab IV+CHOP58.3
Rituximab SC+CHOP65.4

[back to top]

Number of SAEs (Zandelisib When Combined With Rituximab)

Measured by the number of SAEs (NCT04745832)
Timeframe: 1 year 7 months

InterventionParticipants (Count of Participants)
Rituximab Plus Zandelisib12
Rituximab Plus Chemotherapy8

[back to top]

Number of Treatment Emergent AEs (Zandelisib When Combined With Rituximab)

Measured by the number of Treatment Emergent AEs (NCT04745832)
Timeframe: 1 year 7 months

InterventionParticipants (Count of Participants)
Rituximab Plus Zandelisib38
Rituximab Plus Chemotherapy37

[back to top]